gene	Gene synonym	Ensembl	Gene description	Uniprot	Chromosome	Position	Protein class	Biological process	Molecular function	Disease involvement	Evidence	HPA evidence	UniProt evidence	NeXtProt evidence	MS evidence	RNA tissue specificity	RNA tissue distribution	RNA tissue specificity score	RNA tissue specific NX	RNA cell line specificity	RNA cell line distribution	RNA cell line specificity score	RNA cell line specific NX	RNA cancer specificity	RNA cancer distribution	RNA cancer specificity score	RNA cancer specific FPKM	RNA brain regional specificity	RNA brain regional distribution	RNA brain regional specificity score	RNA brain regional specific NX	RNA blood cell specificity	RNA blood cell distribution	RNA blood cell specificity score	RNA blood cell specific NX	RNA blood lineage specificity	RNA blood lineage distribution	RNA blood lineage specificity score	RNA blood lineage specific NX	RNA mouse brain regional specificity	RNA mouse brain regional distribution	RNA mouse brain regional specificity score	RNA mouse brain regional specific pTPM	RNA pig brain regional specificity	RNA pig brain regional distribution	RNA pig brain regional specificity score	RNA pig brain regional specific pTPM	Antibody	Reliability (IH)	Reliability (Mouse Brain)	Reliability (IF)	Subcellular location	Secretome location	Blood concentration - Conc. blood IM [pg/L]	Blood concentration - Conc. blood MS [pg/L]	Subcellular main location	Subcellular additional location	Antibody RRID	Pathology prognostics - Breast cancer	Pathology prognostics - Cervical cancer	Pathology prognostics - Colorectal cancer	Pathology prognostics - Endometrial cancer	Pathology prognostics - Glioma	Pathology prognostics - Head and neck cancer	Pathology prognostics - Liver cancer	Pathology prognostics - Lung cancer	Pathology prognostics - Melanoma	Pathology prognostics - Ovarian cancer	Pathology prognostics - Pancreatic cancer	Pathology prognostics - Prostate cancer	Pathology prognostics - Renal cancer	Pathology prognostics - Stomach cancer	Pathology prognostics - Testis cancer	Pathology prognostics - Thyroid cancer	Pathology prognostics - Urothelial cancer	Tissue RNA - adipose tissue [NX]	Tissue RNA - adrenal gland [NX]	Tissue RNA - amygdala [NX]	Tissue RNA - appendix [NX]	Tissue RNA - basal ganglia [NX]	Tissue RNA - bone marrow [NX]	Tissue RNA - breast [NX]	Tissue RNA - cerebellum [NX]	Tissue RNA - cerebral cortex [NX]	"Tissue RNA - cervix, uterine [NX]"	Tissue RNA - colon [NX]	Tissue RNA - corpus callosum [NX]	Tissue RNA - ductus deferens [NX]	Tissue RNA - duodenum [NX]	Tissue RNA - endometrium 1 [NX]	Tissue RNA - epididymis [NX]	Tissue RNA - esophagus [NX]	Tissue RNA - fallopian tube [NX]	Tissue RNA - gallbladder [NX]	Tissue RNA - heart muscle [NX]	Tissue RNA - hippocampal formation [NX]	Tissue RNA - hypothalamus [NX]	Tissue RNA - kidney [NX]	Tissue RNA - liver [NX]	Tissue RNA - lung [NX]	Tissue RNA - lymph node [NX]	Tissue RNA - midbrain [NX]	Tissue RNA - olfactory region [NX]	Tissue RNA - ovary [NX]	Tissue RNA - pancreas [NX]	Tissue RNA - parathyroid gland [NX]	Tissue RNA - pituitary gland [NX]	Tissue RNA - placenta [NX]	Tissue RNA - pons and medulla [NX]	Tissue RNA - prostate [NX]	Tissue RNA - rectum [NX]	Tissue RNA - retina [NX]	Tissue RNA - salivary gland [NX]	Tissue RNA - seminal vesicle [NX]	Tissue RNA - skeletal muscle [NX]	Tissue RNA - skin 1 [NX]	Tissue RNA - small intestine [NX]	Tissue RNA - smooth muscle [NX]	Tissue RNA - spinal cord [NX]	Tissue RNA - spleen [NX]	Tissue RNA - stomach 1 [NX]	Tissue RNA - testis [NX]	Tissue RNA - thalamus [NX]	Tissue RNA - thymus [NX]	Tissue RNA - thyroid gland [NX]	Tissue RNA - tongue [NX]	Tissue RNA - tonsil [NX]	Tissue RNA - urinary bladder [NX]	Tissue RNA - vagina [NX]	Tissue RNA - B-cells [NX]	Tissue RNA - dendritic cells [NX]	Tissue RNA - granulocytes [NX]	Tissue RNA - monocytes [NX]	Tissue RNA - NK-cells [NX]	Tissue RNA - T-cells [NX]	Tissue RNA - total PBMC [NX]	Cell RNA - A-431 [NX]	Cell RNA - A549 [NX]	Cell RNA - AF22 [NX]	Cell RNA - AN3-CA [NX]	Cell RNA - ASC diff [NX]	Cell RNA - ASC TERT1 [NX]	Cell RNA - BEWO [NX]	Cell RNA - BJ [NX]	Cell RNA - BJ hTERT+ [NX]	Cell RNA - BJ hTERT+ SV40 Large T+ [NX]	Cell RNA - BJ hTERT+ SV40 Large T+ RasG12V [NX]	Cell RNA - CACO-2 [NX]	Cell RNA - CAPAN-2 [NX]	Cell RNA - Daudi [NX]	Cell RNA - EFO-21 [NX]	Cell RNA - fHDF/TERT166 [NX]	Cell RNA - HaCaT [NX]	Cell RNA - HAP1 [NX]	Cell RNA - HBEC3-KT [NX]	Cell RNA - HBF TERT88 [NX]	Cell RNA - HDLM-2 [NX]	Cell RNA - HEK 293 [NX]	Cell RNA - HEL [NX]	Cell RNA - HeLa [NX]	Cell RNA - Hep G2 [NX]	Cell RNA - HHSteC [NX]	Cell RNA - HL-60 [NX]	Cell RNA - HMC-1 [NX]	Cell RNA - HSkMC [NX]	Cell RNA - hTCEpi [NX]	Cell RNA - hTEC/SVTERT24-B [NX]	Cell RNA - hTERT-HME1 [NX]	Cell RNA - HUVEC TERT2 [NX]	Cell RNA - K-562 [NX]	Cell RNA - Karpas-707 [NX]	Cell RNA - LHCN-M2 [NX]	Cell RNA - MCF7 [NX]	Cell RNA - MOLT-4 [NX]	Cell RNA - NB-4 [NX]	Cell RNA - NTERA-2 [NX]	Cell RNA - PC-3 [NX]	Cell RNA - REH [NX]	Cell RNA - RH-30 [NX]	Cell RNA - RPMI-8226 [NX]	Cell RNA - RPTEC TERT1 [NX]	Cell RNA - RT4 [NX]	Cell RNA - SCLC-21H [NX]	Cell RNA - SH-SY5Y [NX]	Cell RNA - SiHa [NX]	Cell RNA - SK-BR-3 [NX]	Cell RNA - SK-MEL-30 [NX]	Cell RNA - T-47d [NX]	Cell RNA - THP-1 [NX]	Cell RNA - TIME [NX]	Cell RNA - U-138 MG [NX]	Cell RNA - U-2 OS [NX]	Cell RNA - U-2197 [NX]	Cell RNA - U-251 MG [NX]	Cell RNA - U-266/70 [NX]	Cell RNA - U-266/84 [NX]	Cell RNA - U-698 [NX]	Cell RNA - U-87 MG [NX]	Cell RNA - U-937 [NX]	Cell RNA - WM-115 [NX]	Blood RNA - basophil [NX]	Blood RNA - classical monocyte [NX]	Blood RNA - eosinophil [NX]	Blood RNA - gdT-cell [NX]	Blood RNA - intermediate monocyte [NX]	Blood RNA - MAIT T-cell [NX]	Blood RNA - memory B-cell [NX]	Blood RNA - memory CD4 T-cell [NX]	Blood RNA - memory CD8 T-cell [NX]	Blood RNA - myeloid DC [NX]	Blood RNA - naive B-cell [NX]	Blood RNA - naive CD4 T-cell [NX]	Blood RNA - naive CD8 T-cell [NX]	Blood RNA - neutrophil [NX]	Blood RNA - NK-cell [NX]	Blood RNA - non-classical monocyte [NX]	Blood RNA - plasmacytoid DC [NX]	Blood RNA - T-reg [NX]	Blood RNA - total PBMC [NX]	Brain RNA - amygdala [NX]	Brain RNA - basal ganglia [NX]	Brain RNA - cerebellum [NX]	Brain RNA - cerebral cortex [NX]	Brain RNA - hippocampal formation [NX]	Brain RNA - hypothalamus [NX]	Brain RNA - midbrain [NX]	Brain RNA - olfactory region [NX]	Brain RNA - pons and medulla [NX]	Brain RNA - thalamus [NX]
ABCB1	"ABC20, CD243, CLCS, GP170, MDR1, P-gp, PGY1"	ENSG00000085563	ATP binding cassette subfamily B member 1	P08183	7	87503633-87713323	"Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	Transport		Cancer-related genes	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		adrenal gland: 57.8;intestine: 49.6	Cell line enhanced	Detected in some		CACO-2: 29.4;HEK 293: 9.0;HEL: 16.3;Hep G2: 8.1;RPTEC TERT1: 11.3;SH-SY5Y: 36.0	Cancer enhanced	Detected in many		renal cancer: 14.2	Low region specificity	Detected in all			Cell type enhanced	Detected in many		MAIT T-cell: 19.2	Group enriched	Detected in many	8	NK-cells: 11.4;T-cells: 19.2									"CAB001716, HPA002199"	Enhanced		Approved	"Nucleoplasm,Focal adhesion sites,Cytosol"				"Nucleoplasm, Focal adhesion sites, Cytosol"		"CAB001716: , HPA002199: AB_1844428"	unprognostic (5.38e-3)	unprognostic (2.45e-2)	unprognostic (1.42e-1)	unprognostic (1.06e-1)	unprognostic (2.25e-2)	unprognostic (9.99e-5)	unprognostic (2.23e-3)	unprognostic (5.65e-3)	unprognostic (1.14e-1)	unprognostic (5.17e-2)	prognostic favourable (3.33e-4)	unprognostic (5.19e-1)	prognostic favourable (2.95e-4)	unprognostic (2.06e-1)	unprognostic (1.50e-1)	unprognostic (3.83e-1)	unprognostic (6.12e-2)	2.6	57.8	9.4	3.2	11.5	1.2	3.4	5.1	10.5	5.5	22.7	3.8	2	14.4	9.4	3.5	2	3.2	9	1.8	9.2	6.6	19.1	15.6	3.8	2.2	9.4	5.7	2.2	1.5	1.7	1.3	3.1	11.1	2.7	10.7	7.6	1.5	2.1	1.1	1.3	49.6	5.7	9	2.4	1.7	1.3	8.6	0.1	2.4	1.4	2.2	2.6	5.9	1.9	0	0.1	0	11.4	19.2	1.5	0	0	1.7	0	0	0	0	0	1.9	0	0	29.4	0	0	0	0	0	2.1	0	0	0	9	16.3	1.9	8.1	0	0	0	0	0	0	0.1	1.4	0	0	0.1	0	0	0	0.5	0	0	0	0	11.3	0	0.4	36	0	0	0	0	0	0.2	0	1.8	0	0.4	3.2	0	0	0	0	1.5	0	0	0	7.8	0	19.2	0.4	2	4.7	0	1.9	1.2	4.8	0.1	11.4	0	0	0	1.5	9.4	11.5	5.1	10.5	9.2	6.6	9.4	5.7	11.1	8.6
ABCG2	"ABCP, BCRP, CD338, EST157481, MXR"	ENSG00000118777	ATP binding cassette subfamily G member 2 (Junior blood group)	Q9UNQ0	4	88090264-88231322	"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins"	Transport		Cancer-related genes	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		ductus deferens: 49.6;intestine: 56.6;seminal vesicle: 61.0	Cell line enhanced	Detected in many		A549: 19.9;BEWO: 34.7;MCF7: 11.5;RPMI-8226: 17.4	Low cancer specificity	Detected in many			Low region specificity	Detected in all			Cell type enhanced	Detected in some		MAIT T-cell: 5.7	Low lineage specificity	Detected in many											"CAB037299, HPA054719"	Enhanced		Supported	"Nucleoplasm,Plasma membrane"				Plasma membrane	Nucleoplasm	"CAB037299: AB_476804, HPA054719: "	unprognostic (5.04e-1)	unprognostic (3.05e-2)	unprognostic (2.01e-1)	unprognostic (1.10e-1)	unprognostic (1.01e-3)	unprognostic (9.19e-2)	unprognostic (1.09e-1)	unprognostic (1.30e-1)	unprognostic (9.14e-2)	unprognostic (1.37e-1)	unprognostic (3.01e-3)	unprognostic (4.52e-2)	unprognostic (1.67e-3)	unprognostic (8.82e-3)	unprognostic (7.04e-2)	unprognostic (1.30e-1)	unprognostic (1.92e-1)	2.8	2.5	11.6	0.8	14.8	1.2	2.4	4.3	9.7	13.6	12.5	8.4	49.6	24.9	14.4	4.2	1.5	6.1	3.3	2	16	12.2	2.3	19.7	3	0.8	17.6	5.6	5.6	0.6	3.2	7	12.3	17	5.5	8.1	6.9	2.9	61	0.4	0.6	56.6	11.8	15.7	0.9	1.2	1.9	5.5	0	3.8	0.8	1.3	2	3.1	1.2	0.5	0	0.2	2.4	5.7	0.7	0.7	19.9	5.9	0	0.2	0	34.7	0.7	0.6	1	1.7	4.4	0.2	0	0.2	0.1	5.8	0.2	0.6	1.5	5.6	0.9	0.2	0.1	5.9	0	0.3	0	0.1	2.4	2.3	0.1	1.8	0.4	0	0.6	11.5	2.7	0.1	2	0	1.3	0	17.4	0	4.2	0.1	0.2	4.1	0.4	0.5	0.1	0	0	0.8	0.7	0.2	0	5.5	2.1	0	1.5	0	0.8	0	0	0	1.9	0	5.7	0.1	0.7	0.6	0	1.2	0.7	0.3	0	2.4	0.2	0.5	1.7	0.7	11.6	14.8	4.3	9.7	16	12.2	17.6	5.6	17	5.5
ACE	"ACE1, CD143, DCP1"	ENSG00000159640	Angiotensin I converting enzyme	P12821	17	63477061-63498380	"Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"		"Carboxypeptidase, Hydrolase, Metalloprotease, Protease"	FDA approved drug targets	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enriched	Detected in many	5	intestine: 205.6	Group enriched	Detected in some	4	ASC TERT1: 35.9;HUVEC TERT2: 18.3	Low cancer specificity	Detected in all			Low region specificity	Detected in some			Cell type enhanced	Detected in some		memory B-cell: 3.7	Group enriched	Detected in many	23	B-cells: 3.7;monocytes: 2.0;T-cells: 1.9									"CAB002426, CAB002921, HPA029298, HPA069790"	Enhanced		Approved	Vesicles	Secreted to blood	92000000	92000000	Vesicles		"CAB002426: AB_442052, CAB002921: , HPA029298: AB_10960255, HPA069790: "	unprognostic (4.72e-2)	unprognostic (4.16e-1)	unprognostic (1.93e-3)	unprognostic (6.06e-2)	unprognostic (2.78e-1)	unprognostic (1.35e-2)	unprognostic (4.37e-1)	unprognostic (1.54e-1)	unprognostic (1.56e-1)	unprognostic (1.25e-2)	unprognostic (3.13e-2)	unprognostic (2.38e-1)	unprognostic (7.66e-2)	unprognostic (9.07e-2)	unprognostic (1.66e-1)	unprognostic (1.08e-1)	unprognostic (2.76e-2)	6.8	2	0.5	2.4	4.2	0	2.9	0.5	1.1	5.3	83.2	0.7	37.7	46.4	4.5	5.1	1.7	1.5	4.4	4.7	0.6	0.7	2.6	1.4	16.3	2.2	0.4	0.7	1.4	3	3.6	3.6	3.6	0.8	3.4	1.4	1.7	2.5	20.1	3.6	1.3	205.6	2.4	0.6	1.4	1.9	32.6	1.3	0.5	6.9	3.1	2.2	1.7	1.6	3.7	0.1	0	2	0	1.9	0.4	0	0	0	0	1.5	35.9	0.4	1.3	2.6	0	0	0.5	3.1	0.7	1	6.1	0	1.7	0	0	0	0.7	3.4	0	0	0.8	0	0	2.4	0	0	0	18.3	3	0	0	0.6	0	0.7	0.2	0.3	0.1	0.2	0.5	0	0	4.5	3.2	0	0	0	1.6	0.2	0	0.1	0.1	0.3	0	0	0	0	0.5	0	0.2	0	0	0	0.4	0.6	0.9	3.7	1.9	1.4	0.1	0	0	0	0	0	2	0	0	0.4	0.5	4.2	0.5	1.1	0.6	0.7	0.4	0.7	0.8	1.3
ACKR1	"CCBP1, CD234, DARC, Dfy, FY, GPD"	ENSG00000213088	Atypical chemokine receptor 1 (Duffy blood group)	Q16570	1	159203307-159206500	"Blood group antigen proteins, CD markers, G-protein coupled receptors, Predicted membrane proteins"		"Blood group antigen, G-protein coupled receptor, Receptor, Transducer"		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level		Tissue enhanced	Detected in many		adipose tissue: 109.8	Group enriched	Detected in some	6	HEL: 22.0;HSkMC: 23.9	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Not detected	Not detected			Not detected	Not detected			Low region specificity	Detected in all			Low region specificity	Detected in all			"HPA016421, HPA017672"	Enhanced									"HPA016421: AB_1849219, HPA017672: AB_1849221"	unprognostic (8.74e-3)	prognostic favourable (2.52e-5)	unprognostic (9.73e-2)	unprognostic (1.91e-1)	unprognostic (2.34e-3)	unprognostic (3.84e-3)	prognostic favourable (1.48e-4)	unprognostic (7.80e-2)	unprognostic (2.22e-1)	unprognostic (3.46e-2)	unprognostic (1.65e-3)	unprognostic (1.81e-1)	unprognostic (3.82e-3)	unprognostic (5.17e-3)	unprognostic (2.40e-1)	prognostic unfavourable (9.76e-4)	unprognostic (2.30e-2)	109.8	4	6.7	16.2	4.2	5.7	54.5	23.3	5.4	40.1	13.1	2.4	10.2	6.5	28.8	23	32.6	27.1	26.9	47.1	9.1	3.4	5.7	1.3	27.8	36.8	19.2	0.6	22.3	8.1	3.9	2	5.8	14	29.1	7.1	5.3	12.8	9.8	38.3	19.8	11.5	36.6	9.4	25	13	21.6	6.4	3	16.5	29.9	15.5	42.3	24.2	0	0	0	0.4	0	0	0.5	0	0	0	0	0	0.1	0	0	0	0.2	0	0	0	0	0	0	0	0	0	0.2	0	0	22	0	0	4.1	0	0	23.9	0	0	3	0.3	0	0	0	0	0	0	0.4	0	0	0	0	0	0	1.6	0	0.1	0	0	0	0	1	0	1.1	0	0	0	0	0	0	0	2.9	0	0.4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.5	6.7	4.2	23.3	5.3	9.1	3.4	19.2	0.6	14	6.4
ADAM10	"CD156c, HsT18717, kuz, MADM"	ENSG00000137845	ADAM metallopeptidase domain 10	O14672	15	58588807-58749978	"Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	Notch signaling pathway	"Hydrolase, Metalloprotease, Protease"	"Alzheimer disease, Amyloidosis, Cancer-related genes, Disease mutation, Neurodegeneration"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in all		U-2197: 76.0	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all			Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB001709, HPA050670"	Approved		Supported	"Nucleoplasm,Vesicles,Plasma membrane"	Intracellular and membrane	8200000	8200000	Plasma membrane	"Nucleoplasm, Vesicles"	"CAB001709: , HPA050670: "	unprognostic (1.43e-1)	unprognostic (1.38e-1)	unprognostic (2.77e-1)	unprognostic (5.04e-2)	unprognostic (3.09e-1)	unprognostic (2.70e-3)	unprognostic (7.48e-2)	prognostic unfavourable (8.46e-5)	unprognostic (3.99e-2)	unprognostic (1.19e-1)	prognostic unfavourable (1.90e-4)	unprognostic (6.69e-2)	unprognostic (2.57e-2)	unprognostic (2.57e-3)	unprognostic (9.14e-2)	unprognostic (2.09e-2)	unprognostic (1.60e-2)	25.9	11.1	15.5	17.1	17.7	15.6	20	25.2	17.6	18.6	20.1	15.7	12.7	13.9	19.9	11.8	17.1	13.8	18	18.8	17.6	13.7	20.8	14.8	25	26.1	23.1	12.4	13.9	13.1	10.9	11.6	36.1	14.5	23.6	16.7	14.6	12.4	19.1	8.9	15.4	15.6	12.8	30.4	40.4	18.4	8.5	18.9	38.5	27.3	9.2	14.9	30	19.1	6.2	12.7	26.9	23.7	9.8	12.2	12.8	11.8	26.9	7.3	8	9.4	13.6	18.5	10.2	30.4	7.5	10.5	12.4	15.7	5.5	31.6	9.1	24.3	4.4	10.8	10	8.2	5.6	9.4	9.8	11.5	10.5	6.6	27.2	11.9	8	5.2	7.7	14.6	5.9	15	13.2	4.4	21.9	7.6	10	3.8	9.1	24	14.1	17.5	32.1	8	5.2	11.1	12.9	17.6	7.7	13.3	10.3	9.9	11	76	9.8	8.4	18.1	6	13.8	12.9	17.3	12.9	18.8	10.4	8.1	21.5	12.2	5.3	8	7.1	12.7	6.2	8.4	7	26.9	9.8	23.7	5.8	10.3	12.8	15.5	17.7	25.2	16.9	17.6	13.7	23.1	12.4	14.5	18.9
ADAM17	"CD156B, cSVP, TACE"	ENSG00000151694	ADAM metallopeptidase domain 17	P78536	2	9488486-9555792	"CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	Notch signaling pathway	"Hydrolase, Metalloprotease, Protease"		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Low cell line specificity	Detected in all			Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all			Low region specificity	Detected in all			Low region specificity	Detected in all			"HPA010738, CAB025906, HPA051575"	Approved		Supported	Cytosol	Intracellular and membrane	27000	27000	Cytosol		"CAB025906: , HPA010738: AB_1078100, HPA051575: "	unprognostic (2.28e-1)	unprognostic (1.29e-3)	unprognostic (1.28e-1)	unprognostic (3.51e-3)	unprognostic (1.57e-1)	unprognostic (5.15e-2)	unprognostic (2.12e-3)	unprognostic (1.55e-1)	unprognostic (4.09e-2)	unprognostic (3.69e-1)	unprognostic (3.53e-3)	unprognostic (3.13e-1)	unprognostic (3.82e-3)	unprognostic (8.63e-2)	unprognostic (2.61e-1)	unprognostic (4.48e-2)	prognostic unfavourable (4.23e-5)	18.6	11	13.6	15.4	13.8	21.9	14.7	20.4	15.5	14	11.7	13.8	8.3	8.7	14.2	15.8	18.7	10.7	17.4	13.4	11.2	12.4	12.4	7.8	24.7	15	11.6	11.7	18.1	9.6	10.9	11.9	29	11.2	8.2	9.4	10.6	12.5	9.8	12.3	16.7	11.1	13.9	14.3	21.4	8.9	17.4	12.3	14.7	12.5	13.9	20.3	12.3	14.4	7	7.7	16	10.2	6	7.9	6	7.7	12.7	13.4	13.9	26.5	19.8	24.2	8.1	13.8	9.4	13.9	11.2	18.7	22.1	11.8	10.2	14.2	9.9	17.2	12.9	8.8	9.9	11.3	9.6	9.9	37.5	11	12.7	22.1	17.4	15	29.1	23.5	15.3	8.5	10	7.3	8.3	11.1	11.1	5.2	9.6	13.2	10.5	12.5	12.9	7.9	19.8	9.1	11.1	19.3	5.7	14.2	18.8	16.7	8.7	11.7	15.4	11.1	10	19.2	13.8	7.1	19.8	16	9.8	7.6	6.1	10.2	7.9	7	5	5.1	7.7	5.1	4.5	4.6	11.8	6	9.5	4.3	5.7	6	13.6	13.8	20.4	13.1	11.2	12.4	11.6	11.7	11.2	12.3
ADAM8	"CD156, CD156a, MS2"	ENSG00000151651	ADAM metallopeptidase domain 8	P78325	10	133262403-133276868	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Hydrolase, Metalloprotease, Protease"		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 56.8;bone marrow: 37.1;lymphoid tissue: 28.3	Cell line enhanced	Detected in some		A-431: 22.3;BEWO: 32.2;CAPAN-2: 27.3;HaCaT: 26.8;HDLM-2: 17.2;U-87 MG: 13.7	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Group enriched	Detected in many	4	basophil: 20.7;eosinophil: 56.8;neutrophil: 32.9	Lineage enriched	Detected in all	7	granulocytes: 56.8	Not detected	Not detected			Not detected	Not detected			HPA064637	Approved				Intracellular and membrane					HPA064637: 	unprognostic (8.24e-2)	unprognostic (6.07e-3)	unprognostic (1.27e-3)	unprognostic (5.18e-2)	unprognostic (8.26e-2)	unprognostic (6.47e-2)	unprognostic (5.59e-2)	unprognostic (2.22e-1)	unprognostic (2.57e-1)	unprognostic (1.94e-3)	unprognostic (3.37e-2)	unprognostic (5.47e-2)	prognostic unfavourable (3.99e-10)	unprognostic (1.92e-1)	unprognostic (3.02e-2)	unprognostic (1.28e-1)	unprognostic (9.32e-2)	4.8	1	0.7	18	1.6	37.1	3.1	1.7	1.2	3.8	4.8	0.9	0.2	3.5	1.8	1.6	2.8	3.6	10.1	4.1	0.8	1.1	2.8	4.3	13	25	1	0.2	1.7	2.4	0.1	2	7.5	1.6	2.9	0.9	2.9	5.5	0.7	1.5	1.9	6	1.6	1.5	28.3	6.9	2.3	0.5	6.6	2	1.8	19.7	12	2.8	2.5	8.6	56.8	5.4	5.5	5.5	4.6	22.3	0.6	0.2	0.3	0.1	0	32.2	0.2	0.5	0.1	0.1	1.7	27.3	0.4	0.6	0	26.8	0	4.6	0	17.2	0.3	0.3	0.1	0	0.2	1.3	6.3	0.1	0.4	0.2	0.4	0	1.2	0.9	0	1.8	0	7.6	0.1	0.6	0.1	0.2	2.4	0.3	0.5	0	0.3	0.1	0.1	0.4	0.4	0.7	0.6	0	0.6	0.2	0.3	1.3	0.8	0.2	13.7	0.7	0.1	20.7	5.4	56.8	5.5	2.1	4	2.5	3.7	5.2	8.6	1.5	1.4	2	32.9	5.5	2	0.1	3.8	4.6	0.7	1.6	1.7	1.2	0.8	1.1	1	0.2	1.6	0.5
ADGRE2	"CD312, EMR2"	ENSG00000127507	Adhesion G protein-coupled receptor E2	Q9UHX3	19	14732393-14778541	"CD markers, Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins"	"Cell adhesion, Inflammatory response"	"G-protein coupled receptor, Receptor, Transducer"	Disease mutation	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 28.7;lymphoid tissue: 38.9	Cell line enhanced	Detected in some		HEL: 10.1;HMC-1: 16.3;NB-4: 9.8;RPMI-8226: 7.2;U-937: 12.9	Low cancer specificity	Detected in many			Low region specificity	Detected in many			Group enriched	Detected in many	5	basophil: 19.6;eosinophil: 24.2;intermediate monocyte: 15.7;neutrophil: 19.1;non-classical monocyte: 28.7	Group enriched	Detected in many	8	granulocytes: 24.2;monocytes: 28.7									HPA055200			Uncertain	"Vesicles,Cytosol"				Vesicles	Cytosol	HPA055200: 	unprognostic (2.46e-2)	unprognostic (3.58e-2)	unprognostic (2.21e-1)	unprognostic (1.66e-1)	unprognostic (9.10e-2)	unprognostic (3.58e-2)	unprognostic (2.77e-2)	unprognostic (3.88e-2)	unprognostic (4.28e-1)	unprognostic (1.22e-1)	unprognostic (2.32e-1)	unprognostic (2.70e-2)	prognostic unfavourable (4.35e-6)	unprognostic (1.46e-1)	unprognostic (2.45e-3)	unprognostic (2.50e-1)	unprognostic (1.01e-1)	6.3	3.1	1.7	22.9	1.9	7.2	4.4	1	1.3	14.9	8.1	2.5	0.9	2.4	12	1	1.9	2.3	3.3	7.3	2	1.8	3.4	4.3	15.6	37.4	2.2	0	5.3	3.5	0.7	1.6	10.9	2.4	3.8	2.5	3.2	2.4	3.9	3.5	3	3	2	3.1	38.9	2	2.2	1.4	2.8	3.4	5.2	2.8	7.5	2.1	0.1	3.1	24.2	28.7	1.2	0	1.8	0.2	1	0.1	0.2	0.1	0.3	1.1	0.8	1.1	0	0	0.2	0.2	0.2	0.1	0.6	1.7	0.3	0.1	0	0.2	0.2	10.1	3.2	0.2	0.5	3.7	16.3	0.8	1.4	3.6	0.6	0.1	2.3	0.4	1.2	0.5	1.3	9.8	0.4	0.2	0.1	1.4	7.2	0	0.3	0.1	0.2	2.1	1.7	0.4	0.3	4.7	0.3	0.3	0.2	0.2	0.1	0.2	0.1	0.2	1	12.9	0.5	19.6	4.4	24.2	0	15.7	0	0	0	0	3.1	0.1	0	0	19.1	1.2	28.7	0.6	0	1.8	1.7	1.9	1	1.3	2	1.8	2.2	0	2.4	1.4
ADGRE5	"CD97, TM7LN1"	ENSG00000123146	Adhesion G protein-coupled receptor E5	P48960	19	14380501-14408725	"CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters"	Cell adhesion	"G-protein coupled receptor, Receptor, Transducer"		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 95.3	Low cell line specificity	Detected in many			Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all			Low region specificity	Detected in all			Low region specificity	Detected in many			HPA013707	Enhanced		Approved	Cytosol	Secreted to blood	930000	930000	Cytosol		HPA013707: AB_1846345	unprognostic (3.16e-1)	unprognostic (1.80e-1)	unprognostic (5.10e-2)	unprognostic (2.30e-1)	unprognostic (2.85e-2)	unprognostic (7.24e-2)	prognostic unfavourable (3.73e-5)	unprognostic (7.51e-2)	unprognostic (6.06e-3)	unprognostic (3.14e-2)	unprognostic (1.08e-3)	unprognostic (2.37e-1)	prognostic unfavourable (1.87e-6)	unprognostic (2.08e-2)	unprognostic (4.14e-2)	unprognostic (2.44e-2)	unprognostic (6.41e-2)	17.7	8.9	2.5	23	4	55.3	14.3	1.1	5.2	21.7	15.9	12.9	0.5	12.9	56.9	18.5	11.6	19.1	27.1	16.4	3	2.4	10.7	15.5	30.3	41.1	6.3	3.2	10.7	16.2	2.4	3.3	18.2	5.9	11.3	9	6.9	17	3.6	12.5	6	22.2	36.2	4.2	56.9	15	6.9	4.9	24.3	8.6	3.7	22.5	34.7	12.4	3.9	13.3	95.3	43.2	22.8	25.8	23.3	30.6	21.8	0.2	20.9	9.3	15.2	3.3	21.2	34.3	15.3	16.8	6.2	31.1	3.5	21.5	27.3	7.3	5.6	10.3	6.9	19.1	6.4	6.9	32.2	2.7	11.4	14.8	32.1	6.6	0.3	15.5	5.3	1.5	9	27.5	16.6	6.9	0.9	19.8	0.6	27.1	2	9.2	16	5.1	2.7	0.2	0.7	12.1	17.4	15.1	4.5	13.7	3.7	5.2	8.6	21.6	34.9	0	0.1	0.2	18.6	26.5	19.4	42	18.6	95.3	25.8	36.7	17.3	3.9	13.1	17.8	13.3	2.6	9.4	12.8	82.7	22.8	43.2	6.4	9	23.3	2.5	4	1.1	5.2	3	2.4	6.3	3.2	5.9	4.9
ALCAM	"CD166, MEMD"	ENSG00000170017	Activated leukocyte cell adhesion molecule	Q13740	3	105366909-105576900	"Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Transporters"	"Adaptive immunity, Cell adhesion, Immunity"		Cancer-related genes	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		parathyroid gland: 122.5	Cell line enhanced	Detected in many		hTERT-HME1: 64.6;U-138 MG: 77.9	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in many		myeloid DC: 20.7	Lineage enriched	Detected in many	6	dendritic cells: 20.7	Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB002148, HPA010926"	Enhanced				Intracellular and membrane	1800000000	1800000000			"CAB002148: AB_442053, HPA010926: AB_1078449"	unprognostic (6.82e-2)	unprognostic (2.66e-1)	unprognostic (2.13e-1)	unprognostic (2.19e-1)	unprognostic (9.48e-3)	unprognostic (2.08e-2)	unprognostic (1.63e-3)	unprognostic (3.89e-2)	unprognostic (1.75e-1)	unprognostic (4.01e-2)	unprognostic (1.09e-1)	unprognostic (1.07e-1)	prognostic favourable (3.15e-4)	unprognostic (3.15e-1)	unprognostic (4.47e-2)	unprognostic (9.57e-2)	unprognostic (7.76e-2)	16.6	14.1	23.6	5.2	31.1	4.2	34.2	4.2	25.3	12.9	8.2	25	13.9	7.2	7	15.4	4	20.6	9.9	4.7	23.2	24.3	9.6	19.4	29.6	4.2	45.1	19.7	24.6	15.3	122.5	11.9	5.3	31.5	14	6.6	3	17.9	17.5	0.9	5.9	7.3	10.8	35.3	3	14.2	2.3	43.8	2.2	25.6	2.7	6.2	9.9	5.5	3.5	20.7	3.7	3.2	0.4	1.6	2	38.4	14.8	10.7	5.4	16.2	7.1	0.1	31.5	18.4	20.3	28.6	0.1	8	2.7	13.1	44.3	29.8	1.7	25	60.2	2.5	2.6	0.3	11.4	0.7	18.2	15.6	0.1	12.6	18.7	26	64.6	22.3	0	4.6	26.6	2.6	2.2	5.7	2.2	16.8	1.4	0.9	0.1	30.8	4.3	7.7	21.5	3.2	3.1	2	6	10.3	46.2	77.9	26.6	3.4	37.2	0	0	0.2	17.7	3.3	33.2	0	3.2	2.4	0.4	1.5	1.4	3.5	1.1	0.7	20.7	2.2	0.2	0.2	3.7	0.4	0.8	7.4	1.6	2	23.6	31.1	4.2	24.6	23.2	24.3	45.1	19.7	31.5	43.8
ALK	CD246	ENSG00000171094	ALK receptor tyrosine kinase	Q9UM73	2	29192774-29921566	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		brain: 8.1;pituitary gland: 17.9	Cell line enriched	Detected in some	6	SH-SY5Y: 26.4	Group enriched	Detected in some	5	glioma: 1.0;melanoma: 1.5;ovarian cancer: 0.7;thyroid cancer: 1.3	Low region specificity	Detected in many			Not detected	Not detected			Not detected	Not detected			Low region specificity	Detected in many			Low region specificity	Detected in many			HPA010694	Approved		Supported	Plasma membrane				Plasma membrane		HPA010694: AB_1078133	unprognostic (4.96e-2)	unprognostic (1.11e-2)	unprognostic (1.45e-1)	unprognostic (4.56e-7)	unprognostic (7.17e-2)	unprognostic (1.71e-1)	unprognostic (9.07e-3)	unprognostic (6.29e-3)	unprognostic (1.18e-1)	unprognostic (1.01e-1)	unprognostic (2.67e-4)	unprognostic (3.70e-2)	unprognostic (2.06e-2)	unprognostic (7.15e-2)	unprognostic (1.98e-1)	unprognostic (1.38e-1)	unprognostic (3.61e-2)	1.8	3.1	3.6	1.2	4.4	0.3	1.1	0.5	8.1	0.7	2.1	2	0	0.7	0.5	0.5	0.6	0.5	1.2	0.4	3.4	4.9	0.4	0.5	1.1	0.5	2.7	4.2	0.6	0.4	0.4	17.9	0.5	5.5	0.5	1.2	2.4	0.9	0.8	0.3	0.9	1.5	0.9	2.1	0.5	0.8	4.9	0.9	0	1.6	0	0.3	0.6	1.2	0	0	0	0.2	0	0.7	0	0	0	0.4	0	0.4	0	0	0.1	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0.1	0.5	0	3.5	0	0	0.1	0.3	26.4	0	0	0.6	0	0	0	0.2	0.1	0	0	0	0	0	3.1	0	4	0	0.1	0	0.7	0	0.2	0	0	0.4	0	0	0	0	0	0	0.2	0	0	0	3.6	4.4	0.5	5.9	3.4	4.9	2.7	4.2	5.5	0.9
ANPEP	"CD13, gp150, LAP1, p150, PEPN"	ENSG00000166825	"Alanyl aminopeptidase, membrane"	P15144	15	89784889-89815401	"CD markers, Enzymes, Plasma proteins, Predicted membrane proteins"	"Angiogenesis, Differentiation, Host-virus interaction"	"Aminopeptidase, Developmental protein, Host cell receptor for virus entry, Hydrolase, Metalloprotease, Protease, Receptor"		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		intestine: 195.3;kidney: 78.7;pancreas: 93.9	Cell line enhanced	Detected in many		ASC TERT1: 77.0;BJ: 76.7;BJ hTERT+: 109.7;HMC-1: 69.8;HSkMC: 67.4;HUVEC TERT2: 85.8;TIME: 85.8;U-2197: 93.5	Low cancer specificity	Detected in all			Low region specificity	Detected in some			Cell type enriched	Detected in many	5	neutrophil: 59.4	Lineage enriched	Detected in many	5	granulocytes: 59.4	Low region specificity	Detected in all			Low region specificity	Detected in single			"CAB002417, HPA004625"	Enhanced		Supported	Plasma membrane		1500000000	1500000000	Plasma membrane		"CAB002417: AB_563491, HPA004625: "	unprognostic (6.31e-2)	unprognostic (7.94e-3)	unprognostic (6.91e-2)	unprognostic (2.16e-1)	unprognostic (2.50e-1)	unprognostic (1.13e-1)	unprognostic (2.23e-2)	unprognostic (1.89e-1)	unprognostic (2.50e-1)	unprognostic (7.73e-2)	unprognostic (5.28e-3)	unprognostic (3.96e-1)	unprognostic (4.04e-3)	unprognostic (3.20e-2)	unprognostic (2.01e-2)	unprognostic (4.61e-3)	unprognostic (1.99e-2)	21.3	1.1	0.6	2.9	0.8	9.5	17	1	1.3	8.2	21.2	0.8	0.5	195.3	1.4	8.4	3.6	1.4	27.7	3.7	0.4	0.3	78.7	37.7	9.7	9.3	0.9	0.9	1.8	93.9	0	0.7	14.7	1.3	8.6	4.7	4	6.6	1.8	1.6	4.9	155.8	4.3	1.2	7.2	0.8	4.7	0.2	5.6	1.5	4.2	3.8	4.7	3	0	6.9	59.4	12.8	0	0	5.5	0	4.9	0	0	60.1	77	0.5	76.7	109.7	9.4	8.3	0.5	0	0	0.9	65.8	0	0.5	0	3.7	0	0	14.5	0.4	11.4	35.4	1	69.8	67.4	0.1	29.7	0	85.8	0.4	0.1	3.6	0	0	34.1	0.2	5.2	0	0	0.8	42.9	0	0.1	0.7	0	0.1	0	0	6.7	85.8	41.4	0	93.5	0	0	0	0	0.1	0	2.2	5.7	12.8	10.4	0	7	0	0	0	0	6.9	0	0	0	59.4	0	12	0.1	0	5.5	0.6	0.8	1	1.3	0.4	0.3	0.9	0.9	1.3	0.2
ART1	"ART2, CD296"	ENSG00000129744	ADP-ribosyltransferase 1	P52961	11	3645128-3664416	"CD markers, Enzymes, Predicted membrane proteins"		"Glycosyltransferase, Transferase"		Evidence at transcript level	Evidence at transcript level	Evidence at transcript level	Evidence at transcript level		Group enriched	Detected in some	20	skeletal muscle: 50.9;tongue: 13.7	Not detected	Not detected			Not detected	Not detected			Not detected	Not detected			Not detected	Not detected			Not detected	Not detected			Not detected	Not detected			Not detected	Not detected			HPA051148	Uncertain									HPA051148: 	unprognostic (3.73e-1)							unprognostic (4.58e-2)		unprognostic (3.12e-2)	unprognostic (1.35e-1)	unprognostic (3.01e-1)	unprognostic (1.19e-1)	unprognostic (1.06e-1)		unprognostic (1.73e-1)		1.5	0.1	0.1	0	0.1	0	0	0.1	0.4	0	0	0	0	0	0.1	0.5	0.6	0.1	0	0.2	0.1	0.1	0.4	0	0.3	0	0.1	0.2	0	0	0	0	0	0.4	0.2	0	0.3	0.2	0.1	50.9	0	0	0	0.1	0	0	0.1	0	0	0.1	13.7	0.5	0	0	0.5	0	0.6	0	0	0.3	0	0.2	0	0	0	0	0	0	0	0	0	0.6	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.5	0	0.3	0	0.5	0	0	0	0	0	0	0.6	0	0	0	0	0.2	0.3	0	0.5	0	0	0.4	0	0	0	0	0	0.1	0.1	0.1	0.4	0.1	0.1	0.1	0.2	0.4	0
ART4	"CD297, DO, DOK1"	ENSG00000111339	ADP-ribosyltransferase 4 (Dombrock blood group)	Q93070	12	14825569-14843533	"Blood group antigen proteins, CD markers, Enzymes, Predicted membrane proteins, Predicted secreted proteins"		"Blood group antigen, Glycosyltransferase, Transferase"		Evidence at protein level	Evidence at transcript level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		liver: 33.7;lymphoid tissue: 17.8;placenta: 17.8	Cell line enhanced	Detected in some		AN3-CA: 5.1;HEL: 10.0;Hep G2: 6.0;HUVEC TERT2: 22.9	Cancer enhanced	Detected in some		liver cancer: 3.8	Not detected	Not detected			Low cell type specificity	Detected in some			Low lineage specificity	Detected in many			Region enhanced	Detected in single		olfactory region: 2.2	Low region specificity	Detected in many			HPA075664			Approved	Rods & Rings	Secreted to blood	11000000	11000000	Rods & Rings		HPA075664: 	unprognostic (2.50e-2)	unprognostic (1.12e-1)	unprognostic (1.57e-1)	unprognostic (1.18e-2)	unprognostic (1.55e-1)	unprognostic (1.37e-2)	unprognostic (1.92e-1)	unprognostic (1.90e-2)	unprognostic (1.10e-1)	unprognostic (2.64e-1)	unprognostic (1.37e-1)	unprognostic (1.90e-2)	unprognostic (2.62e-3)	unprognostic (4.33e-3)	unprognostic (1.25e-3)	unprognostic (1.05e-1)	unprognostic (1.71e-1)	2.7	2	0.2	1.7	0.2	2.4	2.1	0.2	0.2	1.4	1.3	0.1	1.9	0	1.1	3.7	3.1	1.9	6.1	10.1	0.2	0.2	6.6	33.7	2.1	17	0.2	0	1.3	1.9	0	0.4	17.8	0.3	0.8	0.2	0	0.7	0.4	1.9	0.5	0.8	1.5	0.2	17.8	0.5	1.4	0	0.1	4.6	1.3	1.3	1.3	1.2	0.6	0.6	1.4	0.4	0.6	1.3	0.3	0	0	0.2	5.1	0	0	0.1	0	0	0	0	0.3	0	0	0	0	0	0	0	0	0	0	10	0	6	1.3	0	0	0	0	0	0	22.9	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2	0	0.1	0	0.1	0	2.2	0	0	0	0	0	0	0	0	0	0	1.1	0.4	0.4	0.5	0.3	0.4	0.5	0.3	0.3	0.2	0.6	0.5	1.3	1.4	0.6	0.2	0.6	0.2	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0	0.3	0
ATP1B3	"CD298, FLJ29027"	ENSG00000069849	ATPase Na+/K+ transporting subunit beta 3	P54709	3	141876124-141926514	"CD markers, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Ion transport, Potassium transport, Sodium transport, Sodium/potassium transport, Transport"			Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Low cell line specificity	Detected in all			Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all			Low region specificity	Detected in all							"CAB020697, HPA048963"	Enhanced		Supported	Plasma membrane		100000	100000	Plasma membrane		"CAB020697: , HPA048963: "	unprognostic (2.31e-1)	unprognostic (1.11e-3)	unprognostic (2.75e-1)	prognostic favourable (5.19e-5)	unprognostic (2.60e-2)	unprognostic (3.31e-2)	prognostic unfavourable (6.32e-6)	unprognostic (8.11e-3)	unprognostic (6.99e-2)	unprognostic (5.37e-3)	unprognostic (1.48e-2)	unprognostic (1.43e-1)	prognostic unfavourable (1.29e-5)	unprognostic (5.14e-2)	unprognostic (2.04e-1)	unprognostic (7.19e-3)	unprognostic (6.15e-2)	50.5	79.9	12.7	26.3	23.3	17.5	105.9	25.7	35.1	17.7	48.2	9.1	16.8	37.3	17.9	14.6	36.9	20	47.8	44	16	18.9	24.9	7.7	44.9	43.4	21.3	12.8	34.7	11.5	6.3	33.8	32.6	43.3	20.5	58.1	23.9	18.4	24.8	7.4	85.4	57.3	24.3	28.4	16.5	13.5	21.1	13.6	14.5	15.6	41.4	18.4	21.9	31.5	10.4	26.8	13.6	60.9	7.8	20	22.5	46.3	28.8	27.1	25.4	72.9	21.2	62.2	54.4	49.5	39.6	44.9	44.8	23.3	37.9	49.2	41.3	101.8	26.9	26	45.1	20.6	34.1	33	32.5	29	28.8	27.2	26	22.5	62.1	31	30	42.2	22.7	33.6	40.5	21.1	27.6	45.5	37.7	13.8	37.9	20.3	38.5	33.2	35.8	22.4	15.2	71	33.1	73	25.2	33.1	29.3	34.8	13.4	52	31.6	25.1	32.2	61	45.4	29.6	28.6	13.6	27.1	8.9	19.2	44.5	14.1	10.4	15.6	20	26.8	7.5	9.2	16.7	1.9	7.8	60.9	16.4	16.9	22.5	12.7	23.3	25.7	35.1	16	18.9	21.3	12.8	43.3	13.6
BCAM	"CD239, LU"	ENSG00000187244	Basal cell adhesion molecule (Lutheran blood group)	P50895	19	44809059-44821421	"Blood group antigen proteins, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Cell adhesion	"Blood group antigen, Receptor"		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		kidney: 101.8	Cell line enhanced	Detected in many		BEWO: 30.8;HaCaT: 62.8;SK-BR-3: 58.9;T-47d: 33.4;U-2 OS: 28.9	Cancer enhanced	Detected in all		ovarian cancer: 493.9	Low region specificity	Detected in all			Not detected	Not detected			Not detected	Not detected			Low region specificity	Detected in all			Low region specificity	Detected in all			HPA005654	Uncertain		Approved	Nucleoli fibrillar center		16000000	16000000	Nucleoli fibrillar center		HPA005654: 	unprognostic (5.63e-2)	unprognostic (2.98e-2)	prognostic unfavourable (2.31e-4)	prognostic unfavourable (1.24e-5)	unprognostic (1.60e-2)	unprognostic (1.23e-3)	unprognostic (2.01e-1)	unprognostic (2.25e-2)	unprognostic (1.60e-1)	unprognostic (6.17e-2)	unprognostic (2.61e-3)	unprognostic (1.41e-1)	prognostic favourable (5.94e-6)	unprognostic (1.83e-2)	unprognostic (5.74e-2)	unprognostic (2.14e-2)	unprognostic (9.97e-3)	28.9	7.2	4.9	8.1	5.4	1.4	33.1	3.4	8.7	33.5	8.5	4.4	17.8	5.7	24.8	26.5	15.6	46.3	23.2	23.8	4.5	4.2	101.8	13.2	41.6	5.8	4.4	6.5	30.4	17.8	5.8	9.8	28.7	7	42.7	2.4	21.4	17.8	27.3	16.7	12.7	7.4	12.5	3.8	14.2	9.6	13.6	2.6	5.7	93	23.7	8.5	14.2	30.7	0	0	0	0	0	0	0.2	7.1	9.2	0.2	25.6	0.1	0.1	30.8	2.8	1.3	2.3	1.5	13.8	17.6	0	14.2	0.3	62.8	2.2	15.7	0.7	0	1.6	0	1.9	19.1	5.2	0	3.4	2.5	6.1	0.8	0.9	1.4	1.4	0.1	0.3	3.6	0	0.2	2.9	3.2	0.1	3	0.7	19.2	4.5	0	0.1	11.4	58.9	0.6	33.4	1	3.7	0.6	28.9	0.7	1.3	0.1	0.2	0	0.2	0	2.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2	4.9	5.4	3.4	8.7	4.5	4.2	4.4	6.5	7	2.6
BMPR1A	"ACVRLK3, ALK3, CD292"	ENSG00000107779	Bone morphogenetic protein receptor type 1A	P36894	10	86756601-86932838	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"		"Kinase, Receptor, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in many			Low cell line specificity	Detected in many			Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in many			Low lineage specificity	Detected in many			Low region specificity	Detected in all			Low region specificity	Detected in all			CAB019398	Approved		Approved	Cytosol				Cytosol		CAB019398: 	unprognostic (1.36e-1)	unprognostic (2.46e-1)	unprognostic (3.34e-1)	unprognostic (9.61e-2)	unprognostic (1.05e-3)	unprognostic (9.34e-2)	prognostic unfavourable (8.93e-4)	unprognostic (3.64e-1)	unprognostic (2.38e-2)	unprognostic (1.53e-1)	unprognostic (9.24e-2)	unprognostic (9.42e-2)	unprognostic (4.32e-2)	unprognostic (1.80e-1)	unprognostic (1.47e-1)	unprognostic (1.01e-2)	unprognostic (1.07e-1)	8.9	7	9.4	7.9	12.4	0.9	10.7	14.1	9.2	19.4	20.6	10.9	7.7	6.2	16.3	12.3	8.4	10.9	10.8	11	7.7	6.1	8.2	4.6	7.4	2.9	7.3	7.6	16.1	10.6	10	14	7.4	8.5	12.8	9.3	10.9	12.6	14.2	8.4	11.3	9.8	16.5	12.2	3.4	12.1	7.8	9.2	0.3	19.4	7.8	5.7	16	11.4	1.8	1.1	3.6	0.8	0.9	1.4	0.3	7.5	3.8	14.7	12.5	7.7	5	2.6	7.6	8	4.5	5.2	6.5	6.7	2.3	3.5	9.7	8.1	6.5	8.3	6.6	2.5	3.7	2.9	3.6	10.7	4.1	4	20.4	4.4	3.5	6	4.4	0	4.5	1.6	5.2	3.2	2.6	3.2	8	1.8	0	5.8	0	9.2	7.2	1.5	4.8	8.5	4.3	5.1	7.3	2	3.8	3.2	5.2	6.6	7	0.4	7	2.9	2.8	2.7	2.6	2	0.8	0.6	1.4	0.5	0.9	1.8	1.4	1.2	0.3	1.5	1	1.1	3.6	0.9	0.6	1.1	0.7	0.3	9.4	12.4	14.1	9.2	7.7	6.1	7.3	7.6	8.5	9.2
BMPR1B	"ALK6, CDw293"	ENSG00000138696	Bone morphogenetic protein receptor type 1B	O00238	4	94757968-95158448	"CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"	Chondrogenesis	"Kinase, Receptor, Serine/threonine-protein kinase, Transferase"	"Disease mutation, Dwarfism"	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		"cervix, uterine: 28.0;ductus deferens: 25.1;prostate: 25.3;seminal vesicle: 32.0"	Cell line enhanced	Detected in many		A549: 18.3;MCF7: 9.2;SH-SY5Y: 15.3	Cancer enhanced	Detected in many		breast cancer: 32.4;prostate cancer: 24.7	Low region specificity	Detected in all			Low cell type specificity	Detected in some			Low lineage specificity	Detected in many			Low region specificity	Detected in all			Low region specificity	Detected in all														unprognostic (2.25e-1)	unprognostic (1.80e-2)	unprognostic (1.40e-3)	prognostic favourable (2.84e-4)	unprognostic (1.57e-1)	unprognostic (4.22e-2)	unprognostic (1.92e-1)	unprognostic (2.86e-2)	unprognostic (2.95e-2)	unprognostic (1.01e-1)	unprognostic (3.97e-2)	unprognostic (3.93e-1)	unprognostic (1.62e-3)	unprognostic (7.89e-4)	unprognostic (6.22e-2)	unprognostic (3.81e-3)	unprognostic (2.63e-2)	1.1	5.6	12.7	0.8	15	0.7	1.7	11.6	12.7	28	1.2	5.5	25.1	0.7	5.3	3.2	1.1	14.3	3.4	1.3	13.4	5.9	9.3	1.4	2.4	0.5	5.4	8.6	7.6	1.7	0.6	2.4	1.2	12.1	25.3	0.8	0.7	1.4	32	3.3	1.4	0.6	1.2	7.5	1.4	2.8	4.3	11.2	10.8	0.8	0.1	0.6	0.7	0.7	0.4	0.5	1.9	0.9	0.8	1.6	0.3	0	18.3	4.9	0	1.9	4.5	0.1	0.1	0	0.1	0.4	0	0.1	0	0.2	0.8	1	2.9	6.7	0	0	4.5	0	1.1	0	0.5	0.4	0	2.8	7.5	2.8	5.6	0	0	0	7	9.2	0.6	0.1	1.8	3.1	0.1	2.7	0.1	3.5	0.1	0.2	15.3	0.2	2.5	2.5	1.9	0	0	3.9	3.1	0.1	3.3	0	0	0	1.5	0	0.4	1.9	0.3	0.5	0.4	0.5	0.7	0.4	0.6	0.3	0.3	0.3	0.5	0.5	0.8	0.8	0.9	0.5	1.6	0.3	12.7	15	11.6	11.8	13.4	5.9	5.4	8.6	12.1	11.2
BSG	"CD147, EMMPRIN, OK"	ENSG00000172270	Basigin (Ok blood group)	P35613	19	571277-583493	"Blood group antigen proteins, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Transporters"		Blood group antigen		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Low cell line specificity	Detected in all			Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all			Low region specificity	Detected in all							"CAB002427, HPA036048, HPA074870"	Enhanced		Approved	Vesicles		3400000	3400000	Vesicles		"CAB002427: AB_563501, HPA036048: , HPA074870: "	unprognostic (1.88e-1)	unprognostic (4.85e-2)	unprognostic (9.53e-3)	prognostic favourable (2.59e-4)	unprognostic (3.34e-1)	unprognostic (1.38e-2)	prognostic unfavourable (5.48e-6)	unprognostic (1.54e-3)	unprognostic (1.55e-1)	unprognostic (9.46e-2)	unprognostic (4.48e-3)	unprognostic (2.61e-2)	prognostic favourable (1.95e-6)	unprognostic (1.22e-1)	unprognostic (1.03e-1)	unprognostic (7.30e-2)	unprognostic (3.22e-1)	53	74.8	60	33.3	73	86.3	42.3	36.2	103	41.7	93.4	57.8	37.3	50.1	56	62.2	35.1	48.8	52	205.8	58.5	45.9	78.5	39.1	36.1	22.6	57.6	44	51.3	64.2	28.2	48.2	96.2	57.9	49.5	39.6	109.4	44	48.4	97.4	38.1	45.5	52.9	34.9	28.3	63.9	76.8	30.4	31.8	61.9	45.9	31.2	48.5	31.5	22	43.8	89.4	58.7	30.9	44.5	65.5	63.7	86.1	41.1	92.3	122.3	52.6	87.4	53.1	66.4	64.1	55.8	68.6	69.1	22.9	61.7	48	104.1	41.6	64.5	22.2	48	89.2	15.7	72.8	92.8	77.3	37.9	74	54.7	65.5	36.8	41.1	45.9	73.9	108.2	37.6	114.5	27.6	72.7	96.4	44.1	55.5	33.6	75.4	75.7	47.9	63.7	58	110.2	44.5	78.8	46.7	117.3	50.5	61.5	39.1	101.9	80.1	69.8	70.2	21.7	116.7	52.6	76.1	32	58.7	62	44.5	45.2	39.5	22	30.2	42.6	39.9	18.3	23.1	29.1	89.4	30.9	48.3	43.8	35.1	65.5	60	73	36.2	103	58.5	45.9	57.6	44	57.9	30.4
BST1	CD157	ENSG00000109743	Bone marrow stromal cell antigen 1	Q10588	4	15702950-15738313	"CD markers, Enzymes, Plasma proteins, Predicted intracellular proteins"		"Hydrolase, Transferase"		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 59.5;bone marrow: 54.9;intestine: 61.3	Cell line enhanced	Detected in many		THP-1: 36.3;TIME: 20.0;U-937: 23.7;WM-115: 21.6	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Cell type enhanced	Detected in many		classical monocyte: 52.7;neutrophil: 59.5	Group enriched	Detected in many	105	dendritic cells: 16.6;granulocytes: 59.5;monocytes: 52.7	Not detected	Not detected			Low region specificity	Detected in all			HPA050121	Uncertain				Intracellular and membrane	170000000	170000000			HPA050121: 	unprognostic (2.95e-1)	unprognostic (3.61e-1)	unprognostic (1.27e-1)	unprognostic (4.00e-2)	unprognostic (7.49e-2)	unprognostic (2.89e-1)	unprognostic (4.55e-2)	unprognostic (2.70e-1)	unprognostic (1.75e-1)	unprognostic (1.84e-1)	unprognostic (1.08e-1)	unprognostic (4.06e-2)	unprognostic (4.83e-3)	unprognostic (1.94e-3)	unprognostic (3.11e-1)	unprognostic (1.57e-2)	unprognostic (1.95e-1)	14.3	2	1.1	5.6	2	54.9	6.6	0.8	1.5	7.2	33.8	1.5	2.1	20.4	6.4	7	4.6	5.6	10.3	14.5	1.8	0.8	6.6	3.7	9.4	9.6	1.3	1.9	5.5	1	0.4	1.3	8	1.3	7.5	4	5.4	2.8	2.2	3.4	3.5	61.3	7.9	1.5	13.6	2.4	2.4	1.2	2.8	3.5	2.9	1.8	7.5	16.1	0.4	16.6	59.5	52.7	0.1	0.3	19.6	0.2	5.4	0.5	0.4	13.2	3.1	0.7	10.3	0.9	9.4	10.6	0.1	5.6	0.3	0.9	5.2	0.1	1.5	0.2	8	0.3	0.2	2.4	0.3	0.2	3.4	3.2	7.1	2.7	0.7	6	0.5	1.4	0.3	0.2	5.5	0.1	1	1.9	1.2	1.1	0.3	0.7	0.2	0.3	0.3	0.7	2	0.2	0.3	6.8	0.2	36.3	20	0.3	0.4	3.7	0.4	0.2	0	0.2	1.3	23.7	21.6	7.6	52.7	3.9	0.2	19.8	0.3	0.4	0.1	0.1	16.6	0.2	0.2	0.1	59.5	0.1	13.6	5.5	0.2	19.6	1.1	2	0.8	1.5	1.8	0.8	1.3	1.9	1.3	1.2
BST2	"CD317, tetherin"	ENSG00000130303	Bone marrow stromal cell antigen 2	Q10589	19	17402939-17405648	"CD markers, Plasma proteins, Predicted membrane proteins"	"Antiviral defense, B-cell activation, Immunity, Innate immunity"			Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		ovary: 101.0	Cell line enhanced	Detected in many		BJ hTERT+ SV40 Large T+ RasG12V: 78.1	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all											HPA017060	Enhanced		Supported	"Golgi apparatus,Plasma membrane,Cytosol"				"Golgi apparatus, Plasma membrane, Cytosol"		HPA017060: AB_1845467	prognostic favourable (6.69e-4)	unprognostic (1.75e-1)	unprognostic (8.42e-3)	unprognostic (8.93e-3)	unprognostic (4.87e-2)	unprognostic (2.25e-1)	unprognostic (2.26e-1)	unprognostic (1.07e-1)	unprognostic (3.25e-1)	unprognostic (6.46e-2)	unprognostic (6.56e-3)	unprognostic (1.64e-1)	prognostic unfavourable (3.56e-9)	unprognostic (1.05e-1)	prognostic unfavourable (4.22e-4)	unprognostic (1.08e-1)	unprognostic (2.46e-2)	29.6	72.2	8.4	31.1	9.8	13.6	27.9	2.5	7.6	14.4	12	5.6	24.8	6.9	13.4	36.7	8.6	26.8	30.1	13.9	7.9	4.9	24.7	30.8	44.9	16.6	10	5.2	101	6.9	0.3	8.6	31.5	8.8	15.6	4.8	8.4	11.4	17.5	6	3.2	14	11.3	9	32.9	12.3	8.5	9.4	10.3	10.3	5.9	12.3	14	42.4	26.2	74.1	35.8	66.4	57.9	32.6	54.5	39.2	0	0.1	18.1	0	0.1	6.2	0.1	3	58	78.1	18.4	35.4	30.4	42.9	24.2	0.1	26.4	2.9	1.8	33.5	0.2	0.4	63.6	17.9	33.2	14.3	38.6	0.1	0	19.1	0	14.7	17.3	75.8	0	10.7	6.8	25.1	19.9	50.8	12.8	0.1	63.5	13.8	0.1	0	0.1	40.1	1.5	48.2	30.4	20.3	0.1	0.2	1.4	0	0.4	39.1	51	20.1	0.1	56.7	0.2	35.8	61.6	21	32.6	66.4	30.8	21	27.5	30.2	50.7	26.2	22.5	25.6	20.3	57.9	59.3	74.1	24.8	54.5	8.4	9.8	2.5	7.6	7.9	4.9	10	5.2	8.8	9.4
BTLA	"BTLA1, CD272"	ENSG00000186265	B and T lymphocyte associated	Q7Z6A9	3	112463968-112499561	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	6	blood: 37.2;lymphoid tissue: 30.9	Group enriched	Detected in some	4	ASC diff: 2.4;Daudi: 1.9;U-698: 6.1	Low cancer specificity	Detected in some			Not detected	Not detected			Cell type enhanced	Detected in many		memory B-cell: 22.6;naive B-cell: 37.2	Lineage enriched	Detected in many	4	B-cells: 37.2	Not detected	Not detected							"HPA047211, HPA062029"	Enhanced									"HPA047211: , HPA062029: "	unprognostic (1.13e-3)	unprognostic (2.13e-3)	unprognostic (5.79e-4)	unprognostic (1.01e-4)	unprognostic (7.08e-2)	unprognostic (7.74e-6)	unprognostic (6.20e-3)	unprognostic (7.59e-3)	unprognostic (5.98e-2)	unprognostic (1.53e-5)	unprognostic (2.33e-2)	unprognostic (1.23e-1)	unprognostic (1.57e-5)	unprognostic (2.57e-1)	unprognostic (2.46e-2)	unprognostic (1.65e-1)	unprognostic (1.42e-2)	0.6	0.3	0.3	20.3	0.4	1.2	1.1	0.4	0.3	0.5	1.2	0.1	0	0.9	0.4	0.1	2.3	0.5	1	0.4	0.3	0.3	1	0.5	1.2	30.9	0.3	0	0.4	0.3	0	0.4	0.3	0.1	0.5	0.9	0.2	5.7	0.4	0.3	0.5	6	0.2	0.4	18.6	1.7	0.6	0	14.6	0.9	1.1	19.4	2.8	0.5	37.2	8.6	0.1	0	0.1	5.1	2.4	0	0	0	0.3	2.4	0	0	0.1	0	0	0.1	0	0	1.9	0.1	0.1	0	0.8	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.7	0	0.3	0	0	0	0	0.6	0	0	0	0.3	0	0	0	0.4	0.1	0.2	0	0	0.1	0	0	0	0	6.1	0.1	0	0	0	0	0	4.1	0	3.1	22.6	5.1	2.4	1.5	37.2	4.8	4.7	0.1	0.1	0	8.6	1.1	2.4	0.3	0.4	0.4	0.3	0.3	0.3	0.3	0	0.1	0
BTN3A1	"BT3.1, BTF5, BTN3.1, CD277"	ENSG00000026950	Butyrophilin subfamily 3 member A1	O00481	6	26402237-26415216	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"			Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Low cell line specificity	Detected in many			Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all											HPA012565	Approved		Uncertain	Vesicles				Vesicles		HPA012565: AB_1845494	unprognostic (2.82e-2)	unprognostic (6.43e-2)	unprognostic (1.45e-3)	unprognostic (4.72e-3)	unprognostic (1.41e-2)	unprognostic (1.42e-1)	unprognostic (3.10e-2)	unprognostic (9.31e-2)	unprognostic (9.81e-2)	unprognostic (8.60e-3)	unprognostic (1.19e-1)	unprognostic (2.41e-1)	prognostic unfavourable (4.15e-5)	unprognostic (2.45e-1)	unprognostic (5.02e-2)	unprognostic (3.26e-2)	prognostic favourable (4.81e-4)	11.3	14.3	6.7	33.5	5.4	10.3	10.2	10.7	5.9	18.5	14.9	10	10.1	11.5	22.3	14.1	13.1	9.6	16.5	9	5.3	6.1	9.7	11.4	29.9	24.1	7.1	5.4	15.5	9.4	5.6	11.2	8.5	7.8	17.9	12.1	12.3	16.7	10	4.8	9.7	20.6	10.2	9	45.2	12.5	4.9	6.7	16.5	8.5	9.8	32.9	11.6	12.9	9.8	4.4	17.4	5.9	18.4	23.4	12.1	3.7	3.2	4.7	4.8	13.6	14.5	0.5	3	12	6.9	20.3	0.1	8.1	9.7	10.6	5.5	2.5	1.5	4.8	4	9.5	3.3	5.1	3.9	2.2	6.1	4.7	4.7	7.8	2.7	6	2.8	9.7	1.2	12.7	2.8	0.3	8.5	2.9	0.5	1	11.8	2.1	22	4.2	4.7	2.5	5	1.7	3.6	6.8	3.3	1.9	2.4	5.3	1.3	1.5	2.9	21.7	22.1	3.5	8.1	10.6	4.1	17.4	5.3	13.5	23.4	5.7	20.9	9.8	14.6	21.7	4.4	5.3	12.7	16.8	11.9	18.4	5.9	2.1	16.9	12.1	6.7	5.4	10.7	5.9	5.3	6.1	7.1	5.4	7.8	6.7
C5AR1	"C5A, C5AR, C5R1, CD88"	ENSG00000197405	Complement C5a receptor 1	P21730	19	47290023-47322066	"CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"	Chemotaxis	"G-protein coupled receptor, Receptor, Transducer"		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		blood: 75.8	Cell line enhanced	Detected in many		CAPAN-2: 5.8;HMC-1: 7.4;U-87 MG: 8.8;U-937: 8.9	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Cell type enhanced	Detected in many		neutrophil: 75.8	Group enriched	Detected in many	42	granulocytes: 75.8;monocytes: 20.5	Low region specificity	Detected in many			Low region specificity	Detected in all			"CAB002720, HPA014520, HPA048012"	Approved		Supported	Vesicles				Vesicles		"CAB002720: , HPA014520: AB_1846337, HPA048012: "	unprognostic (5.95e-2)	prognostic favourable (4.71e-4)	unprognostic (1.70e-2)	unprognostic (1.25e-1)	unprognostic (4.08e-2)	unprognostic (1.11e-1)	unprognostic (1.80e-2)	unprognostic (4.41e-2)	unprognostic (5.45e-2)	prognostic unfavourable (9.55e-4)	unprognostic (2.02e-1)	unprognostic (9.56e-2)	prognostic unfavourable (1.16e-4)	unprognostic (1.96e-3)	prognostic unfavourable (7.99e-4)	unprognostic (1.82e-2)	unprognostic (6.54e-2)	33.7	8	1.9	34.9	7	46.2	8.7	0.7	3	5.6	6	3.7	1.6	1	4.1	4.9	3.5	14.3	16.5	11.7	7.6	3.2	5.3	9.1	38.1	26.9	3.8	1.2	7.6	3.6	1.3	27.9	12.8	10.9	4.2	1.9	7.8	2.9	1.1	7	1.1	3	11.4	11.2	48.8	4.2	6.3	1.3	2.3	2.5	1.7	3.4	12.2	2.7	0.1	1.1	75.8	20.5	0.1	0.1	2.6	1.4	5.3	0.3	0.5	1	0.4	1.1	1	0.6	0.3	0.1	0.2	5.8	0.4	1.1	1.2	2	0.7	0.8	0.2	1	0.7	0.2	4.9	0.8	0.6	2.6	7.4	0.8	3	0.6	0.9	0	0.3	2.6	0.2	1.5	0.3	3.4	1.8	0.8	0.3	0.1	0.4	1.8	1.2	0	0.1	0.5	0.5	0.8	0.4	3	0	0.1	3.1	0.4	0.3	0.4	0.4	0.3	8.8	8.9	0.3	7	8.9	6.9	0.1	15.1	0	0	0	0	1.1	0.1	0	0	75.8	0.1	20.5	0.2	0	2.6	1.9	7	0.7	3	7.6	3.2	3.8	1.2	10.9	1.3
CCR1	"CD191, CKR-1, CMKBR1, MIP1aR, SCYAR1"	ENSG00000163823	C-C motif chemokine receptor 1	P32246	3	46201709-46208396	"CD markers, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 34.0;lymphoid tissue: 40.2	Cell line enhanced	Detected in some		Karpas-707: 76.5;RPMI-8226: 35.1;U-266/70: 13.4;U-266/84: 39.6	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in many			Low lineage specificity	Detected in many							Low region specificity	Detected in all														unprognostic (3.95e-1)	unprognostic (2.17e-1)	unprognostic (1.20e-1)	unprognostic (2.16e-1)	unprognostic (1.05e-1)	unprognostic (6.66e-2)	unprognostic (1.16e-1)	unprognostic (8.82e-2)	unprognostic (4.91e-3)	unprognostic (2.20e-3)	unprognostic (1.09e-1)	unprognostic (9.60e-2)	prognostic unfavourable (1.01e-4)	unprognostic (1.08e-1)	unprognostic (5.52e-3)	unprognostic (1.47e-1)	unprognostic (2.38e-1)	21.2	6	5.1	23.8	8.4	11.2	4.9	1	3.7	1.9	2.9	7.2	0.5	3.9	2	5.1	2	4.5	6.7	4.1	5.4	3.2	4.4	9.6	11.6	26.3	9	1.6	2.8	2.3	1	2.6	14.9	6.9	2.3	4.1	2.9	3.3	1.3	1.4	1.4	4.5	8.5	11.6	40.2	2.9	1.2	8.7	2.2	1.8	1	5.5	6.9	1.5	0.9	15.3	32.5	34	22.1	15.3	11.8	0	0	0	0	0	0.8	0	0	0	0	0	0.1	0.3	0	0.1	0	0	0	0	0	0	0	0	0	0	0	1	1.4	0	0	0	0	0	0	76.5	0	0	0	2.8	0	0	0	0	35.1	0	1.2	0	0	0	0.1	0.3	0	8	0	0.2	0	0	0	13.4	39.6	0	6.8	6	0.1	21.5	34	6.8	3.1	21.4	15.3	0.9	0	2.5	15.3	0	0	0.4	32.5	22.1	13.1	5.5	0	11.8	5.1	8.4	1	3.3	5.4	3.2	9	1.6	6.9	8.7
CCR2	"CC-CKR-2, CD192, CKR2, CMKBR2, FLJ78302, MCP-1-R"	ENSG00000121807	C-C motif chemokine receptor 2	P41597	3	46353734-46360928	"CD markers, G-protein coupled receptors, Predicted membrane proteins"	"Host-virus interaction, Inflammatory response"	"G-protein coupled receptor, Receptor, Transducer"		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	6	blood: 96.3;lymphoid tissue: 36.1	Cell line enhanced	Detected in some		Karpas-707: 47.4;THP-1: 22.5;U-266/70: 109.2;U-266/84: 43.5	Low cancer specificity	Detected in many			Low region specificity	Detected in some			Cell type enhanced	Detected in many		basophil: 96.3	Low lineage specificity	Detected in all			Low region specificity	Detected in some			Low region specificity	Detected in single			CAB003793	Approved									CAB003793: AB_344889	unprognostic (1.09e-2)	unprognostic (6.28e-4)	unprognostic (3.49e-2)	unprognostic (6.35e-4)	unprognostic (1.89e-2)	unprognostic (4.16e-4)	unprognostic (8.06e-2)	prognostic favourable (5.87e-4)	unprognostic (6.33e-2)	unprognostic (3.27e-2)	unprognostic (3.12e-1)	unprognostic (1.56e-1)	unprognostic (5.52e-3)	unprognostic (1.29e-1)	unprognostic (3.35e-2)	unprognostic (4.88e-2)	unprognostic (4.19e-1)	2.5	1.3	0.6	20.7	0.8	0.9	1.9	0.5	0.8	4.3	5.8	0.5	1.5	5.6	2.6	2.4	6.1	2.2	2.5	1.8	0.6	0.6	3.7	1.8	8.6	30.1	1.6	0.1	1.7	1.7	0	0.8	2.1	1.8	3.7	4	2.6	10.2	3.5	0.8	1.3	7.3	5.6	1.5	36.1	3.7	1.5	0.5	3.6	2	3.5	5.9	5.8	1.7	1.6	29	96.3	28.4	2.5	19.3	13.5	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	47.4	0	0	0	0.2	0	0	0	0	0.4	0	0	0	0	0	0.2	0	0	22.5	0	0	0	0	0	109.2	43.5	0	0	0.8	0	96.3	28.4	0.4	2.5	2.6	19.3	1.6	5.2	4.2	29	0.3	0.1	0.1	0.7	2.5	0	23	2.3	13.5	0.6	0.8	0.5	0.8	0.6	0.6	1.6	0.1	1.8	0.5
CCR3	"CC-CKR-3, CD193, CKR3, CMKBR3"	ENSG00000183625	C-C motif chemokine receptor 3	P51677	3	46163604-46266706	"CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"	Host-virus interaction	"G-protein coupled receptor, Receptor, Transducer"		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level		Tissue enriched	Detected in many	25	blood: 175.9	Cell line enriched	Detected in some	9	RPMI-8226: 24.9	Not detected	Not detected			Low region specificity	Detected in single			Group enriched	Detected in some	22	basophil: 175.9;eosinophil: 152.0	Lineage enriched	Detected in many	92	granulocytes: 175.9	Not detected	Not detected			Not detected	Not detected			CAB003795	Uncertain									CAB003795: AB_562259	unprognostic (1.56e-2)	unprognostic (6.65e-3)	unprognostic (1.01e-1)	unprognostic (3.98e-2)	unprognostic (1.41e-1)	unprognostic (3.25e-3)	unprognostic (3.11e-7)	unprognostic (4.36e-2)	unprognostic (3.35e-2)	unprognostic (3.43e-2)	unprognostic (4.81e-2)	unprognostic (3.94e-2)	unprognostic (3.17e-6)	unprognostic (1.35e-2)	unprognostic (1.72e-2)	unprognostic (2.41e-1)	unprognostic (9.81e-2)	0.6	0.2	0.3	2.9	1.1	0.4	0.3	0.2	0.8	0.3	1.3	0.2	0.2	2.9	0.8	0.2	0.4	0.5	1.3	0.3	0.2	0.2	0.5	1.2	5.8	0.6	0.3	0.2	0.2	0.3	0	0.3	7	0.7	1	1.4	0.9	2.4	0.2	3.2	3.6	5.1	1.6	0.5	2.7	2.2	0.4	0.2	0.6	1.8	2.8	0.6	4	0.3	0	0.2	175.9	0	0	1.9	0.3	0.4	0	0	0	0	0	0.4	0	0	0	0	0.6	2.2	0	0.7	0	0.2	0	0.3	0	0	0	0	0	0	0	0.1	0.1	0	1.1	0	0	0	0	1	0	0.4	0.1	0.3	0.1	0	0.2	0	24.9	0	2	0.1	0	0	0.7	0	0	0.6	0	0.1	0.2	0	0.1	2.7	2.1	0	0	0.5	0	175.9	0	152	0	0	0	0	0.1	0	0	0	0	0	7.3	0	0	0.2	1.9	0.3	0.3	1.1	0.2	0.8	0.2	0.2	0.3	0.2	0.7	0.2
CCR4	"CC-CKR-4, CD194, ChemR13, CKR4, CMKBR4, k5-5"	ENSG00000183813	C-C motif chemokine receptor 4	P51679	3	32951574-32956349	"CD markers, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level		Group enriched	Detected in many	5	blood: 28.9;lymphoid tissue: 57.1	Cell line enriched	Detected in some	17	HDLM-2: 65.5	Low cancer specificity	Detected in many			Not detected	Not detected			Cell type enriched	Detected in some	5	T-reg: 28.9	Lineage enriched	Detected in single	48	T-cells: 28.9	Not detected	Not detected			Low region specificity	Detected in all			HPA031613	Approved		Supported	Plasma membrane				Plasma membrane		HPA031613: AB_10601096	unprognostic (4.63e-3)	unprognostic (8.70e-3)	unprognostic (2.82e-3)	unprognostic (2.64e-3)	unprognostic (1.18e-1)	unprognostic (4.59e-7)	unprognostic (3.02e-1)	unprognostic (5.05e-3)	unprognostic (1.53e-2)	unprognostic (1.69e-2)	unprognostic (1.75e-1)	unprognostic (2.17e-1)	unprognostic (9.88e-3)	unprognostic (2.04e-1)	unprognostic (5.53e-4)	unprognostic (1.54e-1)	unprognostic (1.40e-1)	1.5	0.6	0.3	12.6	0.4	1.5	1.1	0.3	0.3	1.1	1.1	0.1	0.7	0.4	1	0.6	1.6	0.8	3.8	0.8	0.3	0.3	1.8	0.9	6	24.1	0.3	0	0.5	0.5	0.5	0.5	0.1	0.1	1.5	1.2	0.8	4.3	0.2	1.8	2.2	5	0.4	0.4	10.2	1.3	2.7	0	57.1	1.3	2.8	29.7	8.6	1.1	0.2	0.2	0.5	0.1	0.1	28.9	0.8	0	0	0	0	0	0	0.1	0	0	0.1	0	0.1	0.1	0	0	0	0.1	0	0	0	65.5	0	3.9	0.2	0	0	0	0.1	0	0	0.1	0	0	1	0.2	0	0	0.5	0	0	0	0	0	0	0	0.1	0	0	0.2	0	0	0	0	0.1	0	0.1	0.1	0.1	0	0	0	0.1	0	0	0.5	0.1	0.1	0.2	0.1	0.2	0.1	6	1.8	0	0.2	0.1	0.1	0.5	0.1	0.1	0.2	28.9	0.8	0.3	0.4	0.3	0.3	0.3	0.3	0.3	0	0.1	0
CCR5	"CC-CKR-5, CD195, CKR-5, CKR5, CMKBR5, IDDM22"	ENSG00000160791	C-C motif chemokine receptor 5 (gene/pseudogene)	P51681	3	46370854-46376206	"CD markers, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"	Host-virus interaction	"G-protein coupled receptor, Host cell receptor for virus entry, Receptor, Transducer"	"Diabetes mellitus, FDA approved drug targets"	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 24.5	Group enriched	Detected in some	17	Karpas-707: 11.8;U-266/84: 5.0	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Cell type enhanced	Detected in many		MAIT T-cell: 24.5	Lineage enriched	Detected in many	4	T-cells: 24.5	Low region specificity	Detected in many			Low region specificity	Detected in many														unprognostic (4.32e-3)	unprognostic (1.94e-3)	unprognostic (1.89e-3)	prognostic favourable (7.42e-5)	unprognostic (1.80e-2)	prognostic favourable (9.33e-5)	unprognostic (3.38e-3)	unprognostic (9.90e-3)	unprognostic (7.65e-2)	unprognostic (6.22e-2)	unprognostic (1.36e-1)	unprognostic (5.34e-2)	unprognostic (1.14e-3)	unprognostic (8.34e-2)	unprognostic (4.69e-2)	unprognostic (3.14e-2)	unprognostic (2.42e-2)	7.1	2.3	3.4	13.8	6.1	0.8	2.1	0.8	2.5	2.3	3	3	0.8	3.8	3.7	4	2.6	2.6	5	3.6	1.6	2	2.7	3	9.3	11.9	8.1	0.5	3	2.1	0.4	1.9	1.2	4	2.8	3.8	3.5	4.4	2.5	0.8	1.1	7.2	2.9	6.1	14.6	6	0.9	5.9	2	2.6	1.5	13.9	5.7	2	0.3	5.5	5.6	2.1	3.2	24.5	1.5	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0.2	0	0	0	0	0	0	0	11.8	0	0	0.1	0.1	0	0	0	0.1	0.1	0	0.1	0	0	0	0	0	0.1	0.4	0.2	0	0	0	0	0.4	5	0	0	0.3	0	5.6	1.1	0	6.7	2.1	24.5	0.3	2.9	9.7	5.5	0	0.3	2.6	0.3	3.2	0	5.2	4.5	1.5	3.4	6.1	0.8	2.5	1.6	2	8.1	0.5	4	5.9
CCR6	"BN-1, CD196, CKR-L3, CMKBR6, DCR2, DRY-6, GPR-CY4, GPR29, STRL22"	ENSG00000112486	C-C motif chemokine receptor 6	P51684	6	167111807-167139696	"CD markers, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	5	blood: 30.7;intestine: 9.9;lymphoid tissue: 33.7	Cell line enriched	Detected in some	5	Hep G2: 14.1	Not detected	Not detected			Low region specificity	Detected in some			Group enriched	Detected in many	4	MAIT T-cell: 30.7;memory B-cell: 23.8;memory CD4 T-cell: 11.9;naive B-cell: 28.2;T-reg: 20.9	Group enriched	Detected in many	5	B-cells: 28.2;T-cells: 30.7	Region enriched	Detected in single	8	basal ganglia: 0.9	Not detected	Not detected			"CAB006820, HPA014488"	Approved									"CAB006820: , HPA014488: AB_1846639"	unprognostic (1.12e-2)	unprognostic (2.92e-2)	unprognostic (2.07e-3)	unprognostic (2.08e-1)	unprognostic (8.43e-2)	unprognostic (2.05e-4)	unprognostic (2.39e-1)	unprognostic (4.98e-3)	unprognostic (1.29e-1)	unprognostic (1.40e-1)	unprognostic (4.19e-2)	unprognostic (4.26e-2)	unprognostic (2.68e-4)	unprognostic (3.74e-2)	unprognostic (7.96e-2)	unprognostic (2.26e-1)	unprognostic (1.77e-1)	0.5	0.3	1	24.4	1.5	1.3	1.1	0.3	1.1	0.6	3	0.1	0	1.4	0.3	0.8	2.1	0.5	3.1	0.3	0.9	0.9	1	0.5	3.3	27.3	0.6	0	0.3	0.3	0	0.4	0.5	0.2	0.5	1.2	0.3	5	0.8	0.3	1.1	9.9	0	0.4	23.4	2.2	2.7	0.1	3.7	0.6	2.1	33.7	4.8	0.4	28.2	5.4	0.2	0	0.4	30.7	2.5	0.1	0.2	0.2	0.2	0	0	0.2	0	0	0	0	1.5	0.2	1.3	0.3	0	0	0.3	0.2	0.1	2.6	0.7	0.1	0.3	14.1	0	0.7	0.2	0	0.1	0	0	0	0.1	0.3	0	0	0.1	0.2	0.1	0	0.2	0.2	0.2	0.4	0	0.8	0.4	0	0	0.1	0	0.1	0	0	0.8	0.1	0.3	0.5	0.3	0.4	0	0.2	0.6	0	0	0.1	1.6	0	30.7	23.8	11.9	4.7	5.4	28.2	0.1	0	0.2	0.4	0	0.6	20.9	2.5	1	1.5	0.3	1.1	0.9	0.9	0.6	0	0.2	0.1
CCR7	"BLR2, CD197, CDw197, CMKBR7, EBI1"	ENSG00000126353	C-C motif chemokine receptor 7	P32248	17	40553769-40565472	"Cancer-related genes, CD markers, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	Cancer-related genes	Evidence at protein level	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	11	blood: 252.3;lymphoid tissue: 110.6	Cell line enriched	Detected in some	79	HDLM-2: 171.5	Low cancer specificity	Detected in many			Not detected	Not detected			Cell type enhanced	Detected in many		naive CD4 T-cell: 252.3	Lineage enriched	Detected in many	4	T-cells: 252.3	Not detected	Not detected			Low region specificity	Detected in all			"CAB003796, HPA031383, HPA074467"	Enhanced		Approved	Mitochondria				Mitochondria		"CAB003796: AB_562261, HPA031383: , HPA074467: "	prognostic favourable (3.84e-4)	prognostic favourable (8.03e-6)	unprognostic (2.26e-3)	unprognostic (1.32e-3)	unprognostic (2.35e-3)	prognostic favourable (7.61e-7)	unprognostic (2.71e-4)	unprognostic (2.58e-2)	unprognostic (4.48e-2)	unprognostic (4.68e-4)	unprognostic (1.10e-2)	unprognostic (3.11e-1)	unprognostic (1.08e-3)	unprognostic (3.12e-1)	prognostic unfavourable (7.72e-4)	unprognostic (1.02e-1)	unprognostic (7.95e-2)	2.8	0.4	0.2	26	0.2	5.2	1.7	0.2	0.3	2.2	1.2	0.3	0.8	0.3	1.2	0.5	1.4	2.3	2	1.9	0.2	0.2	1.5	1.7	3.4	110.6	0.3	0.2	1.5	0.3	0	1	1	0.4	1.3	2.1	0.7	8.4	0.2	0.2	1.1	16.2	0.2	0.4	20.3	1.8	1.2	0.3	57.1	2	1.2	53.8	4.2	1.3	58.8	2.9	2.3	0.3	44.1	252.3	109.3	0	0.1	0	0	0	0	2.1	0	0	0	0	0	0	0	0.1	0	0	0	0	0	171.5	0	0	0	0	0	0.4	0	0	0	0	0	0	0.1	0	0	0	0.1	0.3	0	0	0.5	0.1	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0.2	0	0.9	0.1	1.1	0.2	0	0	1.1	0.3	0.2	3.1	0.1	3.6	37.2	53.3	15.3	0.2	58.8	252.3	133.9	2.3	44.1	0.2	2.9	30.3	109.3	0.2	0.2	0.2	0.3	0.2	0.2	0.3	0.2	0.4	0.3
CCR8	"CDw198, CKR-L1, CMKBR8, CMKBRL2, CY6, GPR-CY6, TER1"	ENSG00000179934	C-C motif chemokine receptor 8	P51685	3	39329706-39333511	"CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level		Group enriched	Detected in some	7	blood: 19.8;lymphoid tissue: 19.3;urinary bladder: 5.3	Cell line enriched	Detected in some	22	HDLM-2: 48.9	Low cancer specificity	Detected in some			Not detected	Not detected			Cell type enriched	Detected in some	5	T-reg: 19.8	Lineage enriched	Detected in single	30	T-cells: 19.8	Not detected	Not detected			Low region specificity	Detected in all			HPA042383	Enhanced									HPA042383: 	unprognostic (2.16e-1)	unprognostic (2.12e-2)	unprognostic (2.91e-2)	unprognostic (1.04e-1)	unprognostic (2.38e-2)	unprognostic (7.63e-4)	unprognostic (3.31e-1)	unprognostic (1.27e-1)	unprognostic (2.30e-3)	unprognostic (3.37e-2)	unprognostic (7.40e-2)	unprognostic (2.99e-1)	unprognostic (4.65e-8)	unprognostic (7.96e-2)	unprognostic (2.24e-2)	unprognostic (2.56e-1)	unprognostic (4.14e-1)	0.3	0.2	0.2	3.1	0.2	0	0.3	0.2	0.2	0.3	0.5	0.1	0.1	0	0.3	0.1	0.8	0.1	2.1	0.2	0.2	0.2	0.5	0.3	1.4	2.8	0.1	0.1	0.2	0.3	0	0.2	0.1	0.1	0.4	1.3	0.1	0.5	0.1	0.2	1	1.2	0.1	0.4	1.7	0.8	0.3	0.1	19.3	0.4	1.2	3.5	5.3	0.3	0	0	0	0	0.6	19.8	0.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	48.9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	1.2	2.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	1.8	0	0	0.2	0	0	0.6	0	0	19.8	0.6	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.1	0.1	0.1
CCR9	"CDw199, GPR-9-6, GPR28"	ENSG00000173585	C-C motif chemokine receptor 9	P51686	3	45886504-45903177	"CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"	Host-virus interaction	"G-protein coupled receptor, Receptor, Transducer"		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level		Tissue enriched	Detected in some	7	lymphoid tissue: 130.2	Cell line enriched	Detected in single	324	MOLT-4: 48.7	Not detected	Not detected			Not detected	Not detected			Group enriched	Detected in some	5	memory B-cell: 17.5;naive B-cell: 9.2;T-reg: 5.7	Group enriched	Detected in many	42	B-cells: 17.5;T-cells: 5.7	Low region specificity	Detected in some			Low region specificity	Detected in all			CAB006839	Uncertain									CAB006839: 	unprognostic (3.08e-3)	unprognostic (3.37e-1)	unprognostic (5.56e-2)	unprognostic (1.78e-1)	unprognostic (8.65e-3)	unprognostic (7.88e-3)	unprognostic (4.54e-1)	unprognostic (2.94e-2)	unprognostic (3.00e-1)	unprognostic (1.77e-1)	unprognostic (8.06e-2)	unprognostic (1.16e-1)	unprognostic (2.59e-2)	unprognostic (1.88e-1)	unprognostic (4.34e-1)	unprognostic (2.27e-1)	unprognostic (7.20e-3)	0.1	0.1	0.1	1.8	0.1	0.7	0.1	0.1	0.3	0.1	2.2	0.1	0.1	7	0.2	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.4	0.2	0.2	0.8	0.1	0.1	0.1	0.1	0	0.2	0.1	0.1	0.1	0.3	0.1	0.1	0.2	0.2	0.1	10.7	0.1	0.2	2.2	0.3	0.1	0.1	130.2	0.1	0.1	0.7	0.1	0.1	17.5	0.2	0	0	0	5.7	1.8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	48.7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0.2	0	0.3	17.5	2.2	1.8	0.2	9.2	0.3	0.1	0	0	0	0.2	5.7	1.8	0.1	0.1	0.1	0.3	0.1	0.1	0.1	0.1	0.1	0.1
CD101	"IGSF2, V7"	ENSG00000134256	CD101 molecule	Q93033	1	117001750-117036476	"CD markers, Predicted membrane proteins"				Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 33.7;lung: 17.5	Cell line enriched	Detected in some	9	HMC-1: 24.7	Low cancer specificity	Detected in many			Low region specificity	Detected in many			Cell type enhanced	Detected in many		eosinophil: 33.7	Group enriched	Detected in many	17	dendritic cells: 12.2;granulocytes: 33.7;monocytes: 17.4	Not detected	Not detected			Low region specificity	Detected in some			"HPA049527, HPA057763"	Approved		Uncertain	Mitochondria		42000	42000	Mitochondria		"HPA049527: , HPA057763: "	unprognostic (1.25e-1)	unprognostic (7.95e-3)	unprognostic (5.40e-3)	unprognostic (4.10e-3)	unprognostic (2.62e-1)	unprognostic (4.00e-2)	unprognostic (3.03e-2)	unprognostic (3.58e-3)	unprognostic (3.57e-2)	unprognostic (7.29e-3)	unprognostic (3.15e-1)	unprognostic (4.54e-2)	unprognostic (7.15e-6)	unprognostic (7.00e-2)	unprognostic (8.07e-2)	unprognostic (5.05e-2)	unprognostic (5.28e-2)	0.9	1.7	0.8	11.3	1.1	5.7	0.8	0.2	1.1	1.3	5	0.6	1.2	4.6	1.7	0.4	1.8	1.5	1.4	2.6	1.1	0.5	1.3	0.8	17.5	4	1.3	0.2	1	2.3	0	0.8	0.5	1.1	1.6	3.2	0.7	2.1	1.3	0.5	1.8	10.9	1.6	2	7.8	1.8	0.9	1.2	6.4	0.9	2.4	7.4	2.4	1.8	0.1	12.2	33.7	17.4	0	1.2	2.5	0.4	0	0.8	2.7	0	0	0	0	0	0	0	0.1	0	0	0.3	0	1.2	1.8	0.1	0	0	1	0.1	0.8	0	0	0.1	24.7	0.3	1.2	0	0.1	0.2	0.1	0.6	0.1	1.5	0	2.8	0.8	0	0	0.5	0	0.6	0.6	0.4	0.6	0.4	0.5	0.3	0.9	0.6	0.5	0.1	0.4	0.5	0.2	0.2	0.1	0	0.7	1.9	1.5	0	7.6	33.7	0.1	10	0.7	0.1	0.2	1.2	12.2	0	0.3	1.2	0.3	0	17.4	0	1.1	2.5	0.8	1.1	0.2	1.1	1.1	0.5	1.3	0.2	1.1	1.2
CD109	"CPAMD7, DKFZp762L1111, FLJ38569"	ENSG00000156535	CD109 molecule	Q6YHK3	6	73695785-73828316	"CD markers, Plasma proteins, Predicted membrane proteins"		"Protease inhibitor, Serine protease inhibitor"		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enriched	Detected in many	7	parathyroid gland: 203.4	Cell line enhanced	Detected in many		ASC TERT1: 61.6;BJ hTERT+: 37.8	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Cell type enhanced	Detected in some		myeloid DC: 2.6	Low lineage specificity	Detected in many			Low region specificity	Detected in some			Low region specificity	Detected in all			"HPA008992, HPA015723"	Enhanced		Supported	Plasma membrane		120000000	120000000	Plasma membrane		"HPA008992: , HPA015723: "	unprognostic (2.28e-1)	unprognostic (1.03e-1)	unprognostic (7.76e-2)	unprognostic (1.52e-2)	unprognostic (9.17e-3)	unprognostic (1.36e-1)	unprognostic (1.03e-3)	unprognostic (1.23e-3)	unprognostic (7.49e-2)	unprognostic (2.47e-1)	unprognostic (1.15e-3)	unprognostic (8.81e-2)	prognostic unfavourable (2.65e-4)	prognostic unfavourable (7.96e-5)	unprognostic (9.50e-2)	unprognostic (2.02e-1)	prognostic unfavourable (4.68e-4)	27.4	1.5	1.6	1.9	2.2	1.9	6.5	0.4	1.9	15	7.1	3.4	2	1.5	22.5	8.5	22.4	3.4	2.4	8.2	1.8	1.4	3.5	1.4	14.5	1.4	1.7	1.4	2.8	1.2	203.4	0.6	5	3	7.1	2.1	0.6	4.2	2.2	4.1	12.4	2.4	12.6	4.5	1.7	1.5	3.3	2.8	6.3	1.7	16.8	4.7	8.7	8	0.3	2.6	1.4	0.4	0.6	0.4	0.3	9.2	8.3	0.5	0	12.7	61.6	0	8.4	37.8	2.8	6.1	0	5.4	0	5.2	17.3	26.1	0.9	16.9	3.7	2.5	1.4	3.3	6.8	1.4	2.7	0	0	16.9	13.4	5.2	21.1	20	0	0	12.6	0.2	0.2	0	0.6	5.4	0.7	2.4	11.4	1.2	1	0	0	19.1	0.1	8.3	0.2	1.5	18.5	26.4	3.7	4.7	7.2	0.1	5.2	0	10.6	0	23.4	0.6	0.4	0.3	0.2	0.2	0.1	0.2	0.3	0.2	2.6	0.3	0.4	0.2	1.4	0.6	0.2	1.4	0.1	0.3	1.6	2.2	0.4	1.9	1.8	1.4	1.7	1.4	3	2.8
CD14		ENSG00000170458	CD14 molecule	P08571	5	140631728-140633701	"Cancer-related genes, CD markers, Plasma proteins, Predicted secreted proteins"	"Immunity, Inflammatory response, Innate immunity"		Cancer-related genes	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in all	4	blood: 189.4;liver: 165.8	Cell line enhanced	Detected in many		A549: 8.9;CACO-2: 13.6;SiHa: 16.3	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in many		classical monocyte: 189.4	Group enriched	Detected in many	5	granulocytes: 52.3;monocytes: 189.4	Low region specificity	Detected in all			Low region specificity	Detected in all			"HPA001887, HPA002127, CAB033631, CAB072865, CAB072866"	Enhanced		Supported	Vesicles	Secreted to blood	15000000000	15000000000	Vesicles		"CAB033631: AB_781932, CAB072865: , CAB072866: , HPA001887: AB_1078442, HPA002127: AB_1078440"	unprognostic (1.92e-1)	unprognostic (1.68e-1)	unprognostic (3.42e-3)	unprognostic (3.89e-2)	unprognostic (3.29e-2)	unprognostic (1.54e-1)	unprognostic (4.71e-3)	unprognostic (4.88e-2)	unprognostic (2.16e-1)	unprognostic (1.06e-1)	unprognostic (1.83e-1)	unprognostic (2.43e-1)	prognostic unfavourable (6.80e-5)	unprognostic (1.20e-2)	unprognostic (6.87e-3)	unprognostic (8.12e-2)	unprognostic (6.92e-2)	27.9	44.1	9	42.7	25.2	9.8	11.7	3.5	8.9	5.6	10	6	1.8	5.4	5.6	24	4.5	12	14.6	18.9	11.7	7.4	12.7	165.8	23.8	34.7	21.6	2.9	14.2	5.3	4.3	10.1	37.3	18.9	8.5	9.2	14.6	28.5	5.8	10.2	3.5	12.1	21.4	18.2	35.5	6.6	6.5	17.3	2.2	7.9	5.8	6.6	15.9	3.8	0.5	23.6	52.3	189.4	0.2	0.4	124.2	0.1	8.9	0.1	0.5	1.2	0.3	0.4	0.8	4.1	1.3	1.6	13.6	2.1	0.4	0.6	4.9	3.8	0	1.6	0.2	0.1	0.9	0.3	0.5	1.8	4.8	1	0.4	3.9	0.2	0.2	1.3	0	0.2	0.2	1.2	0.3	0	0.5	0.2	0.3	0.3	0.4	1.1	0.2	0	2.4	1	16.3	0.4	0.5	0.3	1.7	0.6	0.2	0.3	1.5	1.2	0.7	0.9	0.5	0.4	0.4	0.1	0.4	189.4	1	0.3	36.6	0.4	0.5	0.2	0.2	23.6	0.1	0.3	0.2	52.3	0.2	4.8	1.3	0.1	124.2	9	25.2	3.5	8.9	11.7	7.4	21.6	2.9	18.9	17.3
CD151	"PETA-3, RAPH, SFA-1, TSPAN24"	ENSG00000177697	CD151 molecule (Raph blood group)	P48509	11	832843-839831	"Blood group antigen proteins, CD markers, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters"	Host-virus interaction	Blood group antigen	"Deafness, Epidermolysis bullosa"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in many		ASC diff: 113.5	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all			Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB002428, HPA011906"	Supported					680000	680000			"CAB002428: AB_564129, HPA011906: AB_1846245"	unprognostic (1.50e-1)	unprognostic (1.12e-2)	unprognostic (5.47e-2)	unprognostic (5.45e-3)	unprognostic (4.10e-3)	unprognostic (2.45e-2)	prognostic unfavourable (5.58e-4)	prognostic unfavourable (9.46e-4)	unprognostic (5.47e-2)	unprognostic (2.41e-1)	unprognostic (1.02e-3)	unprognostic (3.31e-1)	unprognostic (4.39e-2)	unprognostic (6.23e-3)	unprognostic (3.24e-1)	prognostic favourable (6.92e-4)	unprognostic (7.83e-2)	63.1	28.1	7.4	19.1	8.1	3.4	133.2	7.9	11.3	39.8	36	9.5	37.8	23.2	55.7	45.3	43.1	29.3	63	85.2	7.3	7.9	52.8	47.2	45.8	16.3	7.5	10.3	29.8	82.7	27.8	14.1	58.6	10.7	52	16.5	31.2	62.9	41.1	19.2	17.1	46	62.4	6.7	15.8	31.7	20.8	5.5	2.4	43.2	27.1	16.1	35.9	34.9	2.1	8.1	14.9	14.3	5.2	4.8	6.5	39.5	54.8	7.9	23.7	113.5	47.2	12.4	62	42.3	31.3	26.5	28.5	56.5	0	24.8	92.6	36.1	7	54.7	7.9	14.8	26.9	10.9	16.9	21.7	43.2	8.8	15.2	45.6	36.6	18.3	32.3	36.9	13.3	5.1	46.7	22.2	0.2	10.4	5.2	65.8	2	16.4	8.5	69.6	11.5	10.9	12.2	57.4	32	10.8	12.9	10.7	63.1	42.6	21.1	13.7	34.3	6.9	7.1	0.4	42	9.2	23.5	14.9	12	9.6	4.2	12.6	4.8	2.1	3.5	3.6	8.1	1.5	1.5	2.2	5.7	5.2	14.3	1.3	2.1	6.5	7.4	8.1	7.9	11.3	7.3	7.9	7.5	10.3	10.7	5.5
CD160	"BY55, NK1, NK28"	ENSG00000117281	CD160 molecule	O95971	1	145719471-145739288	"CD markers, Predicted intracellular proteins"	"Adaptive immunity, Angiogenesis, Immunity, Innate immunity"	Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 33.9;brain: 15.2;intestine: 19.9;lymphoid tissue: 17.4	Low cell line specificity	Detected in many			Not detected	Not detected			Region enriched	Detected in many	5	cerebellum: 15.2	Group enriched	Detected in many	9	gdT-cell: 33.9;MAIT T-cell: 14.4;memory CD8 T-cell: 22.9;naive CD8 T-cell: 27.3;NK-cell: 23.2	Group enriched	Detected in many	11	NK-cells: 23.2;T-cells: 33.9	Not detected	Not detected												Intracellular and membrane						unprognostic (6.54e-4)	unprognostic (1.06e-1)	unprognostic (4.25e-2)	unprognostic (6.91e-2)	unprognostic (3.33e-1)	unprognostic (3.40e-2)	unprognostic (1.35e-1)	unprognostic (8.25e-3)	unprognostic (5.76e-2)	unprognostic (2.68e-1)	unprognostic (2.24e-2)	unprognostic (7.49e-3)	unprognostic (3.48e-5)	unprognostic (4.05e-2)	unprognostic (2.03e-1)	unprognostic (2.89e-2)	unprognostic (2.92e-4)	0.6	0.2	2.2	3.6	2.6	5.1	0.6	15.2	3.1	0.8	9.3	0.4	0.3	5.6	0.8	1.4	0.9	0.6	1.2	0.6	1.6	2.2	0.5	5.9	3.8	6	1.6	0.3	1.1	2.2	0	0.4	1.8	0.6	1.3	1	0.9	3	0.4	1	1.1	19.9	1.4	1	17.4	0.8	0.8	0.3	2.9	0.4	0.3	3.1	0.7	0.3	0.2	0.3	2.7	0.4	23.2	33.9	20.2	1.3	1	1.6	0.9	0	0.3	0.3	0.1	0	0.2	0.1	0.6	0.1	1.7	1.3	0.2	1.6	0.2	0.2	0.1	3.5	1.6	3.1	4.6	1.2	0.1	2	3.2	0.2	0.4	0.1	0.3	0	0.8	1.5	0.1	1.5	1.2	4	1.1	2.8	0.3	0.2	1	0	0.6	1.2	1.5	0.9	1.3	0.6	1.5	2	1.8	1.3	0.6	0.7	3	2.3	1.6	0.6	0.7	2.4	0.2	2.7	0.1	0.1	33.9	0.1	14.4	0.2	0.4	22.9	0	0.2	0.2	27.3	1.7	23.2	0.4	0.3	0	20.2	2.2	2.6	15.2	3.1	1.6	2.2	1.6	0.3	0.6	0.3
CD163	"M130, MM130, SCARI1"	ENSG00000177575	CD163 molecule	Q86VB7	12	7470813-7503893	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	"Acute phase, Inflammatory response"			Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		lymphoid tissue: 113.6	Cell line enhanced	Detected in some		ASC diff: 2.1;CACO-2: 1.9;HSkMC: 5.9	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Group enriched	Detected in some	10	classical monocyte: 28.2;myeloid DC: 25.3	Group enriched	Detected in many	40	dendritic cells: 25.3;monocytes: 28.2	Low region specificity	Detected in many			Low region specificity	Detected in single			"CAB002432, HPA046404, HPA051974"	Enhanced		Approved	Plasma membrane	Secreted to blood	1600000000	1600000000	Plasma membrane		"CAB002432: AB_563510, HPA046404: AB_2679655, HPA051974: AB_2681678"	unprognostic (1.13e-1)	unprognostic (2.13e-1)	unprognostic (5.02e-3)	unprognostic (2.72e-1)	unprognostic (6.17e-3)	unprognostic (2.09e-1)	unprognostic (1.02e-1)	unprognostic (1.21e-1)	unprognostic (2.78e-1)	prognostic unfavourable (7.27e-4)	unprognostic (1.04e-1)	unprognostic (6.50e-2)	unprognostic (1.84e-2)	unprognostic (8.77e-2)	unprognostic (4.95e-2)	unprognostic (1.61e-1)	unprognostic (1.20e-2)	66.7	23.8	2.1	44.6	7.2	4.1	23.2	2.8	4.9	11.3	25.3	1.6	1.4	3.5	7.2	16.8	11.3	20.1	13.2	15.7	2.8	1.8	43.9	38.9	81	99.8	6.9	0.5	10.3	6.7	3.1	11.7	31.9	9.9	6.8	6.5	9.8	8.6	2.2	15.2	4	12.5	37.2	5.7	113.6	10.2	19.6	4.3	3.4	15.5	2.9	3.5	20.1	8.3	0	25.3	0.6	28.2	0	0	6.3	0	0	0	0	2.1	1.1	0.4	0	0.1	0	0	1.9	0	0	0	0	0.3	0	0	0	0	0	0.2	0	0.6	0	0.6	0.3	5.9	0	0.4	0.6	0	0	0	0.2	0	0.1	0.6	0.6	0	0.1	1	0.1	0	0	0.3	0.6	0.1	0.2	0	0	0.3	0	1.1	0.3	0.2	0	0.3	0	0	0.3	0	0.1	0.5	28.2	0.1	0	2.5	0	0	0	0	25.3	0	0	0	0.6	0	0	0.3	0	6.3	2.1	7.2	2.8	2.4	2.8	1.8	6.9	0.5	9.9	4.3
CD163L1	"CD163B, M160, SCARI2, WC1"	ENSG00000177675	CD163 molecule like 1	Q9NR16	12	7346685-7479897	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"				Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		intestine: 18.4;lymphoid tissue: 31.2	Cell line enhanced	Detected in many		HDLM-2: 8.2;HUVEC TERT2: 8.8;TIME: 8.3;U-87 MG: 19.4	Low cancer specificity	Detected in many			Low region specificity	Detected in many			Not detected	Not detected			Not detected	Not detected											HPA015663	Enhanced		Approved	"Nucleoplasm,Centrosome,Cytosol"	Intracellular and membrane	170000	170000	"Centrosome, Cytosol"	Nucleoplasm	HPA015663: AB_2072575	unprognostic (1.25e-3)	unprognostic (1.77e-1)	unprognostic (1.42e-2)	unprognostic (7.46e-3)	unprognostic (2.29e-2)	unprognostic (7.79e-2)	unprognostic (9.39e-2)	unprognostic (4.44e-3)	unprognostic (1.07e-1)	unprognostic (8.35e-2)	unprognostic (1.08e-1)	unprognostic (3.08e-1)	unprognostic (1.26e-6)	unprognostic (8.59e-2)	unprognostic (1.17e-1)	unprognostic (1.52e-1)	unprognostic (1.69e-1)	5	1.7	1.2	19.1	1.2	0	2.5	0.8	1.6	1.4	9.2	0.3	1	5.5	1.2	8.5	1.8	1.3	2.6	3.2	1.2	1	1.7	1.5	2.8	14.6	1.1	0.7	1	1	0.1	1.4	6.8	3.3	1.4	15.1	2.7	2.5	1.4	1.1	1.4	18.4	1.8	1	31.2	2.6	4.6	0.2	9.5	1.7	6.4	12.9	4.3	1.2	0.2	0.7	0.7	0.8	0	0	0.2	0.2	0.4	0.2	0	1	0.3	0	0.8	1.8	0.2	0.8	0	1.4	0	0.3	0.8	0	0	1.1	1.4	8.2	0	0	0.4	1.2	0	0.5	0	0.3	0	0.2	3.3	8.8	0.1	4.7	5.2	0	0	6.5	0.2	0	1.5	1.5	1.8	0	0	1.2	5.5	4.3	6.8	0	0	5.4	8.3	3	2.7	0.3	0	0.1	0.1	0	19.4	0.4	5.7	0	0.8	0.7	0	0.8	0	0	0	0	0.7	0.2	0	0	0	0	0	0	0	0.2	1.2	1.2	0.8	1.6	1.2	1	1.1	0.7	3.3	0.2
CD164	"DFNA66, MGC-24, MUC-24"	ENSG00000135535	CD164 molecule	Q04900	6	109366514-109382812	"CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Myogenesis"		"Deafness, Non-syndromic deafness"	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Low cell line specificity	Detected in all			Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all			Low region specificity	Detected in all			Low region specificity	Detected in all			HPA010636	Uncertain				Intracellular and membrane					HPA010636: AB_1078447	unprognostic (1.23e-2)	unprognostic (1.61e-2)	unprognostic (3.89e-2)	unprognostic (2.21e-1)	unprognostic (1.47e-1)	unprognostic (1.04e-2)	unprognostic (1.97e-3)	unprognostic (1.80e-1)	unprognostic (1.30e-1)	unprognostic (1.09e-1)	unprognostic (8.88e-2)	unprognostic (1.38e-1)	unprognostic (7.11e-2)	unprognostic (1.29e-1)	unprognostic (1.84e-1)	unprognostic (3.01e-1)	unprognostic (1.51e-1)	85	37.6	17.1	37.2	28.5	38	72.9	11.2	19.2	34.2	55.2	31.1	57.4	50.5	35.6	44.4	29.6	31.7	58.1	32	18.6	22.6	67.4	66.1	52.5	60.9	45.2	16.7	38	49.2	30.4	55	106.6	28.2	33.4	57.4	44.1	75.1	49.6	38.5	30.6	100.2	41.5	42.8	43.2	55.8	38.1	30.2	50.7	73.3	25	34.7	40.3	37.2	32.6	54.2	66.1	48.9	61.1	46.7	83.2	20.2	11.3	6	38.1	87.1	84.2	36.9	38.1	48.1	34.3	49.4	22.7	30.9	16.4	36.9	41.2	20	22.6	24.4	53	33.5	22.6	27.8	12.1	27.3	51.7	32.8	66.4	65.9	48.4	33.9	31	31.7	26.5	43.7	47.3	21.2	30.9	40.9	9	18.5	20.4	17.8	20.6	50.5	27.3	6.4	13	23.2	31.1	55.5	27.2	43.5	32	22.4	16.4	32.1	30.1	16.6	23.3	18.9	40.3	38.5	23	66.1	47.6	39.9	44.7	48.9	46.4	32.6	36.5	40.9	47.1	28.8	38.3	40.7	32.7	61.1	45.5	54.2	46.7	83.2	17.1	28.5	11.2	19.2	18.6	22.6	45.2	16.7	28.2	30.2
CD180	"LY64, Ly78, RP105"	ENSG00000134061	CD180 molecule	Q99467	5	67179613-67196799	"CD markers, Predicted membrane proteins"	"Immunity, Inflammatory response, Innate immunity"	Receptor		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 29.2;lymphoid tissue: 38.7	Group enriched	Detected in some	10	Daudi: 22.8;Karpas-707: 21.4;U-266/70: 17.4;U-266/84: 24.2;U-698: 6.4	Low cancer specificity	Detected in many			Low region specificity	Detected in many			Cell type enhanced	Detected in many		memory B-cell: 28.7;naive B-cell: 29.2	Group enriched	Detected in many	23	B-cells: 29.2;dendritic cells: 8.5;monocytes: 11.6	Low region specificity	Detected in many			Low region specificity	Detected in many			HPA003740	Enhanced									HPA003740: AB_1078450	unprognostic (9.33e-2)	unprognostic (4.58e-2)	unprognostic (2.81e-3)	unprognostic (5.85e-3)	unprognostic (2.25e-2)	unprognostic (4.04e-3)	unprognostic (1.09e-1)	unprognostic (4.95e-2)	unprognostic (5.83e-2)	unprognostic (3.71e-1)	unprognostic (2.16e-1)	unprognostic (1.46e-1)	unprognostic (2.09e-1)	unprognostic (1.16e-1)	unprognostic (3.70e-2)	unprognostic (1.21e-1)	unprognostic (2.18e-2)	9.6	1.6	1.4	24.3	3.2	1.9	5.7	0.6	1.3	1	2.1	1.6	0	1.8	0.9	1	1.7	1.3	1.5	4.6	1.2	1.1	2.5	2.7	3	30.4	4.1	0.6	1.5	1	0.2	1.1	2.9	2.2	1.5	2.5	0.4	3.1	0.4	0.6	0.7	8.4	1.6	3.5	38.7	1.9	0.8	2.8	1.9	1.2	0.2	31.3	4.1	0.8	29.2	8.5	0.3	11.6	0.7	0	2.8	0.1	0	0	0	0	0	0	0	0	0	0	0	0	22.8	0.4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	21.4	0	0	0	0.3	0	0	0.1	0	0.3	0	0	0	0	0	0	0	0	1.7	0	0	0	0.3	0.1	17.4	24.2	6.4	0	1.4	0	0	4.1	0.3	0	7.4	0	28.7	0	0	8	29.2	0	0	0.3	0.7	11.6	8.5	0	2.8	1.4	3.2	0.6	1.3	1.2	1.1	4.1	0.6	2.2	2.8
CD19		ENSG00000177455	CD19 molecule	P15391	16	28931939-28939346	"CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins"	"Adaptive immunity, Immunity"		FDA approved drug targets	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in some	6	blood: 47.6;intestine: 16.7;lymphoid tissue: 40.3	Cell line enhanced	Detected in some		Daudi: 52.1;REH: 27.6;U-698: 11.8	Low cancer specificity	Detected in many			Not detected	Not detected			Group enriched	Detected in some	93	memory B-cell: 36.0;naive B-cell: 47.6	Lineage enriched	Detected in single	106	B-cells: 47.6	Not detected	Not detected			Low region specificity	Detected in all			CAB016110	Enhanced									CAB016110: AB_626952	unprognostic (3.27e-3)	unprognostic (1.19e-3)	unprognostic (6.63e-2)	unprognostic (1.09e-2)	unprognostic (8.68e-3)	unprognostic (3.11e-5)	unprognostic (2.61e-1)	unprognostic (6.96e-3)	unprognostic (1.29e-2)	unprognostic (4.29e-3)	unprognostic (1.12e-1)	unprognostic (1.30e-1)	unprognostic (5.41e-6)	unprognostic (2.06e-1)	unprognostic (1.83e-1)	unprognostic (1.36e-1)	unprognostic (2.07e-1)	0.4	0.2	0.2	37	0.2	2.3	0.2	0.1	0.2	0.2	0.9	0.1	0	0.2	0.2	0.1	1.4	0.3	0.2	0.2	0.2	0.2	0.7	0.3	1.4	32	0.2	0	0.3	0.2	0	0.2	0	0	0.4	0.5	0.1	5.9	0	0.1	0.1	16.7	0	0.2	40.3	1.3	1.9	0	2.4	0.7	0.2	38.7	1.8	0.3	47.6	0	0.4	0.1	0	0.1	1.8	0	0	0	0	0	0	0	0	0	0	0	0	0	52.1	0.4	0	0	0	0	0	0	0	0	0	0.1	0	0	0.7	0	0	0	0	0	0.2	0	0	0	0	0.2	0	0	27.6	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	11.8	0	0.1	0	0.4	0	0	0	0	0	36	0	0	0	47.6	0.1	0	0.3	0	0.1	0	0	1.8	0.2	0.2	0.1	0.2	0.2	0.2	0.2	0	0	0
CD1A	CD1	ENSG00000158477	CD1a molecule	P06126	1	158254137-158258269	"CD markers, Predicted membrane proteins"	"Adaptive immunity, Immunity"			Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enriched	Detected in some	5	lymphoid tissue: 105.1	Cell line enriched	Detected in single	106	MOLT-4: 35.7	Low cancer specificity	Detected in many			Not detected	Not detected			Group enriched	Detected in some	23	classical monocyte: 5.9;intermediate monocyte: 3.7;memory B-cell: 6.8;myeloid DC: 10.2;naive B-cell: 5.4	Group enriched	Detected in many	35	B-cells: 6.8;dendritic cells: 10.2;monocytes: 5.9									"CAB000009, HPA010734"	Enhanced									"CAB000009: AB_2073290, HPA010734: AB_1078452"	unprognostic (7.21e-5)	prognostic favourable (6.37e-4)	unprognostic (1.37e-5)	unprognostic (2.55e-2)	unprognostic (2.83e-1)	unprognostic (1.16e-2)	unprognostic (9.93e-4)	unprognostic (1.49e-2)	unprognostic (3.12e-1)	unprognostic (3.86e-2)	unprognostic (6.99e-2)	unprognostic (5.12e-2)	unprognostic (5.49e-5)	unprognostic (5.58e-2)	unprognostic (1.72e-1)	unprognostic (1.76e-1)	unprognostic (8.81e-2)	0.1	0	0.1	0.9	0.1	0	1	0.1	0.1	0.9	0.1	0.1	0.1	0	0.2	0.1	8	0	0.6	0.1	0.1	0	0.2	0.1	1.8	1.9	0.1	0.1	0.1	0.1	0	0.1	0.1	0.1	0.1	1.2	0.1	0.9	0.1	0.1	20.9	0.3	0.1	0.1	1.4	0.3	0.2	0.1	105.1	0.1	1	2.7	0.4	1.1	6.8	10.2	0	5.9	0	0.2	1.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	35.7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	5.9	0	0	3.7	0.2	6.8	0	0	10.2	5.4	0.1	0	0	0	0.2	0.2	0	1.5	0.1	0.1	0.1	0.1	0.1	0	0.1	0.1	0.1	0.1
CD1B	CD1	ENSG00000158485	CD1b molecule	P29016	1	158327951-158331531	"CD markers, Predicted membrane proteins"	"Adaptive immunity, Immunity"			Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enriched	Detected in some	12	lymphoid tissue: 188.8	Cell line enriched	Detected in single	1104	MOLT-4: 110.4	Low cancer specificity	Detected in some			Not detected	Not detected			Cell type enriched	Detected in some	6	myeloid DC: 16.3	Lineage enriched	Detected in many	6	dendritic cells: 16.3									HPA021824	Approved									HPA021824: AB_1846262	unprognostic (7.72e-3)	unprognostic (1.55e-4)	unprognostic (1.66e-5)	unprognostic (1.04e-2)		unprognostic (1.06e-3)	unprognostic (1.81e-1)	unprognostic (2.89e-4)	unprognostic (2.27e-2)	unprognostic (2.19e-1)	unprognostic (1.33e-1)	unprognostic (9.53e-2)	unprognostic (3.23e-1)	unprognostic (3.52e-1)	unprognostic (1.56e-1)	unprognostic (1.89e-1)	unprognostic (3.53e-2)	0.8	0.1	0.2	1.9	0.2	0	0.6	0.2	0.2	0.8	0.6	0.3	0.2	0	0.3	0.2	0.9	0.7	1.3	0.2	0.2	0	0.6	0.3	1.7	4	0.2	0.2	0.3	0.3	0	0.2	0.2	0.2	0.2	5.6	0.2	0.6	0.2	0.2	6.2	0.8	0.3	0.2	1.9	0.9	0.2	0.2	188.8	0.4	0.4	2.4	0.5	0.8	0	16.3	0	2.9	0	0	0.7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	110.4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2.9	0	0	2.3	0	0	0	0	16.3	0	0	0	0	0	0	0	0	0.7	0.2	0.2	0.2	0.2	0.2	0	0.2	0.2	0.2	0.2
CD1C	CD1	ENSG00000158481	CD1c molecule	P29017	1	158289786-158293630	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"			Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	8	blood: 70.8;lymphoid tissue: 111.4	Cell line enriched	Detected in some	14	MOLT-4: 34.7	Low cancer specificity	Detected in many			Not detected	Not detected			Group enriched	Detected in some	5	memory B-cell: 18.6;myeloid DC: 70.8	Group enriched	Detected in many	8	B-cells: 18.6;dendritic cells: 70.8															240000	240000				unprognostic (2.55e-3)	prognostic favourable (1.79e-5)	unprognostic (1.75e-5)	unprognostic (3.09e-5)	unprognostic (3.12e-2)	unprognostic (8.13e-3)	unprognostic (2.01e-1)	unprognostic (3.80e-3)	unprognostic (7.11e-3)	unprognostic (1.87e-1)	unprognostic (7.41e-2)	unprognostic (1.93e-1)	unprognostic (1.04e-1)	unprognostic (1.46e-1)	unprognostic (1.67e-1)	unprognostic (8.05e-2)	unprognostic (1.99e-1)	1.8	0.4	0.5	8.2	0.6	0	2.2	0.5	0.5	1.1	1.2	0.5	1.3	0.4	1.4	1.2	1.8	1.6	5.1	0.6	0.5	0.3	1.6	1.5	2.8	13.2	0.6	0.5	0.7	0.7	0	0.6	0.7	0.6	1	4.8	0.9	3	1	0.6	5.5	11.7	1.3	0.5	24.6	1.2	0.8	0.5	111.4	1	2.4	20.5	1.4	1.3	18.6	70.8	0.2	5.9	0.9	0.1	3.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	34.7	0	0.4	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2.5	0	0.6	0	0.1	5.9	0	0	5.1	0	18.6	0	0	70.8	9.3	0	0	0.2	0.9	0.6	0.3	0.1	3.3	0.5	0.6	0.5	0.5	0.5	0.3	0.6	0.5	0.6	0.5
CD1D		ENSG00000158473	CD1d molecule	P15813	1	158179947-158184896	"Cancer-related genes, CD markers, Predicted membrane proteins"	"Immunity, Innate immunity"		Cancer-related genes	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 49.5;lymphoid tissue: 17.8	Cell line enhanced	Detected in some		HBEC3-KT: 9.1;HHSteC: 14.1;MOLT-4: 18.6;THP-1: 11.4	Low cancer specificity	Detected in many							Group enriched	Detected in many	6	classical monocyte: 49.5;intermediate monocyte: 22.4;myeloid DC: 49.5	Group enriched	Detected in many	8	dendritic cells: 49.5;monocytes: 49.5					Low region specificity	Detected in all			"CAB016107, HPA072662"	Enhanced		Supported	Endoplasmic reticulum		720000	720000	Endoplasmic reticulum		"CAB016107: AB_626960, HPA072662: "	unprognostic (8.67e-2)	unprognostic (6.99e-2)	unprognostic (2.48e-1)	unprognostic (1.48e-2)	unprognostic (1.05e-1)	unprognostic (1.42e-1)	unprognostic (3.85e-1)	unprognostic (9.67e-3)	unprognostic (2.37e-1)	unprognostic (3.52e-1)	unprognostic (2.23e-2)	unprognostic (4.46e-2)	prognostic unfavourable (2.12e-5)	unprognostic (9.31e-3)	unprognostic (2.35e-1)	unprognostic (2.32e-2)	unprognostic (3.38e-1)	1.5	1.2	0	8.6	0	2.6	1.2	0	0	0.8	2.5			9.5	1.5	0	0.4	1.4	2	1.4	0	0.1	1.6	10.5	2.3	5.5	0.2		0.3	0.7	0	0.6	0		1.4	3.7		0.7	0.3	0.6	0	12.2	2.2	0.4	17.8	1.4	1.4			1.8		3.4	1.6	0.5	6.3	49.5	2.5	49.5	0.1	0.1	23.5	0	0	0	0	2.2	0	0	0	0	0	0	0	0	0.6	3.2	0	4.8	0	9.1	0	0	0.1	0.2	0	0	14.1	0.1	0	5.3	0.7	0	1.1	0	0	0	0	0	18.6	1.8	0.8	0	0	0	0	0.9	0	1.8	0	0	0	0	0	11.4	0	0	2.9	0	0	0.5	0	0.5	0	5.2	0.7	0	49.5	0.1	0	22.4	0.1	6.3	0	0	49.5	4.7	0	0	2.5	0.1	3.6	0.5	0	23.5										
CD1E		ENSG00000158488	CD1e molecule	P15812	1	158353696-158357553	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"			Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enriched	Detected in many	10	lymphoid tissue: 308.0	Cell line enriched	Detected in single	1338	MOLT-4: 167.8	Low cancer specificity	Detected in many			Not detected	Not detected			Cell type enriched	Detected in some	13	myeloid DC: 29.7	Lineage enriched	Detected in many	13	dendritic cells: 29.7					Low region specificity	Detected in all			HPA057769	Uncertain				Intracellular and membrane					HPA057769: 	unprognostic (7.94e-3)	unprognostic (1.85e-5)	unprognostic (1.47e-2)	unprognostic (1.64e-2)	unprognostic (1.76e-2)	unprognostic (1.29e-2)	unprognostic (2.33e-1)	unprognostic (1.54e-3)	unprognostic (1.24e-1)	unprognostic (1.74e-1)	unprognostic (1.60e-1)	unprognostic (8.55e-2)	unprognostic (1.69e-2)	unprognostic (1.50e-1)	unprognostic (2.49e-1)	unprognostic (8.50e-2)	unprognostic (2.45e-1)	1	0.2	0.7	2.8	0.7	0	1.1	0.7	0.7	1.5	1	0.7	0.7	1.2	0.9	0.7	7	1.9	3.9	0.7	0.7	0.2	2	0.7	2.4	4.7	0.7	0.7	0.7	0.8	0	0.7	0.7	0.7	1.8	4.8	0.8	1.9	0.8	0.8	11.5	2.1	0.8	0.7	3.8	3.1	0.9	0.7	308	1	1.3	8.1	2.4	2.7	0	29.7	0	2.2	0	0.1	1.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	167.8	0	0	0	0	0	0	0	0	0.1	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2.2	0	0	1.1	0.1	0	0	0	29.7	0	0	0	0	0	0	0	0	1.1	0.7	0.7	0.7	0.7	0.7	0.2	0.7	0.7	0.7	0.7
CD2	SRBC	ENSG00000116824	CD2 molecule	P06729	1	116754385-116769228	"CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	Cell adhesion		FDA approved drug targets	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	7	blood: 101.7;lymphoid tissue: 164.4	Group enriched	Detected in some	25	HDLM-2: 61.1;MOLT-4: 44.9	Low cancer specificity	Detected in all			Low region specificity	Detected in some			Group enriched	Detected in many	6	gdT-cell: 44.4;MAIT T-cell: 42.5;memory CD4 T-cell: 65.3;memory CD8 T-cell: 74.2;naive CD4 T-cell: 34.2;naive CD8 T-cell: 52.4;NK-cell: 101.7;T-reg: 62.3	Group enriched	Detected in many	9	NK-cells: 101.7;T-cells: 74.2	Region enhanced	Detected in single		basal ganglia: 0.3	Low region specificity	Detected in many			"CAB002430, HPA003883"	Enhanced									"CAB002430: AB_442057, HPA003883: AB_1846263"	prognostic favourable (4.36e-4)	prognostic favourable (1.47e-4)	unprognostic (3.34e-3)	prognostic favourable (1.69e-5)	unprognostic (1.52e-1)	prognostic favourable (7.46e-5)	unprognostic (9.32e-3)	unprognostic (1.61e-2)	prognostic favourable (3.97e-5)	prognostic favourable (7.72e-4)	unprognostic (4.18e-2)	unprognostic (3.31e-1)	prognostic unfavourable (4.82e-6)	unprognostic (6.16e-2)	unprognostic (6.61e-2)	unprognostic (2.73e-2)	unprognostic (7.63e-3)	3	1.1	0.6	14.5	0.5	2.4	1.7	0.5	0.6	2.9	6	0.6	0.6	4.8	1.7	2.1	3.8	3.1	4.8	1.4	0.6	0.6	3.3	2.5	8.1	33	1.2	0.6	1.9	1.6	0	1	1	1	2.9	4.7	2.3	4.1	1.3	1	1.2	18.8	0.9	1.8	28.8	6.5	1.1	0.8	164.4	3.5	3.4	30.8	7.7	2.7	0.3	9.3	1.4	0.5	101.7	74.2	45.9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	61.1	0	0.1	0	0	0	0.1	2	0	0	0	0	0	0	0.1	0	0	44.9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2	0.1	0	0.7	0.5	0.1	44.4	0.3	42.5	0.3	65.3	74.2	9.3	0.2	34.2	52.4	1.4	101.7	0.2	2	62.3	45.9	0.6	0.5	0.5	0.6	0.6	0.6	1.2	0.6	1	0.8
CD200	"MOX1, MOX2, MRC, OX-2"	ENSG00000091972	CD200 molecule	P41217	3	112332347-112362812	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"				Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		placenta: 63.5	Cell line enhanced	Detected in some		AF22: 31.2;HHSteC: 11.5;NTERA-2: 19.5;REH: 16.7;SK-MEL-30: 11.5;WM-115: 34.0	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Group enriched	Detected in some	16	memory B-cell: 9.9;naive B-cell: 36.4	Lineage enriched	Detected in many	25	B-cells: 36.4	Low region specificity	Detected in all			Low region specificity	Detected in all			HPA031149	Approved									HPA031149: AB_10600694	unprognostic (1.84e-1)	unprognostic (5.08e-2)	unprognostic (1.79e-1)	unprognostic (2.03e-3)	unprognostic (4.97e-1)	unprognostic (1.21e-2)	unprognostic (9.29e-2)	unprognostic (2.25e-2)	unprognostic (3.06e-1)	unprognostic (3.14e-2)	unprognostic (1.21e-2)	unprognostic (1.27e-1)	unprognostic (8.97e-2)	unprognostic (1.06e-2)	unprognostic (2.80e-1)	unprognostic (4.49e-2)	unprognostic (1.22e-2)	12.8	9.5	18.1	10.9	34.3	1.8	7.1	20.9	38.3	16	4.5	11	1.5	2.6	21.4	5.7	7	20.3	10.1	5.8	17.3	42.4	4.9	1	7.2	17.7	12.7	19.3	9.3	3.8	10.9	27.9	63.5	19.6	9.7	6.5	7.5	5.4	13	1.4	2.8	4.3	13.9	8.4	4.4	3.4	2.3	6.7	12.7	12.4	1.6	17.6	13.9	3.9	36.4	1.1	1.2	0.1	0.6	1.4	1.3	0	0	31.2	0	0	0	0.1	0	0.1	0	0	0	0	0.1	1.7	0	0	3.3	0.1	0.1	0.1	0.3	0	0.1	0.2	11.5	0	0	0.2	0.1	0.6	0	4.4	0	0.3	0	0	0.4	0.1	19.5	0	16.7	0	0.2	0.2	0	8.2	9.6	0	0.1	11.5	0	0.1	0	0.1	1.1	0	0.1	0	0.1	0	0.3	0	34	1.2	0.1	0.1	0.1	0	1.4	9.9	0.8	0.2	0.5	36.4	0.9	0.5	0.7	0.6	0.1	1.1	0.4	1.3	18.1	34.3	20.9	38.3	17.3	42.4	12.7	19.3	19.6	6.7
CD207	"CLEC4K, Langerin"	ENSG00000116031	CD207 molecule	Q9UJ71	2	70830214-70835822	"CD markers, Disease related genes, Predicted membrane proteins"				Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		lymphoid tissue: 16.5;skin 1: 42.3	Cell line enriched	Detected in some	4	AN3-CA: 13.7	Low cancer specificity	Detected in many			Not detected	Not detected			Cell type enriched	Detected in single	18	myeloid DC: 4.0	Lineage enriched	Detected in single	18	dendritic cells: 4.0	Not detected	Not detected			Low region specificity	Detected in many			"CAB002222, HPA011216"	Enhanced		Approved	Cytosol				Cytosol		"CAB002222: AB_563850, HPA011216: AB_1078453"	unprognostic (1.45e-2)	unprognostic (8.28e-3)	unprognostic (9.34e-2)	unprognostic (1.65e-1)	unprognostic (1.38e-1)	unprognostic (2.23e-1)	unprognostic (3.02e-1)	unprognostic (1.27e-3)	unprognostic (1.05e-1)	unprognostic (4.86e-2)	unprognostic (3.45e-1)	unprognostic (1.63e-1)	unprognostic (7.92e-4)	unprognostic (2.13e-2)	unprognostic (1.81e-1)	unprognostic (1.98e-1)	unprognostic (2.46e-2)	0.5	0.1	0.1	1.8	0.1	0	1.4	0.1	0.1	2.4	1.7	0.1	0.1	1.6	1.1	0.4	9.7	0.3	2.9	0.3	0.1	0.1	0.2	0.9	3.7	0.2	0.1	0.1	0.2	0.2	0	1.1	0.1	0.1	1	1.1	0.4	1.2	0.2	0.1	42.3	2.6	0.1	0.1	1.5	0.4	0.4	0.1	3.3	0.2	11.3	16.5	0.3	1.9	0	4	0	0.2	0	0	0.5	0	0	0	13.7	0.1	0	0.9	0.1	0	0	0	0	0	0	0	0	0	3.3	0	0	0.2	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0.1	0	0	0.1	0	0.3	0	0.1	1.9	0	0	0	2.4	0	0.5	0	0.5	0	0	0	0	0	0	0	0.1	0	0.2	0	0	0	0	0	0	0	4	0	0	0	0	0	0.1	0	0	0.5	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
CD209	"CDSIGN, CLEC4L, DC-SIGN, DC-SIGN1"	ENSG00000090659	CD209 molecule	Q9NNX6	19	7739994-7747564	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Cell adhesion, Endocytosis, Host-virus interaction, Immunity, Innate immunity"	"Host cell receptor for virus entry, Receptor"		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		lymphoid tissue: 47.9	Cell line enriched	Detected in single	14	THP-1: 8.6	Low cancer specificity	Detected in many			Low region specificity	Detected in many			Cell type enhanced	Detected in some		classical monocyte: 3.7;intermediate monocyte: 3.5;myeloid DC: 3.4	Low lineage specificity	Detected in many											"CAB032436, CAB033831"	Supported				Intracellular and membrane	970000	970000			"CAB032436: AB_639039, CAB033831: AB_1121347"	unprognostic (2.76e-1)	unprognostic (1.15e-2)	unprognostic (5.36e-3)	unprognostic (1.25e-1)	unprognostic (4.43e-2)	unprognostic (1.40e-1)	unprognostic (5.45e-2)	unprognostic (3.83e-2)	unprognostic (2.10e-2)	unprognostic (1.24e-1)	unprognostic (9.65e-2)	unprognostic (1.39e-1)	prognostic unfavourable (1.15e-5)	unprognostic (1.70e-1)	unprognostic (5.51e-2)	unprognostic (6.17e-2)	unprognostic (1.09e-1)	20.3	4.5	0.5	4.1	1.8	0	6.8	4.5	0.9	2	5.6	0.7	0.3	7.2	1.1	7.3	2.4	3.3	4.4	7.8	0.4	0.7	2.2	5	3.7	47.9	1.1	0.5	1.8	3.8	0.4	1	12.1	1.8	3.6	7.4	3.2	3	0.7	3.5	1.6	10.1	5.2	0.9	1.4	2.6	2.1	0.3	2.3	2.1	2.1	1.3	6.8	1.6	0.3	3.4	0.9	3.7	0.3	0.2	1	0.1	0	0	0	0.1	0	0.2	0.1	0	0	0	0	0.1	0.1	0.6	0	0	0	0	0	0	0	0.1	0.3	0.1	0	0.1	0.2	0	0	0.1	0	0	0.2	0.2	0	0	0	0.1	0.1	0	0.1	0	0.2	0.1	0.1	0.2	0.6	0	0.1	0	0.2	8.6	0.1	0.1	0	0.2	0	0.1	0	0	0.1	0.1	0.1	0.5	3.7	0.2	0.2	3.5	0.1	0.2	0.1	0.1	3.4	0.3	0.1	0.2	0.9	0.3	0.1	0.3	0.1	1	0.5	1.8	4.5	0.9	0.4	0.7	1.1	0.5	1.8	0.3
CD22	"SIGLEC-2, SIGLEC2"	ENSG00000012124	CD22 molecule	P20273	19	35319261-35347355	"CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Cell adhesion		FDA approved drug targets	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 39.3;lymphoid tissue: 77.8;ovary: 35.4	Cell line enhanced	Detected in some		Daudi: 68.2;REH: 20.2;U-698: 54.2;WM-115: 12.4	Low cancer specificity	Detected in many			Low region specificity	Detected in many			Group enriched	Detected in some	25	memory B-cell: 29.8;naive B-cell: 39.3	Lineage enriched	Detected in many	28	B-cells: 39.3	Low region specificity	Detected in single			Low region specificity	Detected in many			"CAB002418, HPA024353"	Enhanced									"CAB002418: AB_563529, HPA024353: AB_10600695"	unprognostic (2.80e-3)	unprognostic (3.99e-2)	unprognostic (6.79e-3)	unprognostic (9.17e-2)	unprognostic (3.07e-1)	unprognostic (6.45e-3)	unprognostic (3.79e-1)	unprognostic (3.32e-2)	unprognostic (1.79e-1)	unprognostic (2.47e-1)	unprognostic (1.75e-3)	unprognostic (1.98e-2)	unprognostic (1.48e-2)	unprognostic (9.05e-2)	unprognostic (3.04e-1)	unprognostic (2.35e-2)	unprognostic (1.48e-1)	2.1	1	5.5	57.9	6.8	3.1	0.5	0.7	3.2	1.4	1	0.9	0.5	0.4	1.4	0.9	4.4	7.9	2.9	0.8	9.9	4.2	1.4	0.6	5.5	52.6	9.8	0.5	35.4	0.5	0	0.7	1	0.9	2.8	1.5	1.1	5.9	1.1	0.5	0	11.6	2	13.5	64.1	1.4	1.2	0.6	5	1.1	2.3	77.8	4.3	0.9	39.3	1.3	0.3	0.3	0	0	1.4	0.2	0.4	0	0	0	0	1	0	0	0	0.1	0	1.2	68.2	1.4	0	0.1	0	0	0	0.3	0	0	0	0.5	0	0	3.1	0	0	0	1	0	0.3	0	0.6	0.1	0	0	0	0.1	20.2	0.1	0	0	0	0	0	0	0.3	1.6	0.1	0	0	0.6	0.3	0	0	0	0	54.2	0.5	0.2	12.4	0	0	0	0	0.3	0	29.8	0	0	1.3	39.3	0	0	0.3	0	0.2	1.1	0	1.4	5.5	6.8	0.7	3.2	9.9	4.2	9.8	0.5	0.9	0.6
CD226	"DNAM-1, DNAM1, PTA1, TLiSA1"	ENSG00000150637	CD226 molecule	Q15762	18	69831158-69961803	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	Cell adhesion	Receptor		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		lymphoid tissue: 31.9;parathyroid gland: 82.5	Group enriched	Detected in some	6	HEL: 44.3;HMC-1: 19.7	Not detected	Not detected			Low region specificity	Detected in many			Group enriched	Detected in many	8	gdT-cell: 19.4;MAIT T-cell: 7.3;memory CD4 T-cell: 16.1;memory CD8 T-cell: 11.8;naive CD4 T-cell: 9.0;naive CD8 T-cell: 9.7;NK-cell: 14.0;T-reg: 5.5	Group enriched	Detected in many	11	NK-cells: 14.0;T-cells: 19.4	Not detected	Not detected			Low region specificity	Detected in all			"HPA015715, HPA050348"	Supported		Uncertain	Midbody		27000000	27000000	Midbody		"HPA015715: AB_1846278, HPA050348: "	unprognostic (1.42e-4)	unprognostic (1.30e-3)	unprognostic (9.01e-3)	unprognostic (3.49e-5)	unprognostic (4.15e-1)	unprognostic (9.52e-4)	unprognostic (3.68e-3)	unprognostic (2.93e-2)	unprognostic (3.43e-1)	unprognostic (3.31e-3)	unprognostic (8.36e-2)	unprognostic (1.43e-1)	unprognostic (2.72e-3)	unprognostic (2.20e-1)	unprognostic (3.91e-2)	unprognostic (2.27e-1)	unprognostic (3.58e-2)	1.2	0.6	1	7.5	2	1.7	0.8	0.7	0.9	1.5	2.9	0.3	0.1	1.1	1	1.4	0.8	0.8	1.4	0.9	1.9	1.3	1.3	3.1	5.2	14	1.7	0	1	0.6	82.5	2.4	0.6	1.3	0.9	1.2	2.4	5.4	0.6	1.1	0.4	6	1.3	4.2	31.9	1.4	1.8	0.5	6.4	1.8	2.6	10.1	2	1.6	0.4	1.5	0.9	0.6	14	19.4	6.6	0	0	0.1	0.1	0	0	0	0.2	0	0.1	0.1	0	0	0	0	0.1	0	0.1	0.1	0.1	2.3	0	44.3	0.1	0	0	0.3	19.7	0	0.5	0.1	0.3	0	0.1	4.5	0.2	0	0.3	0.2	0	0.2	0	0	0	0	0	0.3	0	0	0	0	0	0	0.2	0.3	0.1	0	0.1	5.4	0.1	0	0.1	0	0.2	0.1	0	0.5	19.4	0.4	7.3	0.4	16.1	11.8	1.5	0.1	9	9.7	0.9	14	0.6	0.1	5.5	6.6	1	2	0.7	0.9	1.9	1.3	1.7	0	1.3	0.5
CD244	"2B4, NAIL, NKR2B4, Nmrk, SLAMF4"	ENSG00000122223	CD244 molecule	Q9BZW8	1	160830160-160862855	"CD markers, Plasma proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity, Innate immunity"	Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	6	blood: 75.8;lymphoid tissue: 22.1	Cell line enhanced	Detected in some		HEL: 10.6;HMC-1: 37.4;NB-4: 7.4;U-937: 14.9	Low cancer specificity	Detected in many			Low region specificity	Detected in some			Cell type enhanced	Detected in many		basophil: 75.8	Lineage enriched	Detected in many	5	granulocytes: 75.8					Not detected	Not detected														unprognostic (6.11e-3)	unprognostic (1.54e-2)	unprognostic (1.85e-2)	unprognostic (6.95e-6)	unprognostic (5.79e-2)	unprognostic (1.43e-4)	unprognostic (1.93e-2)	unprognostic (7.36e-2)	unprognostic (3.36e-1)	unprognostic (2.85e-1)	unprognostic (1.60e-1)	unprognostic (2.32e-1)	unprognostic (5.40e-4)	unprognostic (1.71e-1)	unprognostic (1.51e-1)	unprognostic (1.87e-1)	unprognostic (1.79e-1)	2.9	0.4	0.5	3.3	0.5	8.6	0.6	0.3	0.7	0.9	3.1	0.4	1.6	2.8	1.4	0.7	1	0.7	1.7	2	0.5	0.5	0.7	4.1	5.3	7.4	1.7	0	1.6	0.5	0	0.5	1.8	1.1	1.6	1.2	1	1.6	0.9	1.1	0.5	6	2.6	1.5	22.1	0.8	2.8	0.6	0.7	0.6	0	4	1.5	0.8	0	7.9	75.8	13.2	14	14.8	11.3	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0.1	0	0	0	0	0	0	0	0	10.6	0	0	0.2	3.4	37.4	0	0	0	0	0	0	0.1	0	0	1	7.4	0	0	0	0	0	0	0	0	0	0	0	0	0	3.9	0	0	0	0	0	1.4	0.5	0	0	14.9	0	75.8	8.2	20.1	14.8	11.2	7.3	0	0.8	8.1	7.9	0	1.1	7.8	0.6	14	13.2	0.4	0	11.3	0.5	0.5	0.3	0.7	0.5	0.5	1.7	0	1.1	0.6
CD247	"CD3H, CD3Q, CD3Z"	ENSG00000198821	CD247 molecule	P20963	1	167430640-167518610	"CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins"	"Adaptive immunity, Host-virus interaction, Immunity"	Receptor	FDA approved drug targets	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	5	blood: 62.8;lymphoid tissue: 129.5	Group enriched	Detected in some	28	HDLM-2: 47.8;MOLT-4: 50.5	Low cancer specificity	Detected in many			Low region specificity	Detected in many			Group enriched	Detected in many	26	gdT-cell: 62.8;MAIT T-cell: 35.4;memory CD4 T-cell: 32.4;memory CD8 T-cell: 36.7;naive CD4 T-cell: 41.3;naive CD8 T-cell: 33.5;NK-cell: 33.4;T-reg: 39.0	Group enriched	Detected in many	31	NK-cells: 33.4;T-cells: 62.8	Region enhanced	Detected in single		thalamus: 0.7	Low region specificity	Detected in all			"CAB004651, HPA008750"	Enhanced									"CAB004651: AB_425347, HPA008750: AB_1857863"	prognostic favourable (9.12e-4)	unprognostic (3.21e-3)	unprognostic (7.09e-3)	prognostic favourable (8.63e-6)	unprognostic (1.99e-2)	prognostic favourable (3.98e-4)	unprognostic (1.79e-2)	unprognostic (1.11e-2)	unprognostic (5.46e-3)	unprognostic (9.73e-3)	unprognostic (1.33e-2)	unprognostic (2.50e-1)	prognostic unfavourable (9.94e-6)	unprognostic (1.60e-1)	unprognostic (5.33e-2)	unprognostic (4.02e-2)	unprognostic (5.94e-3)	2.3	0.5	0.9	13.5	2.1	17.8	1.3	1.2	1.1	1.4	4.4	0.7	0.7	2.9	1.5	1.6	1.4	1.2	2.9	1	0.8	1.4	1.9	3.2	7.3	24.3	1	0.5	1	0.5	0	0.6	1.3	0.7	2	1.8	1.7	3.3	0.4	1.4	0.6	9.8	0.8	0.9	28.6	2.7	0.9	0.5	129.5	1.8	0.9	18.1	3.5	1.4	1.5	0.4	1.4	0.2	33.4	62.8	31.4	0	0	0	0	0	0	0	0	0	0	0	0	0	1.7	0	0	0	0	0	0	47.8	0.1	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0	0	50.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0.1	0.2	0	0	0	1	0.1	0	62.8	0.2	35.4	1.5	32.4	36.7	0.2	0.5	41.3	33.5	1.4	33.4	0.1	0.4	39	31.4	0.9	2.1	1.2	1.1	0.8	1.4	1	0.5	0.7	0.5
CD248	"CD164L1, TEM1"	ENSG00000174807	CD248 molecule	Q9HCU0	11	66314487-66317044	"CD markers, Predicted membrane proteins"				Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		placenta: 71.0	Cell line enhanced	Detected in some		ASC diff: 66.6;ASC TERT1: 65.7;BJ hTERT+: 43.3;fHDF/TERT166: 58.0;HSkMC: 70.0;U-2197: 104.8	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Cell type enriched	Detected in some	6	naive CD8 T-cell: 17.8	Lineage enriched	Detected in single	122	T-cells: 17.8	Low region specificity	Detected in all			Low region specificity	Detected in many			HPA051856	Enhanced		Approved	"Nucleoplasm,Plasma membrane"		27000000	27000000	Plasma membrane	Nucleoplasm	HPA051856: 	unprognostic (2.26e-1)	unprognostic (1.72e-1)	unprognostic (8.95e-2)	unprognostic (2.77e-2)	unprognostic (1.14e-2)	unprognostic (2.61e-1)	unprognostic (7.21e-3)	unprognostic (1.36e-2)	unprognostic (1.01e-1)	unprognostic (2.82e-2)	unprognostic (6.31e-2)	unprognostic (4.77e-2)	prognostic unfavourable (2.69e-7)	unprognostic (1.90e-2)	unprognostic (2.92e-2)	unprognostic (1.25e-1)	unprognostic (1.30e-2)	59.2	3.5	0.8	14.4	2.5	0	55.2	0.6	2.2	21.2	7.6	1.9	6.3	2.7	14.1	22.9	14.8	17.7	12.3	18.2	1.2	0.5	5.3	1.7	9.3	16.2	1.3	1.6	15.6	4.9	1.4	2.3	71	2.1	10.6	2.7	11.5	4.6	8	6.7	13.3	7.5	27.6	1.2	1.9	7.5	8	0.7	4.1	9.4	6.6	4.5	19.5	17.6	0.1	0	0	0	0	17.8	1.9	0	0	0.6	0	66.6	65.7	0	28.8	43.3	2.1	2	0	0	0	0.7	58	0	0	0	0.4	0	0	0	0	0.4	13.2	0	0	70	0	2.8	0	0	0	0	0	0	0.4	0.4	0.3	0.1	1.2	0	0	0	0	0.3	1	0	0.1	0	0	0	0	0	0.1	104.8	0	0	0	0	0	0	0	0	0	0	0.1	0	0.8	0	0	2.3	0	0.1	2.8	17.8	0	0	0	0	0	1.9	0.8	2.5	0.6	2.2	1.2	0.5	1.3	1.6	2.1	0.7
CD27	"S152, TNFRSF7, Tp55"	ENSG00000139193	CD27 molecule	P26842	12	6444867-6451718	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins"	Apoptosis	Receptor	"Cancer-related genes, Disease mutation"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 82.3;lymphoid tissue: 60.4	Group enriched	Detected in some	141	Daudi: 63.7;U-698: 35.3	Low cancer specificity	Detected in all			Not detected	Not detected			Cell type enhanced	Detected in many		T-reg: 82.3	Group enriched	Detected in many	7	B-cells: 41.8;T-cells: 82.3	Not detected	Not detected			Low region specificity	Detected in many			"CAB002420, HPA038936"	Enhanced					28000	28000			"CAB002420: AB_563539, HPA038936: "	unprognostic (2.75e-3)	prognostic favourable (3.77e-5)	unprognostic (8.87e-3)	prognostic favourable (2.90e-4)	unprognostic (2.35e-1)	prognostic favourable (6.65e-7)	unprognostic (3.56e-2)	unprognostic (9.37e-2)	prognostic favourable (5.50e-4)	unprognostic (1.31e-3)	unprognostic (4.32e-2)	unprognostic (2.74e-1)	prognostic unfavourable (1.19e-6)	unprognostic (2.80e-1)	unprognostic (3.15e-1)	unprognostic (1.28e-1)	unprognostic (7.35e-2)	1.1	0.6	0.4	40.8	0.5	2	1.2	0.4	0.4	1.7	10	0.2	0.5	5.3	0.8	0.6	4.9	1.6	3.7	0.9	0.4	0.4	1.7	1	2.9	49.5	0.4	0.1	1	0.5	0	0.6	0.4	0.2	1.3	2.9	1.2	10.7	1.4	0.4	0.6	19.4	0.2	0.6	45.7	3.7	0.5	0.1	33.5	3.1	2.3	60.4	9.1	1.2	41.8	0.3	0.8	0.1	8.3	82.3	22.1	0	0	0	0	0	0	0	0	0	0	0	0	0	63.7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0.1	0	0	0.3	0	0.2	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0.1	0	0	0	0	35.3	0	0	0	0.8	0.1	0.1	16.7	0.1	28.7	41.8	40.1	37.5	0.1	10.5	55.6	39.1	0.8	8.3	0.1	0.3	82.3	22.1	0.4	0.5	0.4	0.4	0.4	0.4	0.4	0.1	0.2	0.1
CD274	"B7-H, B7-H1, B7H1, PD-L1, PDCD1LG1, PDL1"	ENSG00000120217	CD274 molecule	Q9NZQ7	9	5450503-5470566	"Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor	"Cancer-related genes, FDA approved drug targets"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		lung: 23.9;placenta: 56.0	Cell line enhanced	Detected in many		HDLM-2: 33.4;HHSteC: 22.3;U-251 MG: 37.0	Low cancer specificity	Detected in many			Low region specificity	Detected in many			Cell type enhanced	Detected in many		basophil: 8.4	Group enriched	Detected in many	6	granulocytes: 8.4;T-cells: 2.4	Low region specificity	Detected in many			Low region specificity	Detected in all			CAB076385	Enhanced									CAB076385: AB_2687655	prognostic favourable (8.89e-4)	unprognostic (4.54e-2)	prognostic favourable (1.64e-5)	unprognostic (1.27e-2)	unprognostic (2.96e-2)	unprognostic (1.08e-1)	unprognostic (4.61e-2)	unprognostic (1.44e-1)	unprognostic (1.68e-2)	unprognostic (5.67e-4)	unprognostic (7.39e-3)	unprognostic (1.69e-2)	unprognostic (1.24e-2)	unprognostic (1.35e-1)	unprognostic (1.49e-2)	unprognostic (2.67e-1)	unprognostic (9.02e-2)	3.4	2.1	1.7	10.8	3.2	1.4	2.2	2.5	3.3	2	2.3	2.5	2.8	2.6	1.7	2.4	3	1.9	4.3	9.5	1.4	3.7	3	3.6	23.9	6.4	2.3	0.7	1.7	2.7	3.8	7.4	56	3.2	2.9	2.2	3.3	1.7	1.6	4.3	1.3	2.7	2.3	2.4	12.8	1.9	1.2	1	11.6	3.7	2.1	5.8	3.1	1.9	0.9	0	8.4	0.1	0.4	2.4	0.7	5.8	0.1	0	0.2	0	0	0	11.7	9.9	3	4.1	0	1.9	0	0.2	0.3	0.2	0	5	9.7	33.4	0	3.3	0.1	0	22.3	0	0	0.2	0	6.1	9.1	5.7	0	1.1	9	0	0.1	0	0	0.1	0	1.6	0.3	0.6	0.1	0	0.1	0.1	0.9	0.7	0	0.1	10.7	6.3	2	0.1	37	0.2	0.1	0.1	2.1	0.1	0	8.4	0.1	0.3	1.2	0.1	2.1	0.9	2.4	1.8	0	0.2	1.3	0.7	5.7	0.4	0	0	1.1	0.7	1.7	3.2	2.5	3.3	1.4	3.7	2.3	0.7	3.2	1
CD276	"B7-H3, B7H3, B7RP-2"	ENSG00000103855	CD276 molecule	Q5ZPR3	15	73683966-73714518	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"				Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in many			Cell line enhanced	Detected in many		U-2197: 54.4	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enriched	Detected in single	4	neutrophil: 4.0	Lineage enriched	Detected in single	5	granulocytes: 4.0	Low region specificity	Detected in all			Low region specificity	Detected in all			"HPA009285, HPA017139, CAB017826"	Enhanced		Approved	Vesicles		8900000	8900000	Vesicles		"CAB017826: , HPA009285: AB_1078258, HPA017139: AB_1845246"	unprognostic (1.05e-1)	unprognostic (4.74e-3)	unprognostic (4.57e-3)	unprognostic (9.62e-2)	unprognostic (1.26e-2)	unprognostic (5.50e-3)	prognostic unfavourable (9.81e-4)	unprognostic (2.57e-3)	unprognostic (1.89e-1)	unprognostic (3.75e-2)	unprognostic (1.54e-2)	unprognostic (3.29e-2)	prognostic unfavourable (6.31e-5)	unprognostic (1.17e-1)	unprognostic (9.22e-2)	unprognostic (1.21e-1)	unprognostic (1.34e-3)	32.3	16.6	5.8	9.2	3.9	0.6	17.1	3.6	5.3	19.4	8.3	5.1	4.2	8.8	17.2	17.9	6.3	8.1	14.3	12.3	5.6	3.6	7.2	22.9	9.3	6.7	4.6	3.8	16.8	14.3	3.5	5.3	27.7	7.9	16.5	4.2	20.5	12.8	7.8	7.1	12.6	7	13.8	4.4	7.4	8.4	9.9	3.9	1.2	7.8	8.3	4.7	12.4	13.6	0.4	0.5	4	0.6	0.8	0.2	0	9.7	12.1	8.3	18.1	15.2	9.2	25.3	11.4	9.4	7.5	6.8	21.2	20.4	0.1	18.6	10.8	41.6	8.8	10.1	1.2	7.4	20.1	0.7	12.6	10.2	4.6	0.1	12.1	7.3	4.9	6.8	4.4	9.8	3.1	0.2	1.7	15	0.1	0.5	20.1	8.8	0.1	12.2	1.6	6.5	13.5	5.7	13.8	10.5	5.2	20.5	8.7	5.3	11.4	16.6	14.9	54.4	11.5	0.2	0.2	0.2	27.5	0.8	11.4	0.9	0.3	0.5	0.1	0.6	0.2	0.2	0.1	0.2	0.2	0.4	0.2	0.1	4	0.8	0.3	0.5	0.1	0	5.8	3.9	3.6	5.2	5.6	3.6	4.6	3.8	7.9	3.9
CD28		ENSG00000178562	CD28 molecule	P10747	2	203706475-203738912	"CD markers, Predicted membrane proteins"				Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 32.7;lymphoid tissue: 48.6	Group enriched	Detected in some	14	Karpas-707: 72.1;RPMI-8226: 33.0;U-266/70: 59.3;U-266/84: 53.0	Low cancer specificity	Detected in many			Not detected	Not detected			Cell type enhanced	Detected in many		T-reg: 32.7	Lineage enriched	Detected in many	6	T-cells: 32.7	Region enhanced	Detected in single		olfactory region: 1.3	Low region specificity	Detected in all			HPA070003	Enhanced									HPA070003: 	unprognostic (5.54e-2)	unprognostic (2.16e-4)	unprognostic (1.90e-3)	unprognostic (2.49e-3)	unprognostic (3.44e-2)	unprognostic (6.07e-5)	unprognostic (9.09e-2)	unprognostic (4.66e-2)	unprognostic (3.40e-1)	unprognostic (1.15e-1)	unprognostic (2.65e-1)	unprognostic (1.68e-1)	unprognostic (5.78e-5)	unprognostic (4.77e-2)	unprognostic (2.93e-2)	unprognostic (7.79e-2)	unprognostic (8.96e-2)	5.1	0.6	0.4	14.2	0.5	1.9	3.3	0.3	0.4	1.1	1.6	0.4	0.2	0.6	1.1	2.3	1.5	2.1	3	4.5	0.4	0.5	1.7	1.5	3.8	23.3	0.5	0.2	1.4	0.6	0	0.6	11	0.2	1.2	1.3	1.2	3.1	0.8	0.7	1	7.2	0.9	0.8	9	1.6	0.9	0	48.6	1.5	0.8	29.9	4.5	1.4	0.1	0	5.1	0.2	0	32.7	4.7	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0.1	0	72.1	0	0	3.8	0	0	0	0	0	33	0	0	0	0	0	0	0	0	0	0	0	0	0	0	59.3	53	0.5	0	0	0	0.5	0.2	0.3	3	0.1	18.2	0.1	19.4	9.5	0	0.1	17	6.5	5.1	0	0.1	0	32.7	4.7	0.4	0.5	0.3	0.4	0.4	0.5	0.5	0.2	0.2	0
CD300A	"CMRF-35-H9, CMRF35H, IGSF12, IRC1, IRC2, Irp60"	ENSG00000167851	CD300a molecule	Q9UGN4	17	74466416-74484796	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Immunity"	Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	5	blood: 81.1;brain: 28.7;lymphoid tissue: 57.8	Group enriched	Detected in some	5	HMC-1: 41.3;NB-4: 16.8;RPMI-8226: 32.5	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Low cell type specificity	Detected in many			Low lineage specificity	Detected in all											HPA011645	Approved				Intracellular and membrane	2800000	2800000			HPA011645: AB_1846988	unprognostic (1.99e-1)	unprognostic (4.60e-2)	unprognostic (3.88e-2)	unprognostic (3.30e-2)	unprognostic (2.73e-1)	unprognostic (2.01e-1)	unprognostic (1.04e-2)	unprognostic (2.63e-1)	unprognostic (1.11e-1)	unprognostic (1.17e-2)	unprognostic (7.87e-2)	unprognostic (1.07e-1)	prognostic unfavourable (1.91e-5)	unprognostic (5.97e-2)	unprognostic (5.45e-3)	unprognostic (1.36e-1)	unprognostic (5.72e-2)	8.6	4.5	9.8	16	17.7	11.9	4.4	2.2	11.5	2	4.8	3.7	0	6	1.9	1.3	2.1	2.1	7.7	3.4	7.3	4.2	3	7.5	10.6	19	20.1	0.3	1.5	2.1	0.3	3	6.9	12.6	2.8	4.7	2.3	3	1.3	1.1	2.3	7.4	6	28.7	57.8	2.4	1.5	17.4	4.1	1.9	0.5	6	5.4	2.1	2.2	19.4	81.1	45.7	52.1	29.5	19.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	3.5	0	0	0	1.9	41.3	0	0	0	0	0	0	2.7	0	0	0.5	16.8	0	0	0	0	32.5	0	0	0	0	0	0	0	0	4.8	0	0	0	0	0	0	0.1	0	0	6.3	0	81.1	20.4	57.3	29.5	45.7	6.2	2.2	6.1	8.7	19.4	0.6	2.3	7.1	71.6	52.1	44.2	18.1	0.3	19.2	9.8	17.7	2.2	11.5	7.3	4.2	20.1	0.3	12.6	17.4
CD300C	"CMRF-35A, CMRF35, CMRF35A, IGSF16, LIR"	ENSG00000167850	CD300c molecule	Q08708	17	74541108-74546143	"CD markers, Predicted membrane proteins"	Immunity	Receptor		Evidence at transcript level	Evidence at transcript level	Evidence at transcript level	Evidence at transcript level		Tissue enhanced	Detected in many		blood: 46.8	Cell line enhanced	Detected in some		HEL: 5.2;HMC-1: 25.6;THP-1: 4.8;U-937: 12.1	Low cancer specificity	Detected in many			Low region specificity	Detected in many			Group enriched	Detected in many	4	classical monocyte: 28.6;intermediate monocyte: 46.8;myeloid DC: 32.5;non-classical monocyte: 46.4	Group enriched	Detected in many	5	dendritic cells: 32.5;monocytes: 46.8									"HPA014523, HPA060349"	Approved		Uncertain	"Golgi apparatus,Vesicles,Mitochondria"				Golgi apparatus	"Vesicles, Mitochondria"	"HPA014523: AB_1846293, HPA060349: "	unprognostic (1.55e-2)	unprognostic (2.60e-1)	unprognostic (9.99e-3)	unprognostic (3.79e-1)	unprognostic (1.21e-1)	unprognostic (3.47e-2)	unprognostic (3.81e-2)	unprognostic (2.19e-1)	unprognostic (1.68e-2)	unprognostic (7.51e-2)	unprognostic (6.51e-2)	unprognostic (1.50e-2)	unprognostic (1.37e-3)	unprognostic (6.27e-2)	prognostic unfavourable (8.53e-5)	unprognostic (1.16e-2)	unprognostic (1.09e-1)	9.8	2.8	3.6	9	4.6	10.9	1.8	0.4	2.9	1.2	1.7	2.9	0	1.5	1.4	1.9	1	1.9	2.8	3.4	2	1.7	1.9	2.1	11.2	12.3	5.3	1.3	1.1	1.3	0.5	1.2	3.8	3.9	1.9	1.8	1.8	1.8	0.7	1.1	0.9	2.3	4.1	7.1	14.2	1.6	0.9	2.7	0.1	1.6	0.1	1.4	3.5	1.1	0.4	32.5	8.4	46.8	8.6	0.1	10.7	0	0.1	0	0	0	0	0	0	0.1	0	0	0	0.1	0	0.6	0	0	0	0	0	0	0	5.2	0	0	0	2.4	25.6	0	0	0	0	0	0	0.4	0	0	0	2.6	0	0.1	0	0	3.1	0	0	0	0	0	0.1	0	0	4.8	0	0.3	0	0.1	0	0	0	0	0.7	12.1	0	8.4	28.6	1.4	0.1	46.8	0.1	0.4	0	0	32.5	0.3	0	0	1	8.6	46.4	2.1	0	10.7	3.6	4.6	0.4	2.9	2	1.7	5.3	1.3	3.9	2.7
CD300E	"CD300LE, CLM2, IREM2"	ENSG00000186407	CD300e molecule	Q496F6	17	74609887-74623738	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	Immunity	Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 36.5;bone marrow: 22.5;lymphoid tissue: 21.0	Cell line enhanced	Detected in some		HeLa: 1.7;SCLC-21H: 1.5	Low cancer specificity	Detected in many			Low region specificity	Detected in some			Group enriched	Detected in some	5	classical monocyte: 22.7;intermediate monocyte: 36.5;non-classical monocyte: 36.3	Lineage enriched	Detected in many	6	monocytes: 36.5	Low region specificity	Detected in single							HPA015570	Uncertain									HPA015570: AB_1846294	unprognostic (1.70e-1)	unprognostic (6.82e-2)	unprognostic (1.76e-1)	unprognostic (2.63e-2)	unprognostic (1.42e-2)	unprognostic (2.12e-1)	unprognostic (1.68e-2)	unprognostic (7.80e-3)	unprognostic (4.51e-1)	unprognostic (1.53e-1)	unprognostic (2.69e-2)	unprognostic (5.15e-2)	unprognostic (4.19e-7)	unprognostic (1.90e-2)	unprognostic (2.00e-4)	unprognostic (7.38e-3)	unprognostic (1.19e-1)	8.5	0.7	0.5	21	0.6	22.5	0.7	1.2	1	0.5	1.2	0.3	0	0	0.7	3	0.9	1.5	1.9	2	0.5	0.5	2.5	1.1	14.3	9.4	0.5	0.2	1	0.8	0	0.5	1.7	0.7	0.6	0.2	1.1	0.6	1.6	1.6	0.6	0.7	5.3	0.9	14.3	0.8	0.7	0.3	0.2	1.2	0.8	0.8	1.8	0.6	0	5.9	0.5	36.5	0	0	11.6	0.2	0	1.1	0.1	0	0.1	0.2	0.2	0.2	0	0.1	1.1	0	0.5	0.2	0.3	0.2	0	0.1	0	0.1	0.1	0	1.7	0.8	0	0.9	0.3	0.1	0.3	0	0	0	0.2	0.5	0	0.9	0.2	0.8	0.5	0.4	0.2	0	0.2	0.1	0.6	1.5	0.5	0.3	0	0.1	0.6	0	0	0.5	0.7	0.7	0.2	0.9	0	0.1	0	0.6	0.5	0	22.7	0.1	0	36.5	0	0	0	0	5.9	0	0	0	0.5	0	36.3	0.1	0	11.6	0.5	0.6	1.2	1	0.5	0.5	0.5	0.2	0.7	0.3
CD300LB	"CLM7, TREM5"	ENSG00000178789	CD300 molecule like family member b	A8K4G0	17	74521174-74531474	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	Immunity	Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level		Group enriched	Detected in many	4	adipose tissue: 20.7;blood: 30.7;bone marrow: 8.8;lymphoid tissue: 10.9	Group enriched	Detected in some	6	HL-60: 4.5;NB-4: 5.9;THP-1: 4.6;U-937: 2.7	Low cancer specificity	Detected in some			Low region specificity	Detected in some			Cell type enhanced	Detected in many		eosinophil: 30.7	Group enriched	Detected in many	52	dendritic cells: 10.5;granulocytes: 30.7;monocytes: 13.0																				unprognostic (1.39e-1)	unprognostic (2.44e-2)	unprognostic (1.37e-1)	unprognostic (4.39e-2)	unprognostic (3.59e-2)	unprognostic (1.15e-1)	unprognostic (6.41e-2)	unprognostic (7.69e-2)	unprognostic (2.05e-1)	unprognostic (2.95e-2)	unprognostic (6.24e-2)	unprognostic (3.32e-1)	unprognostic (2.49e-4)	unprognostic (2.92e-2)	unprognostic (1.79e-2)	unprognostic (7.08e-2)	unprognostic (4.01e-2)	20.7	0.9	0.2	10.9	0.5	8.8	2	0.4	0.5	0.6	0.8	0.3	0.1	0.7	0.7	1	1.1	1.2	2.8	1.6	1.5	0.4	1.2	1	4.4	6.5	1.2	0.1	2	2.3	0	0.7	1.1	1	0.8	1.1	1.6	1.2	0.1	0.3	0.4	2	2.2	0.6	6.6	0.7	0.7	0.1	0.9	0.6	0.1	2.2	2.6	0.7	0	10.5	30.7	13	0.3	0.1	4.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0	0	0	0	4.5	0.5	0	0	0	0	0	0	0	0	0	0	5.9	0.4	0.1	0	0	0.3	0	0	0	0	0	0	0	0	4.6	0	0	0	0.7	0	0	0	0	0.7	2.7	0	0.6	13	30.7	0	5.6	0.1	0	0	0	10.5	0	0	0.1	13.8	0.3	0.7	6.6	0	4.2	0.2	0.5	0.4	0.5	1.5	0.4	1.2	0.1	1	0.1
CD300LD	"CD300D, CMRF35A4"	ENSG00000204345	CD300 molecule like family member d	Q6UXZ3	17	74579365-74592283	"CD markers, Predicted membrane proteins"	Immunity	Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level		Tissue enhanced	Detected in some		blood: 8.5;bone marrow: 3.2	Cell line enhanced	Detected in some		HMC-1: 4.4;RPMI-8226: 2.7	Not detected	Not detected							Cell type enriched	Detected in some	7	neutrophil: 8.5	Lineage enriched	Detected in many	7	granulocytes: 8.5									HPA027756	Uncertain									HPA027756: AB_10601097			unprognostic (8.03e-2)											unprognostic (3.30e-1)				0.3	0.2	0.1	2.2	0.1	3.2	0.2	0.2	0.3	0.4	0.2			0	0.2	0	0.2	0.4	0.3	0.3	0.1	0.1	0.1	0.2	0.9	0.7	0.1		0.1	0.1	0	0.1	0.1		0.1	0		1.1	0	0.1	1.6	0.9	0.1	0.1	1.4	0.2	1.7			0.1		0.6	0.4	0.1	0.5	0.7	8.5	0.7	0.8	1.3	0.2	0.4	0.3	0.5	1	0.6	0	0.3	0	0	0	0.1	0.3	0.4	0.5	0.3	0.5	0.5	0.3	0.5	0	0.5	0.2	0.2	1.5	0.7	0	1.1	4.4	0.6	0.4	0.3	0.5	0	0.5	1.7	0.2	1.4	0.2	0.6	0.5	0.6	0.4	0.6	2.7	0.5	0.8	0.5	0.5	0.7	0.4	0	0.6	0.1	0.5	0.6	0.5	1.1	0	0.8	0.3	0.6	0.2	0.3	0.3	0.8	0.4	0.4	0.4	0.7	0.2	0.3	0.3	0.2	0.7	0.5	0.5	0.4	8.5	0.8	0.4	0.5	1.3	0.2										
CD300LF	"CD300f, CLM1, IGSF13, IREM1, NKIR"	ENSG00000186074	CD300 molecule like family member f	Q8TDQ1	17	74694311-74712978	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	Immunity	Receptor		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	5	blood: 47.8;bone marrow: 18.2;lung: 24.1;lymphoid tissue: 29.1	Group enriched	Detected in some	6	THP-1: 15.6;U-937: 30.2	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Cell type enhanced	Detected in many		eosinophil: 47.8	Group enriched	Detected in many	46	dendritic cells: 13.5;granulocytes: 47.8;monocytes: 38.1									HPA013712	Supported									HPA013712: 	unprognostic (6.51e-2)	unprognostic (1.49e-3)	unprognostic (3.81e-2)	unprognostic (4.00e-2)	unprognostic (8.51e-2)	unprognostic (6.74e-2)	unprognostic (1.79e-1)	unprognostic (3.17e-3)	unprognostic (1.53e-2)	unprognostic (1.77e-1)	unprognostic (9.81e-2)	unprognostic (2.41e-1)	unprognostic (1.95e-1)	unprognostic (9.60e-2)	unprognostic (4.14e-2)	unprognostic (7.75e-2)	unprognostic (4.79e-2)	3.3	1	1.2	9.8	3.1	18.2	0.9	1.5	1.3	0.8	2.3	3.1	0	2.7	0.7	0.7	0.9	1.1	1.9	2.4	1.3	1.2	1.1	1.5	24.1	15.6	3.8	0.5	0.9	0.9	0	1	2.1	2.6	1.4	2.6	0.8	1.9	0.3	0.5	0.5	3.4	2.3	5.8	29.1	1	0.7	2.4	1.1	0.8	0	4.2	2.8	0.8	0	13.5	47.8	38.1	0.7	0.1	8.2	0	0	0	0	0	0	0	0	0	0	0	0.2	0	0.1	0	0	0	0	0	0	0	0	2	0	0	0	0.6	0.7	0	0	0	0	0	0	0	0	0	0	3.6	0	0	0.2	0	0.2	0	0	0	0	0	0	0	0	15.6	0	0	0	0	0	0.6	0	0	0	30.2	0	8.4	20.2	47.8	0	34.4	0.1	0	0	0	13.5	0	0	0	15.9	0.7	38.1	1.4	0	8.2	1.2	3.1	1.5	1.3	1.3	1.2	3.8	0.5	2.6	2.4
CD300LG	"CLM9, Trem4"	ENSG00000161649	CD300 molecule like family member g	Q6UXG3	17	43847148-43863629	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	Immunity	Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		adipose tissue: 76.1;breast: 45.4	Cell line enhanced	Detected in some		BEWO: 2.0;NB-4: 1.1	Low cancer specificity	Detected in single			Not detected	Not detected			Cell type enhanced	Detected in some		basophil: 2.4	Low lineage specificity	Detected in many																	870000	870000				unprognostic (2.38e-2)	unprognostic (2.06e-3)	unprognostic (2.63e-1)	unprognostic (2.72e-1)	unprognostic (3.18e-1)	unprognostic (2.73e-1)	unprognostic (1.40e-4)	unprognostic (1.77e-1)	unprognostic (1.33e-1)	unprognostic (2.01e-2)	unprognostic (4.08e-3)	unprognostic (8.69e-4)	unprognostic (2.12e-5)	unprognostic (1.30e-3)	unprognostic (1.45e-1)	unprognostic (1.76e-2)	unprognostic (1.57e-1)	76.1	0.9	0.1	2.8	0.2	0	45.4	0.1	0.5	2.2	6.1	0.1	1.2	0	1.7	5.4	1.5	1.8	1.7	10.5	0.1	0	1.9	1.4	4.6	0.5	0.1	0.2	0.8	1.1	0.2	0.1	25.2	0.2	2.6	0.1	1.4	1.7	0.8	8.2	3.1	0.9	0.3	0.1	1.1	1	16	0.1	2.1	1.2	1.7	0.2	1.5	7.8	0.5	1.6	2.4	0.2	0.6	0.2	0.1	0.1	0	0.1	0.3	0	0	2	0.3	0	0.6	0.2	0	0.2	0	1	0	0.1	0	0.4	0.3	0.4	0	0.5	1	0.4	0	0.1	0	0.2	0	0.1	0	0	0.2	0	0	0.1	0	1.1	0	0.2	0	0	0	0.1	0	0.3	0.7	0	0.1	0.2	0.2	0.1	0	0.2	0.6	0.4	0.3	0.1	0.6	0.3	0.4	0.1	0.1	2.4	0.2	0.2	0.1	0.1	0.1	0.1	0.2	0.2	1.6	0.5	0.2	0.2	1.2	0.6	0.1	0.4	0.1	0.1	0.1	0.2	0.1	0.4	0.1	0	0.1	0.2	0.2	0.1
CD302	"BIMLEC, CLEC13A, DCL-1, KIAA0022"	ENSG00000241399	CD302 molecule	Q8IX05	2	159768630-159798255	"CD markers, Predicted membrane proteins"		Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level		Tissue enhanced	Detected in all		liver: 113.8	Cell line enriched	Detected in many	5	ASC diff: 76.1	Low cancer specificity	Detected in many			Low region specificity	Detected in all			Low cell type specificity	Detected in many			Group enriched	Detected in many	190	dendritic cells: 17.0;granulocytes: 19.1;monocytes: 20.8	Low region specificity	Detected in all			Low region specificity	Detected in all									16000	16000				unprognostic (2.52e-1)	unprognostic (5.44e-2)	unprognostic (1.19e-2)	unprognostic (1.50e-1)	unprognostic (2.03e-1)	unprognostic (6.88e-2)	unprognostic (1.68e-2)	unprognostic (9.12e-3)	unprognostic (5.29e-3)	unprognostic (2.37e-2)	unprognostic (4.38e-2)	unprognostic (2.14e-1)	unprognostic (4.67e-3)	unprognostic (1.75e-2)	unprognostic (6.61e-2)	unprognostic (7.45e-2)	unprognostic (3.61e-3)	27.1	9.4	5	6.1	5.9	10.1	28.6	3.3	4.3	13.8	13.8	4	2.6	8.7	11.4	11	7.9	9.7	11.7	13.7	5.6	3.3	9.3	113.8	22.9	23.3	5.9	2.7	16.3	9	4.7	4	7	6.3	11.5	7.7	13.7	7.7	7.8	6.1	4.9	13.9	12.1	8.7	18.9	8.5	9.2	5.9	0.7	26.6	6.3	3.4	12.4	23.8	0	17	19.1	20.8	0	0	7.5	0	0.5	0.4	0	76.1	15.9	0	1.9	7.6	2.2	3.3	0.6	0.7	0.1	0.8	4	0	1.6	0.8	3.1	0.5	2.6	2.9	0.5	1.1	3.8	5.7	2.1	12.6	0.4	2.4	0	5.6	0.2	2.7	2.8	0.2	0	4.1	0.7	2.3	0	0.6	0	0.4	0.1	0.9	1	0.6	1.8	1.7	1.5	5.5	1.9	4.4	0	0.1	1.2	0.3	0	0	3	0.5	0.9	6.2	20.8	19.1	0	16.4	0	0	0	0	17	0	0	0	19.1	0	15.6	4.5	0	7.5	5	5.9	3.3	4.3	5.6	3.3	5.9	2.7	6.3	5.9
CD320	"8D6, 8D6A"	ENSG00000167775	CD320 molecule	Q9NPF0	19	8302127-8308356	"CD markers, Disease related genes, Predicted membrane proteins"		Growth factor	Disease mutation	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in many		NB-4: 74.9;RPMI-8226: 68.0	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in many			Low lineage specificity	Detected in many			Low region specificity	Detected in all			Low region specificity	Detected in all			"HPA014500, HPA073489"	Approved		Approved	Cytosol		400000	400000	Cytosol		"HPA014500: AB_1846295, HPA073489: "	unprognostic (9.97e-2)	unprognostic (2.62e-1)	unprognostic (3.51e-1)	unprognostic (2.54e-3)	unprognostic (2.17e-1)	unprognostic (2.39e-2)	prognostic unfavourable (4.02e-4)	unprognostic (4.19e-2)	unprognostic (7.13e-2)	unprognostic (1.31e-1)	unprognostic (9.35e-3)	unprognostic (1.25e-1)	unprognostic (2.03e-1)	unprognostic (1.07e-1)	unprognostic (8.92e-2)	unprognostic (3.14e-1)	unprognostic (9.90e-2)	23.1	20.1	13.1	13.4	14.9	6.3	39	12.6	19.1	12	23.2	9.7	10.5	16.6	15.8	58.1	11.4	14.9	28.9	20.7	13.2	18.7	15.2	16.3	15.1	18	18	8.5	14	27.6	7.6	11.9	38	19.9	19.7	14.2	18.6	16.5	12.8	14	6.4	17.4	11.9	11.9	32.8	21.3	23.7	9.3	14.3	22.4	9.3	8.6	12.1	19.6	10.3	25	0.8	0.6	18	51.3	15	12.7	13	2.9	37.3	9.4	4.9	6.8	6.6	9	13.4	10.3	13.9	7.7	11.5	21	4.9	8.2	0	10.6	2.6	16.1	39.9	5.5	11.2	19.8	6.3	10.5	13.9	4.7	2.5	7.8	6.5	13.1	16.8	39.6	5.2	12	11.1	74.9	20.4	54.5	13.7	3.9	68	10	0.3	27	11.7	13.8	5.9	16.8	0.4	4.7	7.3	15.4	11.4	23	21	37.7	23.6	12.5	11	38.6	16.7	0	0.6	0	51.3	0.6	29.2	10.3	34	27.4	1.1	9.9	23.1	26	0.8	18	0.4	25	21.7	15	13.1	14.9	12.6	19.1	13.2	18.7	18	8.5	19.9	9.3
CD33	"FLJ00391, p67, SIGLEC-3, SIGLEC3"	ENSG00000105383	CD33 molecule	P20138	19	51225064-51243860	"CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins"	Cell adhesion		FDA approved drug targets	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 49.3;lymphoid tissue: 45.4	Cell line enhanced	Detected in some		HEL: 27.9;HL-60: 37.1;HMC-1: 27.8;NB-4: 17.7;RPMI-8226: 20.0;THP-1: 21.8;U-937: 27.4	Low cancer specificity	Detected in many			Low region specificity	Detected in many			Group enriched	Detected in many	7	classical monocyte: 37.6;intermediate monocyte: 27.3;myeloid DC: 49.3;non-classical monocyte: 12.6	Group enriched	Detected in many	9	dendritic cells: 49.3;monocytes: 37.6									"CAB011442, HPA035832, HPA064807"	Approved		Supported	"Nucleoplasm,Plasma membrane"		1400000	1400000	"Nucleoplasm, Plasma membrane"		"CAB011442: , HPA035832: , HPA064807: "	unprognostic (1.18e-2)	unprognostic (1.45e-2)	unprognostic (2.80e-2)	unprognostic (7.14e-2)	unprognostic (3.71e-1)	unprognostic (9.43e-2)	unprognostic (2.59e-1)	unprognostic (5.90e-3)	unprognostic (1.76e-1)	unprognostic (1.56e-1)	unprognostic (2.53e-1)	unprognostic (6.28e-2)	unprognostic (6.88e-4)	unprognostic (7.79e-2)	unprognostic (3.35e-2)	unprognostic (6.49e-2)	unprognostic (1.67e-1)	10.2	4.3	3.6	8.4	6	23	6.5	0.8	3.5	2.6	2.7	4.4	0.3	2.5	2.3	5.2	1.7	3.9	5.3	7.5	3.1	2.5	4.1	6.4	11.6	45.4	6.4	1.8	1.9	1.9	0.5	1.7	5.4	5.2	2.6	3.4	2.6	2.9	2.1	1.2	2.5	4	5.6	9.9	31.6	2.8	1.5	5.8	2.5	1.7	0.2	2.7	4.7	2.3	0.1	49.3	4.6	37.6	3.3	0.2	14.7	0.1	0	0	0	0	0	0	0	0.8	0	0	0	0	1.7	0.1	0	0.1	0	0	0	0	0	27.9	0.1	0	0	37.1	27.8	0	0	0	0	0	5.1	7	0	0	0	17.7	0	8.5	0	1.4	20	0.1	0	0	0	0	0	0.1	0	21.8	0.2	4.8	0.4	0.6	0	0.1	2.4	0	3.2	27.4	0.1	3.3	37.6	2.3	0	27.3	0.1	0	0	0.1	49.3	0.1	0	0	4.6	3.3	12.6	1.4	0.2	14.7	3.6	6	0.8	3.5	3.1	2.5	6.4	1.8	5.2	5.8
CD34		ENSG00000174059	CD34 molecule	P28906	1	207880972-207911402	"CD markers, Predicted membrane proteins"	Cell adhesion			Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Group enriched	Detected in some	6	HUVEC TERT2: 31.8;MOLT-4: 31.4	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in some			Low lineage specificity	Detected in many			Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB000018, HPA036722, HPA036723"	Enhanced		Approved	"Nucleoplasm,Plasma membrane,Cell Junctions"		69000000	69000000	"Plasma membrane, Cell Junctions"	Nucleoplasm	"CAB000018: AB_2063006, HPA036722: , HPA036723: "	unprognostic (3.82e-1)	unprognostic (1.67e-1)	unprognostic (1.04e-1)	unprognostic (3.09e-1)	unprognostic (1.24e-1)	prognostic favourable (5.93e-5)	unprognostic (1.25e-2)	unprognostic (7.74e-2)	unprognostic (7.65e-2)	unprognostic (3.53e-1)	unprognostic (1.37e-3)	unprognostic (6.95e-2)	prognostic unfavourable (8.47e-4)	unprognostic (1.51e-2)	unprognostic (1.30e-1)	unprognostic (1.60e-1)	unprognostic (1.01e-2)	61.9	8.8	4.6	12.8	7.6	1.9	37.5	3.1	6.7	38.3	15.9	5.2	20.5	5	41.4	40.3	33.8	22.3	20.6	51.2	5.4	4.9	18.8	2.2	25	11.9	8.1	6.7	20.7	8.6	7.8	3.6	78.9	6.3	21	7.4	12.8	12.4	20.5	39.7	21.2	12.1	42.3	4.7	9.2	11.3	23.1	4.7	3.5	25.8	35.9	11	33.6	33.1	0.6	1.7	1.6	0.3	0.6	0.5	1.5	0	0	0	0	1.6	0.1	0.1	0.2	1.1	0.3	0.9	0	0	0	3.1	0.3	0	0	0	0.3	0	0	1	0	0	0	0	0	0.1	0	0.1	0	31.8	0	0	0.8	0	31.4	0.1	0.2	0	0	1.8	0	0.1	0	0	0.1	0	0.3	0	1.1	0	4.8	0.1	1.5	0	0	0	0	0	0.1	0	0.2	1.6	0.2	0.3	0.5	0.2	0.5	0.3	0.3	0.2	0.2	0.6	0.3	0.3	1.1	0.6	0.3	1.7	0.2	1.5	4.6	7.6	3.1	6.7	5.4	4.9	8.1	6.7	6.3	4.7
CD36	"FAT, GP3B, GP4, GPIV, SCARB3"	ENSG00000135218	CD36 molecule	P16671	7	80369575-80679277	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters"	"Cell adhesion, Transport"	Receptor	"Cancer-related genes, Disease mutation"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		adipose tissue: 464.3;breast: 156.1	Group enriched	Detected in some	5	ASC diff: 80.8;HEL: 38.4	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Group enriched	Detected in many	4	classical monocyte: 104.4;intermediate monocyte: 30.4;myeloid DC: 56.9	Group enriched	Detected in many	45	dendritic cells: 56.9;monocytes: 104.4	Low region specificity	Detected in many							"HPA002018, CAB025866, HPA071026"	Enhanced		Enhanced	Golgi apparatus		92000000	92000000	Golgi apparatus		"CAB025866: , HPA002018: AB_1078464, HPA071026: "	unprognostic (7.16e-2)	unprognostic (1.80e-2)	unprognostic (1.06e-3)	unprognostic (6.52e-2)	unprognostic (2.05e-1)	unprognostic (1.28e-1)	unprognostic (2.63e-1)	unprognostic (9.35e-2)	unprognostic (2.64e-2)	unprognostic (1.97e-1)	unprognostic (1.23e-3)	unprognostic (1.18e-1)	unprognostic (1.84e-3)	prognostic unfavourable (4.47e-4)	unprognostic (7.05e-3)	unprognostic (4.87e-2)	unprognostic (2.73e-3)	464.3	3.6	1.2	8.9	1.3	10.9	156.1	0.5	0.5	1.8	31.8	0.6	3.3	9.8	1.8	7.5	7.5	3.3	7.2	76.8	1.8	1.9	2.2	13.3	11.5	4.8	0.6	0.3	2.5	3.9	3.1	0.8	37.9	2.9	9.2	3.5	0.8	4.6	2.3	23.6	5.4	23.4	4.7	0.8	42.8	5	6	0.5	2.7	13.6	15.3	1.4	9.4	19.2	0.3	56.9	1.8	104.4	0.7	0.2	60.2	0	0	0.2	0.1	80.8	0.8	0.1	0.2	2.7	0	0	0	0	0	0.1	0.3	0	1	0.1	0	0.1	0.1	38.4	0.1	6.1	0	0	0	7.8	3.1	0	0	0.2	1.3	0	0.4	0	0	0.2	0	0	0	0	0.1	0.1	0	0.2	0.3	0.2	0.1	0	2.7	4.4	0	0.1	0.5	0.1	0	0	0.1	0.1	0	13.2	10.2	0.9	104.4	0.3	0.2	30.4	0.2	0.3	0	0	56.9	0	0.1	0	1.8	0.7	7.5	14.3	0.1	60.2	1.2	1.3	0.5	0.5	1.8	1.9	0.6	0.3	2.9	0.5
CD37	TSPAN26	ENSG00000104894	CD37 molecule	P11049	19	49335171-49343335	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"				Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 163.4;lymphoid tissue: 109.6	Cell line enhanced	Detected in some		Daudi: 65.7;HMC-1: 65.1;RPMI-8226: 23.4;THP-1: 23.4;U-937: 17.4	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all			Low region specificity	Detected in many			Low region specificity	Detected in all			"CAB002492, HPA032120, HPA032121"	Enhanced									"CAB002492: AB_563554, HPA032120: AB_2674162, HPA032121: AB_2674163"	unprognostic (4.30e-3)	unprognostic (2.39e-3)	unprognostic (8.85e-2)	prognostic favourable (4.51e-4)	unprognostic (5.46e-2)	unprognostic (4.59e-3)	unprognostic (1.76e-1)	unprognostic (6.23e-2)	unprognostic (5.34e-2)	unprognostic (2.23e-1)	unprognostic (1.22e-1)	unprognostic (3.06e-1)	unprognostic (2.45e-3)	unprognostic (7.12e-2)	unprognostic (3.35e-2)	unprognostic (7.22e-2)	unprognostic (7.71e-2)	7.3	3.1	3.4	62.9	4.8	48.7	3.7	1	3.1	1.9	4.2	8.5	0	3.2	2	2.2	5.9	2.9	5.2	10.4	3.8	3.8	4.3	2.7	25.3	109.6	6.9	1.7	2.5	1.6	0.5	1.9	5.4	4.7	3.5	1.7	2.7	10.7	1.4	1.1	2	39.3	1.7	14.5	88.1	5.1	2.9	5	47.9	3.4	1.7	86.8	10.2	2.4	163.4	53.7	84.4	62.8	27.9	43.5	58.8	0	0.1	0.3	0.1	0	0	0	0	0	0	0	0	0	65.7	0	0	0.1	0	0	0	10.4	0	11.5	0	0.1	0	1.9	65.1	0	0	0	0	0	0.6	3.6	0	0	0.1	1.2	0	0	0.6	0	23.4	0	0	0	0	0	0	0	0	23.4	0.1	0	0.2	0	0	0	0	14.5	0	17.4	0	42.8	58.2	71.7	34.3	53.4	34.7	137.2	41.8	36.4	41.1	163.4	43.5	36.3	84.4	27.9	62.8	53.7	40.9	58.8	3.4	4.8	1	3.1	3.8	3.8	6.9	1.7	4.7	5
CD38		ENSG00000004468	CD38 molecule	P28907	4	15778275-15853230	"Cancer-related genes, CD markers, Enzymes, Predicted intracellular proteins"		"Hydrolase, Receptor, Transferase"	"Cancer-related genes, Diabetes mellitus"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	6	lymphoid tissue: 94.9;seminal vesicle: 104.1	Cell line enhanced	Detected in some		Daudi: 49.8;Karpas-707: 13.9;MOLT-4: 12.6;REH: 10.0;U-266/70: 10.8;U-698: 9.4	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Cell type enhanced	Detected in many		NK-cell: 15.3	Group enriched	Detected in all	4	B-cells: 9.0;dendritic cells: 5.1;NK-cells: 15.3	Low region specificity	Detected in all							"CAB002493, HPA022132, CAB025255, HPA052381"	Enhanced		Supported	Plasma membrane				Plasma membrane		"CAB002493: AB_563556, CAB025255: , HPA022132: AB_1846300, HPA052381: AB_2681807"	unprognostic (1.27e-2)	unprognostic (8.06e-3)	unprognostic (1.06e-2)	prognostic favourable (9.68e-4)	unprognostic (1.13e-1)	unprognostic (1.82e-3)	unprognostic (2.74e-1)	unprognostic (8.51e-2)	unprognostic (5.87e-2)	unprognostic (6.15e-6)	unprognostic (5.23e-1)	unprognostic (4.34e-1)	unprognostic (6.63e-6)	unprognostic (1.79e-1)	unprognostic (5.74e-2)	unprognostic (2.12e-2)	unprognostic (2.13e-1)	4.1	3.3	3.8	17.6	8.5	9.3	2.6	0.7	12	1	3.2	10.4	14.6	4.3	0.7	0.9	2.3	2.4	1.5	5	4	4.2	1.2	5.4	4.7	16.1	4.9	3.1	0.6	0.7	0	2.5	0.6	3.1	10.8	2.7	4.4	2.8	104.1	14.2	0.5	6.2	0.9	1.8	20.6	2	0.7	2.5	94.9	2.8	2	13.2	7.6	0.9	9	5.1	1.3	2.2	15.3	2.3	3.7	0	4.8	0	0	0	0	0	0	0	0	0.1	0	0	49.8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	13.9	0	0	12.6	3	0	0	10	0	7.8	0	0	0	0.6	0	0	0.2	0	2.2	0.2	0	0	0	0	10.8	0.1	9.4	0.1	2.4	0.1	0	1.7	0	1.1	2.2	0.3	9	1.4	1.2	4.1	6.6	2.3	1.8	1.3	15.3	1.4	5.1	2.1	3.7	3.8	8.5	0.7	6.2	4	4.2	4.9	3.1	3.1	2.5
CD3D	T3D	ENSG00000167286	CD3d molecule	P04234	11	118338954-118342744	"CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor	"FDA approved drug targets, SCID"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	8	blood: 108.7;lymphoid tissue: 181.4	Cell line enriched	Detected in some	5	MOLT-4: 152.7	Low cancer specificity	Detected in all			Not detected	Not detected			Group enriched	Detected in many	53	gdT-cell: 105.6;MAIT T-cell: 68.6;memory CD4 T-cell: 88.1;memory CD8 T-cell: 97.6;naive CD4 T-cell: 78.8;naive CD8 T-cell: 98.6;T-reg: 108.7	Lineage enriched	Detected in many	63	T-cells: 108.7	Low region specificity	Detected in some			Low region specificity	Detected in all			CAB013055	Enhanced									CAB013055: 	prognostic favourable (3.00e-4)	prognostic favourable (8.46e-5)	unprognostic (1.05e-2)	prognostic favourable (1.73e-7)	unprognostic (6.00e-2)	prognostic favourable (1.70e-4)	unprognostic (3.82e-1)	unprognostic (2.40e-2)	unprognostic (2.24e-3)	unprognostic (1.01e-2)	unprognostic (5.69e-2)	unprognostic (2.55e-1)	prognostic unfavourable (3.07e-5)	unprognostic (9.00e-2)	unprognostic (2.02e-1)	unprognostic (3.66e-2)	prognostic favourable (6.16e-4)	2.6	0.8	0.5	17.4	0.7	4.8	1.7	0.5	0.7	1.3	4.1	0.7	0.8	4.1	1.2	1.6	3.2	1.9	2.9	1	0.7	0.4	2.6	1.9	6.1	40.8	0.9	0.5	1	1.2	0	0.7	0.8	0.7	2.2	4.3	1.1	9	0.8	0.7	1.3	19.3	1	1.5	28.6	4.4	0.8	0.5	181.4	2.7	2.8	32.6	5.7	2.4	0.5	0.3	1.7	0.3	0.2	108.7	64.9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0.1	0	0	0	0	0	0	5.8	0	0	0	152.7	28.5	0.1	0	0	0	0	0	0	0	0	0	0.3	0	0.1	0	0	0	0.2	0.1	0	0.1	0.1	0	0	0	0	0.5	0.3	0.2	105.6	0.2	68.6	0.5	88.1	97.6	0.3	0.2	78.8	98.6	1.7	0.2	0.3	0.3	108.7	64.9	0.5	0.7	0.5	0.7	0.7	0.4	0.9	0.5	0.7	0.5
CD3E		ENSG00000198851	CD3e molecule	P07766	11	118304545-118316175	"CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor	FDA approved drug targets	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enriched	Detected in many	5	lymphoid tissue: 294.2	Cell line enriched	Detected in some	77	MOLT-4: 118.0	Low cancer specificity	Detected in all			Low region specificity	Detected in single			Group enriched	Detected in many	36	gdT-cell: 59.5;MAIT T-cell: 50.2;memory CD4 T-cell: 50.7;memory CD8 T-cell: 55.7;naive CD4 T-cell: 61.3;naive CD8 T-cell: 62.0;NK-cell: 21.8;T-reg: 46.8	Group enriched	Detected in many	29	NK-cells: 21.8;T-cells: 62.0	Not detected	Not detected			Low region specificity	Detected in all			"CAB000010, HPA040957, HPA043955, CAB072863, CAB072864"	Enhanced									"CAB000010: AB_2631163, CAB072863: , CAB072864: , HPA040957: AB_2677222, HPA043955: AB_2678747"	prognostic favourable (1.72e-4)	prognostic favourable (1.62e-4)	unprognostic (1.51e-2)	prognostic favourable (2.30e-6)	unprognostic (4.31e-2)	prognostic favourable (1.32e-4)	unprognostic (3.60e-3)	unprognostic (3.85e-2)	prognostic favourable (1.18e-4)	unprognostic (6.11e-3)	unprognostic (1.59e-1)	unprognostic (3.59e-1)	prognostic unfavourable (1.12e-5)	unprognostic (5.46e-2)	unprognostic (9.28e-2)	unprognostic (3.13e-2)	unprognostic (1.12e-2)	3.9	1	0.5	16.7	0.7	6.8	1.9	0.5	0.7	2.1	4.7	0.9	0.7	4.4	2	1.4	3.3	3	4	1.4	0.5	0.5	3.3	2.6	7.3	40.9	1.3	0.6	1.5	1.3	0	0.9	1.2	0.9	2.6	3.9	1.9	6.4	1.1	0.8	1.3	21.1	1.1	1.9	34.5	4.6	1.2	0.5	294.2	3.4	2.1	37.8	6.3	3	0.2	0.9	1.4	0.2	21.8	62	32.9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0.3	0	0	118	0.1	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2	1.2	1.5	0	0.1	0	1.3	0.2	0.2	59.5	0.1	50.2	0.1	50.7	55.7	0.1	0.2	61.3	62	1.4	21.8	0.2	0.9	46.8	32.9	0.5	0.7	0.5	0.7	0.5	0.5	1.3	0.6	0.9	0.5
CD3G		ENSG00000160654	CD3g molecule	P09693	11	118344344-118355161	"CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor	FDA approved drug targets	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enriched	Detected in many	4	lymphoid tissue: 187.6	Cell line enriched	Detected in single	78	MOLT-4: 64.9	Low cancer specificity	Detected in many			Not detected	Not detected			Group enriched	Detected in many	30	gdT-cell: 43.5;MAIT T-cell: 25.6;memory CD4 T-cell: 36.1;memory CD8 T-cell: 37.1;naive CD4 T-cell: 37.6;naive CD8 T-cell: 46.7;T-reg: 34.2	Lineage enriched	Detected in many	37	T-cells: 46.7	Not detected	Not detected			Low region specificity	Detected in all			"CAB017520, HPA038494"	Enhanced		Supported	"Plasma membrane,Cytosol"				"Plasma membrane, Cytosol"		"CAB017520: AB_831094, HPA038494: "	prognostic favourable (6.33e-4)	prognostic favourable (2.61e-4)	unprognostic (4.58e-3)	unprognostic (3.12e-5)	unprognostic (6.30e-2)	prognostic favourable (3.00e-4)	unprognostic (1.98e-2)	unprognostic (1.54e-2)	unprognostic (8.25e-3)	unprognostic (1.08e-3)	unprognostic (1.54e-2)	unprognostic (2.19e-1)	prognostic unfavourable (9.33e-5)	unprognostic (1.60e-1)	unprognostic (2.37e-2)	unprognostic (4.13e-2)	unprognostic (2.10e-3)	1.1	0.6	0.4	7.1	0.4	0.5	0.8	0.3	0.3	0.7	2.3	0.4	0.4	2	0.9	0.6	1.5	1.1	1.9	0.6	0.4	0.4	1.2	0.9	2.4	17.2	0.5	0.2	0.7	0.7	0	0.5	0.4	0.3	1	1.6	0.9	2.9	0.3	5.9	0.6	8.1	0.2	0.8	11.5	2.4	0.5	0.2	187.6	1.4	1.7	19.2	2.5	1.1	0.1	0.2	1.2	0.2	0.2	46.7	14.1	0	0.1	0	0.1	0	0	0.3	0	0	0	0	0	0.1	0.2	0	0	0	0	0	0	0.2	0.2	0	0.1	0	0	0	0.1	0	0	0	0	0	0.8	0.2	0	0.2	64.9	0.4	0	0	0	0	0.1	0	0	0.1	0	0	0.4	0	0.2	0.1	0	0	0.1	0.1	0	0.1	0.2	0.1	0.1	0.1	0	0.6	0.2	0.2	43.5	0.1	25.6	0.1	36.1	37.1	0.1	0.1	37.6	46.7	1.2	0.2	0.1	0.2	34.2	14.1	0.4	0.4	0.3	0.3	0.4	0.4	0.5	0.2	0.3	0.2
CD4		ENSG00000010610	CD4 molecule	P01730	12	6786858-6820808	"CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Host-virus interaction, Immunity"	"Host cell receptor for virus entry, Receptor"	FDA approved drug targets	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		lymphoid tissue: 111.5;parathyroid gland: 78.4	Group enriched	Detected in some	6	HEL: 33.5;HL-60: 13.5;NB-4: 19.3;THP-1: 38.1;U-937: 35.9	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Group enriched	Detected in many	17	classical monocyte: 42.2;intermediate monocyte: 42.5;memory CD4 T-cell: 29.1;myeloid DC: 29.3;naive CD4 T-cell: 24.8;non-classical monocyte: 33.3;plasmacytoid DC: 46.7;T-reg: 26.4	Group enriched	Detected in many	20	dendritic cells: 46.7;monocytes: 42.5;T-cells: 29.1	Region enriched	Detected in single	15	basal ganglia: 41.4	Low region specificity	Detected in many			"CAB000011, HPA004252, HPA004472, CAB068180"	Enhanced		Supported	Plasma membrane				Plasma membrane		"CAB000011: AB_442062, CAB068180: , HPA004252: AB_1078466, HPA004472: AB_1078465"	unprognostic (1.39e-2)	unprognostic (1.12e-2)	unprognostic (2.75e-2)	prognostic favourable (2.16e-4)	unprognostic (7.76e-2)	unprognostic (4.82e-3)	unprognostic (3.70e-2)	unprognostic (2.74e-2)	unprognostic (7.04e-2)	unprognostic (2.40e-1)	unprognostic (1.13e-1)	unprognostic (1.92e-1)	prognostic unfavourable (7.45e-4)	unprognostic (1.06e-1)	unprognostic (4.65e-3)	unprognostic (9.08e-3)	unprognostic (2.95e-1)	13.8	5.4	6.1	16	5.8	4.4	5.6	1.2	4.3	4.5	5.1	8.6	1.8	3.6	3.5	8.3	3	5.5	7.3	5.4	4.9	4.4	6.1	32.2	24	30.8	6.3	3.1	3	3.1	78.4	3.4	10.9	6.2	4.1	6.5	5.7	5.4	3.9	1.9	3.5	9.5	5.2	10.2	49.1	3.9	2.8	5.7	111.5	3.9	4.1	18.6	8.6	3.2	0.1	46.7	1.9	42.5	0.3	29.1	33.6	0	0	1.2	0	0	0	0.1	0	0.8	0	0	0	0	0.1	0	0	0	0	0	0	1.7	0	33.5	0	0.2	3.7	13.5	0	0	0	0	0	0	0	0	0	0	4.8	19.3	0.3	0	0	0	4.1	0	0	0.1	0	0	0	0	0	38.1	0	0	0	0	0	0	0	0	0	35.9	0	0.1	42.2	0.3	0.3	42.5	1.1	0	29.1	0.1	29.3	0.1	24.8	0.1	1.9	0.3	33.3	46.7	26.4	33.6	6.1	5.8	1.2	4.3	4.9	4.4	6.3	3.1	6.2	5.7
CD40	"Bp50, p50, TNFRSF5"	ENSG00000101017	CD40 molecule	P25942	20	46118272-46129863	"Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins"	Immunity	Receptor	"Cancer-related genes, Disease mutation"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in many		CAPAN-2: 26.7;EFO-21: 46.9	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in many		memory B-cell: 36.1;naive B-cell: 41.3	Group enriched	Detected in many	6	B-cells: 41.3;monocytes: 10.8	Low region specificity	Detected in many			Low region specificity	Detected in many			"CAB002495, HPA031567, HPA031568, CAB072868"	Enhanced				Secreted to blood	16000	16000			"CAB002495: AB_563562, CAB072868: , HPA031567: AB_2673936, HPA031568: AB_2673937"	unprognostic (6.41e-2)	unprognostic (1.55e-2)	unprognostic (7.08e-3)	unprognostic (6.21e-2)	unprognostic (4.23e-3)	unprognostic (1.25e-1)	unprognostic (7.64e-3)	unprognostic (1.34e-1)	unprognostic (4.15e-2)	unprognostic (7.16e-2)	unprognostic (2.48e-2)	unprognostic (7.04e-2)	prognostic unfavourable (4.48e-4)	unprognostic (1.22e-1)	unprognostic (4.95e-2)	unprognostic (1.60e-2)	unprognostic (2.28e-2)	13	4.6	3.6	38.6	4.7	1.1	11.6	9.7	4.4	11.3	9.2	3.6	7.8	6.5	9.6	8.6	9.9	9.7	8.6	9.5	4.5	2.6	10	10	18.8	34.7	3.3	3.2	14.8	14	12.1	5.9	6.5	5.4	14.7	5.2	13.7	13	11.6	7.5	9	11.8	10	4.6	30.1	8.4	4.4	4.4	11.5	16.5	6.7	46	12.5	13.8	41.3	4.1	1	10.8	0.6	1.4	4.8	9	1.4	0	4.5	1.7	0.9	1.8	1.6	0.5	1.3	1.3	0	26.7	14.5	46.9	0.3	1.1	0.8	5.7	1.4	9.7	0	3.4	0	2.5	13.4	0	4.6	6	2.2	5.5	0	10.1	1.1	0	0.2	0	0	0	0.6	0	0.3	0.3	1.5	11.8	0.1	0	0	7.9	4.5	0	0.9	4.8	0	0	15	0	0	0	0	9.9	3.4	1.7	0	1	7.7	0.1	1.3	10.8	0.9	36.1	0.7	0.5	4.1	41.3	1.4	1	0.7	0.6	7.5	2.1	1	4.8	3.6	4.7	9.7	4.4	4.5	2.6	3.3	3.2	5.4	4.4
CD40LG	"CD154, CD40L, gp39, hCD40L, HIGM1, IMD3, TNFSF5, TRAP"	ENSG00000102245	CD40 ligand	P29965	X	136648193-136660390	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins"		Cytokine	"Cancer-related genes, Disease mutation"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	5	blood: 29.2;intestine: 8.7;lymphoid tissue: 33.7	Cell line enriched	Detected in single	72	MOLT-4: 22.4	Low cancer specificity	Detected in many			Not detected	Not detected			Group enriched	Detected in many	5	gdT-cell: 9.4;MAIT T-cell: 22.9;memory CD4 T-cell: 29.2;naive CD4 T-cell: 28.1	Lineage enriched	Detected in single	58	T-cells: 29.2	Not detected	Not detected			Low region specificity	Detected in many			HPA045827	Enhanced				Secreted to blood					HPA045827: AB_10959606	unprognostic (1.94e-5)	unprognostic (1.24e-2)	unprognostic (3.26e-1)	unprognostic (1.27e-3)	unprognostic (4.71e-2)	unprognostic (3.56e-5)	unprognostic (3.66e-2)	unprognostic (5.48e-3)	unprognostic (2.77e-1)	unprognostic (2.14e-4)	unprognostic (1.87e-1)	unprognostic (1.55e-1)	unprognostic (6.70e-4)	unprognostic (2.15e-1)	unprognostic (5.19e-2)	unprognostic (2.36e-3)	unprognostic (2.92e-2)	2	0.5	0.3	22.4	0.3	1.4	1.2	0.3	0.3	2	3.3	0.1	0	1.7	1.5	1.3	1.6	1.6	2.6	1.1	0.4	0.4	1.6	1.1	4	14.6	0.4	0	0.7	0.6	0	0.4	0.2	0.3	1	3.1	1	4.9	1.3	0.4	1.1	8.7	0.5	0.6	9.9	1.7	0.6	0.1	33.7	1.4	2	26.1	3	1.4	0	0	0.5	0	0.2	29.2	4.7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3	0	0	0	0.1	0.2	0	0	0	0	0	0	0	0	0	22.4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.4	0	0.1	9.4	0	22.9	0	29.2	4.1	0	0	28.1	0.2	0.5	0.2	0	0	3.3	4.7	0.3	0.3	0.3	0.3	0.4	0.4	0.4	0	0.3	0.1
CD44	"CD44R, CSPG8, HCELL, IN, MC56, MDU2, MDU3, MIC4, Pgp1"	ENSG00000026508	CD44 molecule (Indian blood group)	P16070	11	35138870-35232402	"Blood group antigen proteins, Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	Cell adhesion	"Blood group antigen, Receptor"	"Cancer-related genes, FDA approved drug targets"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in many			Low cell line specificity	Detected in many			Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all			Low region specificity	Detected in many			Low region specificity	Detected in many			"CAB000112, CAB000316, HPA005785"	Enhanced		Enhanced	"Golgi apparatus,Plasma membrane"	Secreted - unknown location	2400000000	2400000000	Plasma membrane	Golgi apparatus	"CAB000112: , CAB000316: AB_2076596, HPA005785: AB_1078467"	unprognostic (5.33e-2)	unprognostic (1.85e-1)	unprognostic (4.97e-2)	unprognostic (9.90e-3)	unprognostic (3.50e-3)	unprognostic (1.46e-2)	unprognostic (1.56e-2)	unprognostic (8.12e-2)	unprognostic (1.57e-1)	unprognostic (4.18e-2)	unprognostic (1.51e-3)	unprognostic (4.63e-2)	prognostic unfavourable (1.78e-8)	unprognostic (6.41e-2)	unprognostic (4.14e-2)	unprognostic (3.93e-2)	unprognostic (7.98e-2)	45.5	9	10.5	42.5	21.7	53	35.6	4.7	13.4	43.2	19.5	26.3	8.3	10.6	80.5	20.3	66.5	18.6	48	11.7	14.9	9.3	12.4	9.1	43.4	48.4	31.5	6.1	12.8	83.9	0.8	3.8	19.4	40.7	30.1	24.5	30.2	148.2	22.4	15.9	107.7	18.9	44.5	100.5	30.9	19.9	7.2	20.3	17.9	20.6	53.9	53.7	55	54.2	22.7	41	19.1	65.2	54.6	53.1	59.9	41.5	37.6	0.3	0.1	22.7	62.8	0.1	81.5	63.8	45.4	25.3	2.5	13.1	0	10.9	115.5	71.7	0.8	88.6	62.4	8.9	0.4	1.5	18.5	0	22.4	21.1	97.8	28.3	70	61.1	49.6	15.9	0.3	13.6	43.5	0.2	1.9	13.9	0.8	11.1	0.1	7.7	0.6	66.5	12	0.1	0.1	15.4	0.4	36.9	2.2	1.2	45.6	56.6	10.2	69.4	83.7	23.6	25.4	0.2	85.9	11.9	82.2	19.1	65.2	6	26.2	45.7	37	22.7	39.8	34.9	41	16.2	34.5	28.7	16.4	54.6	59.3	14.2	53.1	59.9	10.5	21.7	4.7	13.4	14.9	9.3	31.5	6.1	40.7	20.3
CD46	"MCP, MGC26544, MIC10, TLX, TRA2.10"	ENSG00000117335	CD46 molecule	P15529	1	207752057-207795513	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins"	"Complement pathway, Fertilization, Host-virus interaction, Immunity, Innate immunity"	"Host cell receptor for virus entry, Receptor"	"Cancer-related genes, Disease mutation, Hemolytic uremic syndrome"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Low cell line specificity	Detected in all			Low cancer specificity	Detected in all			Low region specificity	Detected in all			Group enriched	Detected in all	4	basophil: 41.7;eosinophil: 63.7;neutrophil: 69.8	Lineage enriched	Detected in all	5	granulocytes: 69.8									"CAB010401, HPA016903"	Enhanced		Uncertain	Plasma membrane		1000000	1000000	Plasma membrane		"CAB010401: AB_2291289, HPA016903: AB_1846309"	unprognostic (1.42e-2)	prognostic unfavourable (8.54e-5)	unprognostic (3.94e-2)	unprognostic (2.14e-2)	unprognostic (3.28e-2)	unprognostic (6.30e-2)	unprognostic (1.91e-2)	unprognostic (1.82e-1)	unprognostic (1.25e-1)	unprognostic (2.74e-1)	unprognostic (8.79e-2)	unprognostic (2.50e-1)	unprognostic (6.78e-3)	prognostic favourable (2.38e-4)	unprognostic (1.76e-1)	unprognostic (8.23e-2)	unprognostic (1.49e-2)	38	78	13	22.9	20.5	18.5	57	12.9	17.8	27.5	35.4	25.3	64.3	32.9	39.7	32.6	43.2	30.4	25.2	20.6	16.1	15.5	50.8	57.8	43.6	25	21.4	13.2	27.6	47.9	86.6	32.7	119.6	29.1	47	28.5	26.7	68.4	60.5	18.8	18.4	39.8	25	21.8	26.9	33.9	16.5	20.7	20.3	25.3	21.8	30.3	37.2	27	7.7	8.1	69.8	14.1	7.5	13.5	14.9	26.2	14.8	13.9	6.4	44	43.5	21.2	19.7	28.7	13	17.7	14.6	69.9	4	20.1	19.6	35.6	10.4	27	19.9	20.2	14.8	8.7	16.3	26.1	28	19	30.4	37.4	40.3	19.6	15.5	36.4	18.3	17.5	20	12.3	9	16.7	15.9	14.8	6.1	22.1	24.7	53.3	52	14.1	9.6	24.9	56.1	32.3	44.1	16.3	31.2	14	12.5	29.4	22.4	23.6	28.5	12.1	20.5	12.5	13.1	41.7	13.5	63.7	9.2	14	12.5	7.7	11.7	10.1	8.1	6	13.5	11.2	69.8	7.5	14.1	4.2	10.1	14.9	13	20.5	12.9	17.8	16.1	15.5	21.4	13.2	29.1	20.7
CD47	"IAP, MER6, OA3"	ENSG00000196776	CD47 molecule	Q08722	3	108043094-108091862	"CD markers, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	Cell adhesion			Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Low cell line specificity	Detected in many			Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all			Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB016055, HPA044659"	Approved		Supported	"Vesicles,Plasma membrane"		2000000	2000000	Plasma membrane	Vesicles	"CAB016055: AB_627086, HPA044659: AB_2679040"	unprognostic (3.54e-2)	unprognostic (4.74e-2)	unprognostic (3.19e-2)	prognostic unfavourable (2.44e-4)	unprognostic (4.49e-2)	unprognostic (2.14e-1)	unprognostic (2.05e-3)	unprognostic (8.77e-3)	unprognostic (7.35e-2)	unprognostic (1.53e-1)	unprognostic (1.69e-2)	unprognostic (2.87e-1)	prognostic unfavourable (1.69e-4)	unprognostic (7.37e-2)	unprognostic (3.78e-1)	prognostic favourable (7.29e-5)	unprognostic (1.83e-1)	16.2	24.3	23	28.8	46.5	58	29	44	55.5	20.5	25.7	42.5	13.4	19.8	16.2	30.4	46.7	31.7	26	26.7	24.1	24.4	19.1	22.1	49.6	35.1	27.4	28.8	16.2	25.7	11.5	34.8	23.3	43.6	40.2	29	15.7	43.8	18.9	18.1	19.3	21.2	21	37.7	29	33.4	20.6	25	34.4	30.1	22	42.5	25.1	29.1	40.1	35.6	44.1	64.4	45.1	65.3	51.7	45.4	8.2	16.4	9.3	23.6	25.4	21.7	17.2	26.9	13.4	22.9	0.4	25.7	20.9	27.9	16.5	31.2	9.1	17.3	17.5	12.3	6.3	53.1	7.6	0.7	13.7	37.8	71.8	16.3	10.6	12.8	10.3	13.2	12.5	49.6	19.9	23.3	45.9	14.2	6.8	20.9	24.5	12.1	29.5	34	18.1	12.5	7.8	10.2	20.4	17.4	36.9	12.4	12.7	34.7	6.4	19.4	11.6	19.2	13	29.3	25.3	19	9.5	31.7	24.7	44.1	40.2	48.1	35	40.1	47	42	35.6	39.2	35.4	38.3	30.1	45.1	64.4	27.7	65.3	51.7	23	46.5	44	55.5	24.1	24.4	27.4	28.8	43.6	25
CD48	"BCM1, BLAST, hCD48, mCD48, SLAMF2"	ENSG00000117091	CD48 molecule	P09326	1	160678746-160711851	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"				Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 81.3;lymphoid tissue: 86.3	Cell line enhanced	Detected in some		Daudi: 38.0;HMC-1: 42.5;U-266/70: 90.0;U-266/84: 60.1	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all											"CAB002497, HPA055146"	Enhanced		Supported	"Nucleoli fibrillar center,Plasma membrane,Cytosol"	Intracellular and membrane	2600000	2600000	Plasma membrane	"Nucleoli fibrillar center, Cytosol"	"CAB002497: AB_563586, HPA055146: "	prognostic favourable (3.91e-4)	unprognostic (1.72e-3)	prognostic favourable (4.17e-4)	unprognostic (1.58e-3)	unprognostic (2.36e-1)	unprognostic (1.71e-3)	unprognostic (2.09e-2)	unprognostic (2.19e-2)	unprognostic (1.92e-1)	unprognostic (3.02e-2)	unprognostic (1.38e-1)	unprognostic (1.65e-1)	prognostic unfavourable (3.36e-4)	unprognostic (3.21e-1)	unprognostic (4.69e-2)	unprognostic (9.38e-2)	unprognostic (8.51e-2)	5.5	1.4	1	44.6	0.9	23.1	2.8	0.6	0.7	3.2	5	0.5	1.1	3.2	1.9	2.5	7.3	2.1	4.8	1.8	1	1	3.6	3.1	15.4	86.3	1.6	0.3	2.3	1.5	0	1.3	2.2	0.8	2.8	5.7	2.4	13.9	1.5	1.3	1.2	21.2	1.7	3.8	66.6	5	1.3	0.2	50.8	2.9	3.6	58	8.6	2.6	34.6	53.6	35.8	74.1	24.9	57.9	81.3	0.1	0	0	0	0	0	0	0	0	0	0	0	0	38	0	0	0.1	0	0	0	1	0	0.3	0	0	0	4.5	42.5	0	0	0	0	0	0	13.9	0	0	13.2	6.5	0	0	0.8	0	5.8	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	90	60.1	15.4	0	11.4	0	28.2	52.2	35.8	42.4	74.1	57.9	34.6	48.3	48.8	53.6	27.9	49.7	52.5	13.4	24.9	73.5	9.4	36.4	81.3	1	0.9	0.6	0.7	1	1	1.6	0.3	0.8	0.2
CD5	"LEU1, T1"	ENSG00000110448	CD5 molecule	P06127	11	61102395-61127852	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"				Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	4	blood: 36.3;lymphoid tissue: 96.2	Cell line enriched	Detected in single	99	MOLT-4: 38.4	Low cancer specificity	Detected in many			Low region specificity	Detected in single			Group enriched	Detected in many	20	gdT-cell: 12.9;MAIT T-cell: 9.3;memory CD4 T-cell: 31.2;memory CD8 T-cell: 20.6;naive CD4 T-cell: 25.9;naive CD8 T-cell: 19.5;T-reg: 36.3	Lineage enriched	Detected in many	32	T-cells: 36.3	Low region specificity	Detected in single			Low region specificity	Detected in all			"CAB015392, CAB020308, HPA043416, HPA060839"	Enhanced									"CAB015392: AB_2075324, CAB020308: , HPA043416: , HPA060839: "	prognostic favourable (4.05e-4)	prognostic favourable (9.16e-5)	unprognostic (2.33e-1)	prognostic favourable (9.00e-5)	unprognostic (1.02e-2)	prognostic favourable (7.41e-6)	unprognostic (2.45e-3)	unprognostic (1.37e-2)	prognostic favourable (3.93e-4)	unprognostic (1.25e-2)	unprognostic (5.00e-2)	unprognostic (2.14e-1)	prognostic unfavourable (8.94e-5)	unprognostic (4.78e-2)	unprognostic (1.02e-2)	unprognostic (2.38e-1)	unprognostic (1.06e-1)	2.1	0.6	0.5	19.4	0.4	6.5	1.3	0.3	0.6	1.6	2.5	0.3	0.3	1.7	1.1	1.7	1.9	1.4	3.9	0.8	0.6	1.3	1.9	1.1	7.1	28.8	0.4	0.1	1.1	0.9	0	0.8	0.4	0.3	1.4	1.5	1.6	15.5	1.3	0.6	1.3	10.2	0.4	0.7	13.8	4.8	1.3	0.1	96.2	1.7	2.4	42.2	5.4	1.5	1.1	1.1	0.4	0.7	0.1	36.3	14.6	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	38.4	0	0	0	0.1	0	0.3	0	0	0.3	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0.1	0.1	12.9	0.1	9.3	0.4	31.2	20.6	0.9	1.1	25.9	19.5	0.4	0.1	0.7	1.1	36.3	14.6	0.5	0.4	0.3	0.6	0.6	1.3	0.4	0.1	0.3	0.1
CD52	"CDW52, EDDM5, HE5"	ENSG00000169442	CD52 molecule	P31358	1	26317957-26320523	"Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins"			"Cancer-related genes, FDA approved drug targets"	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level		Group enriched	Detected in many	7	blood: 495.7;epididymis: 978.9	Group enriched	Detected in some	9	Daudi: 74.4;REH: 108.7;U-266/84: 108.6;U-698: 120.3	Low cancer specificity	Detected in all			Low region specificity	Detected in single			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all																						prognostic favourable (1.85e-5)	unprognostic (3.28e-3)	unprognostic (1.93e-2)	prognostic favourable (2.06e-4)	unprognostic (4.18e-2)	prognostic favourable (4.45e-4)	unprognostic (9.11e-2)	unprognostic (2.98e-2)	unprognostic (7.73e-3)	unprognostic (6.27e-2)	unprognostic (4.58e-1)	unprognostic (1.70e-1)	prognostic unfavourable (5.85e-4)	unprognostic (3.64e-1)	unprognostic (6.14e-2)	unprognostic (7.95e-2)	unprognostic (1.26e-1)	9.5	0.9	0.8	23	1.4	5.7	4.7	0.3	0.8	0.9	3.7	0.3	93.2	1	1.1	978.9	2.9	1.5	2.2	1.5	0.6	0.2	3.5	3.2	43.4	54.6	0.8	0.6	0.8	1	0	0.7	0.7	0.7	1.7	2.5	1.3	5.7	2.9	0.4	1.9	39.6	1.1	1.2	98.7	2.7	5.3	0.4	24.7	3.2	2.1	30.4	4.3	1.7	292	87.6	258.4	194.6	94.3	308.1	495.7	0.2	0	0	0	0	0.1	1.5	0	0.1	0	0	0	0	74.4	0.1	0	0	0	0	0	0	0	3.6	0	0.1	0	0.7	11.6	0	0	0	0	0	2.4	0.1	0	0.4	0.8	6.6	0.3	0	108.7	0.1	1.6	0	0	0.2	1	0	0.1	0.1	0	1.3	0.1	0	0.2	0	0.1	0.3	108.6	120.3	0	1.8	0	12.4	126.8	258.4	194.7	194.6	155.1	292	244.1	190.3	87.6	273.7	166.6	171.2	9.6	94.3	167.6	28.6	308.1	495.7	0.8	1.4	0.3	0.8	0.6	0.2	0.8	0.6	0.7	0.4
CD53	"MOX44, TSPAN25"	ENSG00000143119	CD53 molecule	P19397	1	110873154-110899928	"CD markers, Predicted membrane proteins, Transporters"				Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 146.7;lymphoid tissue: 103.0	Cell line enhanced	Detected in some		Daudi: 85.8;HDLM-2: 36.9;HMC-1: 54.0;Karpas-707: 33.7;U-266/70: 46.6;U-698: 26.6	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all			Low region specificity	Detected in all			Low region specificity	Detected in all			HPA047216	Enhanced									HPA047216: 	unprognostic (2.93e-2)	unprognostic (1.25e-2)	unprognostic (7.45e-3)	unprognostic (1.02e-3)	unprognostic (8.88e-2)	unprognostic (3.78e-2)	unprognostic (2.96e-1)	unprognostic (6.07e-2)	unprognostic (2.83e-2)	unprognostic (2.03e-1)	unprognostic (5.09e-2)	unprognostic (1.62e-1)	prognostic unfavourable (2.60e-4)	unprognostic (9.58e-2)	unprognostic (4.95e-2)	unprognostic (1.33e-1)	unprognostic (7.72e-2)	29.7	8.1	6.1	50.6	10.3	20.4	6.6	1.6	5.8	4.5	9.6	7.6	1.2	6.7	4.3	6	5.5	9.9	11	6.4	6.4	5.9	9.6	8.8	28.9	93.8	13.3	2.7	4.7	3.8	0.8	3.1	10.6	8.5	5.2	10.5	4.5	10.1	2.3	2.3	2.2	35.2	10	14.9	103	7.5	4.8	10	37.2	4.6	4.1	82.1	15.2	4	97.5	74.6	138	97	59.2	91.8	146.7	0.1	0	0	0	0	0	0	0	0	0	0	0	0	85.8	0	0	0	0	0	0	36.9	0	4.5	0	0	0	10.3	54	0	0	0	0	0	1.9	33.7	0	0	17.4	12.2	0	0	16.9	0.1	17.8	0	0	0	0	0	0	0	0	15.4	3	0	0	0	0	46.6	21.1	26.6	0.2	11.9	0.6	138	87	54.1	91.8	93.3	82.8	97.5	67.5	80.8	74.6	83.3	49.2	70.8	136.2	59.2	97	61.4	85	146.7	6.1	10.3	1.6	5.8	6.4	5.9	13.3	2.7	8.5	10
CD55	"CR, CROM, DAF, TC"	ENSG00000196352	CD55 molecule (Cromer blood group)	P08174	1	207321376-207386804	"Blood group antigen proteins, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	"Complement pathway, Host-virus interaction, Immunity, Innate immunity"	"Blood group antigen, Host cell receptor for virus entry, Receptor"	Disease mutation	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in many		HeLa: 77.5;HMC-1: 103.6;PC-3: 61.7;U-2197: 62.8	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in all		neutrophil: 101.4	Low lineage specificity	Detected in all											"HPA002190, CAB010454, HPA024386"	Enhanced				Secreted to blood	310000000	310000000			"CAB010454: AB_2075970, HPA002190: AB_1078472, HPA024386: AB_1846319"	unprognostic (4.08e-2)	unprognostic (3.22e-1)	unprognostic (3.41e-1)	unprognostic (1.63e-1)	unprognostic (9.05e-2)	unprognostic (1.08e-2)	unprognostic (1.05e-1)	unprognostic (1.22e-1)	unprognostic (1.06e-1)	unprognostic (3.57e-2)	unprognostic (1.55e-2)	unprognostic (1.86e-1)	prognostic unfavourable (9.36e-4)	unprognostic (3.41e-2)	unprognostic (2.04e-1)	unprognostic (9.70e-2)	unprognostic (2.33e-2)	21.8	63.2	5.8	27.2	20.2	31.9	17.9	4.6	10.5	34	14.8	13.8	7.8	12.8	16.3	11.9	36.1	10.4	18	32	7.5	10.1	9.6	16.7	114.6	41.1	16.7	4.7	31.3	9.1	8.1	12.8	107	11.9	9.7	12.4	8.2	82.3	12.8	108.8	37.5	26	23.5	11.4	30.4	17.7	10.2	18.8	4.2	13.2	31.4	19.1	39.3	19.1	18.6	18.3	101.4	31.6	19	16.9	20.3	4.7	6.5	0	2.1	8.3	8.9	33.9	9	15.8	5.2	5.6	20.4	6.8	9.2	7.5	5.3	2.7	10.4	2	4.8	4.2	3.8	11.9	77.5	3.3	27	7.2	103.6	4.2	24.4	6.4	28.1	26.8	12.8	4.4	2.9	5.1	0.7	5	6.6	61.7	1	6.4	7.2	8.6	4.5	2.6	0	48.7	9.9	7.8	8.4	6.1	11.7	2.6	5	62.8	3.4	3.7	4.3	6.2	7.1	2.9	11.9	39.3	26.9	35.9	5.5	26.3	8.2	16.9	7.4	5.8	18.3	18.6	16.9	16.4	101.4	19	31.6	9.8	5	20.3	5.8	20.2	4.6	10.5	7.5	10.1	16.7	4.7	11.9	18.8
CD58	LFA3	ENSG00000116815	CD58 molecule	P19256	1	116514535-116571039	"CD markers, Predicted membrane proteins"				Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in all		Karpas-707: 45.9	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all																	7100000	7100000				unprognostic (4.48e-3)	unprognostic (3.20e-1)	unprognostic (2.95e-2)	unprognostic (4.03e-2)	unprognostic (8.45e-2)	unprognostic (1.95e-1)	prognostic unfavourable (2.32e-6)	unprognostic (9.84e-2)	unprognostic (7.17e-2)	unprognostic (4.72e-2)	prognostic unfavourable (5.60e-4)	unprognostic (2.82e-1)	unprognostic (1.66e-2)	unprognostic (1.86e-1)	unprognostic (3.68e-2)	unprognostic (2.17e-2)	unprognostic (9.66e-2)	21.5	9.6	5.9	17.6	8.7	29.9	15.2	2.2	7.7	15.8	24.7	5.9	10.4	17	12.4	15.3	22.1	11	19.2	23.9	7.3	4.8	32.8	11	22.4	14.5	9.6	3.7	6.5	6.6	6.5	12	10	9.3	9.4	17.9	6.4	18.4	15.3	8.8	14.9	48.3	16.3	11.5	23.1	11.1	6.5	8.8	9.3	12	22.9	18.2	15.4	16.2	6	12.4	47.3	17.1	4.9	17.8	9.5	11.7	6.8	4.9	4.7	8.4	14.2	3.1	6	10.5	10.5	10.3	3	22.8	2.1	11.2	10.5	15.2	3.7	10.3	11.2	11.5	4.2	10.6	12.4	4.2	5.4	14.6	14.8	3.8	14.1	8.8	7.8	6	9.3	45.9	6.4	21.1	6.2	11.1	2.4	7.4	12.4	16.9	2.8	21.2	9.7	1.7	3.5	12.1	9	34	4.7	5.5	11.2	7.6	5.8	10.3	15.4	6.9	12.3	1.4	17.5	7.3	37.7	28.7	14.7	24.4	11.5	14.2	7.9	6	10.1	9.5	12.4	2.1	1.4	5.8	47.3	4.9	17.1	1.4	17.8	9.5	5.9	8.7	2.2	7.7	7.3	4.8	9.6	3.7	9.3	8.8
CD59	"16.3A5, EJ16, EJ30, EL32, G344, MIC11, MIN1, MIN2, MIN3, MSK21, p18-20"	ENSG00000085063	CD59 molecule (CD59 blood group)	P13987	11	33703010-33736491	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"			"Cancer-related genes, Disease mutation, Hereditary hemolytic anemia"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		placenta: 285.5	Cell line enhanced	Detected in many		TIME: 213.3;U-2197: 176.7	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in many			Low lineage specificity	Detected in all											"CAB001448, HPA026494"	Supported		Uncertain	"Golgi apparatus,Vesicles"	Intracellular and membrane	98000000	98000000	"Golgi apparatus, Vesicles"		"CAB001448: AB_563604, HPA026494: AB_1846321"	unprognostic (2.07e-2)	prognostic unfavourable (3.81e-5)	unprognostic (7.40e-2)	unprognostic (1.14e-2)	unprognostic (2.11e-2)	prognostic unfavourable (3.10e-5)	unprognostic (5.65e-2)	unprognostic (1.46e-1)	unprognostic (4.47e-2)	unprognostic (2.98e-1)	prognostic unfavourable (2.92e-5)	unprognostic (1.66e-2)	prognostic favourable (1.39e-10)	prognostic unfavourable (9.03e-4)	unprognostic (1.31e-1)	unprognostic (1.03e-2)	unprognostic (3.09e-1)	96.7	41	36.7	26.3	44.3	23.8	76	25.9	32.7	44.8	36.9	24	57.9	16.5	45.4	132.8	68.4	53.2	67.6	90.5	35.6	38.4	100	61	86.4	39.8	39.7	25.8	39.3	52.3	60.6	48	285.5	68.7	47.4	37.7	51.4	114.8	62.6	70.6	43.4	25	52.4	32.9	26.2	54.7	28.1	23.1	16.1	85.9	57.7	40	51.2	63.4	13.5	20.5	42.8	4.8	17.7	60.4	11.1	16.5	15.5	4.6	13.5	107.8	84.5	2.7	94.2	105.1	23.6	27.7	7.2	49.8	1.2	16.8	101.4	18.7	8.5	93.9	33.2	26.3	12.9	1.7	54.9	10.8	29.4	9.9	5.7	39.2	23.8	20	96.4	144	11.6	38.3	148.6	15.1	4.6	4.1	2.5	80.9	1.7	14.4	13.3	71.3	28.3	3.2	4.3	32.8	15.2	17.3	11.6	1	213.3	54.3	13	176.7	32.6	17	33.2	1.6	46.7	0	94.3	30.5	4.8	42.8	11.3	1.6	14.4	13.5	24	12.7	20.5	10.6	15.7	9.3	28.4	17.7	0.9	10.5	60.4	11.1	36.7	44.3	25.9	32.7	35.6	38.4	39.7	25.8	68.7	23.1
CD6	Tp120	ENSG00000013725	CD6 molecule	P30203	11	60971680-61020377	"CD markers, Predicted membrane proteins, Predicted secreted proteins"	"Adaptive immunity, Cell adhesion, Immunity, Innate immunity"			Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 23.0;lymphoid tissue: 58.1	Cell line enriched	Detected in some	18	MOLT-4: 28.6	Low cancer specificity	Detected in many			Low region specificity	Detected in some			Group enriched	Detected in many	34	gdT-cell: 12.4;MAIT T-cell: 11.1;memory CD4 T-cell: 23.0;memory CD8 T-cell: 21.4;naive CD4 T-cell: 15.5;naive CD8 T-cell: 11.1;T-reg: 10.1	Lineage enriched	Detected in single	52	T-cells: 23.0	Low region specificity	Detected in single			Low region specificity	Detected in all			"CAB002489, CAB016252"	Enhanced				Secreted to blood	110000	110000			"CAB002489: AB_563605, CAB016252: AB_631163"	prognostic favourable (1.95e-4)	prognostic favourable (1.57e-5)	unprognostic (4.47e-2)	prognostic favourable (2.41e-4)	unprognostic (2.06e-2)	prognostic favourable (5.10e-6)	unprognostic (8.45e-3)	unprognostic (8.21e-3)	unprognostic (2.87e-3)	unprognostic (5.32e-3)	unprognostic (2.07e-1)	unprognostic (5.35e-1)	prognostic unfavourable (1.82e-4)	unprognostic (1.77e-1)	unprognostic (4.95e-2)	unprognostic (6.19e-2)	unprognostic (5.96e-2)	1.5	0.5	0.8	26.4	0.4	5.5	0.9	0.5	1.4	1.3	3.3	0.6	0.8	2.2	1.4	1.5	1.9	1.3	5	1.3	0.7	1.8	1.6	1.1	6.9	25.6	1.7	0.5	0.7	0.8	0	0.6	0.6	0.4	1.2	1.6	1.2	7	0.3	0.3	0.9	13	0.7	0.9	18.4	3.4	0.9	0.1	58.1	1.6	1.9	42	3.7	1.3	0.4	0.1	0.3	0	0	23	5.1	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0.8	0	0	0	0	0	0	0	1.5	0	0	0	0.1	0.1	0	0	0	0	0	0.1	0	0	0	28.6	0	0.1	0.1	0.1	0	0.6	0	0.1	0.1	0.2	0	0.3	0	0.2	0.3	0	0	0	0.1	0	0.1	0	0	0.2	0	0	0	0	0	12.4	0	11.1	0.4	23	21.4	0.1	0.4	15.5	11.1	0.3	0	0	0	10.1	5.1	0.8	0.4	0.5	1.4	0.7	1.8	1.7	0.5	0.4	0.1
CD63	"ME491, MLA1, TSPAN30"	ENSG00000135404	CD63 molecule	P08962	12	55725323-55729707	"CD markers, Plasma proteins, Predicted membrane proteins, Transporters"	"Protein transport, Transport"			Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in all		ASC diff: 272.1	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all			Low region specificity	Detected in all			Low region specificity	Detected in all			"HPA010088, CAB026356"	Supported		Supported	Vesicles	Intracellular and membrane			Vesicles		"CAB026356: AB_629864, HPA010088: AB_1846323"	unprognostic (8.76e-3)	unprognostic (8.81e-2)	unprognostic (1.27e-1)	unprognostic (1.28e-3)	unprognostic (9.48e-2)	unprognostic (3.66e-3)	prognostic unfavourable (1.37e-4)	unprognostic (1.11e-1)	unprognostic (6.50e-2)	unprognostic (1.08e-1)	unprognostic (1.66e-2)	unprognostic (3.10e-1)	unprognostic (2.70e-2)	unprognostic (4.82e-2)	unprognostic (5.21e-2)	unprognostic (1.85e-3)	unprognostic (9.02e-2)	115.3	88.2	42.5	44.9	37.2	67.4	106.3	13.7	33.1	80.6	84.7	34.4	71.5	39.9	99.7	177.9	70.9	60.4	102.7	154.4	36.9	39	106.6	92.5	109.6	113.8	49.8	27.2	93.8	187.1	33.3	49.3	176.9	50.8	82.9	81.8	102.1	105	83.7	92.7	38.5	72.4	88.2	43.6	107.7	74.8	52.1	30.5	17.6	108.1	50.7	47.4	96.3	82.2	9.6	40.3	147.4	50.8	58.4	29.8	56.6	21.9	38.3	21	20.4	272.1	170.6	27.7	89.3	163.9	52.9	57.7	42.7	44.3	6.3	28.5	133	20.4	15.2	37	68.1	17.8	14.3	34.5	29.9	23.5	108.3	15.3	82.2	125.6	36.8	58.8	53.9	58.3	19.4	44.2	168.3	35.1	3.1	20.8	19.1	44.5	6.9	46.1	15.8	89.5	74.8	8.2	21	24.5	18.5	160.6	26.1	51.2	43.3	34.2	25	47.2	29.9	18.1	11.2	4.4	98.1	9.9	62.5	89.6	50.8	147.4	29.8	38.5	21.8	9.6	11.9	23.7	40.3	6.5	5.3	18.1	55.7	58.4	26.1	27	10	56.6	42.5	37.2	13.7	33.1	36.9	39	49.8	27.2	50.8	30.5
CD68	"DKFZp686M18236, GP110, LAMP4, macrosialin, SCARD1"	ENSG00000129226	CD68 molecule	P34810	17	7579467-7582113	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"				Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		blood: 179.1;lymphoid tissue: 139.1	Cell line enhanced	Detected in many		ASC diff: 73.3;U-87 MG: 115.5	Low cancer specificity	Detected in many			Low region specificity	Detected in all			Cell type enhanced	Detected in many		classical monocyte: 155.1;intermediate monocyte: 179.1;non-classical monocyte: 170.1	Group enriched	Detected in many	11	dendritic cells: 68.4;monocytes: 179.1	Low region specificity	Detected in all							"CAB000051, CAB000066, HPA048982, CAB072861, CAB072862"	Enhanced		Supported	"Golgi apparatus,Vesicles"				"Golgi apparatus, Vesicles"		"CAB000051: AB_2314148, CAB000066: AB_2074844, CAB072861: , CAB072862: , HPA048982: "	unprognostic (2.16e-2)	unprognostic (1.47e-2)	unprognostic (6.46e-2)	unprognostic (1.49e-3)	unprognostic (1.78e-2)	unprognostic (1.97e-1)	unprognostic (4.75e-4)	unprognostic (2.83e-2)	unprognostic (1.31e-1)	unprognostic (6.85e-2)	unprognostic (1.04e-1)	unprognostic (2.59e-1)	prognostic unfavourable (1.14e-5)	unprognostic (1.58e-1)	unprognostic (8.91e-2)	unprognostic (1.61e-1)	unprognostic (1.65e-2)	118.4	28.5	12.5	46.8	21.6	46.8	40.9	2.9	11.2	27.1	38.1	15.5	2.1	57	9.6	24.1	26.9	17.3	33.7	39	10.1	6.9	20.9	43.1	84.4	102.5	21.1	4.4	15.8	7.5	2.1	8.5	34.7	15.7	12.1	18.5	12.8	22.2	4.4	16.1	9.4	58.3	15.6	26	139.1	17.6	9.4	16.3	13.3	8.8	12.3	21.1	31.4	19.1	3.7	68.4	11	179.1	0.9	0.5	125.6	35.1	7.1	0.4	0.5	73.3	28	0.3	11.2	30.7	14.9	17.4	1.5	10.6	0.4	12.8	32.6	1.5	0.1	7.1	10.1	0.3	1.3	5.6	1.7	8.5	6.2	2.7	31.7	8.8	1.4	31.2	23	3.9	2.2	3.6	14.4	0.2	0.2	2.4	0.4	5.2	0.4	0.6	20.7	3	1.5	0.2	0.4	9.3	4.7	10.9	0.2	21.6	12.2	19	1.1	19	14.6	0.2	0.2	0.2	115.5	6.9	9.6	10.1	155.1	0.9	0.4	179.1	0.5	3.7	0.2	0.3	40.9	2	0.3	0.2	11	0.9	170.1	68.4	0.3	125.6	12.5	21.6	2.9	11.2	10.1	6.9	21.1	4.4	15.7	16.3
CD69	CLEC2C	ENSG00000110848	CD69 molecule	Q07108	12	9752486-9760901	"CD markers, Predicted membrane proteins"				Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		bone marrow: 52.1;lymphoid tissue: 56.4	Cell line enhanced	Detected in some		HL-60: 12.4;K-562: 24.0;MOLT-4: 8.6;U-266/70: 9.8;U-698: 11.1;U-937: 41.1	Low cancer specificity	Detected in many			Low region specificity	Detected in many			Low cell type specificity	Detected in many			Group enriched	Detected in many	4	NK-cells: 14.8;T-cells: 18.3	Not detected	Not detected			Not detected	Not detected			"CAB002503, HPA050525"	Enhanced									"CAB002503: AB_563625, HPA050525: "	prognostic favourable (3.31e-5)	unprognostic (1.84e-2)	unprognostic (1.80e-2)	unprognostic (1.73e-2)	unprognostic (1.66e-1)	unprognostic (7.10e-3)	unprognostic (4.76e-3)	unprognostic (9.53e-3)	unprognostic (9.73e-3)	unprognostic (1.64e-2)	unprognostic (1.96e-2)	unprognostic (1.75e-1)	prognostic unfavourable (7.87e-5)	unprognostic (2.88e-2)	unprognostic (3.32e-2)	unprognostic (4.28e-2)	unprognostic (1.65e-1)	10.1	2.2	1.3	19.9	1.4	52.1	7	0.5	0.9	9	9.6	4.6	0.8	2.8	5.1	5.1	10.6	6.4	13.6	3.1	2	2.2	4.7	6.2	27	31.6	4.5	0.6	3.4	1.4	0.9	3.4	1.9	3.5	7.4	8	3.3	6	2	1.5	3.3	14.3	5	8.3	43.3	4.3	4.5	1.6	56.4	5.5	6.1	26.7	27.4	5.9	3.9	0	3.1	0.1	14.8	18.3	3.8	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6	0.1	0	0	0.6	0	0	0	0	5.1	0	0	0.6	12.4	0.5	0	0	0	0	0.2	24	0	0	0	8.6	2.5	0	0	0	0	0	0.3	3.5	0	0	0	0	0	0	0	0	0	0	0	0	9.8	1.1	11.1	0	41.1	0	0.7	0.1	3.1	13.7	0	18.3	3.3	8.7	9.9	0	3.9	12.6	9.2	0.2	14.8	0	0	4.3	3.8	1.3	1.4	0.5	0.9	2	2.2	4.5	0.6	3.5	1.6
CD7	"GP40, LEU-9, Tp40, TP41"	ENSG00000173762	CD7 molecule	P09564	17	82314868-82317602	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	5	blood: 54.1;lymphoid tissue: 127.6	Group enriched	Detected in some	6	Hep G2: 21.1;MOLT-4: 48.0	Low cancer specificity	Detected in all			Not detected	Not detected			Cell type enhanced	Detected in many		NK-cell: 54.1	Group enriched	Detected in many	21	NK-cells: 54.1;T-cells: 19.0									"CAB002594, HPA039079"	Enhanced									"CAB002594: , HPA039079: "	unprognostic (3.14e-3)	prognostic favourable (5.51e-4)	unprognostic (1.89e-2)	prognostic favourable (2.03e-5)	unprognostic (7.69e-3)	unprognostic (1.09e-3)	unprognostic (3.28e-2)	unprognostic (1.34e-1)	prognostic favourable (2.69e-4)	unprognostic (3.16e-2)	unprognostic (1.03e-1)	unprognostic (2.24e-1)	prognostic unfavourable (7.75e-11)	unprognostic (4.69e-2)	unprognostic (1.55e-1)	unprognostic (1.97e-1)	unprognostic (1.55e-3)	4.7	0.7	0.5	23.4	0.4	14.5	1.7	0.4	0.3	1.9	8	0.3	0.5	7.7	1.8	1.9	3.4	2.4	3.5	1.4	0.5	0.6	2.8	4.1	9.5	50.2	0.9	0	1.6	1	0	1	4	0.4	2.7	1	1.8	6	1.1	0.5	1	17.5	0.5	1.6	33	4.6	0.9	0.1	127.6	2.2	1	33.3	4.6	2.2	0.1	1.7	0.6	0.1	54.1	19	7.1	0	0	0	0	0	0.1	5.5	0	0	0	0.1	0.2	0	0	0	0.1	0.2	0	0	0	0	0	0.1	0.2	21.1	0.2	0	0	1.2	0	0	0	0	0	0	0	0	48	0	0	0.1	0	0	0.9	0.1	0	0.1	0.1	0.7	0.4	0	0	0	0	0.1	0.1	0.4	0	0.5	0	0	0.1	0	0	0	0.1	0.1	17.6	0	15.1	0.1	7.9	12.8	0	0	19	18.9	0.6	54.1	0.1	1.7	6.8	7.1	0.5	0.4	0.4	0.3	0.5	0.6	0.9	0	0.4	0.1
CD70	"CD27L, CD27LG, TNFSF7"	ENSG00000125726	CD70 molecule	P32970	19	6583183-6604103	"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins"		Cytokine	"Cancer-related genes, Disease mutation"	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 23.3;lymphoid tissue: 12.7	Cell line enhanced	Detected in many		SiHa: 36.0;THP-1: 29.6;U-251 MG: 43.8;U-266/70: 78.0;U-266/84: 56.4	Cancer enhanced	Detected in many		renal cancer: 24.7	Not detected	Not detected			Cell type enhanced	Detected in many		memory B-cell: 13.9;T-reg: 23.3	Group enriched	Detected in many	38	B-cells: 13.9;T-cells: 23.3									HPA046582			Uncertain	Nucleoplasm				Nucleoplasm		HPA046582: 	unprognostic (8.71e-2)	unprognostic (9.91e-2)	unprognostic (1.61e-1)	unprognostic (2.33e-4)	unprognostic (1.73e-2)	unprognostic (1.51e-2)	unprognostic (1.61e-1)	prognostic unfavourable (6.29e-4)	unprognostic (1.36e-2)	unprognostic (1.25e-1)	unprognostic (1.92e-1)	unprognostic (1.72e-1)	prognostic unfavourable (3.22e-4)	unprognostic (2.57e-2)	unprognostic (1.40e-1)	unprognostic (2.27e-1)	unprognostic (2.08e-1)	5.3	0.2	0.2	9.3	0.2	1.4	2.2	0.9	0.9	1.4	4.1	0.2	0.1	1	0.4	1.8	4	0.7	0.8	0.4	0.2	0.2	1.7	0.4	1.9	6.1	0.4	0.1	0.3	0.4	0	0.3	0.3	0.2	0.9	3.1	0.2	3.1	1.2	1.2	3.3	5.2	0.7	0.5	11.8	1.7	1.9	0.1	3.2	0.8	1.8	12.7	3.1	1.1	13.9	0.1	0.2	0	0.4	23.3	0.9	0.2	7.4	0	14.5	0.3	0.2	0	0	0	0	0.5	0	0.1	13.9	0.8	0	10.1	8.9	0.7	0	0	0.3	0	11	0	0	0	0.4	0.1	0	8.5	6.1	0	0.2	0.4	0.2	0	0.2	17.5	0.1	13.4	3.7	0	3	4.7	0	0	0	36	0	0.1	0.1	29.6	0.2	0.1	6.5	0	43.8	78	56.4	25.1	8	4.4	2.8	0.2	0	0	1.9	0	4.8	13.9	3.2	5	0	4	0.4	1.3	0.1	0.4	0	0.1	23.3	0.9	0.2	0.2	0.9	0.9	0.2	0.2	0.4	0.1	0.2	0.1
CD72	"CD72b, LYB2"	ENSG00000137101	CD72 molecule	P21854	9	35609533-35646810	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"				Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	13	blood: 75.5;lymphoid tissue: 59.7	Cell line enhanced	Detected in some		Daudi: 12.4;Karpas-707: 8.0;REH: 5.2;U-698: 27.7	Low cancer specificity	Detected in all			Low region specificity	Detected in some			Group enriched	Detected in some	16	memory B-cell: 34.3;naive B-cell: 75.5	Lineage enriched	Detected in many	22	B-cells: 75.5	Region enriched	Detected in single	7	basal ganglia: 3.6	Low region specificity	Detected in all			"CAB002505, HPA044658"	Enhanced		Approved	"Nucleoplasm,Mitochondria"				"Nucleoplasm, Mitochondria"		"CAB002505: AB_563629, HPA044658: "	unprognostic (1.13e-2)	unprognostic (1.26e-2)	unprognostic (1.21e-2)	unprognostic (8.82e-2)	unprognostic (1.87e-2)	unprognostic (7.81e-2)	unprognostic (7.11e-2)	unprognostic (2.95e-1)	unprognostic (3.29e-2)	unprognostic (2.02e-2)	unprognostic (1.95e-1)	unprognostic (2.89e-1)	prognostic unfavourable (2.49e-8)	unprognostic (1.42e-1)	unprognostic (2.32e-2)	unprognostic (1.23e-1)	unprognostic (3.59e-2)	1.9	1.2	0.8	16.6	1.1	2.6	1.3	0.6	0.6	0.7	0.9	0.2	0.5	0.3	0.8	2.1	0.8	0.7	1.6	0.6	0.8	0.7	1.5	2.3	2.2	26.8	0.8	0.1	0.5	1.4	0.5	1.6	1.5	1.1	0.9	0.3	1.1	3.4	0.1	0.5	0.8	5.2	0.6	1.8	59.7	0.8	0.8	0.2	1.5	1.4	0.3	22.2	4.9	0.6	75.5	3.4	0.2	0.6	1.7	0.7	2.5	0.1	0	0.4	0.2	0.7	3.8	0.1	0.2	0.1	0.3	0.5	0	0.1	12.4	0	0.2	0	0	0.1	0.4	1.2	0.3	0.4	0	0	0.4	0.2	2.8	1.1	0	0.2	0.3	0	0	8	0.7	0	0.2	1.6	0.1	0.1	5.2	0	3.8	0	0	0.2	0.4	0	0.1	0	0.1	0.1	0	0.5	0.1	0.1	0	0.1	0.2	27.7	0.5	0.4	0	0	0.3	0	0.5	0.6	0.7	34.3	0.2	0.3	3.4	75.5	0.1	0.4	0.2	1.7	0	1.8	0.3	2.5	0.8	1.1	0.6	0.6	0.8	0.7	0.8	0.1	1.1	0.2
CD74	DHLAG	ENSG00000019582	CD74 molecule	P04233	5	150401637-150412929	"Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Chaperone	Cancer-related genes	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		blood: 504.7	Cell line enhanced	Detected in many		CAPAN-2: 115.7;Daudi: 178.0;HDLM-2: 255.6;REH: 154.1;RPMI-8226: 104.9;U-266/70: 85.9;U-698: 98.6	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Group enriched	Detected in all	4	classical monocyte: 191.6;intermediate monocyte: 303.5;memory B-cell: 467.7;myeloid DC: 437.9;naive B-cell: 504.7;non-classical monocyte: 140.0;plasmacytoid DC: 303.2	Group enriched	Detected in all	5	B-cells: 504.7;dendritic cells: 437.9;monocytes: 303.5	Low region specificity	Detected in many			Low region specificity	Detected in all			"CAB002506, HPA010592"	Enhanced		Supported	Golgi apparatus		90000	90000	Golgi apparatus		"CAB002506: AB_563630, HPA010592: AB_1078482"	prognostic favourable (1.06e-4)	unprognostic (1.48e-2)	unprognostic (4.80e-3)	prognostic favourable (6.53e-6)	unprognostic (1.41e-1)	unprognostic (4.53e-2)	unprognostic (2.05e-1)	unprognostic (3.69e-3)	unprognostic (1.54e-2)	unprognostic (3.48e-2)	unprognostic (2.20e-2)	unprognostic (2.64e-1)	unprognostic (5.44e-3)	unprognostic (1.73e-1)	unprognostic (4.95e-2)	unprognostic (2.05e-1)	unprognostic (4.24e-2)	137.8	95.7	53.2	177	81.4	40.7	104.2	8.4	43.5	89.6	68.2	79	30	98.3	60	73.9	43.6	68.1	81.3	104.1	46.9	43.5	168.3	60.1	222.5	310.1	78.3	23.1	53.4	34.1	15.1	51	27.9	79.8	72.6	63.6	72.9	123	55.4	40.5	56.6	182.8	55.1	123.1	372.1	77.3	23.7	68.1	201.1	83.4	45.6	288.2	91.7	47	504.7	437.9	76.1	303.5	42.2	41.2	238.1	1.9	0	0	0.1	0.1	0.1	0.6	0	0	0	0	23.1	115.7	178	7.2	0	0.5	0	0	0	255.6	0	5.8	0.1	14.1	0.3	0.4	0.3	1.4	0	0	0	0	0.4	70.9	0	0	0.2	0.8	0.3	0	154.1	0.2	104.9	0.5	7.5	0.2	0.5	0.3	0.2	5.1	4.7	21.3	0.2	0.6	0.5	0.5	0.2	85.9	9.2	98.6	41.3	8	37.7	6.3	191.6	76.1	16.8	303.5	18.7	467.7	14.8	24.8	437.9	504.7	7.8	13.5	16.8	42.2	140	303.2	41.2	238.1	53.2	81.4	8.4	43.5	46.9	43.5	78.3	23.1	79.8	68.1
CD79A	"IGA, MB-1"	ENSG00000105369	CD79a molecule	P11912	19	41877120-41881372	"Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"		Cancer-related genes	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	7	blood: 125.3;intestine: 43.5;lymphoid tissue: 119.2	Group enriched	Detected in some	24	Daudi: 155.5;REH: 48.3;U-698: 135.4	Low cancer specificity	Detected in many			Not detected	Not detected			Group enriched	Detected in some	38	memory B-cell: 106.4;naive B-cell: 125.3	Lineage enriched	Detected in many	41	B-cells: 125.3	Low region specificity	Detected in many			Low region specificity	Detected in all			CAB000019	Enhanced									CAB000019: AB_2244527	prognostic favourable (8.45e-5)	unprognostic (1.63e-3)	unprognostic (4.13e-3)	unprognostic (1.31e-3)	unprognostic (2.02e-1)	prognostic favourable (1.18e-5)	unprognostic (1.23e-2)	unprognostic (8.11e-3)	unprognostic (9.41e-3)	unprognostic (1.12e-2)	unprognostic (2.53e-1)	unprognostic (2.32e-1)	prognostic unfavourable (2.15e-5)	unprognostic (6.08e-2)	unprognostic (3.39e-1)	unprognostic (1.17e-1)	unprognostic (1.46e-1)	1.3	0.6	0.5	103.8	0.5	5.4	1.3	0.5	0.5	1.8	6.3	0.1	0.1	4.9	0.6	0.2	4.4	1	2.3	0.8	0.5	0.5	2.3	0.9	4.3	114.9	0.5	0.1	0.6	0.6	0	0.5	0.5	0.1	1	3.4	1.8	13.6	1.2	0.5	0.5	43.5	0.2	0.5	108.1	9.7	0.8	0.1	32	2.4	1.9	119.2	6.8	1	125.3	3	0.7	0.3	0.2	2.3	4.5	0.1	0	0	0	0	0	0	0	0	0	0	0	0	155.5	0.1	0	0	0	0	0	0	0	0.2	0	0.1	0	0.2	0.1	0	0	0	0	0	0.3	0	0	0.1	0.1	0.9	0	0	48.3	0	0.2	0	0	0	0	0	0	0.1	0	0.4	0.1	0	0.4	0	0	0.7	0.1	135.4	0	4.6	0	0.7	0.1	0.5	0.1	0.1	0	106.4	0.3	0.1	0.2	125.3	0.4	2.3	0.4	0.2	0.3	3	0.8	4.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.1	0.1	0.1
CD79B	"B29, IGB"	ENSG00000007312	CD79b molecule	P40259	17	63928740-63932354	"Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins"	"Adaptive immunity, Immunity"		"Cancer-related genes, Disease mutation"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	4	blood: 138.8;lymphoid tissue: 56.6	Cell line enhanced	Detected in some		Daudi: 114.9;REH: 37.8;U-698: 157.4	Low cancer specificity	Detected in all			Not detected	Not detected			Group enriched	Detected in many	5	memory B-cell: 100.6;naive B-cell: 138.8	Lineage enriched	Detected in many	6	B-cells: 138.8	Not detected	Not detected			Not detected	Not detected			"HPA009178, CAB009751"	Enhanced									"CAB009751: AB_2275844, HPA009178: AB_1078483"	unprognostic (3.90e-3)	unprognostic (1.61e-3)	unprognostic (5.21e-2)	unprognostic (3.45e-3)	unprognostic (4.22e-3)	prognostic favourable (2.35e-4)	unprognostic (1.82e-1)	unprognostic (9.25e-3)	unprognostic (3.89e-2)	unprognostic (1.48e-1)	unprognostic (1.04e-1)	unprognostic (2.87e-2)	unprognostic (2.50e-3)	unprognostic (1.89e-1)	unprognostic (1.44e-1)	unprognostic (4.28e-2)	unprognostic (2.75e-1)	1.7	0.7	0.4	50.6	0.4	11.1	1.2	0.3	0.4	0.6	1.7	0.3	0.3	0.7	0.6	0.5	2.6	0.6	1.4	3.4	0.4	0.2	2.3	1.7	1.3	56.6	0.4	0.3	0.6	1.6	0	9	0.5	0.3	1	1.3	0.8	8.9	0.9	1.2	0.9	22.4	0.5	0.4	56	1.8	0.6	0.3	3.7	1.4	1.7	46.6	4.5	0.9	138.8	4.2	0.5	25	3.4	9.2	9	0.1	0	0	0	0	0	0	0	0	0	0	0	0	114.9	0.8	0	0	0	0	0	0	0	0.3	0	0	0	0	0	0	0	0	0	0.1	0.1	6.3	0	0	0	2.4	0	0	37.8	0.1	0.5	0	0	0	0	0.1	0	0	0	1.7	0.1	0	0.4	0	0	5.8	5.6	157.4	0	0.2	0	0.5	1.1	0	4.2	16.5	4.8	100.6	5.4	2.8	4.2	138.8	3.7	2.2	0.5	3.4	25	0.6	9.2	9	0.4	0.4	0.3	0.4	0.4	0.2	0.4	0.3	0.3	0.3
CD80	"B7-1, B7.1, CD28LG, CD28LG1"	ENSG00000121594	CD80 molecule	P33681	3	119524293-119559602	"CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	Host-virus interaction	"Host cell receptor for virus entry, Receptor"	FDA approved drug targets	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in some		lymphoid tissue: 17.5	Cell line enhanced	Detected in some		Daudi: 8.0;HDLM-2: 28.3;Karpas-707: 11.8;U-266/70: 5.1	Low cancer specificity	Detected in some			Not detected	Not detected			Group enriched	Detected in some	4	memory B-cell: 4.3;non-classical monocyte: 1.1;T-reg: 3.3	Group enriched	Detected in many	24	B-cells: 4.3;monocytes: 1.1;T-cells: 3.3					Low region specificity	Detected in all			"CAB025368, HPA050092"	Enhanced				Intracellular and membrane					"CAB025368: , HPA050092: "	unprognostic (2.36e-1)	unprognostic (1.55e-2)	unprognostic (5.91e-2)	unprognostic (1.24e-1)	unprognostic (3.14e-1)	unprognostic (1.18e-1)	unprognostic (1.86e-2)	unprognostic (4.14e-3)	unprognostic (1.02e-2)	unprognostic (4.96e-3)	unprognostic (1.16e-2)	unprognostic (1.15e-1)	unprognostic (9.03e-8)	unprognostic (3.20e-1)	unprognostic (3.65e-2)	unprognostic (7.81e-3)	unprognostic (1.94e-2)	0.7	0.6	0.4	11.7	0.3	1.5	1.2	0.3	0.3	0.6	0.7	0.3	0.7	1.3	0.4	0.6	0.7	0.3	1	0.5	0.9	0.3	0.7	2	6.2	7.4	0.4	0	0.3	0.9	0	1.1	0.7	0.6	0.6	1.7	0.8	3.9	0.2	0.5	0.4	2.4	0.2	0.8	17.5	0.6	0.4	0	5.6	1.6	0.8	17.2	1.8	0.4	4.3	0.1	0	1.1	0	3.3	0.2	0	0	0	0	0	0	0	0	0	0	0	0	0	8	0	0	0	0	0	0	28.3	0	0.4	0	0	0	0	0	0	0	0	0	0	0.9	11.8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0.3	0	5.1	0.2	0.9	0	0	0	0	0.1	0	0	0.6	0	4.3	0.5	0.3	0.1	0.6	0	0	0	0	1.1	0	3.3	0.2	0.4	0.3	0.3	0.3	0.9	0.3	0.4	0	0.6	0
CD81	"TAPA-1, TAPA1, TSPAN28"	ENSG00000110651	CD81 molecule	P60033	11	2376177-2397419	"CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters"	"Adaptive immunity, Host-virus interaction, Immunity"	"Host cell receptor for virus entry, Receptor"		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in many		ASC diff: 231.4	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in many		memory B-cell: 41.4;naive B-cell: 37.6	Lineage enriched	Detected in all	4	B-cells: 41.4	Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB002507, HPA007234"	Supported		Supported	Plasma membrane		1900000	1900000	Plasma membrane		"CAB002507: AB_563639, HPA007234: AB_1846333"	unprognostic (2.96e-1)	unprognostic (3.40e-1)	prognostic unfavourable (7.56e-4)	unprognostic (1.84e-2)	prognostic unfavourable (8.21e-5)	unprognostic (6.03e-2)	unprognostic (1.75e-1)	unprognostic (1.31e-1)	unprognostic (2.09e-1)	unprognostic (1.24e-1)	prognostic favourable (3.86e-4)	unprognostic (3.07e-3)	unprognostic (2.08e-1)	unprognostic (3.55e-2)	unprognostic (1.67e-1)	unprognostic (2.06e-1)	unprognostic (2.06e-1)	102.5	43.7	52.8	40.1	57	9.6	79.3	31.7	63.2	124.7	88.9	75.8	261.4	21.1	143.5	141.5	56.8	123.1	86.8	101.2	46.6	52.8	65.5	123.9	107.4	82.4	70.4	51.3	77.9	62.4	41.4	42.9	61.2	63	89.3	34	46.6	59.7	263.3	22.6	59.6	39.7	138.9	59.3	64.5	52.1	57.6	53.3	25.3	66.3	38.5	37.9	93.5	80.2	41.4	2.1	5.7	1.8	3.5	9.9	2.7	24.5	25.5	20.5	31.3	231.4	131.6	17.2	46.5	103	37.6	38	23.9	0.1	21	16.8	130.3	32.3	12.6	33.1	15.5	9.9	38.9	3.2	9.7	0	76.6	13.6	27.6	95.6	47.3	15.3	23.3	35.9	14.3	36.9	52.5	18.8	11.5	17.4	24.6	20.7	23.7	10.3	13.4	40.4	16.6	22.1	24.5	14.8	39	28	12.9	24.9	47.8	19.2	14.2	35.9	15.9	27.3	6.2	38.3	27.9	8.1	32.8	0.2	0.9	5.7	6	1.4	9.9	41.4	4.3	9.4	0.6	37.6	2.6	5	0.3	3.5	1.8	2.1	3	2.7	52.8	57	31.7	63.2	46.6	52.8	70.4	51.3	63	53.3
CD82	"IA4, KAI1, R2, ST6, TSPAN27"	ENSG00000085117	CD82 molecule	P27701	11	44564427-44620363	"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"			Cancer-related genes	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in many		HMC-1: 77.3;LHCN-M2: 45.7;U-87 MG: 54.7	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in all		neutrophil: 80.5	Group enriched	Detected in all	6	B-cells: 51.1;granulocytes: 80.5;T-cells: 25.6	Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB002508, HPA028900, HPA061418"	Supported		Approved	Vesicles				Vesicles		"CAB002508: AB_563640, HPA028900: AB_10603558, HPA061418: "	unprognostic (5.31e-2)	unprognostic (4.62e-1)	unprognostic (2.38e-2)	unprognostic (1.33e-1)	unprognostic (2.79e-1)	unprognostic (1.37e-2)	unprognostic (1.78e-1)	unprognostic (7.29e-2)	unprognostic (3.48e-1)	unprognostic (2.97e-1)	unprognostic (2.58e-2)	unprognostic (1.58e-1)	unprognostic (3.48e-3)	unprognostic (1.86e-3)	unprognostic (2.33e-2)	unprognostic (2.88e-2)	unprognostic (6.30e-2)	14.7	4.9	16.3	21.6	23.1	43.6	13.8	6.3	13.6	17.5	20.7	23	53	25.9	4.8	13.5	58.3	19.8	21.7	12.7	16.9	13.3	10.2	18.8	38.8	22.8	17.9	9.2	9	11.6	2.8	3.9	20.7	14	14.3	6.8	18.6	29.8	55.2	10.5	34.6	36	8.9	10.2	21.9	22.5	4.5	12.6	23.9	8.3	23.5	33.5	16.3	28.1	51.1	6.7	80.5	9.1	7.2	25.6	9.5	5	0.7	6.6	1.3	4.5	17.2	0.2	2.9	23.6	5.1	13	0.3	3.4	5.2	3.5	1.4	19.2	0.9	15	11.8	23.2	0.4	32.5	1.5	0.1	3.3	8.9	77.3	23.7	17.6	21.4	11.4	9	0.2	1.6	45.7	3.6	8.6	16.7	0.2	0.3	0.2	27.6	7.3	3	4.9	0.2	0.3	1.8	27.6	3.8	26.3	8.8	5	16.2	2.1	0.3	27.5	0.6	0	0.1	54.7	4.9	8.6	48.4	9.1	16	4.9	4.8	8.5	51.1	24.9	11.6	2.2	30.9	8.6	3.8	80.5	7.2	3.4	6.7	25.6	9.5	16.3	23.1	6.3	13.6	16.9	13.3	17.9	9.2	14	12.6
CD83	"BL11, HB15"	ENSG00000112149	CD83 molecule	Q01151	6	14117256-14136918	"CD markers, Predicted membrane proteins"				Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		bone marrow: 70.0;lymphoid tissue: 64.5	Cell line enhanced	Detected in many		Daudi: 28.6;HDLM-2: 25.7;U-698: 44.0	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in many			Low lineage specificity	Detected in all			Low region specificity	Detected in many			Low region specificity	Detected in all			"CAB002509, HPA041454"	Enhanced									"CAB002509: AB_563641, HPA041454: "	unprognostic (2.22e-3)	unprognostic (1.92e-2)	unprognostic (1.22e-1)	unprognostic (6.39e-2)	unprognostic (5.83e-2)	unprognostic (3.02e-2)	unprognostic (1.00e-2)	unprognostic (9.05e-3)	unprognostic (9.05e-2)	unprognostic (3.91e-2)	unprognostic (7.37e-2)	unprognostic (6.68e-2)	prognostic favourable (3.49e-4)	unprognostic (2.30e-1)	unprognostic (7.07e-2)	unprognostic (1.40e-2)	unprognostic (2.46e-2)	14	8.3	6.1	64.5	5.7	70	7.5	14.2	11.8	17	2	24.7	3.4	1.8	3.7	8.3	3.6	1.8	9.9	2.6	7.3	12.7	9.7	6	29	19.5	7.8	2.2	9.7	1.6	2.2	4.1	3.4	10.8	5.2	3.8	3.5	16.4	7.8	1.8	2.6	6.9	2.7	11.1	16.5	2.2	4	2.8	33.8	2.3	6.2	57.5	16.4	9.8	19.1	5.2	1.3	15.4	2.6	3.6	2.3	6.5	0.3	4.9	6.8	7.2	1.6	0.1	1.8	6.7	3.2	5.6	0.5	4.3	28.6	5.5	0.5	0.7	1.8	2	10.6	25.7	2.7	3.9	8.5	0.7	0.2	5.7	6.3	1.9	0.9	3	1	0.1	0.8	0	0.3	2.4	4.5	10.8	2	1.3	4.4	10.7	4	2.3	6.5	1	1.9	0.4	0.2	4.9	1.1	4.6	0.1	4.9	3.1	0.7	4.4	0.3	0	44	1	7.8	7.4	0	1.7	1.1	2.7	10.7	2.9	11.5	2.5	2.2	5.2	19.1	1.8	2.1	1.3	2.6	15.4	1.8	3.6	2.3	6.1	5.7	14.2	11.8	7.3	12.7	7.8	2.2	10.8	2.8
CD84	"hCD84, mCD84, SLAMF5"	ENSG00000066294	CD84 molecule	Q9UIB8	1	160541095-160579516	"CD markers, Predicted membrane proteins"	"Adaptive immunity, Autophagy, Cell adhesion, Immunity, Innate immunity"	Receptor		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		lymphoid tissue: 26.0	Cell line enhanced	Detected in some		Daudi: 12.4;HEL: 23.7;HL-60: 6.7;HMC-1: 27.1;MOLT-4: 6.6;U-698: 16.7	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all			Low region specificity	Detected in all			Low region specificity	Detected in all			"HPA063316, HPA068020, HPA070502"	Enhanced		Enhanced	"Vesicles,Plasma membrane"		36000000	36000000	Plasma membrane	Vesicles	"HPA063316: , HPA068020: , HPA070502: "	unprognostic (4.38e-2)	unprognostic (6.16e-3)	unprognostic (1.00e-2)	unprognostic (8.16e-2)	unprognostic (2.35e-1)	unprognostic (2.00e-2)	unprognostic (3.84e-1)	unprognostic (2.54e-2)	unprognostic (8.60e-2)	unprognostic (1.80e-1)	unprognostic (8.26e-2)	unprognostic (1.57e-1)	unprognostic (1.30e-2)	unprognostic (2.15e-1)	unprognostic (4.14e-2)	unprognostic (1.24e-1)	unprognostic (1.08e-1)	15.9	4.8	3.8	18.5	4.5	6.7	3.7	1.3	3.4	3.3	3.2	7.9	7.7	2.5	2.5	4.3	2.7	3.1	6.4	5	3.8	3	3.1	5.1	9.2	26	6	2.2	1.8	4.3	0.9	1.9	7.1	5.3	3.7	4.7	2.4	4.3	9.8	1.6	2.7	9.6	4.1	11.1	25.6	3.5	2.8	5.9	13.8	2.9	2.3	16.3	5.8	2.7	5.1	5.4	21	7.3	1	8.2	6.1	0	0	0	0	0	0	0	0	0	0	0	0	0	12.4	0	0	0	0	0	0	0	0	23.7	0	0	0	6.7	27.1	0	0	0	0	0	0.4	0.1	0	0	6.6	5	0	0	0.2	0	1	0	0	0	0	0	0	0	0	2.1	0	0	0	0	0	0	0	16.7	0	1.5	0	21	7.3	11	6.9	6.3	5.2	5.1	5.9	8.2	5.4	4.7	3.5	6.3	1	1	2.4	3.2	7.9	6.1	3.8	4.5	1.3	3.4	3.8	3	6	2.2	5.3	5.9
CD86	"B7-2, B7.2, CD28LG2"	ENSG00000114013	CD86 molecule	P42081	3	122055366-122121139	"CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Host-virus interaction, Immunity"	"Host cell receptor for virus entry, Receptor"	FDA approved drug targets	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 27.0;brain: 26.1	Cell line enriched	Detected in some	7	HDLM-2: 78.9	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Group enriched	Detected in many	8	classical monocyte: 25.6;intermediate monocyte: 26.4;memory B-cell: 13.6;myeloid DC: 25.9;naive B-cell: 8.0;non-classical monocyte: 27.0	Group enriched	Detected in many	17	B-cells: 13.6;dendritic cells: 25.9;monocytes: 27.0					Low region specificity	Detected in all			CAB004319	Approved					220000	220000			CAB004319: AB_627200	unprognostic (1.81e-1)	unprognostic (3.78e-3)	unprognostic (3.04e-2)	unprognostic (3.52e-2)	unprognostic (1.36e-1)	unprognostic (2.79e-1)	unprognostic (1.15e-1)	unprognostic (8.56e-2)	unprognostic (7.72e-3)	unprognostic (1.21e-1)	unprognostic (1.28e-1)	unprognostic (1.98e-1)	prognostic unfavourable (9.83e-5)	unprognostic (9.72e-2)	unprognostic (1.70e-2)	unprognostic (9.78e-2)	unprognostic (8.67e-2)	10.5	4.7	7.1	23.6	9.5	6	3.6	1.5	6.3	2.9	4.3	9.8	0.6	2.5	2.6	5.2	2.8	3.3	10.4	3.5	7.3	6	4	7.8	13	17.8	11.7	3	2.5	2.3	2.1	2.6	10.3	8.1	3.1	5.6	3	3.6	1.8	1.3	2.4	6.9	5.1	26.1	22.5	3.4	2.4	10.3	7.7	2.3	2.1	15	9.2	2.2	13.6	25.9	0.3	27	1.2	0.4	9.3	0	0	0	0	0	0	0	0	0	0	0	0	0	10.7	0	0	0	0	0	0	78.9	0	0	0	0	0	0.2	0	0	0.1	0	0	0	0	0.2	0	0	0	0.6	0	0	0	0	8.5	0	0	0	0	0	0	0	0	0.6	0.1	0	0	0	0	4.2	0.1	9.4	0	0.2	0	0	25.6	0.2	0	26.4	0	13.6	0.1	0.1	25.9	8	0	0	0.3	1.2	27	2.6	0.4	9.3	7.1	9.5	1.5	6.3	7.3	6	11.7	3	8.1	10.3
CD8A	CD8	ENSG00000153563	CD8a molecule	P01732	2	86784610-86808396	"CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"		Disease mutation	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	14	blood: 82.2;lymphoid tissue: 262.3	Cell line enriched	Detected in some	4	MOLT-4: 17.4	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Group enriched	Detected in some	13	MAIT T-cell: 36.7;memory CD8 T-cell: 82.2;naive CD8 T-cell: 77.8	Lineage enriched	Detected in many	20	T-cells: 82.2					Low region specificity	Detected in all			"CAB000012, HPA037756, CAB075722"	Enhanced		Supported	Plasma membrane	Intracellular and membrane	500000	500000	Plasma membrane		"CAB000012: AB_2075537, CAB075722: , HPA037756: "	unprognostic (1.29e-3)	prognostic favourable (4.54e-4)	unprognostic (9.26e-3)	prognostic favourable (6.15e-6)	unprognostic (7.28e-2)	unprognostic (2.79e-3)	unprognostic (1.03e-2)	unprognostic (2.00e-2)	unprognostic (1.35e-2)	unprognostic (4.50e-3)	unprognostic (1.09e-1)	unprognostic (1.14e-1)	prognostic unfavourable (1.91e-5)	unprognostic (1.36e-1)	unprognostic (1.48e-1)	unprognostic (6.74e-2)	unprognostic (1.56e-2)	2.4	1.4	1.4	7.4	2.8	6.8	1.5	1.4	1.2	2.1	5.3	0.8	0.8	4.2	1.5	2.1	2	2.1	4.5	1.6	1.2	1.6	1.3	2.1	6	23.8	1	0.5	1.7	1.2	0	0.9	0.6	0.7	2.3	1.9	1.8	3	1.1	0.8	0.7	12.2	0.7	1.7	46.4	5.4	1	0.5	262.3	2.2	1.6	8.1	3.8	1.9	0	0.1	0.6	0.1	4	82.2	17.4	0.3	0.2	0	0	0	0	0.3	0	0	0	0	0.5	0	0.1	0.4	0	0	0.7	0	0	0	0.2	0	0	0	0	0.1	0	0	0.7	0	0	0	0	0.3	0	0.8	17.4	1.1	0.6	0.3	0.1	0.9	3.9	0	0.4	0.9	2.4	0.2	0.1	0	0.4	0.5	0	0	0.6	0.1	0	0.1	0.3	0.9	0	0	0.1	0.1	0.1	0	4.8	0	36.7	0	0.3	82.2	0	0	0.3	77.8	0.6	4	0.1	0.1	0.1	17.4	1.4	2.8	1.4	1.2	1.2	1.6	1	0.5	0.7	0.5
CD8B	CD8B1	ENSG00000172116	CD8b molecule	P10966	2	86815339-86861924	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"			Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	5	blood: 132.1;lymphoid tissue: 61.5	Cell line enriched	Detected in some	55	RPMI-8226: 154.8	Low cancer specificity	Detected in many			Low region specificity	Detected in all			Group enriched	Detected in some	10	memory CD8 T-cell: 73.5;naive CD8 T-cell: 132.1	Lineage enriched	Detected in many	40	T-cells: 132.1									"CAB004353, HPA029164"	Enhanced		Supported	Plasma membrane	Intracellular and membrane			Plasma membrane		"CAB004353: AB_627211, HPA029164: "	unprognostic (1.83e-3)	unprognostic (1.98e-3)	unprognostic (2.22e-2)	prognostic favourable (7.88e-7)	unprognostic (6.23e-2)	unprognostic (7.05e-3)	unprognostic (1.11e-2)	unprognostic (2.59e-2)	unprognostic (5.50e-3)	unprognostic (5.91e-2)	unprognostic (9.25e-2)	unprognostic (4.60e-1)	prognostic unfavourable (7.11e-6)	unprognostic (7.84e-2)	unprognostic (3.00e-1)	unprognostic (1.86e-2)	unprognostic (4.33e-2)	1.2	0.7	1	5.3	1	3.9	1	1.3	1.3	21.2	1.1	1	1	2.5	1.2	1	1	1.1	1.8	1	1	1.8	1	1	2.7	14.4	1.7	1	1.3	1	6.4	7.4	1	2.2	1.3	1.3	1	1	1	1	0.9	11.4	1	1.5	12.7	2.3	1	1	61.5	1.5	1	8.1	1.8	1.3	0.1	0.1	3.2	0.1	0.1	132.1	36.3	0	0	0	0	0	0	0	0	0	0	0	2.8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9	0	0	0	0	0	154.8	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0.9	0	0	0	3.2	0.1	0	2	0.1	10	0	0.2	73.5	0	0.1	0.5	132.1	0.7	0.1	0.1	0.1	0.2	36.3	1	1	1.3	1.3	1	1.8	1.7	1	2.2	1
CD9	"BA2, MIC3, MRP-1, P24, TSPAN29"	ENSG00000010278	CD9 molecule	P21926	12	6199715-6238271	"Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Transporters"	"Cell adhesion, Fertilization"		Cancer-related genes	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in many		CAPAN-2: 127.8;HUVEC TERT2: 82.6;RT4: 94.7;TIME: 188.9	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Group enriched	Detected in many	21	basophil: 137.8;eosinophil: 98.3	Lineage enriched	Detected in many	24	granulocytes: 137.8	Low region specificity	Detected in all			Low region specificity	Detected in all			CAB002490	Supported		Supported	Plasma membrane		68000000	68000000	Plasma membrane		CAB002490: AB_563643	unprognostic (1.38e-1)	unprognostic (6.36e-3)	unprognostic (8.27e-3)	unprognostic (6.98e-3)	unprognostic (3.89e-1)	unprognostic (2.81e-1)	unprognostic (1.32e-1)	unprognostic (2.08e-2)	unprognostic (2.90e-1)	unprognostic (2.60e-2)	prognostic unfavourable (1.59e-4)	unprognostic (2.30e-1)	prognostic favourable (6.49e-5)	unprognostic (6.10e-2)	unprognostic (1.77e-1)	prognostic favourable (8.93e-5)	unprognostic (9.26e-2)	38.1	44.5	20	24.1	36.2	3.1	48.2	6.8	29.6	55	68.3	63.1	151.6	19.5	36.2	43.4	139.8	38.4	23.2	39.2	30.3	15.6	39.9	12.2	61.1	8.2	43.3	23.3	14.1	23.3	89.5	15.2	13	28.7	77.9	73.5	25.5	91.6	180.4	11.3	60.1	29.6	62.2	48.9	12.2	27.7	10.4	47.7	6	63.6	112.3	85.8	54.5	76	1.9	0.9	137.8	5.6	0.2	1.1	5.6	33.9	14.9	0.3	9.2	14.7	15.1	12.9	20.1	40.2	6.9	10.6	10.9	127.8	0.1	5	4.3	74.5	7.8	40.2	5.3	1.7	5.5	0.1	11.3	2.3	6.3	0.1	42.8	0	29.9	12.6	10.9	82.6	1.5	0.1	4.3	48.6	0.1	3.7	11.6	15	0.3	24.6	43.2	67.6	94.7	0	2.9	20	16.6	17.2	7.7	3.5	188.9	0.7	18.9	0.7	2.4	0.1	0.1	5.1	11.8	0	18.6	137.8	5.6	98.3	0.1	1.8	0.2	0.5	0.1	0.1	0.9	1.9	0.4	1.1	2.6	0.2	0	0.3	0	5.6	20	36.2	6.8	29.6	30.3	15.6	43.3	23.3	28.7	47.7
CD93	"C1qR(P), C1QR1, C1qRP, CDw93, dJ737E23.1, ECSM3, MXRA4"	ENSG00000125810	CD93 molecule	Q9NPY3	20	23079349-23086340	"CD markers, Plasma proteins, Predicted membrane proteins"	"Cell adhesion, Host-virus interaction"	Receptor		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Group enriched	Detected in some	4	HUVEC TERT2: 57.0;TIME: 72.2;U-937: 96.6	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in some		classical monocyte: 14.4;neutrophil: 17.4	Group enriched	Detected in many	40	dendritic cells: 5.5;granulocytes: 17.4;monocytes: 14.4	Low region specificity	Detected in all			Low region specificity	Detected in all			"HPA009300, HPA012368"	Enhanced		Approved	"Vesicles,Plasma membrane"		440000000	440000000	"Vesicles, Plasma membrane"		"HPA009300: AB_1846342, HPA012368: AB_1846341"	unprognostic (2.05e-1)	unprognostic (2.85e-1)	unprognostic (1.07e-1)	unprognostic (4.83e-2)	unprognostic (2.31e-1)	unprognostic (2.66e-2)	unprognostic (6.45e-2)	unprognostic (2.77e-1)	unprognostic (4.51e-1)	unprognostic (3.74e-2)	unprognostic (2.61e-1)	unprognostic (1.81e-1)	prognostic unfavourable (2.74e-4)	unprognostic (8.81e-3)	unprognostic (6.13e-2)	unprognostic (4.49e-2)	unprognostic (3.11e-2)	50.5	6.1	2.4	15	3.4	4.7	31.4	1	3	13.6	8.1	1.7	3.9	3.2	14.3	12.5	10	13.6	14.2	33.3	2.4	2.2	10.8	10.9	34.8	25.3	4.1	1.2	11.6	5.9	5.1	4.3	48.9	5.3	9.7	4.3	4.9	5.9	3.9	16.2	6.8	7.7	15.4	4.3	17.5	7.5	6.9	3.3	6.9	12.3	9.3	4.5	15.6	12.2	0	5.5	17.4	14.4	0	0.3	4.7	0	0	0.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	57	0.1	0	0	0	0	2	0	0	0.1	0	4.4	0	0	0	0	0	0	0	0	17	72.2	0	0	0	0	0	0	0	0	96.6	0	0	14.4	0.2	0.2	10.3	0	0	0.1	0	5.5	0	0	0	17.4	0	4.2	0.7	0.3	4.7	2.4	3.4	1	3	2.4	2.2	4.1	1.2	5.3	3.3
CD96	TACTILE	ENSG00000153283	CD96 molecule	P40200	3	111292719-111665750	"CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	Cell adhesion		"Craniosynostosis, Disease mutation"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	4	blood: 32.0;lymphoid tissue: 82.4	Cell line enhanced	Detected in some		HEL: 6.7;MOLT-4: 29.2;RT4: 27.1;U-937: 24.2	Low cancer specificity	Detected in many			Low region specificity	Detected in some			Low cell type specificity	Detected in many			Group enriched	Detected in many	5	NK-cells: 20.0;T-cells: 32.0	Not detected	Not detected			Low region specificity	Detected in all			HPA066754	Enhanced					37000	37000			HPA066754: 	unprognostic (1.06e-3)	unprognostic (3.95e-3)	unprognostic (4.16e-3)	unprognostic (1.91e-5)	unprognostic (4.72e-3)	prognostic favourable (5.52e-4)	unprognostic (2.12e-2)	unprognostic (3.48e-2)	unprognostic (6.06e-2)	unprognostic (4.84e-3)	unprognostic (2.44e-2)	unprognostic (2.77e-1)	prognostic unfavourable (2.02e-6)	unprognostic (3.12e-1)	unprognostic (4.42e-2)	unprognostic (3.90e-2)	prognostic favourable (5.23e-5)	5.7	0.9	0.4	18.6	0.5	8.6	3.1	0.6	0.4	2.2	7.1	0.6	0.5	3.6	1.7	1.8	3.4	2.1	3.5	1.3	0.4	0.5	2.3	2.7	9.7	21.9	1.5	0.2	1.4	0.8	0	1.1	1.1	1	2.6	3.7	2.5	4	1.6	0.6	1.3	13.4	1.4	2	14.2	3.5	1	0.4	82.4	4.8	2.3	23.9	9.9	3.2	5.5	0.1	3.8	0.2	20	32	11.2	0	0	0.1	0	0.1	0	0.3	0	0	0	0	0.1	0.8	0.1	0.1	0	0.3	0	0	0	0.1	0	6.7	0	0.1	0	0.3	0.6	0	0	0	0.1	0	0.1	0.9	0	0	29.2	0.1	0.3	0	0	0.9	0.2	0.2	27.1	0	0	0.1	0.4	0	0.1	0.1	0	0.1	0.5	0.1	0	2.6	0.8	0	0.1	24.2	5.2	0.5	0.1	3.8	20.2	0	32	2.8	18.6	23.5	0.1	5.5	19.4	23.6	0.8	20	0.2	0.1	11.8	11.2	0.4	0.5	0.6	0.4	0.4	0.5	1.5	0.2	1	0.4
CD99	MIC2	ENSG00000002586	CD99 molecule (Xg blood group)	P14209	X	2691133-2741309	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Cell adhesion			Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		brain: 359.1;breast: 433.0;heart muscle: 347.0	Cell line enhanced	Detected in many		ASC diff: 124.2	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all							Low region specificity	Detected in all			"CAB000020, HPA035304"	Supported		Approved	Golgi apparatus		34000000	34000000	Golgi apparatus		"CAB000020: AB_2076419, HPA035304: AB_10672861"	unprognostic (3.71e-3)	unprognostic (2.90e-1)	unprognostic (5.97e-3)	unprognostic (7.01e-3)	unprognostic (2.14e-2)	unprognostic (6.98e-3)	unprognostic (3.89e-3)	unprognostic (1.54e-2)	unprognostic (1.06e-1)	unprognostic (1.05e-1)	unprognostic (1.59e-2)	unprognostic (1.87e-1)	prognostic unfavourable (5.87e-7)	unprognostic (2.11e-2)	unprognostic (2.18e-1)	unprognostic (5.37e-2)	unprognostic (3.61e-2)	45.7	14.1	85.8	14.4	100.5	11.1	433	45.7	60.9	243.9	31.8	4.5	4.5	19.9	258.4	18.3	26.1	22.2	35.2	347	103.4	14.7	66.4	24.6	24.5	16.6	161	56.6	187.4	28.9	3.3	67	138.7	185.5	30.5	20.6	4.5	18.1	37.7	18.9	28	23.8	31.1	359.1	18.5	21.7	23.3	101.3	4.5	15.2	4.5	16.1	24.7	208.8	32.7	62.6	4.3	47.1	32.1	107.1	103.6	23.8	27.4	30.6	41.4	124.2	94.2	18.4	64	100.3	40.2	58.6	39.5	16.8	1.6	12.5	88.7	9.3	12.2	16.1	33.4	32.4	30.8	4.6	19.1	34.3	39.4	7.3	36.5	58.5	19.9	22	15.5	73.3	5.7	0	37.9	18.7	63.6	24.9	10	29.9	10.8	25.6	45.2	23.2	16.4	0.1	13.5	15.4	13.8	38.4	12.2	22.8	67.6	49.6	8.4	47.3	21.5	0.1	0	10.4	33.2	18.3	30.9	1.8	47.1	1.5	107.1	11.6	60.4	32.7	72.6	94.6	44.6	20.2	26.8	57.1	4.3	32.1	2.6	62.6	74.3	103.6	85.8	100.5	45.7	60.9	103.4	14.7	161	56.6	185.5	101.3
CDCP1	"CD318, SIMA135"	ENSG00000163814	CUB domain containing protein 1	Q9H5V8	3	45082278-45146422	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"				Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in many			Cell line enhanced	Detected in many		CAPAN-2: 23.3;HBEC3-KT: 26.6;hTEC/SVTERT24-B: 66.0;hTERT-HME1: 44.8;PC-3: 20.6;RPTEC TERT1: 20.4	Low cancer specificity	Detected in all			Region enriched	Detected in some	5	pons and medulla: 5.5	Group enriched	Detected in some	5	myeloid DC: 4.0;neutrophil: 1.8;NK-cell: 7.1	Group enriched	Detected in many	5	dendritic cells: 4.0;granulocytes: 1.8;NK-cells: 7.1	Not detected	Not detected			Low region specificity	Detected in all			"HPA010978, HPA010979, CAB025637"	Enhanced				Intracellular and membrane					"CAB025637: , HPA010978: AB_1846403, HPA010979: AB_1846401"	unprognostic (9.31e-2)	unprognostic (4.50e-2)	unprognostic (1.67e-2)	unprognostic (2.66e-1)	unprognostic (1.11e-2)	unprognostic (1.51e-3)	unprognostic (2.94e-2)	prognostic unfavourable (1.41e-5)	unprognostic (2.15e-1)	unprognostic (1.00e-1)	prognostic unfavourable (1.48e-4)	unprognostic (2.14e-2)	unprognostic (9.98e-3)	unprognostic (3.59e-2)	unprognostic (2.99e-1)	unprognostic (1.21e-1)	unprognostic (1.34e-1)	2.3	0.7	0.5	5.6	1	0.2	4.4	0.3	0.7	6.9	17.4	1.1	10.1	11.4	3.2	11.1	28.6	2.4	9.8	0.8	1	0.5	4.4	0.8	7.1	1.4	0.6	0.3	1.6	13.9	0	2.3	4	5.5	5.2	11.3	0.5	11.4	13	0.6	15.2	29.8	1.8	1.3	0.8	10.8	1.3	0.5	1	21.8	19.2	19.1	7.3	11.7	0.2	4	1.8	0.9	7.1	0.3	0.3	12	3.6	0	0	0	0.6	2.9	2.2	0.3	1.1	1	5.1	23.3	0	2.7	0.7	9.7	0	26.6	2.2	0	0	0	4.1	0	2	0	0.9	0.9	14	66	44.8	0.2	7	0	3.4	0	0	0.2	1.7	20.6	0	0	2	20.4	9.8	0.8	0	4.5	1.2	0	5.6	0.1	0.9	0	0	0.8	0	0	0	0	0.3	0.2	0.2	0.4	0.9	0.1	0.1	0.1	0	0.1	0.3	0.1	4	0.2	0.2	0.1	1.8	7.1	0	0.1	0	0.3	0.5	1	0.3	0.7	1	0.5	0.6	0.3	5.5	0.5
CDH1	"CD324, UVO, uvomorulin"	ENSG00000039068	Cadherin 1	P12830	16	68737225-68835548	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Cell adhesion		"Cancer-related genes, Disease mutation, Ectodermal dysplasia"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		intestine: 125.5	Cell line enhanced	Detected in some		BEWO: 105.6;CACO-2: 35.5;CAPAN-2: 49.6;HaCaT: 47.9;hTCEpi: 33.8;MCF7: 29.3;RT4: 36.5;T-47d: 31.5	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Group enriched	Detected in some	12	myeloid DC: 2.8;plasmacytoid DC: 8.5	Lineage enriched	Detected in single	18	dendritic cells: 8.5	Low region specificity	Detected in many			Low region specificity	Detected in many			"CAB000087, HPA004812, CAB028364, CAB072855, CAB072856, CAB072857"	Enhanced		Supported	"Golgi apparatus,Plasma membrane,Cell Junctions"		22000000	22000000	"Plasma membrane, Cell Junctions"	Golgi apparatus	"CAB000087: AB_2533003, CAB028364: AB_2076812, CAB072855: , CAB072856: , CAB072857: , HPA004812: AB_1078369"	unprognostic (3.95e-2)	unprognostic (1.91e-1)	unprognostic (1.12e-3)	unprognostic (1.13e-1)	unprognostic (1.42e-1)	unprognostic (2.78e-1)	unprognostic (5.04e-3)	unprognostic (1.63e-1)	unprognostic (5.47e-2)	unprognostic (2.85e-1)	unprognostic (1.19e-2)	unprognostic (3.61e-1)	prognostic favourable (2.06e-4)	unprognostic (1.21e-1)	unprognostic (2.62e-1)	unprognostic (2.51e-1)	unprognostic (5.92e-2)	1.1	0.7	1.3	14.8	1.5	0.5	15.3	0.8	1.1	14.4	63.8	1.8	42.4	25.5	4.7	18.6	48.5	9.7	48.9	0.8	1.5	1	24.2	64.9	24.4	0.5	1.8	0.9	5.6	71.5	62.2	13.2	55.2	2.8	28.9	25.9	11.8	66.6	43.7	0.8	30.5	125.5	1.5	1.1	3.5	21.6	2.1	1.8	11.7	83	26.2	32.6	16.8	21.7	0	8.5	0	0	0.3	0.4	0.1	21.3	2.2	0	0	0	0	105.6	0	0	0	0	35.5	49.6	0	0.4	0	47.9	0	23.8	0	4.1	0.6	0	0.1	7.6	0	0	0.2	0	33.8	0	0	0	0	0	0	29.3	0	0.1	0.8	0.1	0	0	0.3	8.7	36.5	1.3	0.1	0.2	0	9	31.5	0	0	0	0.1	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0.4	2.8	0	0	0	0	0.3	0	8.5	0.1	0.1	1.3	1.5	0.8	1.1	1.5	1	1.8	0.9	2.8	1.8
CDH2	"CD325, CDHN, NCAD"	ENSG00000170558	Cadherin 2	P19022	18	27950966-28177446	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Cell adhesion			Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		heart muscle: 77.6;parathyroid gland: 35.4	Cell line enhanced	Detected in many		AF22: 56.4;BJ: 40.7;fHDF/TERT166: 84.2	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Group enriched	Detected in some	5	basophil: 4.4;neutrophil: 4.1	Lineage enriched	Detected in single	5	granulocytes: 4.4	Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB000141, CAB018580, HPA058574, CAB078686"	Enhanced		Supported	"Plasma membrane,Cell Junctions"		160000000	160000000	"Plasma membrane, Cell Junctions"		"CAB000141: , CAB018580: AB_626778, CAB078686: , HPA058574: "	unprognostic (9.42e-2)	unprognostic (2.69e-3)	unprognostic (9.07e-3)	unprognostic (5.45e-2)	unprognostic (1.14e-1)	unprognostic (9.30e-2)	unprognostic (3.97e-2)	unprognostic (2.53e-3)	unprognostic (6.70e-3)	unprognostic (1.00e-2)	unprognostic (7.53e-2)	unprognostic (3.51e-2)	unprognostic (3.02e-2)	unprognostic (1.93e-3)	unprognostic (6.69e-2)	unprognostic (1.33e-1)	unprognostic (2.59e-3)	0.6	29.6	9.8	1.5	9.4	0.5	0.5	5.7	16.1	3.2	2	8	0.2	0.8	3.1	1.9	0.6	4.7	1.7	77.6	9.9	9.6	9.2	23.3	0.7	1.1	6	9.1	3.4	0.7	35.4	5.4	0.5	5.9	1.4	0.8	6.8	0.5	4.6	0.4	0.5	0.9	3.2	6.7	5.9	2.5	19.6	7.4	0.9	2.8	0	1	1	1.3	0	0	4.4	0	0.7	0.9	0	0	4.5	56.4	0	8.9	1.8	0	40.7	12.4	16.6	15.2	0	0	0	21.9	84.2	6	9.2	0	23.6	0.1	5.9	0	15.2	14	8.5	0	0	0.8	0.1	38.1	6.7	14.5	0	0	12.9	0	10.2	0	7.5	4.9	0	6.7	7.7	0	1.8	14.7	25.5	0	0	4.5	0	0	2.2	36	11.5	0.5	29.4	0	0	0	6.9	0	27.7	4.4	0	0	0	0	0.9	0	0	0.1	0	0	0	0	4.1	0.7	0	0	0	0	9.8	9.4	5.7	10.1	9.9	9.6	6	9.1	5.9	7.4
CDH5	"7B4, CD144"	ENSG00000179776	Cadherin 5	P33151	16	66366622-66404786	"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Cell adhesion		Cancer-related genes	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		placenta: 96.6	Group enriched	Detected in some	6	HUVEC TERT2: 111.2;TIME: 95.3	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Not detected	Not detected			Not detected	Not detected			Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB028366, HPA075875"	Approved		Supported	"Nucleoplasm,Nuclear membrane,Plasma membrane"		1000000000	1000000000	Plasma membrane	"Nucleoplasm, Nuclear membrane"	"CAB028366: AB_2276033, HPA075875: "	unprognostic (1.05e-1)	unprognostic (8.13e-2)	unprognostic (6.11e-2)	unprognostic (4.89e-2)	unprognostic (4.96e-2)	unprognostic (5.50e-3)	unprognostic (9.38e-2)	unprognostic (5.28e-2)	unprognostic (1.32e-1)	unprognostic (1.46e-1)	unprognostic (2.33e-2)	unprognostic (2.32e-1)	prognostic unfavourable (5.14e-4)	unprognostic (9.49e-3)	unprognostic (3.01e-2)	unprognostic (2.22e-1)	unprognostic (3.15e-2)	48.7	5.6	4	6.2	5.8	0.6	28.1	2.6	4.8	11.1	6.6	3.4	5.5	3.7	18.7	11.2	8.4	7.2	12.6	21.7	4.5	4.3	7.8	12.7	43.7	9.7	6.5	2.8	7.7	3.6	5	3.5	96.6	7.6	9	4.8	8.5	5.2	4.4	19	7	6.8	12.1	5.4	10.8	5.7	6.7	3.3	1.2	16.6	15.7	4.5	11.7	11.3	0	0.6	0.4	0.8	0.1	0.1	1.1	0	0	0.6	0	0	0	7.2	0	0	0	0	0	0	0	17.9	0	0.1	0	0	0	0	0	0.1	0	0	0.3	0	0	0	0	0	0	111.2	0	0	0	0	0	0	0.1	0	0	0	0	0.2	0	0	0	0	2.3	0	0	0	95.3	0	0.1	0	0	0	0	0	0	0	0	0.4	0.8	0	0	0	0.1	0	0	0.1	0.4	0	0.1	0	0.4	0.1	0	0.6	0.1	1.1	4	5.8	2.6	4.8	4.5	4.3	6.5	2.8	7.6	3.3
CEACAM1	"BGP, BGP1, CD66a"	ENSG00000079385	Carcinoembryonic antigen related cell adhesion molecule 1	P13688	19	42507304-42561234	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"				Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		intestine: 58.7;liver: 46.1;lymphoid tissue: 46.5	Group enriched	Detected in some	4	CAPAN-2: 12.5;Hep G2: 35.4;RT4: 23.3;SK-MEL-30: 26.2	Low cancer specificity	Detected in many			Low region specificity	Detected in some			Group enriched	Detected in some	9	eosinophil: 20.6;neutrophil: 12.7	Lineage enriched	Detected in many	11	granulocytes: 20.6									"CAB002146, HPA011041"	Enhanced				Intracellular and membrane	180000000	180000000			"CAB002146: AB_563614, HPA011041: AB_1078481"	unprognostic (7.13e-3)	unprognostic (2.15e-1)	unprognostic (2.67e-2)	prognostic favourable (6.32e-7)	unprognostic (3.04e-1)	unprognostic (1.80e-3)	unprognostic (1.21e-1)	unprognostic (4.45e-2)	unprognostic (4.43e-1)	unprognostic (5.46e-3)	unprognostic (4.87e-2)	unprognostic (4.03e-1)	unprognostic (1.92e-2)	unprognostic (1.88e-1)	unprognostic (1.06e-1)	unprognostic (7.55e-2)	unprognostic (5.52e-3)	5.3	5	0.4	30.2	0.7	15.8	5.3	0.5	0.5	7.7	58.7	0.9	2.5	11.8	3.5	1.5	35.6	1.7	4.3	3.8	0.5	0.5	24	46.1	5.4	8.6	1.8	0	2.5	1	0	3.7	16.8	1	8.8	35.6	1.7	20.7	5.4	0.9	1.7	54.9	3	1.5	5.5	3.6	1.3	0.7	1.2	2.3	18.5	46.5	7.8	12.7	1.9	0.1	20.6	1.8	0	1.5	0.3	0.1	2.3	0.1	0.1	0	0	6	0	0.1	0.4	0.2	0.9	12.5	0.7	5	0	0.3	0	3.4	0.1	0	0.2	0.1	0.1	35.4	0.7	0	5.1	0	0	0	0	0.3	0	1.6	0	0.4	0.1	0	0.1	0.7	0.7	0	0.5	0.2	23.3	0.1	0	0	0	26.2	0.1	0	0.8	0.1	0.2	0.1	0.1	0.7	0	1.3	0	0.1	0.1	0.4	0	20.6	0	0.9	0.2	1.9	0.5	0.2	0.1	0.3	0.4	0.1	12.7	0	1.8	0	1.5	0.3	0.4	0.7	0.5	0.5	0.5	0.5	1.8	0	1	0.7
CEACAM3	"CD66d, CGM1"	ENSG00000170956	Carcinoembryonic antigen related cell adhesion molecule 3	P40198	19	41796437-41811553	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"				Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 60.0;bone marrow: 35.4	Cell line enhanced	Detected in single		PC-3: 3.7	Not detected	Not detected			Low region specificity	Detected in single			Cell type enriched	Detected in some	7	neutrophil: 60.0	Lineage enriched	Detected in many	7	granulocytes: 60.0									HPA011041	Approved									HPA011041: AB_1078481	unprognostic (1.60e-1)	unprognostic (1.14e-1)	unprognostic (2.23e-2)	unprognostic (2.95e-2)	unprognostic (2.19e-1)	unprognostic (8.09e-3)	unprognostic (1.44e-1)	unprognostic (2.85e-1)	unprognostic (1.49e-1)	unprognostic (3.19e-2)	unprognostic (1.62e-1)	unprognostic (8.07e-2)	unprognostic (1.32e-2)	unprognostic (1.32e-1)	unprognostic (4.68e-2)	unprognostic (8.44e-2)	unprognostic (2.83e-1)	0.9	0.3	0.3	3.6	0.8	35.4	0.7	0.2	0.8	0.6	1	0	0	0.2	0.4	0.2	1.2	0.7	0.4	5.1	0.4	0.3	0.4	1.1	14	11.5	1.8	0.1	0.7	1	0.2	0.3	4.6	0.5	0.3	0.3	1.4	0.8	0.2	1.5	0.2	0.6	0.4	0.3	10.7	0.4	0.9	0.2	1.6	0.5	0.3	2.7	0.8	0.6	0	0.8	60	8.9	0	0	0.6	0	0.6	0	0	0	0	0	0	0	0	0	0.9	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3.7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0.1	0	0.6	0.8	0	0	3.9	0	0	0	0	0.8	0	0	0	60	0	8.9	0	0	0.6	0.3	0.8	0.2	0.8	0.4	0.3	1.8	0.1	0.5	0.2
CEACAM5	"CD66e, CEA"	ENSG00000105388	Carcinoembryonic antigen related cell adhesion molecule 5	P06731	19	41708585-41729798	"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins"	"Apoptosis, Cell adhesion"		"Cancer-related genes, Oncogene"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		esophagus: 103.5;intestine: 118.2;lymphoid tissue: 100.6	Cell line enriched	Detected in some	6	HaCaT: 17.0	Cancer enhanced	Detected in many		colorectal cancer: 1007.1	Not detected	Not detected			Low cell type specificity	Detected in some			Low lineage specificity	Detected in single											"CAB000021, CAB000022, HPA011041, HPA019758"	Enhanced		Supported	Plasma membrane	Intracellular and membrane	19000000	19000000	Plasma membrane		"CAB000021: , CAB000022: AB_2335697, HPA011041: AB_1078481, HPA019758: AB_1846326"	unprognostic (1.54e-2)	unprognostic (7.59e-2)	unprognostic (5.49e-3)	unprognostic (1.80e-1)		unprognostic (1.38e-2)		unprognostic (2.22e-1)	unprognostic (3.49e-1)	unprognostic (2.11e-1)	unprognostic (2.19e-2)	unprognostic (2.89e-1)	unprognostic (8.67e-9)	unprognostic (2.92e-1)	unprognostic (2.71e-2)	unprognostic (6.31e-2)	unprognostic (1.85e-1)	0.1	0.1	0.1	78.8	0.1	0	0.1	0.1	0.2	12.5	117.1	0.2	0.1	2.5	0.9	0.1	103.5	0.3	1.2	0.1	0.1	0.1	0.1	0.1	3.3	0.1	0.1	0.1	0.2	0.2	0	0.2	0.5	0.1	0.3	118.2	0.2	6.8	0.1	0.1	0.6	12.8	3.3	0.1	0.1	20.1	0.2	0.1	0.6	0.2	29.4	100.6	2	14.1	0.6	0.6	1.8	0.7	0.6	0.5	0.3	0	0.2	0	0.1	0	0	0.2	0	0	0	0	0.7	2.6	0	0.1	0	17	0	0	0	0.2	0	0.1	0	0	0	0	0.2	0	0	0.1	0	0	0	0	0.1	1.2	0.2	0	0.4	1.4	0.3	0	0.1	0	0.5	0.9	0.2	0	0	0	0.1	0	0.2	0	0.4	0	0.4	0.4	0	0	0.1	0.1	0.2	1.2	0.3	0.8	0.3	0.2	0.1	0.5	0.2	0.3	0.6	0.6	0.4	0.5	1.8	0.6	0.7	0.5	0.3	0.3	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.1
CEACAM6	"CD66c, NCA"	ENSG00000086548	Carcinoembryonic antigen related cell adhesion molecule 6	P40199	19	41750977-41772208	"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Apoptosis, Cell adhesion"		"Cancer-related genes, Oncogene"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		esophagus: 81.4;gallbladder: 75.7;lung: 129.1	Cell line enriched	Detected in some	8	A549: 57.9	Low cancer specificity	Detected in many			Not detected	Not detected			Cell type enhanced	Detected in some		neutrophil: 2.6	Group enriched	Detected in many	6	granulocytes: 2.6;monocytes: 1.3									"CAB008370, HPA011041"	Enhanced					79000000	79000000			"CAB008370: AB_592067, HPA011041: AB_1078481"	unprognostic (1.00e-2)	unprognostic (2.05e-1)	unprognostic (2.62e-2)	unprognostic (8.22e-2)	unprognostic (1.39e-1)	unprognostic (9.06e-3)	unprognostic (2.32e-2)	unprognostic (1.37e-1)	unprognostic (2.49e-1)	unprognostic (5.22e-2)	unprognostic (3.70e-3)	unprognostic (1.93e-1)	unprognostic (2.42e-4)	unprognostic (4.08e-1)	unprognostic (8.71e-3)	unprognostic (2.85e-1)	unprognostic (7.68e-2)	0.3	0.3	0.3	7.4	0.3	29.7	0.3	0.3	0.3	16.8	35.3	0.2	0.1	5.8	0.9	0.2	81.4	1.1	75.7	2.3	0.3	0.3	0.3	0.8	129.1	0.1	0.3	0.1	0.3	1.7	0	0.3	32.1	0.2	0.9	43.1	0.2	50.1	0.1	0.3	2.1	12.8	0.9	0.3	0.8	2.6	0.3	0.1	1	0.3	25.3	58.1	2.3	21	0.1	0.3	2.6	1.3	0.1	0.3	5.2	0	57.9	0	0	0	0	0.1	0	0	0	0	1.9	1.6	0	0	0	6.9	0	0	0	0.1	0	0	0.1	0	0	0.3	0.1	0	0	0	0	0.1	0	0	0	3.9	0	0	0.1	1.6	0	0	0	0.3	0.2	0.6	0	0	1.5	0	0.2	0.6	0.1	0	0.1	0.2	0.1	0.1	0	0	0	0.1	0	0	0.3	0.1	0.3	1.3	0	0	0	0	0.1	0.1	0	0	2.6	0.1	0.5	0.3	0	5.2	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.1	0.2	0.1
CEACAM8	"CD66b, CGM6"	ENSG00000124469	Carcinoembryonic antigen related cell adhesion molecule 8	P31997	19	42580241-42595055	"CD markers, Plasma proteins, Predicted intracellular proteins"	Cell adhesion			Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in some	5	bone marrow: 71.0;placenta: 35.6	Low cell line specificity	Detected in some			Not detected	Not detected			Not detected	Not detected			Group enriched	Detected in some	5	neutrophil: 4.2;non-classical monocyte: 3.0	Group enriched	Detected in many	6	granulocytes: 4.2;monocytes: 3.0									CAB033676	Approved				Intracellular and membrane	15000000	15000000			CAB033676: AB_1125678		unprognostic (2.01e-1)	unprognostic (4.52e-2)		unprognostic (3.31e-1)			unprognostic (6.30e-2)		unprognostic (2.68e-1)	unprognostic (1.62e-1)		unprognostic (1.71e-2)	unprognostic (7.77e-2)		unprognostic (9.62e-2)		0.2	0	0.1	0	0.1	71	0.1	0.1	0.4	0	0.4	0	0	0	0.1	0	0.1	0	0	6.6	0.1	0.1	0.1	0.4	4	0.1	0.1	0	0	0.1	0	0.1	35.6	0.1	0	0.1	0	0.1	0	0.7	0.2	0	0	0.1	10.1	0	0.1	0.1	1.9	0.1	0	0	0	0.7	0.5	0.1	4.2	3	0.6	0.4	4.1	0.8	0.2	1.1	2.1	0	0.5	0.3	1.3	0	0	0.1	0.2	0.4	1.2	0.3	0.5	0.5	0	0.3	0	0.2	0.3	0.5	0.7	0.7	0.1	0.8	0.6	0	0.1	0.1	0.1	0	0.7	1.5	0	0.3	0.4	0.9	0.5	0.1	0.5	0.5	1.3	0.4	0.5	0.7	0.8	0.1	0.3	1.2	1.3	0.9	0.8	1.4	0.3	1.5	0.5	1.5	1.3	0.7	0.8	1.3	0.7	0.6	0.5	0.5	0.2	0.2	0.2	0.2	0.2	0.2	0	0.5	0.3	0.4	4.2	0.6	3	0.1	0.1	4.1	0.1	0.1	0.1	0.4	0.1	0.1	0.1	0	0.1	0.1
CLEC10A	"CD301, CLECSF13, CLECSF14, HML, HML2"	ENSG00000132514	C-type lectin domain containing 10A	Q8IUN9	17	7074537-7080307	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Endocytosis, Immunity, Innate immunity"			Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 81.1;lymphoid tissue: 49.3	Cell line enhanced	Detected in some		HUVEC TERT2: 1.6;NB-4: 4.0	Low cancer specificity	Detected in all			Low region specificity	Detected in single			Cell type enriched	Detected in some	12	myeloid DC: 81.1	Lineage enriched	Detected in many	12	dendritic cells: 81.1									HPA021937	Approved									HPA021937: AB_1846905	unprognostic (3.96e-3)	unprognostic (1.71e-3)	unprognostic (2.95e-2)	unprognostic (2.04e-3)	unprognostic (4.54e-2)	prognostic favourable (1.26e-5)	unprognostic (1.07e-1)	prognostic favourable (9.24e-4)	unprognostic (2.70e-2)	unprognostic (1.41e-1)	unprognostic (1.12e-1)	unprognostic (2.30e-1)	unprognostic (6.12e-2)	unprognostic (1.43e-1)	prognostic unfavourable (4.22e-4)	unprognostic (3.23e-1)	unprognostic (3.65e-1)	12.7	4	0.4	14.3	0.5	0.6	6.6	0.4	0.6	4.9	9.7	0.8	1.7	7.9	6.4	31.3	6.9	6.1	12.2	17.5	0.4	0.4	4.4	6.2	22	49.3	0.6	0.6	4.1	3.3	0.4	2	1.3	2	7.2	9.7	3.8	5	5.9	6.1	5.1	14.3	9.6	0.9	10.2	4.4	3.7	0.5	5.4	4.7	9.9	10.4	9.8	4.6	0	81.1	0.3	6.6	0.3	0	3.3	0	0	0	0	0.3	0	0.1	0.1	0	0	0	0	0	0.5	0	0	0.4	0	0	0	0	0	0	0	0.9	0	0	0	0	0	0	0	1.6	0.3	0.3	0	0	0	4	0	0.2	0	0	0.2	0	0	0	0	0	0	0	0	0.3	0	0	0.1	0.3	0.3	0.6	0	0	0.1	0	0.1	0	5.5	0	0	6.6	0	0	0	0	81.1	0	0	0	0.3	0.3	0	1.6	0	3.3	0.4	0.5	0.4	0.6	0.4	0.4	0.6	0.6	2	0.5
CLEC4C	"BDCA2, CD303, CLECSF11, CLECSF7, DLEC, HECL"	ENSG00000198178	C-type lectin domain family 4 member C	Q8WTT0	12	7729415-7751605	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity, Innate immunity"			Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enriched	Detected in some	8	blood: 80.0	Cell line enriched	Detected in some	4	HDLM-2: 6.5	Not detected	Not detected			Not detected	Not detected			Cell type enriched	Detected in some	16	plasmacytoid DC: 80.0	Lineage enriched	Detected in many	16	dendritic cells: 80.0									HPA029432	Approved									HPA029432: AB_10601259	unprognostic (3.55e-3)	unprognostic (3.01e-2)		unprognostic (1.03e-1)	unprognostic (3.70e-2)	unprognostic (7.37e-5)		unprognostic (2.36e-2)	unprognostic (2.06e-1)	unprognostic (2.55e-2)	unprognostic (6.98e-2)	unprognostic (1.39e-1)	unprognostic (1.88e-3)	unprognostic (2.82e-2)	unprognostic (3.18e-3)	unprognostic (2.36e-2)	unprognostic (1.25e-1)	0.3	0.2	0.2	1.6	0.2	1.8	2	0.2	0.6	0.2	0.2	0.1	0.1	0	0.2	0.1	0.3	0.5	1.2	0.3	0.2	0.2	0.5	0.3	1.5	7	0.2	0.1	0.4	0.2	0	0.2	0.1	0.1	0.2	0	0.4	0.3	2	0.2	0.3	0.3	0.1	0.2	4.6	0.3	9.9	0.1	6.7	0.3	0.1	7.1	1.9	0.3	0.5	80	4.9	0.1	0.5	0	0.5	0.2	0	0.3	0.3	0.5	0	0.4	0	0	0.1	0	0.5	0.6	0.3	0	0	0.3	0	0	0.2	6.5	0.1	0.3	0.7	0.2	0	0.6	1.3	0.4	0.3	0	0	0.1	0.2	1	0	0.1	0.1	0.8	1.4	0.2	0.1	0	0.1	0.1	0.4	0.2	0.2	0.1	0.1	0	0.9	0.1	0.4	0.4	0.2	0.1	0.1	0.6	0.2	1.4	0.1	0.3	0.3	0.9	0.1	4.9	0	0	0	0.1	0	0	0.7	0.5	0	0	2.6	0.5	0	80	0	0.5	0.2	0.2	0.2	0.6	0.2	0.2	0.2	0.1	0.1	0.1
CLEC4M	"CD209L, CD299, DC-SIGN2, DC-SIGNR, DCSIGNR, HP10347, LSIGN"	ENSG00000104938	C-type lectin domain family 4 member M	Q9H2X3	19	7763149-7769605	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Endocytosis, Host-virus interaction, Immunity, Innate immunity"	"Host cell receptor for virus entry, Receptor"		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in some	7	liver: 38.5;lymphoid tissue: 30.1	Group enriched	Detected in some	6	HUVEC TERT2: 2.5;K-562: 3.4;Karpas-707: 1.3;RPMI-8226: 1.7	Not detected	Not detected			Not detected	Not detected			Cell type enriched	Detected in single	7	memory B-cell: 1.7	Lineage enriched	Detected in single	18	B-cells: 1.7									"CAB033689, CAB033691, HPA042661"	Supported				Intracellular and membrane	890000	890000			"CAB033689: AB_831088, CAB033691: AB_2081354, HPA042661: "	unprognostic (1.56e-1)				unprognostic (3.03e-1)	unprognostic (1.00e-1)	unprognostic (1.71e-2)	unprognostic (1.26e-2)	unprognostic (1.64e-1)	unprognostic (6.58e-2)		unprognostic (1.27e-1)	unprognostic (4.58e-3)	unprognostic (4.60e-2)	unprognostic (5.15e-2)		unprognostic (1.43e-1)	0.9	0.9	0.1	0.5	0.1	0	0.1	0.2	0.1	0.1	0.3	0.1	0.1	0	0.3	0.1	1.2	0.6	0.1	0.1	0.1	0	0.1	38.5	2.5	30.1	0.1	0.1	2.7	0.1	0	0.1	4.8	0.2	0.1	0	0.1	0.8	0.1	0.1	0	0.5	0.1	0.1	0.2	0	1.4	0.1	0.1	0.2	0.1	0.2	0.1	0.1	1.7	0	0	0	0	0	0	0.1	0	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2	2.5	3.4	1.3	0	0	0	0	0	0	0	0.2	1.7	0	0.3	0	0	0	0	0	0.1	0	0	0	0	0.1	0	0.1	0	0	0	0	0	0	0	0	0	0	0	1.7	0	0	0	0.2	0	0	0	0	0	0	0	0	0.1	0.1	0.2	0.1	0.1	0	0.1	0.1	0.2	0.1
CR1	"CD35, KN"	ENSG00000203710	Complement C3b/C4b receptor 1 (Knops blood group)	P17927	1	207496147-207641765	"Blood group antigen proteins, CD markers, Plasma proteins, Predicted membrane proteins"	"Complement pathway, Host-virus interaction, Immunity, Innate immunity"	"Blood group antigen, Host cell receptor for virus entry, Receptor"		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 23.2;lymphoid tissue: 42.3	Group enriched	Detected in some	9	HL-60: 8.8;HMC-1: 20.6;NB-4: 8.2	Low cancer specificity	Detected in single			Low region specificity	Detected in single			Group enriched	Detected in many	5	basophil: 23.2;eosinophil: 9.4;neutrophil: 9.1	Lineage enriched	Detected in many	8	granulocytes: 23.2									"CAB002491, CAB016271, HPA042455, HPA043579, HPA049348"	Enhanced					27000000	27000000			"CAB002491: AB_563553, CAB016271: AB_627040, HPA042455: , HPA043579: , HPA049348: "	unprognostic (1.74e-1)	unprognostic (3.16e-2)	unprognostic (2.75e-2)	unprognostic (6.12e-2)	unprognostic (1.58e-2)	unprognostic (7.14e-2)	unprognostic (2.84e-1)	unprognostic (3.86e-2)	unprognostic (2.02e-1)	unprognostic (2.80e-1)	unprognostic (1.32e-1)	unprognostic (1.84e-1)	unprognostic (2.29e-3)	unprognostic (4.38e-2)	unprognostic (3.32e-2)	unprognostic (6.45e-2)	unprognostic (3.50e-3)	9	1.1	0.6	17	0.6	5.8	1.5	0.4	0.5	0.6	1.7	0.2	0	0.5	0.7	5.6	1.4	2.2	1.1	8	0.6	0.5	2.3	3.8	4	42.3	0.6	0	1.7	1.2	0	0.6	5.5	1	1.7	0.7	0.5	1.9	0	0.8	0.5	5.1	3.6	0.7	42	1.1	0.9	0.1	1.3	0.7	0	11.1	3.2	1.3	2.8	0.2	23.2	2.3	0	0.6	0.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.4	0	0	0	8.8	20.6	0	0	0	0	0	0.3	0	0	0	0	8.2	1.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	23.2	2.3	9.4	0	1.4	0.4	2.8	0.6	0.3	0.2	1.4	0.1	0.1	9.1	0	1.2	0	0	0.6	0.6	0.6	0.4	0.5	0.6	0.5	0.6	0	1	0.1
CR2	"C3DR, CD21"	ENSG00000117322	Complement C3d receptor 2	P20023	1	207454230-207489895	"CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Complement pathway, Host-virus interaction, Immunity, Innate immunity"	"Host cell receptor for virus entry, Receptor"	Systemic lupus erythematosus	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enriched	Detected in some	6	lymphoid tissue: 97.2	Cell line enhanced	Detected in some		Daudi: 21.1;MOLT-4: 11.5;RPMI-8226: 4.1	Low cancer specificity	Detected in many			Not detected	Not detected			Group enriched	Detected in some	8	memory B-cell: 13.3;naive B-cell: 16.2	Lineage enriched	Detected in many	9	B-cells: 16.2	Low region specificity	Detected in some			Low region specificity	Detected in some			"CAB002659, HPA052942, HPA060715"	Enhanced					150000000	150000000			"CAB002659: , HPA052942: AB_2681994, HPA060715: AB_2684349"	prognostic favourable (6.90e-4)	unprognostic (1.22e-1)	unprognostic (9.95e-2)	unprognostic (3.64e-2)	unprognostic (2.65e-1)	unprognostic (1.27e-3)	unprognostic (1.18e-1)	unprognostic (6.62e-3)	unprognostic (1.91e-2)	unprognostic (1.79e-1)	unprognostic (1.20e-1)	unprognostic (7.95e-2)	unprognostic (2.14e-1)	unprognostic (1.12e-1)	unprognostic (2.19e-1)	unprognostic (2.09e-2)	unprognostic (3.35e-2)	0.5	0.3	0.4	97.2	0.3	0	0.4	0.3	0.3	0.3	1.2	0	0	0	0.3	0	2.8	0.3	0.3	0.3	0.4	0.4	1.4	0.4	2	72.8	0.4	0	0.4	0.4	0	0.3	0	0	0.5	0.9	0	6	0	0.4	0.3	11.5	0	0.4	63.4	1.4	0.5	0	6.5	0.7	0.3	56.3	0.6	0.3	16.2	0	0.2	0	0	1.8	1.1	0	0	0	0	0	0	0	0	0	0	0	0.2	0	21.1	0	0	0	0	0	0	0	0.8	0.8	0	0	0	0	0	0	0	0	0	0	0.3	0	0	0.1	11.5	0	1.9	0.2	0	0.2	4.1	0	0	1	0	0	0	0	0	0	0	0	0.2	0	0	0.1	0	2.6	0	0	0	0	0	0	0.3	0	0.5	13.3	0.7	0.5	0	16.2	1.8	1.6	0.2	0	0	0	0	1.1	0.4	0.3	0.3	0.3	0.4	0.4	0.4	0	0	0
CRTAM	CD355	ENSG00000109943	Cytotoxic and regulatory T cell molecule	O95727	11	122838500-122872639	"CD markers, Predicted membrane proteins"	"Adaptive immunity, Immunity"			Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enriched	Detected in some	5	brain: 140.8	Cell line enriched	Detected in single	34	SCLC-21H: 17.0	Low cancer specificity	Detected in many			Region enriched	Detected in some	24	cerebellum: 140.8	Cell type enhanced	Detected in many		NK-cell: 25.7	Group enriched	Detected in many	5	NK-cells: 25.7;T-cells: 16.7	Region enriched	Detected in single	44	cerebellum: 115.2	Low region specificity	Detected in all									3200000	3200000				unprognostic (3.51e-3)	unprognostic (6.73e-4)	unprognostic (1.33e-2)	unprognostic (3.73e-3)	unprognostic (2.40e-2)	unprognostic (5.25e-4)	unprognostic (1.25e-1)	unprognostic (3.66e-2)	unprognostic (5.27e-2)	unprognostic (1.71e-1)	unprognostic (5.49e-3)	unprognostic (2.32e-1)	unprognostic (1.83e-4)	unprognostic (6.01e-2)	unprognostic (4.26e-2)	unprognostic (3.87e-2)	unprognostic (6.59e-2)	0.4	0.3	0.3	2.7	0.4	1.9	0.4	140.8	0.4	0.3	0.4	0.2	0.1	0.4	0.8	0.4	0.3	0.3	1.8	0.3	0.3	0.3	0.3	1	2.2	10.6	0.4	0.1	0.3	0.3	0	0.3	0.2	5.8	0.3	0.5	0.3	0.7	0.1	0.3	0.3	1.3	0.2	1.2	4.4	0.7	0.3	0.1	3.3	0.3	0.2	4.3	1.1	0.3	0.1	1.7	0.6	4.4	25.7	16.7	2.8	0	0.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2	0.1	0	0	0.5	0.5	0	0.1	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	17	0	0	0	0.2	0	0.1	0	0.1	0	0.1	0	0	0	0	0	0.2	0	0.1	2.2	0.2	6.7	2.7	6.5	0	0.7	13.5	1.7	0.1	2.2	16.7	0.6	25.7	4.4	0.1	0	2.8	0.3	0.4	140.8	0.4	0.3	0.3	0.4	0.1	5.8	0.1
CSF1R	"C-FMS, CD115, CSFR, FMS"	ENSG00000182578	Colony stimulating factor 1 receptor	P07333	5	150053291-150113372	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"	"Immunity, Inflammatory response, Innate immunity"	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		blood: 82.5;lymphoid tissue: 82.6	Group enriched	Detected in some	5	BEWO: 50.6;SK-BR-3: 19.3	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in many		intermediate monocyte: 60.7;non-classical monocyte: 82.5	Lineage enriched	Detected in many	4	monocytes: 82.5	Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB008970, HPA012323"	Uncertain		Supported	"Vesicles,Plasma membrane"	Intracellular and membrane	1500000000	1500000000	"Vesicles, Plasma membrane"		"CAB008970: , HPA012323: AB_1848977"	unprognostic (3.82e-2)	unprognostic (1.31e-1)	unprognostic (1.86e-3)	unprognostic (9.83e-2)	unprognostic (1.20e-1)	unprognostic (7.33e-2)	unprognostic (1.03e-1)	unprognostic (1.45e-1)	unprognostic (9.37e-2)	unprognostic (1.11e-2)	unprognostic (2.49e-1)	unprognostic (1.65e-1)	prognostic unfavourable (1.08e-4)	unprognostic (3.67e-2)	prognostic unfavourable (4.92e-4)	unprognostic (1.72e-2)	unprognostic (4.61e-2)	20.9	12.4	18.2	28.1	18.9	1.8	7.7	2.8	13.5	9.3	8.3	25.4	1.1	9.2	5.9	13.1	8.4	7.9	16.1	8.7	16.4	13.7	7.8	15.1	13.7	25.4	21.3	6	5.3	5.2	5.9	6.4	52.1	17.1	8.5	8.4	16.8	8	8.7	3	5.8	14.5	16.2	25.8	82.6	9	4.9	23	3.1	4.2	2.9	8.2	16.4	4.7	0	19.1	2.9	82.5	0	0.1	13.9	1.7	0	0	0	0.8	0.2	50.6	0.1	0	0	0	1.5	0	2.3	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0.1	0.4	1.1	0	0	0	0	0	0	0	2	0	0	0	0.7	0.2	0	0	0	0.1	0	19.3	0	0	7.2	0	0.3	0	0	1.3	0	0.1	0	2.6	0.9	0	0.4	18.1	0.5	0.1	60.7	0	0	0	0	19.1	0	0	0	2.9	0	82.5	1.4	0	13.9	18.2	18.9	2.8	13.4	16.4	13.7	21.3	6	17.1	23
CSF2RA	"alphaGMR, CD116, CSF2R"	ENSG00000198223	Colony stimulating factor 2 receptor alpha subunit	P15509	X	1268800-1310381	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins"		Receptor	"Cancer-related genes, Disease mutation, FDA approved drug targets"	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 60.2;placenta: 79.5	Group enriched	Detected in some	7	BEWO: 59.0;HMC-1: 17.7;SK-MEL-30: 41.3	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Group enriched	Detected in many	4	classical monocyte: 30.0;eosinophil: 36.0;intermediate monocyte: 17.7;myeloid DC: 31.9;neutrophil: 60.2;plasmacytoid DC: 30.5	Group enriched	Detected in many	28	dendritic cells: 31.9;granulocytes: 60.2;monocytes: 30.0									CAB016148	Uncertain				Secreted to blood	9400000	9400000			CAB016148: AB_626868	unprognostic (4.19e-2)	prognostic favourable (2.38e-5)	unprognostic (5.47e-2)	unprognostic (4.33e-2)	unprognostic (4.88e-2)	prognostic favourable (2.81e-4)	unprognostic (8.24e-2)	unprognostic (2.17e-1)	unprognostic (5.55e-2)	unprognostic (8.48e-2)	unprognostic (8.89e-2)	unprognostic (3.80e-1)	unprognostic (2.89e-2)	unprognostic (8.91e-3)	prognostic unfavourable (5.53e-4)	unprognostic (3.60e-1)	unprognostic (9.44e-2)	8.7	2.3	11.8	11.1	11.1	8.9	17.7	3.4	9.6	3.1	2.2	0.6	0.6	2.2	4.4	0.6	2.1	2.2	5.7	3.7	15	4.7	2.4	1.7	11.2	8.3	18.8	6.5	3.5	1	0.2	2.1	79.5	13.2	1.5	3.3	0.6	3.1	1	0.6	1.8	3.3	2.9	25.5	12.6	1.7	0.6	16.3	0.6	2.5	0.6	10.4	4.2	1.5	0.3	31.9	60.2	30	1.4	0.2	10.1	0.1	3.4	0.2	0	0	0	59	0	0.1	0.1	0	1.2	0.3	0	3.8	0	0	0	0	0	1.1	0	0	2.4	0	0	1.3	17.7	0	0	0	0	0	0	0.1	0	0.1	0.1	5.4	0.5	0.1	0	0.1	0.1	0	0.1	0	0.1	1	0	41.3	2.7	4.9	0	0	1.7	0.3	0	0.1	0.1	0.1	0	5.3	0	2.4	30	36	0	17.7	0.2	0.3	0	0	31.9	0.1	0	0	60.2	1.4	8.4	30.5	0.1	10.1	11.8	11.1	3.4	9.6	15	4.7	18.8	6.5	13.2	16.3
CSF2RB	"betaGMR, CD131, IL3RB, IL5RB"	ENSG00000100368	Colony stimulating factor 2 receptor beta common subunit	P32927	22	36913628-36940449	"CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	FDA approved drug targets	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 53.1;placenta: 73.6	Group enriched	Detected in some	6	HEL: 26.3;HMC-1: 82.6	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Group enriched	Detected in many	6	basophil: 53.1;neutrophil: 20.1	Lineage enriched	Detected in many	14	granulocytes: 53.1					Low region specificity	Detected in all			HPA078677			Approved	Golgi apparatus				Golgi apparatus		HPA078677: 	unprognostic (1.67e-2)	unprognostic (9.44e-3)	unprognostic (1.03e-2)	unprognostic (6.66e-3)	unprognostic (1.51e-1)	prognostic favourable (7.47e-5)	unprognostic (1.86e-1)	unprognostic (1.94e-2)	unprognostic (4.38e-1)	unprognostic (9.57e-2)	unprognostic (1.33e-1)	unprognostic (3.21e-1)	unprognostic (1.82e-3)	unprognostic (5.76e-2)	unprognostic (3.65e-2)	unprognostic (1.95e-1)	unprognostic (8.52e-2)	8.5	1.8	1.5	28.9	1.5	21.7	6	0.6	1	3	5.9	2	0.4	4.5	2.2	2.8	4	3.6	5.5	4.2	1.4	1.4	2.4	3.5	12.6	34.1	2.9	0.2	2.5	1.9	0.3	1.2	73.6	2.4	3.5	3.8	2.8	9.7	1	2.6	3.8	10.2	3	2.9	25.2	3.9	2.1	1.9	8.2	3.4	4.8	30.5	8.2	4.3	0.4	3.8	53.1	2.1	0	0.6	1.8	0	0	0	0	0	0	1.9	0	0	0	0	0	0	6.6	0	0	0	0	0	0	3.9	0	26.3	0	0	0	0.4	82.6	0	0	0	0	4.6	0	3.2	0	0	0	2.7	0	0	2.6	0	9.8	0	0	0	0	0	0.6	0	0	2.3	0	0.2	0	0	0	0.4	0.2	1.6	0	3.8	0	53.1	1.9	5.8	0	2.1	0	0.4	0	0	1.2	0.3	0	0	20.1	0	1.7	3.8	0.6	1.8	1.5	1.5	0.6	1	1.4	1.4	2.9	0.2	2.4	1.9
CSF3R	"CD114, GCSFR"	ENSG00000119535	Colony stimulating factor 3 receptor	Q99062	1	36466043-36483278	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	Cell adhesion	Receptor	"Cancer-related genes, Disease mutation, FDA approved drug targets"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	4	blood: 167.3;bone marrow: 88.9;lymphoid tissue: 71.4;placenta: 152.7	Group enriched	Detected in some	18	BEWO: 34.1;NB-4: 9.2;THP-1: 22.4;U-937: 21.6	Low cancer specificity	Detected in many			Low region specificity	Detected in many			Cell type enriched	Detected in some	8	neutrophil: 167.3	Lineage enriched	Detected in many	8	granulocytes: 167.3	Low region specificity	Detected in many			Low region specificity	Detected in many			"CAB017116, HPA048086"	Enhanced				Intracellular and membrane					"CAB017116: , HPA048086: "	unprognostic (5.57e-3)	unprognostic (8.05e-2)	unprognostic (7.23e-2)	unprognostic (3.87e-2)	unprognostic (2.88e-1)	unprognostic (2.92e-2)	unprognostic (2.86e-2)	unprognostic (1.35e-1)	unprognostic (1.83e-1)	unprognostic (5.65e-2)	unprognostic (2.47e-1)	unprognostic (3.44e-1)	prognostic unfavourable (5.72e-4)	unprognostic (6.33e-2)	prognostic unfavourable (3.79e-4)	unprognostic (2.03e-1)	unprognostic (2.31e-2)	8.5	1.5	2.9	39.5	3.2	88.9	2.4	0.7	2.9	1.1	1.1	4.2	0.4	0.6	0.7	1.1	1.2	6.9	4.3	5.6	2.6	2	1.7	4.5	26.9	27.5	7.2	1.1	1.1	1.3	0.3	1.1	152.7	3.8	1.3	0.5	2.1	1.6	0.5	0.6	0.3	1.6	3.1	7.1	71.4	2.2	1.4	3.3	1.1	1	0.4	0.9	4.6	3.9	0	8.2	167.3	22.1	0.2	0	10.3	0	0	0	0	0	0	34.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.7	0.8	1.1	0	0	0	0	0	0	0.1	0	0	0	0	9.2	0	0	0.2	0	0	0	0	0	0	0	0.4	0	0	22.4	0	0	0	0	0	0	0.1	0	0	21.6	0	0	22.1	0.6	0	4.8	0	0	0	0	8.2	0	0	0	167.3	0.2	1.8	0.2	0	10.3	2.9	3.2	0.7	2.9	2.6	2	7.2	1.1	3.8	3.3
CTLA4	"CD, CD152, CELIAC3, GSE, IDDM12"	ENSG00000163599	Cytotoxic T-lymphocyte associated protein 4	P16410	2	203867786-203873960	"CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"		"Diabetes mellitus, Disease mutation, FDA approved drug targets, Systemic lupus erythematosus"	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 24.8;lymphoid tissue: 31.2	Cell line enhanced	Detected in some		SK-MEL-30: 3.8;U-266/70: 5.8;U-266/84: 16.4	Low cancer specificity	Detected in many			Low region specificity	Detected in single			Cell type enriched	Detected in some	6	T-reg: 24.8	Lineage enriched	Detected in single	248	T-cells: 24.8	Not detected	Not detected			Low region specificity	Detected in some								Intracellular and membrane						unprognostic (1.92e-2)	unprognostic (9.13e-3)	unprognostic (1.47e-3)	unprognostic (9.89e-6)	unprognostic (1.86e-1)	prognostic favourable (4.48e-5)	unprognostic (1.02e-1)	unprognostic (1.75e-2)	unprognostic (1.84e-3)	unprognostic (2.65e-3)	unprognostic (2.77e-1)	unprognostic (3.76e-1)	unprognostic (9.86e-10)	unprognostic (4.13e-2)	unprognostic (7.45e-2)	unprognostic (4.94e-2)	unprognostic (1.19e-2)	1.6	0.2	0.2	24.1	0.3	2.9	1.3	0.2	0.6	0.8	1.6	0.1	0.6	0.2	1.1	0.1	2	1.2	3.6	0.5	0.3	0.5	1.6	0.6	5.8	27.9	0.3	0.3	0.7	0.3	0.1	0.6	0.1	1.7	1.1	1.7	0.8	1.4	0.6	0.2	1	10.3	0.3	1.5	6.7	1.2	1.7	0.1	14.2	1.9	3.3	31.2	4.6	1.3	0	0	0	0	0	24.8	0.4	0	0	0	0	0	0.1	0.1	0	0	1.3	0	0	0	0	0	0	0	0	0	0.3	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0	1.3	0.1	0	0	0	0	0	0	0.2	0.6	0	0	0	0	0	0	3.8	0	0.2	0	0.5	0	0.3	0	5.8	16.4	0.1	0	0	0	0	0	0	0.3	0	0.1	0	4	0.4	0	0	0.7	0.1	0	0	0	0	24.8	0.4	0.2	0.3	0.2	0.6	0.3	0.5	0.3	0.3	1.7	0.1
CXCR1	"CD181, CDw128a, CKR-1, CMKAR1, IL8RA"	ENSG00000163464	C-X-C motif chemokine receptor 1	P25024	2	218162845-218166995	"Cancer-related genes, CD markers, G-protein coupled receptors, Predicted membrane proteins"	Chemotaxis	"G-protein coupled receptor, Receptor, Transducer"	Cancer-related genes	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enriched	Detected in many	4	blood: 144.6	Cell line enriched	Detected in single	26	HMC-1: 11.3	Low cancer specificity	Detected in some			Low region specificity	Detected in some			Cell type enriched	Detected in some	16	neutrophil: 144.6	Lineage enriched	Detected in many	59	granulocytes: 144.6	Not detected	Not detected							HPA031991	Uncertain									HPA031991: 	unprognostic (2.80e-1)	unprognostic (2.91e-2)	unprognostic (3.53e-2)	unprognostic (5.74e-2)	unprognostic (1.19e-1)	unprognostic (1.68e-1)	unprognostic (2.14e-2)	unprognostic (3.36e-2)	unprognostic (2.32e-1)	unprognostic (1.57e-1)	unprognostic (8.27e-2)	unprognostic (2.15e-2)	unprognostic (2.88e-1)	unprognostic (5.47e-2)	unprognostic (2.97e-1)	unprognostic (1.30e-1)	unprognostic (8.85e-2)	11.5	0.4	0.8	21.1	0.7	7.3	0.6	0.9	2.6	0.6	0.6	0.2	0	0	0.5	0.1	1.3	2.8	3.6	3.8	0.9	0.6	0.7	2.9	20.3	33.4	5.9	0	1.7	1.2	0	0.8	2.1	2.3	0.9	0.1	1.4	0.6	0	1	0.5	0.6	1.4	3.4	33.7	1	1.4	0.7	0.1	0.9	0.6	0.4	4.5	4.1	0	0	144.6	0.2	0.1	2.4	0.7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0	0	11.3	0	0.4	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8.7	0.2	0.2	2.4	0	0	0	0.2	0.6	0	0	0	0.9	144.6	0.1	0.2	0	0	0.7	0.8	0.7	0.9	2.6	0.9	0.6	5.9	0	2.3	0.7
CXCR2	"CD182, CMKAR2, IL8RB"	ENSG00000180871	C-X-C motif chemokine receptor 2	P25025	2	218125289-218137253	"Cancer-related genes, CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"	Chemotaxis	"G-protein coupled receptor, Receptor, Transducer"	Cancer-related genes	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enriched	Detected in many	5	blood: 216.1	Group enriched	Detected in some	11	BEWO: 12.1;HL-60: 6.7;HMC-1: 14.1;THP-1: 12.8;U-937: 12.6	Low cancer specificity	Detected in many			Low region specificity	Detected in many			Cell type enriched	Detected in many	59	neutrophil: 216.1	Lineage enriched	Detected in many	109	granulocytes: 216.1	Low region specificity	Detected in single							"CAB016268, HPA031999, HPA032017"	Enhanced		Supported	"Nucleoplasm,Plasma membrane,Microtubules,Mitotic spindle"				Plasma membrane	"Nucleoplasm, Microtubules, Mitotic spindle"	"CAB016268: AB_626893, HPA031999: AB_2674105, HPA032017: AB_2674112"	unprognostic (4.89e-2)	unprognostic (2.01e-1)	unprognostic (5.63e-2)	unprognostic (1.10e-2)	unprognostic (1.58e-1)	unprognostic (3.13e-1)	unprognostic (1.33e-1)	unprognostic (2.13e-1)	unprognostic (5.96e-2)	unprognostic (1.22e-2)	unprognostic (5.67e-2)	unprognostic (1.41e-1)	unprognostic (7.54e-2)	unprognostic (1.04e-1)	unprognostic (7.23e-2)	unprognostic (8.18e-2)	unprognostic (5.48e-2)	9.3	0.9	1.3	25.6	1.5	4	0.6	1.2	1.3	5.2	0.6	0.5	2.5	0	0.8	1.1	18.1	3.3	5.2	4.3	1.5	0.6	0.7	4.6	16.7	40.5	6.6	0	1.2	1.7	0	0.7	4.5	1.7	1.9	0.3	1.8	3.3	2.6	0.6	3	0.7	1.4	4.1	30.6	1	1.1	0.7	0.6	0.6	4.8	10.1	5.4	6.4	0	1.6	216.1	1.9	0.4	1.9	1	0	0	0.1	0	0	0	12.1	0	0	0	0	0	0	0	0	0	0.5	0	0.2	0	0	0	0.1	0	0	0	6.7	14.1	0	0.1	0	0	0	0	0.5	0	0	0.3	1	0.2	0	0.3	0	1	0	0.7	0	0	0	0.1	0	0	12.8	0	0	0	1.1	0	0	0	0	0	12.6	0	3.6	1.9	3.2	1.9	0.5	0	0	0	0.4	0.8	0	0	0.7	216.1	0.4	0.2	1.6	0	1	1.3	1.5	1.2	1.3	1.5	0.6	6.6	0	1.7	0.7
CXCR3	"CD183, CKR-L2, CMKAR3, GPR9, IP10-R, MigR"	ENSG00000186810	C-X-C motif chemokine receptor 3	P49682	X	71615916-71618517	"CD markers, G-protein coupled receptors, Predicted membrane proteins"	"Angiogenesis, Apoptosis, Chemotaxis"	"G-protein coupled receptor, Receptor, Transducer"		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	5	blood: 61.7;lymphoid tissue: 24.5	Cell line enriched	Detected in some	15	RPMI-8226: 31.7	Low cancer specificity	Detected in many			Not detected	Not detected			Cell type enhanced	Detected in many		plasmacytoid DC: 61.7	Group enriched	Detected in many	4	dendritic cells: 61.7;NK-cells: 38.1;T-cells: 26.6	Not detected	Not detected			Low region specificity	Detected in all			HPA045942	Enhanced									HPA045942: 	unprognostic (4.84e-3)	unprognostic (3.05e-3)	unprognostic (1.61e-1)	prognostic favourable (3.44e-6)	unprognostic (3.93e-2)	prognostic favourable (3.35e-4)	unprognostic (1.01e-2)	unprognostic (5.24e-2)	prognostic favourable (2.90e-4)	unprognostic (6.32e-2)	unprognostic (1.34e-1)	unprognostic (2.39e-1)	prognostic unfavourable (1.67e-6)	unprognostic (4.67e-2)	unprognostic (2.18e-1)	unprognostic (2.91e-2)	unprognostic (5.76e-2)	0.9	0.9	0.4	9	0.4	6	0.6	0.3	0.3	1.9	2.4	0.4	0.5	5.4	3.3	1.4	1.3	1.1	2.6	2.4	0.3	0.4	1.9	0.8	4.5	19	0.4	0.1	1.6	0.8	0	0.6	0.7	0.5	2.9	0.8	1.5	3.9	1	0.4	0.5	9.1	0.3	0.7	13.9	2.6	0.6	0	14	1.9	1.7	24.5	1.7	1.8	9.8	61.7	0.4	0	38.1	26.6	6.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.7	0	0	0.1	1	0	0	0	0	31.7	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0.1	0	2.1	0	0	0	0	17.3	0	8.9	9.8	19.6	26.6	1.6	1.8	1.2	11.1	0.4	38.1	0	61.7	17.8	6.3	0.4	0.4	0.3	0.3	0.3	0.4	0.4	0.1	0.5	0
CXCR4	"CD184, D2S201E, fusin, HM89, HSY3RR, LESTR, NPY3R, NPYR, NPYY3R"	ENSG00000121966	C-X-C motif chemokine receptor 4	P61073	2	136114349-136118165	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"	Host-virus interaction	"G-protein coupled receptor, Host cell receptor for virus entry, Receptor, Transducer"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		bone marrow: 149.9;lymphoid tissue: 186.3	Cell line enhanced	Detected in many		Daudi: 75.5;Karpas-707: 40.5;MOLT-4: 68.5;REH: 36.3;U-266/70: 87.9;U-698: 88.4	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all			Low region specificity	Detected in many			Low region specificity	Detected in all														unprognostic (1.19e-1)	unprognostic (1.46e-2)	unprognostic (2.69e-1)	unprognostic (5.97e-2)	unprognostic (1.29e-2)	unprognostic (1.12e-2)	unprognostic (4.99e-2)	unprognostic (9.25e-2)	unprognostic (6.06e-2)	prognostic favourable (2.05e-4)	unprognostic (1.23e-1)	unprognostic (2.66e-1)	prognostic unfavourable (1.41e-7)	prognostic unfavourable (5.67e-4)	unprognostic (1.57e-1)	unprognostic (3.47e-2)	unprognostic (9.33e-2)	15.4	26.5	3	39.1	3.4	149.9	9.7	0.8	2.1	7.7	8.7	6.8	1.5	1.6	8.3	3.8	16.4	9.1	12	5.4	4.1	4.7	8.2	7.1	29.3	94.5	6.5	1.3	6.3	3.1	0.7	8.1	7.8	6.1	6.8	7	10	10.6	2.2	3.2	2.3	57.8	3.8	22.9	82.4	8	7.2	3.4	186.3	9.2	4.6	97.5	50	6.6	47.3	16.8	37.8	7.2	4	32	11.9	0.1	0	1.2	0	0	0	0	0	0	0	0	0.2	0	75.5	0.2	0	0	0.2	0	0	3.8	0.9	4.5	12	0	0	10.4	8.2	0	0	0	0	7.2	0.1	40.5	0	0.2	68.5	9.3	1.2	0.3	36.3	8.4	13.2	0.6	0	4.2	3.5	0	0.2	0	0	20.5	1	0	0.2	0	0	87.9	14.8	88.4	0	17.2	0	17.9	7.2	29.6	22.9	3.8	18.7	30.1	21.1	21.7	6.6	47.3	32	30.1	37.8	4	2.1	16.8	18.9	11.9	3	3.4	0.8	2.1	4.1	4.7	6.5	1.3	6.1	3.4
CXCR5	"BLR1, CD185, MDR15"	ENSG00000160683	C-X-C motif chemokine receptor 5	P32302	11	118883766-118897799	"CD markers, G-protein coupled receptors, Predicted membrane proteins"	B-cell activation	"G-protein coupled receptor, Receptor, Transducer"		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	5	blood: 35.5;lymphoid tissue: 45.6	Group enriched	Detected in some	10	Daudi: 10.3;U-698: 36.2	Not detected	Not detected			Region enriched	Detected in single	4	cerebellum: 4.0	Group enriched	Detected in some	8	memory B-cell: 24.2;naive B-cell: 35.5	Lineage enriched	Detected in many	9	B-cells: 35.5	Not detected	Not detected			Low region specificity	Detected in some			"CAB026149, HPA042432"	Enhanced									"CAB026149: , HPA042432: "	unprognostic (8.51e-2)	unprognostic (1.52e-2)	unprognostic (1.68e-1)	unprognostic (1.19e-1)		unprognostic (4.02e-5)		unprognostic (2.08e-2)	unprognostic (3.23e-3)	unprognostic (1.19e-2)	unprognostic (3.66e-1)	unprognostic (2.41e-3)	unprognostic (1.52e-5)	unprognostic (4.21e-1)	unprognostic (2.03e-3)	unprognostic (1.38e-1)	unprognostic (1.90e-1)	0.4	0.8	0.6	31.8	0.6	7.3	0.1	4	0.9	0.1	3.6	0.2	0.1	0.1	0.2	0.1	2.6	0	0.5	0.9	0.7	0.5	0.8	1	0.9	31.5	0.3	0.1	0.3	0.5	0	0.9	0.1	0.2	2.9	0.3	0.3	3.6	0.1	1.3	0.9	8.6	0.1	0.3	45.6	1.3	0.1	0.1	1.9	0.7	1.3	41.8	3.9	0.9	35.5	0	0	0	0	3.9	1.9	0	0	0.4	0	0	0	0	0	0	0	0	0.1	0.4	10.3	0.2	0	0.6	0	0	0	0	0.1	2.3	0	0	0	0.2	0.8	0	0	0	0	0	0	0.1	0	0.5	0.4	0.9	0	0	0.3	0	0.1	0	0	0.3	0.4	0	0	0.4	0.1	0.5	0	0.2	0.4	0	0	0.2	0	36.2	0	0.4	0	0	0	0	0.3	0	0.3	24.2	3.9	1	0	35.5	0.4	0.3	0	0	0	0	0.5	1.9	0.6	0.6	4	0.9	0.7	0.5	0.3	0.1	0.2	0.1
CXCR6	"BONZO, CD186, STRL33, TYMSTR"	ENSG00000172215	C-X-C motif chemokine receptor 6	O00574	3	45940933-45948353	"CD markers, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"		Evidence at transcript level	Evidence at transcript level	Evidence at transcript level	Evidence at transcript level		Tissue enhanced	Detected in many		blood: 81.3	Group enriched	Detected in some	6	BEWO: 4.1;CAPAN-2: 15.4	Low cancer specificity	Detected in many			Low region specificity	Detected in single			Cell type enriched	Detected in many	4	MAIT T-cell: 81.3	Lineage enriched	Detected in many	6	T-cells: 81.3	Not detected	Not detected			Low region specificity	Detected in many														unprognostic (2.05e-3)	prognostic favourable (4.92e-4)	unprognostic (1.77e-3)	prognostic favourable (6.74e-6)	unprognostic (6.67e-2)	prognostic favourable (2.16e-4)	unprognostic (2.09e-2)	unprognostic (1.51e-2)	unprognostic (1.93e-2)	unprognostic (3.65e-4)	unprognostic (8.57e-2)	unprognostic (1.07e-1)	prognostic unfavourable (2.42e-5)	unprognostic (2.25e-2)	unprognostic (4.42e-2)	unprognostic (3.46e-2)	unprognostic (1.57e-2)	2.5	1.1	0.5	7.6	0.5	0.5	2.1	0.4	0.5	2.3	9.9	1.1	1.5	3	2.7	3.2	3	2.4	5.2	1.7	0.6	0.6	2.5	2.5	9.2	10.4	0.6	0.2	3.7	1.6	0	0.9	18.9	1	2.6	2.6	3	3.3	0.2	7.7	1.1	10.8	1	1.3	22.3	6	2.3	0.2	5.2	4.1	5.3	14.6	5.2	2.6	0	0.1	0.1	0	13.4	81.3	3.8	0.3	0.1	0	0.3	0	0	4.1	0.2	0	0	0	1.1	15.4	0.3	0.1	0	0	0	0	0	0	0	0.4	0.7	0.1	0	0.3	0	0	0	0	0	0	0.2	0.5	0	0.2	0.8	0.2	0.3	0.6	0.1	0	0	0	1.7	0	0.1	0.3	0.9	0	0.2	0.8	0.4	1.5	0.7	0	0.1	0.1	0	0.2	0.2	0.1	0.1	0	0	0	17.3	0	81.3	0	4.9	20.3	0	0	0.2	3.1	0.1	13.4	0	0.1	14.5	3.8	0.5	0.5	0.4	0.5	0.6	0.6	0.6	0.2	1	0.2
DDR1	"CAK, CD167, EDDR1, NEP, NTRK4, PTK3A, RTK6"	ENSG00000204580	Discoidin domain receptor tyrosine kinase 1	Q08345	6	30876421-30900156	"CD markers, Enzymes, Predicted intracellular proteins, Predicted membrane proteins"	"Lactation, Pregnancy"	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in many		HaCaT: 31.2;HBEC3-KT: 24.0;RT4: 31.9;T-47d: 35.8	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in some			Low lineage specificity	Detected in many			Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB010162, CAB025656, HPA057194"	Approved		Approved	"Nucleoplasm,Cell Junctions"	Intracellular and membrane	2100000	2100000	"Nucleoplasm, Cell Junctions"		"CAB010162: AB_2092090, CAB025656: , HPA057194: "	unprognostic (2.11e-2)	unprognostic (9.31e-2)	unprognostic (1.01e-1)	unprognostic (1.09e-1)	unprognostic (2.07e-1)	unprognostic (7.75e-3)	unprognostic (6.43e-2)	unprognostic (1.92e-1)	unprognostic (1.73e-1)	unprognostic (1.42e-1)	unprognostic (1.50e-1)	unprognostic (4.41e-2)	prognostic favourable (3.31e-10)	unprognostic (1.42e-1)	unprognostic (2.53e-1)	unprognostic (5.49e-3)	unprognostic (4.09e-2)	6.7	11.3	23.5	7.9	36.2	2.2	12.5	6.8	42.2	9.7	25.2	57.4	17.6	16.8	7.7	10.5	30.5	31.7	18.9	8.7	27.8	20.8	19.8	3.5	13.2	3.1	55.7	19.8	11.3	20.9	28.2	14.6	13.3	34.7	17.7	14.9	4	28.3	20.5	9.1	41.3	32.1	3.1	43.2	5.1	52.2	5.1	37	8.7	20.9	10.5	7.6	16.3	16.6	1.8	0.4	0	0.2	0	1.8	0.9	19.3	6.4	9.1	1.9	0.6	0.8	5.6	0.5	0.1	0.2	0	8.6	10.3	0.1	10.8	1.7	31.2	1.9	24	0.1	10.7	3.4	0	5.8	2.2	1.8	0	0.4	1.2	12.4	0.1	0.2	0.7	5.6	0.2	1.3	12.2	0.6	0	1.5	1.3	1.3	6.8	0.7	4.6	31.9	1.6	0.8	1.8	14.4	7	35.8	0.2	1.4	4.5	4.2	0.4	4.5	0.2	0	0.8	2.9	0	3.9	0	0.2	0	1.1	0	0.8	0.4	0.2	0.7	0.4	1.8	1.2	1.8	0	0	0	0.4	0	0.9	23.5	36.2	6.8	25	27.8	20.8	55.7	19.8	34.7	37
DDR2	"NTRKR3, TKT, TYRO10"	ENSG00000162733	Discoidin domain receptor tyrosine kinase 2	Q16832	1	162631373-162787400	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	Osteogenesis	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, Dwarfism, FDA approved drug targets"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in many			Cell line enhanced	Detected in many		ASC diff: 60.6;ASC TERT1: 59.9;BJ hTERT+: 44.3;fHDF/TERT166: 31.7;HSkMC: 42.5	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in some		gdT-cell: 1.1;MAIT T-cell: 1.3	Lineage enriched	Detected in single	5	T-cells: 1.3	Low region specificity	Detected in all			Low region specificity	Detected in all			HPA070112			Supported	"Plasma membrane,Actin filaments"		850000	850000	"Plasma membrane, Actin filaments"		HPA070112: 	unprognostic (4.12e-2)	unprognostic (2.73e-1)	unprognostic (6.97e-3)	unprognostic (4.52e-2)	unprognostic (1.17e-1)	unprognostic (8.16e-2)	unprognostic (1.81e-1)	unprognostic (1.19e-1)	unprognostic (6.62e-2)	unprognostic (2.24e-2)	unprognostic (1.00e-1)	unprognostic (1.15e-1)	prognostic unfavourable (1.73e-7)	unprognostic (1.56e-3)	unprognostic (8.26e-3)	unprognostic (7.57e-2)	unprognostic (4.10e-3)	42.1	43.5	4.7	10.9	6.9	0.2	15.6	7.9	7.1	30.3	30.4	9	18.6	3.3	24.2	17.7	25	13.4	16.6	15.4	7.9	4.7	4	3.3	8.9	5.1	12.9	3.4	26.4	2.2	2.1	4	6.6	12.7	21.8	9.1	30.7	6.4	19.3	5.2	6.1	10.1	34.3	19.7	3.4	14.1	8.3	7.5	0	8.6	12.8	4.1	29	18.3	0.1	0.2	0	0	0.2	1.3	0	0.1	0	0	16	60.6	59.9	0.2	23.6	44.3	10.3	14.9	0	0	0	0	31.7	0	0	0.1	14.1	12.7	0.1	0	0	0	26.3	0	0	42.5	0.1	18.2	0.4	11.8	0.1	5	9.4	0	0	0	0.1	0.1	0	6.7	0.1	0	0	0	9.7	0	0	0.8	0	0	0.6	16.5	3.6	8.3	3.2	0.7	1.3	0	14.9	0	16.7	0	0	0	1.1	0	1.3	0	0.8	0.1	0	0.1	0	0	0	0.2	0	0.2	0	0	4.7	6.9	7.9	7.1	7.9	4.7	12.9	3.4	12.7	7.5
DPP4	"ADCP2, CD26, DPPIV"	ENSG00000197635	Dipeptidyl peptidase 4	P27487	2	161992241-162074542	"CD markers, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	Cell adhesion	"Aminopeptidase, Hydrolase, Protease, Receptor, Serine protease"	FDA approved drug targets	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		intestine: 133.1;parathyroid gland: 75.5	Cell line enhanced	Detected in some		ASC diff: 41.8;ASC TERT1: 42.4;BJ hTERT+: 38.9;RPTEC TERT1: 56.7	Low cancer specificity	Detected in all			Low region specificity	Detected in single			Cell type enhanced	Detected in many		MAIT T-cell: 26.7	Lineage enriched	Detected in many	10	T-cells: 26.7	Low region specificity	Detected in many			Low region specificity	Detected in many			CAB045970	Enhanced				Secreted in other tissues	170000000	170000000			CAB045970: AB_11140529	unprognostic (4.47e-2)	unprognostic (4.47e-2)	unprognostic (8.89e-2)	unprognostic (3.36e-1)	unprognostic (7.25e-2)	unprognostic (5.40e-2)	unprognostic (2.78e-1)	unprognostic (3.54e-2)	unprognostic (3.58e-1)	unprognostic (4.73e-1)	unprognostic (2.36e-1)	prognostic unfavourable (1.98e-4)	prognostic favourable (1.35e-6)	unprognostic (4.68e-2)	unprognostic (6.33e-2)	prognostic favourable (4.99e-4)	unprognostic (1.21e-2)	9.5	2.9	0.3	3.2	0.5	0	5	0.3	1.4	2.2	50	0.2	36.9	19.1	2.2	3.5	1.2	1.2	5.2	2.1	0.4	0.3	29.1	12.2	5.4	2.1	0.4	0.2	2.7	1.8	75.5	0.3	24	0.2	21.1	2.8	0.6	46.9	38.8	2.4	4.4	133.1	0.9	0.8	5	1.2	0.6	0.1	6.2	1	1.4	1.1	1	2.6	0.1	2.1	0.3	0	2.6	26.7	2.5	0	0	0.1	0	41.8	42.4	0.1	7.7	38.9	2.1	7.6	7.8	0.2	0	2.9	13.4	0.2	0.1	0	1.3	2.4	0.1	0	0	11.7	17.1	0	0	4.8	0	13.1	0.1	1.2	0	0	0.7	0	0.7	0.1	0.4	16	0	0	0.1	56.7	0	0	0.1	0	0	0	0	0	6.9	4.5	0.2	0.2	0	0	0	0	4.6	0	0	0	0	0	3.2	0	26.7	0.1	8.3	5.2	0.6	0	8.3	3.3	0.3	2.6	0	2.1	0.9	2.5	0.3	0.5	0.3	1.4	0.4	0.3	0.4	0.2	0.2	0.1
ENG	"CD105, END, HHT1, ORW, ORW1"	ENSG00000106991	Endoglin	P17813	9	127815012-127854756	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins"	"Angiogenesis, Cell adhesion"		"Cancer-related genes, Disease mutation"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in many		HUVEC TERT2: 66.9;TIME: 136.5	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Group enriched	Detected in many	4	classical monocyte: 12.2;intermediate monocyte: 17.7;myeloid DC: 6.4;NK-cell: 4.6;non-classical monocyte: 13.0	Group enriched	Detected in many	4	dendritic cells: 6.4;monocytes: 17.7;NK-cells: 4.6	Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB000096, HPA011862, HPA067440, CAB072873"	Enhanced		Supported	"Nuclear bodies,Plasma membrane"		260000000	260000000	Plasma membrane	Nuclear bodies	"CAB000096: AB_563482, CAB072873: , HPA011862: AB_1846217, HPA067440: "	unprognostic (2.28e-1)	unprognostic (1.13e-1)	unprognostic (3.87e-2)	unprognostic (2.96e-2)	unprognostic (1.77e-1)	prognostic favourable (6.61e-4)	prognostic favourable (5.62e-6)	unprognostic (2.15e-1)	unprognostic (4.06e-1)	unprognostic (3.87e-2)	unprognostic (2.20e-2)	unprognostic (8.98e-2)	prognostic unfavourable (4.26e-4)	unprognostic (3.33e-3)	unprognostic (7.35e-2)	unprognostic (2.84e-1)	unprognostic (1.27e-1)	40.3	19.3	6.4	26.6	10.5	5.5	52.7	3.9	8.6	26.3	14	7.6	18.5	11.2	27	25.2	17.2	23.2	28.3	105.4	8	5	40.8	26.8	66.7	44.1	10.6	7	66.4	9.6	8.6	12.5	60.2	10.1	23.1	6.4	35.5	9.9	51.7	24.1	10.1	14.5	23.1	8.7	52.4	11.6	37.2	7.7	6.7	35.4	19.3	11	20.3	44.8	1.1	6.4	0.3	17.7	4.6	2.3	4.6	0.1	0.1	0.9	0	16.8	11.5	29.6	19.5	14	10.4	6.1	0	0.1	0.1	9.5	35.8	0.3	0	3.1	3.4	0	0	5.5	11	0.6	13.1	2.6	0	19.7	0.7	13.5	4.9	66.9	0	0.1	12.1	0.1	0	0.2	0.2	0.5	8.7	1.7	0.1	0	0	0.1	0.2	10.3	9	2.6	1.8	3.9	136.5	34.1	1.8	22.2	0	0.7	0.1	0.1	9.2	6.8	11.2	0	12.2	0.3	1.3	17.7	0.4	0.4	2.1	2.3	6.4	1.1	1.3	2	0.3	4.6	13	2.4	0.8	4.6	6.4	10.5	3.9	8.6	8	5	10.6	7	10.1	7.7
ENPEP	"CD249, gp160"	ENSG00000138792	Glutamyl aminopeptidase	Q07075	4	110365733-110565285	"CD markers, Enzymes, Plasma proteins, Predicted membrane proteins"		"Aminopeptidase, Hydrolase, Metalloprotease, Protease"		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		intestine: 165.1;kidney: 63.8	Cell line enhanced	Detected in some		BEWO: 4.5;HEK 293: 12.1;MOLT-4: 2.9	Cancer enriched	Detected in many	8	renal cancer: 41.0	Low region specificity	Detected in single			Not detected	Not detected			Not detected	Not detected			Low region specificity	Detected in many			Low region specificity	Detected in many			HPA005128	Enhanced					37000000	37000000			HPA005128: AB_1844795	unprognostic (2.73e-3)	unprognostic (2.84e-3)	unprognostic (5.16e-3)	unprognostic (3.48e-1)	unprognostic (2.90e-1)	unprognostic (8.74e-2)	unprognostic (3.34e-2)	unprognostic (1.03e-1)	unprognostic (1.35e-2)	unprognostic (1.22e-1)	unprognostic (1.93e-1)	unprognostic (9.47e-2)	unprognostic (4.49e-3)	unprognostic (3.43e-3)	unprognostic (1.52e-2)	unprognostic (8.46e-2)	unprognostic (2.49e-3)	5.8	1	0.4	0.4	0.6	0	2.8	0.3	1	1.1	54.4	0.4	0.7	11.1	5.3	2.4	0.8	1.4	1.1	2.3	0.5	0.3	63.8	14.5	2.7	0.5	0.4	0.3	1	1	33.3	0.8	4.4	0.5	1.4	0	0.8	0.6	0.5	2.3	0.4	165.1	3.1	0.5	4.7	0.7	0.4	0.4	1.4	2.4	2	0.4	1	1	0	0	0	0	0	0.7	0	0	0.4	0.1	0	0.1	0.3	4.5	0.6	0	0.2	0.4	0.1	0	0	0.2	0.1	0	0.2	0	0.1	0	12.1	0	0	0	0	0	0	1.6	0	0	0	0	0	0	0.2	1.6	2.9	0.5	0.5	0	0.2	0	0.5	0	0.5	0.1	0.3	0	2.1	0	0	0	0	0	0	0.3	0	1.2	2.2	0	0.1	0	0.2	0	0	0	0	0	0.7	0	0	0	0	0	0	0	0	0	0	0	0	0	0.4	0.6	0.3	1	0.5	0.3	0.4	0.3	0.5	0.4
ENPP1	"M6S1, NPPS, PC-1, PCA1, PDNP1"	ENSG00000197594	Ectonucleotide pyrophosphatase/phosphodiesterase 1	P22413	6	131808016-131895155	"CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins"	Biomineralization	Hydrolase	"Diabetes mellitus, Disease mutation, Obesity"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in many			Cell line enhanced	Detected in many		ASC diff: 22.6;LHCN-M2: 13.5;U-138 MG: 18.1	Low cancer specificity	Detected in all			Low region specificity	Detected in single			Cell type enhanced	Detected in some		NK-cell: 4.6	Low lineage specificity	Detected in many			Low region specificity	Detected in many			Low region specificity	Detected in many			"CAB032904, HPA062066"	Enhanced				Secreted - unknown location	2500000	2500000			"CAB032904: AB_2099635, HPA062066: "	unprognostic (1.47e-1)	unprognostic (1.23e-1)	unprognostic (2.15e-1)	unprognostic (1.60e-3)	unprognostic (2.40e-1)	unprognostic (1.11e-1)	unprognostic (2.00e-1)	unprognostic (1.60e-2)	unprognostic (7.22e-3)	unprognostic (8.96e-2)	unprognostic (1.95e-1)	unprognostic (3.00e-1)	unprognostic (2.61e-2)	unprognostic (1.41e-1)	unprognostic (1.96e-1)	unprognostic (1.84e-1)	unprognostic (3.28e-3)	17.2	2.1	0.5	1.9	0.5	0	30.5	0.6	0.4	8.5	2.8	1.6	8.3	1.1	25.7	7.1	1.5	6.4	2.6	1.9	0.5	0.7	10.9	19.4	2	0.7	1.1	0	7.3	17.5	22.2	27	28.9	0.8	3.3	1.2	13.4	5.4	6.5	2.1	1.7	2.6	6.8	2	1.2	1.7	4.6	0.3	2	13.2	6.9	1.4	3.2	7.7	0.6	2.2	1.4	0.3	4.6	1.7	0.1	0	0.8	0.8	0	22.6	3.5	0	5.8	6	2.3	6.3	2.5	0.7	0	0.5	3.7	0	0.8	0.1	9.7	0.2	1.1	0	0.7	7.5	0.7	0	2.7	5.8	0.2	6.2	0.2	2.7	0	1.2	13.5	1.6	0	0	5.1	0.8	0	6.6	0.1	0.1	0.3	2.2	0	0.1	0.8	2.6	2.5	0	1.8	18.1	0.6	1.2	5.7	2.2	0	0	8.3	0	2.2	1.4	0.2	0.3	0.3	0.2	1.7	0.3	0.3	0.3	2.2	0.6	0.3	0.3	1	4.6	0.3	0.3	0.2	0.1	0.5	0.5	0.6	0.4	0.5	0.7	1.1	0	0.8	0.3
ENPP3	"B10, CD203c, gp130RB13-6, PD-IBETA, PDNP3"	ENSG00000154269	Ectonucleotide pyrophosphatase/phosphodiesterase 3	O14638	6	131628442-131747418	"CD markers, Enzymes, Predicted intracellular proteins, Predicted secreted proteins"		Hydrolase		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		ductus deferens: 29.0;intestine: 45.4;seminal vesicle: 70.7	Group enriched	Detected in some	18	HEL: 5.0;Hep G2: 16.6;HMC-1: 7.4	Cancer enriched	Detected in many	8	renal cancer: 49.6	Low region specificity	Detected in single			Cell type enriched	Detected in single	74	basophil: 18.2	Lineage enriched	Detected in single	74	granulocytes: 18.2	Low region specificity	Detected in some							HPA043772	Enhanced				Secreted - unknown location	480000	480000			HPA043772: AB_10795616	unprognostic (2.74e-1)	unprognostic (1.99e-2)	unprognostic (1.84e-1)	unprognostic (5.41e-3)	unprognostic (6.07e-2)	unprognostic (4.86e-5)	unprognostic (1.13e-1)	unprognostic (7.20e-3)	unprognostic (1.17e-1)	unprognostic (1.13e-1)	unprognostic (2.21e-3)	unprognostic (2.34e-1)	prognostic unfavourable (1.96e-4)	unprognostic (2.80e-2)	unprognostic (7.85e-2)	unprognostic (2.29e-1)	unprognostic (1.31e-3)	0.8	7.9	0.5	2	0.5	0	4	2.1	0.4	19	18.5	0.2	29	9.3	6.2	7.2	0.5	2.3	1.8	0.2	0.4	0.7	11.9	2.7	1.7	0.2	0.5	0.2	0.9	0.2	0	0.5	0.4	0.2	3.7	4.8	0.6	14.9	70.7	0.2	0.8	45.4	1.9	0.4	0.5	0.7	1	0.2	4.1	0.5	1.2	0.5	0.9	1.2	0	0	18.2	0	0.2	0.2	0	0	0	0	0	0	0.1	0.1	0	0	0	0	0	0	0.2	0	0	0	0	0.1	0	0.5	0.1	5	0	16.6	0	0.1	7.4	0	0	0	0	0	0.1	0	0.1	0	0	0.5	0	0	0	0	0	0	0	0.2	0	0	0	0.1	0	0	0	0.1	0	0	0	0.3	0	0.2	0.1	0	0	18.2	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0.5	0.5	2.1	0.4	0.4	0.7	0.5	0.2	0.2	0.2
ENTPD1	"ATPDase, CD39, NTPDase-1, SPG64"	ENSG00000138185	Ectonucleoside triphosphate diphosphohydrolase 1	P49961	10	95711779-95869695	"CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins"		Hydrolase	"Disease mutation, Hereditary spastic paraplegia, Neurodegeneration"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		endometrium 1: 59.4	Group enriched	Detected in some	7	HDLM-2: 56.0;Karpas-707: 46.0	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in many		eosinophil: 37.4	Low lineage specificity	Detected in many											"CAB002494, HPA014067"	Enhanced		Uncertain	Microtubules				Microtubules		"CAB002494: AB_563557, HPA014067: AB_1848178"	unprognostic (1.14e-1)	unprognostic (1.01e-2)	unprognostic (3.11e-1)	unprognostic (5.67e-2)	unprognostic (9.68e-3)	unprognostic (3.45e-3)	unprognostic (6.31e-2)	unprognostic (5.26e-3)	unprognostic (2.73e-1)	unprognostic (1.28e-2)	unprognostic (6.40e-2)	unprognostic (1.41e-1)	prognostic unfavourable (5.33e-5)	unprognostic (9.79e-2)	unprognostic (2.30e-1)	prognostic favourable (7.89e-4)	unprognostic (5.09e-2)	10.4	7.5	7.4	16.2	8.4	15.6	8.8	7.6	6.9	18.9	12.7	13.1	8.7	5.8	59.4	12.8	13.2	15.6	22.2	6.8	7.4	7.4	6.2	3.9	14.8	14.5	8.5	4.9	10.3	2.8	3	4.3	24	9.9	14.7	9.1	10.8	6.7	12.7	3.3	5.5	12.2	37.2	17.9	25.3	7.5	5.4	7.2	3.5	13.4	12.5	21.1	25.2	12.4	6	11.8	37.4	15.2	0.5	5.1	4.6	0.1	0.3	0.9	0.8	0	0	0.5	0.5	0.4	0	0	0.5	0.1	1	0.6	0	0.2	0	0	0	56	0.7	0.6	0.4	0.7	0	1.5	0.2	0	0	0.2	0	7.4	0.6	46	0	0.6	0.4	1.5	0.6	0.2	2.3	0.3	0.7	0.5	0.2	0.7	1	0.3	1.1	0.7	0.5	1.6	0.8	0.4	0.2	0.6	0.6	6.6	0.9	0	0.6	3.1	0.2	0.1	15.2	37.4	0.1	10.7	0.3	6	0.6	0.3	11.8	4.6	0.1	0.1	26.7	0.5	2.4	0.7	5.1	4.6	7.4	8.4	7.6	6.9	7.4	7.4	8.5	4.9	9.9	7.2
EPCAM	"17-1A, 323/A3, CD326, CO-17A, EGP-2, EGP34, EGP40, Ep-CAM, ESA, GA733-2, HEA125, KS1/4, KSA, Ly74, M4S1, MH99, MIC18, MK-1, MOC31, TACST-1, TACSTD1, TROP1"	ENSG00000119888	Epithelial cell adhesion molecule	P16422	2	47345158-47387601	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		Tumor antigen	"Cancer-related genes, Disease mutation, FDA approved drug targets, Hereditary nonpolyposis colorectal cancer"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		intestine: 303.2	Cell line enhanced	Detected in many		A-431: 58.3;CACO-2: 75.6;CAPAN-2: 106.4;RPTEC TERT1: 45.4;SCLC-21H: 41.1	Low cancer specificity	Detected in many			Low region specificity	Detected in many			Cell type enhanced	Detected in single		plasmacytoid DC: 1.9	Lineage enriched	Detected in single	5	dendritic cells: 1.9	Not detected	Not detected			Low region specificity	Detected in some			"CAB003809, HPA026761, CAB030012, CAB055098, HPA067463"	Enhanced		Supported	Plasma membrane				Plasma membrane		"CAB003809: AB_562285, CAB030012: AB_756075, CAB055098: AB_2335685, HPA026761: AB_1848198, HPA067463: "	unprognostic (6.79e-2)	unprognostic (2.28e-1)	unprognostic (1.59e-2)	unprognostic (1.16e-2)	unprognostic (1.61e-1)	unprognostic (3.49e-2)	unprognostic (2.01e-1)	unprognostic (3.61e-2)	unprognostic (3.40e-1)	prognostic favourable (3.30e-4)	unprognostic (5.27e-2)	unprognostic (3.28e-2)	prognostic favourable (1.04e-6)	unprognostic (6.38e-3)	unprognostic (1.28e-1)	unprognostic (6.45e-3)	unprognostic (6.08e-2)	0.4	2.1	1.8	49.8	3	0.2	8.9	0.6	1	10.8	155.8	0.7	31.5	66.8	4.4	35.2	2.8	10.2	41.6	0.4	1.7	2.7	60.2	1.2	22.6	0.4	1.2	0.4	3.8	54.1	19.8	38.7	2.2	0.9	9	70.5	0.7	47.2	25	0.5	2	303.2	1.7	1.4	0.5	15.3	5.5	0.9	1.7	83.6	4.2	4.1	4.1	2.1	0.2	1.9	0.4	0.2	0	0	0.6	58.3	0.6	0	0.1	0	0	37	0	0	0	0	75.6	106.4	0	16.4	0.1	27.5	0.5	6.9	0.2	0	6.7	0	0.3	29.7	0	0	0	0	2	0	0	0.1	17.4	0	0	29.8	0	2.8	19.1	3.8	0	0	14.8	45.4	25.8	41.1	0.3	0.4	21.7	0	18.3	0.1	0	0	0.7	0.2	0.1	4.6	0	0	0	0	0	0	0	0.4	0	0	0	0.2	0	0	0.7	0	0	0	0	0	0.2	1.9	0	0.6	1.8	3	0.6	1	1.7	2.7	1.2	0.4	0.9	0.9
ERBB2	"CD340, HER-2, HER2, NEU, NGL"	ENSG00000141736	Erb-b2 receptor tyrosine kinase 2	P04626	17	39687914-39730426	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Transcription, Transcription regulation"	"Activator, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, FDA approved drug targets"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in many			Cell line enriched	Detected in many	27	SK-BR-3: 263.9	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in many		gdT-cell: 8.8	Lineage enriched	Detected in many	4	T-cells: 8.8	Low region specificity	Detected in many			Low region specificity	Detected in all			"CAB000043, HPA001060, HPA001338, HPA001383, CAB020416, CAB062555"	Enhanced		Supported	"Plasma membrane,Cytosol"		430000	430000	Plasma membrane	Cytosol	"CAB000043: AB_2335701, CAB020416: AB_442047, CAB062555: , HPA001060: , HPA001338: , HPA001383: AB_1078500"	unprognostic (1.97e-1)	unprognostic (6.60e-3)	unprognostic (6.21e-2)	prognostic unfavourable (8.99e-8)	unprognostic (2.96e-2)	unprognostic (1.40e-2)	unprognostic (1.97e-2)	unprognostic (9.04e-2)	unprognostic (1.79e-2)	unprognostic (1.20e-3)	prognostic unfavourable (9.17e-4)	unprognostic (3.92e-1)	prognostic favourable (2.41e-14)	unprognostic (9.29e-2)	unprognostic (1.40e-1)	unprognostic (3.75e-2)	unprognostic (1.96e-1)	5.8	2.4	5.2	10.4	7	0.1	20.1	4.2	7	19.1	46.5	9.1	55.2	21.6	14.9	18.7	40.9	22.7	26.6	24.8	6.3	3.1	37.5	21.5	17.6	3.7	5.1	5.6	19.3	16.2	27.7	8.1	60.8	7.5	23.6	16.6	15.9	28.7	58.1	8.9	35.3	47.2	10.9	4.5	4	17.1	6.5	3.7	2.8	35.7	20.8	22.9	19.7	20.3	1.3	0.3	2.1	0.4	0.9	8.8	2.2	3.1	3.8	4.2	2.7	5.1	3.6	5.7	2.2	3.7	4.9	4.2	2.8	8.6	0.2	4.6	5.1	9.8	0.2	5.1	2.3	0.4	3.2	0.1	3	4.5	3	0	0	3.5	4.8	3	1.8	2	0.4	0.1	3.6	4.8	0.5	0.2	7.6	0.9	0.3	1.7	0.4	5	9.8	0.8	0.2	4.2	263.9	1.3	7.4	0.1	0.2	2.5	3.3	3.2	1.4	0.4	0.2	0.2	0.2	0	8.2	1.6	0.4	0.8	8.8	0.3	0.7	0.9	0.5	2.5	0.3	1.3	1	2.5	2.1	0.9	0.2	0.2	0.4	2.2	5.2	7	4.2	7	6.3	3.1	5.1	5.6	7.5	3.7
EVI2B	"CD361, D17S376, EVDB"	ENSG00000185862	Ecotropic viral integration site 2B	P34910	17	31303766-31314112	"CD markers, Predicted membrane proteins"			Proto-oncogene	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 133.6;lymphoid tissue: 72.8	Cell line enhanced	Detected in many		Daudi: 23.7;HL-60: 26.7;HMC-1: 37.7;Karpas-707: 26.7;NB-4: 21.1;RPMI-8226: 39.0;THP-1: 33.7	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in all		neutrophil: 133.6	Group enriched	Detected in all	4	granulocytes: 133.6;monocytes: 34.3					Low region specificity	Detected in all			HPA007436	Enhanced									HPA007436: AB_1848307	unprognostic (1.07e-2)	unprognostic (1.20e-2)	unprognostic (5.97e-2)	unprognostic (4.09e-3)	unprognostic (2.99e-2)	unprognostic (1.41e-2)	unprognostic (3.06e-1)	unprognostic (3.36e-2)	unprognostic (1.93e-2)	unprognostic (1.48e-1)	unprognostic (1.78e-2)	unprognostic (2.34e-1)	prognostic unfavourable (2.05e-4)	unprognostic (1.56e-2)	unprognostic (3.32e-2)	unprognostic (8.64e-2)	unprognostic (2.73e-2)	15	3.6	4.4	37.7	5.8	44	4.2	1.7	4.4	3.7	10.7	6.5	0.3	6	2.8	4.8	7.1	4.7	8.1	6.7	6.4	4.4	7.8	7.1	38.5	37.5	10.2	2.6	3.8	2.7	0.4	2.1	4.8	7.8	5.3	8.1	2.5	6.6	1.5	2.3	2.4	23.3	4.2	22	72.8	8	3.7	6.7	26.1	4	3	43	13	7.6	18.6	14.6	133.6	34.3	4.1	16.4	19.8	0.1	0.1	0	0	1.9	2.5	0	0.2	1.6	1.9	3.7	0	0.9	23.7	0	1.5	0.1	0	0.3	2.2	0	0	0.5	0	0	19.5	26.7	37.7	4.5	0	1.1	1.5	1.9	0.3	26.7	5.6	0	7.8	21.1	0	0	13.6	0.1	39	0	0	0	0	0.1	0	0.1	0	33.7	2	0.5	0	0.2	1.9	5.1	0.2	5.1	2.4	9.2	0.6	78.9	30.5	74.5	8.2	23.2	7.9	18.6	12.6	10.6	14.6	14.3	9.7	9.1	133.6	4.1	34.3	8.4	16.4	19.8	4.4	5.8	1.7	4.4	6.4	4.4	10.2	2.6	7.8	6.7
F11R	"CD321, JAM-1, JAM-A, JAM1, JAMA, JCAM, PAM-1"	ENSG00000158769	F11 receptor	Q9Y624	1	160995211-161021348	"CD markers, Plasma proteins, Predicted membrane proteins"	Host-virus interaction	"Host cell receptor for virus entry, Receptor"		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in many		CAPAN-2: 37.7;HaCaT: 49.4	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Group enriched	Detected in many	4	eosinophil: 44.5;neutrophil: 32.2	Lineage enriched	Detected in all	5	granulocytes: 44.5	Low region specificity	Detected in all			Low region specificity	Detected in many			"CAB004671, HPA043616, HPA061700"	Enhanced		Supported	"Cell Junctions,Microtubules"		41000000	41000000	Microtubules	Cell Junctions	"CAB004671: AB_425964, HPA043616: , HPA061700: "	unprognostic (1.60e-2)	unprognostic (5.78e-3)	unprognostic (1.78e-3)	unprognostic (2.24e-1)	unprognostic (4.99e-2)	unprognostic (4.89e-2)	unprognostic (2.28e-1)	unprognostic (2.55e-1)	unprognostic (6.35e-2)	unprognostic (1.98e-3)	unprognostic (1.87e-2)	unprognostic (1.24e-1)	unprognostic (1.78e-1)	unprognostic (2.50e-1)	unprognostic (1.59e-1)	unprognostic (9.72e-3)	unprognostic (5.01e-2)	20.7	13.3	3	9.6	3.6	6.4	11.8	2	3.5	14.5	36.3	3.9	21.4	20.5	8.6	11.2	41.5	12.3	30.5	10	3.4	3.2	35.9	69.8	55	10.4	3.6	1.8	10.9	37.9	18.5	16.3	61.8	5.3	17.8	19.5	5.7	59.3	23.7	9	22	59.8	4.9	4	27	18.8	11	3.3	8.1	52.2	25.8	29.9	16.8	19.7	1.3	7	44.5	8.9	2.2	3.8	6.6	28.5	3.7	1.1	0.3	0.8	0	23.3	0.1	0	1	1	26.4	37.7	2.1	19.4	0	49.4	5.8	24.5	1.5	1.6	4.3	6	1.5	12	1.1	5.6	17.8	0.3	31	0.1	8.2	23.2	8.1	0.6	0.1	12.3	1.7	3.2	19.7	5.3	2.6	0	9.2	16.6	21.7	8.2	2.1	6.9	29.7	6.1	32.3	10	13.9	0.1	0.7	0.1	0.2	6.9	13.6	0.7	4.4	5.5	1.8	7.6	8.9	44.5	3.8	4.5	2	1.3	3.5	2.3	7	0.9	3.4	2.7	32.2	2.2	3.4	5.3	1.5	6.6	3	3.6	2	3.5	3.4	3.2	3.6	1.8	5.3	3.3
F3	"CD142, TF"	ENSG00000117525	"Coagulation factor III, tissue factor"	P13726	1	94529225-94541800	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	"Blood coagulation, Hemostasis"		"Cancer-related genes, FDA approved drug targets"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in many		A-431: 115.2;HaCaT: 54.6;HBEC3-KT: 141.7;U-2197: 53.8	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in some		neutrophil: 2.8	Low lineage specificity	Detected in single			Low region specificity	Detected in all			Low region specificity	Detected in many			"CAB009438, HPA049292, HPA069132"	Uncertain		Approved	Vesicles	Secreted to blood			Vesicles		"CAB009438: AB_668005, HPA049292: , HPA069132: "	unprognostic (3.86e-2)	unprognostic (1.19e-1)	unprognostic (8.04e-2)	unprognostic (1.64e-1)	unprognostic (2.69e-2)	unprognostic (1.23e-3)	unprognostic (4.93e-2)	unprognostic (8.00e-2)	unprognostic (5.88e-1)	unprognostic (1.35e-1)	prognostic unfavourable (1.07e-4)	unprognostic (1.25e-1)	prognostic unfavourable (2.02e-8)	unprognostic (4.84e-2)	unprognostic (4.08e-1)	unprognostic (1.23e-1)	unprognostic (1.08e-1)	45.5	9.8	27	14.1	42.9	2.1	55.1	3.4	27.9	14.8	18.7	20.9	18.7	18.3	30.5	23.7	21.3	25.4	30.9	18.8	26.9	14.5	6.6	2.8	31.4	5.8	14.1	20.3	41.6	35	6.1	28.8	65.4	39.2	29.7	22.2	49.9	29.2	33	2.4	17.7	19.2	5.9	46.3	2.9	18.2	16.4	16	0	21.8	17.3	11.9	24.7	22.3	0.5	0.9	2.8	0.8	0.7	0.4	0.2	115.2	0.2	0.2	0	12.6	6.2	6.5	16.4	9.8	17.8	19.4	2	24.7	0	8.4	20.3	54.6	1.4	141.7	29.3	0.1	0.1	0	3.5	0.3	4.2	0	0	10.7	3.2	8.4	41.1	0.1	0.1	0.1	12.4	0.2	0.1	2.4	1.1	0.2	0.1	1.1	0	2.2	0.3	0.1	0.3	13.1	5.4	0.4	0.1	1.5	0	10.8	0.3	53.8	4.9	0.1	0.1	0	8.2	0.6	0.4	1.7	0.8	0.1	0.3	0.3	0.4	0.2	0.3	0.2	0.2	0.5	0.3	0.3	2.8	0.7	0.2	0.9	0.2	0.2	27	42.9	3.4	27.1	26.9	14.5	14.1	20.3	39.2	16
FAS	"APO-1, APT1, CD95, FAS1, TNFRSF6"	ENSG00000026103	Fas cell surface death receptor	P25445	10	88990582-89015785	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins"	Apoptosis	"Calmodulin-binding, Receptor"	"Cancer-related genes, Disease mutation"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in many		Karpas-707: 43.8	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in many		neutrophil: 40.1	Group enriched	Detected in all	5	granulocytes: 40.1;T-cells: 30.9					Low region specificity	Detected in all			HPA027444	Uncertain		Supported	"Nuclear bodies,Plasma membrane,Cytosol"	Secreted to blood	450000	450000	Plasma membrane	"Nuclear bodies, Cytosol"	HPA027444: AB_10601378	unprognostic (6.84e-2)	unprognostic (2.88e-3)	unprognostic (8.38e-3)	unprognostic (1.94e-1)	unprognostic (2.35e-2)	unprognostic (9.56e-2)	unprognostic (7.00e-2)	unprognostic (2.05e-1)	unprognostic (3.01e-1)	unprognostic (7.70e-2)	unprognostic (1.26e-2)	unprognostic (1.98e-1)	unprognostic (1.52e-3)	unprognostic (2.10e-1)	unprognostic (2.32e-2)	unprognostic (4.95e-3)	unprognostic (1.65e-1)	13.5	26.3	6.1	17.3	7.7	12.4	10.6	2.1	7.2	15.6	14.2	6.1	7	5.9	15.7	16.6	14.1	14.2	14.5	8.9	8.2	2.7	11.7	21.9	28.6	15.6	6	3.9	24.7	4.1	4.5	4.6	9	7.5	22.3	21.3	4.4	7.1	8.5	4.3	9.6	16.3	12.5	10.2	15.3	5	7.3	5.1	12.5	10	15.8	14.4	14.8	21.4	3	4	40.1	6.8	1.2	30.9	3.9	8.5	3.3	1.7	5.5	14.2	21	0	18.9	19.1	0.7	3.7	0	9.3	1.7	7.3	17.7	1.3	0.3	15.8	1.3	27.5	2.7	0.1	1.8	5.6	13.6	0.9	0.4	26	14.2	11.8	25.5	1.6	0	43.8	19.2	0.7	2.7	1.4	0.2	0.9	0.1	0.1	1.7	26.5	2.7	0.1	0.1	2.7	0	0.3	6	0.3	4.1	6	3.4	5.6	4.3	17.2	1.7	0.1	5	3.4	1.8	11.3	3.2	9.4	3.3	3.9	4.8	3	10.4	7.2	4	0.7	1.2	3.4	40.1	1.2	6.8	0	30.9	3.9	6.1	7.7	2.1	7.2	8.2	2.7	6	3.9	7.5	5.1
FASLG	"APT1LG1, CD178, FasL, TNFSF6"	ENSG00000117560	Fas ligand	P48023	1	172659018-172666874	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"	"Apoptosis, Transcription, Transcription regulation"	"Cytokine, Repressor"	Cancer-related genes	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 25.6;lymphoid tissue: 13.4	Cell line enhanced	Detected in some		ASC diff: 1.0;LHCN-M2: 2.4;NB-4: 1.2	Low cancer specificity	Detected in many			Low region specificity	Detected in single			Cell type enhanced	Detected in many		gdT-cell: 25.6	Group enriched	Detected in many	12	NK-cells: 16.0;T-cells: 25.6	Not detected	Not detected			Low region specificity	Detected in all			HPA054959	Approved				Secreted to blood					HPA054959: 	unprognostic (1.09e-3)	unprognostic (1.41e-2)	unprognostic (8.69e-2)	unprognostic (1.54e-7)	unprognostic (3.29e-1)	unprognostic (2.23e-3)	unprognostic (5.44e-2)	unprognostic (1.84e-2)	unprognostic (4.67e-2)	unprognostic (4.76e-2)	unprognostic (8.88e-2)	unprognostic (1.07e-1)	prognostic unfavourable (1.59e-6)	unprognostic (3.49e-2)	unprognostic (1.22e-1)	unprognostic (1.15e-2)	unprognostic (3.82e-3)	0.9	1.1	0.5	1.9	0.7	3.6	1.8	0.5	0.8	0.7	2.6	0.6	0	3	3.9	1.2	1	0.8	1.6	1.2	0.5	0.5	1.2	2.2	6.8	7.7	1.4	0	1.5	0.6	0	0.7	2.4	0.6	4.7	1.2	2.8	1.9	0.3	0.4	0.5	3.8	1.9	1.7	13.4	2.1	0.4	0	1.2	1.1	0	10.1	1.4	0.9	0	0	1.6	0	16	25.6	5.5	0	0	0.3	0.1	1	0	0.5	0.2	0	0	0.1	0	0.5	0.5	0.1	0	0.8	0	0.2	0	0.1	0	0	0.3	0	0	0.2	0.1	0	0.2	0.4	0.7	0	0.2	0.6	2.4	0	0	1.2	0.4	0	0	0	0.1	1	0.2	0	0.1	0	0.1	0	0.1	0	0	0.1	0.1	0.3	0.3	0.7	0	0	0	0.1	0.1	1.6	0	0	25.6	0	15.8	0	5.4	13.7	0	0	1.1	11.7	0.8	16	0	0	0.1	5.5	0.5	0.7	0.5	0.8	0.5	0.5	1.4	0	0.6	0
FCAMR	"CD351, FCA/MR, FKSG87"	ENSG00000162897	Fc fragment of IgA and IgM receptor	Q8WWV6	1	206957965-206970625	"CD markers, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in some	8	kidney: 23.9;liver: 7.6;lymphoid tissue: 23.0	Cell line enhanced	Detected in some		CACO-2: 1.9;HMC-1: 1.0	Cancer enhanced	Detected in some		renal cancer: 5.6	Not detected	Not detected			Not detected	Not detected			Not detected	Not detected											HPA056505	Enhanced					3600000	3600000			HPA056505: 	unprognostic (2.94e-1)	unprognostic (1.06e-1)	unprognostic (8.53e-2)	unprognostic (2.92e-1)	unprognostic (7.44e-2)	unprognostic (4.55e-3)	unprognostic (2.69e-3)	unprognostic (1.08e-4)	unprognostic (3.61e-2)	unprognostic (1.25e-1)	unprognostic (1.82e-1)	unprognostic (1.23e-1)	unprognostic (1.11e-1)	unprognostic (1.29e-1)	unprognostic (3.88e-2)	unprognostic (2.08e-1)	unprognostic (1.26e-1)	0.1	0.1	0.1	23	0.1	0	0.1	0.1	0.1	0.1	0.3	0.1	0.1	0.6	0.1	0.1	0.3	0.1	0.1	0.1	0.1	0.1	23.9	7.6	0.1	8.3	0.1	0.1	0.1	0.1	0	0.1	0.1	0.1	0.1	0	0.1	2.4	0.1	0.1	0.1	1	0.1	0.5	0.6	0.1	0.2	0.1	0.2	0.2	0.1	9.1	0.1	0.1	0	0.4	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0.2	0.3	0	1.9	0.3	0.1	0.1	0	0.1	0	0	0.4	0	0	0.2	0	0	0	0	1	0	0.1	0	0.2	0	0.1	0	0	0	0.2	0.4	0.1	0	0.2	0.5	0	0.2	0	0	0	0	0.8	0	0	0.5	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.4	0	0	0	0	0	0	0	0	0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
FCAR	CD89	ENSG00000186431	Fc fragment of IgA receptor	P24071	19	54874248-54890472	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"		"IgA-binding protein, Receptor"		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		bone marrow: 28.1;lung: 19.5;lymphoid tissue: 15.9	Cell line enhanced	Detected in single		THP-1: 1.7	Not detected	Not detected			Low region specificity	Detected in many			Group enriched	Detected in some	6	classical monocyte: 2.6;neutrophil: 6.1	Group enriched	Detected in many	44	granulocytes: 6.1;monocytes: 2.6					Low region specificity	Detected in many			HPA014050	Approved		Supported	Plasma membrane	Intracellular and membrane			Plasma membrane		HPA014050: AB_1846338	unprognostic (1.46e-1)	unprognostic (5.74e-2)	unprognostic (1.30e-1)	unprognostic (4.71e-3)	unprognostic (3.46e-1)	unprognostic (2.02e-1)	unprognostic (7.99e-2)	unprognostic (1.54e-2)	unprognostic (1.59e-2)	unprognostic (4.70e-2)	unprognostic (1.41e-2)	unprognostic (7.05e-2)	unprognostic (4.19e-6)	unprognostic (9.23e-2)	unprognostic (8.10e-3)	unprognostic (8.04e-3)	unprognostic (9.81e-2)	4	0.6	0.4	1.5	4.4	28.1	0.8	0.1	1	0.6	0.6	0.7	0	0.6	0.6	0.6	0.6	3.8	0.6	8.2	2	0.4	0.6	1.8	19.5	15.9	1.2	0	2.2	0.6	0.6	0.3	1.5	4.3	0.6	0.6	0.9	0.6	0.6	0.6	0.6	0.6	0.7	2.7	14.9	0.9	2.1	0	1	0.6	0.3	0.6	4.4	4.8	0	0	6.1	2.6	0	0	0.7	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0	0	0	0.1	0	1.7	0.4	0	0	0.1	0	0	0	0	0	0	0	0	2.6	0	0	0.7	0	0	0	0	0	0	0	0	6.1	0	0.1	0	0	0.7	0.4	4.4	0.1	1	2	0.4	1.2	0	4.3	0
FCER2	"CD23, CD23A, CLEC4J, FCE2"	ENSG00000104921	Fc fragment of IgE receptor II	P06734	19	7688758-7702146	"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"		"IgE-binding protein, Receptor"	Cancer-related genes	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in some	8	blood: 87.2;lymphoid tissue: 38.4	Cell line enriched	Detected in some	14	HDLM-2: 97.5	Low cancer specificity	Detected in many			Not detected	Not detected			Group enriched	Detected in some	23	memory B-cell: 28.2;naive B-cell: 87.2	Lineage enriched	Detected in many	34	B-cells: 87.2	Low region specificity	Detected in single			Low region specificity	Detected in all			"CAB002624, HPA008928"	Enhanced				Secreted to blood	59000	59000			"CAB002624: , HPA008928: AB_1846285"	unprognostic (3.20e-4)	unprognostic (1.87e-3)	unprognostic (1.95e-2)	unprognostic (2.44e-2)	unprognostic (4.77e-2)	unprognostic (1.77e-3)	unprognostic (1.64e-1)	unprognostic (1.89e-3)	unprognostic (2.71e-1)	unprognostic (1.88e-1)	unprognostic (2.04e-2)	unprognostic (8.55e-2)	unprognostic (2.46e-4)	unprognostic (2.99e-1)	unprognostic (1.80e-1)	unprognostic (4.89e-2)	unprognostic (5.17e-2)	2.4	0.3	0.5	17.1	0.5	2.3	1.2	0.3	1.1	0.3	1	0.1	0.4	1.3	0.3	2.3	1	0.4	0.5	0.8	0.3	0.3	0.6	0.6	0.8	21.1	0.3	0	0.4	0.3	0	0.3	0.3	0.1	0.3	0.8	0	7.5	0.7	0.4	0.6	7.7	0.4	0.3	38.4	0.8	0.5	0	6.3	0.7	0	33.8	2	0.5	87.2	0.7	0.2	2.5	0	0	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	97.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3.2	0	0	0	0	0	0	0	0	1.2	0	0	0.1	0	0	0	0	0	0	7.1	0	0	0.5	0	0	2.5	0	28.2	0	0	0.7	87.2	0	0	0.2	0	0.7	0.1	0	3	0.5	0.5	0.3	0.3	0.3	0.3	0.3	0	0.1	0
FCGR1A	"CD64, CD64A"	ENSG00000150337	Fc fragment of IgG receptor Ia	P12314	1	149782671-149792518	"CD markers, FDA approved drug targets, Predicted membrane proteins"	"Immunity, Innate immunity"	"IgG-binding protein, Receptor"	FDA approved drug targets	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 35.6;epididymis: 33.2	Cell line enriched	Detected in some	5	THP-1: 59.6	Cancer enhanced	Detected in many		glioma: 10.3					Group enriched	Detected in some	7	classical monocyte: 35.6;intermediate monocyte: 14.0;myeloid DC: 9.5;neutrophil: 25.5	Group enriched	Detected in many	80	dendritic cells: 9.5;granulocytes: 25.5;monocytes: 35.6																				unprognostic (5.27e-2)	unprognostic (2.89e-2)	unprognostic (2.34e-2)	unprognostic (7.97e-2)	unprognostic (8.44e-3)	unprognostic (1.73e-1)	unprognostic (7.69e-2)	unprognostic (1.04e-1)	unprognostic (1.88e-2)	unprognostic (1.72e-1)	unprognostic (1.98e-2)	unprognostic (6.18e-2)	prognostic unfavourable (4.83e-8)	unprognostic (1.28e-1)	unprognostic (4.51e-2)	unprognostic (9.99e-2)	unprognostic (9.03e-2)	3.9	2.4	6.7	14.1	4.4	5	0.7	0.3	3.5	1.1	0.3			0	0.1	33.2	0.3	0.7	2.4	0.7	5.3	4.9	1	1.1	8.9	3.4	10.1		0.3	1	0.5	1.2	10.8		0.4	0.3		0.7	0.2	0	0	0.1	5.5	14.3	7	0.3	0.9			0.3		0	3.3	0	0.2	9.5	25.5	35.6	0	0.2	11.2	0.1	0	0	0	0	0	0.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3.9	1	0	0	0	0	0	0	0	0	0.2	0	12.2	0	0	0	0	0.1	0	0	0	0	0.4	0	0	0.4	59.6	0	0	0	0	0	0	0	0	0	7.2	0	0.5	35.6	0.4	0	14	0.2	0.2	0	0.1	9.5	0	0	0	25.5	0	2.8	0.2	0.1	11.2										
FCGR2A	"CD32, CD32A, CDw32, FCG2, FCGR2, FCGR2A1, IGFR2"	ENSG00000143226	Fc fragment of IgG receptor IIa	P12318	1	161505430-161524013	"CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Immunity	"IgG-binding protein, Receptor"	FDA approved drug targets	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 182.8	Cell line enhanced	Detected in some		HEL: 14.0;HMC-1: 28.2;K-562: 8.3;NB-4: 7.9;THP-1: 30.0;U-937: 12.9	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enriched	Detected in many	6	neutrophil: 182.8	Lineage enriched	Detected in many	7	granulocytes: 182.8									"HPA010718, HPA010776, HPA014730"	Enhanced		Supported	"Golgi apparatus,Plasma membrane"		55000000	55000000	Plasma membrane	Golgi apparatus	"HPA010718: AB_1078463, HPA010776: , HPA014730: "	unprognostic (2.57e-2)	unprognostic (1.16e-1)	unprognostic (1.48e-2)	unprognostic (4.12e-2)	unprognostic (5.89e-2)	unprognostic (6.17e-2)	unprognostic (1.24e-2)	unprognostic (1.17e-1)	unprognostic (7.63e-2)	unprognostic (1.17e-3)	unprognostic (2.43e-2)	unprognostic (2.91e-1)	prognostic unfavourable (6.49e-7)	unprognostic (8.85e-3)	unprognostic (6.47e-3)	unprognostic (1.54e-1)	unprognostic (3.42e-2)	36.8	12.6	13.2	44.6	19.2	18.6	8.2	2.2	10.1	9.1	7.1	10	0	3.8	4.7	6.6	5.5	11.6	17	11.3	17	8.9	11.5	7.1	44.1	50	25.9	1.7	8	5.8	2.8	6.1	47.5	19.6	7	9.9	10.8	8.3	4.8	7.3	3	7.3	17.6	30.9	43.4	5.9	4.8	19.2	3.2	6.3	2.5	4.4	19.3	4.5	0.2	7	182.8	27.2	0	0	10.6	0	0	0	1.2	0	0.2	0	0	0.3	0	0	0	0	1	0	0	0	0	0	0	0	0	14	0.2	0	0.3	4	28.2	0.3	0	0	0	0	8.3	0.2	0	0	0.2	7.9	0	0.6	0.1	0.6	3.8	0	0	0	0	0	0	2.3	0	30	0	0.1	0	0	0	0	0	0.3	0.2	12.9	3.5	0.1	27.2	31.6	0	20.7	0	0.2	0	0	7	0.1	0	0	182.8	0	16.7	0.2	0	10.6	13.2	19.2	2.2	10.1	17	8.9	25.9	1.7	19.6	19.2
FCGR2B	"CD32, CD32B, FCG2, FCGR2"	ENSG00000072694	Fc fragment of IgG receptor IIb	P31994	1	161663147-161678654	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins"	Host-virus interaction	"IgG-binding protein, Receptor"	"Cancer-related genes, FDA approved drug targets, Proto-oncogene, Systemic lupus erythematosus"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	6	blood: 53.3;placenta: 83.2	Cell line enhanced	Detected in some		Daudi: 18.2;HMC-1: 23.0;NB-4: 5.1;RPMI-8226: 8.2	Low cancer specificity	Detected in many							Cell type enhanced	Detected in many		basophil: 53.3;memory B-cell: 42.2	Group enriched	Detected in many	18	B-cells: 42.2;dendritic cells: 14.5;granulocytes: 53.3									"CAB007796, HPA014730"	Enhanced									"CAB007796: AB_562288, HPA014730: "	unprognostic (1.58e-1)	unprognostic (5.14e-2)	unprognostic (3.32e-3)	unprognostic (3.12e-2)	unprognostic (6.79e-3)	unprognostic (4.05e-3)	unprognostic (1.27e-1)	unprognostic (4.65e-3)	unprognostic (1.91e-1)	unprognostic (4.72e-2)	unprognostic (2.89e-2)	unprognostic (3.49e-1)	prognostic unfavourable (8.82e-4)	unprognostic (3.51e-2)	unprognostic (6.36e-2)	unprognostic (4.31e-1)	unprognostic (3.37e-1)	11.3	2.4	0	2	0.2	0	4.1	0	0	1.9	3.4			0.2	0.9	0.2	2.1	2.1	2.3	3.7	0	0.2	2	9.5	5.6	2.5	0.5		0.8	0.6	0	0.3	83.2		0.3	2		3.3	0.2	0.5	2	4.6	3.1	4.7	6.7	1.5	0.1			1.7		5.6	3.3	1.2	42.2	14.5	53.3	1.9	0.1	0.3	2.4	0	0.1	0	1.9	0	0	0	0	0	0	0	0	0	18.2	0	0	0	0	0	0	0	0	0	0	0	0	0	23	0	0	0	0	0	0	1.1	0	0	0	5.1	0.1	0	0	0	8.2	0	0	0.1	0.1	0	0	1.6	0	0.3	0	0	0	0	0	0	0	1.5	0	2.2	0	53.3	1.8	5.4	0.3	1.9	0.1	42.2	0.1	0.2	14.5	34.3	0	0.3	11.2	0.1	1.7	0	0	2.4										
FCGR3A	"CD16, CD16a, FCG3, FCGR3"	ENSG00000203747	Fc fragment of IgG receptor IIIa	P08637	1	161541759-161550737	"CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"		"IgG-binding protein, Receptor"	FDA approved drug targets	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 223.6;lymphoid tissue: 60.8	Cell line enhanced	Detected in some		HaCaT: 1.7;SH-SY5Y: 1.3;U-2197: 1.1;U-266/70: 1.7	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in many		intermediate monocyte: 109.4;non-classical monocyte: 223.6	Group enriched	Detected in many	4	granulocytes: 73.0;monocytes: 223.6									"CAB032435, HPA055431"	Supported				Secreted to blood	2500000000	2500000000			"CAB032435: AB_626925, HPA055431: "	unprognostic (5.27e-2)	unprognostic (9.95e-2)	unprognostic (2.37e-2)	unprognostic (1.66e-1)	unprognostic (1.39e-1)	unprognostic (1.82e-1)	unprognostic (2.24e-2)	unprognostic (6.06e-2)	unprognostic (2.41e-1)	unprognostic (1.64e-1)	unprognostic (1.98e-2)	unprognostic (7.52e-2)	prognostic unfavourable (3.22e-6)	unprognostic (1.14e-1)	unprognostic (4.66e-2)	unprognostic (1.03e-2)	unprognostic (7.51e-2)	11.9	9.7	7.5	20.5	12.4	4.4	4.1	1.6	7	1.9	2.1	5.5	0.8	0.8	1.1	2.4	1	2.4	5.1	6.4	6.3	7.3	2.6	22.5	43.2	8	12.7	1.9	1.4	2.9	1.8	3.9	14.6	6.8	2.6	2.3	2.2	2.7	1.3	1.3	0.3	1.2	14.3	25.7	60.8	1.3	1.2	8	1.4	1.8	1.3	1.3	6.3	2.3	0.1	11.7	73	223.6	7.9	33.9	35.8	0	0	0	0	0	0	0.9	0	0	0	0	0	0	0.7	0.1	0	1.7	0	0	0	0.1	0	0.2	0	0	0	0.3	0.8	0.2	0	0	0	0	0.2	0.1	0	0	0.3	0.5	0.5	0	0.8	0.5	0.4	0	0	0.5	1.3	0.4	0.2	0	0	0.1	0	0	0.1	1.1	0	1.7	0	0.4	0	0	0	0.3	1.6	0.5	33.9	109.4	0.3	0.1	0.3	13.2	11.7	0	0.2	12.2	73	7.9	223.6	0.2	0.1	35.8	7.5	12.4	1.6	7	6.3	7.3	12.7	1.9	6.8	8
FCGR3B	"CD16, CD16b, FCG3, FCGR3"	ENSG00000162747	Fc fragment of IgG receptor IIIb	O75015	1	161623196-161631963	"CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"		"IgG-binding protein, Receptor"	FDA approved drug targets	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level		Tissue enriched	Detected in many	8	blood: 334.5	Cell line enhanced	Detected in single		K-562: 1.4	Low cancer specificity	Detected in many			Low region specificity	Detected in many			Cell type enriched	Detected in some	95	neutrophil: 334.5	Lineage enriched	Detected in many	95	granulocytes: 334.5														Secreted to blood						unprognostic (1.60e-1)	unprognostic (1.36e-1)	unprognostic (1.59e-3)	unprognostic (4.16e-2)	unprognostic (1.15e-1)	unprognostic (6.52e-2)	unprognostic (3.97e-2)	unprognostic (6.96e-3)	unprognostic (2.53e-2)	unprognostic (1.02e-1)	unprognostic (1.07e-1)	unprognostic (8.67e-2)	unprognostic (5.16e-2)	unprognostic (1.35e-1)	unprognostic (8.37e-3)	unprognostic (2.28e-1)	unprognostic (9.24e-2)	9.9	0.8	1.8	30.8	1.5	13.8	1.5	0.9	1.8	0.9	0.8	0.5	0.2	0	0.4	0.5	1.7	2.8	6.8	4.6	1.2	0.9	0.9	2.9	15.2	16.9	5	0.5	1.2	1.2	0	0.6	4.5	1.9	1.5	0	1.3	0.9	0.9	0.8	1.4	0.8	2	4	44.3	1.3	1.5	0.9	0.6	0.8	0.2	0.9	11.1	4.7	0	0.1	334.5	3.5	0.1	0.5	0.5	0	0	0	0	0	0	0	0	0.5	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0.5	0	0	0	0	0	1.4	0	0	0	0	0.3	0.4	0	0	0	0	0	0.2	0	0.5	0	0.4	0.1	0	0	0	0	0.1	0	0	0.2	0	0.4	0	0.3	0	0	0	0.5	0.5	1.2	0	0	0	0.2	0.1	0	0	0.1	334.5	0.1	3.5	0	0	0.5	1.8	1.5	0.9	1.8	1.2	0.9	5	0.5	1.9	0.9
FCRL1	"CD307a, FCRH1, IFGP1, IRTA5"	ENSG00000163534	Fc receptor like 1	Q96LA6	1	157794403-157820105	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"		Receptor		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in some	4	blood: 31.6;lymphoid tissue: 55.1	Group enriched	Detected in some	33	Daudi: 5.6;U-698: 18.9	Low cancer specificity	Detected in some			Not detected	Not detected			Group enriched	Detected in some	51	memory B-cell: 16.8;naive B-cell: 31.6	Lineage enriched	Detected in single	66	B-cells: 31.6					Low region specificity	Detected in all			HPA013323	Enhanced					120000	120000			HPA013323: AB_1848480	unprognostic (6.52e-4)	unprognostic (3.49e-3)	unprognostic (8.68e-3)	unprognostic (8.08e-3)	unprognostic (1.31e-1)	unprognostic (1.01e-5)	unprognostic (1.47e-2)	unprognostic (5.48e-3)	unprognostic (1.40e-2)	unprognostic (4.30e-2)	unprognostic (1.81e-1)	unprognostic (2.85e-2)	unprognostic (1.44e-3)	unprognostic (1.96e-1)	unprognostic (1.65e-2)	unprognostic (4.80e-2)	unprognostic (6.74e-2)	0.5	0.2	0.2	55.1	0.2	6.2	0.3	0.2	0.2	0.2	0.7	0	0	0	0.2	0.1	2.4	0.3	0.2	0.3	0.2	0.2	0.7	0.5	1.9	19.2	0.2	0	0.2	0.3	0	0.2	0	0	0.5	0.3	0.3	5.4	0.7	0.2	0.2	10.1	0	0.2	25.3	0.4	0.2	0	1.1	0.7	0.4	49	4.5	0.8	31.6	0	0.4	0.2	0	0.1	0.9	0	0	0	0	0	0	0	0	0	0	0	0	0	5.6	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3	0	18.9	0	0	0	0	0	0	0	0.2	0	16.8	0	0	0	31.6	0	0	0.4	0	0.2	0	0.1	0.9	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0	0	0
FCRL2	"CD307b, FCRH2, IRTA4, SPAP1"	ENSG00000132704	Fc receptor like 2	Q96LA5	1	157745733-157777132	"CD markers, Predicted membrane proteins"		Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in some	7	blood: 20.2;intestine: 14.9;lymphoid tissue: 27.0	Group enriched	Detected in some	4	Daudi: 14.7;U-698: 11.9	Low cancer specificity	Detected in some			Not detected	Not detected			Group enriched	Detected in some	50	memory B-cell: 20.2;naive B-cell: 10.8	Lineage enriched	Detected in single	65	B-cells: 20.2																				unprognostic (3.94e-3)	unprognostic (1.47e-3)	unprognostic (3.49e-2)	unprognostic (3.69e-3)		unprognostic (5.11e-5)	unprognostic (1.67e-2)	unprognostic (4.77e-3)	unprognostic (8.19e-2)	unprognostic (8.66e-3)	unprognostic (1.20e-2)	unprognostic (4.19e-2)	unprognostic (4.60e-7)	unprognostic (2.89e-1)	unprognostic (2.29e-1)	unprognostic (7.92e-2)	unprognostic (2.48e-1)	0.4	0.2	0.2	22.6	0.2	1.5	0.2	0.1	0.2	0.2	1.3	0.1	0.1	1.2	0.3	0.1	1.4	0.2	0.4	0.2	0.2	0.2	0.5	0.9	0.7	15.6	0.3	0.1	0.5	0.2	0	0.2	0.1	0.2	0.4	1.7	0.6	2.8	0.7	0.1	0.2	14.9	0.1	0.2	27	0.8	0.2	0.1	0.3	0.5	0.1	23.3	1.4	0.2	20.2	0	0.3	0	0	0	0.4	0	0	0	0	0	0	0	0	0	0	0	0	0.1	14.7	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0.3	0	0	0	0	0	0	0	0.1	0	0	0.2	0	0	0	0	0	0	0	0.2	0	0.1	0	0	3.1	0	11.9	0	0	0	0.3	0	0	0	0	0	20.2	0	0	0	10.8	0	0	0	0	0	0	0	0.4	0.2	0.2	0.1	0.2	0.2	0.2	0.3	0.1	0.2	0.1
FCRL3	"CD307c, FCRH3, IFGP3, IRTA3, SPAP2, SPAP2a, SPAP2b, SPAP2c, SPAP2d, SPAP2e"	ENSG00000160856	Fc receptor like 3	Q96P31	1	157674321-157700857	"CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"		Receptor		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in some		blood: 20.3;lymphoid tissue: 32.2	Cell line enriched	Detected in some	7	Daudi: 14.3	Low cancer specificity	Detected in some			Not detected	Not detected			Cell type enhanced	Detected in many		naive B-cell: 20.3	Group enriched	Detected in many	56	B-cells: 20.3;NK-cells: 10.7;T-cells: 10.8					Low region specificity	Detected in all			HPA048022	Enhanced									HPA048022: 	unprognostic (6.73e-3)	unprognostic (5.06e-4)	unprognostic (1.13e-2)	unprognostic (2.08e-4)	unprognostic (3.86e-1)	unprognostic (1.74e-5)	unprognostic (1.09e-2)	unprognostic (4.29e-3)	unprognostic (3.69e-3)	unprognostic (2.46e-4)	unprognostic (1.13e-1)	unprognostic (2.55e-2)	unprognostic (2.01e-4)	unprognostic (1.55e-1)	unprognostic (1.29e-1)	unprognostic (2.21e-1)	unprognostic (6.69e-2)	0.4	0.2	0.2	29.4	0.2	0.4	0.3	0.2	0.2	0.3	0.6	0	0	0	0.5	0.2	1.5	0.3	0.6	0.3	0.2	0.2	0.5	0.6	0.9	26.4	0.4	0	0.2	0.2	0	0.3	0	0	0.5	0.6	0.2	5.6	0	0.4	0.2	8.7	0.1	0.2	22.4	0.6	0.2	0	5.2	0.6	0.6	32.2	1.2	0.3	20.3	0	0.2	0	10.7	10.8	3.5	0	0	0	0	0	0	0	0	0	0	0	0	0	14.3	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2	0	2.1	0	0	0	0	0	0	10.8	0	1	16.1	1.4	7.2	0	20.3	0.1	4.7	0.2	10.7	0	0	5.6	3.5	0.2	0.2	0.2	0.2	0.2	0.2	0.4	0	0	0
FCRL4	"CD307d, FCRH4, IGFP2, IRTA1"	ENSG00000163518	Fc receptor like 4	Q96PJ5	1	157573749-157598080	"Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor	Cancer-related genes	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level		Group enriched	Detected in some	4	intestine: 5.4;lymphoid tissue: 15.6	Cell line enriched	Detected in single	102	U-266/70: 10.1	Not detected	Not detected			Not detected	Not detected			Cell type enriched	Detected in single	12	memory B-cell: 1.1	Lineage enriched	Detected in single	12	B-cells: 1.1					Low region specificity	Detected in many			HPA054030	Approved									HPA054030: 	unprognostic (6.06e-2)	unprognostic (3.41e-3)	unprognostic (2.57e-1)	unprognostic (5.08e-2)		unprognostic (4.69e-4)		unprognostic (2.06e-2)			unprognostic (6.38e-2)			unprognostic (1.99e-1)	unprognostic (2.14e-1)	unprognostic (3.37e-1)	unprognostic (6.77e-2)	0.1	0.1	0.1	15.6	0.1	0	0.1	0.1	0.2	0.1	0.3	0	0	0	0.1	0	0.1	0.1	0	0.1	0.1	0.1	0.1	0.1	0.1	5.1	0.1	0	0.1	0.1	0	0.1	0	0	0.1	0.4	0	2.5	0	0.1	0.1	5.4	0	0.1	2.2	0.3	0.1	0	1.1	0.1	1.9	14.9	0.4	0.1	1.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10.1	0	0	0	0	0	0	0	0	0	0	0	1.1	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0	0	0
FCRL5	"BXMAS1, CD307e, FCRH5, IRTA2"	ENSG00000143297	Fc receptor like 5	Q96RD9	1	157513377-157552520	"CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins"		Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 13.3;lymphoid tissue: 39.1;salivary gland: 12.4	Group enriched	Detected in some	5	U-266/70: 5.6;U-698: 12.0	Low cancer specificity	Detected in some			Not detected	Not detected			Group enriched	Detected in some	18	memory B-cell: 11.4;naive B-cell: 13.3	Lineage enriched	Detected in single	19	B-cells: 13.3														Secreted to blood	36000000	36000000				unprognostic (1.30e-3)	unprognostic (3.51e-2)	unprognostic (7.59e-3)	unprognostic (1.57e-2)	unprognostic (9.41e-3)	unprognostic (4.32e-5)	unprognostic (2.61e-2)	unprognostic (6.93e-2)	unprognostic (7.40e-2)	unprognostic (7.66e-3)	unprognostic (4.01e-1)	unprognostic (1.39e-1)	unprognostic (9.51e-10)	unprognostic (1.20e-1)	unprognostic (4.40e-1)	unprognostic (8.99e-2)	unprognostic (2.78e-1)	0.7	0.4	0.3	33.9	0.3	1.1	1.3	0.3	0.3	1.6	7.4	0.1	0	3.6	0.5	0.1	4.6	0.8	0.8	0.4	0.3	0.3	1.6	0.8	1.6	17.4	0.3	0	0.6	0.4	0	0.3	0	0	0.5	2.7	1	12.4	0.8	0.3	0.3	6.4	0.1	0.3	29.5	2.5	0.9	0	3.1	1.1	0.7	39.1	5.3	0.6	13.3	0.6	0	0	0	0	0.6	0	0	0	0	0	0	0	0	0	0	0	0	0	1.7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3	0	0	0	0.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5.6	0.1	12	0	0	0	0	0	0	0	0	0	11.4	0	0	0	13.3	0	0	0	0	0	0.6	0	0.6	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0	0	0
FGFR1	"BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM"	ENSG00000077782	Fibroblast growth factor receptor 1	P11362	8	38411138-38468834	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters"	"Transcription, Transcription regulation"	"Heparin-binding, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Craniosynostosis, Disease mutation, Dwarfism, FDA approved drug targets, Holoprosencephaly, Hypogonadotropic hypogonadism, Kallmann syndrome, Mental retardation"	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in many		AN3-CA: 109.2;BJ hTERT+: 49.8	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in many			Low lineage specificity	Detected in many			Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB033614, HPA056402"	Approved					120000000	120000000			"CAB033614: AB_783377, HPA056402: "	unprognostic (9.53e-2)	unprognostic (7.33e-2)	unprognostic (2.44e-1)	unprognostic (1.35e-2)	unprognostic (4.23e-3)	unprognostic (7.02e-2)	unprognostic (6.59e-2)	unprognostic (2.77e-1)	unprognostic (1.81e-1)	unprognostic (3.99e-2)	unprognostic (7.97e-3)	unprognostic (4.59e-2)	unprognostic (7.69e-2)	unprognostic (6.87e-3)	unprognostic (5.60e-2)	unprognostic (4.59e-3)	unprognostic (1.05e-3)	41.1	8.6	12.5	14.5	12.2	7.2	39.5	45	10.5	36	31.5	10.1	11.6	5.5	29.3	20.6	22.9	29.4	32.4	31.7	12.8	10.1	11.8	5.4	18.6	9.7	11.4	14.3	42	51.2	11.5	22.3	28.4	20	28.2	10.8	35.8	14	31.6	12	12.9	14.4	52.4	15.6	4.5	16.4	16.4	8.5	11.3	12.6	13	9.8	39.6	41.2	1.6	0.7	1.8	1.1	0.8	5.7	0.7	2.4	9.3	40.3	109.2	25.1	17.9	26.6	24.8	49.8	17.3	18	6	1.4	0.3	6.9	23.8	0	19.1	1.2	20	6.5	4.2	0	1.5	5.9	14.1	5.8	0.1	16.2	0.1	14	2.8	16.6	2.2	0.1	8.1	2.8	17	1.9	28.4	3.9	15.7	4.2	0	8.4	0	1.6	3.6	4.4	0.2	1	2.2	1.1	10.4	11.3	6.2	31.2	5.9	0.4	0.7	0	13.4	0.3	5.9	1.4	1.1	0.4	5.7	0.3	3.9	0.7	2.7	3.7	0.1	1.6	1.5	4.1	1.8	0.8	0.5	0.7	2.2	0.7	12.5	12.2	45	10.5	12.8	10.1	11.4	14.3	20	8.5
FGFR2	"BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25"	ENSG00000066468	Fibroblast growth factor receptor 2	P21802	10	121478334-121598458	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"	Apoptosis	"Heparin-binding, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Craniosynostosis, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Lacrimo-auriculo-dento-digital syndrome, Mental retardation, Proto-oncogene"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		brain: 74.8	Cell line enhanced	Detected in some		AN3-CA: 57.8;BEWO: 19.4;CACO-2: 15.1;HaCaT: 17.4;HAP1: 18.7;NTERA-2: 18.5;T-47d: 15.5	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Group enriched	Detected in some	15	basophil: 10.8;eosinophil: 4.6	Lineage enriched	Detected in single	35	granulocytes: 10.8	Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB010886, HPA035305"	Uncertain		Supported	"Nucleoplasm,Vesicles,Cell Junctions"	Secreted - unknown location	500000	500000	Cell Junctions	"Nucleoplasm, Vesicles"	"CAB010886: AB_259379, HPA035305: AB_10672862"	unprognostic (5.53e-2)	prognostic favourable (8.79e-4)	unprognostic (1.08e-1)	unprognostic (5.23e-2)	unprognostic (1.73e-1)	prognostic favourable (9.32e-4)	unprognostic (1.53e-1)	unprognostic (4.96e-3)	unprognostic (1.74e-1)	unprognostic (1.56e-1)	unprognostic (1.07e-1)	unprognostic (3.74e-2)	unprognostic (1.01e-1)	unprognostic (6.11e-2)	unprognostic (2.54e-1)	unprognostic (6.93e-2)	unprognostic (2.25e-1)	2.1	8.8	16.4	3	30.3	0	9.9	15.8	21.3	6.8	14.1	55.7	5.6	4.2	22	6.6	10.2	12.5	12.5	1.4	20.6	11.1	11.4	16.1	13.1	1	41.2	13.3	7.4	12.8	25.5	2.5	6.2	30.2	11.7	8.7	16.4	23.8	24.3	0.4	45.4	4.7	18.3	74.8	0.5	9.3	2.9	32.1	0.8	23.4	1.6	3.4	6.9	8.5	0.1	0.1	10.8	0.1	0.1	0.3	0	2.2	0.1	9	57.8	0	0	19.4	0.1	0	0	0	15.1	0.3	0	4.1	0.9	17.4	18.7	4	0	0	4	0	0	0.3	0.4	0	3.8	0	8.4	0	0.2	0	0	0	0	3.5	0	0	18.5	0	0	0	2.2	5.6	4.9	0.1	0.1	0.1	10.6	0	15.5	0	0	0.1	2.8	0	0.2	0	0	0	0.1	0	0.1	10.8	0.1	4.6	0.1	0	0	0	0.3	0	0	0.1	0	0.1	0.5	0.1	0	0.1	0	0	16.4	30.3	15.8	21.3	20.6	11.1	41.2	13.3	30.2	32.1
FGFR3	"ACH, CD333, CEK2, JTK4"	ENSG00000068078	Fibroblast growth factor receptor 3	P22607	4	1793293-1808872	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"	Apoptosis	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Craniosynostosis, Deafness, Disease mutation, Dwarfism, Ectodermal dysplasia, FDA approved drug targets, Lacrimo-auriculo-dento-digital syndrome"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enriched	Detected in many	4	skin 1: 131.7	Cell line enhanced	Detected in many		CACO-2: 19.1;HaCaT: 14.9;Hep G2: 32.1;NTERA-2: 15.6;RT4: 19.1	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Not detected	Not detected			Not detected	Not detected			Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB004231, HPA067204"	Enhanced		Supported	Endoplasmic reticulum	Intracellular and membrane	670000	670000	Endoplasmic reticulum		"CAB004231: AB_627596, HPA067204: "	unprognostic (1.34e-1)	unprognostic (5.29e-3)	unprognostic (1.49e-1)	prognostic unfavourable (3.77e-4)	unprognostic (5.90e-2)	unprognostic (1.24e-3)	unprognostic (7.22e-2)	unprognostic (2.54e-1)	unprognostic (1.99e-1)	unprognostic (2.17e-1)	unprognostic (1.38e-1)	unprognostic (2.88e-2)	unprognostic (1.30e-1)	unprognostic (9.11e-3)	unprognostic (1.98e-1)	unprognostic (4.74e-2)	unprognostic (1.97e-1)	1.5	1.5	24.7	1.7	30.3	1.6	4.2	10.2	22	4.1	4.9	15.8	3.4	9.9	1.8	2.7	26.9	2	5	2	21.6	11.7	9.6	7.4	4.5	1.3	17.6	21.5	1.1	23	1.2	3	5.6	15.1	3.7	3.8	1.7	3.8	9	1.7	131.7	7.4	1.3	9	2.1	4.9	8.1	10.6	0.1	1.3	8.5	7.3	8.5	10.1	0.1	0.6	0.1	0.1	0.2	0.3	0	0	1.5	9	2.6	0	0.1	9.2	1	0.1	0.4	0.2	19.1	0.4	0	7.6	0.3	14.9	2.6	0.1	0.1	0.1	9.6	5.9	1.5	32.1	0	0	0.1	0	5	0.1	0	0	6.4	0	0	9.5	0.3	0.2	15.6	0	0.5	0.5	0.1	1.3	19.1	2.6	0.7	0.8	1.6	0	8.9	1.1	0.4	0	0.9	0.2	0.6	0	0	0	0.1	0.7	0.5	0	0.1	0	0	0	0.3	0	0	0	0	0.1	0	0.1	0.1	0.2	0	0.6	0.1	0	24.7	30.3	10.2	22	21.6	11.7	17.6	21.5	15.1	10.6
FGFR4	"CD334, JTK2"	ENSG00000160867	Fibroblast growth factor receptor 4	P22455	5	177086886-177098144	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters"		"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		gallbladder: 33.6;kidney: 37.7;liver: 45.3	Group enriched	Detected in many	4	CACO-2: 42.0;Hep G2: 42.0;RH-30: 67.6	Low cancer specificity	Detected in many			Low region specificity	Detected in some			Cell type enhanced	Detected in some		neutrophil: 3.0	Low lineage specificity	Detected in many			Not detected	Not detected			Low region specificity	Detected in all			"CAB005196, HPA027273, HPA027369, HPA028251"	Approved				Intracellular and membrane	4300000	4300000			"CAB005196: AB_631512, HPA027273: AB_10600212, HPA027369: AB_10599427, HPA028251: AB_10601221"	unprognostic (1.96e-1)	unprognostic (2.10e-2)	unprognostic (1.12e-1)	unprognostic (9.06e-3)	unprognostic (2.87e-1)	unprognostic (1.95e-2)	unprognostic (7.85e-3)	unprognostic (9.19e-2)	unprognostic (4.25e-1)	unprognostic (4.46e-2)	unprognostic (1.16e-1)	unprognostic (3.48e-2)	unprognostic (1.78e-1)	unprognostic (1.71e-3)	unprognostic (2.41e-1)	unprognostic (5.75e-2)	unprognostic (4.68e-2)	0.5	5.7	0.7	14.3	0.6	0.1	1.6	2.6	0.5	2.8	10.4	0.9	0.7	13.5	0.9	4.8	1.6	1.7	33.6	0.7	0.8	0.3	37.7	45.3	25.3	2.5	0.7	1	13.6	26	0	0.7	1.3	0.8	4	3.7	2	1.6	0.3	4.3	0.5	17.3	1.6	0.8	11.2	5.4	2.9	0.4	0.3	0.8	2.3	0.7	1.9	3.6	1.1	0.9	3	1.1	0.4	0.4	0	0.7	11.8	0.2	2.9	0	0	5.8	0	0	0	0	42	1.6	1.2	5.5	0	0.6	2.3	0.4	0	0.7	2.8	0.1	0.6	42	1.3	0.1	1	0.2	0	2.1	0	0	3.9	0.1	0.9	9.6	0	0.8	7.1	1	1.9	67.6	7.1	5.7	0.1	0.4	0.7	0.4	3	1.4	2.9	0.6	0.2	0	5.7	0	0.1	0.4	0.4	0.7	0	0.2	0.5	1.5	1.1	0.4	0.4	0.3	0.3	1.1	0.4	0	0.1	0.6	0.4	0.4	3	0.4	0.3	0.9	0.2	0	0.7	0.6	2.6	0.5	0.8	0.3	0.7	1	0.8	0.4
FLT3	"CD135, FLK2, STK1"	ENSG00000122025	Fms related tyrosine kinase 3	P36888	13	28003274-28100592	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, RAS pathway related proteins"	Host-virus interaction	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 29.9;brain: 19.3;lymphoid tissue: 15.0	Group enriched	Detected in some	11	REH: 27.8;THP-1: 17.1	Cancer enhanced	Detected in some		breast cancer: 1.8	Region enhanced	Detected in many		cerebellum: 19.3	Group enriched	Detected in some	11	myeloid DC: 29.9;plasmacytoid DC: 12.1	Lineage enriched	Detected in many	16	dendritic cells: 29.9	Low region specificity	Detected in many			Low region specificity	Detected in all			HPA047539			Approved	Endoplasmic reticulum		180000	180000	Endoplasmic reticulum		HPA047539: 	unprognostic (2.19e-3)	unprognostic (3.16e-3)	unprognostic (6.54e-3)	unprognostic (9.96e-2)	unprognostic (3.88e-1)	unprognostic (3.96e-7)	unprognostic (7.99e-3)	unprognostic (1.65e-2)	unprognostic (5.37e-2)	unprognostic (1.01e-2)	unprognostic (1.96e-1)	unprognostic (1.03e-1)	unprognostic (4.56e-2)	unprognostic (3.65e-1)	unprognostic (3.91e-2)	unprognostic (2.51e-1)	unprognostic (2.22e-1)	0.9	0.6	0.6	7.2	1.1	7.5	2.6	19.3	3.5	0.9	1.2	0.1	0.1	0.4	0.8	0.8	1	1.2	4.6	0.5	0.9	1.7	2.8	0.7	2.7	15	1.8	1.1	0.5	5.7	0	0.4	0	7.4	0.6	1.4	0.1	2.3	0.6	0.4	1.2	3	1.3	4.4	8.8	0.9	1.2	0	8.2	0.6	0	5.8	2.4	0.7	0.1	29.9	1.4	1.8	0.8	0	1.2	0	0	0	0	0	0	0	0	0	0	0	0	0	1.5	0.1	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0.2	2	0.5	0	27.8	0	0	0	0	0.4	0	0	0	0	0	17.1	0	0	0	0	0	0	0	0	0	0	0	1	1.8	1.4	0	0.3	0	0.1	0	0	29.9	0	0	0	0	0.8	0	12.1	0	1.2	0.6	1.1	19.3	3.5	0.9	1.7	1.8	1.1	7.4	0
FZD10	CD350	ENSG00000111432	Frizzled class receptor 10	Q9ULW2	12	130162459-130165740	"CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"	Wnt signaling pathway	"Developmental protein, G-protein coupled receptor, Receptor, Transducer"		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		esophagus: 26.9;lymphoid tissue: 18.6	Group enriched	Detected in some	4	AF22: 8.4;BEWO: 9.7;hTCEpi: 5.6;RPTEC TERT1: 2.9;RT4: 4.7	Low cancer specificity	Detected in many			Low region specificity	Detected in all			Not detected	Not detected			Not detected	Not detected			Region enhanced	Detected in some		thalamus: 7.6	Low region specificity	Detected in many			"HPA014484, HPA014485"	Uncertain		Approved	Nucleoplasm				Nucleoplasm		"HPA014484: AB_1849132, HPA014485: AB_1849134"	unprognostic (2.41e-3)	unprognostic (3.29e-1)	unprognostic (4.74e-2)	prognostic favourable (5.05e-7)	unprognostic (2.81e-2)	unprognostic (4.63e-2)	unprognostic (8.62e-3)	unprognostic (6.33e-2)	unprognostic (5.41e-2)	unprognostic (3.77e-2)	unprognostic (2.70e-1)	unprognostic (2.24e-3)	unprognostic (2.66e-9)	unprognostic (2.18e-1)	unprognostic (3.07e-1)	unprognostic (1.49e-2)	unprognostic (1.07e-1)	1.1	0.4	1	0.5	1.9	0.2	1.5	5.4	2.1	11.6	0.6	2.1	1.6	0.4	5.1	3.4	26.9	2.2	7.1	0.5	1	1	0.4	0.2	2	0.9	1.6	1.2	3.4	1.1	0.2	1.4	9.2	1.9	3.7	0.6	3	5.4	3.1	1.2	10.2	0.7	0.9	1.2	0.3	1	0.7	2	0.6	1.7	9	18.6	5.1	7.2	0	0	0.4	0.2	0	0.1	0	0	0	8.4	0	0	0	9.7	0	0	0	0	0	0	0	0.7	0	0.6	1.5	0.7	0	0	0.3	0	1.1	0	0	0.1	0	0	5.6	0	0	0	0	0	0	0	0	0	0.9	0	0	0	0.1	2.9	4.7	0.1	0	0.5	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0.2	0	0.4	0	0	0.1	0	0	0	0	0	0	0	0.1	0	0.2	0	0	0	1	1.9	5.4	2.1	1	1	1.6	1.2	1.9	2
FZD4	"CD344, EVR1"	ENSG00000174804	Frizzled class receptor 4	Q9ULV1	11	86945679-86955391	"CD markers, Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins"	Wnt signaling pathway	"Developmental protein, G-protein coupled receptor, Receptor, Transducer"	Disease mutation	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		adipose tissue: 75.7	Cell line enhanced	Detected in many		ASC diff: 25.4;Hep G2: 31.8;HSkMC: 18.3;HUVEC TERT2: 36.0;TIME: 17.6	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in single			Low lineage specificity	Detected in single			Low region specificity	Detected in all			Low region specificity	Detected in many			"HPA042328, HPA074833"	Approved		Approved	"Nucleoplasm,Plasma membrane"				Plasma membrane	Nucleoplasm	"HPA042328: AB_10962494, HPA074833: "	unprognostic (6.49e-2)	unprognostic (1.49e-2)	unprognostic (1.03e-1)	unprognostic (1.03e-1)	unprognostic (5.87e-2)	unprognostic (5.51e-2)	unprognostic (1.82e-1)	unprognostic (6.97e-2)	unprognostic (3.33e-2)	unprognostic (3.79e-2)	unprognostic (1.36e-2)	unprognostic (2.22e-1)	prognostic favourable (8.60e-5)	unprognostic (1.05e-2)	unprognostic (9.96e-2)	unprognostic (9.22e-2)	unprognostic (1.97e-1)	75.7	5.3	3.4	6	4.8	0.5	57.8	1.5	4.3	11.5	9	1.4	32.6	2	13.1	13.5	6.3	9.6	8.7	12.5	3.1	2.2	17	8.9	19	4.7	2.9	3.2	12.8	6	4.4	10.1	7.3	5.5	9.3	4.3	20	7.1	56	17.9	3.7	5.4	8.6	2.8	8.6	8.2	5.5	1.6	0.5	11.4	11.1	3	8.3	20.7	0.4	0.2	0.8	0.4	1.4	0.3	0	0.5	0.4	1	2	25.4	6.6	1.4	3.2	2.9	1.2	1.3	2.7	0.3	0	0.7	1	1	1.2	0.5	1	0.1	0.8	1	0.8	31.8	7.5	0	0	18.3	0.2	1.1	0.2	36	1.4	0.1	0.8	0.8	0	0	1.5	7.2	0	1.9	0	3.5	5.2	0.2	0.3	1.3	0.3	0.5	4.6	0	17.6	3	2	3.6	0.6	0.1	0.5	0	0.4	0	0.8	0.7	0.3	0.1	0.3	0.2	0.1	0.2	0.3	0.2	0.1	0.4	0.2	0.3	0.8	1.4	0.4	0.2	0	0	3.4	4.8	1.5	4.3	3.1	2.2	2.9	3.2	5.5	1.6
FZD9	"CD349, FZD3"	ENSG00000188763	Frizzled class receptor 9	O00144	7	73433783-73436120	"CD markers, G-protein coupled receptors, Predicted membrane proteins"	Wnt signaling pathway	"Developmental protein, G-protein coupled receptor, Receptor, Transducer"		Evidence at transcript level	Evidence at transcript level	Evidence at transcript level	Evidence at transcript level		Tissue enhanced	Detected in many		skeletal muscle: 14.4	Cell line enhanced	Detected in some		HEK 293: 8.2;MCF7: 3.6;NTERA-2: 6.4	Cancer enhanced	Detected in many		melanoma: 6.8	Low region specificity	Detected in all			Not detected	Not detected			Not detected	Not detected			Low region specificity	Detected in all			Low region specificity	Detected in many														unprognostic (9.60e-2)	unprognostic (4.03e-2)	unprognostic (3.16e-2)	unprognostic (9.15e-3)	unprognostic (1.10e-1)	unprognostic (6.91e-2)	unprognostic (2.29e-2)	unprognostic (2.26e-1)	unprognostic (2.04e-1)	unprognostic (7.17e-3)	unprognostic (1.20e-1)	unprognostic (7.24e-2)	unprognostic (5.90e-5)	unprognostic (8.99e-2)	unprognostic (4.57e-2)	unprognostic (1.22e-1)	unprognostic (5.21e-2)	4.4	1.2	6.8	0.7	4.7	2.4	1.1	3.3	7	1.1	1.3	4.5	0	1.9	0.9	0.9	1.3	0.9	0.7	0.8	7.1	6.3	0.9	0.8	0.9	0.9	7	4.5	0.9	3.8	1.6	4.3	1.9	5	3	0.8	1.4	4.4	1.4	14.4	1.7	2.9	0.9	3.6	1	1	5.4	6.7	0.3	0.9	1.7	0.8	0.7	0.3	0	0.6	0.1	0	0	0	0	0.6	2.6	2.8	3	0	0.1	0	1.9	0	0.4	0.1	0.7	0	0	0.9	0.1	0.2	1.3	0	0	0	8.2	0	0.6	0.8	1.1	0	0.3	0.3	0	0.1	0	0.2	2.7	0	0.2	3.6	0	0	6.4	0	0	0	0	0	0	1.7	2.6	2.3	1.7	1.7	1.7	0.8	0.1	0	0.7	0	0	0.4	0	0	0	0.6	1.7	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0.6	0	0	6.8	4.7	3.3	7	7.1	6.3	7	4.5	5	6.7
GGT1	"CD224, D22S672, D22S732, GGT"	ENSG00000100031	Gamma-glutamyltransferase 1	P19440	22	24583750-24629005	"Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"	Glutathione biosynthesis	"Acyltransferase, Hydrolase, Protease, Transferase"	Mental retardation	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		kidney: 54.1;seminal vesicle: 41.7	Cell line enhanced	Detected in many		HDLM-2: 35.8;Karpas-707: 52.7;RPMI-8226: 51.8;RPTEC TERT1: 48.2	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in many			Low lineage specificity	Detected in all											"HPA045635, HPA047534, HPA065444"	Supported		Approved	Vesicles	Intracellular and membrane	4600000	4600000	Vesicles		"HPA045635: , HPA047534: , HPA065444: "	unprognostic (8.13e-3)	unprognostic (4.76e-1)	unprognostic (8.29e-2)	unprognostic (1.28e-2)	unprognostic (3.70e-2)	unprognostic (1.43e-2)	unprognostic (5.60e-3)	unprognostic (1.68e-1)	unprognostic (2.21e-1)	prognostic favourable (7.44e-4)	unprognostic (4.55e-2)	unprognostic (2.55e-2)	prognostic favourable (4.83e-4)	unprognostic (1.44e-2)	unprognostic (5.37e-2)	unprognostic (1.74e-1)	unprognostic (6.10e-2)	1.6	0.5	1.7	1.7	2.2	2.7	8.2	2.3	2.6	7.3	7.9	1.6	23.7	22.3	1.4	19.9	1.2	0.8	12.2	2	1.8	1.2	54.1	29.2	14.3	3.2	1.7	1.6	1.3	17.3	0	1.6	1.4	2.2	14.7	2.4	1.4	8.7	41.7	0.9	1.1	20.9	1.7	1.9	4.7	6.6	5	2.1	2.4	4.8	1.6	5.5	2.1	1.1	3.3	7.5	15.9	14.6	6.6	8.6	6.6	0.2	19.4	0.2	0	0	0.1	0.5	0.1	0.6	0.2	0.2	2.6	4.3	0.2	4.3	0	2.8	1.4	0.2	0.1	35.8	2.9	0.1	8.6	14.1	1.5	0.3	12	0.4	0.2	0.6	0.4	0.1	2	52.7	0.2	0.4	0.3	14.6	1.4	0.2	0.2	2.2	51.8	48.2	0.6	0.2	0.3	0.1	9.4	0.2	9.4	11.1	2.2	3.5	2.3	10.9	0.3	15.8	6	0.2	7.4	15.1	0.1	5.2	14.6	0.4	1.4	6.8	5.2	3.3	7.7	3.4	7.5	0.3	1	1.9	15.9	6.6	5.5	0.1	8.6	6.6	1.7	2.2	2.3	2.6	1.8	1.2	1.7	1.6	2.2	2.1
GP1BA	"CD42b, GP1B, GPIbalpha"	ENSG00000185245	Glycoprotein Ib platelet alpha subunit	P07359	17	4932297-4935030	"CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins"	"Blood coagulation, Cell adhesion, Hemostasis"		"Bernard Soulier syndrome, Disease mutation, von Willebrand disease"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enriched	Detected in many	5	lymphoid tissue: 37.8	Cell line enriched	Detected in some	24	HEL: 39.3	Low cancer specificity	Detected in many			Low region specificity	Detected in some			Cell type enriched	Detected in some	7	basophil: 7.5	Lineage enriched	Detected in single	25	granulocytes: 7.5	Not detected	Not detected			Not detected	Not detected			"CAB002496, HPA013316"	Supported					2000000000	2000000000			"CAB002496: AB_563748, HPA013316: AB_1855459"	unprognostic (4.87e-4)	unprognostic (8.21e-2)	unprognostic (2.81e-2)	unprognostic (6.11e-3)	unprognostic (1.50e-2)	unprognostic (1.59e-3)	unprognostic (7.30e-3)	unprognostic (5.58e-2)	unprognostic (2.19e-1)	unprognostic (1.64e-1)	unprognostic (6.54e-4)	unprognostic (1.27e-1)	unprognostic (4.85e-3)	unprognostic (4.58e-3)	unprognostic (2.56e-1)	unprognostic (3.53e-4)	unprognostic (8.35e-2)	0.7	0.1	0.4	15.8	1.2	5.3	0.7	1.9	0.7	0.7	1	0.2	0.2	1.5	0.6	0.7	5.7	0.8	0.3	4.2	0.5	0.4	1	1.6	3.5	37.8	0.4	0.2	0.7	0.4	0	0.4	1.1	0.4	0.7	0.6	0.3	7.7	0.2	3	4.6	3.7	0.2	0.4	13	0.9	0.6	0.2	2	0.8	0.8	17.6	0.9	1.1	0	0.3	7.5	0.2	0	0.2	3.6	0	1.3	0.3	0.2	0	0	0.6	0.2	0	0	0	1.1	0.1	1.2	0.4	0	1.3	0	0	0	0.4	1	39.3	0.5	0	0	0.2	1.4	0	0	0	0	0	0.4	0.4	0	0.4	0.3	0.2	0.1	0.2	0.6	0.3	0.2	0	0.7	0	0.2	0.5	0	0.2	1.6	0.7	0.1	0.2	0.2	0.8	0.1	0.7	0.2	0.9	0.6	0.6	0.4	7.5	0.1	0	0	0.2	0.2	0	0	0	0.2	0	0.1	0.1	1	0	0.1	0.3	0	3.6	0.4	1.2	1.9	0.4	0.5	0.4	0.4	0.2	0.4	0.2
GP1BB	"CD42c, GPIbbeta"	ENSG00000203618	Glycoprotein Ib platelet beta subunit	P13224	22	19722945-19724771	"CD markers, Disease related genes, Predicted membrane proteins"	"Blood coagulation, Cell adhesion, Hemostasis"		"Bernard Soulier syndrome, Disease mutation"	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 61.7;brain: 19.6	Cell line enhanced	Detected in some		HEK 293: 5.6;K-562: 10.1;NB-4: 8.4;REH: 10.2;SH-SY5Y: 4.9;U-2 OS: 10.2	Not detected	Not detected							Group enriched	Detected in some	5	basophil: 6.3;neutrophil: 11.0	Lineage enriched	Detected in many	6	granulocytes: 11.0	Low region specificity	Detected in many			Low region specificity	Detected in many									110000000	110000000																					0.9	0.5	16.7	1.2	19.6	0.5	0.5	7.3	9	0.5	1.7			1.2	0.7	0.5	1.8	0.5	0.7	2.9	15	4.1	0.5	0.9	0.6	0.6	2.7		0.5	0.5	0.5	2.5	0.6		1.3	0.7		1.9	0.5	1.2	10.4	0.5	1	0.2	1.8	1.9	0.5			0.7		0.7	0.5	0.2	0.1	1.7	11	1.2	0.1	0.3	61.7	0	0.9	0	0	0	0	0.1	1.5	0	0	0	0	0	0.1	0.2	0	0.5	0	0	0	1.7	5.6	2.3	0	0	0	0	2.7	0	0	0.1	0	0	10.1	0.1	0.1	0.4	0.4	8.4	0.4	3.1	10.2	0	0.1	0	0	3.7	4.9	0.1	0	0	0	0	0	0	10.2	0.1	0	0.7	0	0	0	0.2	0	6.3	1.2	1.1	0.2	0.3	0.1	0	0.1	0	0.4	0.1	0.1	0.1	11	0.1	0	1.7	0.3	61.7										
GP5	CD42d	ENSG00000178732	Glycoprotein V platelet	P40197	3	194394821-194398354	"CD markers, Plasma proteins, Predicted membrane proteins"	"Blood coagulation, Cell adhesion, Hemostasis"			Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in some		lymphoid tissue: 3.7	Cell line enriched	Detected in some	9	HEL: 18.6	Cancer enriched	Detected in single	5	testis cancer: 0.5	Not detected	Not detected			Cell type enhanced	Detected in some		naive CD4 T-cell: 2.0;naive CD8 T-cell: 2.2	Group enriched	Detected in many	6	dendritic cells: 1.1;T-cells: 2.2	Low region specificity	Detected in many			Not detected	Not detected			HPA072646			Uncertain	Cytosol		400000000	400000000	Cytosol		HPA072646: 	unprognostic (3.74e-2)	unprognostic (3.40e-1)	unprognostic (5.22e-2)	unprognostic (2.96e-2)	unprognostic (1.74e-2)	unprognostic (1.35e-3)	unprognostic (1.69e-3)	unprognostic (1.68e-1)	unprognostic (3.41e-1)	unprognostic (2.80e-2)	unprognostic (1.65e-1)	unprognostic (5.51e-2)	unprognostic (1.21e-2)	unprognostic (4.18e-2)	unprognostic (3.14e-1)	unprognostic (1.72e-2)	unprognostic (1.94e-1)	0.3	0	0.4	2.1	0.5	1.6	0.3	0.3	0.3	0.6	0.3	0.3	0.3	0	0.3	0.3	0.3	2.5	0.3	0.3	0.4	0.6	0.3	0.6	0.9	3.7	0.3	0.3	0.8	0.3	0	0.4	0.3	0.3	0.3	0.1	0.3	0.3	0.3	0.3	0.1	0.9	0.3	0.3	1.7	0.2	0.3	0.3	0.3	1	0.3	1.9	0.3	0.5	0.1	1.1	0.2	0	0	2.2	0.4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	18.6	0	0	0	0	0.1	0	0	0	0	0	0	0.1	0	0	1.9	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0.2	0	0	0.1	0	0.3	0	0.5	0.4	0.1	0.1	2	2.2	0.1	0	0	1.1	0	0.4	0.4	0.5	0.3	0.3	0.4	0.6	0.3	0.3	0.3	0.3
GP9	"CD42a, GPIX"	ENSG00000169704	Glycoprotein IX platelet	P14770	3	129060767-129062406	"CD markers, Disease related genes, Predicted membrane proteins"	"Blood coagulation, Cell adhesion, Hemostasis"		"Bernard Soulier syndrome, Disease mutation"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in some	4	blood: 27.1;bone marrow: 10.0;lymphoid tissue: 24.5	Cell line enriched	Detected in some	14	HEL: 42.2	Not detected	Not detected			Not detected	Not detected			Group enriched	Detected in some	5	basophil: 8.8;neutrophil: 7.5	Lineage enriched	Detected in many	6	granulocytes: 8.8	Low region specificity	Detected in many			Low region specificity	Detected in all			HPA063182	Enhanced					68000000	68000000			HPA063182: 			unprognostic (1.70e-1)	unprognostic (3.97e-1)	unprognostic (1.10e-1)			unprognostic (3.80e-2)		unprognostic (2.50e-2)		unprognostic (3.24e-1)	unprognostic (2.53e-2)	unprognostic (8.47e-2)		unprognostic (8.70e-2)		0.2	0.1	0.1	0.1	0.1	10	0.1	0	0.6	0.4	0.5	0	0	0.1	0.1	0	0.1	0.3	0.1	5	0.8	0.1	0.1	0.4	4.8	0	0.8	0.2	0.5	0.1	0	0.3	1.5	0.4	0.1	0.4	0.2	0	0.6	0.2	0	0.1	0	0.1	24.5	0.3	2.2	0	0	0.6	0.6	0	0.6	3	0.1	1.5	8.8	0.6	0	0.2	27.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	42.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	2.9	0	0	0	0	0	0	0	0	0	0	0	8.8	0.6	0.1	0.1	0.3	0.1	0	0	0.2	0.3	0.1	0	0	7.5	0	0	1.5	0	27.1	0.1	0.1	0	0.6	0.8	0.1	0.8	0.2	0.4	0
GYPA	"CD235a, GPA, MN, MNS"	ENSG00000170180	Glycophorin A (MNS blood group)	P02724	4	144109303-144140786	"Blood group antigen proteins, CD markers, Predicted membrane proteins"	Host-virus interaction	"Blood group antigen, Host cell receptor for virus entry, Receptor"		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enriched	Detected in some	9	bone marrow: 56.9	Cell line enriched	Detected in some	4	HEL: 55.7	Not detected	Not detected			Not detected	Not detected			Cell type enhanced	Detected in single		naive B-cell: 1.5	Low lineage specificity	Detected in single											"CAB002658, HPA014811"	Enhanced		Approved	"Nucleoplasm,Plasma membrane,Cytosol"				"Nucleoplasm, Plasma membrane, Cytosol"		"CAB002658: , HPA014811: AB_1849827"					unprognostic (1.60e-1)								unprognostic (2.47e-2)					0.1	0	0.2	0.1	0.4	56.9	0.1	0.1	0.5	0.1	0.1	0.1	0.1	0	0.1	0.1	0.1	0	0.1	0.1	0.2	0.3	1.7	1.3	3.2	0.1	0.3	0.1	0.1	0.1	0	0.3	4.8	0.1	0.1	0	0.1	0.1	0.1	0.1	0	0.1	0.1	0.1	6.2	0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	1.5	0.3	0.4	0.2	0.2	0.6	0.8	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	55.7	0	0	0	0	0	0	0	0	0	0	13.7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.4	0.2	0	0.4	0	0.2	0.9	0.1	0.2	0.2	1.5	0.2	0.6	0.2	0.2	0.2	0.3	0	0.8	0.2	0.4	0.1	0.5	0.2	0.3	0.3	0.1	0.1	0.1
GYPB	"CD235b, GPB, MNS, SS"	ENSG00000250361	Glycophorin B (MNS blood group)	P06028	4	143996104-144019345	"Blood group antigen proteins, CD markers, Predicted intracellular proteins, Predicted membrane proteins"		Blood group antigen		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level		Tissue enriched	Detected in some	5	bone marrow: 37.1	Cell line enriched	Detected in some	4	HEL: 59.9	Not detected	Not detected			Not detected	Not detected			Not detected	Not detected			Not detected	Not detected																Intracellular and membrane																							0.2	0	0.2	0.1	0.1	37.1	0.1	0.1	0.3	0.1	0.1	0.1	0.1	0	0.1	0.1	0.1	0	0.1	0.1	0.1	0.1	0.6	0.8	0.6	0.1	0.1	0.1	0.1	0.1	0	0.2	3.3	0.1	0.1	0	0.1	0.1	0.1	0.1	0	0.1	0.1	0.1	6.8	0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.4	0	0	0	0	3.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	59.9	0	0	0	0	0	0	0	0	0	0	14.6	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0.4	0	3.2	0.2	0.1	0.1	0.3	0.1	0.1	0.1	0.1	0.1	0.1
GYPC	"CD236, CD236R, Ge, GPC, GYPD"	ENSG00000136732	Glycophorin C (Gerbich blood group)	P04921	2	126655933-126696670	"Blood group antigen proteins, CD markers, Predicted membrane proteins"		Blood group antigen		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in many		HHSteC: 61.5;K-562: 45.7;SK-MEL-30: 90.3;U-266/70: 51.0	Cancer enhanced	Detected in all		melanoma: 66.9	Low region specificity	Detected in all			Low cell type specificity	Detected in many			Low lineage specificity	Detected in all			Low region specificity	Detected in all							"HPA008965, CAB009445"	Enhanced		Supported	Plasma membrane				Plasma membrane		"CAB009445: AB_2116251, HPA008965: AB_1078455"	unprognostic (1.63e-2)	unprognostic (7.14e-3)	unprognostic (8.39e-2)	unprognostic (3.31e-3)	unprognostic (4.19e-2)	unprognostic (1.69e-2)	unprognostic (8.82e-2)	unprognostic (3.52e-1)	unprognostic (1.19e-1)	unprognostic (2.21e-1)	unprognostic (1.25e-1)	unprognostic (1.11e-1)	unprognostic (2.05e-2)	unprognostic (2.73e-2)	unprognostic (1.51e-1)	unprognostic (2.29e-1)	unprognostic (8.00e-3)	44.5	21.7	3.9	34.5	5.3	95	99.8	1.3	4.3	20.7	24.8	5.9	9.8	5	20.3	26	22.9	18.5	21.4	61.2	4.4	3.4	15.2	6.3	29.5	75.8	8	3.7	37.4	18.7	1.7	5.5	17.5	5.6	24.5	5.5	13.8	13	15.5	48.9	11.3	15.2	34.8	8.3	41.1	13.5	13.4	4.6	28.5	11.6	29.9	22.5	37.1	38.8	21.2	9.9	4.2	7.7	14.7	41.4	21.8	0.1	0	22.1	0	16.4	14.4	0	3.3	25.6	4	11.9	0	0	0	0	9.2	0	12	0	1.3	10.5	0	37.1	0	0	61.5	12.9	0.1	32.3	0	3.2	0	0.1	45.7	30.7	9.6	0	0	20.5	6.6	0	2.4	1.6	0	1.6	0	0	0	0	0	90.3	0	35.3	8.9	15.2	0.1	1	0.1	51	33	0	7.3	18.8	13.7	0.1	5.9	0.4	32.3	7.7	36.4	18.9	29.3	39.1	9.9	21.2	41.4	40.4	4.2	14.7	4.7	5.5	35.1	21.8	3.9	5.3	1.3	4.3	4.4	3.4	8	3.7	5.6	4.6
HMMR	"CD168, RHAMM"	ENSG00000072571	Hyaluronan mediated motility receptor	O75330	5	163460203-163491945	"CD markers, FDA approved drug targets, Predicted intracellular proteins"			FDA approved drug targets	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		lymphoid tissue: 54.5;testis: 16.7	Low cell line specificity	Detected in many			Low cancer specificity	Detected in many			Low region specificity	Detected in some			Cell type enhanced	Detected in some		T-reg: 4.8	Low lineage specificity	Detected in many			Low region specificity	Detected in single			Low region specificity	Detected in all			"CAB002433, HPA040025, HPA043926, HPA061524"	Enhanced		Enhanced	"Microtubules,Centrosome,Cytosol"				Microtubules	"Centrosome, Cytosol"	"CAB002433: AB_564080, HPA040025: , HPA043926: , HPA061524: "	unprognostic (3.53e-3)	unprognostic (1.01e-1)	unprognostic (3.38e-3)	unprognostic (8.88e-3)	unprognostic (2.12e-1)	prognostic unfavourable (5.52e-4)	prognostic unfavourable (1.93e-7)	prognostic unfavourable (1.09e-4)	unprognostic (5.68e-2)	unprognostic (2.50e-1)	prognostic unfavourable (3.71e-5)	unprognostic (1.02e-1)	unprognostic (0.00e+0)	unprognostic (1.65e-2)	unprognostic (4.98e-2)	unprognostic (2.39e-1)	unprognostic (1.77e-2)	1.6	1.4	0.6	13.4	0.6	11.4	2.4	0.4	0.9	1.7	5	0.6	0.6	4.5	0.6	2.3	6.4	0.5	0.9	1.6	0.8	0.7	1.4	1.8	2.5	10.9	1	0.4	0.6	1.1	0.6	0.5	6.9	1.1	0.7	5.6	0.4	1.6	0.2	1.4	2.3	4.8	1.4	1.9	8.6	2.6	16.7	0.3	54.5	0.7	5.6	10.8	1.8	2.1	1.2	1.8	0.6	0.7	1.5	4.8	0.8	21.1	13.3	27.1	14.5	1.4	2.6	20.2	20.1	9.8	25.2	22.9	27	40.8	35.1	19.2	6.2	24.4	31.3	19	43	31.8	9.7	21	9.5	13.1	0.4	18.6	19.4	0.7	1.1	23.6	18.5	14.3	19.8	28.8	26.2	7.7	19.6	10.6	23.4	14.5	21.4	36.3	17.6	9.8	5.7	22.7	12.6	29.9	9.4	11.4	27.6	14.9	9.3	18.1	15.3	14.4	26.9	15.5	25.9	28.3	11.9	28.8	17.3	0.5	0.7	0	0.5	0.3	0.9	1.2	1	0.6	0.9	0.9	0.4	0.7	0.6	1.5	0	1.8	4.8	0.8	0.6	0.6	0.4	0.9	0.8	0.7	1	0.4	1.1	0.3
ICAM1	"BB2, CD54"	ENSG00000090339	Intercellular adhesion molecule 1	P05362	19	10270835-10286615	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Receptor"	"Cancer-related genes, FDA approved drug targets"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		liver: 68.3;lung: 91.3	Cell line enhanced	Detected in many		HHSteC: 31.1;Karpas-707: 88.5	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in many			Low lineage specificity	Detected in all			Low region specificity	Detected in all			Low region specificity	Detected in many			"HPA002126, CAB002142, HPA004877"	Enhanced		Uncertain	"Plasma membrane,Cytosol"		3100000000	3100000000	"Plasma membrane, Cytosol"		"CAB002142: AB_563596, HPA002126: AB_1078470, HPA004877: AB_1846317"	prognostic favourable (7.09e-4)	unprognostic (1.88e-1)	unprognostic (1.94e-1)	unprognostic (2.63e-2)	unprognostic (3.25e-3)	unprognostic (3.05e-1)	unprognostic (1.45e-2)	unprognostic (3.48e-1)	unprognostic (3.18e-2)	unprognostic (1.09e-2)	unprognostic (1.49e-2)	unprognostic (1.79e-1)	prognostic unfavourable (1.32e-6)	unprognostic (2.77e-1)	unprognostic (2.16e-2)	unprognostic (2.25e-1)	unprognostic (3.70e-3)	26.1	8.6	4	41	4.1	36.5	15	1	4.5	5.6	10	2.7	1.6	6.1	8.5	7.7	7.9	10.7	19.8	16.3	2.6	2.1	10.9	68.3	91.3	32.8	5.4	1.7	12.4	7.2	2.5	4	9.3	6.8	10.4	6.6	10.6	7.2	3.6	13.9	6.9	7.9	8	7.8	42.2	7.3	6.5	3.6	8.3	11.6	13.7	13.4	14.8	17.1	2.2	13.3	22.2	14.2	7.9	5.6	8.9	8.2	0.1	1.5	0	0.4	0.9	2.1	1.7	18.5	4.1	12.5	2.7	9.3	7.6	25.8	0.7	1.7	0.3	0	8.7	22.7	0	0.7	0.2	11.3	31.1	0.2	4.5	10.9	0.7	2.6	4	2.1	2.8	88.5	0.3	0.6	0.1	6.4	0.5	4.7	0.2	0	28.1	7	0	0	0.2	11.4	0.6	18.1	1.4	0.5	6.4	4.2	0.4	2.3	0.1	27	27.8	4.7	6.8	4.9	6.2	2.2	13.9	2.6	3	14.2	5.6	2.2	2.4	3.6	13.3	0.9	1	2.2	22.2	7.9	7.9	7.5	3.4	8.9	4	4.1	1	4.5	2.6	2.1	5.4	1.7	6.8	3.6
ICAM2	CD102	ENSG00000108622	Intercellular adhesion molecule 2	P13598	17	64002594-64020634	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Cell adhesion			Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		blood: 74.5;lymphoid tissue: 63.9	Group enriched	Detected in many	6	HUVEC TERT2: 163.3;TIME: 41.2	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all			Low region specificity	Detected in all			Low region specificity	Detected in many			HPA071155			Approved	"Plasma membrane,Cytosol"		1200000000	1200000000	Plasma membrane	Cytosol	HPA071155: 	unprognostic (9.43e-3)	unprognostic (3.31e-2)	unprognostic (5.15e-2)	unprognostic (1.15e-1)	unprognostic (8.97e-2)	unprognostic (1.64e-3)	unprognostic (1.34e-1)	unprognostic (3.74e-1)	unprognostic (8.28e-2)	unprognostic (2.15e-1)	unprognostic (4.18e-2)	unprognostic (1.55e-2)	unprognostic (9.07e-2)	unprognostic (1.48e-1)	unprognostic (3.93e-2)	unprognostic (6.04e-2)	unprognostic (2.29e-1)	36	3.6	8.4	13	11.5	8.3	34.1	3.5	7.7	9.4	9.7	5.6	2.8	6.4	9.8	5.2	9.5	7.4	8.8	22.8	9.5	8.9	10.5	8.7	27.9	24	12.3	3.1	6.3	7.4	3.1	4.5	36.8	9.1	7.9	8.5	8.1	8.8	4.3	17.1	5.5	10.8	13.9	10.5	63.9	8	4	7.4	14.3	11.6	9	18	12.8	23.6	49	30.9	56.5	74.5	26	65.3	67.5	0	0	0	0	1.3	1.5	0.4	0.1	0.1	0	0.1	0.3	6.8	11.5	2.1	0	0	0.1	0	0.2	2.5	0	10.3	0.6	1.2	0.2	1.7	0	0	0	0.1	0	163.3	8.4	6.7	0	0	12.8	1.5	0	0	7.8	0	15.9	0.8	1.6	0	0	0	0	0	0	1.3	41.2	0	0.1	0.8	0	6.4	2.2	10.2	0	2.1	0	56.5	30	8.9	45.8	66.5	52.8	36.5	60.1	42.8	30.9	49	65.3	40.7	3.6	26	74.5	10	64.5	67.5	8.4	11.5	3.5	7.7	9.5	8.9	12.3	3.1	9.1	7.4
ICAM3	"CD50, CDW50, ICAM-R"	ENSG00000076662	Intercellular adhesion molecule 3	P32942	19	10333776-10339823	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Phagocytosis"			Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 172.3;bone marrow: 51.5;lymphoid tissue: 68.5	Cell line enhanced	Detected in many		Karpas-707: 64.3;NB-4: 41.4;RPMI-8226: 48.2;U-266/84: 34.1;U-937: 33.8	Low cancer specificity	Detected in many			Low region specificity	Detected in many			Cell type enhanced	Detected in all		neutrophil: 172.3	Lineage enriched	Detected in all	4	granulocytes: 172.3									"CAB002498, HPA049820"	Enhanced		Approved	"Nucleoplasm,Nuclear membrane,Mitochondria"		370000000	370000000	Mitochondria	"Nucleoplasm, Nuclear membrane"	"CAB002498: AB_563593, HPA049820: "	unprognostic (6.85e-4)	unprognostic (5.28e-3)	unprognostic (3.09e-3)	unprognostic (1.57e-2)	unprognostic (5.34e-3)	unprognostic (5.79e-6)	unprognostic (5.05e-3)	unprognostic (3.73e-2)	unprognostic (1.73e-3)	unprognostic (7.93e-2)	unprognostic (3.45e-2)	unprognostic (2.54e-1)	unprognostic (5.62e-4)	unprognostic (1.13e-1)	unprognostic (1.06e-2)	unprognostic (3.43e-1)	unprognostic (1.84e-1)	6.8	2.8	1.7	23.5	1.9	51.5	5.5	0.6	1.5	3	6.8	1.1	1.2	4.3	1.7	3	4	2.9	7.2	6.4	1.1	0.9	5.1	28.7	13.2	68.5	1.8	1.4	1.7	6.8	0.2	0.4	4.8	1.5	2.8	3.3	2.4	10.3	1.3	5	1.6	11.9	1.8	1	39.4	5.4	1.4	1	47.6	3	5.7	38.4	4.5	4.9	25.5	28.4	172.3	33.5	31	41	43.1	2.6	1.3	0.9	2.9	1.6	1.3	1.6	1.6	1.1	1.4	1.2	1.1	1.8	0	5.7	1.4	1.1	0	1.2	0.4	19.8	0.8	5	1.2	5	0.8	18.3	20.7	1.1	1	1.6	0.5	0.6	2.7	64.3	1.5	5.4	2.4	41.4	0.7	9	1.5	0.6	48.2	1.4	2.3	0.3	1.2	1.4	4.5	3.6	3.9	5.2	1.1	6.3	0.5	7	1.6	3.1	34.1	7.6	4.5	33.8	4.9	15.3	33.1	72	33.8	24.4	41	25.5	32.7	31.2	28.4	23.9	29.3	27.4	172.3	31	33.5	4.8	36.9	43.1	1.7	1.9	0.6	1.5	1.1	0.9	1.8	1.4	1.5	1
ICAM4	"CD242, LW"	ENSG00000105371	Intercellular adhesion molecule 4 (Landsteiner-Wiener blood group)	Q14773	19	10286967-10288522	"Blood group antigen proteins, CD markers, Predicted intracellular proteins, Predicted membrane proteins"	Cell adhesion	Blood group antigen		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	6	blood: 53.1;bone marrow: 13.7;lung: 13.5	Cell line enhanced	Detected in some		HEL: 35.3;HMC-1: 8.9;K-562: 18.3;NB-4: 15.2;U-937: 8.5	Not detected	Not detected			Group enriched	Detected in some	4	cerebral cortex: 2.0;pons and medulla: 2.4	Cell type enriched	Detected in many	5	non-classical monocyte: 53.1	Lineage enriched	Detected in many	6	monocytes: 53.1														Intracellular and membrane																							1.9	0.4	0.4	1.6	0.4	13.7	0.6	0.2	2	1	2.9	0.2	0	1.1	1.1	2.9	2.3	1.1	1.1	1.1	0.5	0.3	1.6	1.7	13.5	3.3	0.4	0	1.2	0.4	0.1	0.4	1.9	2.4	2.4	0.5	0.9	2.5	2.7	1.7	0.8	1.4	0.2	0.9	2.8	1.6	0.6	0.3	1.5	0.9	0	4.5	3.3	0.7	0.5	8.4	4.5	53.1	0.1	0.6	2.4	0.1	0.1	0.1	0.2	0	0	3.1	0.3	0.1	0	0	3.9	0.2	0.4	0.4	0	0.3	0.1	0	0	0.3	0.2	35.3	0.2	5.3	1	0.6	8.9	0.2	0	0.1	0.1	0	18.3	1.6	0	0.1	0.9	15.2	0.1	0.1	2.6	1.5	6.7	0	0.1	0	0.1	0.3	0.1	0.1	0.1	1	0.3	0.1	0	0.3	0	0.5	0.9	0.1	0.3	8.5	0.2	4.5	2.6	2.6	0.2	9.7	0.5	0.5	0.3	0.2	8.4	0.4	0.3	0.1	0.7	0.1	53.1	2.7	0.6	2.4	0.4	0.4	0.2	2	0.5	0.3	0.4	0	2.4	0.3
ICOS	"AILIM, CD278"	ENSG00000163600	Inducible T cell costimulator	Q9Y6W8	2	203936748-203961577	"CD markers, Disease related genes, Predicted membrane proteins"				Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	4	blood: 18.4;bone marrow: 13.8;lymphoid tissue: 51.8	Group enriched	Detected in some	100	HEL: 5.9;MOLT-4: 15.3	Low cancer specificity	Detected in many			Not detected	Not detected			Cell type enhanced	Detected in many		T-reg: 18.4	Lineage enriched	Detected in single	58	T-cells: 18.4	Low region specificity	Detected in single							"CAB032575, HPA034865"	Approved		Approved	"Plasma membrane,Actin filaments"	Intracellular and membrane			Plasma membrane	Actin filaments	"CAB032575: AB_2122593, HPA034865: "	unprognostic (2.66e-2)	unprognostic (2.13e-3)	unprognostic (4.19e-4)	unprognostic (2.35e-5)	unprognostic (1.07e-1)	prognostic favourable (1.80e-4)	unprognostic (9.38e-2)	unprognostic (2.89e-2)	unprognostic (1.49e-2)	unprognostic (3.51e-4)	unprognostic (7.50e-2)	unprognostic (2.12e-1)	unprognostic (2.86e-5)	unprognostic (7.05e-2)	unprognostic (2.48e-2)	unprognostic (1.93e-1)	unprognostic (8.82e-3)	1.5	0.3	0.2	15.6	0.2	13.8	0.7	0.2	0.2	0.8	1.2	0	0.2	0.5	1.2	0.5	1.1	1.2	1.6	0.5	0.2	0.2	1	0.8	4	19.4	0.3	0	0.6	0.3	0	0.4	0.1	0.1	0.7	1.1	0.7	2.9	0	0.2	0.6	6.2	0.3	0.4	6.1	1	0.6	0	51.8	1.4	2.4	28.9	3	0.9	0	0	0	0	0.3	18.4	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5.9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	15.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	2.4	0	2.9	0	10.5	4.6	0	0	11	5	0	0.3	0	0	18.4	3	0.2	0.2	0.2	0.2	0.2	0.2	0.3	0	0.1	0
ICOSLG	"B7-H2, B7H2, B7RP-1, B7RP1, CD275, GL50, ICOS-L, ICOSL, KIAA0653"	ENSG00000160223	Inducible T cell costimulator ligand	O75144	21	44217014-44240966	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, B-cell activation, Immunity"			Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		bone marrow: 14.1	Cell line enhanced	Detected in many		Daudi: 14.0	Not detected	Not detected			Low region specificity	Detected in all			Cell type enhanced	Detected in some		naive B-cell: 6.5	Low lineage specificity	Detected in many											"CAB026037, HPA029179"	Uncertain		Approved	"Plasma membrane,Cytoplasmic bodies"		150000000	150000000	"Plasma membrane, Cytoplasmic bodies"		"CAB026037: , HPA029179: "	unprognostic (3.03e-2)	unprognostic (1.40e-4)	unprognostic (3.52e-2)	unprognostic (1.94e-2)	unprognostic (6.74e-2)	unprognostic (9.40e-2)	unprognostic (6.94e-2)	unprognostic (3.71e-1)	unprognostic (1.40e-1)	unprognostic (3.76e-2)	unprognostic (1.40e-1)	unprognostic (2.42e-1)	unprognostic (3.00e-2)	unprognostic (3.11e-1)	unprognostic (1.36e-1)	unprognostic (1.47e-1)	unprognostic (1.84e-1)	2.3	3	5.3	3.9	7.1	14.1	2.3	2.3	5.9	2.9	2.3	2.3	2.3	1.8	2.3	2.3	4	2.7	3.5	3.7	8.8	3.7	5.3	2.7	2.3	6.5	6.5	2.3	2.3	2.3	0	2.3	2.3	2.3	2.3	1.2	2.3	2.3	2.3	2.3	5.5	2.9	2.3	8.4	3.2	4.2	2.3	2.3	2.3	2.3	2.3	4.5	2.4	2.6	6.5	1.6	1	0.8	0.5	1.1	0.4	0.3	3.3	0.1	2.8	0.8	1.1	7.7	0.7	0.6	0.4	0.2	5.6	0.4	14	2.1	0.3	4.2	1.9	1.3	0.2	1.4	1.4	0.4	2.7	1.6	0.7	6	10.3	1.1	1.9	0.9	0.9	0.8	2.3	1.3	0.2	3.6	0.3	7.9	2	3.5	11.9	0.9	8.2	0.6	7.4	1.4	0	9.3	13.2	0.3	3.8	8.6	0.8	0.4	3.3	0.3	0.2	12.1	8.2	11.7	4.3	5.6	1.8	0.6	0.8	0.4	0.3	0.8	0.3	3.7	0.8	0.5	0.5	6.5	0.8	1.1	1	0.5	0.5	1.6	0.4	0.4	5.3	7.1	2.3	2.3	8.8	3.7	6.5	2.3	2.3	2.3
IFITM1	"9-27, CD225, IFI17"	ENSG00000185885	Interferon induced transmembrane protein 1	P13164	11	313506-315272	"CD markers, Plasma proteins, Predicted membrane proteins, Transporters"	"Antiviral defense, Immunity, Innate immunity, Osteogenesis"			Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in many		BJ hTERT+ SV40 Large T+: 120.0;BJ hTERT+ SV40 Large T+ RasG12V: 215.2;HMC-1: 66.4	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Group enriched	Detected in all	6	eosinophil: 56.6;gdT-cell: 120.0;MAIT T-cell: 80.7;memory CD4 T-cell: 128.1;memory CD8 T-cell: 121.4;naive CD4 T-cell: 123.5;naive CD8 T-cell: 123.4;neutrophil: 106.8;NK-cell: 164.4;T-reg: 70.4	Group enriched	Detected in all	7	granulocytes: 106.8;NK-cells: 164.4;T-cells: 128.1									"HPA004810, CAB017615"	Enhanced		Supported	Cytosol				Cytosol		"CAB017615: AB_2264496, HPA004810: AB_1851419"	unprognostic (1.03e-3)	unprognostic (6.79e-2)	unprognostic (1.03e-1)	unprognostic (2.98e-1)	unprognostic (2.57e-1)	unprognostic (9.06e-2)	unprognostic (7.58e-2)	unprognostic (3.03e-1)	unprognostic (6.21e-2)	unprognostic (5.53e-2)	unprognostic (6.64e-3)	unprognostic (1.48e-2)	prognostic unfavourable (5.77e-9)	unprognostic (7.29e-2)	unprognostic (6.29e-2)	unprognostic (3.15e-2)	unprognostic (3.82e-2)	81.1	14.2	17.4	36.7	24.5	41.2	57	11.9	23.1	71	28.2	12.9	20.6	17.2	48.3	152.4	44.4	67.2	31.2	62.6	19.8	13.9	59.8	34.5	44.1	159.7	34.8	14.7	100.2	16.3	22.3	23.3	36.3	27.3	38.7	22.1	49.5	27.4	41.6	38.7	23.6	33	46	37.9	112.9	20.5	29.4	20.1	42.7	48.3	28	50.3	39.3	52.8	13	4.3	106.8	18.6	164.4	128.1	147.7	6.2	0.1	52.2	4.2	3.8	13.4	0.3	11.1	51.9	120	215.2	0.1	43.5	0.1	8.3	11.6	14.8	1.6	1.1	2.4	13.2	2.7	6.4	4	0.4	34.6	9.3	66.4	25.1	0	1.3	0.1	0.2	22.7	52.7	0	0.9	4.6	17.9	14.8	1.6	1.2	0.1	1.2	32.1	0	0	0	5.8	0.6	10.6	2.1	0.8	0.3	0.1	0.1	0	0	3.7	2	0.3	0.1	14	0.1	15.6	2.3	56.6	120	10.9	80.7	13	128.1	121.4	4.3	11.3	123.5	123.4	106.8	164.4	18.6	1.2	70.4	147.7	17.4	24.5	11.9	23.1	19.8	13.9	34.8	14.7	27.3	20.1
IFNGR1	"CD119, IFNGR"	ENSG00000027697	Interferon gamma receptor 1	P15260	6	137197484-137219449	"CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Disease mutation, FDA approved drug targets"	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in all		hTCEpi: 57.5	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all							Low region specificity	Detected in all			"CAB025889, HPA029213, HPA063871"	Approved		Approved	Plasma membrane				Plasma membrane		"CAB025889: , HPA029213: AB_10601023, HPA063871: "	unprognostic (1.73e-1)	unprognostic (8.86e-2)	unprognostic (9.85e-3)	unprognostic (1.71e-1)	unprognostic (6.55e-2)	unprognostic (1.25e-1)	unprognostic (4.05e-1)	unprognostic (6.97e-2)	unprognostic (9.86e-2)	unprognostic (1.57e-2)	unprognostic (4.09e-2)	unprognostic (2.85e-1)	prognostic unfavourable (5.48e-4)	unprognostic (1.58e-1)	unprognostic (2.87e-2)	unprognostic (1.81e-2)	unprognostic (5.38e-3)	69.5	22.2	17.4	36.9	23.5	37.7	65.3	8.4	18.5	23.6	27.1	27.8	13.8	28	19.2	21.2	23	20.3	25.9	53.7	20.6	17.4	19.3	66.4	58.7	86.9	33.8	13.2	19.2	17.5	9.2	12.8	47	29.9	20.1	22.8	11.6	24.5	18	25.3	24	46.7	22.5	45.7	69.1	20.3	14.1	26.3	14.5	22.8	19.7	38.2	25	22.3	12.2	39.4	92.3	65.4	5.4	29.7	52.3	4.9	4.7	6.2	8	41.1	21.7	5.2	14.1	20.8	9.1	12.4	30.7	9.6	4.9	22.4	8.1	30.5	5.5	14.2	12.8	10.5	7.6	7.7	5.8	45.4	23.2	23.9	11.4	47.8	57.5	7.6	12.4	11.4	6.4	8.3	6.9	5.5	3.8	11	5.1	3.8	11.8	6.5	7.3	15.9	23.2	6.3	9.7	17.3	10.2	12.7	3.6	15.8	15.9	8.9	6.5	11.6	7.4	6.2	5.8	5.5	4.6	15.9	8.6	16.5	65.4	43.3	14.1	63	29.7	10.9	8	11.8	39.4	12.2	5.2	5.8	92.3	5.4	44.1	10.1	5.6	52.3	17.4	23.5	8.4	18.5	20.6	17.4	33.8	13.2	29.9	26.3
IGF1R	"CD221, IGFIR, IGFR, JTK13, MGC18216"	ENSG00000140443	Insulin like growth factor 1 receptor	P08069	15	98648971-98964530	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"		"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Low cell line specificity	Detected in many			Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in many		neutrophil: 7.7	Group enriched	Detected in many	5	granulocytes: 7.7;T-cells: 2.9	Low region specificity	Detected in all							"CAB010268, HPA045563"	Approved		Approved	Vesicles		36000	36000	Vesicles		"CAB010268: AB_671792, HPA045563: "	unprognostic (1.30e-3)	unprognostic (5.81e-3)	unprognostic (1.53e-1)	unprognostic (3.34e-2)	unprognostic (2.65e-1)	unprognostic (2.05e-2)	unprognostic (1.29e-2)	unprognostic (6.87e-2)	unprognostic (2.64e-2)	unprognostic (2.87e-2)	unprognostic (8.56e-2)	unprognostic (1.62e-1)	prognostic favourable (3.75e-7)	unprognostic (1.57e-1)	unprognostic (3.59e-1)	unprognostic (1.41e-1)	unprognostic (1.06e-1)	8.4	12.7	11.5	5.9	13.5	16.3	18.5	23	15.7	15.3	13.4	10.4	22.7	4.2	15.3	16.3	9.2	18.9	7.7	11.6	11.7	7.3	17	2	11	4.9	8	11.8	23.2	22.5	4.7	13.8	17.5	9.5	21.7	7.2	16.7	12.5	23.2	9.1	13	7.5	18.1	8	7.3	10.7	12	11.5	10.7	16.1	7	5.6	12.8	21.6	1	0.4	7.7	0.6	1	2.9	0.7	3.3	16.5	11.6	0.2	5.8	4.2	7.7	3.7	7.4	1.2	1.1	7.1	8.8	0.8	10.7	7.2	15.8	5.1	15	1	0	5.2	12.5	18.5	14.2	5.1	6.6	1.3	6.6	7.1	2.1	10.2	4.1	0.6	2.9	5.7	23.4	2.5	4.4	10.8	0.9	4	9	3	3.5	20.3	3.9	17.3	26.7	1.5	14.4	8.1	3.1	11.3	1.1	15	3	5.8	1	4.4	2.7	2.2	4.9	2.8	4	0.6	1.8	0.9	0.6	0.6	0.4	0.8	0.3	0.4	1	2.9	1	7.7	1	0.5	0.3	0	0.7	11.5	13.5	23	15.7	11.7	7.3	8	11.8	9.5	11.5
IGF2R	"CD222, CI-M6PR, CI-MPR, CIMPR, M6P-R, MPR1, MPR300, MPRI"	ENSG00000197081	Insulin like growth factor 2 receptor	P11717	6	159969099-160113507	"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	Transport	Receptor	Cancer-related genes	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in all		HBEC3-KT: 59.6;hTERT-HME1: 60.7	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in many		neutrophil: 13.3	Low lineage specificity	Detected in many			Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB009661, HPA011332"	Supported		Enhanced	"Golgi apparatus,Vesicles"		150000000	150000000	"Golgi apparatus, Vesicles"		"CAB009661: AB_2122795, HPA011332: AB_1846276"	prognostic unfavourable (3.01e-4)	prognostic unfavourable (2.92e-5)	unprognostic (5.83e-2)	unprognostic (1.72e-1)	unprognostic (4.15e-1)	unprognostic (3.25e-1)	unprognostic (7.32e-3)	unprognostic (2.32e-1)	unprognostic (1.62e-1)	unprognostic (1.07e-2)	unprognostic (2.37e-1)	unprognostic (1.45e-1)	unprognostic (5.74e-3)	unprognostic (1.16e-1)	unprognostic (1.46e-1)	unprognostic (1.85e-1)	prognostic unfavourable (6.08e-4)	28	22.2	6.8	13.5	8.1	16.7	39.4	6.4	8.2	14.9	17.3	9.5	13	9.4	19.6	16	16.7	13.1	17.9	27.9	6.7	6.2	20.6	26.6	32.6	44.7	12.3	3.6	18	19.6	23.5	13.6	15.5	10	14.1	13.3	13.9	18.2	13.5	62	15.9	15.4	16.5	7.6	30.2	14.4	13.8	9	37.9	18.5	17.3	14.1	16.3	26.9	0.4	2.9	13.3	2	1	3.6	0.9	7.7	7	12.4	17.4	45.3	25	16.8	12.2	26.4	10.1	17.4	10.6	12.2	3.2	13.7	13.4	10.4	9.3	59.6	17	16.8	6.6	1.4	12.2	19.1	26.8	7.4	12.1	19.9	19.1	21	60.7	6.5	13.9	17.4	15.9	5.7	3.4	7.4	5.5	7.5	8	8.5	16.3	14.3	7.8	4.1	9.1	16.5	14.8	16.5	6.2	21	9.8	9.8	10.3	21.1	22.3	10.3	14.4	3.3	18.9	10.2	15.1	0.1	2	1.1	3.6	0.8	1.4	0.3	1.2	1.7	0.3	0.4	1	2.4	13.3	1	1.4	2.9	0.7	0.9	6.8	8.1	6.4	8.2	6.7	6.2	12.3	3.6	10	9
IGLL1	"14.1, CD179B, IGL5, IGLL, IGVPB"	ENSG00000128322	Immunoglobulin lambda like polypeptide 1	P15814	22	23573125-23580308	"CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"			Disease mutation	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in some	35	blood: 11.6;bone marrow: 37.7;lymphoid tissue: 29.4;testis: 20.8	Cell line enriched	Detected in some	34	REH: 126.8	Cancer enhanced	Detected in some		stomach cancer: 2.1	Not detected	Not detected			Group enriched	Detected in some	8	memory B-cell: 11.6;naive B-cell: 9.8	Lineage enriched	Detected in many	8	B-cells: 11.6									"HPA051134, HPA071406"	Enhanced		Approved	Endoplasmic reticulum	Secreted to blood	1E+11	1E+11	Endoplasmic reticulum		"HPA051134: , HPA071406: "	unprognostic (6.21e-2)	unprognostic (5.12e-2)	unprognostic (7.31e-2)	unprognostic (4.75e-2)	unprognostic (1.56e-1)	unprognostic (5.91e-6)		unprognostic (1.08e-1)	unprognostic (5.27e-2)	unprognostic (6.17e-3)	unprognostic (5.89e-2)	unprognostic (9.07e-2)	unprognostic (1.99e-4)	unprognostic (2.35e-2)	unprognostic (5.16e-1)	unprognostic (2.28e-2)	unprognostic (1.21e-2)	0	0	0.1	0.1	0.2	37.7	0	0.2	0.1	0	0	0	0	0.1	0.2	0	0	0	0	0	0.1	0.1	0.1	0	0.2	0.6	0	0	0.1	0	0	0.1	0	0	0	0	0	0.7	0	0	0	0	0	0	0.4	0	20.8	0	29.4	0	0	1.1	0	0	11.6	1.3	0	0	0	0	1.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0.7	0	0	0	0	0	0	0	0	0	0	0	0	3.7	0	0	0	0	0	0	0	0	0	0	2.2	0.4	0	0	126.8	0	2.7	0	0	0	0	0	0.1	0	0	1	0	0	0	0	0	0.1	0	0	0	0.3	0	0	0	0	0	0	0	11.6	0	0	0	9.8	0	0	0	0	0	1.3	0	1.5	0.1	0.2	0.2	0.1	0.1	0.1	0	0	0	0
IGSF8	"CD316, CD81P3, EWI2, PGRL"	ENSG00000162729	Immunoglobulin superfamily member 8	Q969P0	1	160091340-160098943	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"				Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		brain: 54.2	Cell line enhanced	Detected in all		SK-MEL-30: 58.0	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in many			Low lineage specificity	Detected in all			Low region specificity	Detected in all			Low region specificity	Detected in all			"HPA011917, HPA075970"	Approved		Supported	Vesicles		190000	190000	Vesicles		"HPA011917: AB_1851536, HPA075970: "	unprognostic (4.08e-1)	prognostic unfavourable (7.32e-4)	unprognostic (1.30e-2)	unprognostic (9.31e-2)	unprognostic (1.46e-1)	unprognostic (1.20e-1)	unprognostic (1.71e-1)	unprognostic (1.01e-3)	unprognostic (1.63e-2)	unprognostic (1.65e-1)	unprognostic (1.09e-1)	unprognostic (1.63e-1)	unprognostic (2.31e-1)	unprognostic (2.60e-2)	unprognostic (2.35e-1)	unprognostic (3.74e-3)	unprognostic (1.75e-3)	9.9	10.4	25.2	9	30.3	2.4	11.1	40.9	54.2	9.6	11.8	53.5	6.4	18.2	8.6	16.6	7	13.9	8.5	11.6	32.4	24.1	10.4	19.3	10.1	10.3	32.2	29.9	15.1	19.1	9	8.7	7.8	25.9	13.8	7.4	11.2	21	14	6	34	14.4	5.1	42.6	10.6	9.8	11.5	25.3	6.2	10	5.9	6.2	6	6.9	14.3	5.6	1.2	4	4.7	15.6	6.4	8.8	5.3	6.9	17.6	4.1	2.6	14.6	4.3	5.7	9.3	8.7	6	6.1	13	16.3	6.3	17	2.8	6.4	1.3	15.5	5	1.6	5.9	10.3	6.8	4.4	14.5	3.1	13	6	1.9	1.9	2.2	7.5	2.1	8.4	11	10.3	14.6	8.5	6.3	3.5	9.4	8.5	9.2	2.9	12.6	5	16.2	58	11.5	5.7	1.9	4.1	8.9	7.4	3.5	20.6	22.8	5.8	14.5	1.7	10.7	0	2.9	1.2	13.3	4	11.7	12.2	11	15.4	3.3	14.3	14.8	15.6	0.8	4.7	2.4	5.6	14.9	6.4	25.2	30.3	40.9	54.2	32.4	24.1	32.2	29.9	25.9	25.3
IL10RA	"CD210, CD210a, CDW210A, HIL-10R, IL10R"	ENSG00000110324	Interleukin 10 receptor subunit alpha	Q13651	11	117986348-118003037	"CD markers, Disease related genes, Predicted membrane proteins"		Receptor	Disease mutation	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		lymphoid tissue: 56.2	Cell line enhanced	Detected in some		Daudi: 14.5;HDLM-2: 36.2;Karpas-707: 13.6;RPMI-8226: 16.5	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in many			Low lineage specificity	Detected in all			Low region specificity	Detected in all			Low region specificity	Detected in all														unprognostic (1.01e-2)	unprognostic (2.07e-3)	unprognostic (1.58e-2)	unprognostic (7.08e-2)	unprognostic (8.27e-2)	prognostic favourable (4.47e-4)	unprognostic (5.27e-2)	unprognostic (4.84e-2)	unprognostic (7.70e-3)	unprognostic (5.94e-2)	unprognostic (2.14e-2)	unprognostic (3.83e-1)	prognostic unfavourable (1.45e-5)	unprognostic (1.82e-1)	unprognostic (8.43e-3)	unprognostic (2.19e-1)	unprognostic (1.27e-1)	11.3	6.5	2.9	29.6	3.5	27.2	7.2	1.1	3	3.4	7.9	4.7	0.5	3.8	5.5	11	4.3	4.9	9.7	7.6	3	3.6	5	6.4	13.6	49.8	4.7	1.4	3.4	3.6	1.3	3.4	6.9	4.5	5.8	7.5	6.4	7.9	1.9	2.6	3	17.6	5	8	56.2	4.9	3.1	3.5	9.6	3.6	3.9	32.2	9.5	3.4	4.6	15.4	1.2	23.9	23.7	30.7	22.8	0	0	0	0	0	0	0	0	0	0	0	0	0	14.5	0.1	0	0	0.2	0	0	36.2	0	0.1	0	0	0	0	4	0	0	0	0	0	2.6	13.6	0	0	0.2	2.8	0	0	0	0	16.5	0	0	0.2	0	0	0	0	0	1	0	0	0	0	0	2.8	0.4	3.8	0	5.4	0	1.1	15.8	0.8	19.7	23.9	14.2	4.6	19	22.7	15.4	2.3	6.9	12.3	1.2	23.7	18.8	6	30.7	22.8	2.9	3.5	1.1	3	3	3.6	4.7	1.4	4.5	3.5
IL10RB	"CDW210B, CRF2-4, CRFB4, D21S58, D21S66, IL-10R2"	ENSG00000243646	Interleukin 10 receptor subunit beta	Q08334	21	33266358-33310187	"CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Antiviral defense	Receptor		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Low cell line specificity	Detected in all			Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all											"CAB020670, HPA047550"	Approved		Approved	Cytosol		1300000	1300000	Cytosol		"CAB020670: , HPA047550: "	unprognostic (8.43e-2)	unprognostic (6.50e-2)	unprognostic (5.88e-2)	unprognostic (1.77e-1)	unprognostic (1.48e-2)	unprognostic (7.78e-2)	unprognostic (1.97e-3)	unprognostic (1.26e-1)	unprognostic (5.69e-3)	unprognostic (1.31e-1)	unprognostic (1.19e-1)	unprognostic (6.93e-2)	prognostic unfavourable (5.62e-9)	unprognostic (3.09e-1)	unprognostic (2.76e-1)	unprognostic (1.29e-2)	unprognostic (1.05e-1)	17.6	11	5.4	19.6	7.3	8.9	21.5	3.6	4.4	15.2	29.2	10.3	10.6	19.6	17.5	9.6	22.7	13.2	14.8	12.3	5.6	5.4	11.6	27.5	19.3	36.1	6.6	3.1	18.2	23.2	5.5	9.7	47.4	9.3	17.7	20.8	11.7	26	9.7	12.4	13.8	53.6	12.2	8	31.7	17.6	8.4	7.3	34	14.3	15.3	26.2	15.1	22.6	13.8	19.4	57.9	34.7	14	19.5	20.4	10.2	7.9	1.5	6.4	32.2	23.6	11.3	7.9	22.3	8.7	12.5	7.5	12.7	2.9	9.1	13.7	12.8	4.2	5.4	5.7	9.5	5.9	8	6	5.6	22.4	10.2	19.3	23.7	10.2	15.1	8.9	11.5	7.1	24	12	10.7	6.8	9.8	1.1	4.2	6.3	3.6	12.1	7.8	6.1	2	2.9	16.2	12	13.7	8	38.4	10.4	8.7	8.5	14.8	4.3	12.7	14.2	1.7	15.4	14.6	5.6	22.3	30.1	24.8	8.8	34.4	9.6	13.6	11.1	10.6	17.8	13.8	10.5	10.4	57.9	14	34.7	19.4	19.5	20.4	5.4	7.3	3.6	4.4	5.6	5.4	6.6	3.1	9.3	7.3
IL12RB1	"CD212, IL12RB"	ENSG00000096996	Interleukin 12 receptor subunit beta 1	P42701	19	18058995-18098944	"CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	Disease mutation	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 28.6;lymphoid tissue: 21.4	Cell line enhanced	Detected in some		Daudi: 10.4;HDLM-2: 17.6;Karpas-707: 30.1;U-698: 8.8	Low cancer specificity	Detected in many			Low region specificity	Detected in many			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all							Low region specificity	Detected in all			HPA074414			Approved	Plasma membrane	Intracellular and membrane			Plasma membrane		HPA074414: 	unprognostic (7.70e-3)	prognostic favourable (3.41e-4)	unprognostic (9.08e-3)	unprognostic (1.18e-4)	unprognostic (2.91e-1)	unprognostic (1.33e-3)	unprognostic (2.27e-1)	unprognostic (8.99e-2)	unprognostic (1.65e-2)	unprognostic (1.35e-1)	unprognostic (1.51e-1)	unprognostic (2.94e-1)	prognostic unfavourable (5.90e-5)	unprognostic (1.49e-1)	unprognostic (2.21e-2)	unprognostic (4.34e-2)	unprognostic (2.93e-2)	1.9	1.5	1.3	17.5	2.1	5.6	1.2	0.5	1	0.9	3.4	2.4	1.1	2.9	1	2.4	1.3	1.5	2.5	1.4	1.3	1.2	1.8	1.8	5	16	2	0.2	1.1	1.3	1.2	1.1	2.4	1.4	1.7	2	1.1	6.6	0.2	0.9	1	8	1	2.4	21.4	2.3	0.7	2.2	10.1	1.3	0.7	16.9	3.8	1	4.9	5.9	6.2	14	16.2	28.6	9	0.2	0.1	0.1	0.2	0	0.1	0.5	0.1	0.1	0.2	0.6	0.2	1	10.4	0.1	0.1	0.2	0.1	0	0	17.6	0.2	1.2	0.3	0.2	0.4	0.7	1.7	0	0	0.3	0.1	0	0.2	30.1	0	0.1	4.9	0.2	0.1	0.1	3.5	0.1	0.4	0	0	0.2	0.1	0.2	0.2	0.2	0.2	5.7	0.2	0.3	0.3	0.1	0.1	3.6	5.4	8.8	0.4	6	0.7	3.3	5.1	3.6	22.8	14	28.6	4.9	15.5	18.3	5.9	3.7	8.7	15.2	6.2	16.2	13.2	3.5	20.5	9	1.3	2.1	0.5	1	1.3	1.2	2	0.2	1.4	2.2
IL13RA1	"CD213a1, IL-13Ra, NR4"	ENSG00000131724	Interleukin 13 receptor subunit alpha 1	P78552	X	118727572-118794539	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"		Receptor		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in many		HDLM-2: 45.1	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Group enriched	Detected in many	6	classical monocyte: 6.9;eosinophil: 7.1;myeloid DC: 10.9;neutrophil: 19.0	Group enriched	Detected in many	6	dendritic cells: 10.9;granulocytes: 19.0;monocytes: 6.9	Low region specificity	Detected in all			Low region specificity	Detected in all			HPA001587			Approved	"Nucleoplasm,Vesicles"	Intracellular and membrane	4500000	4500000	Vesicles	Nucleoplasm	HPA001587: AB_1079133	unprognostic (5.14e-3)	unprognostic (4.72e-2)	unprognostic (7.12e-2)	unprognostic (7.75e-2)	unprognostic (8.81e-3)	unprognostic (3.82e-2)	unprognostic (1.11e-1)	unprognostic (1.89e-1)	unprognostic (1.51e-1)	unprognostic (2.44e-1)	unprognostic (1.90e-1)	unprognostic (8.21e-2)	prognostic unfavourable (1.19e-8)	unprognostic (1.88e-2)	unprognostic (2.37e-2)	unprognostic (2.82e-2)	unprognostic (5.08e-2)	31.5	17.5	9.3	15.3	13.3	2.1	19.8	3.6	10.2	16.6	23.8	12.6	7.2	18.9	16.6	18	33	15.4	17.7	17.5	11.4	9.4	22.7	73.3	27.7	33.9	15.2	6	25.2	12.9	9.5	16.1	15.2	13.4	15.3	25.2	14.5	21.8	13	22.3	10.2	37.7	16.3	24.5	17.4	18.5	9.9	11.9	4.8	24	20.1	20	16.5	15.4	1.9	10.9	19	6.9	0	0.1	1.7	8.2	10.2	4.9	13.4	11.1	33.1	8.8	17.3	24.1	8.3	10.8	5.9	15.3	0	30.5	23.8	7.9	5.3	7.3	9.2	45.1	4.1	1.4	9.3	15.1	6.8	0.1	3.6	30.1	6.7	11.3	13.9	17.2	4.4	0.9	11.7	12.1	0	2.2	4.4	9.9	0	12	0	12.4	9	1.8	1.7	27.2	10	6.8	6.4	7.8	21.9	16.2	7.7	27.2	13.5	0.2	4.1	0	35.7	4.2	6.8	0	6.9	7.1	0	1.7	0	1.9	0	0	10.9	1.8	0	0	19	0	0.6	1.9	0.1	1.7	9.3	13.3	3.6	10.2	11.4	9.4	15.2	6	13.4	11.9
IL13RA2	"CD213a2, CT19, IL-13R, IL13BP"	ENSG00000123496	Interleukin 13 receptor subunit alpha 2	Q14627	X	115003975-115019977	"Cancer-related genes, CD markers, Predicted membrane proteins"		Receptor	Cancer-related genes	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		pituitary gland: 16.1;testis: 31.5	Group enriched	Detected in some	9	PC-3: 26.4;U-2197: 84.9;U-251 MG: 57.0;U-87 MG: 33.8	Cancer enhanced	Detected in many		glioma: 17.2	Low region specificity	Detected in many			Not detected	Not detected			Not detected	Not detected			Region enhanced	Detected in some		olfactory region: 8.7	Low region specificity	Detected in many			"HPA045831, HPA067363"			Approved	"Nucleoplasm,Vesicles,Plasma membrane,Cell Junctions"				"Plasma membrane, Cell Junctions"	"Nucleoplasm, Vesicles"	"HPA045831: , HPA067363: "	unprognostic (1.97e-1)	unprognostic (2.83e-1)	unprognostic (6.62e-4)	unprognostic (7.39e-2)	unprognostic (8.45e-2)	unprognostic (1.80e-1)	prognostic favourable (3.55e-4)	unprognostic (3.54e-1)	unprognostic (2.85e-1)	unprognostic (1.92e-2)	unprognostic (2.20e-3)	unprognostic (2.19e-2)	unprognostic (1.53e-5)	unprognostic (1.58e-1)	unprognostic (1.63e-1)	unprognostic (9.70e-3)	unprognostic (1.20e-1)	0.5	4.8	3.7	3.9	11.3	0	0.8	0.3	3.1	1.2	0.4	2.1	5.7	0.3	0.9	4.4	0.5	0.1	0.8	0.6	5.1	11.2	3.5	9.6	1	0.1	1.2	2.6	0.1	0.1	0.5	16.1	2.1	3.9	4.3	0.7	1.6	0.8	3.7	0	0.1	0.3	0.4	0.6	0.2	0.1	31.5	1.4	0	1.3	0.2	0.2	1.9	0.1	0	0	0	0	0	0	0	0	0	0.9	0	0.1	0.7	0	5.8	5.5	0	0	0	0	0	0.1	2.9	0	0	1	0	0	0	0	0	0	0.5	0	0	1	0.1	0.9	5.4	0	0	0.6	0	0	0	0	0	26.4	0	0	0	0.4	0	0	1.3	0.4	0	0.1	0	0	0	3	0	84.9	57	0	0	0	33.8	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3.7	11.3	0.3	3.1	5.1	11.2	1.2	2.6	3.9	1.4
IL15RA	"CD215, IL-15RA"	ENSG00000134470	Interleukin 15 receptor subunit alpha	Q13261	10	5943639-5978187	"CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"		Receptor		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in many			Cell line enhanced	Detected in many		CAPAN-2: 29.4;EFO-21: 17.9;HDLM-2: 32.1;HHSteC: 18.3	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in many			Low lineage specificity	Detected in all											CAB026215	Approved				Secreted to blood					CAB026215: 	unprognostic (2.86e-2)	unprognostic (8.41e-2)	unprognostic (6.13e-2)	unprognostic (4.45e-2)	unprognostic (7.87e-2)	unprognostic (5.49e-2)	prognostic unfavourable (2.67e-6)	unprognostic (5.09e-3)	unprognostic (1.82e-2)	unprognostic (1.69e-1)	prognostic unfavourable (5.35e-4)	unprognostic (6.18e-3)	prognostic unfavourable (1.27e-12)	unprognostic (4.43e-2)	unprognostic (4.69e-2)	unprognostic (4.08e-2)	unprognostic (5.75e-2)	20.5	5.6	2.2	13	4.1	6.4	33.9	1.4	2.6	12.7	15.6	1.6	7.7	10.1	10.9	9.4	14.3	10.6	18.7	19.2	2.6	1.9	7.8	17.5	35.7	15.2	4	2	8.7	9.6	0.9	3.9	15.5	3.6	13.2	7.4	6.4	8.9	9.4	9.2	7.6	18.8	10.8	2.7	18.8	10.3	5	2.7	3.5	13.9	7.5	9.8	12.9	17.3	7	4.2	6.3	19.5	6.8	18.7	6.7	6.9	1	0	0.3	9.1	2.2	1.8	3.5	7.6	4.7	4.9	0.1	29.4	0.8	17.9	6.6	6.6	0.8	5.2	1	32.1	1.4	0.8	1.7	0.5	18.3	0.4	0.2	1.8	1.7	2.5	0.1	11.4	8.5	9.8	0.1	3.6	1.4	3.4	0.2	3.2	4.1	0	5.6	1.1	0.5	0	0	5.3	0.5	0.2	2.5	3.2	4.5	0.1	0.5	12.7	4.7	8.9	2.3	0.1	2.2	5.2	0.3	6.3	16	3.9	12.3	19.5	18.7	7	9.5	12.5	4.2	3.3	4.1	7.1	4.7	6.8	11.7	0	10.2	6.7	2.2	4.1	1.4	2.6	2.6	1.9	4	2	3.6	2.7
IL17RA	"CD217, CDw217, hIL-17R, IL-17RA, IL17R"	ENSG00000177663	Interleukin 17 receptor A	Q96F46	22	17084954-17115694	"CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins"		Receptor		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		lymphoid tissue: 50.0	Cell line enhanced	Detected in many		HL-60: 27.0;NB-4: 23.7;THP-1: 34.1	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in many		neutrophil: 15.6	Low lineage specificity	Detected in many			Low region specificity	Detected in many			Low region specificity	Detected in all			CAB024996	Enhanced		Approved	"Nucleoplasm,Cytosol"	Secreted - unknown location	20000	20000	"Nucleoplasm, Cytosol"		CAB024996: 	unprognostic (1.92e-1)	unprognostic (3.15e-1)	unprognostic (1.65e-2)	unprognostic (9.83e-2)	unprognostic (7.66e-2)	unprognostic (5.15e-2)	unprognostic (3.56e-2)	unprognostic (1.22e-2)	unprognostic (1.41e-2)	unprognostic (8.52e-2)	unprognostic (1.91e-1)	unprognostic (3.04e-1)	unprognostic (1.96e-2)	prognostic favourable (8.35e-4)	unprognostic (2.16e-2)	unprognostic (1.27e-1)	unprognostic (6.51e-3)	17.7	7.6	6.5	13.6	13.8	40.5	24.7	4	6.7	8.6	8.1	7.7	4.6	6.2	7.4	9.4	6.8	7.8	7.4	8.8	6.1	4.9	8.3	11.6	16.8	39.2	10.3	2	7.7	7.7	6.9	5.4	6.2	8.3	6.9	5.7	5.3	7	5.3	5.3	8.6	9.1	8.3	11.2	23.4	7.3	5.3	9.7	50	7.9	3.2	11	6.3	12.8	0.5	3.6	15.6	6.9	1.4	2.4	2	3.6	2.1	1.9	2.4	3.8	2.2	2.4	5.3	3.5	2.5	3.2	2	2.4	3.3	2.2	5.3	5.8	2.6	2.5	1.8	5.3	3.1	0	1.2	1.2	4.4	27	8.4	3.3	3.7	2.2	1.7	2.7	1.4	3.4	2.5	3	3.2	23.7	1	2	0.7	0.4	0.6	2.4	2.7	1.3	0	3.7	3.2	2.6	2.5	34.1	7.4	2	2.8	2.9	1.9	2.8	1.5	1.6	2.8	13.1	2.1	6.7	6.9	6.1	1.1	3.2	0.9	0.4	1.5	1.1	3.6	0.5	2.4	1.8	15.6	1.4	2.9	1.7	0.9	2	6.5	13.8	4	6.7	6.1	4.9	10.3	2	8.3	9.7
IL18R1	"CD218a, IL-1Rrp, IL1RRP"	ENSG00000115604	Interleukin 18 receptor 1	Q13478	2	102311529-102398775	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Inflammatory response	Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		lung: 39.3	Cell line enhanced	Detected in some		HDLM-2: 13.5;HHSteC: 29.2;HMC-1: 19.6;U-937: 31.3	Low cancer specificity	Detected in many			Low region specificity	Detected in many			Cell type enhanced	Detected in many		NK-cell: 26.8	Low lineage specificity	Detected in many			Low region specificity	Detected in single			Low region specificity	Detected in all			HPA007615	Approved		Approved	Mitochondria	Intracellular and membrane			Mitochondria		HPA007615: AB_1851675	unprognostic (3.60e-3)	unprognostic (9.75e-3)	unprognostic (1.12e-3)	unprognostic (3.01e-2)	unprognostic (2.34e-3)	unprognostic (7.11e-2)	unprognostic (2.95e-2)	unprognostic (1.74e-2)	unprognostic (3.59e-1)	unprognostic (7.86e-2)	unprognostic (3.40e-2)	unprognostic (1.70e-1)	prognostic unfavourable (4.52e-4)	unprognostic (2.62e-1)	unprognostic (1.62e-2)	unprognostic (5.71e-2)	unprognostic (2.48e-2)	17.8	2.6	1.4	8.3	1.7	12.5	11.2	0.8	1.3	8.2	8.1	0.7	6.6	5.1	4.2	5.7	4.5	4.5	14.1	10.5	1.7	1.9	7.4	8.8	39.3	29.6	2	0.1	3.3	2.6	0.8	4.6	10.7	1.6	6.3	3.4	5	3	28.4	2.8	3.2	10.7	7.9	1.9	19.5	4.6	2.4	0.4	2.5	3.2	3.2	6.6	8.2	12.9	0.1	6.8	5.5	0.1	26.8	10.6	1.1	0.8	0.2	0	0	0.7	0.7	1.6	0	0.5	0	0.3	0	0.4	0	0	0	0.5	0	1.8	0	13.5	0.7	2.4	0.6	0.1	29.2	5.1	19.6	6.7	1.1	2.1	3.5	4.9	0	0	0	0	0	0.9	0.3	0.5	0	0	0	0.2	0.5	0	0	0.6	0	0.1	0	0.1	0.4	0.6	0.4	2.3	0.4	0	0	0	0.1	31.3	2.3	5.5	0	2.4	4.2	0.1	10.6	0.1	2.4	3	2	0.1	0.4	0.8	4.1	26.8	0	6.8	2.4	1.1	1.4	1.7	0.8	1.3	1.7	1.9	2	0.1	1.6	0.4
IL18RAP	"AcPL, CD218b"	ENSG00000115607	Interleukin 18 receptor accessory protein	O95256	2	102418689-102452565	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	Inflammatory response	Receptor		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level		Tissue enhanced	Detected in many		blood: 34.6;bone marrow: 50.2;lymphoid tissue: 29.8	Cell line enriched	Detected in some	10	U-937: 34.0	Low cancer specificity	Detected in many			Not detected	Not detected			Cell type enhanced	Detected in many		NK-cell: 34.6	Group enriched	Detected in many	108	granulocytes: 22.5;NK-cells: 34.6;T-cells: 22.1	Not detected	Not detected			Not detected	Not detected			CAB025270	Enhanced									CAB025270: 	unprognostic (1.73e-3)	unprognostic (6.27e-3)	unprognostic (5.07e-3)	unprognostic (4.64e-6)	unprognostic (2.90e-1)	unprognostic (1.18e-2)	unprognostic (5.86e-5)	unprognostic (5.09e-3)	unprognostic (4.02e-2)	unprognostic (1.57e-3)	unprognostic (4.78e-2)	unprognostic (5.31e-2)	unprognostic (1.51e-2)	unprognostic (2.71e-1)	unprognostic (6.35e-2)	unprognostic (8.56e-2)	unprognostic (2.73e-2)	3.6	0.3	0.2	6.1	0.5	50.2	0.9	0.3	0.4	1.2	4.8	0.5	0	1.2	1.2	2.1	0.8	3.8	3	2.1	0.2	0.2	0.9	2.6	9.6	16.4	0.9	0	1.1	0.4	0	0.9	0.8	0.2	0.6	0.9	1.5	0.8	0.3	0.6	0.2	8.1	1	1	29.8	1.5	1.3	0	1.3	0.8	0.9	3.5	2.5	1.3	0	0.2	22.5	0	34.6	22.1	2	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2	0	0.5	0	0	0	1.3	3.2	0	0	0	0	0	0	0	0	0	0	1.9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	34	0.2	0	0	6.1	15.7	0	22.1	0	2	4.2	0.1	0	0	0.5	22.5	34.6	0	0.2	0.1	2	0.2	0.5	0.3	0.4	0.2	0.2	0.9	0	0.2	0
IL1R1	"CD121A, D2S1473, IL1R, IL1RA"	ENSG00000115594	Interleukin 1 receptor type 1	P14778	2	102064544-102179874	"Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters"	Inflammatory response	Receptor	"Cancer-related genes, FDA approved drug targets"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in many		ASC diff: 93.4;ASC TERT1: 41.7;HHSteC: 29.3;HSkMC: 115.0	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in some		neutrophil: 4.0	Low lineage specificity	Detected in many			Low region specificity	Detected in many			Low region specificity	Detected in many			"HPA001237, HPA005823, CAB007779, HPA029560"	Approved		Approved	"Nucleoplasm,Vesicles,Plasma membrane,Cytosol"	Secreted to blood	1000000	1000000	"Nucleoplasm, Vesicles"	"Plasma membrane, Cytosol"	"CAB007779: AB_562073, HPA001237: , HPA005823: , HPA029560: "	unprognostic (6.16e-3)	unprognostic (3.55e-2)	unprognostic (3.33e-1)	unprognostic (1.22e-1)	unprognostic (4.26e-2)	unprognostic (7.10e-2)	unprognostic (2.01e-1)	unprognostic (3.36e-2)	unprognostic (1.44e-1)	unprognostic (3.16e-1)	unprognostic (4.26e-2)	unprognostic (7.77e-2)	prognostic unfavourable (6.92e-6)	unprognostic (2.48e-2)	unprognostic (6.95e-2)	unprognostic (4.83e-2)	unprognostic (7.73e-2)	48.6	25.2	2.6	18.2	5.2	4	92.4	2.4	3.9	47.8	21	2.5	34.3	5.2	15.2	30.2	18.2	17.1	25.8	27	4.2	2.5	23.7	74.8	40.5	28	5.6	1.1	25.1	17.1	16.9	7.3	66.2	10.9	26	8.4	8.6	12.7	36.4	15.5	13.5	13	15.1	10	19.2	15.6	13.4	2.8	3.5	33.6	9	9.6	32	36.4	0.1	0.1	4	0.5	0.8	1.8	0.2	0.2	1.8	0	1.5	93.4	41.7	0.6	3.9	17.7	2.8	4.2	0.8	0.4	0	2.9	7.8	0.7	0	0.3	2.3	7.7	0	0.1	0.4	4.3	29.3	0	0	115	0.3	3.1	0.7	1.2	0.4	0.1	4	0.7	0	0.1	0.1	0.1	0	0.2	0	2.6	1.9	0	0	1.7	1.1	0	1.6	0.1	0	8	0.5	13.4	0.3	0	0	0	3.1	0	0.5	0.6	0.5	0.1	0	0	0.7	0.1	1.1	0	0.1	0.1	0	0.1	4	0.8	0	0.1	1.8	0.2	2.6	5.2	2.4	3.9	4.2	2.5	5.6	1.1	10.9	2.8
IL1R2	"CD121b, IL1RB"	ENSG00000115590	Interleukin 1 receptor type 2	P27930	2	101991844-102028544	"Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"		Receptor	Cancer-related genes	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 73.2;lymphoid tissue: 74.1	Cell line enriched	Detected in some	19	HDLM-2: 100.0	Low cancer specificity	Detected in many			Region enriched	Detected in many	4	midbrain: 9.2	Cell type enriched	Detected in some	25	neutrophil: 73.2	Lineage enriched	Detected in many	25	granulocytes: 73.2	Low region specificity	Detected in many			Not detected	Not detected			"HPA027597, HPA027598"	Uncertain				Secreted to blood	21000000	21000000			"HPA027597: AB_10600768, HPA027598: AB_10601229"	unprognostic (3.54e-2)	unprognostic (1.87e-1)	unprognostic (1.21e-1)	unprognostic (3.83e-2)	unprognostic (6.59e-2)	unprognostic (1.42e-1)	unprognostic (6.36e-2)	unprognostic (4.82e-3)	unprognostic (1.62e-2)	unprognostic (7.15e-2)	unprognostic (8.20e-3)	unprognostic (1.07e-1)	prognostic unfavourable (5.58e-12)	unprognostic (1.92e-1)	unprognostic (7.51e-2)	unprognostic (1.77e-1)	unprognostic (6.62e-2)	9.1	3.2	1.2	16.4	1.9	22.3	1.6	1.2	1.9	6.4	13.4	0.4	0.1	0.1	1.3	1.3	20.4	9.7	3.4	15.1	1.2	0.5	5.8	8.2	25.5	74.1	9.2	0.2	2.5	1.4	0	2.4	24.9	2.2	1.1	20	1.8	4.3	0.8	2.8	14.1	2.2	1.3	4.4	47.5	14.6	1.6	1.1	1.6	1.8	8.5	25.1	3.2	9.1	0	2.8	73.2	0.8	0	1.1	0.2	1.5	0.1	0	0	0.2	0.2	0.1	0	0	0	0	1.6	0	0	3.3	0	0.6	0	0.1	0	100	0.1	0	0	0.8	0.5	0	0	2.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5.2	0.3	0	0	0	0	0.1	0	0	0	0.2	0	1.6	0	0	0	0	0.1	0	0	0	0.8	0	0	0.4	0	0	0.1	0	2.8	0	0	0	73.2	0	0	0	1.1	0.2	1.2	1.9	1.2	1.9	1.2	0.5	9.2	0.2	2.2	1.1
IL21R	CD360	ENSG00000103522	Interleukin 21 receptor	Q9HBE5	16	27402162-27452042	"Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins"		Receptor	"Cancer-related genes, Disease mutation"	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	6	blood: 17.9;lymphoid tissue: 47.8	Cell line enhanced	Detected in some		Daudi: 10.1;HDLM-2: 42.9;Karpas-707: 19.9;RH-30: 15.1;RPMI-8226: 24.0;U-266/70: 10.0	Low cancer specificity	Detected in many			Low region specificity	Detected in many			Low cell type specificity	Detected in many			Low lineage specificity	Detected in many			Low region specificity	Detected in many			Low region specificity	Detected in all			HPA042296	Uncertain		Uncertain	"Plasma membrane,Cytosol"				"Plasma membrane, Cytosol"		HPA042296: AB_10806236	unprognostic (2.91e-2)	unprognostic (2.65e-3)	unprognostic (6.64e-4)	unprognostic (1.58e-3)	unprognostic (2.14e-1)	prognostic favourable (7.29e-4)	unprognostic (8.33e-2)	unprognostic (2.06e-1)	unprognostic (8.50e-6)	unprognostic (2.26e-2)	unprognostic (1.13e-2)	unprognostic (8.71e-2)	unprognostic (2.34e-10)	unprognostic (8.79e-2)	unprognostic (4.42e-2)	unprognostic (1.50e-1)	unprognostic (9.58e-2)	0.8	0.6	0.6	33.6	3.7	5.7	0.6	0.5	1.6	0.5	0.9	0.3	0	0.5	0.5	1.3	1	0.8	1.1	1.8	0.6	2.3	1.6	1.3	5.6	20.9	1.3	0	0.5	0.5	0	0.9	0.9	1.9	0.9	0.9	1.8	3.7	0.3	0.7	0.7	4	0.6	1.7	11.2	1.3	1	1.4	47.8	1.3	0.8	31.7	2.7	0.8	11.5	1.6	0.7	17.9	6.3	10.3	4.2	0	0	0.1	0.1	0	0.5	0.3	0.3	0	0	0.9	0	0	10.1	0.1	0.8	0	0	0	0	42.9	0	2.1	0	0.2	1.4	0	0.6	1.5	0	2.7	0	0	0.1	19.9	1.5	0	0	0.2	0.3	0	0.1	15.1	24	0	0	0.1	0	0	0	1.1	0	0.5	1.1	0.8	0.2	0.2	0	10	3.5	2.3	2.1	0.5	0	0.2	0.3	0	9.8	5.8	3.6	1	6.3	10.3	1.6	11.5	6.9	6.7	0.7	6.3	17.9	0.7	7.6	4.2	0.6	3.7	0.5	1.6	0.6	2.3	1.3	0	1.9	1.4
IL2RA	"CD25, IDDM10, IL2R"	ENSG00000134460	Interleukin 2 receptor subunit alpha	P01589	10	6010689-6062370	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Immunity	Receptor	"Cancer-related genes, Diabetes mellitus, Disease mutation, FDA approved drug targets"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	4	adipose tissue: 16.5;blood: 55.4;lymphoid tissue: 56.7	Cell line enriched	Detected in some	59	HDLM-2: 153.9	Low cancer specificity	Detected in many			Region enhanced	Detected in single		pons and medulla: 2.4	Group enriched	Detected in many	6	basophil: 30.3;T-reg: 55.4	Group enriched	Detected in many	12	granulocytes: 30.3;T-cells: 55.4	Low region specificity	Detected in many			Low region specificity	Detected in all			"CAB002419, HPA054622"	Enhanced					110000	110000			"CAB002419: AB_563538, HPA054622: "	unprognostic (2.82e-1)	unprognostic (8.10e-3)	unprognostic (1.75e-2)	unprognostic (5.86e-2)	unprognostic (1.50e-1)	unprognostic (1.45e-3)	unprognostic (2.78e-2)	unprognostic (2.73e-1)	unprognostic (5.03e-2)	unprognostic (6.32e-2)	unprognostic (7.21e-2)	unprognostic (2.07e-1)	prognostic unfavourable (2.08e-9)	unprognostic (2.10e-2)	unprognostic (4.66e-2)	unprognostic (2.22e-1)	unprognostic (5.10e-2)	16.5	2.5	0.3	10.9	0.6	0.1	1.4	0.3	0.3	0.6	3.1	0.1	0	1.3	0.8	4.9	1.9	0.8	2.2	1.9	0.4	0.5	2.6	1.3	4	50.4	0.5	0	0.6	1	0	1.8	1.8	2.4	1.1	1.6	3.4	2.2	0.5	0.8	0.6	10.3	3.5	2.2	56.7	1.4	0.4	0	4.5	4.2	2	16.8	5	0.6	3.6	0	30.3	0	2.9	55.4	0.7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	153.9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0.1	0	0	0	0	0.1	0	0	2.6	0	0	0	30.3	0	4.5	0.1	0	0.5	3.6	6.8	0.7	0	1.5	0.5	0	0.2	2.9	0	0	55.4	0.7	0.3	0.6	0.3	0.3	0.4	0.5	0.5	0	2.4	0
IL2RB	"CD122, IL15RB"	ENSG00000100385	Interleukin 2 receptor subunit beta	P14784	22	37125838-37175054	"Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	Host-virus interaction	Receptor	"Cancer-related genes, FDA approved drug targets"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 51.6;lymphoid tissue: 35.0;placenta: 58.5	Cell line enriched	Detected in some	8	HDLM-2: 104.1	Low cancer specificity	Detected in all			Not detected	Not detected			Group enriched	Detected in many	4	gdT-cell: 14.7;NK-cell: 51.6	Group enriched	Detected in many	32	NK-cells: 51.6;T-cells: 14.7	Region enriched	Detected in single	7	basal ganglia: 1.6	Low region specificity	Detected in all			HPA062657	Enhanced									HPA062657: 	unprognostic (3.38e-3)	unprognostic (1.21e-2)	prognostic favourable (6.76e-4)	prognostic favourable (3.18e-5)	unprognostic (2.44e-2)	unprognostic (9.69e-3)	unprognostic (2.60e-1)	unprognostic (5.22e-2)	unprognostic (1.03e-3)	unprognostic (5.37e-2)	unprognostic (1.09e-1)	unprognostic (2.74e-1)	prognostic unfavourable (3.50e-7)	unprognostic (4.63e-2)	unprognostic (7.96e-2)	unprognostic (3.94e-3)	unprognostic (2.46e-2)	2.2	1	0.8	20.5	0.8	12.3	1.6	0.6	0.7	1.3	5.5	0.6	1.4	1.8	4.3	2.8	2.6	1.8	5.8	3.7	0.7	0.8	1.9	6	7.4	20.8	0.8	0.2	1.5	1	0	1.1	58.5	0.7	3.5	1.8	2.9	3.7	2.1	0.9	4	7.3	0.6	1.1	35	2.3	1.1	0.2	21	2.1	1.8	28.7	4	1.5	0.3	0	1	0.1	51.6	14.7	7.9	0	0	0.2	0	0	0	0.3	0	0	0	0	0	0	0	4.6	0	0	0	0	0	104.1	0.1	0.2	0	0	0	0	5.1	0	0	0	0	0	0	0.2	0	0.1	0	0.8	0.6	0	0	0	0.2	0	0	0	0	0	0	0.1	0	0.1	0	0	2.8	0	0.1	7.5	12.8	0	0.1	0	0.1	1	0	0.1	14.7	0.1	8.1	0.1	3.3	8.2	0	0.3	1.1	4.3	0.3	51.6	0.1	0	6.8	7.9	0.8	0.8	0.6	0.7	0.7	0.8	0.8	0.2	0.7	0.2
IL2RG	"CD132, CIDX, IMD4, SCIDX1"	ENSG00000147168	Interleukin 2 receptor subunit gamma	P31785	X	71107404-71112108	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	Host-virus interaction	Receptor	"Cancer-related genes, Disease mutation, FDA approved drug targets, SCID"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	5	blood: 115.3;lymphoid tissue: 169.3	Cell line enriched	Detected in some	6	Karpas-707: 220.5	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all											"HPA046641, HPA049691"	Enhanced		Approved	Vesicles				Vesicles		"HPA046641: AB_2679733, HPA049691: "	unprognostic (2.97e-3)	unprognostic (4.24e-2)	unprognostic (1.23e-1)	prognostic favourable (1.73e-4)	unprognostic (8.25e-2)	unprognostic (1.93e-3)	unprognostic (1.37e-1)	unprognostic (1.53e-1)	unprognostic (1.91e-3)	unprognostic (1.23e-2)	unprognostic (4.36e-1)	unprognostic (1.45e-1)	prognostic unfavourable (2.28e-7)	unprognostic (1.73e-1)	unprognostic (4.69e-2)	unprognostic (4.89e-2)	unprognostic (9.54e-2)	5.8	1.3	1.4	39.5	1.4	12.8	3.6	0.8	0.9	2.9	16.6	0.9	0.9	8.2	3	2.1	5.3	3.1	5.3	2.6	1.4	1.5	3.7	4.7	13.6	70.4	1.8	0.6	2.9	1.5	0	1.2	5.3	1.5	3.2	20.8	2.9	10.4	1.8	1.6	2.7	28.6	1.5	2.9	58.7	6	2	0.9	169.3	3.3	4.2	61.4	7.6	3.1	51.9	30.6	65.6	19.7	94.6	115.3	99	0.1	0	0	0	0	0	0	0	0	0	0	0.3	0.8	17.2	1.2	0	0.1	0	0	0	14.4	0	2.2	0	0	0	8.9	0.4	0	0	0	0	0	3.8	220.5	0	0	31.9	17.4	0	0	7.3	0	1.8	0	0	0	0	0.2	0	0	0	0.3	0	0	0.1	0	0	12.6	22.2	11.1	0.2	37	0	35.2	8.5	13.4	107.2	19.7	105.6	51.9	97.7	110.4	20.3	51.6	68	84.9	65.6	94.6	13.5	30.6	115.3	99	1.4	1.4	0.8	0.9	1.4	1.5	1.8	0.6	1.5	0.9
IL3RA	CD123	ENSG00000185291	Interleukin 3 receptor subunit alpha	P26951	X	1336616-1382689	"CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	FDA approved drug targets	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	6	blood: 163.1;breast: 50.7;vagina: 65.4	Cell line enhanced	Detected in some		HDLM-2: 47.8;NB-4: 9.2;RPMI-8226: 19.5	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Group enriched	Detected in many	16	basophil: 163.1;plasmacytoid DC: 49.1	Group enriched	Detected in many	33	dendritic cells: 49.1;granulocytes: 163.1									"HPA003539, CAB018374"	Uncertain									"CAB018374: AB_2233620, HPA003539: AB_1078438"	prognostic favourable (9.78e-4)	prognostic favourable (4.27e-4)	unprognostic (8.13e-2)	unprognostic (9.32e-2)	unprognostic (2.09e-1)	unprognostic (1.29e-3)	unprognostic (1.32e-1)	unprognostic (1.67e-1)	unprognostic (1.38e-1)	unprognostic (3.73e-2)	unprognostic (5.77e-3)	unprognostic (1.43e-1)	unprognostic (1.50e-3)	unprognostic (9.41e-2)	unprognostic (2.85e-3)	unprognostic (2.49e-1)	unprognostic (1.46e-1)	14.9	1.2	7.8	7.7	7.8	12.1	50.7	5	10.1	9.7	4.6	1.5	1.5	2.4	13.8	1.5	2.8	4.2	5.6	9.2	11.1	2.4	5.4	1.5	15.9	12.3	8.5	3.9	7.6	2.6	0.6	3.7	9.3	10.9	4.4	3.1	1.5	5.6	1.5	5.7	6.8	5.4	6.1	7.6	5.3	4.2	1.5	7.9	1.5	7	1.5	6.4	6.8	65.4	0.7	49.1	163.1	3.2	1.1	0	0.7	0.1	3.9	1.5	0.5	0	0	0.5	0.5	0.1	0	0	0.3	0.6	0.5	2.7	0	3.8	0	0	0	47.8	1.6	0.2	0.7	0.1	0	0.3	6.6	0	0	0	0	3.1	0.1	2.5	0	0.6	0.2	9.2	1.2	0.2	0.5	1.7	19.5	0	0.5	0.2	0.1	0.2	0.1	1.1	0.5	7.3	0.1	0.2	0.6	0.2	0.1	5.2	1.4	0.4	4.3	1.1	0	163.1	0.4	6.7	0	2.4	0	0.2	0	0	1.1	0.7	0	0	0.3	1.1	3.2	49.1	0	0.7	7.8	7.8	5	10.1	11.1	2.4	8.5	3.9	10.9	7.9
IL4R	CD124	ENSG00000077238	Interleukin 4 receptor	P24394	16	27313668-27364778	"Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	Immunity	Receptor	"Cancer-related genes, FDA approved drug targets"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in many		Daudi: 35.8;HBEC3-KT: 34.4;U-698: 33.3	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in many		naive B-cell: 34.4	Group enriched	Detected in all	6	B-cells: 34.4;granulocytes: 11.9	Low region specificity	Detected in many			Low region specificity	Detected in many			"CAB004451, HPA050124, HPA070380"	Enhanced		Supported	"Nucleoplasm,Plasma membrane,Centriolar satellite"	Secreted to blood	49000	49000	Plasma membrane	"Nucleoplasm, Centriolar satellite"	"CAB004451: AB_626889, HPA050124: , HPA070380: "	unprognostic (6.80e-2)	unprognostic (6.35e-2)	unprognostic (2.84e-1)	prognostic favourable (6.43e-4)	unprognostic (1.12e-1)	unprognostic (1.14e-1)	unprognostic (2.33e-2)	unprognostic (1.95e-3)	unprognostic (1.34e-1)	unprognostic (1.54e-1)	unprognostic (2.41e-1)	unprognostic (1.97e-1)	prognostic unfavourable (1.23e-5)	unprognostic (1.49e-2)	unprognostic (1.73e-1)	unprognostic (1.36e-1)	unprognostic (9.58e-2)	20.7	14.8	8.7	31.6	10.6	36.9	12	4.4	7.7	20.8	30.3	5.9	11.5	10.9	18	12.8	24.7	13.6	25.1	12.3	6.7	4.4	13.3	39.1	40.9	44.8	10.8	1.7	14.7	11.3	3.8	5.5	16.1	10.1	18.8	15.1	12.3	7.7	11.5	7.2	9.9	18.6	39.6	13.6	31.8	21.1	10.4	9.8	9.1	8.6	13.7	38.4	31.6	15.4	34.4	1.6	11.9	2.6	3.3	4	1.8	11.3	3	1.9	3.9	0.9	4.5	4.1	7.2	8.3	2.9	2.3	6.1	31.4	35.8	9	11.3	12.1	2.1	34.4	2.5	31	1	6.7	1.8	9.3	13	1.8	19.1	6.9	13.9	13.2	7.9	15.4	2.9	3	4.6	5	0.1	5.4	2.4	2.6	0.1	14.9	2.9	13.3	13	0.6	0.3	1	6.9	1.5	2.6	6.9	23	6.5	2.9	5.8	5	1.8	0.5	33.3	0.7	6	0	0.5	2.6	4.7	1.7	1.1	1.3	7.7	2.6	1.7	1.6	34.4	4	1.9	11.9	3.3	0.6	1.6	1.8	1.8	8.7	10.6	4.4	7.7	6.7	4.4	10.8	1.7	10.1	9.8
IL5RA	"CD125, CDw125, IL5R"	ENSG00000091181	Interleukin 5 receptor subunit alpha	Q01344	3	3066326-3126613	"CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	FDA approved drug targets	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 70.1;fallopian tube: 18.6	Cell line enriched	Detected in some	30	HMC-1: 41.0	Cancer enhanced	Detected in some		prostate cancer: 1.4	Low region specificity	Detected in many			Group enriched	Detected in some	196	basophil: 31.4;eosinophil: 70.1	Lineage enriched	Detected in single	308	granulocytes: 70.1	Not detected	Not detected			Low region specificity	Detected in many								Intracellular and membrane	92000	92000				unprognostic (1.38e-3)	unprognostic (2.26e-2)	unprognostic (2.66e-1)	unprognostic (6.13e-3)	unprognostic (2.66e-1)	unprognostic (1.54e-3)	unprognostic (7.79e-3)	unprognostic (8.42e-2)	unprognostic (2.83e-1)	unprognostic (1.67e-1)	unprognostic (9.84e-4)	unprognostic (4.32e-3)	unprognostic (3.08e-2)	unprognostic (6.95e-2)	unprognostic (2.20e-1)	unprognostic (7.49e-2)	unprognostic (4.93e-2)	0.5	0.2	6.7	0.6	6.2	0.7	1.3	0.2	0.3	1.8	0.9	1.8	0	2.2	0.6	8.2	0.6	18.6	2	2.4	2.3	2.1	0.6	1.3	7.9	1.2	0.1	0	3.8	0.5	0.1	7.5	0.1	11.8	2.6	1.4	0.5	2.2	0.1	0.3	0.4	2.1	0.6	0.6	4.6	1.3	1.6	0.7	1.1	0.4	1.1	1.9	4.2	0.4	0.1	0	70.1	0	0	0.2	0.1	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0.2	0	0	0	1.3	41	0	0	0	0	0	0	0.6	0	0.1	0	1.3	0	0	0	0	0.1	0.1	0	1.1	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	31.4	0	70.1	0.2	0	0	0.1	0.2	0.1	0	0.1	0	0.1	0.2	0	0	0	0	0.1	6.7	6.2	0.2	0.3	2.3	2.1	0.1	0	11.8	0.7
IL6R	CD126	ENSG00000160712	Interleukin 6 receptor	P08887	1	154405193-154469450	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Cancer-related genes, FDA approved drug targets"	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		skeletal muscle: 59.6	Cell line enhanced	Detected in many		THP-1: 54.6;U-266/84: 64.3	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in many		neutrophil: 35.0	Low lineage specificity	Detected in many			Low region specificity	Detected in many			Low region specificity	Detected in all								Intracellular and membrane	22000000	22000000				unprognostic (1.19e-1)	unprognostic (3.97e-1)	unprognostic (1.19e-1)	unprognostic (1.08e-1)	unprognostic (1.95e-1)	unprognostic (4.47e-2)	unprognostic (1.01e-1)	unprognostic (1.05e-2)	unprognostic (3.27e-1)	unprognostic (6.42e-2)	prognostic favourable (1.65e-4)	unprognostic (7.94e-2)	unprognostic (1.05e-1)	unprognostic (7.75e-2)	unprognostic (1.51e-1)	unprognostic (3.35e-1)	unprognostic (1.07e-1)	8.4	4	4.7	14.8	5.1	9	6.5	1.4	6.3	6.1	16.9	4.8	1.2	9.6	6.3	4.7	5.2	7.9	6.9	5	5.2	2.9	8.9	38.1	20.8	15.4	7.2	2.2	5.7	5.3	0	7.7	3.7	7.8	4.5	6	3.6	5.4	1.7	59.6	4.7	12.6	5.3	5	11.3	6.6	3.7	5	4.2	2.5	6.1	13.3	6.3	4.8	0.6	14.3	35	11.7	0.5	8	5.5	0.8	1.4	0.1	0.1	0.9	1.3	0.1	0.8	0.6	0.5	0.2	0.1	0.9	0	1.9	1	0.4	0.2	4.4	0.4	14.7	0.4	0.2	0.6	3.3	0.1	2.3	1.3	0.7	2.7	0.4	6.6	0.6	0.1	6.1	0.1	0.3	0	3.8	0.4	3.3	0	0	12.7	2.7	1.1	0.1	0	0.2	9	14.8	0.8	54.6	0.6	0.9	0.9	0.8	0.5	10.4	64.3	0.1	1.1	14.8	1.4	2.8	11.7	10.4	0.2	7.1	0.6	0.6	6.4	0.7	14.3	0.2	6.4	2.2	35	0.5	3	5.1	8	5.5	4.7	5.1	1.4	6.3	5.2	2.9	7.2	2.2	7.8	5
IL6ST	"CD130, GP130"	ENSG00000134352	Interleukin 6 signal transducer	P40189	5	55935095-55994993	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"	Host-virus interaction	Receptor	Cancer-related genes	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in many		ASC TERT1: 57.0;BJ hTERT+: 58.0;HHSteC: 64.9	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in many		naive CD4 T-cell: 21.0	Lineage enriched	Detected in many	5	T-cells: 21.0	Low region specificity	Detected in all			Low region specificity	Detected in all			"HPA010558, CAB025784"	Approved		Supported	"Golgi apparatus,Plasma membrane"	Secreted to blood	100000000	100000000	Plasma membrane	Golgi apparatus	"CAB025784: , HPA010558: AB_1078439"	unprognostic (1.81e-2)	unprognostic (1.25e-1)	unprognostic (7.61e-2)	unprognostic (3.95e-2)	unprognostic (8.93e-2)	unprognostic (3.99e-2)	unprognostic (5.18e-2)	unprognostic (9.53e-3)	unprognostic (1.89e-2)	unprognostic (2.29e-1)	unprognostic (4.78e-2)	unprognostic (1.59e-1)	prognostic unfavourable (5.05e-4)	unprognostic (3.69e-2)	unprognostic (1.06e-1)	unprognostic (1.80e-1)	unprognostic (1.25e-1)	44.8	34.2	24.7	25.5	23.4	8.8	76.9	15.9	22.9	38.1	23.9	15	29	8.7	26.1	24.9	22.7	23.1	31.1	31.9	21.9	19.7	37.2	71.2	36.3	70	25.8	14.7	42.1	16.4	35.8	36.2	97	22.5	31.9	17.1	20	26.3	33	27.1	12.5	20.6	36.6	33.8	35.5	19.7	13.7	20.3	19.4	37.6	12.5	18.7	33.7	51.1	0.7	2.1	0.9	3.8	0.8	21	4	9.4	11.8	3.8	9.1	27.3	57	15.8	28.2	58	15.2	22.7	16.5	9	0.3	21.1	17.4	4.1	3	8.4	31.2	0.8	3	2.2	9.7	13.6	64.9	0.2	4.5	49.9	4.6	33	16.1	34.7	1.6	39.8	17.5	1.6	0.4	0.4	0.6	3.9	0.5	10.7	5.4	8.3	5.6	2	3.4	11.4	3.8	11.6	19	1.5	55.7	5.9	6.7	23.8	14.8	9.8	4.2	0.3	15.8	0.4	15.3	0.2	3.8	0.1	0.8	3.5	0.4	0.7	4.9	0.8	2.1	0.6	21	5.9	0.9	0.8	0.6	1.8	3.4	4	24.7	23.4	15.9	22.9	21.9	19.7	25.8	14.7	22.5	20.3
IL7R	CD127	ENSG00000168685	Interleukin 7 receptor	P16871	5	35852695-35879603	"Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Cancer-related genes, Disease mutation, SCID"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	5	blood: 70.3;intestine: 34.0;lung: 52.6;lymphoid tissue: 133.1	Cell line enhanced	Detected in many		BJ: 21.7;fHDF/TERT166: 40.7;HBF TERT88: 37.4;REH: 84.6	Low cancer specificity	Detected in all			Not detected	Not detected			Group enriched	Detected in many	5	gdT-cell: 19.2;MAIT T-cell: 70.3;memory CD4 T-cell: 39.9;memory CD8 T-cell: 28.0;naive CD4 T-cell: 34.5;naive CD8 T-cell: 22.5;NK-cell: 19.1	Group enriched	Detected in many	33	NK-cells: 19.1;T-cells: 70.3	Low region specificity	Detected in single			Low region specificity	Detected in single			CAB010215			Supported	"Plasma membrane,Centriolar satellite"	Intracellular and membrane	180000	180000	"Plasma membrane, Centriolar satellite"		CAB010215: AB_673727	unprognostic (2.93e-3)	unprognostic (3.38e-2)	unprognostic (3.82e-3)	unprognostic (5.58e-3)	unprognostic (3.06e-2)	unprognostic (1.74e-1)	unprognostic (2.51e-3)	unprognostic (5.53e-2)	unprognostic (1.12e-1)	unprognostic (9.29e-3)	unprognostic (1.43e-1)	unprognostic (2.69e-1)	unprognostic (1.76e-2)	unprognostic (5.64e-2)	unprognostic (3.27e-3)	unprognostic (2.22e-1)	unprognostic (1.78e-1)	6.7	3.6	0.7	34	0.7	3.1	4.8	0.5	0.6	4.8	20.6	0.3	0.9	3.5	1.8	2.9	6.6	3.7	8.5	1.9	0.7	0.7	7	2.7	52.6	133.1	0.8	0.1	2.5	1.7	0	1.5	1.2	0.8	3.3	5.4	1.7	13.2	1.8	0.9	1.8	34	1.2	1.5	32.3	7.8	3	0.4	130.9	5.1	5.3	42.9	12.6	4.6	0.4	0.3	1.3	0.2	19.1	70.3	12.7	0.1	0	0.1	0.1	0.1	0.1	0.2	21.7	11	19.6	11.6	0.1	0.1	2.1	0	40.7	3.5	0	1.3	37.4	1.8	0.2	0.6	2.3	0	0.3	0.1	1.5	0.3	0	4.2	0.9	0.5	0.1	0.3	15.4	0	0.5	0.2	0.1	1	84.6	1.1	0.1	0	1.2	0	0	3.6	0.3	0	0.1	0	1.5	7.7	13.1	3.3	2.8	0.1	0	2.4	3.9	2	5.9	0.5	0.2	0.1	19.2	0.2	70.3	0.2	39.9	28	0.1	0.4	34.5	22.5	1.3	19.1	0.2	0.3	6.7	12.7	0.7	0.7	0.5	0.6	0.7	0.7	0.8	0.1	0.8	0.4
IL9R	CD129	ENSG00000124334	Interleukin 9 receptor	Q01113	X	155997581-156010817	"CD markers, Predicted membrane proteins"		Receptor		Evidence at protein level	Evidence at protein level	Evidence at transcript level	Evidence at protein level		Tissue enhanced	Detected in some		blood: 6.3;urinary bladder: 10.9	Cell line enriched	Detected in some	11	HMC-1: 74.2	Cancer enhanced	Detected in some		urothelial cancer: 1.4	Group enriched	Detected in some	6	basal ganglia: 1.7;pons and medulla: 4.7;thalamus: 1.5	Cell type enhanced	Detected in many		eosinophil: 6.3	Group enriched	Detected in many	25	B-cells: 4.1;granulocytes: 6.3;T-cells: 2.4	Not detected	Not detected			Low region specificity	Detected in many			"HPA063240, HPA064557"	Approved				Intracellular and membrane					"HPA063240: , HPA064557: "	unprognostic (1.07e-2)	unprognostic (3.27e-3)	unprognostic (9.52e-3)	unprognostic (4.13e-2)	unprognostic (7.35e-2)	unprognostic (3.26e-4)	unprognostic (8.94e-2)	unprognostic (3.56e-2)	unprognostic (2.01e-1)	unprognostic (1.82e-1)	unprognostic (2.90e-2)	unprognostic (2.04e-1)	unprognostic (3.98e-8)	unprognostic (2.06e-1)	unprognostic (2.38e-1)	unprognostic (4.07e-1)	prognostic favourable (1.90e-7)	0.3	0.1	0.3	1.1	1.7	0.4	0.3	0.4	0.3	0.3	0.3	0.3	0.3	0.7	3	0.3	0.5	0.4	0.9	0.3	0.3	0.2	0.3	0.5	1.3	3.2	0.3	0.3	0.3	0.3	0	0.3	0.3	4.7	0.4	1.2	0.3	0.4	0.3	0.3	0.4	2.4	0.3	0.3	3.5	0.8	0.3	1.5	0.3	0.4	0.3	2.9	10.9	0.3	4.1	0	6.3	0	0.1	2.4	0.3	0	0	0	0.1	0	0	0.1	0	0	0	0	0	0.1	0	0	0	0.1	0	0	0	0.1	0.1	6.8	0	0	0	0.1	74.2	0	0	0	0	0	1	0.2	0	0.3	2.6	1.3	0	0	0.1	0	0	0	5.5	0	0	0	0.1	0	0	0.1	0	0	0.1	0	0	0.3	0.1	0.2	0	0.1	0	0	0	6.3	0	0	0	1.8	0.8	1.3	0	4.1	0	0	1.8	0.1	0	0	2.4	0.3	0.3	1.7	0.4	0.3	0.3	0.2	0.3	0.3	4.7	1.5
INSR	CD220	ENSG00000171105	Insulin receptor	P06213	19	7112255-7294034	"CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"	Carbohydrate metabolism	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Diabetes mellitus, Disease mutation, FDA approved drug targets"	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		pancreas: 64.5	Cell line enhanced	Detected in many		Karpas-707: 30.6;U-266/70: 22.6	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in many			Group enriched	Detected in many	7	dendritic cells: 8.8;granulocytes: 5.1;monocytes: 10.5	Low region specificity	Detected in all			Low region specificity	Detected in all			"HPA036302, HPA036303"	Uncertain		Approved	"Vesicles,Plasma membrane"		72000	72000	Vesicles	Plasma membrane	"HPA036302: , HPA036303: "	unprognostic (4.64e-2)	unprognostic (2.42e-1)	unprognostic (9.65e-3)	unprognostic (9.70e-2)	unprognostic (1.44e-1)	unprognostic (1.15e-2)	unprognostic (2.58e-1)	unprognostic (5.09e-2)	unprognostic (1.97e-1)	unprognostic (3.05e-1)	unprognostic (9.29e-2)	unprognostic (1.86e-1)	unprognostic (6.33e-2)	unprognostic (3.45e-3)	unprognostic (2.43e-1)	unprognostic (2.75e-1)	unprognostic (8.82e-2)	13.9	14.7	7.1	3.5	8.2	4.5	12	12	8.2	10.3	15.2	11.7	10.6	8.4	15.5	6.1	4.7	13.1	7.7	17.7	6.4	5.8	18.7	32.5	5.3	2.2	10.1	4.9	28.3	64.5	11.6	11.6	26.2	8	10.5	8.9	11	12	10.6	15.1	7.3	16	10.6	6.8	47.3	8.7	6.9	9.7	2.2	17.1	5	3.2	11.3	16	1.1	8.8	5.1	10.5	0.8	0.7	1.3	3.7	2.1	1.9	2.9	10.6	3.7	6.4	2.1	1.9	1.2	1.2	5.3	4.3	4.7	5.3	3.8	1	4.6	0.9	0.7	0	3.7	0	1.5	11.5	4.6	2.2	3.8	5.7	2.4	0.1	2.8	2.1	5.7	30.6	0.9	1.7	1.6	3.8	1.8	3.3	16.3	1.1	4.1	0.1	15.5	3.7	2.8	3.8	2	2.1	0.9	10.8	2	2.2	1.4	4.7	2.8	22.6	12.3	10.9	2.6	3.8	0	2	8.2	5.1	0.2	7.8	0.3	0.8	0.3	0.1	8.8	1.1	0.7	0.1	1.7	0.8	10.5	7.4	0	1.3	7.1	8.2	12	8.2	6.4	5.8	10.1	4.9	8	9.7
ITGA1	"CD49a, VLA1"	ENSG00000213949	Integrin subunit alpha 1	P56199	5	52787896-52959210	"Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Transporters"	Cell adhesion	"Integrin, Receptor"	Cancer-related genes	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in many			Cell line enhanced	Detected in many		fHDF/TERT166: 21.0;HHSteC: 25.8;WM-115: 19.1	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in some		memory CD8 T-cell: 1.8	Group enriched	Detected in many	5	granulocytes: 1.2;T-cells: 1.8	Low region specificity	Detected in all			Low region specificity	Detected in all			HPA042555	Uncertain					2300000	2300000			HPA042555: AB_10794281	unprognostic (1.48e-1)	unprognostic (1.07e-2)	unprognostic (2.44e-1)	unprognostic (1.33e-1)	unprognostic (1.38e-1)	unprognostic (9.89e-3)	unprognostic (2.74e-1)	unprognostic (1.72e-1)	unprognostic (1.79e-3)	unprognostic (1.50e-2)	unprognostic (2.62e-1)	unprognostic (9.86e-2)	prognostic unfavourable (2.24e-4)	unprognostic (3.13e-3)	unprognostic (2.06e-2)	unprognostic (1.07e-2)	unprognostic (1.62e-2)	22.6	20.2	2.3	12.7	2.7	0	12.4	1.2	2.9	10.9	28.2	1.5	13.6	5.3	15.9	12.5	22.3	9.2	13.9	11.1	2.5	2.2	17.9	40.4	28.8	10.2	3.1	1.4	9.6	3.3	11.5	3	24.8	3.3	26.1	8.2	5.9	2.9	18.2	9.7	2.4	13.5	52.8	2.7	66	16.8	4.1	1.6	0.6	10.7	3.5	2.2	42.7	17.8	0	0.1	1.2	0.3	0	1.8	0.1	0	0	2	0	5.8	1.7	1.2	2.7	7.2	1.6	4.8	3.7	0.3	0	0.9	21	1.4	0.4	2.3	1.5	0	1.5	0	3.4	2.7	25.8	0	0	3.9	0.2	1.9	0.7	0.3	0	0	2.4	0	0.8	0	1.1	0.7	0	1.9	0	3.1	0	0.1	9.1	2.7	0.6	0.6	0	0	2.1	4.4	0.4	0.1	1.4	0	0	0	2.8	0	19.1	0	0.3	1.1	0.1	0	0	0	0.6	1.8	0.1	0	0.2	0	1.2	0	0	0	0.1	0.1	2.3	2.7	1.2	2.9	2.5	2.2	3.1	1.4	3.3	1.6
ITGA2	CD49b	ENSG00000164171	Integrin subunit alpha 2	P17301	5	52989326-53094779	"Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Integrin, Receptor"	Cancer-related genes	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in many			Cell line enhanced	Detected in many		BJ hTERT+: 30.1;HaCaT: 30.4;HUVEC TERT2: 28.0;TIME: 23.9	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in some			Low lineage specificity	Detected in many			Not detected	Not detected			Low region specificity	Detected in many			"CAB017690, HPA060991, HPA063556"	Enhanced		Approved	"Nucleoplasm,Cytosol"		46000000	46000000	Nucleoplasm	Cytosol	"CAB017690: AB_1124939, HPA060991: AB_2684405, HPA063556: AB_2685040"	unprognostic (8.35e-2)	unprognostic (1.33e-1)	unprognostic (3.85e-3)	unprognostic (1.07e-1)	unprognostic (1.22e-1)	unprognostic (3.70e-2)	unprognostic (2.67e-3)	unprognostic (2.38e-2)	unprognostic (1.87e-1)	unprognostic (1.69e-2)	prognostic unfavourable (1.02e-5)	unprognostic (4.27e-1)	unprognostic (3.88e-2)	unprognostic (2.87e-2)	unprognostic (1.84e-1)	unprognostic (1.30e-1)	unprognostic (1.11e-1)	1.9	14	2.9	4.7	13.4	0.4	7.9	1.8	6.8	7.1	6.5	22.5	12.1	7.6	5.1	10.4	16.7	2.8	9.3	2.5	5.4	3.6	15.1	1.8	17.2	1.4	18.3	4.5	1.8	2.7	16.1	2.5	4.8	10.7	8.5	6	0.8	15.8	16.8	1.2	16.9	17	2.5	8.4	9.1	7.4	1.3	13	1.5	2.5	7.4	10	7.5	11.1	0.5	1.5	1.7	0.6	0.2	0.6	0.3	19.5	5	0.4	0.2	1.3	2.4	1.5	19.8	30.1	0.7	1.2	9.4	13.8	0	3.4	8.4	30.4	1.6	22.2	2.9	0	1.5	1.4	1.3	5.6	4.6	0.2	0.4	1	3.9	19.9	3.5	28	0	0	0.5	3.6	0.2	0	1.2	10.1	0	0.1	0	6.3	10.4	0.2	1.1	1	1.3	2	3.2	0	23.9	3.6	2.1	0.5	3.9	0	0	0	21.8	0	15.9	1.7	0.6	0.2	0.6	0.2	0.4	0.4	0.5	0.5	0.1	0.5	0.5	0.6	0.8	0.2	0.1	1.5	0.4	0.3	2.9	13.4	1.8	6.8	5.4	3.6	18.3	4.5	10.7	13
ITGA2B	"CD41, CD41B, GP2B, PPP1R93"	ENSG00000005961	Integrin subunit alpha 2b	P08514	17	44372180-44389505	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Cell adhesion	"Integrin, Receptor"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 28.5;epididymis: 25.2;lymphoid tissue: 22.8	Group enriched	Detected in some	13	HEL: 69.4;HMC-1: 118.6	Low cancer specificity	Detected in some			Low region specificity	Detected in many			Cell type enriched	Detected in some	10	basophil: 28.5	Lineage enriched	Detected in single	54	granulocytes: 28.5	Low region specificity	Detected in single							"CAB018611, HPA031168, HPA031169, HPA031170, HPA031171"	Enhanced		Approved	Plasma membrane		1100000000	1100000000	Plasma membrane		"CAB018611: AB_2265153, HPA031168: AB_10670151, HPA031169: AB_10669671, HPA031170: AB_10696214, HPA031171: AB_10669773"	unprognostic (6.11e-2)	unprognostic (3.23e-2)	unprognostic (1.23e-1)	unprognostic (4.85e-2)	unprognostic (1.59e-2)	unprognostic (3.98e-3)	unprognostic (4.23e-5)	unprognostic (1.25e-1)	unprognostic (1.33e-2)	unprognostic (7.22e-2)	unprognostic (2.97e-3)	unprognostic (1.30e-1)	unprognostic (8.83e-9)	unprognostic (7.82e-2)	unprognostic (1.85e-1)	unprognostic (1.95e-1)	unprognostic (2.25e-1)	0.7	0.2	1.4	0.4	1	15.2	0.6	3.8	2.4	1.2	0.9	0.4	0.4	0.1	1.1	25.2	0.7	1.9	1.4	10.6	0.9	1.6	1	0.4	6.5	0.5	0.7	0.8	2.1	2.5	0.1	2.5	1.9	1.1	0.6	0.3	0.6	0.4	1.6	0.8	0.1	0.6	0.4	0.8	22.8	0.2	3	0.4	0.4	5.2	1	0.6	0.7	1.9	0	0.5	28.5	0.2	0	0.2	11.1	0	0.1	0.7	0	0	0	2.8	0	0	0.1	0.2	0	0	0	0	0	0.1	0.2	0	0	0	0.4	69.4	0	0.6	0	0	118.6	0.2	0	0	0	0	0	0.1	0	0.2	0	7.2	0.1	0.1	0.1	0	0	0	0	0	0.2	0	0.1	0	0.6	0.2	0	0	0.1	0	0	0	0	0.1	0.1	0	0.1	28.5	0.2	2.1	0.1	0	0.2	0	0	0	0.3	0	0	0	2.8	0	0	0.5	0	11.1	1.4	1	3.8	2.4	0.9	1.6	0.7	0.8	1.1	0.4
ITGA3	"CD49c, GAP-B3, MSK18, VCA-2, VLA3a"	ENSG00000005884	Integrin subunit alpha 3	P26006	17	50055968-50090481	"Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	Cell adhesion	"Integrin, Receptor"	"Cancer-related genes, Disease mutation, Epidermolysis bullosa"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in many			Cell line enhanced	Detected in many		HBEC3-KT: 74.7;hTERT-HME1: 64.9;RPTEC TERT1: 65.8;U-138 MG: 65.1;U-87 MG: 112.1;WM-115: 67.6	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in some		T-reg: 1.1	Lineage enriched	Detected in single	4	T-cells: 1.1	Low region specificity	Detected in all			Low region specificity	Detected in all			"HPA008572, CAB018594"	Enhanced		Supported	Plasma membrane		180000	180000	Plasma membrane		"CAB018594: AB_668044, HPA008572: AB_2668094"	unprognostic (3.24e-3)	prognostic unfavourable (6.75e-4)	unprognostic (9.51e-2)	unprognostic (3.46e-3)	unprognostic (3.45e-3)	prognostic unfavourable (1.36e-4)	unprognostic (8.28e-3)	unprognostic (2.76e-3)	unprognostic (1.26e-3)	unprognostic (1.82e-2)	prognostic unfavourable (5.95e-5)	unprognostic (7.05e-2)	unprognostic (1.14e-1)	unprognostic (1.93e-1)	unprognostic (1.30e-1)	unprognostic (1.28e-2)	unprognostic (2.35e-2)	15.7	15.8	4.1	8.6	5.1	0.1	8.7	7.7	6.5	10.9	20.9	2.3	8.9	17.1	11.6	11.6	12.8	14.5	32.6	8.4	4.2	5.4	36	1.7	37.6	3.2	3.2	6.7	10.7	8	13	11.2	26.4	4.3	12	8.9	11.6	10	9.7	6.6	17.3	37.3	11.6	3.3	6.5	13.7	3.9	1.5	3.3	36.1	13.3	8.3	19	8.1	0.2	0	0	0	0	1.1	0.2	20.5	27.2	0.1	0.8	0.5	2.1	4.4	9.6	20.8	14.6	11.1	0.6	32.1	0	60.9	7	14.6	0.2	74.7	8.9	2.5	0.4	0	6.9	0.1	12.9	0	0.6	2.6	36.9	14.6	64.9	10.7	0	0.3	27.4	5.9	0	0	0.6	16.5	0	1.4	1.5	65.8	35.8	1.1	0.4	10.5	1.4	24.1	2.4	0.2	23.1	65.1	20.5	0.6	37.5	0.9	1.5	0.6	112.1	0.2	67.6	0	0	0	0.8	0	1	0.2	0.1	0.1	0	0.2	0.2	0.6	0	0	0	0	1.1	0.2	4.1	5.1	7.7	6.5	4.2	5.4	3.2	6.7	4.3	1.5
ITGA4	CD49d	ENSG00000115232	Integrin subunit alpha 4	P13612	2	181457202-181536187	"Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Cell adhesion	"Integrin, Receptor"	"Cancer-related genes, FDA approved drug targets"	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 38.4;lymphoid tissue: 101.6	Cell line enhanced	Detected in many		fHDF/TERT166: 38.7;HEL: 61.5;MOLT-4: 71.7	Low cancer specificity	Detected in many			Low region specificity	Detected in many			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all			Low region specificity	Detected in many			Region enriched	Detected in many	7	cerebellum: 26.0	HPA074961			Approved	Plasma membrane	Intracellular and membrane	100000	100000	Plasma membrane		HPA074961: 	unprognostic (5.31e-2)	unprognostic (1.54e-1)	unprognostic (1.99e-2)	unprognostic (3.94e-2)	unprognostic (3.76e-1)	prognostic favourable (8.29e-4)	unprognostic (1.27e-1)	unprognostic (1.11e-2)	unprognostic (1.76e-1)	unprognostic (2.67e-2)	unprognostic (1.85e-1)	unprognostic (1.94e-1)	prognostic unfavourable (3.08e-5)	unprognostic (2.26e-2)	unprognostic (8.64e-3)	unprognostic (2.49e-1)	unprognostic (2.57e-2)	3.8	1.7	1.3	39.7	1.1	19.2	3.2	2.4	1.9	6.7	4.8	0.5	1.1	3.8	3	3.1	2.9	2.1	6.9	1.7	2.9	1.3	3	2.5	13.6	33.7	1.2	0.5	1.8	1.6	0	1.3	7.1	0.9	3.8	4.9	2.9	7.5	2	1	1.5	11.6	2.4	1.6	36	4.4	1.2	0.2	101.6	2.6	1.5	14.3	6	4.1	11	19.1	38.4	38.3	8.8	15.9	16.2	0	0.2	1	0	9.1	13.8	0	8.9	11.2	4.8	10.1	0	0	7.1	0	38.7	5.3	3.1	0.1	5.8	0	0.7	61.5	0.2	0	0.9	27.2	1.5	9.8	0	0.3	0	0.4	0	10.4	3	0	71.7	19.1	0.8	0	15.7	4.5	1	0	0	1.6	0.6	0	0	0.3	0	18	4.8	1.5	0.9	0.1	1.8	20.4	15.1	4	0.8	13.5	20.6	6.7	16.2	38.4	12.9	38.3	9.7	11	14.6	15.9	19.1	10	8.5	10.4	2.1	8.8	37.5	5	3.7	16.2	1.3	1.1	2.4	1.9	2.9	1.3	1.2	0.5	0.9	0.2
ITGA5	"CD49e, FNRA"	ENSG00000161638	Integrin subunit alpha 5	P08648	12	54395261-54419460	"Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Integrin, Receptor"	Cancer-related genes	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		smooth muscle: 137.7	Cell line enhanced	Detected in many		HUVEC TERT2: 140.8;TIME: 134.1;U-87 MG: 66.9	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Cell type enhanced	Detected in many		neutrophil: 31.5	Low lineage specificity	Detected in many			Region enriched	Detected in single	7	basal ganglia: 9.3	Low region specificity	Detected in some			"HPA002642, CAB009008"	Enhanced					23000000	23000000			"CAB009008: AB_647474, HPA002642: AB_1078469"	unprognostic (7.51e-3)	prognostic unfavourable (4.07e-6)	prognostic unfavourable (8.43e-4)	unprognostic (1.58e-1)	unprognostic (8.51e-3)	prognostic unfavourable (2.91e-4)	prognostic unfavourable (2.23e-5)	prognostic unfavourable (2.44e-4)	unprognostic (2.76e-2)	unprognostic (6.19e-2)	unprognostic (8.99e-2)	unprognostic (8.28e-2)	prognostic unfavourable (1.32e-8)	unprognostic (2.11e-3)	unprognostic (3.35e-2)	prognostic unfavourable (8.89e-4)	unprognostic (2.18e-3)	23.3	7.9	2.1	32.2	2.8	9.2	30.5	1.2	2.2	16	66.9	2.2	19	3.4	19.3	13.8	18.2	12	12.4	20.3	2.9	0.8	4.6	15.2	20.4	9.2	3.2	1.2	13.6	5.3	3.7	1.8	57.7	3.3	26.6	10.2	4.9	4.4	28.9	10	8.8	14.9	137.7	3.5	3.1	19.7	6.6	2.5	3	7.3	5.8	4.5	82.1	20.6	0.1	22.2	31.5	22.9	9.1	5.6	12.4	6.6	2.4	4.6	0	14.3	30.5	12	30	31.2	30.9	22.8	1.6	1.5	0	21.9	31.3	1	1.2	8.3	21.4	0	1.2	2.9	3.3	0.1	19.8	9	4.6	22	4.1	36.2	27.9	140.8	2.4	0	17.5	0.6	1.3	10.1	1.8	1.9	1.4	3.1	0.6	4.9	0.1	0	0	6	0.4	0.2	0.7	8.1	134.1	37.6	6.7	9.2	12.4	0	0.3	0	66.9	8.6	12.2	5.6	22.9	0.1	5.6	10	4.4	0	4.2	4.2	22.2	0.1	3.1	2.6	31.5	9.1	7.6	1.2	1.7	12.4	2.1	2.8	1.2	2.2	2.9	0.8	3.2	1.2	3.3	2.5
ITGA6	CD49f	ENSG00000091409	Integrin subunit alpha 6	P23229	2	172427354-172506282	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	Cell adhesion	"Integrin, Receptor"	"Cancer-related genes, Epidermolysis bullosa"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in many		BJ: 50.1;HaCaT: 55.2;HBEC3-KT: 108.5;hTCEpi: 47.3;hTERT-HME1: 48.1	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in many		eosinophil: 16.2	Group enriched	Detected in many	34	granulocytes: 16.2;NK-cells: 5.5;T-cells: 10.0	Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB009009, HPA012696, HPA027582"	Enhanced					45000000	45000000			"CAB009009: AB_2128038, HPA012696: AB_1851822, HPA027582: AB_10602606"	unprognostic (1.02e-1)	unprognostic (3.33e-1)	unprognostic (2.59e-2)	unprognostic (5.96e-2)	unprognostic (4.93e-2)	prognostic unfavourable (1.03e-4)	unprognostic (1.19e-1)	unprognostic (1.61e-3)	unprognostic (9.34e-2)	unprognostic (6.01e-2)	unprognostic (1.85e-3)	unprognostic (1.84e-1)	prognostic favourable (2.35e-11)	unprognostic (3.35e-2)	unprognostic (3.32e-1)	unprognostic (2.98e-2)	unprognostic (1.21e-3)	28	3.1	9.8	19.1	10.5	1.6	30.1	3	8.4	27	34.9	9.4	42.3	28.5	28.2	11.3	17	11.1	23.8	21.7	9.7	8.2	22	4.9	29	14.9	9.8	5.1	7.6	31.3	7.4	4.9	38.7	12.6	14.3	25.2	17.6	37.1	32.4	13.5	17.5	44.2	15.2	9.6	14.9	25	12.4	6.9	15.1	11.5	35.2	13.2	24.1	17.3	0.3	0.1	16.2	0.2	5.5	10	3.3	11.4	9.8	4.3	7.7	0.2	0.1	23.6	50.1	5.4	5.1	3.2	5.5	22	0.1	14.1	13.3	55.2	2.8	108.5	9.3	0.1	2.6	0.2	10.5	9.1	0.7	3.1	0.3	1	47.3	0.3	48.1	32.8	0	0.8	6.4	0.5	0.8	2.7	7.8	8.4	0.1	12.8	0.2	7.8	16.1	0.1	0.5	9.2	0	10.7	2	0.2	14.7	7.2	6.5	13.2	8.6	0.7	0.5	0.3	0.2	1.1	28.9	2.6	0.2	16.2	4.2	0	8.5	0.2	5.4	5	0.1	0.3	10	4.6	0.5	5.5	0	0	5.7	3.3	9.8	10.5	3	8.4	9.7	8.2	9.8	5.1	12.6	6.9
ITGAD	"ADB2, CD11d"	ENSG00000156886	Integrin subunit alpha D	Q13349	16	31393312-31426505	"CD markers, Predicted membrane proteins"	Cell adhesion	"Integrin, Receptor"		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level		Tissue enriched	Detected in some	9	lymphoid tissue: 25.4	Cell line enhanced	Detected in single		NB-4: 1.7	Low cancer specificity	Detected in single			Not detected	Not detected			Cell type enhanced	Detected in some		gdT-cell: 1.1;NK-cell: 2.6	Group enriched	Detected in many	19	NK-cells: 2.6;T-cells: 1.1	Low region specificity	Detected in many							HPA026786	Uncertain									HPA026786: AB_10603773	unprognostic (2.79e-2)	unprognostic (2.39e-4)	unprognostic (2.88e-2)	unprognostic (3.24e-2)	unprognostic (6.17e-2)	unprognostic (1.79e-2)	unprognostic (7.44e-4)	unprognostic (6.99e-3)	unprognostic (6.89e-3)	unprognostic (5.02e-4)	unprognostic (5.50e-2)	unprognostic (1.67e-1)	unprognostic (1.74e-1)	unprognostic (3.80e-2)	unprognostic (3.17e-1)	unprognostic (8.10e-2)	unprognostic (5.51e-2)	0.3	0.1	0.1	1	0.1	2.5	0.2	0.1	0.1	0.2	0.1	0	0	0	1.2	0	0.4	0.2	0.2	0.2	0.1	0.1	0.1	1.2	0.7	4	0.1	0	1.6	0.1	0	0.1	1.2	0	0.1	0	0.2	1.5	0	1.3	0.1	0.3	0	0.2	25.4	0.1	0.2	0	0.4	0.1	0	1.4	0.2	0.1	0	0	0	0	2.6	1.1	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0.8	0.9	0	0.1	0	0	0	0	0	0	0	0	0	0	0.4	0	0	0	0	0	0	0.1	0	0	0.2	1.7	0.3	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2	0	0	0.7	0	0	0	0	0	1.1	0	0	0	0	0	0	0	0	0.4	0	2.6	0	0	0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0	0	0
ITGAE	"CD103, HUMINAE"	ENSG00000083457	Integrin subunit alpha E	P38570	17	3714628-3801243	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	Cell adhesion	"Integrin, Receptor"		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		intestine: 20.2;lung: 25.9;lymphoid tissue: 13.0	Cell line enriched	Detected in single	21	MOLT-4: 15.9	Low cancer specificity	Detected in all			Not detected	Not detected			Group enriched	Detected in some	4	MAIT T-cell: 3.1;memory CD8 T-cell: 7.4;T-reg: 1.9	Lineage enriched	Detected in many	7	T-cells: 7.4	Low region specificity	Detected in some			Low region specificity	Detected in many			"CAB026461, HPA036313"	Approved					13000	13000			"CAB026461: , HPA036313: AB_10795355"	unprognostic (9.81e-2)	unprognostic (1.78e-3)	unprognostic (7.86e-2)	prognostic favourable (1.04e-4)	unprognostic (2.17e-1)	unprognostic (1.45e-2)	unprognostic (2.91e-1)	unprognostic (8.02e-2)	unprognostic (2.92e-2)	unprognostic (1.10e-1)	prognostic favourable (5.78e-4)	unprognostic (3.34e-2)	prognostic unfavourable (1.13e-8)	unprognostic (8.40e-3)	unprognostic (1.15e-1)	unprognostic (1.82e-2)	prognostic favourable (3.56e-4)	3.6	0.2	0.3	13	0.6	8	0.9	0.2	0.2	0.6	9.6	0.2	0	4.9	0.4	0.4	2	1.5	2.7	0.2	0.5	0.4	0.3	0.3	25.9	8.1	0.3	0	0.9	1.2	0.5	0.4	0.1	0.2	1.2	2	0.2	1.8	3.9	0.3	0.6	20.2	2	0.7	1.4	3.6	1.6	0.1	3.1	1	1.5	5.3	1.9	2.5	0.2	0.1	0	1	0	7.4	0.9	0	0	0	0	0	0	0.3	0	0	0	0	0	0	0.5	0	0	0.2	0	0	0	0	0	0	0	0.6	0	0	0.3	0	0	0	0	0	0.1	0.2	0	0.7	15.9	0.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0.7	0	0.3	0.1	0	0	0	0	0	0	0	0.1	0	0.4	0	0.2	1	3.1	0.2	1	7.4	0.1	0	0	0.2	0	0	0.6	0	1.9	0.9	0.3	0.6	0.2	0.2	0.5	0.4	0.3	0	0.2	0.1
ITGAL	"CD11A, LFA-1"	ENSG00000005844	Integrin subunit alpha L	P20701	16	30472658-30523185	"CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Phagocytosis"	"Integrin, Receptor"	FDA approved drug targets	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 36.7;lymphoid tissue: 74.6	Cell line enriched	Detected in some	4	HMC-1: 119.0	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all			Low region specificity	Detected in single			Low region specificity	Detected in all			CAB025011	Enhanced				Intracellular and membrane	1100000	1100000			CAB025011: 	unprognostic (1.10e-2)	unprognostic (4.26e-3)	unprognostic (3.72e-3)	prognostic favourable (5.63e-5)	unprognostic (2.88e-1)	prognostic favourable (3.34e-4)	unprognostic (1.63e-1)	unprognostic (5.69e-3)	prognostic favourable (5.57e-4)	unprognostic (3.37e-2)	unprognostic (4.98e-2)	unprognostic (1.84e-1)	prognostic unfavourable (2.69e-5)	unprognostic (2.89e-1)	unprognostic (3.05e-2)	unprognostic (1.39e-1)	unprognostic (1.71e-2)	2.8	1.1	1.8	29.8	2	15.1	1.8	0.6	1.5	1.3	3	2.7	0.5	2.4	1.7	1.4	2.2	2.6	4.9	1.4	1.3	1.3	2.6	6.7	16.2	29	3.1	1.4	1.4	1.2	0	1.4	1.7	1.7	2	3.4	1.9	6.6	0.7	0.8	1	12.7	1.4	4.7	44.1	3.5	0.8	2.7	74.6	2.8	2	41.8	4.4	1.9	2.1	7.5	7.2	36.7	9.5	22.5	11.5	0	0	0	0	0	0	0	0	0	0	0	0	0	6.6	0	0	0.1	0	0	0	0.1	0	0.4	0	0	0	0.2	119	0	0	0	0	0	0	26.7	0	0	7.9	0.7	0	0	0	0	2.2	0	0	0	0	0	0.2	0	0.4	4.2	0	0	0	0	0	7.5	2.5	0	0.1	0.8	0	3.1	8.4	6.5	22.5	16.9	11.2	2.1	8.8	16.2	7.5	1.3	4.9	11.4	7.2	9.5	36.7	3	6.3	11.5	1.8	2	0.6	1.5	1.3	1.3	3.1	1.4	1.7	2.7
ITGAM	"CD11b, CR3A, MAC-1"	ENSG00000169896	Integrin subunit alpha M	P11215	16	31259990-31332892	"Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Immunity, Innate immunity"	"Integrin, Receptor"	"Cancer-related genes, Systemic lupus erythematosus"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		bone marrow: 93.7	Group enriched	Detected in some	4	HMC-1: 32.7;NB-4: 11.6;U-937: 14.0	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Group enriched	Detected in many	5	basophil: 29.4;classical monocyte: 19.1;eosinophil: 23.8;gdT-cell: 12.2;intermediate monocyte: 7.6;neutrophil: 21.0;NK-cell: 18.8	Low lineage specificity	Detected in all											"HPA002274, CAB025091, CAB072870"	Enhanced					900000	900000			"CAB025091: , CAB072870: , HPA002274: AB_1078435"	unprognostic (1.82e-2)	unprognostic (1.70e-2)	unprognostic (8.78e-2)	unprognostic (2.54e-2)	unprognostic (2.40e-2)	unprognostic (4.20e-2)	prognostic unfavourable (3.43e-4)	unprognostic (1.86e-1)	unprognostic (1.73e-1)	unprognostic (3.29e-3)	unprognostic (1.27e-1)	unprognostic (1.80e-1)	prognostic unfavourable (6.93e-5)	unprognostic (9.89e-2)	prognostic unfavourable (6.93e-4)	unprognostic (3.99e-2)	unprognostic (5.03e-2)	19.7	5	6	14	7.2	93.7	6	2	4.5	2.9	3.2	9.4	0.5	1.8	2.5	3.5	2.2	4.8	4	6.5	4.3	3.9	3	3.3	14.6	22.8	10.5	1.6	2.5	2.9	1.6	1.8	4.9	5.3	3.6	2.7	3.3	3.2	2	1.6	1.5	4.4	6.9	8.6	29.9	2.8	1.5	7.4	2.3	2.1	1.7	6.6	4.9	4.5	1.9	3.4	29.4	19.1	18.8	12.2	8	0.5	1.1	0	0	0	0	0.9	0.1	0	0	0	0.3	0.4	0.8	0.5	0	0.1	0	0.2	0	4.7	0	0.6	0	0	0	1.1	32.7	0	0.1	0	0	0	1.1	0.1	0	0	0	11.6	0	0	0.1	0	0.6	0	1.3	0	0	0	0.3	0.2	0.1	2.7	0	0	0	0	0.1	0.1	0.1	0	0	14	0	29.4	19.1	23.8	12.2	7.6	0.7	1.9	1.3	3.6	3.4	0.3	0.3	3	21	18.8	1.1	0.2	0.5	8	6	7.2	2	4.5	4.3	3.9	10.5	1.6	5.3	7.4
ITGAV	"CD51, MSK8, VNRA, VTNR"	ENSG00000138448	Integrin subunit alpha V	P06756	2	186590065-186680901	"Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Integrin, Receptor"	"Cancer-related genes, FDA approved drug targets"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in many		RT4: 75.3	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in many		basophil: 7.7	Group enriched	Detected in many	4	granulocytes: 7.7;monocytes: 2.3	Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB002499, HPA004856"	Supported		Approved	"Focal adhesion sites,Cytosol"		750000	750000	"Focal adhesion sites, Cytosol"		"CAB002499: AB_563594, HPA004856: AB_1846316"	unprognostic (4.03e-2)	unprognostic (5.17e-3)	unprognostic (1.22e-2)	unprognostic (5.22e-2)	unprognostic (1.33e-1)	unprognostic (1.18e-1)	prognostic unfavourable (2.08e-4)	unprognostic (1.48e-2)	unprognostic (6.95e-2)	unprognostic (2.89e-1)	prognostic unfavourable (5.07e-4)	unprognostic (5.84e-2)	unprognostic (2.67e-2)	prognostic unfavourable (1.05e-6)	unprognostic (2.61e-1)	unprognostic (9.11e-2)	unprognostic (8.07e-2)	23.2	22.1	17.9	18.3	21.8	3.1	25.8	16.7	23.1	22.9	13.6	23.4	11.6	8.4	26	11.4	14.2	14.5	25.2	40.7	16.8	12.3	51.5	9.5	20.6	7.6	24.2	11.6	35.4	18.7	65	11	29.6	22.1	16.5	11.9	83.4	17.9	15.9	13.1	21.5	10.1	29.6	33	12.1	17.3	11.2	17	7.8	33.1	10.9	11.1	17.6	17.9	0.3	0.9	7.7	2.3	0.4	1.1	0.5	9.7	11.7	7.8	24.9	28.7	19.4	29.7	19.2	15.5	6.8	6.8	10.2	33.8	0	37.9	21.6	12.3	3.9	18.1	9.8	1.9	3.5	2.3	15.4	14	11.3	1.6	1.4	14.1	8.6	15.2	12.9	16.2	2.2	4.9	18.1	3.8	0.9	1.3	5.9	5.9	0	15.9	1.3	17.6	75.3	1.6	4.8	22.2	6.9	8.1	5.4	4.5	49.1	42.2	13.2	8.6	16.2	1.2	2	1.1	17	0.6	20.8	7.7	1.1	1.6	1	2.3	0.7	0.3	0.5	0.8	0.9	0.1	0.5	0.5	0.5	0.4	1.2	0.4	1.1	0.5	17.9	21.8	16.7	17.3	16.8	12.3	24.2	11.6	22.1	17
ITGAX	CD11c	ENSG00000140678	Integrin subunit alpha X	P20702	16	31355134-31382997	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	Cell adhesion	"Integrin, Receptor"		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		adipose tissue: 47.9;blood: 31.7;lung: 33.2;lymphoid tissue: 46.3	Cell line enriched	Detected in some	6	HMC-1: 48.1	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Group enriched	Detected in many	4	classical monocyte: 10.1;eosinophil: 9.2;intermediate monocyte: 18.1;myeloid DC: 12.4;neutrophil: 31.7;NK-cell: 14.9;non-classical monocyte: 20.3	Low lineage specificity	Detected in many			Not detected	Not detected			Low region specificity	Detected in all			"CAB004458, HPA004723, CAB072871"	Enhanced									"CAB004458: AB_626859, CAB072871: , HPA004723: AB_1846231"	unprognostic (9.75e-3)	unprognostic (2.49e-2)	unprognostic (1.75e-1)	unprognostic (1.99e-2)	unprognostic (1.89e-1)	unprognostic (2.29e-2)	unprognostic (1.27e-1)	unprognostic (9.59e-2)	unprognostic (8.06e-3)	unprognostic (3.20e-1)	unprognostic (7.75e-2)	unprognostic (3.34e-1)	prognostic unfavourable (1.37e-4)	unprognostic (3.92e-2)	unprognostic (3.04e-2)	unprognostic (2.82e-1)	unprognostic (2.95e-2)	47.9	1.9	4.4	28.1	5.7	28.6	2.9	1.4	4.4	1.8	2.1	17.1	0.6	1.7	2.1	2.5	1.9	4.3	7.7	2.5	5.3	4.6	2.3	4.6	33.2	24.4	13.6	3.8	3	2.1	0.8	2.4	3.3	8.1	2.5	3.2	2.5	4.3	1.3	1.1	1.6	3.8	3.3	15.6	46.3	3.3	0.9	7.5	3.8	2.2	0.9	9.7	5.1	1.9	0.8	12.4	31.7	20.3	14.9	1.8	3.2	0	0.3	0	0.1	0	0	0.2	0	0	0	0	0	0.2	0	4.1	0	0	0	0.1	0	8.1	0	0	0.1	0.1	0	0.4	48.1	0	0	0.7	0.1	0.4	0	0.1	0	0	0	3.8	0.1	0	0	0.1	0	0	0	0	0	0	0	1.2	0	1.4	0.3	0	0.7	0	0	0	0	0	2.2	0.7	0.1	3.9	10.1	9.2	1.8	18.1	0.1	0.8	0	0.3	12.4	0.4	0	0.2	31.7	14.9	20.3	0.2	0	3.2	4.4	5.7	1.4	4.4	5.3	4.6	13.6	3.8	8.1	7.5
ITGB1	"CD29, FNRB, GPIIA, MDF2, MSK12"	ENSG00000150093	Integrin subunit beta 1	P05556	10	32900319-33005792	"Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Integrin, Receptor"	"Cancer-related genes, FDA approved drug targets"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Low cell line specificity	Detected in all			Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all			Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB003434, HPA059297, HPA069003"	Enhanced		Supported	"Endoplasmic reticulum,Plasma membrane,Focal adhesion sites"		540000000	540000000	"Plasma membrane, Focal adhesion sites"	Endoplasmic reticulum	"CAB003434: AB_303570, HPA059297: , HPA069003: "	unprognostic (3.07e-2)	prognostic unfavourable (5.01e-4)	unprognostic (8.67e-2)	unprognostic (4.36e-1)	unprognostic (1.20e-2)	unprognostic (3.87e-2)	unprognostic (1.60e-2)	prognostic unfavourable (3.36e-6)	unprognostic (3.22e-1)	unprognostic (2.36e-3)	unprognostic (3.68e-3)	unprognostic (2.42e-1)	unprognostic (1.02e-3)	unprognostic (1.25e-2)	unprognostic (2.23e-1)	unprognostic (2.48e-1)	unprognostic (3.08e-2)	95.2	30.6	13.7	32.1	19.7	9.7	107.7	6.5	14.8	55.1	61.3	17	80.2	20.2	84.2	56.2	59.9	45	49.8	68.7	15	14.4	47.3	85.8	55.4	34.5	23	11.1	47.4	37.4	17.6	35.2	83.3	19.5	53.1	32.2	18.6	30.3	76.2	58	19.5	42.3	109.3	30.1	59.8	45.4	26.9	18.8	12.7	36.8	27.6	19.4	92.7	47.4	31.3	9.1	4.3	27.1	21.9	68.4	26.2	47.4	69.7	37.6	41.7	90.9	78.3	32.8	159.7	92.6	76.1	69.6	15.6	111.2	12.8	28.9	133.9	33.2	11.3	90.9	84.9	12.6	9.2	15.4	33.2	18.2	64	3.4	15.3	79.3	49.7	80	32.6	93.4	10.6	5.7	125.4	7.8	5.9	3.5	8.4	35.4	3.9	27.9	2.3	108.5	13.8	8.9	22.3	49.8	8.5	35.8	11.4	12.4	104.5	98	56.9	69.6	53.2	5.2	1.1	7.2	72.2	14.6	38.4	1.6	9.8	4.3	25.5	17.8	6	31.3	54.6	37.5	9.1	8.6	7.1	19.1	2.3	21.9	27.1	3.7	68.4	26.2	13.7	19.7	6.5	14.8	15	14.4	23	11.1	19.5	18.8
ITGB2	"CD18, LFA-1, MAC-1, MFI7"	ENSG00000160255	Integrin subunit beta 2	P05107	21	44885953-44931989	"CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Phagocytosis"	"Integrin, Receptor"	Disease mutation	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		blood: 159.7;bone marrow: 91.4;lymphoid tissue: 75.6	Group enriched	Detected in some	5	THP-1: 114.8;U-937: 85.3	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all							Low region specificity	Detected in all			"HPA008877, HPA016894"	Enhanced		Supported	"Plasma membrane,Rods & Rings"		2500000	2500000	Plasma membrane	Rods & Rings	"HPA008877: AB_1846256, HPA016894: AB_1846257"	unprognostic (1.94e-2)	unprognostic (7.66e-3)	unprognostic (1.23e-1)	unprognostic (6.21e-3)	unprognostic (2.95e-2)	unprognostic (9.73e-3)	unprognostic (2.53e-2)	unprognostic (1.82e-1)	unprognostic (1.18e-2)	unprognostic (1.36e-1)	unprognostic (1.20e-1)	unprognostic (6.34e-2)	unprognostic (1.87e-3)	unprognostic (1.42e-1)	unprognostic (4.42e-2)	unprognostic (2.65e-2)	unprognostic (4.83e-2)	59.1	9.8	9	47.5	16.8	91.4	8.4	1.7	8	5.6	7.4	12.2	1.2	6.3	4.9	9	4.8	10.7	10.3	9.7	7.2	6.4	8.1	7	32.9	73.8	14.3	2.9	6.6	5.1	1.1	3.3	12.7	12.1	6.9	4.2	5.2	8.8	2.7	3	4.1	13.2	12.3	18.3	75.6	7.6	4.2	12.2	53.5	4.5	2.2	29	15.7	4.2	9.5	76	104.6	122.9	41	57.4	159.7	0.2	0.7	0	0	0	0	0.2	0	0.4	0	0	0	0	2.4	19.8	0	0	0	0	0	0.2	0.2	2.3	0	0.4	0	15	3.9	0.2	0	0	0	0	0.1	0.2	1	0.5	17	18	0	0.3	0.2	3.5	9.3	0.7	0	0	0.2	0.5	0.3	0.3	0	114.8	0.3	0	1	0	0.5	0.1	0.8	0.4	0	85.3	0.1	10.5	122.9	85.7	57.4	84.1	25.8	6.7	28.4	39.5	76	9.5	19.1	32	104.6	41	81	11.6	20.7	159.7	9	16.8	1.7	8	7.2	6.4	14.3	2.9	12.1	12.2
ITGB3	"CD61, GP3A, GPIIIa"	ENSG00000259207	Integrin subunit beta 3	P05106	17	47253846-47311816	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Integrin, Receptor"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		thyroid gland: 36.6	Cell line enhanced	Detected in some		EFO-21: 45.5;HEL: 40.3;RPTEC TERT1: 26.2;U-87 MG: 20.6;WM-115: 65.7	Group enriched	Detected in many	6	melanoma: 7.5;renal cancer: 3.6;thyroid cancer: 11.5	Low region specificity	Detected in many			Group enriched	Detected in some	19	basophil: 2.8;neutrophil: 2.8	Lineage enriched	Detected in single	19	granulocytes: 2.8									HPA027852	Approved		Supported	"Nucleoplasm,Plasma membrane"	Intracellular and membrane	710000000	710000000	Plasma membrane	Nucleoplasm	HPA027852: AB_10601760	unprognostic (1.13e-2)	unprognostic (1.97e-3)	unprognostic (2.47e-1)	unprognostic (3.00e-2)	unprognostic (1.91e-2)	unprognostic (6.04e-3)	unprognostic (3.70e-1)	unprognostic (3.00e-1)	unprognostic (1.44e-1)	unprognostic (3.85e-1)	unprognostic (6.35e-2)	unprognostic (7.22e-2)	unprognostic (1.36e-1)	unprognostic (1.03e-2)	unprognostic (2.72e-2)	unprognostic (1.48e-1)	unprognostic (1.17e-3)	10	0.6	1	6.2	2.5	2.7	7	0.4	1.6	4.6	13.6	0.9	2.4	2.2	9.7	5.7	6.4	6.4	2.8	8.5	0.7	0.6	16	3.7	5.2	1.2	2.3	0.1	4.6	0.6	0.7	1.6	23.5	1.6	6.4	4.8	1.8	2.5	11.5	4.9	2.4	5	17	1.8	9.5	3.6	2.6	0.6	0.2	36.6	1.9	0.9	11	7.8	0.1	0	2.8	0.1	0	0	9.5	0	0.4	0.1	0	2.3	1	0	1.2	6	2.6	2.4	0	0	0.1	45.5	0.3	0	0	0	3.4	0.8	0	40.3	0.1	0	1.9	0	0	0.9	0	15.2	0.3	11.3	0.1	0	0.5	0	0.2	0	0	0.1	0	1	0	26.2	0	0	0.1	1.5	0	8.2	0	0	12.3	0.5	0.6	0.3	2.8	0	0	0.2	20.6	0	65.7	2.8	0.1	0	0	0	0	0	0	0	0	0.1	0	0	2.8	0	0	0	0	9.5	1	2.5	0.4	1.6	0.7	0.6	2.3	0.1	1.6	0.6
ITGB4	CD104	ENSG00000132470	Integrin subunit beta 4	P16144	17	75721328-75757818	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Cell adhesion	"Integrin, Receptor"	"Cancer-related genes, Disease mutation, Epidermolysis bullosa"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in some		CAPAN-2: 117.5;HaCaT: 45.0;HBEC3-KT: 100.3;hTCEpi: 34.3;RT4: 33.0	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in many		plasmacytoid DC: 8.2	Low lineage specificity	Detected in many			Low region specificity	Detected in many			Low region specificity	Detected in many			"CAB002422, CAB005258, HPA036348, HPA036349"	Enhanced		Supported	"Plasma membrane,Cell Junctions"		79000	79000	"Plasma membrane, Cell Junctions"		"CAB002422: AB_563480, CAB005258: AB_2129021, HPA036348: AB_2675077, HPA036349: AB_2675078"	unprognostic (3.17e-3)	unprognostic (3.52e-1)	unprognostic (4.19e-1)	unprognostic (2.27e-1)	unprognostic (5.75e-2)	unprognostic (6.11e-3)	unprognostic (1.28e-1)	prognostic unfavourable (7.18e-4)	unprognostic (1.05e-1)	unprognostic (4.14e-2)	prognostic unfavourable (6.39e-4)	unprognostic (1.02e-1)	unprognostic (2.23e-2)	unprognostic (1.65e-2)	unprognostic (1.05e-1)	unprognostic (1.07e-1)	unprognostic (1.43e-1)	6.3	3.4	9.7	10.9	9.7	1.4	13.7	4.7	7.7	14.3	32.1	15.6	10	35.3	9.7	8.8	24	13.7	47.8	4.3	9.4	7.9	4.8	1.5	7.4	3.7	10.1	9.1	4.7	6.7	3.1	5.7	50	17.2	19.7	10.4	9.8	52.3	13.2	2.4	47	58.5	7.4	10.7	17	41	3.9	9.8	1.8	3.2	22.1	15.9	17.2	20.5	2.4	8.2	1.3	0.7	0	2.2	0.8	21.8	19.3	0	0.2	0	0.1	26.6	0.1	0	0	0.1	2	117.5	0	4.2	0	45	0.1	100.3	0	0.1	0	0.1	4.9	2.1	0.1	0	0.2	0.1	34.3	0	21.4	0.7	0	2	0	12.2	0.2	0.2	0.1	16.8	0.3	0.5	0.2	26.8	33	0	0.2	0.6	2	0.3	8.4	0.2	2.2	0.6	1	0	0.2	0.7	0.2	0	0.2	0.1	0.3	0	0.4	0	0.7	0.7	2.2	1.4	0.3	1	0.1	2.4	0.9	0.6	1.3	0	0	8.2	1.4	0.8	9.7	9.7	4.7	7.7	9.4	7.9	10.1	9.1	17.2	9.8
JAG1	"AGS, AHD, AWS, CD339, HJ1, JAGL1"	ENSG00000101384	Jagged 1	P78504	20	10637684-10673999	"CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Notch signaling pathway	Developmental protein	"Deafness, Disease mutation"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in many		HBEC3-KT: 55.8;hTERT-HME1: 34.5;U-251 MG: 46.9	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in some		eosinophil: 2.4	Low lineage specificity	Detected in many			Low region specificity	Detected in many			Low region specificity	Detected in many			"CAB010343, HPA021555"	Supported		Approved	"Golgi apparatus,Plasma membrane"		14000000	14000000	"Golgi apparatus, Plasma membrane"		"CAB010343: AB_649685, HPA021555: AB_1851969"	unprognostic (2.23e-1)	unprognostic (2.04e-2)	unprognostic (1.78e-1)	unprognostic (4.15e-2)	unprognostic (1.21e-1)	unprognostic (6.42e-2)	unprognostic (4.21e-2)	unprognostic (8.94e-3)	unprognostic (6.07e-2)	unprognostic (5.20e-2)	prognostic unfavourable (4.10e-6)	unprognostic (5.48e-2)	unprognostic (1.71e-3)	unprognostic (2.22e-1)	unprognostic (1.66e-1)	unprognostic (3.10e-1)	unprognostic (1.41e-3)	27.7	5.6	6.8	14.5	5.4	9.7	56.5	2.9	6.7	34.2	20.1	4.3	17.4	7.2	26.1	22.8	33.9	16.7	23.1	18.8	5.4	5.1	12.9	3.8	22	12.4	5.4	4	14.7	22.2	21.7	6	36.3	6	19.2	12.7	21.4	11.2	23.4	16.8	34.8	11.7	21.4	13	14.2	13.4	9.1	3.8	1.5	14.5	24.6	16.1	18.7	31.4	0	0.9	2.4	2	0.4	0.1	0.4	1	5.2	16.4	20.1	3.1	3	0.6	0.6	3	0.8	0.4	4.6	2.8	0.1	15.4	0.6	21.9	2.4	55.8	0.7	0	1.1	1.7	0.5	21.9	1.5	7	0.1	1.2	16.6	2.7	34.5	5.4	0	2.2	1.5	0	0	5	4.7	5.2	1.3	1	3.2	7.8	6.4	0.7	0.5	1.6	1.1	6.6	0.1	0.8	20.4	3.7	2.6	3	46.9	0.9	0.1	0.2	2.4	2.5	2.9	0	2	2.4	0	0.2	0	0	0	0	0.7	0	0.1	0	1.6	0.4	0.3	0.9	0	0.4	6.8	5.4	2.9	6.7	5.4	5.1	5.4	4	6	3.8
JAM2	"C21orf43, CD322, JAM-B, JAMB, VE-JAM"	ENSG00000154721	Junctional adhesion molecule 2	P57087	21	25639272-25717562	"CD markers, Predicted membrane proteins"				Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		placenta: 66.7	Cell line enhanced	Detected in some		AF22: 18.9;BJ hTERT+: 12.0;HDLM-2: 11.8;U-138 MG: 13.6;U-87 MG: 10.0	Cancer enriched	Detected in all	9	glioma: 27.2	Low region specificity	Detected in all			Low cell type specificity	Detected in many			Low lineage specificity	Detected in many			Low region specificity	Detected in all			Low region specificity	Detected in all			"HPA028789, HPA077346"			Supported	"Nucleoplasm,Plasma membrane"		17000	17000	Plasma membrane	Nucleoplasm	"HPA028789: , HPA077346: "	unprognostic (1.42e-1)	unprognostic (6.39e-2)	unprognostic (1.23e-1)	unprognostic (1.73e-1)	unprognostic (2.02e-2)	unprognostic (1.53e-2)	unprognostic (7.51e-4)	unprognostic (2.61e-2)	unprognostic (4.55e-1)	unprognostic (1.02e-1)	unprognostic (3.46e-2)	unprognostic (3.81e-1)	unprognostic (8.86e-2)	unprognostic (5.71e-3)	unprognostic (2.18e-1)	unprognostic (2.20e-1)	unprognostic (4.85e-3)	16.6	17.2	13.8	8.4	18.9	1.5	14.6	9.9	23.4	18.1	14.7	14.5	8	7.5	20.5	13.5	13.3	12	14.4	21.9	13.5	12.5	6.5	3.5	17.1	4.6	17.6	13.5	18.9	3.9	5.8	7.7	66.7	18.5	12	9.7	11.1	5.5	18	8.4	6.9	9.2	21.8	23	2.8	9.7	25.8	12.2	0.6	9.5	10.1	6.3	13.5	15.1	3.1	1.9	1.9	0.7	2.8	1.1	0.4	0	0	18.9	0.1	0.7	0.2	0.4	0.5	12	1.5	5.7	0	0	0.1	0	0.2	0.1	1.6	0	3.5	11.8	0.5	0.1	0	0.1	0	0	0.1	1.1	0	1.3	0	0	0	0.2	5.8	0.1	0.3	0.1	6	0	2.2	3.9	0.1	0	0	0.3	2.8	0.1	0.2	0	0.7	0.1	0	13.6	1.3	0.1	1.9	1.5	0	0	10	0.1	0.5	1.4	0.7	0.3	0.4	0.5	0.6	0.3	0.4	0.9	0.4	3.1	0.7	1.1	1.9	2.8	0.6	1.9	0.2	0.4	13.8	18.9	9.9	20.5	13.5	12.5	17.6	13.5	18.5	12.2
KDR	"CD309, FLK1, VEGFR, VEGFR2"	ENSG00000128052	Kinase insert domain receptor	P35968	4	55078259-55125595	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins"	"Angiogenesis, Differentiation, Host-virus interaction"	"Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, FDA approved drug targets"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in many			Group enriched	Detected in some	9	HUVEC TERT2: 31.8;TIME: 35.9	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Not detected	Not detected			Not detected	Not detected			Low region specificity	Detected in many			Low region specificity	Detected in all			CAB004028	Enhanced		Supported	Plasma membrane	Intracellular and membrane	7400000	7400000	Plasma membrane		CAB004028: AB_2212507	unprognostic (1.61e-1)	unprognostic (2.03e-1)	unprognostic (9.65e-2)	unprognostic (1.97e-1)	unprognostic (9.63e-2)	unprognostic (1.22e-2)	unprognostic (1.78e-3)	unprognostic (2.59e-2)	unprognostic (1.19e-2)	unprognostic (1.10e-1)	unprognostic (8.79e-3)	unprognostic (1.34e-1)	prognostic unfavourable (7.26e-4)	unprognostic (4.00e-2)	unprognostic (2.30e-1)	unprognostic (3.22e-1)	unprognostic (1.86e-1)	19.7	6.2	1.8	4.4	3.1	0.4	20.5	1.1	2.2	11.4	6	1.8	11.5	2.3	28.8	10.2	5.2	9.5	6.2	12.1	2.3	1.7	7.8	10.4	13.2	14.1	3.1	2.9	6	8.1	8	6.8	34.5	3.9	9.5	1.4	27.6	7.1	10.3	5.3	3	3.8	7.7	2.6	4.4	4.2	5.3	1.2	0.5	20	5.3	3	4.4	12	0.1	0.1	0.7	0	0.2	0.2	0.1	0	0	1.7	0	0.2	0.3	0	0	0	0	0	0	0	0	0.3	0	0	0	0	0	0	0	2.9	0	0	3.7	0	0	0.3	0	0	0.2	31.8	0	0	0.2	0	0	0	0.8	1.1	0	0	0	0	0	0	0	0	0	0	0	0	35.9	0	0	0	0.5	0	0	0	0.4	0	0.1	0.1	0	0.7	0.1	0	0	0	0.2	0	0	0.1	0	0.1	0	0.2	0	0.1	0	0.1	1.8	3.1	1.1	2.2	2.3	1.7	3.1	2.9	3.9	1.2
KEL	"CD238, ECE3"	ENSG00000197993	"Kell blood group, metallo-endopeptidase"	P23276	7	142941114-142962681	"Blood group antigen proteins, Cancer-related genes, CD markers, Enzymes, Predicted intracellular proteins, Predicted membrane proteins"		"Blood group antigen, Hydrolase, Metalloprotease, Protease"	Cancer-related genes	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in some	6	bone marrow: 21.1;testis: 36.4	Group enriched	Detected in some	12	HEL: 14.9;K-562: 12.1	Low cancer specificity	Detected in some			Low region specificity	Detected in some			Cell type enriched	Detected in single	7	intermediate monocyte: 1.4	Lineage enriched	Detected in single	14	monocytes: 1.4	Not detected	Not detected			Low region specificity	Detected in single			HPA064442			Supported	"Nucleoplasm,Plasma membrane,Cytosol"				Plasma membrane	"Nucleoplasm, Cytosol"	HPA064442: 	unprognostic (5.78e-3)	unprognostic (1.08e-5)	unprognostic (5.29e-3)	unprognostic (4.85e-3)	unprognostic (9.68e-2)	unprognostic (1.96e-2)	unprognostic (1.03e-1)	unprognostic (1.54e-2)	unprognostic (5.18e-2)	unprognostic (1.08e-2)	unprognostic (3.71e-2)	unprognostic (3.57e-2)	unprognostic (2.29e-3)	unprognostic (9.24e-2)	unprognostic (7.05e-2)	unprognostic (3.32e-2)	unprognostic (3.25e-3)	0.2	0	0.9	2.5	1.1	21.1	0.2	0.2	0.4	0.4	0.2	0.3	0.2	0	0.2	0.2	0.6	0.1	0.2	0.2	1.4	0.7	0.4	0.2	1.4	5	2	0.2	0.2	0.2	0	0.2	1.1	0.3	0.2	0	0.3	2.5	0.2	0.2	0	0.5	0.2	4.4	3.8	0	36.4	0.3	0.4	0.2	0.2	3.7	0.2	0.2	0	0	0	1.4	0	0	0.1	0	0	0.1	0	0	0	0	0.1	0.1	0	0	0.1	0.1	0	0	0	0	0	0	0	0	0	14.9	0	0	0	0	0.1	0	0	0	0	0	12.1	0.1	0	0	0.5	0.2	0.3	0	0.1	0	0.1	0	1.1	0	0.1	0.1	0	0.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.4	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0.1	0.9	1.1	0.2	0.4	1.4	0.7	2	0.2	0.3	0.3
KIR2DL1	"47.11, CD158A, cl-42, nkat1, p58.1"	ENSG00000125498	"Killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1"	P43626	19	54769811-54784322	"CD markers, Predicted membrane proteins"		Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level		Tissue enhanced	Detected in some		endometrium 1: 2.8;lung: 4.0;lymphoid tissue: 4.5	Cell line enriched	Detected in single	25	U-266/84: 2.5	Not detected	Not detected			Not detected	Not detected			Cell type enhanced	Detected in single		gdT-cell: 1.4	Lineage enhanced	Detected in single		T-cells: 1.4																				unprognostic (2.14e-1)	unprognostic (9.82e-2)		unprognostic (8.18e-2)		unprognostic (2.19e-2)	unprognostic (3.93e-1)	unprognostic (1.55e-2)	unprognostic (3.19e-4)	unprognostic (4.11e-2)	unprognostic (6.87e-2)		unprognostic (1.14e-2)	unprognostic (1.13e-1)	unprognostic (6.84e-2)	unprognostic (3.61e-2)		0.2	0.1	0	0.1	0	0.1	0.1	0	0.6	0.1	0.1	0	0	0.1	2.8	0.1	0.1	0.1	0.1	0.1	0	0	0.4	2.2	4	0.1	0	0	0.1	0.1	0.1	0	1.8	0	0.1	0.1	0.3	0.1	0.1	0.1	0.1	0.1	0.1	0.8	4.5	0.4	1.4	0	0	0.1	0	0.1	0.1	0	0	0	0	0	0.4	1.4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2.5	0	0	0	0	0	0	0	1.4	0	0	0	0	0	0	0	0	0	0	0.4	0	0	0	0	0	0	0	0.6	0	0	0	0	0	0
KIR2DL3	"CD158B2, cl-6, nkat2, nkat2a, nkat2b, p58"	ENSG00000243772	"Killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3"	P43628	19	54738515-54753052	"CD markers, Predicted membrane proteins"		Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level		Tissue enhanced	Detected in some		lung: 3.0;lymphoid tissue: 5.6	Not detected	Not detected			Not detected	Not detected			Not detected	Not detected			Not detected	Not detected			Not detected	Not detected																						unprognostic (7.37e-2)	unprognostic (2.35e-2)		unprognostic (2.23e-1)		unprognostic (6.88e-2)	unprognostic (2.92e-1)	unprognostic (7.76e-3)	unprognostic (1.55e-2)	unprognostic (1.99e-1)	unprognostic (1.41e-2)		unprognostic (2.41e-4)	unprognostic (1.19e-1)	unprognostic (1.91e-1)	unprognostic (1.62e-2)	unprognostic (1.59e-2)	0.5	0.1	0	0.1	0	0.1	0.2	0	0.5	0.1	0.1	0	0	0.1	2.1	0.1	0.1	0.2	0.1	2.2	0	0	0.1	0.4	3	2.4	0	0	1	0.1	0.1	0	0.8	0.1	1.3	0.1	1.1	1.9	0.1	0.1	0.1	0.1	0.1	0	5.6	0.1	0.1	0.8	0.6	0.1	0	0.2	0.3	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.5	0	0	0	0	0.1	0.8
KIR2DL4	"103AS, 15.212, CD158D"	ENSG00000189013	"Killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 4"	Q99706	19	54803535-54814517	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"		Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in some	5	blood: 5.6;intestine: 7.3;lymphoid tissue: 13.9	Not detected	Not detected			Low cancer specificity	Detected in some			Not detected	Not detected			Cell type enriched	Detected in single	56	NK-cell: 5.6	Lineage enriched	Detected in single	56	NK-cells: 5.6														Intracellular and membrane						unprognostic (1.98e-2)	unprognostic (4.16e-2)	unprognostic (1.84e-2)	unprognostic (3.70e-4)	unprognostic (2.23e-1)	unprognostic (5.95e-4)	unprognostic (1.34e-1)	unprognostic (1.49e-1)	unprognostic (2.92e-5)	unprognostic (5.15e-2)	unprognostic (1.14e-1)	unprognostic (1.32e-1)	unprognostic (4.53e-8)	unprognostic (6.47e-2)	unprognostic (2.66e-1)	unprognostic (6.10e-4)	unprognostic (3.59e-3)	0.2	0.3	0	2.8	0	0.3	0.1	0	0.2	0.1	3.8	0	0	0.1	1.4	0.2	0.2	0.2	0.3	0.9	0.1	0	0.2	0.3	1.2	0.3	0	0	1.1	0.1	0.1	0.1	1.7	0	0.2	0.3	0	0.1	0.8	0.1	0.1	7.3	0.1	0	13.9	0.3	0.3	0	0.4	0.5	0	1.5	0.8	0.1	0	0	0	0	5.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5.6	0	0	0	0	0	0	0	0.2	0.1	0	0	0	0	0
KIR3DL1	"AMB11, CD158E1, CD158e1/2, CD158e2, cl-11, cl-2, KIR, nkat3, NKB1, NKB1B"	ENSG00000167633	"Killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1"	P43629	19	54816468-54830778	"CD markers, Predicted membrane proteins"		Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level		Tissue enhanced	Detected in some		blood: 5.4;bone marrow: 2.0;lymphoid tissue: 3.0	Not detected	Not detected			Not detected	Not detected							Cell type enriched	Detected in some	4	gdT-cell: 5.4	Lineage enriched	Detected in many	4	T-cells: 5.4																				unprognostic (3.18e-1)	unprognostic (8.01e-2)		unprognostic (3.53e-2)	unprognostic (4.85e-1)	unprognostic (5.18e-3)	unprognostic (6.19e-2)	unprognostic (4.37e-2)	unprognostic (9.97e-2)	unprognostic (1.89e-2)	unprognostic (3.28e-1)	unprognostic (7.34e-2)	unprognostic (2.07e-3)	unprognostic (3.22e-2)	unprognostic (2.07e-1)	unprognostic (1.73e-1)	unprognostic (2.19e-2)	0.1	0	0	0	0	2	0.1	0	0	0	0			0	0.2	0	0	0	0	0.1	0	0	0	0.3	1.1	0.1	0		0	0	0	0	0		0	0		0	0	0	0	0.2	0	0	3	0	0			0.1		0	0	0	0	0	0	0	1.2	5.4	0.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5.4	0	0	0	0	0.8	0	0	0	0.2	0	1.2	0	0	0	0.5										
KIR3DL2	"CD158K, cl-5, nkat4, nkat4a, nkat4b"	ENSG00000240403	"Killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 2"	P43630	19	54850443-54867207	"CD markers, Predicted membrane proteins"		Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in some		heart muscle: 2.0;lymphoid tissue: 5.3;salivary gland: 2.0	Not detected	Not detected			Not detected	Not detected			Not detected	Not detected			Cell type enhanced	Detected in single		naive CD8 T-cell: 1.2	Lineage enhanced	Detected in single		T-cells: 1.2																				unprognostic (6.99e-2)	unprognostic (1.83e-1)		unprognostic (3.64e-1)		unprognostic (4.56e-4)	unprognostic (1.40e-1)	unprognostic (2.99e-2)	unprognostic (8.39e-3)	unprognostic (5.96e-2)	unprognostic (2.73e-1)	unprognostic (2.12e-1)	unprognostic (4.04e-3)	unprognostic (1.22e-1)	unprognostic (2.58e-1)	unprognostic (1.65e-3)	unprognostic (3.62e-2)	0.2	0	0	0.1	0	1.2	0	0	0	0	0.1	0	0	0	0	0	0	0	0	2	0	0	0	0.3	1.2	0	0	0	0	0	0	0	0	0	0	0	0.6	2	0	0	0	0.8	0	0	5.3	0	0	0	0	0	0	2	0	0	0	0	0.5	0	0	1.2	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0.9	0	0.1	0	0	0	0	1.2	0.5	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0
KIT	"C-Kit, CD117, PBT, SCFR"	ENSG00000157404	KIT proto-oncogene receptor tyrosine kinase	P10721	4	54657918-54740715	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins"		"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		breast: 65.5	Group enriched	Detected in some	13	HEL: 47.7;HMC-1: 100.2	Low cancer specificity	Detected in many			Low region specificity	Detected in all			Group enriched	Detected in some	6	basophil: 12.7;eosinophil: 10.0;NK-cell: 9.7	Group enriched	Detected in many	6	granulocytes: 12.7;NK-cells: 9.7	Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB003288, HPA004471, CAB068253, CAB072867, HPA073252"	Enhanced	Supported	Supported	Plasma membrane		48000000	48000000	Plasma membrane		"CAB003288: AB_2335702, CAB068253: , CAB072867: , HPA004471: AB_1078431, HPA073252: "	unprognostic (1.55e-2)	unprognostic (1.91e-1)	unprognostic (4.04e-2)	unprognostic (8.19e-2)	unprognostic (3.96e-2)	unprognostic (2.18e-2)	unprognostic (2.33e-2)	unprognostic (1.97e-2)	unprognostic (3.60e-2)	unprognostic (1.64e-1)	unprognostic (2.20e-1)	unprognostic (1.92e-2)	prognostic favourable (5.63e-4)	unprognostic (1.34e-3)	unprognostic (1.87e-1)	unprognostic (1.29e-2)	unprognostic (2.30e-1)	8.1	1.6	9.5	6.6	11.8	3.7	65.5	18.3	12	12.1	10.3	6.5	10.2	5.8	8.9	4.2	9.9	2.5	15.5	2.4	36	4.4	9.4	1.1	13.8	3.8	3.6	6	28.5	2.1	1.3	2.3	6.2	5.7	9.6	10.4	20.7	12.9	6.9	1.3	14.6	8.9	10.2	3.9	3.2	12.8	4	4.5	0.4	28.9	4.3	4.9	9.8	12.5	0	1.8	12.7	0.9	9.7	1.9	0.1	0	0	0.7	0	0.1	0	0	0.6	0.9	2.5	3.2	0	0	0	0	1.4	0	0.5	0	2.1	0	1.1	47.7	0	0	0	0	100.2	0	0	0	0	5.6	0.6	0.1	0	0	0.2	0.4	1.3	0	0.1	0	0	0	4.7	1.2	0.4	0	0	0	0	0.5	0	0.1	0	1	0	0	0	0	0.1	0.1	0.1	12.7	0	10	0.1	0	1.9	0	0.3	0.7	1.8	0	0	0	0.8	9.7	0.9	0	0	0.1	9.5	11.8	18.3	12	36	4.4	3.6	6	5.7	4.5
KLRB1	"CD161, CLEC5B, hNKR-P1A, NKR, NKR-P1, NKR-P1A"	ENSG00000111796	Killer cell lectin like receptor B1	Q12918	12	9594551-9607886	"CD markers, Predicted membrane proteins"		Receptor		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enriched	Detected in many	7	blood: 178.9	Cell line enhanced	Detected in some		HEL: 3.0;Karpas-707: 2.2	Low cancer specificity	Detected in many			Low region specificity	Detected in single			Cell type enhanced	Detected in many		MAIT T-cell: 178.9	Group enriched	Detected in many	133	NK-cells: 53.0;T-cells: 178.9					Low region specificity	Detected in all			HPA039113	Approved		Uncertain	"Nucleoplasm,Cytosol"				Nucleoplasm	Cytosol	HPA039113: AB_10674979	prognostic favourable (3.51e-5)	unprognostic (1.23e-3)	unprognostic (7.03e-3)	prognostic favourable (1.42e-5)	unprognostic (1.69e-1)	prognostic favourable (6.99e-5)	unprognostic (1.54e-3)	unprognostic (7.15e-3)	unprognostic (4.12e-1)	unprognostic (8.23e-3)	unprognostic (3.57e-2)	unprognostic (1.65e-1)	unprognostic (1.17e-2)	unprognostic (2.45e-1)	unprognostic (1.34e-1)	prognostic favourable (5.61e-4)	unprognostic (1.17e-2)	3.8	0.8	0.8	22.8	0.8	18.6	2.1	0.5	0.6	2.9	9.1	0	1.3	5	1.8	3.7	2.6	1.8	7.3	1.3	0.7	0.8	3.8	4.9	11.8	23.7	1.1	0.2	2	1	0	0.9	2.1	0.8	1.8	3.9	0.9	4.8	1.4	0.9	0.8	20.4	0.6	1.8	25.2	4.4	1.3	0.2	6.2	1.9	2.9	17.7	5.5	2	0.1	0.3	0.8	0.2	53	178.9	18.5	0	0	1.5	0.1	0	0	1.6	0	0	0	0	0	0.4	1.3	0.1	0	0.2	1.9	0	0	0.2	0	3	0	0.4	0	0.6	0.6	0	0	0	0	0	0.2	2.2	0	0.8	0.8	0.6	0.5	0	1.1	0.2	0.9	0	0.5	0.4	0.6	0.6	0.7	0.1	0.3	0.2	0	1.6	0	0.4	0.7	0.6	0.4	1.5	0	1.8	0.9	0.5	0.1	0	43.1	0.1	178.9	0.1	25.6	28.1	0.1	0.1	1.5	8.7	0.8	53	0.2	0.3	5.7	18.5	0.8	0.8	0.5	0.6	0.7	0.8	1.1	0.2	0.8	0.2
KLRC1	"CD159a, NKG2, NKG2-A, NKG2-B"	ENSG00000134545	Killer cell lectin like receptor C1	P26715	12	10442264-10454685	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"		Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	7	blood: 64.3;lymphoid tissue: 22.1	Cell line enhanced	Detected in some		HeLa: 9.3;Karpas-707: 3.8	Low cancer specificity	Detected in some			Low region specificity	Detected in many			Group enriched	Detected in many	7	gdT-cell: 45.7;NK-cell: 64.3	Group enriched	Detected in many	42	NK-cells: 64.3;T-cells: 45.7									HPA058052			Approved	Plasma membrane				Plasma membrane		HPA058052: 	unprognostic (8.17e-3)	unprognostic (2.13e-2)	unprognostic (1.48e-2)	unprognostic (4.58e-7)	unprognostic (3.57e-1)	unprognostic (1.17e-2)	unprognostic (1.05e-1)	unprognostic (3.68e-2)	unprognostic (3.73e-4)	unprognostic (4.13e-2)	unprognostic (6.49e-2)	unprognostic (2.54e-1)	unprognostic (1.18e-4)	unprognostic (1.88e-1)	unprognostic (3.23e-1)	unprognostic (2.45e-1)	unprognostic (1.92e-3)	2.4	0.5	1.2	5.8	1.4	5.6	2.3	1	2.7	1.7	3.3	0.7	1.2	1.5	5.5	3.9	1.7	2.5	2.4	2.6	1.6	1.3	1.9	2	5.9	10.3	2.3	0.6	1.2	1.4	0.3	1.3	3.6	1.5	1.9	2.5	2	3.1	0.3	0.5	1	5	2.1	2.6	22.1	5.2	1.4	0.5	3.5	1.9	3	2.9	2.9	1.8	0.1	0	1.2	0.1	64.3	45.7	5.1	0.4	1.6	0.1	0.1	0.6	0.4	0.8	0	0	0.8	1.7	0	1.3	0.2	0.1	0.4	0.3	0.6	2.8	1.1	0.9	0.4	2.1	9.3	0	0.1	0.6	0.4	1	0	0.3	0	0.8	1.3	3.8	0.8	0	0.2	2.8	0	0	0.9	0.2	0.3	0.2	0	0.5	0.1	0.8	0	0.3	0.3	0	2.6	0.4	0	0	0.3	0	0	0.7	2.2	0.8	0	0.2	0	0	45.7	0	5.8	0.1	0	7.9	0	0	0	6.9	1.2	64.3	0.1	0	0	5.1	1.2	1.4	1	0.9	1.6	1.3	2.3	0.6	1.5	0.5
KLRC2	"CD159c, NKG2-C"	ENSG00000205809	Killer cell lectin like receptor C2	P26717	12	10426854-10442300	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"		Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level		Tissue enhanced	Detected in many		blood: 32.8;brain: 16.2	Cell line enhanced	Detected in some		HEL: 6.1;HeLa: 19.0;HSkMC: 4.6;U-87 MG: 3.1	Cancer enriched	Detected in single	8	glioma: 3.6	Low region specificity	Detected in all			Group enriched	Detected in some	5	gdT-cell: 10.7;NK-cell: 32.8	Group enriched	Detected in many	92	NK-cells: 32.8;T-cells: 10.7									HPA058052			Approved	Plasma membrane				Plasma membrane		HPA058052: 	unprognostic (9.05e-4)	unprognostic (2.54e-2)	unprognostic (3.77e-2)	unprognostic (2.51e-3)	unprognostic (2.83e-1)	unprognostic (9.49e-4)	unprognostic (1.27e-1)	unprognostic (8.74e-2)	unprognostic (2.88e-1)	unprognostic (4.00e-3)	unprognostic (2.88e-2)	unprognostic (9.16e-3)	unprognostic (1.55e-9)	unprognostic (8.10e-2)	unprognostic (2.34e-1)	unprognostic (8.93e-2)	unprognostic (5.31e-3)	0.5	0.2	8.2	0.6	4.6	2.8	1.1	1.2	16.2	0.4	1.9	2.3	0.1	1	1.4	1	0.8	0.6	1.7	0.2	6.1	5.4	0.1	1.1	1.4	1.5	6.2	2.6	1.5	0.1	0	0.1	0.6	3.7	0.3	1.3	0.1	0.5	0.3	0.1	0.2	1.8	0.1	4.1	8.1	3.2	0.5	1.7	2.2	0.2	0.1	2	1.2	0.1	0	0	0.2	0	32.8	10.7	1.7	0	1	0	0.3	0	0.2	0	0	0	0	0.1	0	0	0.2	0	0	0	0	2.4	0	0	0	6.1	19	0.3	0	0.6	0	4.6	0.1	0	0.4	0	0.1	0	0.7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2	0	0.1	1.2	0.2	0.4	0	0	0	0	0.6	3.1	0.1	0.1	0	0	0	10.7	0	0.2	0	0	4.7	0	0	0	3.7	0.2	32.8	0	0	0	1.7	8.2	4.6	1.2	3.6	6.1	5.4	6.2	2.6	3.7	1.7
KLRD1	CD94	ENSG00000134539	Killer cell lectin like receptor D1	Q13241	12	10226058-10329600	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"		Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	4	blood: 85.5;lymphoid tissue: 31.0;pituitary gland: 44.6	Low cell line specificity	Detected in many			Low cancer specificity	Detected in single			Low region specificity	Detected in many			Group enriched	Detected in many	7	gdT-cell: 67.2;memory CD8 T-cell: 28.0;naive CD8 T-cell: 30.3;NK-cell: 85.5	Group enriched	Detected in many	63	NK-cells: 85.5;T-cells: 67.2	Not detected	Not detected							HPA069688	Uncertain									HPA069688: 	unprognostic (3.75e-2)	unprognostic (2.15e-3)	unprognostic (4.95e-2)	unprognostic (2.48e-3)	unprognostic (2.13e-2)	unprognostic (2.60e-3)	unprognostic (2.26e-2)	unprognostic (1.13e-1)	unprognostic (8.94e-3)	unprognostic (4.53e-3)	unprognostic (8.78e-2)	unprognostic (2.97e-2)	unprognostic (1.47e-3)	unprognostic (1.78e-1)	unprognostic (3.07e-1)	unprognostic (3.06e-1)	unprognostic (1.37e-2)	5.2	1.3	0.9	6.4	1.1	6.9	1.7	0.8	0.9	1.4	2.7	0.6	0.2	1.5	3.3	1.9	2	1.1	1.5	1.7	1	1	1.5	3.7	12.3	10.2	3.8	0.7	0.9	1.9	0	44.6	2.3	0.8	2	0.9	2.1	1.2	0.5	1.1	0.8	10.6	0.5	2.6	31	1.8	1.4	0.4	2.2	1.3	0.3	3.6	6.3	1.3	0.1	0.2	1.2	0.2	85.5	67.2	16.2	0.9	0.7	1.1	1.5	1.5	0.6	0.9	2.3	0.1	0.2	0.7	1.4	1	1.3	1.1	1.8	1.1	0.5	1.3	0.2	2.2	2.8	1.7	2.6	0.6	2.7	1	2.1	0.7	1.7	0.4	1.2	0.3	1	4.9	0.3	1.9	1	1.3	1.7	1.4	0.6	1.6	1.2	0.7	2.1	2.4	1.2	1.1	2.2	0.5	0.8	2	1.7	1.7	3.1	1.5	0.7	2	1.8	1.1	2.6	1.6	1.6	0.1	0.1	0.1	67.2	0.2	7.6	0.1	0.4	28	0.2	0.1	0.1	30.3	1.2	85.5	0.1	0.2	0.1	16.2	0.9	1.1	0.8	0.9	1	1	3.8	0.7	0.8	0.4
KLRK1	"CD314, D12S2489E, KLR, NKG2-D, NKG2D"	ENSG00000213809	Killer cell lectin like receptor K1	P26718	12	10372353-10391874	"Cancer-related genes, CD markers, Predicted membrane proteins, Transporters"	"Adaptive immunity, Differentiation, Immunity, Innate immunity"	Receptor	Cancer-related genes	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 50.8;lymphoid tissue: 30.7	Cell line enriched	Detected in some	8	U-698: 36.0	Not detected	Not detected			Low region specificity	Detected in many			Group enriched	Detected in many	39	gdT-cell: 49.4;MAIT T-cell: 18.5;memory CD8 T-cell: 44.0;naive CD8 T-cell: 44.3;NK-cell: 50.8	Group enriched	Detected in many	47	NK-cells: 50.8;T-cells: 49.4	Not detected	Not detected			Low region specificity	Detected in all			"CAB021896, HPA068877"	Enhanced		Supported	Plasma membrane		33000	33000	Plasma membrane		"CAB021896: , HPA068877: "	unprognostic (3.34e-4)	unprognostic (2.65e-4)	unprognostic (3.25e-1)	unprognostic (2.59e-2)	unprognostic (1.53e-1)	unprognostic (1.01e-5)	unprognostic (5.61e-4)	unprognostic (1.00e-3)	unprognostic (1.33e-1)	unprognostic (9.22e-2)	unprognostic (1.28e-2)	unprognostic (2.10e-2)	unprognostic (6.56e-10)	unprognostic (1.24e-2)	unprognostic (6.32e-2)	unprognostic (7.59e-2)	unprognostic (7.08e-10)	4.1	0.9	1.3	18.3	1.1	10.6	2.1	0.4	0.8	2.8	4.5	1.2	0.6	2	2.4	2.7	3.1	2	7.7	1.3	1.3	1.1	2.4	3.6	13.6	22.2	2.1	0.1	1.5	3.3	0	1.2	1.6	1.2	2.2	2.1	2.4	7	0.6	0.5	1.1	13.1	1.3	2.1	30.7	3.3	1.9	0.6	6	2.9	2.8	11.4	11.3	2.5	1	0.2	0.8	0.1	50.8	49.4	16.7	0.2	0	0.4	1.8	0.1	4.6	0.4	0	0	0	0	0.2	0	0.3	0	0	0.3	0	0.1	0	0	0	0	0.7	0	0	0	0.2	1.6	0	0	0.1	0	0.7	0	0.2	0	0.2	0.1	0.3	0	0.3	0	0	0	0	0.5	0.2	0	0	0	0.1	0.1	0	0.1	0.5	0	0	0	0	36	0.1	0	0.2	0	0	0	49.4	0.1	18.5	0.8	0.3	44	0.1	1	0.4	44.3	0.8	50.8	0.1	0.2	0.1	16.7	1.3	1.1	0.4	0.8	1.3	1.1	2.1	0.1	1.2	0.6
L1CAM	"CD171, HSAS, HSAS1, MASA, MIC5, S10, SPG1"	ENSG00000198910	L1 cell adhesion molecule	P32004	X	153861514-153886174	"CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Differentiation, Neurogenesis"	Developmental protein	"Disease mutation, Hereditary spastic paraplegia, Hirschsprung disease, Mental retardation, Neurodegeneration"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		adrenal gland: 29.6;brain: 54.5	Cell line enhanced	Detected in many		BJ hTERT+: 72.2;BJ hTERT+ SV40 Large T+ RasG12V: 39.7;HeLa: 52.1;RPTEC TERT1: 42.4	Cancer enhanced	Detected in many		melanoma: 34.1	Low region specificity	Detected in all			Group enriched	Detected in some	5	memory B-cell: 1.0;naive B-cell: 2.2	Lineage enriched	Detected in single	7	B-cells: 2.2	Low region specificity	Detected in all			Low region specificity	Detected in all			CAB010896	Enhanced		Approved	"Nucleoplasm,Plasma membrane"		59000000	59000000	Nucleoplasm	Plasma membrane	CAB010896: AB_609903	unprognostic (1.33e-3)	unprognostic (3.43e-2)	unprognostic (2.75e-1)	prognostic unfavourable (8.51e-10)	unprognostic (2.04e-2)	prognostic unfavourable (3.81e-4)	unprognostic (9.44e-2)	prognostic unfavourable (2.36e-6)	unprognostic (1.13e-1)	unprognostic (9.12e-2)	unprognostic (8.52e-3)	unprognostic (8.02e-2)	prognostic unfavourable (1.17e-4)	unprognostic (3.07e-1)	unprognostic (6.31e-2)	unprognostic (1.69e-1)	unprognostic (7.47e-3)	4.4	29.6	19.9	8	21.9	1.2	1.7	54.5	43.6	2.8	16.3	1.5	2	4.9	1.7	3	5.3	2.6	3.2	5.2	11.2	20.6	12.3	1.3	1.3	3.7	7.3	22.4	1.4	3	1	6.1	1.4	19.3	3.5	5.7	6.2	5.9	10.8	1.6	9.9	7.6	6.1	3.5	1.7	4.8	1.5	3.4	0	1.2	1.3	2.6	2.3	3.9	2.2	0	0	0	0	0.3	0.2	17.6	1.3	5.4	0	0	0	2.3	25	72.2	24.2	39.7	7.1	0.1	0	23.9	0.1	0.7	0.6	0.4	12.7	0	0.1	0	52.1	1.1	0	0	4	0.1	0.3	3.6	2.5	0	0	0	0.1	23.9	0	0.5	1.2	0.9	0	31.7	0.1	42.4	0.3	15.9	10.4	14	12.5	10.2	1.3	0.3	0	0	10.6	1.1	11.9	0.2	0.3	0.1	0.1	0.2	20.3	0	0	0	0	0	0	1	0.3	0	0	2.2	0	0	0	0	0	0	0	0.2	19.9	21.9	54.5	30.2	11.2	20.6	7.3	22.4	19.3	3.4
LAG3	CD223	ENSG00000089692	Lymphocyte activating 3	P18627	12	6772512-6778455	"CD markers, Predicted membrane proteins, Predicted secreted proteins"	"Adaptive immunity, Immunity"			Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		lymphoid tissue: 58.1;ovary: 28.4	Cell line enriched	Detected in single	144	HDLM-2: 55.8	Low cancer specificity	Detected in all			Region enhanced	Detected in single		pons and medulla: 2.7	Cell type enhanced	Detected in many		gdT-cell: 11.3;MAIT T-cell: 9.2;memory CD8 T-cell: 10.0	Lineage enriched	Detected in single	56	T-cells: 11.3	Low region specificity	Detected in all			Low region specificity	Detected in many			"CAB002301, HPA013967"	Enhanced				Secreted - unknown location					"CAB002301: AB_564101, HPA013967: AB_1846277"	unprognostic (9.39e-2)	prognostic favourable (3.89e-4)	unprognostic (8.88e-2)	unprognostic (7.00e-3)	unprognostic (1.08e-1)	unprognostic (6.74e-3)	unprognostic (8.85e-2)	unprognostic (4.63e-3)	unprognostic (1.94e-2)	unprognostic (1.97e-3)	unprognostic (8.71e-2)	unprognostic (9.93e-2)	prognostic unfavourable (4.62e-11)	unprognostic (3.07e-2)	unprognostic (2.70e-1)	unprognostic (6.13e-2)	unprognostic (8.19e-3)	1.7	0.4	0.3	33.2	0.3	1	1	0.8	0.7	7.7	4.4	0.5	2.7	2.9	6.4	3.3	2.4	3.8	3	2.2	0.3	0.4	1.2	5.9	3.8	12.4	0.4	0	28.4	0.4	0.1	1	1.3	2.7	2.8	1.8	1.1	2	6.8	0.8	0.6	9.6	1.7	0.9	58.1	2	6.1	0.1	4.1	1	1.3	23.5	2.6	3.6	0	0.2	0	0	0	11.3	0.8	0	0.2	0.3	0.2	0	0	0.1	0	0	0.1	0	0.1	0.1	0	0	0.2	0	0.2	0	0	55.8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3	0	0.3	0	0	0	0	0	0	0	0	0	0	0.1	0	0.1	0.1	0.2	0.2	0	0	0	0	0	0	0	0	0	0	0	11.3	0	9.2	0	2.2	10	0	0	0.6	4	0	0	0	0.2	1.7	0.8	0.3	0.3	0.8	0.7	0.3	0.4	0.4	0	2.7	0.1
LAIR1	CD305	ENSG00000167613	Leukocyte associated immunoglobulin like receptor 1	Q6GTX8	19	54351384-54370558	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		lymphoid tissue: 39.0	Group enriched	Detected in some	5	HMC-1: 6.5;Karpas-707: 16.7;THP-1: 19.0	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Low cell type specificity	Detected in many			Low lineage specificity	Detected in all											HPA011155	Enhanced		Supported	Plasma membrane		130000	130000	Plasma membrane		HPA011155: AB_1852685	unprognostic (1.91e-1)	unprognostic (1.12e-2)	unprognostic (2.81e-2)	unprognostic (1.25e-2)	unprognostic (2.03e-2)	unprognostic (4.38e-2)	unprognostic (2.16e-2)	unprognostic (1.74e-1)	unprognostic (5.00e-2)	unprognostic (2.24e-1)	unprognostic (2.21e-1)	unprognostic (7.11e-2)	prognostic unfavourable (5.01e-5)	unprognostic (1.72e-1)	unprognostic (2.72e-3)	unprognostic (3.52e-2)	unprognostic (5.22e-2)	12.7	7	4.5	10.9	9.9	13.5	6.9	0.5	4.5	2.7	5.1	6.7	0.2	2.7	2.2	6.8	2.5	3.6	4.4	3.9	5.2	4.2	3.8	2.9	16.5	33.1	10.2	1.9	2	2.4	1.4	2.8	7	7	3	2	3.1	3.9	2.2	2.3	2.3	7.6	7.8	11.9	28.6	2.9	3.1	7.4	39	2	0.5	6.1	3.7	1.7	6	10.3	12.4	8.8	5.8	8	5.7	0	0	0	0	0.1	0.1	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0.8	0	0.2	0	0	0	2.7	6.5	0	0	0	0	0	0	16.7	0	0	2.1	1.5	0	0	2.1	0.1	2.5	0	0	0	0.1	0	0	0	0	19	0.1	0	0	0.1	0	0.2	0	0	0.2	2.6	0.2	12.4	4.2	10	8	8.3	4.6	2.3	2.4	4.3	0.1	6	3.8	4.9	0.6	5.8	8.8	10.3	1.6	5.7	4.5	9.9	0.5	4.5	5.2	4.2	10.2	1.9	7	7.4
LAIR2	CD306	ENSG00000167618	Leukocyte associated immunoglobulin like receptor 2	Q6ISS4	19	54497879-54510687	"CD markers, Predicted intracellular proteins, Predicted secreted proteins"		Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in some	4	blood: 12.8;lymphoid tissue: 19.6;pituitary gland: 7.1;placenta: 15.5	Group enriched	Detected in some	5	BEWO: 6.8;Hep G2: 3.3	Low cancer specificity	Detected in many			Low region specificity	Detected in many			Cell type enriched	Detected in some	4	T-reg: 12.8	Lineage enriched	Detected in single	21	T-cells: 12.8														Secreted - unknown location						unprognostic (1.99e-3)	unprognostic (7.49e-2)	unprognostic (4.19e-2)	unprognostic (1.02e-2)	unprognostic (1.42e-1)	unprognostic (4.86e-4)	unprognostic (1.06e-2)	unprognostic (8.37e-2)	unprognostic (1.16e-1)	unprognostic (3.93e-1)	unprognostic (2.21e-1)	unprognostic (9.52e-2)	unprognostic (3.68e-9)	unprognostic (1.21e-2)	unprognostic (3.15e-3)	unprognostic (3.40e-5)	unprognostic (6.71e-2)	0.9	0.5	0.6	5.9	1.7	1.6	0.5	0.2	1.3	0.4	0.6	1.3	0	0.4	0.5	1.3	0.7	0.5	1.3	0.4	1.4	3	0.6	0.8	3.2	12.3	0.6	0.5	0.2	0.9	0.1	7.1	15.5	1.3	0.8	1.3	0.4	0.5	0.4	0.6	0.5	1.2	0.5	1.5	6.6	1	1.2	0.4	19.6	0.5	0	2	0.3	0.3	0	0	0.1	0.1	0.6	12.8	1.8	0	0	0	0	0	0	6.8	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0.1	0	0.2	0	3.3	0	0.3	0	0	0	0	0	0	0	0.3	0	0	0	0.6	0	0	0	0	0	0	0	0	0	0	0	0.3	0	0.4	0	0	0.3	0	0	0.7	0.3	0.1	0	1	0	0	0.1	0	0.2	0	0.4	0	3	2	0	0	0.8	2.7	0.1	0.6	0.1	0	12.8	1.8	0.6	1.7	0.2	1.3	1.4	3	0.6	0.5	1.3	0.4
LAMP1	CD107a	ENSG00000185896	Lysosomal associated membrane protein 1	P11279	13	113297241-113323672	"CD markers, Plasma proteins, Predicted membrane proteins, Transporters"	Host-virus interaction	"Host cell receptor for virus entry, Receptor"		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Low cell line specificity	Detected in all			Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all			Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB004260, HPA014750"	Supported					460000000	460000000			"CAB004260: AB_626851, HPA014750: AB_1846219"	unprognostic (3.98e-1)	unprognostic (1.18e-1)	unprognostic (7.55e-2)	unprognostic (1.37e-1)	unprognostic (1.04e-1)	unprognostic (7.04e-3)	unprognostic (9.26e-2)	unprognostic (1.07e-1)	unprognostic (5.80e-2)	unprognostic (1.44e-2)	unprognostic (2.91e-3)	unprognostic (2.04e-1)	prognostic favourable (4.15e-5)	unprognostic (2.06e-2)	unprognostic (2.22e-1)	unprognostic (2.59e-1)	unprognostic (1.54e-1)	61.3	41.9	34.6	36.7	44.7	28.5	70.7	17.6	50.6	50.4	39	77.9	46.7	49.9	55.7	73.4	50.6	38.1	60.8	45	38	30.7	61.2	83.3	74.6	78.1	64.3	42.3	44.4	79.5	38.2	43.7	68.6	42.1	47	31.3	30.1	60.6	47.8	26.6	72	46.7	43.3	67.6	46.2	43.6	41.6	57.3	34.9	59.5	43.1	37	47.6	48.1	3.1	7.6	12.2	7	5.4	6.5	2.7	43.5	15.2	15.8	43.1	88.8	33.5	29.8	51.5	54.3	32.1	43.1	29.6	81.5	10.3	23.6	52.3	56	15.4	32.7	22	21.5	25.5	17	30.1	27.8	46	51.9	39.9	40.8	44.7	29.7	19.5	38.7	14.1	15.2	39.4	17.5	10.4	25.4	11.9	16.6	15.5	13.7	15.5	29.1	33	14.5	15.2	30.3	45	29.7	43.4	37	58.5	33	35.9	43.5	22.9	28.6	28.2	11	55.1	51.9	38.2	3.8	7	12.2	5.9	5.3	5	3.1	4.6	6.5	3.5	3	5.2	4.3	9.2	5.4	5.8	7.6	4.6	2.7	34.6	44.7	17.6	50.6	38	30.7	64.3	42.3	42.1	57.3
LAMP2	CD107b	ENSG00000005893	Lysosomal associated membrane protein 2	P13473	X	120427827-120469365	"CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters"	Autophagy		"Disease mutation, Glycogen storage disease"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in all		ASC diff: 113.5	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in all		neutrophil: 112.9	Lineage enriched	Detected in all	5	granulocytes: 112.9	Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB005272, HPA029100, HPA029101"	Supported		Approved	"Vesicles,Plasma membrane"		820000000	820000000	"Vesicles, Plasma membrane"		"CAB005272: AB_647855, HPA029100: AB_10795022, HPA029101: "	unprognostic (2.99e-3)	unprognostic (5.26e-2)	unprognostic (2.66e-3)	unprognostic (1.74e-1)	unprognostic (3.10e-1)	unprognostic (2.50e-2)	unprognostic (4.84e-1)	unprognostic (1.56e-1)	unprognostic (1.15e-1)	unprognostic (1.55e-1)	unprognostic (9.73e-2)	unprognostic (1.11e-2)	unprognostic (2.50e-2)	unprognostic (2.85e-1)	unprognostic (6.78e-2)	unprognostic (2.66e-1)	unprognostic (5.53e-3)	21.8	33.6	39.9	16.1	87.9	22.6	27.1	16.2	55.5	33	18.3	88.7	27.9	25.1	20.8	37.5	34.6	22.4	43.3	20.9	52.5	30.3	55	83.7	25.3	14.3	131	36.9	22.7	27.4	28.8	20.2	35.4	58.6	37.3	19.7	17.2	47.8	32.9	32.4	26.9	20.5	21.1	84.3	17.9	23.6	11.9	116.9	21.2	33.7	14.3	15.4	21.1	27	3.7	11.6	112.9	21.7	5.4	5.8	10.5	11.8	11.7	8.6	11.1	113.5	38.8	23.9	20.5	35.8	20	37.4	9.7	21.2	8.4	18.1	35.6	20	12.5	15.5	32.6	9.4	8.9	6.6	13	13	37.8	29	18.4	42	31.2	26.6	17.6	27.2	7.6	30	32.3	21.9	8	14.8	6.7	10.4	6.2	14.6	15	29.2	8.8	2.9	4.6	22	22.4	43.8	13.3	32.4	28.1	28.7	13.9	36.9	55.3	15.1	14.4	5.5	27.4	35.1	68.7	4.9	21.7	41.3	5	18.7	4	3.1	4.8	4.7	11.6	3.7	4.3	4.1	112.9	5.4	17.3	6.3	5.8	10.5	39.9	87.9	16.2	55.5	52.5	30.3	131	36.9	58.6	116.9
LAMP3	"CD208, DC-LAMP, DCLAMP, LAMP, TSC403"	ENSG00000078081	Lysosomal associated membrane protein 3	Q9UQV4	3	183122213-183163839	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"			Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enriched	Detected in many	6	lung: 123.9	Group enriched	Detected in some	6	EFO-21: 57.2;HDLM-2: 14.5;HHSteC: 21.2;hTCEpi: 19.4	Low cancer specificity	Detected in many			Not detected	Not detected			Cell type enhanced	Detected in many		eosinophil: 7.6	Group enriched	Detected in many	8	granulocytes: 7.6;T-cells: 6.6	Not detected	Not detected			Low region specificity	Detected in all			"CAB025133, HPA051467"	Enhanced		Enhanced	Vesicles		47000	47000	Vesicles		"CAB025133: , HPA051467: "	unprognostic (1.43e-3)	unprognostic (2.06e-2)	unprognostic (1.70e-1)	unprognostic (2.99e-3)	unprognostic (1.30e-2)	unprognostic (2.15e-1)	unprognostic (7.67e-2)	unprognostic (8.64e-2)	unprognostic (4.95e-2)	prognostic favourable (9.90e-4)	unprognostic (1.80e-3)	unprognostic (5.80e-2)	prognostic unfavourable (1.89e-7)	unprognostic (3.12e-1)	unprognostic (4.13e-2)	unprognostic (8.35e-2)	unprognostic (1.29e-1)	0.5	0.7	0.4	14.1	0.4	0	0.5	0.3	0.4	1	0.6	0.1	0.6	0.4	0.4	1	2.5	0.5	0.8	0.4	0.4	0.4	0.8	0.6	123.9	11.2	0.4	0.1	0.4	8.3	0	0.6	1	0.6	1	1.7	0.2	6.8	1.9	0.4	1.9	1.4	0.8	0.5	2	0.8	8.4	0	21.3	8.3	3.1	11.3	3.3	0.9	0.4	0	7.6	0.1	0.8	6.6	1.1	3.4	0.1	0	0.5	0	0	2.8	0	0.9	0.6	0.1	0.8	1.8	0	57.2	0.2	0.5	1.2	2.1	0.1	14.5	1.7	0	0.1	0.1	21.2	0	0.5	0.3	19.4	0	2.5	2.6	0.1	3.4	0.1	0	0.8	0.1	0.1	0.8	0	0	0.2	0	1.1	0.2	0.1	0.2	0.1	1.5	1.1	0.1	2.7	0	1	0.1	0	1.2	4.3	0.1	0	0	0	0.4	0.1	7.6	0.4	0	3.2	0.1	2.7	1.7	0	0.4	3.5	2	1.9	0.8	0.1	0	6.6	1.1	0.4	0.4	0.3	0.4	0.4	0.4	0.4	0.1	0.6	0
LEPR	"CD295, OBR"	ENSG00000116678	Leptin receptor	P48357	1	65420652-65641559	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"		Receptor	"Cancer-related genes, FDA approved drug targets, Obesity"	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		liver: 82.8	Cell line enhanced	Detected in many		K-562: 46.1;RPTEC TERT1: 22.3	Cancer enriched	Detected in many	7	liver cancer: 13.1	Low region specificity	Detected in all			Cell type enhanced	Detected in many		basophil: 6.9	Low lineage specificity	Detected in many			Low region specificity	Detected in many			Low region specificity	Detected in some			HPA030899	Approved	Supported			Secreted to blood	8300000	8300000			HPA030899: AB_10610003	unprognostic (1.59e-2)	unprognostic (1.09e-3)	unprognostic (3.09e-1)	unprognostic (8.95e-2)	unprognostic (2.32e-1)	unprognostic (2.64e-1)	unprognostic (2.58e-1)	unprognostic (2.30e-1)	unprognostic (1.78e-1)	unprognostic (6.59e-3)	unprognostic (1.79e-1)	unprognostic (2.41e-1)	unprognostic (7.53e-2)	unprognostic (1.11e-1)	unprognostic (2.27e-1)	unprognostic (3.49e-2)	unprognostic (1.73e-1)	15.9	5.5	3.8	3.7	4.3	3.3	23.5	2.5	3.9	15	9.2	5.6	5.4	3.2	20.6	7.3	10.9	11.7	10.1	9.2	4.3	4.9	14.6	82.8	20.3	9	4.9	3.3	18.4	16.7	3.9	13.1	12.8	8.2	10.8	4.1	18.1	12	5.7	5.6	10.2	7.3	12.9	7	6.4	11.9	6.6	3.1	1.9	13.1	11.2	6.9	13.6	8.6	0.6	1.8	6.9	1.9	1.1	2.3	1.8	1.3	0.8	1.1	1.2	5	4.6	3.8	5.9	3.4	2	1.9	0.6	3.2	0.5	4.4	7.4	1.1	0.9	5.1	5.5	6.9	1.5	7.7	3.5	0.1	3	0.5	0.6	13	3	1.2	4.6	5.8	46.1	0.9	9.5	0.3	0.6	0.1	1.8	0.1	0.1	0.9	0.3	22.3	0.6	0.7	11.3	1.4	0.6	1.6	2.1	2	2.2	2.1	4.3	0.4	3.2	1.3	0.8	0.2	4.4	2.2	2	6.9	1.9	2.8	1.3	1.5	1.3	0.6	1.1	1.1	1.8	0.3	0.9	1.5	1.1	1.1	1.7	1.2	2.3	1.8	3.8	4.3	2.5	3.9	4.3	4.9	4.9	3.3	8.2	3.1
LIFR	CD118	ENSG00000113594	LIF receptor alpha	P42702	5	38474963-38608354	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Cancer-related genes, Disease mutation"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in many			Cell line enhanced	Detected in many		AF22: 39.8;HHSteC: 17.0;SCLC-21H: 26.1	Low cancer specificity	Detected in many			Low region specificity	Detected in all			Not detected	Not detected			Not detected	Not detected			Low region specificity	Detected in all			Low region specificity	Detected in all			"HPA004478, CAB010252"			Approved	"Nuclear speckles,Golgi apparatus"	Intracellular and membrane	74000	74000	Nuclear speckles	Golgi apparatus	"CAB010252: AB_2128043, HPA004478: "	unprognostic (6.00e-3)	unprognostic (2.53e-1)	unprognostic (1.05e-1)	unprognostic (2.81e-3)	unprognostic (8.80e-2)	unprognostic (7.13e-2)	unprognostic (1.11e-1)	prognostic favourable (1.92e-4)	unprognostic (1.78e-1)	unprognostic (9.80e-2)	unprognostic (2.73e-3)	unprognostic (1.06e-1)	prognostic favourable (1.40e-7)	unprognostic (3.69e-2)	unprognostic (1.15e-1)	unprognostic (2.03e-2)	unprognostic (1.65e-1)	35.3	14.7	15.8	8.2	19.2	0.5	33.9	10.1	21.3	27.7	10.4	25.3	22.8	4.9	34.8	14.8	10.4	26	10.2	16.3	19.1	11	20.3	23.9	21.7	20.2	24.3	11.8	17.9	17.8	13.5	12.5	41.5	23.4	23.6	7.5	17.1	24.9	24.7	24	10.5	11.7	26.9	21.4	22.5	18.8	9.3	25.3	4.7	31.4	7.3	8.1	13.6	15.8	0	0	0	0	0	0.2	0	0.6	2.2	39.8	3	11.2	12.4	0.3	3.3	1.9	2.7	1.6	0.4	2.1	0	0.5	4.7	0.3	2.6	0.9	4.6	0	3.6	0	4.2	1.5	17	0	0.2	10.4	0.7	6.5	0.7	3.7	1	6.4	3.3	0.5	0	0.1	1	7.1	0	8.4	0	2.6	1	26.1	3.2	13.7	0.6	0	0.9	0	0.7	4.3	8.5	10.1	2	0	0	0	7	0	2.4	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0	0	0	15.8	19.2	10.1	21.3	19.1	11	24.3	11.8	23.4	25.3
LILRA1	"CD85i, LIR-6, LIR6"	ENSG00000104974	Leukocyte immunoglobulin like receptor A1	O75019	19	54593582-54602090	"CD markers, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor		Evidence at protein level	Evidence at transcript level	Evidence at transcript level	Evidence at protein level		Group enriched	Detected in some	9	blood: 22.2;lymphoid tissue: 21.0	Cell line enhanced	Detected in some		REH: 1.2;THP-1: 2.3	Low cancer specificity	Detected in some			Low region specificity	Detected in many			Cell type enhanced	Detected in many		intermediate monocyte: 17.9;non-classical monocyte: 22.2	Low lineage specificity	Detected in many																						unprognostic (4.52e-2)	unprognostic (1.12e-1)	unprognostic (6.30e-2)	unprognostic (1.59e-1)	unprognostic (2.34e-1)	unprognostic (9.46e-3)	unprognostic (1.17e-1)	unprognostic (4.07e-2)	unprognostic (1.12e-1)	unprognostic (4.90e-2)	unprognostic (8.72e-2)	unprognostic (1.13e-1)	unprognostic (8.28e-3)	unprognostic (8.82e-2)	unprognostic (3.79e-4)	unprognostic (2.53e-1)	unprognostic (9.83e-2)	0.7	0.9	1	3.7	1.7	1	0.6	0.2	1.3	0.5	0.3	1.1	0	0.4	0.2	1.7	0.6	0.5	1	0.6	0.9	0.8	0.5	2.1	2.4	18.8	1.5	0.5	0.4	0.4	0.6	0.3	0.8	1.6	0.4	0.7	0.8	1	0.3	0.5	0.3	1	0.5	2.2	21	0.5	0.3	1.1	0.1	0.4	0.4	0.9	0.9	0.2	0	5.4	6.1	22.2	0	0	4.2	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0	0.2	0	0	0.2	0	0	0	0	0	0	0.3	0.1	0	0	0	0	0	0	1.2	0	0	0	0	0	0	0.1	0	0	0	2.3	0	0	0	0	0	0	0	0	0	0.8	0	0	7.4	6.1	0	17.9	0	0	0	0	5.4	0	0	0	5.3	0	22.2	0.7	0	4.2	1	1.7	0.2	1.3	0.9	0.8	1.5	0.5	1.6	1.1
LILRA2	"CD85h, ILT1, LIR-7, LIR7"	ENSG00000239998	Leukocyte immunoglobulin like receptor A2	Q8N149	19	54572920-54590287	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	"Immunity, Innate immunity"	Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	4	blood: 21.6;bone marrow: 21.7;lymphoid tissue: 39.9	Cell line enhanced	Detected in some		NB-4: 2.5;REH: 2.9;THP-1: 5.9;U-937: 13.3	Low cancer specificity	Detected in some			Low region specificity	Detected in many			Cell type enhanced	Detected in many		neutrophil: 21.6	Group enriched	Detected in many	7	granulocytes: 21.6;monocytes: 7.1														Secreted to blood	130000000	130000000				unprognostic (2.04e-1)	unprognostic (7.72e-2)	unprognostic (6.94e-2)	unprognostic (1.78e-1)	unprognostic (1.54e-2)	unprognostic (2.65e-2)	unprognostic (8.45e-2)	unprognostic (3.56e-2)	unprognostic (1.22e-1)	unprognostic (3.53e-5)	unprognostic (2.67e-1)	unprognostic (1.12e-1)	unprognostic (5.43e-2)	unprognostic (5.58e-2)	unprognostic (3.30e-4)	unprognostic (4.21e-2)	unprognostic (6.59e-2)	2.8	1.5	1.4	4.7	1.1	21.7	0.9	0.1	2	0.6	0.8	3	0	0.6	0.5	1	0.5	2.3	1	3.7	1.1	1.1	1.2	3.8	6.8	14.6	2.9	0.4	1.1	0.6	0.5	0.4	1.7	1.4	0.6	0.6	1.1	0.8	0.5	0.6	0.7	0.7	1	3.7	39.9	0.7	0.7	2.3	0.7	0.6	0	0.8	0.9	1.8	0.2	2.1	21.6	7.1	0.3	0.1	3	0	0	0.1	0.1	0	0	0.1	0	0	0	0	0	0	0.4	0	0	0.2	0	0	0	0	0	0.1	0.2	0.1	0	0.4	0.3	0	0	0.1	0	0	0.1	0.3	0	0	0.1	2.5	0	0	2.9	0.1	1	0	0.1	0	0	0	0.1	0.1	0.1	5.9	0	0.1	0.1	0.1	0.1	0	0	0.1	0.1	13.3	0.1	2.4	4.9	1.8	0.1	7.1	0	0.1	0.1	0.1	2.1	0.2	0.1	0.1	21.6	0.3	6.8	0.4	0	3	1.4	1.1	0.1	2	1.1	1.1	2.9	0.4	1.4	2.3
LILRA4	"CD85g, ILT7"	ENSG00000239961	Leukocyte immunoglobulin like receptor A4	P59901	19	54333185-54339150	"CD markers, Predicted membrane proteins"	"Immunity, Innate immunity"	Receptor		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in some	13	blood: 49.7;brain: 12.5;lymphoid tissue: 16.8	Cell line enriched	Detected in single	30	RPMI-8226: 3.0	Low cancer specificity	Detected in many			Low region specificity	Detected in all			Cell type enriched	Detected in some	21	plasmacytoid DC: 49.7	Lineage enriched	Detected in many	21	dendritic cells: 49.7									HPA049418	Approved									HPA049418: 	unprognostic (5.11e-2)	unprognostic (1.21e-4)	unprognostic (2.65e-2)	unprognostic (5.94e-2)	unprognostic (1.44e-1)	unprognostic (1.19e-3)	unprognostic (7.62e-2)	unprognostic (1.36e-3)	unprognostic (1.08e-1)	unprognostic (9.46e-2)	unprognostic (4.90e-2)	unprognostic (9.30e-2)	unprognostic (8.28e-7)	unprognostic (2.12e-2)	unprognostic (1.17e-3)	unprognostic (4.53e-1)	unprognostic (5.86e-2)	0.7	0.4	2.1	2.3	2.5	0.6	0.7	1.1	4.3	0.4	0.9	12.5	0	0.7	0.4	0.4	0.6	0.4	0.8	0.4	3.5	1.4	0.4	0.7	1.4	5.3	12.2	1.2	0.4	0.4	0.4	0.3	0.4	7.6	0.5	0.5	0	0.7	0.5	0.4	0.6	2	0.6	7.4	16.8	0.5	0.5	6.7	2.3	0.4	0	10.1	0.7	0.2	2.4	49.7	0	0	0.1	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2.4	0	0	0.2	1.2	0	0	0	0.1	0	49.7	0	0.1	2.1	2.5	1.1	4.3	3.5	1.4	12.2	1.2	7.6	6.7
LILRA5	"CD85, CD85f, ILT11, LILRB7, LIR9"	ENSG00000187116	Leukocyte immunoglobulin like receptor A5	A6NI73	19	54307070-54313139	"CD markers, Predicted membrane proteins, Predicted secreted proteins"	"Immunity, Innate immunity"	Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 30.2;lymphoid tissue: 67.3	Cell line enriched	Detected in single	11	RPMI-8226: 4.0	Low cancer specificity	Detected in many			Not detected	Not detected			Group enriched	Detected in many	8	classical monocyte: 10.6;intermediate monocyte: 27.0;neutrophil: 14.5;non-classical monocyte: 30.2	Group enriched	Detected in many	8	granulocytes: 14.5;monocytes: 30.2														Secreted to blood	370000	370000				unprognostic (8.52e-2)	unprognostic (3.61e-1)	unprognostic (2.23e-1)	unprognostic (1.77e-1)	unprognostic (1.57e-2)	unprognostic (6.56e-2)	unprognostic (2.90e-1)	unprognostic (1.86e-1)	unprognostic (3.11e-1)	unprognostic (6.61e-3)	unprognostic (2.01e-1)	unprognostic (1.50e-1)	prognostic unfavourable (7.78e-4)	unprognostic (3.61e-2)	unprognostic (6.51e-3)	unprognostic (4.68e-2)	unprognostic (6.21e-2)	3.4	0.6	0.3	9.9	0.3	19.1	0.7	0.1	0.3	0.4	0.6	0.1	0	0.8	0.4	2	0.6	2	0.9	7	0.2	0.2	1.7	10.8	14.4	24.2	0.5	0	1.5	0.4	0.1	0.4	1.3	0.6	0.6	0.7	0.6	0.5	0.3	0.9	0.1	1.8	1.3	0.7	67.3	1	0.6	0	0.1	1.4	0.4	0.4	2.7	2.8	0	2.6	14.5	30.2	0	0	5.1	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0.1	0	0	0	0.1	0	0	0	0	0.1	0	0	0	0	0.3	0	0	0.1	0	0	0	0.3	0	0	0	0	0	0	0	0	4	0	0	0	0	0.1	0.1	0.1	0	0.2	0	0	0	0	0	0	0	0	0	0.2	0	0	10.6	0	0	27	0	0	0	0	2.6	0	0	0	14.5	0	30.2	2.1	0	5.1	0.3	0.3	0.1	0.3	0.2	0.2	0.5	0	0.6	0
LILRB2	"CD85d, ILT4, LIR-2, LIR2, MIR-10, MIR10"	ENSG00000131042	Leukocyte immunoglobulin like receptor B2	Q8N423	19	54273821-54281184	"CD markers, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 37.9;bone marrow: 30.3;lymphoid tissue: 31.9	Cell line enhanced	Detected in single		THP-1: 1.1	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Group enriched	Detected in many	5	classical monocyte: 15.9;intermediate monocyte: 33.8;neutrophil: 16.7;non-classical monocyte: 37.9	Group enriched	Detected in many	5	granulocytes: 16.7;monocytes: 37.9															52000000	52000000				unprognostic (1.23e-1)	unprognostic (1.12e-2)	unprognostic (3.21e-2)	unprognostic (3.51e-2)	unprognostic (6.21e-3)	unprognostic (1.70e-2)	unprognostic (1.44e-2)	unprognostic (2.94e-1)	unprognostic (1.08e-2)	unprognostic (2.98e-2)	unprognostic (2.64e-1)	unprognostic (2.15e-1)	prognostic unfavourable (5.45e-7)	unprognostic (1.90e-2)	unprognostic (4.68e-3)	unprognostic (3.72e-1)	unprognostic (9.73e-2)	3.2	1.4	0.4	6.8	0.6	30.3	1	0.3	1.9	0.5	1.1	0.6	0.4	3.3	0.6	0.9	0.5	2.3	6.6	1.5	1.6	0.4	1.5	3.6	18.4	4.9	2.6	0	0.4	0.7	0.2	0.7	0.7	1.8	0.9	1	1.1	7.4	2.6	0.5	0.4	1.5	0.6	3.4	31.9	1	0.3	0.8	0.8	0.6	5	0.7	0.6	1.9	0	5.3	16.7	37.9	0	0.1	8.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6	0	0	0	0	0	0	0	0	0	0	0	0	1.1	0	0	0	0	0	0	0	0	0	0	0	2.6	15.9	4.2	0	33.8	0.1	0	0	0	5.3	0	0	0	16.7	0	37.9	2.2	0.1	8.1	0.4	0.6	0.3	1.9	1.6	0.4	2.6	0	1.8	0.8
LILRB3	"CD85a, HL9, ILT5, LIR-3, LIR3, PIR-B, PIRB"	ENSG00000204577	Leukocyte immunoglobulin like receptor B3	O75022	19	54216278-54223506	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 24.4;bone marrow: 15.3;lymphoid tissue: 23.4	Cell line enhanced	Detected in some		HaCaT: 1.8;HEK 293: 2.5	Low cancer specificity	Detected in many			Low region specificity	Detected in some			Cell type enhanced	Detected in some		neutrophil: 24.4	Group enriched	Detected in many	4	granulocytes: 24.4;monocytes: 9.4																				unprognostic (7.51e-2)	unprognostic (3.52e-2)	unprognostic (9.59e-2)	unprognostic (4.53e-1)	unprognostic (1.83e-3)	unprognostic (5.28e-3)	unprognostic (2.91e-2)	unprognostic (2.55e-1)	unprognostic (5.58e-2)	unprognostic (2.35e-1)	unprognostic (1.43e-1)	unprognostic (1.63e-1)	unprognostic (1.92e-8)	unprognostic (2.18e-1)	unprognostic (2.19e-3)	unprognostic (1.84e-1)	unprognostic (1.75e-1)	5.1	0.8	0.4	8.9	1	15.3	0.8	0.4	0.5	0.7	1.6	0	0.2	0.2	0.6	2.5	0.7	1.3	1.1	7.8	1.5	0.6	0.7	1.5	10.9	19.7	0.5	0	3	1.7	0	0.5	2	0.6	0.9	0	1	0.8	0	1.7	0.6	0.9	0.9	2.2	23.4	0.8	0.7	0	0.3	1.5	0	0.1	6.4	1.1	0.1	4	24.4	9.4	0	0.1	4.5	1.5	0.6	0.4	0.8	0	0	0.5	1.6	0	0	0	1	0	0	0.4	0	1.8	0	0	0	0.4	2.5	1	0.6	0	0	0.9	0	0	0	0	0	0	0.2	0	0	0	1.4	0	1.1	0.5	0.6	0.2	0	0	0.9	1.6	0	0	0.6	0.1	1.5	0	0	0.7	0.8	0	0	0.5	0.3	0	0.3	0.9	0	0.4	9.4	0.3	0	7.5	0.1	0.1	0.1	0	4	0.1	0	0	24.4	0	3.3	0.4	0	4.5	0.4	1	0.4	0.5	1.5	0.6	0.5	0	0.6	0
LILRB4	"CD85k, HM18, ILT3, LIR-5, LIR5"	ENSG00000186818	Leukocyte immunoglobulin like receptor B4	Q8NHJ6	19	54643889-54670359	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 22.8;lymphoid tissue: 33.1	Cell line enriched	Detected in some	35	Karpas-707: 94.9	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Cell type enhanced	Detected in some		plasmacytoid DC: 22.8	Group enriched	Detected in many	69	dendritic cells: 22.8;monocytes: 6.2									HPA052807	Approved					9900	9900			HPA052807: 	unprognostic (4.09e-2)	unprognostic (5.75e-3)	unprognostic (6.06e-2)	unprognostic (1.91e-2)	unprognostic (1.82e-1)	unprognostic (1.55e-1)	unprognostic (5.03e-2)	unprognostic (3.53e-1)	unprognostic (4.13e-2)	unprognostic (1.52e-1)	unprognostic (5.43e-1)	unprognostic (2.79e-1)	unprognostic (1.91e-2)	unprognostic (1.08e-1)	unprognostic (4.42e-2)	unprognostic (4.51e-2)	unprognostic (4.52e-2)	15.4	4.3	5.1	20.1	7.4	4.5	3.1	0.8	5.9	1.6	3.6	12.8	0	4	1	4.7	2.1	4.2	4.4	3.9	5.3	5.3	3.1	3.9	12.3	33.1	10.8	1.9	1.7	1.6	1.5	2.4	4.2	6.6	1.7	5.5	2.9	3.8	1.4	0.8	0.9	5.4	2.1	15.1	18	2.8	1.3	6.9	3.1	2.3	0.7	6.1	13.8	0.8	0.2	22.8	0.1	6.2	0.1	0	1.8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	94.9	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0	0	1.2	0	0	0	0	0	0.3	2.7	0	0	0	0	0	4.5	0	0	6.2	0	0.1	0	0	7	0.2	0	0	0.1	0.1	4.8	22.8	0	1.8	5.1	7.4	0.8	4.5	5.3	5.3	10.8	1.9	6.6	6.9
LILRB5	"CD85c, LIR-8, LIR8"	ENSG00000105609	Leukocyte immunoglobulin like receptor B5	O75023	19	54249431-54257301	"CD markers, Plasma proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		breast: 31.0;lymphoid tissue: 35.1	Cell line enhanced	Detected in some		SiHa: 2.3	Low cancer specificity	Detected in many			Not detected	Not detected			Low cell type specificity	Detected in some			Low lineage specificity	Detected in single											HPA012069	Approved					36000000	36000000			HPA012069: AB_1852873	unprognostic (3.55e-3)	unprognostic (5.38e-2)	unprognostic (2.20e-2)	unprognostic (7.03e-2)	unprognostic (8.86e-2)	unprognostic (5.44e-2)	unprognostic (3.02e-5)	unprognostic (6.80e-2)	unprognostic (2.23e-1)	unprognostic (2.33e-1)	unprognostic (9.95e-2)	unprognostic (8.68e-2)	unprognostic (3.31e-1)	unprognostic (2.07e-1)	unprognostic (4.14e-2)	unprognostic (1.42e-2)	unprognostic (1.73e-1)	23.6	8.3	0.7	5.4	0.8	0.8	31	0.6	0.6	2.1	11.9	0.5	1.6	5.2	1.2	16.2	5.8	4.9	6.2	10	0.7	0.8	2.1	22.8	8.6	13.3	0.8	0	4.1	2.7	0.7	1	5.6	0.7	4	5.5	3.6	2.9	1.1	6.1	2	9	5.9	0.9	35.1	2.4	3.9	0	1.2	2.6	4.9	1.3	10.6	1.8	0.9	0.7	3.1	0.9	0.9	0.5	0.3	0.4	0	0.8	0.5	0.1	0.1	1	1	0.3	0.4	0	0.3	0.6	0.2	0.4	0.1	1.4	0.3	0.5	0	0.5	0.9	1.1	1.7	0.4	0.5	0.6	0.6	0.5	0.3	0.1	0.3	0.5	0.6	1	0.2	0	0.3	0.3	0.6	0	0.6	0.7	0.6	0.2	0.8	0.5	0.9	2.3	0.8	0.7	0.7	0	0.3	0.8	0.7	0.5	0.6	0.3	1.1	0.1	0.4	0.3	0.2	3.1	0.9	0.4	0.4	0.6	0.3	0.4	0.5	0.3	0.3	0.9	0.4	0.4	2.3	0.9	0.8	0.7	0.3	0.3	0.7	0.8	0.6	0.6	0.7	0.8	0.8	0	0.7	0
LRP1	"A2MR, APOER, APR, CD91, IGFBP-3R, IGFBP3R1, LRP, LRP1A"	ENSG00000123384	LDL receptor related protein 1	Q07954	12	57128493-57213351	"Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Endocytosis	"Developmental protein, Receptor"	Disease mutation	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in many		ASC diff: 82.6;ASC TERT1: 83.9;fHDF/TERT166: 36.0;HSkMC: 54.3	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Group enriched	Detected in some	18	classical monocyte: 7.6;intermediate monocyte: 4.0;myeloid DC: 2.8;non-classical monocyte: 3.7	Group enriched	Detected in many	20	dendritic cells: 2.8;monocytes: 7.6	Low region specificity	Detected in all			Low region specificity	Detected in all			"HPA004182, CAB018621, HPA022903"	Supported		Approved	"Nucleoplasm,Vesicles"	Intracellular and membrane	88000000	88000000	Vesicles	Nucleoplasm	"CAB018621: AB_627893, HPA004182: , HPA022903: AB_10602426"	unprognostic (1.65e-1)	unprognostic (1.61e-1)	unprognostic (1.76e-1)	unprognostic (2.71e-1)	unprognostic (5.00e-2)	unprognostic (4.33e-2)	unprognostic (3.98e-1)	unprognostic (8.68e-2)	unprognostic (1.70e-1)	unprognostic (3.37e-3)	unprognostic (1.48e-1)	unprognostic (1.25e-1)	prognostic unfavourable (1.52e-5)	unprognostic (2.81e-3)	unprognostic (6.13e-2)	unprognostic (2.80e-2)	prognostic unfavourable (1.29e-5)	77.8	12	19.8	21.5	21.3	6.1	27.7	28.1	25.3	31.4	19.7	11.9	9	17.8	26.9	18.2	19.2	21	24.1	26	18.6	10.4	6.3	31.4	24.7	5.5	13.9	15.6	56.9	8.8	8.5	8	29.4	17.1	21.4	9.5	20	14.8	17	11.3	15.7	14.2	22.4	14.3	11.3	11.8	11.1	15.4	0.3	13.2	9.3	3.1	22.9	39.4	0	2.8	0.1	7.6	0	0.2	1.9	1.2	2.3	5	4	82.6	83.9	15.2	13.9	18	4.6	4.5	4.3	2	0	1.7	36	5.5	0.8	1.4	1.6	0.1	0.2	0	2.7	9	11.3	0	2.4	54.3	0.5	10.3	1.2	0.2	0	0.2	14.3	0.2	0	0	5.8	1.4	0.5	28.6	0.2	0.3	0.3	0.2	2.7	3.1	0.1	2.2	0.4	0.2	0.2	16.1	6	8.9	0.8	0.1	0	0	28.2	0	3	0	7.6	0	0	4	0	0	0.1	0	2.8	0	0	0.2	0.1	0	3.7	0	0	1.9	19.8	21.3	28.1	19.7	18.6	10.4	13.9	15.6	17.1	15.4
LY75	"CD205, CLEC13B, DEC-205"	ENSG00000054219	Lymphocyte antigen 75	O60449	2	159803355-159904749	"CD markers, Predicted membrane proteins"	Endocytosis	Receptor		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	4	intestine: 28.8;lymphoid tissue: 61.9	Cell line enhanced	Detected in many		CAPAN-2: 10.3;HDLM-2: 9.7;Karpas-707: 41.3;RT4: 14.0;THP-1: 10.4	Low cancer specificity	Detected in many			Low region specificity	Detected in all			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all											"CAB001450, HPA049108, HPA054073"	Enhanced		Approved	Golgi apparatus		960000	960000	Golgi apparatus		"CAB001450: AB_563525, HPA049108: , HPA054073: "	unprognostic (7.29e-3)	unprognostic (1.92e-3)	unprognostic (3.15e-1)	unprognostic (1.52e-2)	unprognostic (4.60e-3)	unprognostic (3.65e-2)	unprognostic (8.87e-2)	unprognostic (6.24e-2)	unprognostic (2.80e-1)	unprognostic (2.36e-1)	unprognostic (8.74e-3)	unprognostic (3.92e-1)	prognostic unfavourable (2.39e-5)	unprognostic (2.66e-1)	unprognostic (4.89e-2)	unprognostic (1.94e-2)	prognostic favourable (3.86e-4)	3.5	1.8	1.9	21.4	2.6	4.9	6.1	1.2	1.8	4.5	9.3	2	1	10.8	2.1	1.9	4.5	5	10.7	2.8	1.8	1.7	2.8	1.2	10.3	33.9	2.5	1.1	1.6	2.3	0.2	1.9	0.8	2.4	2	7.2	1.3	7.2	1.3	0.8	6.5	28.8	1.3	3.4	17.2	3.8	1.1	3	61.9	10.7	3.6	17.1	6.9	3.8	5.8	4.3	5.9	2.6	7.5	8	2.3	1.6	0.1	0	0	0	0.1	0	0	0	0	0	4.1	10.3	7.1	0.3	0	0.2	0	0	0	9.7	0	2	0	0	0.2	1.6	0	0.1	0	0.2	0.1	5.3	0	41.3	0	0	0	2.6	0.2	0	2.7	0	1.7	3.1	14	0	0	3.3	2.4	0	0	10.4	7.9	0	0	0	0	6.3	1	1.4	0	3.6	0	3.4	2	3.5	6.5	2.6	7.1	5.8	5.9	7.5	4.3	4.5	6.7	8	5.9	7.5	1	1.5	4.3	2.3	1.9	2.6	1.2	1.8	1.8	1.7	2.5	1.1	2.4	3
LY9	"CD229, hly9, mLY9, SLAMF3"	ENSG00000122224	Lymphocyte antigen 9	Q9HBG7	1	160796074-160828261	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Cell adhesion, Immunity, Innate immunity"			Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	4	blood: 30.8;intestine: 11.3;lymphoid tissue: 43.7;urinary bladder: 28.6	Cell line enhanced	Detected in some		Daudi: 7.2;Karpas-707: 14.6;U-266/70: 37.2;U-266/84: 14.3	Low cancer specificity	Detected in some			Not detected	Not detected			Group enriched	Detected in many	5	gdT-cell: 30.6;MAIT T-cell: 30.7;memory B-cell: 15.2;memory CD4 T-cell: 26.8;memory CD8 T-cell: 29.6;naive B-cell: 13.9;naive CD4 T-cell: 30.5;naive CD8 T-cell: 30.8;plasmacytoid DC: 18.6;T-reg: 19.7	Group enriched	Detected in many	4	B-cells: 15.2;dendritic cells: 18.6;T-cells: 30.8	Low region specificity	Detected in single			Not detected	Not detected			HPA050917	Approved					23000	23000			HPA050917: 	unprognostic (8.04e-4)	unprognostic (2.31e-5)	unprognostic (8.08e-3)	unprognostic (1.20e-3)	unprognostic (9.83e-3)	unprognostic (1.87e-5)	unprognostic (1.16e-2)	unprognostic (3.84e-3)	unprognostic (1.23e-2)	unprognostic (2.89e-3)	unprognostic (1.64e-1)	unprognostic (2.30e-1)	unprognostic (2.70e-3)	unprognostic (8.69e-2)	unprognostic (9.47e-2)	unprognostic (3.49e-2)	unprognostic (6.88e-2)	2.8	0.5	0.4	20.9	0.4	6.9	2.7	0.4	0.4	1.4	3.7	0.2	0.4	2.4	0.9	0.8	3.5	1	2	0.9	0.4	0.4	1.7	1.3	6.1	35.3	0.4	0	1.1	0.5	0	0.5	0.2	0.1	1	2.3	1	6.5	0.4	0.4	0.8	11.3	0.1	0.7	25.3	3.4	1.1	0	35.7	1.6	1.8	43.7	28.6	1.2	15.2	18.6	0.6	0.2	5.2	30.8	12.9	0	0	0	0	0	0	0.1	0	0	0	0	0	0	7.2	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0.2	0	0	0	0	0	0	14.6	0	0	1.1	0.2	0	0	0.8	0	1.8	0	0	0	0	0	0.4	0	0	0.2	0	0	0	0	0	37.2	14.3	0.1	0	2	0	0.2	0.2	0.1	30.6	0.2	30.7	15.2	26.8	29.6	1.3	13.9	30.5	30.8	0.6	5.2	0.2	18.6	19.7	12.9	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0	0.1	0
MCAM	"CD146, MUC18"	ENSG00000076706	Melanoma cell adhesion molecule	P43121	11	119308529-119321521	"CD markers, Plasma proteins, Predicted membrane proteins"	Cell adhesion			Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in many			Group enriched	Detected in many	4	HUVEC TERT2: 125.3;TIME: 122.3;WM-115: 97.3	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in some		MAIT T-cell: 2.2	Low lineage specificity	Detected in single			Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB002147, HPA008848"	Enhanced		Approved	Plasma membrane		2600000000	2600000000	Plasma membrane		"CAB002147: AB_563499, HPA008848: AB_1078445"	unprognostic (6.45e-2)	prognostic unfavourable (7.61e-4)	unprognostic (7.03e-2)	unprognostic (1.22e-2)	unprognostic (6.67e-2)	unprognostic (2.34e-1)	unprognostic (2.23e-2)	unprognostic (8.42e-2)	unprognostic (2.09e-2)	unprognostic (1.45e-1)	unprognostic (1.58e-1)	unprognostic (9.39e-2)	prognostic unfavourable (5.14e-4)	unprognostic (8.75e-3)	unprognostic (7.84e-2)	unprognostic (2.31e-1)	unprognostic (2.79e-3)	88.2	8.9	6.4	18.5	10.3	0.4	86.1	17.7	13.4	22.3	33.2	13.3	11.7	8.3	40.1	32.5	27.6	29.3	50.9	32	7.1	8.2	7.5	3.8	23.8	13	7.4	8.1	23.6	6.2	54.5	3.9	47.4	11.1	22.9	9.7	25	9.4	44.9	21.1	10.5	15.6	67.1	6.5	9.6	25	18.4	5.4	2.2	13.1	15.7	4.8	55	24.3	0.8	0	0.3	0	0	2.2	0	0	0.5	0.5	0	2.5	0	2.6	0.3	0	3.3	1.5	1.9	0.1	0.1	10.7	1.1	0.3	4.3	0.9	1.7	6	1.5	0.1	12	2.1	5.9	0	0	1.7	0	4.6	2.1	125.3	4	0.1	0.6	0	0.1	1	2.2	0.4	0.1	16.7	3.5	3	0	1.4	0.4	9.6	0.2	27.5	0.4	0.1	122.3	0.3	17.9	0	9.6	0.2	0.2	0	4.9	0	97.3	0	0	0	0	0	2.2	0.8	0.6	1.1	0	0.2	0	0	0.3	0	0	0	1.3	0	6.4	10.3	17.7	13.4	7.1	8.2	7.4	8.1	11.1	5.4
MELTF	"CD228, FLJ38863, MAP97, MFI2, MGC4856, MTf, MTF1"	ENSG00000163975	Melanotransferrin	P08582	3	196988621-197029816	"CD markers, Plasma proteins, Predicted intracellular proteins"	"Ion transport, Iron transport, Transport"			Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enriched	Detected in all	4	salivary gland: 65.7	Cell line enhanced	Detected in many		A-431: 46.1;SK-MEL-30: 57.0	Cancer enhanced	Detected in all		melanoma: 32.7	Low region specificity	Detected in many			Cell type enhanced	Detected in many		MAIT T-cell: 3.3	Group enriched	Detected in many	5	dendritic cells: 1.9;monocytes: 2.1;T-cells: 3.3	Not detected	Not detected			Low region specificity	Detected in some			HPA004880	Approved				Intracellular and membrane	230000000	230000000			HPA004880: AB_1853844	unprognostic (8.68e-3)	unprognostic (3.68e-2)	unprognostic (1.75e-2)	unprognostic (7.68e-3)	unprognostic (1.06e-2)	unprognostic (1.08e-2)	unprognostic (5.53e-2)	unprognostic (1.64e-3)	unprognostic (1.20e-2)	unprognostic (1.23e-1)	unprognostic (3.68e-3)	unprognostic (8.14e-2)	prognostic unfavourable (6.99e-11)	unprognostic (2.29e-1)	unprognostic (2.11e-1)	unprognostic (5.75e-2)	unprognostic (2.09e-2)	6	1.6	1.9	3.5	2	1.8	7.5	2.7	2.8	4.4	5.1	3.3	3.5	2.1	4.9	4.8	2.4	6.4	2.5	3.3	1.8	1.1	5.1	1.4	1.6	1.7	1	1	1.3	4.3	15.9	1.8	4.4	2.9	3.7	1.9	2.9	65.7	4.7	1.4	10.5	8.7	3.1	1.1	1	1.1	2.6	0.9	3.6	2	1.3	2.4	2	5.4	0.2	1.9	0.2	2.1	0.5	3.3	0.6	46.1	10.1	0.1	0.3	1.4	1.9	1.2	0.8	0.4	1.5	1.9	2.8	6.9	1.3	10	1.6	14.4	0.5	0	0.7	2.1	3.2	1.6	2.2	1.2	9.4	0.2	9.2	10.1	1.2	1.3	0.1	0.2	1.2	9.1	0.9	2.8	2.6	0	1	6.6	3.8	1.6	0.5	0.2	0.4	0.9	3.4	9.5	0.8	57	2.8	1.4	0.3	0.3	8.1	1.6	5.7	1.5	12.8	1.2	1.1	2.7	0	0.1	0.3	0	1.2	1	3.3	0.2	1	1	1.9	0.2	0.3	0.1	0.2	0.5	2.1	0	0.1	0.6	1.9	2	2.7	2.8	1.8	1.1	1	1	2.9	0.9
MME	"CALLA, CD10, NEP"	ENSG00000196549	Membrane metalloendopeptidase	P08473	3	155024124-155183729	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, Charcot-Marie-Tooth disease, Disease mutation, FDA approved drug targets, Neurodegeneration, Neuropathy, Spinocerebellar ataxia"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 61.1;intestine: 136.0;kidney: 64.9	Cell line enhanced	Detected in many		ASC TERT1: 95.0;BJ hTERT+: 142.9;HSkMC: 92.1	Low cancer specificity	Detected in many			Low region specificity	Detected in many			Cell type enriched	Detected in single	129	neutrophil: 61.1	Lineage enriched	Detected in single	129	granulocytes: 61.1	Low region specificity	Detected in many			Region enhanced	Detected in many		basal ganglia: 26.8	"CAB000013, HPA052583, HPA056072"	Enhanced					99000	99000			"CAB000013: AB_563478, HPA052583: AB_2681872, HPA056072: AB_2683027"	unprognostic (1.36e-1)	unprognostic (1.02e-3)	unprognostic (8.52e-2)	unprognostic (2.95e-1)	unprognostic (2.78e-2)	unprognostic (6.52e-3)	unprognostic (1.20e-1)	unprognostic (1.67e-2)	unprognostic (8.67e-2)	unprognostic (1.96e-1)	unprognostic (7.30e-3)	unprognostic (1.31e-1)	unprognostic (2.71e-3)	unprognostic (1.50e-1)	unprognostic (7.29e-2)	unprognostic (1.06e-2)	unprognostic (1.37e-2)	26.5	0.4	0.4	3.4	7.4	1.9	14.7	0.4	0.7	4.8	65.6	0.1	18.4	74	2.8	8.1	0.7	0.9	8.5	1.8	0.3	0.4	64.9	11.5	13.7	3	2.1	0.2	0.9	0.6	0	0.6	35	8.6	18.3	0.4	1.3	3.7	11.3	11.7	1.4	136	0.6	0.9	2.7	0.7	1	1.2	13.2	1	5.3	2.3	3.4	4.9	0.1	0.4	61.1	0	0	0	0	0	0	0.1	0	38.6	95	0.2	21.2	142.9	10.8	28.1	0	0	23.4	0	18.8	0	0.7	0.8	26.1	0	0.1	0	0	0	30.9	0	0	92.1	0.1	5.8	41.6	8.2	0	0	17.3	0.1	0	0.1	0.9	0.1	38.8	18.2	0.1	0.6	0.2	0	0.2	0	0	4.1	0	0	23.3	46.7	0.1	15.9	3.7	0	0	30.8	5.6	0	1	0	0	0.1	0	0	0	0	0	0	0	0.1	0	0	61.1	0	0	0.4	0	0	0.4	7.4	0.4	0.7	0.3	0.4	2.1	0.2	8.6	1.2
MPL	"CD110, TPOR"	ENSG00000117400	"MPL proto-oncogene, thrombopoietin receptor"	P40238	1	43337849-43352772	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Cancer-related genes, Disease mutation, FDA approved drug targets"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		lymphoid tissue: 8.6	Cell line enriched	Detected in single	78	HEL: 40.7	Not detected	Not detected			Low region specificity	Detected in single			Cell type enriched	Detected in single	5	neutrophil: 1.6	Lineage enriched	Detected in single	5	granulocytes: 1.6	Region enhanced	Detected in single		cerebral cortex: 1.4	Low region specificity	Detected in all			HPA007619			Supported	"Nuclear membrane,Plasma membrane"				Plasma membrane	Nuclear membrane	HPA007619: AB_1854080	unprognostic (2.74e-1)	unprognostic (6.56e-2)	unprognostic (2.95e-1)	unprognostic (8.71e-2)	unprognostic (1.37e-2)	unprognostic (1.06e-3)	unprognostic (1.19e-1)	unprognostic (1.22e-2)	unprognostic (5.83e-2)	unprognostic (1.03e-1)	unprognostic (5.94e-4)	unprognostic (1.51e-1)	unprognostic (1.19e-4)	unprognostic (2.39e-1)	unprognostic (3.26e-1)	unprognostic (1.03e-4)	unprognostic (1.42e-1)	1.1	0.3	0.9	0.5	0.8	2	0.9	0.5	2.2	0.6	0.6	0.5	0.5	0.3	0.9	1.7	0.9	2.1	0.5	3.9	0.8	0.6	0.5	0.5	2	0.5	0.9	0.5	6.6	1.1	0.6	0.6	2.2	0.5	1.5	0.7	0.5	0.5	0.7	0.6	0.4	1.2	2.1	2.5	8.6	0.5	2.1	0.5	0.5	2.2	2.4	0.5	0.9	0.5	0	0	1.6	0.3	0	0	4	0.1	0.5	0	0	0.1	0	0	0	0	0	0	0.3	0.5	0	0.1	0	0.1	0	0.1	0	0.2	0	40.7	0.4	0.1	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0.3	0.1	0	0	0.1	0.4	0.2	0.2	0	0.3	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3	0	0	0	0	0	0	0	0	1.6	0	0	0	0	4	0.9	0.8	0.5	2.2	0.8	0.6	0.9	0.5	0.5	0.5
MRC1	"bA541I19.1, CD206, CLEC13D, CLEC13DL, MRC1L1"	ENSG00000260314	Mannose receptor C-type 1	P22897	10	17809344-17911170	"CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins"	"Endocytosis, Host-virus interaction"	"Host cell receptor for virus entry, Receptor"	FDA approved drug targets	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		lung: 44.8;lymphoid tissue: 37.8	Group enriched	Detected in some	19	MOLT-4: 17.2;TIME: 16.0	Low cancer specificity	Detected in all							Cell type enriched	Detected in single	15	myeloid DC: 8.2	Lineage enriched	Detected in single	15	dendritic cells: 8.2	Low region specificity	Detected in all			Low region specificity	Detected in some			"HPA004114, HPA045134, CAB068203"	Enhanced					130000000	130000000			"CAB068203: , HPA004114: AB_1846270, HPA045134: AB_2679228"	unprognostic (2.20e-1)	unprognostic (2.07e-1)	unprognostic (1.03e-2)	unprognostic (2.58e-1)	unprognostic (5.62e-2)	unprognostic (4.30e-1)	unprognostic (6.36e-3)	unprognostic (1.35e-1)	unprognostic (1.05e-2)	unprognostic (6.05e-2)	unprognostic (5.61e-2)	unprognostic (4.12e-1)	unprognostic (2.94e-2)	unprognostic (4.97e-2)	unprognostic (3.05e-2)	unprognostic (1.74e-2)	unprognostic (7.02e-2)	34.8	8.3	0.3	6.2	1.2	0	19.8	0.7	0.6	5.2	11.2	0.6	0.9	2.2	4.5	10.4	4.2	1.3	7.9	13.4	0.9		12.4	16.4	44.8	37.8	1	0	3.6	5.1	1.8	2.4	15.4	3.1	5.5	5.1	7	0.7	1.9	5.1	0	6.5	8.2	1.4	30.6	2.2	7.1	0.8	0.8	6.5	3.5	0.7	7.5	5.1	0	8.2	0.1	0.5	0	0.4	0.2	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	17.2	0	0.1	0	0.1	0.3	0.8	0	0	0	0	0	0	0	0	0	16	0	0	0.2	0	0.1	0	0	0	0	0	0	0.5	0	0	0.1	0	0	0.1	0	8.2	0	0	0	0.1	0	0	0.2	0.4	0.2										
MRC2	"CD280, CLEC13E, ENDO180, KIAA0709"	ENSG00000011028	Mannose receptor C type 2	Q9UBG0	17	62627401-62693597	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	Endocytosis	Receptor		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in many			Cell line enhanced	Detected in many		BJ: 46.4;fHDF/TERT166: 31.5;HSkMC: 29.9;U-138 MG: 47.7	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in single		naive CD4 T-cell: 1.0	Low lineage specificity	Detected in single			Low region specificity	Detected in many			Low region specificity	Detected in many			HPA041991	Enhanced					28000000	28000000			HPA041991: AB_10794166	unprognostic (3.22e-1)	unprognostic (2.19e-1)	unprognostic (4.45e-2)	unprognostic (2.59e-2)	unprognostic (4.29e-2)	unprognostic (2.67e-2)	unprognostic (6.21e-2)	unprognostic (1.80e-1)	unprognostic (7.39e-2)	prognostic unfavourable (1.68e-4)	unprognostic (7.70e-2)	unprognostic (7.75e-2)	prognostic unfavourable (4.94e-7)	unprognostic (5.25e-2)	unprognostic (6.13e-2)	unprognostic (3.00e-2)	unprognostic (1.93e-2)	14.7	5.7	2.4	14.7	5.2	3.2	27.3	1.4	3.4	30.4	7	6.5	18.7	4.4	31.7	46.3	15.7	15.7	37.2	44.1	2.5	2.6	8.7	2.2	46.8	2.5	3.4	4	33.6	4.7	0.9	11.3	5.4	6.8	25.7	1.9	35.1	10.9	17.1	7.3	19	7.1	28.7	8.2	9.7	5.8	13.3	2.5	4.8	4.6	21.2	5.3	18.1	18.1	0	0.6	0.2	0	0	1	0	0	8.5	4.6	6.1	12.7	23	0.7	46.4	27.1	6.7	8.1	0.5	0.1	0	3.3	31.5	3.9	0.8	3.8	1.9	5.7	1.3	3.8	6.2	0	19.1	4.8	0	29.9	2	5.9	0.6	3	2.2	0	9.4	1.4	1.2	16.6	1	0.5	4.7	3.3	0	0.7	0.1	0.7	12.1	3.1	0.1	0	0.1	19.3	15.5	47.7	19.5	8.3	8.2	0	0	0	15	4.9	7.5	0	0	0	0	0	0	0	0.5	0	0.6	0	1	0.9	0.2	0	0	0	0.9	0	2.4	5.2	1.4	3.4	2.5	2.6	3.4	4	6.8	2.5
MS4A1	"B1, Bp35, CD20, MS4A2"	ENSG00000156738	Membrane spanning 4-domains A1	P11836	11	60455752-60470760	"CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	B-cell activation		FDA approved drug targets	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	6	blood: 77.7;intestine: 46.1;lymphoid tissue: 134.1	Group enriched	Detected in some	25	Daudi: 120.0;U-698: 60.4	Low cancer specificity	Detected in many			Not detected	Not detected			Group enriched	Detected in some	105	memory B-cell: 77.7;naive B-cell: 77.7	Lineage enriched	Detected in single	105	B-cells: 77.7	Not detected	Not detected			Low region specificity	Detected in some			"CAB000015, HPA014341, HPA014391"	Enhanced		Supported	Plasma membrane				Plasma membrane		"CAB000015: AB_2282030, HPA014341: AB_1846265, HPA014391: AB_1846264"	prognostic favourable (4.34e-5)	unprognostic (4.45e-4)	unprognostic (1.19e-4)	unprognostic (2.04e-3)	unprognostic (1.06e-1)	unprognostic (5.53e-7)	unprognostic (2.46e-3)	unprognostic (1.85e-3)	unprognostic (3.06e-2)	unprognostic (2.89e-4)	unprognostic (6.96e-2)	unprognostic (2.84e-2)	unprognostic (3.96e-5)	unprognostic (2.23e-1)	unprognostic (8.04e-2)	unprognostic (1.44e-1)	unprognostic (1.30e-1)	1.6	0.3	0.3	79	0.3	3.6	0.6	0.3	0.3	0.5	2	0	0	0.2	0.4	0.5	7	0.4	1.3	0.7	0.3	0.3	2	0.9	2.7	81.2	0.3	0.1	0.3	0.4	0	0.4	0.4	0.1	1.1	1.7	0.6	14.5	0.2	0.3	0.3	46.1	0.1	0.4	90.7	2.6	0.6	0	15.7	2.5	2.7	134.1	6.4	0.8	77.7	0	0.2	0	0.7	0.6	3.5	0	0	0	0	0	0	0	0	0	0	0	0	0	120	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	3.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	60.4	0	0	0	0	0	0	0.3	0	0.4	77.7	0.3	0.6	0	77.7	0	0.2	0.2	0.7	0	0	0	3.5	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.1	0.1	0
MSR1	"CD204, SCARA1, SR-A, SR-AI, SR-AII, SR-AIII"	ENSG00000038945	Macrophage scavenger receptor 1	P21757	8	16107878-16567490	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Endocytosis	Receptor	Cancer-related genes	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in all	5	adipose tissue: 88.1;lung: 70.4	Group enriched	Detected in many	7	BJ hTERT+: 47.1;REH: 17.8	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Cell type enhanced	Detected in many		intermediate monocyte: 16.0	Lineage enriched	Detected in many	5	monocytes: 16.0	Low region specificity	Detected in single			Low region specificity	Detected in all			"HPA000272, CAB032491"	Enhanced					25000	25000			"CAB032491: AB_672722, HPA000272: AB_1846269"	unprognostic (8.19e-3)	unprognostic (4.87e-2)	unprognostic (1.93e-2)	unprognostic (2.10e-1)	unprognostic (9.24e-2)	unprognostic (1.32e-2)	unprognostic (5.85e-3)	unprognostic (2.89e-1)	unprognostic (9.70e-2)	unprognostic (1.62e-2)	unprognostic (7.19e-2)	unprognostic (8.82e-2)	unprognostic (2.76e-2)	unprognostic (9.16e-2)	unprognostic (7.39e-2)	unprognostic (6.85e-2)	unprognostic (4.69e-2)	88.1	9	2.2	6.1	4.5	3.7	6.9	10.4	3.3	4.5	3.1	1.8	1	2.1	3.1	6.2	2.4	4.5	11.4	8	3.8	3.1	9.5	13.6	70.4	6.9	4.3	0.8	6.7	3.8	1.2	2.6	10.4	7.7	3.2	3.9	4.5	6.2	2.3	3.2	1.6	4	6.5	11.9	10.9	2.5	4.9	3.1	1.5	2.2	1.7	0.7	10.8	1.8	1.5	1	3	16	0.3	1.3	0.5	0.6	0.9	1.3	0.6	0.6	0.6	0.6	0.3	47.1	0.1	0.2	1.6	0.1	1.5	2.4	0.4	0.3	0.3	0.4	0.9	0.2	1.9	1.9	1.8	1.8	0.4	1	1.1	0.3	0.3	0.3	0.7	0	0.7	1.4	0.9	1.8	0.6	0.6	0.2	0.6	17.8	1	0.4	0.9	2.7	1	0.5	0.4	1.2	0.1	0.1	0.5	1.1	1.2	0.5	4.9	1.2	4.8	3.7	3.2	0.5	0.6	1	1.1	3.1	0.5	0.9	16	0.4	0.9	0.7	0.7	1	1.5	1.3	0.9	3	0.3	7.8	0.5	0.6	0.5	2.2	4.5	10.4	2.7	3.8	3.1	4.3	0.8	7.7	3.1
MST1R	"CD136, CDw136, PTK8, RON"	ENSG00000164078	Macrophage stimulating 1 receptor	Q04912	3	49887002-49903873	"CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Immunity, Innate immunity"	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	Disease mutation	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		gallbladder: 27.7;intestine: 34.3;skin 1: 28.7	Cell line enhanced	Detected in some		CAPAN-2: 35.3;HaCaT: 19.5;HBEC3-KT: 21.2;hTCEpi: 29.8;RT4: 22.8	Low cancer specificity	Detected in many			Not detected	Not detected			Cell type enhanced	Detected in single		MAIT T-cell: 2.1	Lineage enhanced	Detected in single		T-cells: 2.1	Low region specificity	Detected in single			Not detected	Not detected			"HPA007657, HPA008180, CAB008972"	Enhanced		Approved	Cytosol				Cytosol		"CAB008972: , HPA007657: AB_1079292, HPA008180: AB_1079291"	unprognostic (3.84e-3)	unprognostic (3.86e-1)	unprognostic (1.92e-1)	unprognostic (7.33e-3)	unprognostic (3.82e-2)	unprognostic (2.32e-1)	unprognostic (8.07e-3)	unprognostic (1.54e-2)	unprognostic (4.12e-2)	unprognostic (2.15e-1)	unprognostic (1.24e-3)	unprognostic (2.28e-1)	unprognostic (8.08e-3)	unprognostic (2.38e-1)	unprognostic (2.18e-1)	unprognostic (8.00e-3)	prognostic favourable (2.33e-5)	1.7	0.1	0.4	7.5	0.6	0	2.4	0.5	0.7	1.8	20.5	0.7	2	11.2	1.2	1.3	6.1	0.6	27.7	0.9	0.5	0.1	1.4	0.4	5	1.1	0.4	0.6	0.5	4.1	0	1.3	0.8	0.9	1.7	9.7	2.5	2.1	0.4	0.5	28.7	34.3	0.7	0.4	0.6	19.1	1.9	0.4	7.7	1.3	6	4.5	4.3	3.5	0.2	0	0	0	0.6	2.1	0	12.7	4.9	0	0.2	0	0	0.8	0.1	0	0	0	1.2	35.3	0.5	3.1	0.2	19.5	0	21.2	0	0.3	0.3	0	8.4	0.3	0.3	0	0.4	0.1	29.8	0.1	4.2	0	0.2	0.1	0	1.7	0	0	0.1	10.3	0.8	0	0.3	13	22.8	0.3	0	3.6	8.2	0	6.5	0.3	0.1	0	0.1	0.1	0	0.1	0	0	0.1	0	0	0	0	0	0	0	2.1	0	0.1	0	0	0.2	0	0	0	0.6	0	0	0.9	0	0.4	0.6	0.5	0.7	0.5	0.1	0.4	0.6	0.9	0.4
MUC1	"ADMCKD, ADMCKD1, CD227, MCD, MCKD, MCKD1, PEM, PUM"	ENSG00000185499	"Mucin 1, cell surface associated"	P15941	1	155185824-155192916	"Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"			"Cancer-related genes, Tumor suppressor"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		gallbladder: 168.1;kidney: 158.5;lung: 143.5	Group enriched	Detected in many	7	CAPAN-2: 139.8;RPTEC TERT1: 107.3;T-47d: 47.1	Low cancer specificity	Detected in all			Low region specificity	Detected in some			Cell type enhanced	Detected in some		T-reg: 4.0	Group enriched	Detected in many	10	granulocytes: 1.3;T-cells: 4.0									"CAB000036, CAB001986, HPA004179, HPA007235, HPA008855"	Enhanced		Supported	Plasma membrane	Secreted in other tissues	4900000	4900000	Plasma membrane		"CAB000036: AB_2148557, CAB001986: , HPA004179: AB_1846282, HPA007235: AB_1846281, HPA008855: AB_1846283"	unprognostic (4.74e-2)	unprognostic (2.84e-2)	unprognostic (2.19e-1)	unprognostic (8.01e-2)	unprognostic (1.32e-2)	unprognostic (1.70e-1)	unprognostic (2.61e-3)	unprognostic (6.34e-2)	unprognostic (1.43e-1)	unprognostic (3.23e-1)	prognostic unfavourable (4.60e-4)	unprognostic (4.75e-1)	unprognostic (2.05e-2)	unprognostic (1.13e-1)	unprognostic (8.12e-2)	unprognostic (1.42e-1)	unprognostic (1.21e-1)	1.5	0.7	0.8	12.6	1.2	0.9	12.6	0.4	0.7	31.6	15.9	1.2	2.4	2.9	10.5	9.8	51.8	18.7	168.1	0.8	0.5	0.3	158.5	2	143.5	0.3	0.5	0.3	14.9	74.2	0	4.7	15.5	2.1	6.1	16.1	0.8	17	5.9	0.8	1.8	3.6	2.8	0.7	0.6	105	4.3	0.5	0.7	15.7	10.5	47.8	12.3	5.2	0	0.2	1.3	0.1	0	4	0.2	1.8	0.9	0.6	0.5	0.4	0.5	0.2	0.6	1.5	0.7	1.9	0	139.8	0	10.2	1.1	2.8	0.1	0	0.2	1.2	0.1	0.2	11.8	0	0.3	0	4.4	1.2	0.2	0.3	0.2	0.2	1	1.9	0.5	14.2	0.1	0.1	0.4	0.2	0.2	0	3.4	107.3	0.1	0.6	0.2	3.4	5.9	0.1	47.1	0.6	0.2	0.4	0.8	1.3	0.1	2.2	1.1	0	0.7	0.1	0.1	1.3	0.1	0	0	0	0.8	0	2.3	0.4	0.2	0	0.3	0.7	0	0	0	0	4	0.2	0.8	1.2	0.4	0.7	0.5	0.3	0.5	0.3	2.1	0.5
NCAM1	"CD56, NCAM"	ENSG00000149294	Neural cell adhesion molecule 1	P13591	11	112961247-113278436	"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Receptor"	Cancer-related genes	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		brain: 110.6;heart muscle: 67.7	Cell line enhanced	Detected in some		HEL: 19.1;RH-30: 43.1;SCLC-21H: 35.1;SH-SY5Y: 17.2;U-138 MG: 24.0;WM-115: 25.4	Cancer enriched	Detected in many	8	glioma: 31.0	Low region specificity	Detected in all			Cell type enriched	Detected in some	14	NK-cell: 27.2	Lineage enriched	Detected in many	14	NK-cells: 27.2	Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB000142, CAB018071, HPA039835"	Enhanced		Enhanced	"Plasma membrane,Cytosol"	Intracellular and membrane	2800000000	2800000000	Plasma membrane	Cytosol	"CAB000142: , CAB018071: AB_627129, HPA039835: "	unprognostic (7.04e-2)	unprognostic (1.16e-1)	unprognostic (2.77e-2)	unprognostic (2.18e-2)	unprognostic (2.91e-1)	unprognostic (1.74e-3)	unprognostic (2.82e-1)	unprognostic (4.42e-3)	unprognostic (2.13e-1)	unprognostic (1.63e-2)	prognostic favourable (9.11e-6)	unprognostic (8.13e-2)	prognostic unfavourable (8.20e-4)	unprognostic (2.97e-2)	unprognostic (2.24e-1)	unprognostic (3.75e-2)	unprognostic (5.82e-5)	3.5	36.4	22.7	3	35.7	1.8	2.1	20.2	110.6	13.3	9	55.8	0.3	3.4	24.7	3	4.8	8.3	3.6	67.7	22.5	19.2	2.3	2.6	2	1.7	45	27.1	21.9	2.3	1.1	9.1	1.4	38.8	8.4	4.6	5.5	2.5	10.9	14.6	1.8	5.3	25.6	27.6	3.4	6.7	2.9	39.2	0	16.9	0.7	1.7	7	6.5	0	0	0.4	0.1	27.2	2	0.9	0	0	6.7	0.1	0	0.1	0.1	0.3	0	0.2	0.4	0.1	0.1	0.9	6	6.3	0.1	0	0	0	0.1	3.8	19.1	0	0	0.7	0	3.1	4.1	0	0	6.1	0	0	0.3	6.7	0	0	1.6	0.5	0.1	0	43.1	3.1	0	0	35.1	17.2	0	0.1	0	0	0.2	0	24	11.2	0.1	10	0	0.1	0	2.7	9	25.4	0	0.1	0	2	0	0.6	0	0.1	0.2	0	0	0	0.8	0.4	27.2	0	0	0.1	0.9	22.7	35.7	20.2	41.6	22.5	19.2	45	27.1	38.8	39.2
NCR1	"CD335, LY94, NK-p46, NKP46"	ENSG00000189430	Natural cytotoxicity triggering receptor 1	O76036	19	54906150-54916140	"CD markers, Predicted membrane proteins"		Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		lung: 5.5;lymphoid tissue: 13.9	Not detected	Not detected			Cancer enhanced	Detected in single		testis cancer: 1.2	Not detected	Not detected			Cell type enhanced	Detected in single		basophil: 1.0	Low lineage specificity	Detected in single			Not detected	Not detected			Low region specificity	Detected in single			HPA049311			Approved	Endoplasmic reticulum				Endoplasmic reticulum		HPA049311: 	unprognostic (3.92e-2)	unprognostic (2.21e-3)	unprognostic (1.67e-1)	unprognostic (2.87e-4)	unprognostic (2.89e-1)	unprognostic (6.32e-4)	unprognostic (2.22e-2)	unprognostic (3.29e-1)	unprognostic (1.07e-1)	unprognostic (1.89e-2)	unprognostic (1.45e-1)	unprognostic (1.36e-1)	unprognostic (1.15e-5)	unprognostic (1.82e-2)	unprognostic (5.92e-2)	unprognostic (3.81e-3)	unprognostic (6.05e-3)	1.4	0.2	0.1	3.7	0.4	2.1	0.3	0.1	0.3	0.3	2.1	0	0.5	0.1	1.2	1.3	0.3	0.2	2.1	1.9	0.2	0.2	0.3	2.5	5.5	3.8	0.2	0	0.2	0.1	0.1	0.2	0.4	0	0.6	0.2	1	0.4	0.1	0.3	0.5	3.4	1.2	0.2	13.9	0.3	0.4	0	2	0.3	0.1	2.6	0.7	0.3	0.2	0.2	1	0	0.7	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0.3	0	0.1	0.3	0.1	0	0	0.4	0	0	0.1	0.1	0	0.4	0	0	0	0	0	0	0	0	0	0.2	0	0.3	0.3	0	0.1	0.4	0	0	0.1	0	0.2	0	0.4	0.1	0	0	0.3	0.2	0	0.3	0	0.3	0.1	0	0	0.2	0.2	1	0	0	0	0	0	0	0	0	0.1	0.2	0.1	0	0	0.7	0	0.2	0	0	0.1	0.4	0.1	0.3	0.2	0.2	0.2	0	0	0
NCR2	"CD336, LY95, NK-p44"	ENSG00000096264	Natural cytotoxicity triggering receptor 2	O95944	6	41335655-41350887	"CD markers, Predicted membrane proteins"		Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in some		blood: 8.5;intestine: 3.3;lymphoid tissue: 3.7	Cell line enhanced	Detected in some		HMC-1: 1.7;MOLT-4: 2.0	Not detected	Not detected			Not detected	Not detected			Group enriched	Detected in some	13	NK-cell: 2.5;plasmacytoid DC: 8.5	Group enriched	Detected in many	13	dendritic cells: 8.5;NK-cells: 2.5									HPA067249	Uncertain									HPA067249: 		unprognostic (5.81e-2)				unprognostic (3.39e-1)		unprognostic (1.95e-1)		unprognostic (2.12e-2)				unprognostic (1.65e-1)				0.1	0.1	0.1	1.9	0.1	0	0.1	0	0	0	3.3	0	0	2.8	0.1	0	0.2	0	0	0.1	0.1	0	0.1	0.1	0.1	0.4	0	0	0	0.1	0	0	0	0	0.1	1.6	0	0.1	0.2	0	0.1	2.5	0.1	0	0.6	0.1	0.3	0	1.2	0.1	1.7	3.7	0	0.1	0	8.5	0	0	2.5	0.4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.5	1.7	0	0	0	0	0	0	0.9	0	0	2	0	0	0	0	0	0	0	0	0.5	0	0	0	0	0.3	0	0	0	0	0	0	0	0.1	0	0	0	0.4	0	0	0	0	0	0.4	0	0	0	0	0	0	0	0	2.5	0	8.5	0	0	0.1	0.1	0	0	0.1	0	0	0	0	0
NCR3	"1C7, CD337, LY117, NKp30"	ENSG00000204475	Natural cytotoxicity triggering receptor 3	O14931	6	31588895-31592985	"CD markers, Predicted membrane proteins"	Immunity	Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in some		blood: 28.5;lymphoid tissue: 18.5	Cell line enriched	Detected in some	4	NB-4: 9.3	Low cancer specificity	Detected in many			Not detected	Not detected			Cell type enhanced	Detected in many		MAIT T-cell: 28.5	Lineage enriched	Detected in many	4	T-cells: 28.5																				unprognostic (3.99e-3)	unprognostic (9.23e-4)	unprognostic (1.23e-3)	unprognostic (2.49e-4)	unprognostic (2.15e-1)	unprognostic (2.57e-4)	unprognostic (5.99e-2)	unprognostic (1.15e-2)	unprognostic (1.40e-2)	unprognostic (3.62e-2)	unprognostic (1.67e-1)	unprognostic (1.81e-1)	unprognostic (2.21e-4)	unprognostic (1.72e-1)	unprognostic (1.83e-1)	unprognostic (8.17e-2)	unprognostic (1.43e-1)	1.8	0.1	0.2	10.5	0.2	4.3	0.3	0.1	0.1	0.1	0.4	0	0	0.2	0.3	0.5	0.9	0.2	0.3	1.2	0.6	0.1	0.5	1.3	3.9	11.4	0.2	0	0.5	1.1	0	0.1	0.8	0.1	0.3	0.3	0.1	8.4	0.4	0.1	0.3	5.8	0.2	0.2	18.5	0.4	0.8	0	3.6	0.4	0.1	12.8	1	0.3	6.1	0	0.1	0.2	6.4	28.5	2.5	0	0	0	0	0	0	0	0	0	0	0	0	0	1.2	0	0	0	0	0	0	0	0	2.2	0	0	0	0.4	0.8	0	0	0	0	0	0.4	0	0	0	0.1	9.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0.9	0	0.3	0	0	0	0	10.5	0	28.5	6.1	1.2	5.2	0	4.4	0.5	3.3	0.1	6.4	0.2	0	1.7	2.5	0.2	0.2	0.1	0.1	0.6	0.1	0.2	0	0.1	0
NECTIN1	"CD111, CLPED1, ED4, HIgR, HVEC, OFC7, PRR, PRR1, PVRL1, PVRR1, SK-12"	ENSG00000110400	Nectin cell adhesion molecule 1	Q15223	11	119623408-119729084	"CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Receptor"	Ectodermal dysplasia	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		esophagus: 55.3;skin 1: 73.5	Cell line enhanced	Detected in many		HaCaT: 58.1;hTCEpi: 36.2;RT4: 39.4	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in some		plasmacytoid DC: 4.8	Low lineage specificity	Detected in many			Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB016135, HPA026846"	Approved				Secreted in other tissues	97000000	97000000			"CAB016135: AB_626865, HPA026846: AB_1846226"	unprognostic (1.62e-1)	unprognostic (1.16e-1)	unprognostic (1.11e-1)	unprognostic (3.87e-2)	unprognostic (1.26e-1)	unprognostic (3.20e-2)	unprognostic (2.25e-3)	unprognostic (2.03e-1)	unprognostic (3.76e-2)	unprognostic (3.42e-1)	unprognostic (3.58e-2)	unprognostic (3.28e-1)	unprognostic (3.59e-3)	unprognostic (2.13e-2)	unprognostic (1.91e-1)	unprognostic (2.46e-1)	unprognostic (9.62e-2)	3.1	3	7.7	3	11.1	11.9	5.3	8.4	20.8	6.6	7.3	27.3	2.4	9.6	2.3	2	55.3	2.9	2.5	3	16.1	8.2	3	2.4	2.5	1.7	12.7	10.6	1.8	10.8	2.4	4.1	8.2	10.1	5.9	7.8	6.3	8.7	4.4	1.6	73.5	6.9	3.1	14.3	2.2	3.2	1.3	12.4	2.5	1.8	25.3	20.8	17.3	14.8	0.1	4.8	1	1.5	0.1	0.1	0.2	4	3.4	3.2	4.6	1.7	0.5	22.7	1.6	1.5	1.4	1	7.1	13.9	5.4	6.7	1.9	58.1	8.2	29.6	0.6	12.7	1.2	0.7	1.1	3.3	0.7	3.6	9.1	0.5	36.2	4.4	16.2	4.1	0.1	28.9	1.8	10.6	0	2.2	10.6	4.7	0.3	19.4	6.5	1.3	39.4	7.8	17.7	5.5	14.6	0.5	13.3	0.5	2.2	1.2	4.6	10	1.4	5.3	6.6	0	0.4	3	2.8	0	0.3	0.2	0.1	0.5	0	0	0.1	0	0.2	0.1	0	0	1	0.1	1.5	4.8	0	0.2	7.7	11.1	8.4	20.8	16.1	8.2	12.7	10.6	10.1	12.4
NECTIN2	"CD112, HVEB, PRR2, PVRL2, PVRR2"	ENSG00000130202	Nectin cell adhesion molecule 2	Q92692	19	44846175-44889228	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Receptor"		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Low cell line specificity	Detected in many			Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in some		eosinophil: 11.5	Low lineage specificity	Detected in many			Low region specificity	Detected in all			Low region specificity	Detected in all			"HPA012759, CAB026138, HPA073459"	Enhanced		Approved	"Nucleoli fibrillar center,Cell Junctions"		3400000	3400000	"Nucleoli fibrillar center, Cell Junctions"		"CAB026138: , HPA012759: AB_1846227, HPA073459: "	unprognostic (3.30e-2)	unprognostic (2.84e-1)	unprognostic (1.07e-1)	unprognostic (5.61e-3)	unprognostic (7.45e-2)	unprognostic (2.21e-1)	unprognostic (1.66e-2)	unprognostic (6.63e-2)	unprognostic (2.85e-1)	unprognostic (2.97e-1)	unprognostic (6.93e-2)	unprognostic (3.19e-1)	unprognostic (1.60e-1)	unprognostic (2.15e-1)	unprognostic (1.61e-1)	unprognostic (8.19e-2)	unprognostic (2.05e-1)	29.5	28.2	7.9	15.6	7.7	5.6	38	4.5	9	24.2	34	9.3	22.3	24.2	23.2	27.4	33.6	16.7	54.1	21.9	10.5	8.1	29	53.7	39.6	23	8.2	6.8	25.5	20.6	22.5	15.9	45.8	11.2	25.8	14.8	22.9	24.4	28.9	14.6	18.3	42.9	13.8	8.4	31.4	26.2	38.7	5.8	3.8	32.2	19.2	24.1	21.6	31.4	0	3.3	11.5	2.6	0	0.3	0.7	17.8	21.4	27.7	32.7	14	8.5	32.2	15.3	18.9	27.1	31.3	44.1	39.3	0.1	20.7	17.7	24.5	24.5	12.6	21.6	0.7	12.8	10.8	7.4	28.5	33.7	0.1	29	14.9	5.1	12.9	10.5	35	17.6	0.1	13.5	32.5	0.1	1.2	23	6.4	1	9.4	0.7	32.1	22.1	1.3	3.7	19	28.9	6.5	22.5	10.6	34.9	7.4	26.3	5.5	11.2	2.2	6.4	0.1	13.6	2.3	19.3	1.5	2.6	11.5	0	0.9	0.3	0	0.1	0	3.3	0	0	0	2.4	0	0.5	0.3	0	0.7	7.9	7.7	4.5	9	10.5	8.1	8.2	6.8	11.2	5.8
NECTIN3	"CD113, CDw113, DKFZP566B0846, nectin-3, PPR3, PVRL3, PVRR3"	ENSG00000177707	Nectin cell adhesion molecule 3	Q9NQS3	3	111070071-111275563	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	Cell adhesion			Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		placenta: 94.2	Cell line enhanced	Detected in many		TIME: 46.6	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in some		memory CD4 T-cell: 1.7	Lineage enriched	Detected in single	4	T-cells: 1.7	Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB009869, HPA011038"	Approved		Approved	Centriolar satellite		20000000	20000000	Centriolar satellite		"CAB009869: AB_2284699, HPA011038: AB_1079719"	unprognostic (3.76e-2)	unprognostic (3.81e-3)	unprognostic (1.74e-1)	unprognostic (1.97e-2)	unprognostic (1.02e-1)	unprognostic (9.77e-2)	unprognostic (3.26e-3)	unprognostic (3.77e-1)	unprognostic (7.58e-2)	unprognostic (3.94e-2)	unprognostic (5.33e-2)	unprognostic (7.04e-2)	prognostic favourable (9.82e-7)	unprognostic (2.01e-1)	unprognostic (1.97e-1)	unprognostic (2.67e-1)	unprognostic (1.05e-1)	5.6	4	5.4	4.4	6	0	4.5	1.3	8.9	4.6	12.6	6.5	2.8	17.8	5	2.2	3.5	5.4	4.4	4.8	6.3	5	6.9	16.4	5.6	1.9	6	4.1	9.2	4.7	1.9	1.9	94.2	5.5	6.9	12.6	10.7	3.4	4.8	2.3	1.8	18.9	7.2	8.9	1.8	13.2	27.6	4.5	0.4	24.1	2	1.4	5.4	7.7	0.1	0	0.3	0	0.2	1.7	0.7	0	9.9	32.9	2.1	13.3	24.7	2	21.6	22.9	13.4	11.5	9.1	4.6	0	7.2	30.6	0.1	9.2	3.1	24.7	0.2	2.4	0	3.5	0.6	22.5	1.5	0.3	12.5	1.3	8.9	8.6	11.2	0	8.7	28.9	0	2.1	0	9.2	3.6	0	16.3	0	8.4	5.2	0.8	6	0.4	0	4.5	0.3	0.1	46.6	17	7.1	3.1	12.9	4.8	0	0	10.7	0	15.7	0	0	0.3	0.1	0	1.2	0	1.7	1	0	0.1	0.3	0.4	0	0.2	0	0	0.1	0.7	5.4	6	1.3	8.9	6.3	5	6	4.1	5.5	4.5
NGFR	"CD271, p75NTR, TNFRSF16"	ENSG00000064300	Nerve growth factor receptor	P08138	17	49495293-49515017	"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"	"Apoptosis, Biological rhythms, Differentiation, Neurogenesis"	"Developmental protein, Receptor"	Cancer-related genes	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Group enriched	Detected in some	7	RH-30: 54.7;WM-115: 60.7	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enriched	Detected in single	7	plasmacytoid DC: 4.2	Lineage enriched	Detected in single	7	dendritic cells: 4.2	Low region specificity	Detected in many			Group enriched	Detected in some	5	basal ganglia: 13.1;hypothalamus: 8.2;pons and medulla: 3.7	"CAB000143, CAB001995, HPA004765"	Enhanced		Approved	"Nucleoplasm,Plasma membrane"		100000	100000	Nucleoplasm	Plasma membrane	"CAB000143: , CAB001995: , HPA004765: AB_1079233"	unprognostic (6.25e-3)	unprognostic (1.06e-3)	unprognostic (3.39e-3)	unprognostic (6.67e-2)	unprognostic (1.46e-2)	unprognostic (2.26e-1)	unprognostic (8.22e-2)	unprognostic (4.94e-2)	unprognostic (1.08e-2)	unprognostic (4.10e-3)	unprognostic (1.85e-2)	unprognostic (1.25e-1)	unprognostic (3.37e-2)	unprognostic (4.01e-2)	unprognostic (3.06e-2)	unprognostic (2.77e-3)	prognostic unfavourable (3.40e-4)	30.9	24	1.2	9.2	7.4	1	11.7	6.1	4.5	7.6	9.4	10.4	7.9	3.2	6.8	15	11.3	12.6	10.8	22.2	2.4	2.9	4.8	29.1	1.4	11.6	13.8	1.3	7.6	6.2	2.8	6.7	16.7	15.9	17.7	3.4	20.2	17.2	9.7	4.8	8.4	5	10.7	22.4	18.9	4.9	12.2	4.4	0.4	25.8	7.4	7	13.1	6.8	0	4.2	0	0.4	0	0.5	0.2	0	0	1.7	2.7	0	0	0	0	0	0	0	0	0	0	0.5	0	1.3	0.4	1.2	0	0.1	0.2	0.1	0	1	0.1	0	0.1	5.8	0	0.1	0.4	0	0	0	7.9	0.1	0	0	1	0	1	54.7	0	0	0	0.5	0.3	0	0	3.6	0.1	0	0	0	0.9	0.1	2.7	0	0	0	0	0.5	60.7	0	0	0	0.5	0.2	0.1	0	0.3	0	0.1	0	0	0.1	0	0	0.4	4.2	0	0.2	1.2	7.4	6.1	4	2.4	2.9	13.8	1.3	15.9	4.4
NRP1	"CD304, NRP, VEGF165R"	ENSG00000099250	Neuropilin 1	O14786	10	33177492-33336262	"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	"Angiogenesis, Differentiation, Neurogenesis"	"Developmental protein, Heparin-binding, Receptor"	Cancer-related genes	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in many			Cell line enhanced	Detected in many		fHDF/TERT166: 69.8;TIME: 58.0;U-87 MG: 69.5	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enriched	Detected in some	14	plasmacytoid DC: 24.0	Lineage enriched	Detected in many	14	dendritic cells: 24.0	Low region specificity	Detected in many			Low region specificity	Detected in all			"CAB004511, HPA030278"	Approved				Secreted in other tissues	720000000	720000000			"CAB004511: AB_2282634, HPA030278: AB_10601976"	unprognostic (3.19e-1)	prognostic unfavourable (7.10e-5)	unprognostic (1.50e-2)	unprognostic (3.80e-2)	prognostic unfavourable (5.79e-4)	unprognostic (6.17e-2)	unprognostic (1.46e-2)	unprognostic (1.08e-1)	unprognostic (6.66e-2)	unprognostic (2.52e-1)	unprognostic (1.82e-1)	unprognostic (4.78e-2)	prognostic unfavourable (3.87e-4)	prognostic unfavourable (1.22e-5)	unprognostic (3.83e-2)	unprognostic (5.48e-2)	unprognostic (7.79e-2)	69.9	15	4.9	13.6	4.9	0.7	53.8	1.3	5.6	25.1	17.6	2.4	16.4	6.7	29.8	21.9	14.7	17	23.3	50.5	17.2	5.9	47.1	27.4	47.1	30.1	3.5	3.2	27.1	14.1	11.7	6.4	44.3	3.6	25.2	7.8	24.3	11.8	31.6	22.3	9.1	14.6	19.1	5.5	38.7	9.8	15.6	2.8	5.9	30.4	24.6	7.9	22.3	23.8	0.4	24	0.3	1.7	0.6	0.4	0.4	8.7	34	1.7	0.1	33.2	37.2	0.2	35.2	34.3	17.8	19.1	4.3	20.9	0.1	4.2	69.8	2.4	2.1	10.2	14.5	0.1	1.7	0	3.9	7.3	11.7	3.1	0.2	44.4	1.7	42.2	19.1	48.2	0.1	0.2	34.6	14.7	0.2	0.5	0.8	32.3	1.4	3.8	0.1	16.7	0.1	0.8	0.4	3.6	2.7	0.1	0.1	0.4	58	25.4	6	30.5	23.7	0.1	0.1	0.1	69.5	4	22.9	0.2	1.7	0.3	0.3	0.3	0.4	0.4	0.3	0.3	1.4	0.3	0.4	0.3	0.3	0.6	0.1	24	0.3	0.4	4.9	4.9	1.3	5.6	17.2	5.9	3.5	3.2	3.6	2.8
NT5E	"CALJA, CD73, eN, eNT, NT5"	ENSG00000135318	5'-nucleotidase ecto	P21589	6	85449584-85495791	"CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"		Hydrolase	Disease mutation	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in many			Cell line enhanced	Detected in many		LHCN-M2: 108.8;TIME: 63.0;U-87 MG: 98.1	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Group enriched	Detected in many	4	memory B-cell: 13.4;memory CD8 T-cell: 6.6;naive B-cell: 19.9;naive CD8 T-cell: 17.3	Group enriched	Detected in many	47	B-cells: 19.9;T-cells: 17.3	Low region specificity	Detected in some			Low region specificity	Detected in all			HPA017357	Approved		Supported	"Nucleoplasm,Plasma membrane,Cytosol"	Intracellular and membrane	1600000	1600000	Plasma membrane	"Nucleoplasm, Cytosol"	HPA017357: AB_1846330	unprognostic (1.92e-2)	unprognostic (4.44e-3)	unprognostic (1.54e-1)	unprognostic (1.57e-3)	unprognostic (9.33e-2)	unprognostic (1.82e-3)	unprognostic (1.20e-2)	prognostic unfavourable (6.66e-4)	unprognostic (5.45e-2)	unprognostic (1.80e-1)	prognostic unfavourable (1.32e-5)	unprognostic (1.39e-1)	unprognostic (3.11e-2)	prognostic unfavourable (1.02e-4)	unprognostic (3.49e-2)	unprognostic (2.26e-1)	unprognostic (2.78e-1)	12.2	3.2	9.3	7.7	11.6	0.5	16.6	1.1	6.9	58.8	13.9	3.6	8.1	18.6	33.3	14.8	7.6	12.2	15.4	6.1	5.7	5.5	8.8	26	3.4	6.8	6.3	6.6	25.4	1.4	1.6	9.3	42.2	5.3	16.4	15.6	15.3	4.6	17.8	5.7	4.5	14.9	35.3	6.3	7	6	12.4	4.2	1.6	26.5	7.3	7.1	16.6	20.2	19.9	0	0.2	0	0.4	17.3	3.9	5.4	2.9	5	0.1	11.5	36.7	0	35.5	38.9	17.5	32.9	0	54.5	0	12.8	31	2.8	0	35.7	41.7	0	0	0	0.8	0.6	5.7	0	0	9.4	0.4	35.7	22.8	14.5	0	0.1	108.8	0.9	0	0	0.1	3.9	0.1	1.1	0.1	37.9	2.4	0	0.6	0.4	2.2	12	0	0.9	63	14.3	0.1	18	57.7	2.7	1.7	0	98.1	0	44.8	0	0	0.2	2	0	3.5	13.4	2.3	6.6	0	19.9	2.4	17.3	0.2	0.4	0	0	0.8	3.9	9.3	11.6	1.1	6.9	5.7	5.5	6.3	6.6	5.3	4.2
PDCD1	"CD279, hSLE1, PD-1, PD1, SLEB2"	ENSG00000188389	Programmed cell death 1	Q15116	2	241849881-241858908	"CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Apoptosis, Immunity"		"FDA approved drug targets, Systemic lupus erythematosus"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 11.6;lymphoid tissue: 21.5	Group enriched	Detected in some	14	MOLT-4: 9.3;RPMI-8226: 9.4	Low cancer specificity	Detected in many			Not detected	Not detected			Group enriched	Detected in many	5	gdT-cell: 4.1;MAIT T-cell: 3.9;memory CD4 T-cell: 6.8;memory CD8 T-cell: 11.6;T-reg: 3.5	Lineage enriched	Detected in single	93	T-cells: 11.6	Not detected	Not detected			Not detected	Not detected			"HPA035981, CAB038418, CAB076386"	Enhanced									"CAB038418: AB_1160824, CAB076386: AB_881954, HPA035981: AB_10669664"	unprognostic (2.90e-3)	unprognostic (4.50e-3)	unprognostic (7.78e-2)	prognostic favourable (9.44e-5)	unprognostic (7.18e-3)	unprognostic (1.31e-3)	unprognostic (3.83e-2)	unprognostic (7.33e-2)	unprognostic (5.82e-3)	unprognostic (3.75e-2)	unprognostic (6.57e-2)	unprognostic (3.94e-1)	prognostic unfavourable (3.48e-7)	unprognostic (1.20e-2)	unprognostic (3.10e-1)	unprognostic (5.35e-2)	unprognostic (5.06e-3)	1.4	0.4	0	21.5	0.7	3	0.5	0.1	0.3	1.2	1.9	0	0	0.4	0.5	1.6	2	0.8	1.7	9.2	0.2	0.5	1.3	0.5	5.6	16.6	0.1	0.3	0.7	1	0.2	1.9	0.3	0.4	1.3	0.2	1.2	3	0.5	0.2	0.2	4.9	0.4	0.3	9.5	1.9	0.4	0.2	16.6	1.9	3	20.1	1.3	0.8	0.1	0	0	0	0	11.6	1.5	0	0	0	0	0	0	0	0	0	0	0	0.4	0	0	0.1	0	0	0	0	0	0	0	0	0	0.1	0	0	0.6	0	0	0	0	0	0.2	0	0	0.5	9.3	0	0	0	0	0.1	9.4	0	0	0	0	0	0	0	0	0	0	0	0.4	0	0	0	0	0	0	0	0	0	0	0	4.1	0	3.9	0.1	6.8	11.6	0	0	0.5	1.2	0	0	0	0	3.5	1.5	0	0.7	0.1	0.1	0.2	0.5	0.1	0.3	0.4	0.2
PDCD1LG2	"B7-DC, bA574F11.2, Btdc, CD273, PD-L2, PDL2"	ENSG00000197646	Programmed cell death 1 ligand 2	Q9BQ51	9	5510570-5571254	"Cancer-related genes, CD markers, Predicted membrane proteins, Predicted secreted proteins"	"Adaptive immunity, Immunity"	Receptor	Cancer-related genes	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in many			Cell line enhanced	Detected in many		BJ: 25.4;BJ hTERT+: 39.9;HDLM-2: 30.5;TIME: 17.6	Low cancer specificity	Detected in many			Low region specificity	Detected in many			Low cell type specificity	Detected in many			Low lineage specificity	Detected in many			Not detected	Not detected			Low region specificity	Detected in all			HPA013411	Approved		Approved	Cytosol	Secreted - unknown location	34000000	34000000	Cytosol		HPA013411: AB_1855102	unprognostic (3.93e-2)	unprognostic (1.90e-1)	unprognostic (3.51e-3)	unprognostic (6.68e-3)	unprognostic (7.66e-2)	unprognostic (6.77e-2)	unprognostic (5.72e-2)	unprognostic (2.91e-1)	unprognostic (1.68e-1)	unprognostic (4.37e-3)	unprognostic (5.79e-2)	unprognostic (5.29e-2)	prognostic unfavourable (1.15e-4)	unprognostic (5.00e-2)	unprognostic (4.66e-2)	unprognostic (2.01e-1)	unprognostic (7.51e-3)	15.2	1.8	1.2	7.7	1.4	0.2	9.5	0.7	1.2	7	1.9	2.3	0	0.8	2.9	7.2	3.9	3.8	4	5.8	1.2	1.3	2.5	6.4	13.3	10.8	1.6	0.5	4.1	1.8	0.5	1.1	12.9	1.9	5	2.5	2.4	2.9	1.7	5.5	3.6	2.5	4.6	3.7	19.5	1.9	4.2	1.2	8.1	3.5	3.5	8.1	6	5.4	0.5	0.9	4.1	3.6	0	3	0.7	2	0	0	0	1.7	2	0	25.4	39.9	12.3	14.9	0	0.1	0	0	10.3	0.2	0	3.4	12.2	30.5	0	0	0	0	9.9	0	0	1.8	0	5.7	6.7	8	0	3	14.7	0	0	0	0	0	0	15.2	0.2	0	0	0	0	0.5	0	0	0	0	17.6	8.8	0.5	4.2	7	0.4	0	0	5	0	1	4.1	0.9	0	1.4	3.6	1.9	0.5	2.2	0.9	0.9	0.3	0	1	2	0	0.5	0	3	0.7	1.2	1.4	0.7	1.2	1.2	1.3	1.6	0.5	1.9	1.2
PDGFRA	"CD140a, GAS9, PDGFR2"	ENSG00000134853	Platelet derived growth factor receptor alpha	P16234	4	54229097-54298247	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"	"Chemotaxis, Host-virus interaction"	"Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, FDA approved drug targets, Proto-oncogene"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		ovary: 81.5	Cell line enhanced	Detected in some		ASC diff: 81.0;ASC TERT1: 37.9;BJ hTERT+: 47.0;fHDF/TERT166: 32.7;HHSteC: 27.4;HSkMC: 68.9	Cancer enhanced	Detected in all		glioma: 30.8	Low region specificity	Detected in all			Low cell type specificity	Detected in some			Low lineage specificity	Detected in single			Low region specificity	Detected in all			Low region specificity	Detected in all			"HPA004947, CAB018143"	Supported		Approved	"Nucleoplasm,Plasma membrane,Cell Junctions"	Intracellular and membrane	150000	150000	"Nucleoplasm, Plasma membrane, Cell Junctions"		"CAB018143: AB_2162351, HPA004947: "	unprognostic (1.67e-1)	unprognostic (9.35e-2)	unprognostic (4.59e-3)	unprognostic (1.60e-1)	unprognostic (8.92e-2)	prognostic favourable (9.33e-4)	unprognostic (1.24e-1)	unprognostic (2.00e-2)	unprognostic (1.46e-1)	unprognostic (2.18e-2)	unprognostic (2.18e-1)	unprognostic (7.01e-2)	prognostic unfavourable (9.79e-6)	unprognostic (9.58e-3)	unprognostic (9.87e-2)	unprognostic (2.16e-2)	unprognostic (1.72e-3)	35	12.4	12.6	16.1	7.6	0.9	17.2	2.4	20.1	33.2	19.1	9.2	6.4	9.6	27.6	14.6	21.9	22.5	16.2	15.3	8.9	7.4	22.8	8.4	24.1	26.9	9.2	4	81.5	6.8	1.6	2.1	25.1	7.2	18.6	15.2	19.2	8.5	8.3	11.9	7	17.4	19.7	8.8	51.6	13.6	19	9.3	0.5	11.3	12.8	4.3	35.9	24.6	0.9	0.4	2.5	0.4	0.3	0.8	0.3	0	0	0.2	0.1	81	37.9	0.1	4.2	47	0	0.1	11.2	0	0.1	0.1	32.7	0.1	3.2	0	0	0.4	0.1	0.1	0.1	0.2	27.4	0	0	68.9	0	5.3	0	0	0.1	0.1	0.1	0	0	0.2	0.6	0.1	0.1	0	0	0	0.3	0.1	6.6	0	0.1	0	0.1	0	0.1	14.8	0.5	16.2	0	0	0	0.1	0.4	0	0.3	2.5	0.4	0.2	0.5	0.2	0.2	0.6	0.8	0.4	0	0.9	0.7	0.4	2.3	0.3	0.3	0.4	0.2	0.3	12.6	7.6	2.4	7.3	8.9	7.4	9.2	4	7.2	9.3
PDGFRB	"CD140b, JTK12, PDGFR, PDGFR1"	ENSG00000113721	Platelet derived growth factor receptor beta	P09619	5	150113837-150155872	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"	Chemotaxis	"Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in many			Group enriched	Detected in some	4	ASC diff: 169.0;ASC TERT1: 58.5	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in some		gdT-cell: 2.9;non-classical monocyte: 4.1	Group enriched	Detected in many	8	monocytes: 4.1;T-cells: 2.9	Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB003842, CAB018144, HPA028499"	Enhanced		Supported	"Golgi apparatus,Vesicles"		35000000	35000000	Vesicles	Golgi apparatus	"CAB003842: AB_562328, CAB018144: AB_2162497, HPA028499: AB_10602018"	unprognostic (4.75e-2)	unprognostic (2.48e-1)	unprognostic (5.21e-2)	unprognostic (3.60e-2)	unprognostic (3.27e-1)	unprognostic (5.61e-2)	unprognostic (1.02e-1)	unprognostic (3.36e-2)	unprognostic (2.12e-2)	unprognostic (2.57e-3)	unprognostic (6.72e-2)	unprognostic (1.25e-1)	prognostic unfavourable (5.87e-8)	unprognostic (3.13e-3)	unprognostic (1.25e-2)	unprognostic (5.47e-2)	prognostic unfavourable (8.11e-4)	61.8	10.4	8.3	11	9.1	0.5	66.1	4.6	10.4	73.1	15.7	6.7	6.9	5.1	44.3	17.3	21.7	26.1	51.7	24.2	8.2	3.9	17	4.6	28.9	21.5	7.9	8.1	46.5	7.5	10.4	7.7	46.4	7.7	24.2	6.3	22.9	11.2	19.3	29.8	20.3	11.2	29.8	5	19.6	9.2	21.5	6.7	1.4	21.4	16	7.3	23.6	35.1	0.4	0.1	0	4.1	0	2.9	0.6	0	0	1	0	169	58.5	0.3	5.9	24.5	4.1	7	0.6	0	0	0.7	16.9	0	0	0	1.9	0	0	0	0.3	0.4	24	0	0	26.3	0	5.7	0	0	0	0.6	0.6	0	0	0	1.1	0	0.4	0.3	0	0	0	0	3.1	0	0	0	0	0	0	6.7	2.2	2.8	0.3	0	0	0	4.1	0	0.1	0	0	0	2.9	0.6	0	0.4	0.1	0.8	0.1	0.1	0	1.3	0	0	4.1	0	0	0.6	8.3	9.1	4.6	10.4	8.2	3.9	7.9	8.1	7.7	6.7
PLAUR	"CD87, UPAR, URKR"	ENSG00000011422	"Plasminogen activator, urokinase receptor"	Q03405	19	43646095-43670547	"Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Cancer-related genes, FDA approved drug targets"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		blood: 118.0;bone marrow: 165.0	Cell line enhanced	Detected in many		hTEC/SVTERT24-B: 49.4;U-251 MG: 70.2;U-87 MG: 61.3;WM-115: 59.7	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in many		neutrophil: 118.0	Low lineage specificity	Detected in many			Low region specificity	Detected in some			Low region specificity	Detected in all			"HPA050843, CAB073533"	Uncertain		Supported	Plasma membrane	Intracellular and membrane	760000	760000	Plasma membrane		"CAB073533: , HPA050843: "	unprognostic (9.28e-2)	unprognostic (9.65e-3)	unprognostic (1.39e-1)	unprognostic (1.29e-3)	unprognostic (3.59e-3)	unprognostic (1.50e-2)	unprognostic (2.18e-3)	prognostic unfavourable (2.33e-5)	unprognostic (8.08e-3)	unprognostic (4.30e-2)	unprognostic (2.29e-3)	unprognostic (5.30e-2)	prognostic unfavourable (7.83e-9)	unprognostic (4.99e-2)	unprognostic (1.66e-1)	unprognostic (5.45e-2)	unprognostic (9.33e-2)	25.2	3.6	3	23.6	4.8	165	6.3	2.2	6.1	10.7	7.5	4.4	1.8	3.3	9.5	6	8.6	10.6	23	11.5	4.5	3.2	5.1	6.1	39.4	8.1	6	1.1	11.9	4.3	2.5	4.4	12.2	6.9	6.1	6	4.6	11	3.7	7.9	3.5	7.3	7.2	7.1	12.6	12	6.3	6.3	2.5	4.4	7.7	7	22.7	14.9	0.2	21.3	118	50.5	0.6	0.9	21	14	4.9	4.5	0.3	4	14.4	2.7	29.6	30.1	18.7	23.5	0.4	16.6	0.5	7.5	18.3	6	1.2	7.3	20.9	0.9	0.9	2.6	7.4	0.6	5.1	3.1	34.3	14.8	1.4	49.4	7.4	20.6	2.7	0.6	17.9	1	3.4	8.4	1.4	10.6	3.9	3	1	5.8	0.7	0.2	3.9	13.2	3	3.9	0.6	9.8	21.1	41.3	21.2	18.9	70.2	0.6	1.4	0.1	61.3	5.8	59.7	7.2	48.9	72.4	0.7	41.5	0.8	0.2	0.9	0.6	21.3	0.1	0.3	0.4	118	0.6	50.5	6.8	0.3	21	3	4.8	2.2	6.1	4.5	3.2	6	1.1	6.9	6.3
PLXNC1	"CD232, VESPR"	ENSG00000136040	Plexin C1	O60486	12	94148723-94307675	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"				Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		lymphoid tissue: 43.5;retina: 40.6	Cell line enhanced	Detected in many		HAP1: 14.9;SK-MEL-30: 18.5;U-266/70: 29.4;U-266/84: 30.6	Cancer enhanced	Detected in all		melanoma: 24.8	Low region specificity	Detected in all			Cell type enhanced	Detected in many		neutrophil: 14.2	Group enriched	Detected in many	4	granulocytes: 14.2;monocytes: 6.7	Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB026155, HPA066899"	Uncertain		Approved	Mitochondria		82000	82000	Mitochondria		"CAB026155: , HPA066899: "	unprognostic (1.49e-1)	unprognostic (4.01e-2)	unprognostic (5.60e-2)	unprognostic (1.99e-1)	unprognostic (2.33e-1)	unprognostic (3.24e-2)	unprognostic (4.67e-3)	unprognostic (2.80e-2)	unprognostic (3.49e-1)	unprognostic (4.64e-2)	unprognostic (1.78e-2)	unprognostic (2.38e-1)	unprognostic (4.02e-2)	unprognostic (5.33e-3)	unprognostic (3.19e-2)	unprognostic (6.85e-3)	unprognostic (5.48e-2)	6.6	7.5	7.1	16.1	6.9	12.6	3.9	16.8	8.6	8	5.1	3.1	0.8	3.1	7.3	2.2	4.9	4.3	8.3	4.1	6.3	15.2	3.2	2	15.2	43.5	4.5	7.7	13	2.3	0.5	6.3	7.5	5.2	4.3	5.4	40.6	3.7	3.7	2.9	6.6	5	5.7	4.9	28.6	3.4	12.1	3.3	8.6	3.3	2.7	10.2	9.6	6.5	2.4	2.5	14.2	6.7	0.9	1.7	1.5	0.4	0.2	1.2	0.2	0.7	0.5	0.1	0.6	0.8	0.8	2.3	4	0	9.5	0	0.9	0	14.9	0.6	0.5	6.6	0.3	0.5	0.2	2.7	8.3	1.9	3.3	8.2	0	0.9	0.4	0	0.2	11.7	0.2	0.1	0.4	1	2.5	0.5	1.5	0.4	5.2	0	0.7	1	0.7	0.1	0.1	18.5	0	1.6	0.3	0.2	1.1	0.1	0.3	29.4	30.6	0.6	0.1	5.2	0.6	0	3	12.2	1.4	5.2	1.6	2.4	1.6	1.7	2.5	1.4	1.4	1.5	14.2	0.9	6.7	0.9	1	1.5	7.1	6.9	16.8	8.6	6.3	15.2	4.5	7.7	5.2	3.3
PRNP	"AltPrP, CD230, CJD, GSS, PRIP, PRP"	ENSG00000171867	Prion protein	P04156	20	4686236-4701590	"CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Cell cycle, Growth arrest"	Prion	"Amyloidosis, Disease mutation"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in many		WM-115: 114.4	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enriched	Detected in many	6	basophil: 108.1	Lineage enriched	Detected in all	6	granulocytes: 108.1	Low region specificity	Detected in all			Low region specificity	Detected in all			"HPA042754, HPA043398"	Enhanced		Approved	"Nuclear membrane,Vesicles,Cytosol"	Intracellular and membrane	2200000	2200000	"Nuclear membrane, Cytosol"	Vesicles	"HPA042754: AB_10964203, HPA043398: "	unprognostic (1.50e-1)	unprognostic (1.72e-1)	prognostic unfavourable (2.96e-4)	prognostic unfavourable (4.64e-4)	prognostic unfavourable (2.52e-4)	unprognostic (1.94e-2)	prognostic unfavourable (7.41e-5)	unprognostic (7.60e-3)	unprognostic (2.50e-1)	unprognostic (7.12e-2)	unprognostic (3.44e-1)	unprognostic (1.04e-1)	unprognostic (6.75e-2)	unprognostic (7.28e-3)	unprognostic (3.37e-1)	unprognostic (2.04e-1)	unprognostic (1.69e-2)	24.6	27.3	63.4	14.2	73.1	19.8	30.5	87.5	116.1	42	43.4	61.6	8.5	10.6	36.3	17.7	23	24.1	31.4	54.1	64.6	48.9	38.5	22.2	22.2	14.7	47.2	65.6	49.6	11.8	20.7	24.9	18.7	71.6	43.8	20.9	34.1	17.1	45	21.8	26.7	13.5	40.8	53.1	20.3	18.1	19.1	51.4	2.9	25.6	11.8	16.4	27	22.3	4.6	10.5	108.1	11.7	3.6	16.7	10	24.2	20	4.6	7.1	37.3	22.8	4.1	40.2	57.9	19.5	19.9	6.6	18.8	4.4	9.3	78.3	56.5	5	54.7	36.6	3.6	4.3	0	2.3	20.6	45.9	7.9	1.8	20.6	78.9	83.4	65.2	16.7	2.3	15.8	22.4	5.4	3.1	4.8	3.7	29.8	3.8	12.2	4	9.8	4.3	5.4	0.8	11.4	16	57.1	3.3	4.1	25.1	31.8	14.6	17.7	32.6	7.3	14.7	14.8	25.6	5.8	114.4	108.1	11.7	0.8	11.9	9.7	16.7	4.2	9.8	9.4	10.5	4.6	5.8	6.8	0.7	3.6	7.6	3.7	11.4	10	63.4	73.1	87.5	90.4	64.6	48.9	47.2	65.6	71.6	51.4
PROCR	"CCD41, CD201, EPCR"	ENSG00000101000	Protein C receptor	Q9UNN8	20	35172073-35216240	"Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Blood coagulation, Hemostasis"	Receptor		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		placenta: 77.8	Cell line enhanced	Detected in many		HMC-1: 64.9;HUVEC TERT2: 101.2;TIME: 59.8	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in many			Low lineage specificity	Detected in all			Low region specificity	Detected in all			Low region specificity	Detected in all			HPA039461	Enhanced					1600000000	1600000000			HPA039461: AB_10673359	unprognostic (1.51e-1)	unprognostic (1.03e-1)	unprognostic (4.12e-2)	unprognostic (1.68e-1)	unprognostic (2.64e-1)	unprognostic (4.69e-2)	unprognostic (4.69e-2)	unprognostic (1.84e-1)	unprognostic (1.52e-1)	unprognostic (4.76e-2)	unprognostic (5.22e-2)	unprognostic (4.27e-1)	prognostic unfavourable (7.62e-6)	unprognostic (3.37e-2)	unprognostic (2.29e-1)	unprognostic (1.05e-1)	unprognostic (2.19e-2)	51	11.9	2.3	10.1	3.2	4.4	24.6	2.9	2.3	16.8	25	3.1	14.1	8.7	27.7	44.5	19.4	17.3	13.4	27.4	2.7	2.4	11.7	3.8	10.6	30.3	3.1	2.1	19.3	11.5	2.7	4.7	77.8	7.4	15.5	12.3	16.4	4.2	14	17.7	10.4	14	20	5.8	22.1	10.4	9.1	2	0.6	12.1	13	3.9	25.8	14.9	1.6	7.3	4.1	1.7	3.4	14.6	2	2.4	14.5	0	1.5	16	13.1	3.4	3.4	14.9	5.6	11	18.7	12.7	0.4	10.7	3.4	8	3.3	21.7	4.7	0.1	4.5	5.3	3.5	0.7	3.9	0.2	64.9	11.1	8.1	26.6	22.2	101.2	1.8	0.7	5.8	0.8	0.1	0.2	2	15	0.1	2.8	0	9.6	0.9	0.4	0.2	1.8	3.9	3	1.3	0.8	59.8	14.6	7.4	5.5	5.7	0	0.1	0.1	16.8	5.4	3	4.1	1.5	0.9	8.3	1.7	14.6	1	2.6	5.2	7.3	1.6	0.7	6.3	4.1	3.4	1.4	1.2	2	2	2.3	3.2	2.9	2.3	2.7	2.4	3.1	2.1	7.4	2
PROM1	"AC133, CD133, CORD12, MCDR2, PROML1, RP41, STGD4"	ENSG00000007062	Prominin 1	O43490	4	15963076-16084378	"CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"			"Cone-rod dystrophy, Disease mutation, Retinitis pigmentosa, Stargardt disease"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		retina: 52.4;salivary gland: 71.0	Cell line enhanced	Detected in some		AF22: 13.5;CACO-2: 25.1;CAPAN-2: 10.7;EFO-21: 24.5;NTERA-2: 36.4;RPTEC TERT1: 33.7	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Not detected	Not detected			Not detected	Not detected			Low region specificity	Detected in many			Low region specificity	Detected in some			"HPA004922, CAB011525, HPA031053"	Enhanced									"CAB011525: AB_470302, HPA004922: AB_1846238, HPA031053: "	unprognostic (6.33e-2)	unprognostic (2.54e-1)	unprognostic (1.53e-1)	unprognostic (3.39e-1)	unprognostic (2.81e-1)	unprognostic (2.16e-1)	unprognostic (2.39e-1)	unprognostic (6.64e-2)	unprognostic (2.18e-2)	unprognostic (2.17e-1)	unprognostic (1.21e-2)	unprognostic (9.06e-2)	prognostic favourable (2.56e-5)	unprognostic (2.16e-2)	unprognostic (1.02e-1)	unprognostic (9.38e-2)	unprognostic (1.17e-1)	0.5	0.5	2.5	11.5	2.2	1.3	11.2	1	2.2	20.1	13.8	2.3	1.6	5.2	4.7	3.1	1.8	1.9	12.6	2.7	3.1	2.1	30.2	1.6	3.6	0.1	2.3	0.6	1.6	10.7	0	1.8	12.7	2.1	1.6	7.4	52.4	71	2.9	0.7	1.1	13.5	1.7	1.8	0.6	10.9	5	0.9	0.3	1.7	3.8	10.2	3	0.5	0	0	0.1	0	0	0.1	1	0	0	13.5	0	0	0	0	0	0	0	0	25.1	10.7	0.3	24.5	0	0	2.6	0	0	0.1	0	0	0	0.6	0.1	0	0	0	0	0	0	0	0	0.1	0	0	0.1	0	36.4	0	0.9	0	0	33.7	0	4.2	1.4	0	0.8	1	0.2	0	0	0.1	0.1	0	0	0	0	0	0	0	0	0.1	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2.5	2.2	1	2.2	3.1	2.1	2.3	0.6	2.1	0.9
PSG1	"CD66f, PBG1, PSBG1, PSGGA"	ENSG00000231924	Pregnancy specific beta-1-glycoprotein 1	P11464	19	42866464-42879822	"CD markers, Predicted intracellular proteins, Predicted secreted proteins"				Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enriched	Detected in some	362	placenta: 497.6	Cell line enriched	Detected in some	20	U-2197: 95.7	Cancer enhanced	Detected in single		thyroid cancer: 0.5	Not detected	Not detected			Cell type enhanced	Detected in single		neutrophil: 1.0	Low lineage specificity	Detected in single											HPA046327	Supported				Secreted in female reproductive system					HPA046327: 					unprognostic (2.02e-1)	unprognostic (3.54e-1)							unprognostic (2.44e-7)			unprognostic (2.28e-2)		1.3	0	0.1	0	0.1	0	0.6	0.5	0.2	0.3	0.1	0	0	0	0	0	0.1	0.1	0	0.2	0.1	0.1	0.2	0	0	0	0.1	0	0	0.2	0.1	0.1	497.6	0	0	0	0	0.2	0	0.1	0.1	0.1	0.1	0	0.1	0.1	0.2	0	0	0.5	0	0	0.2	0	0.2	0	1	0.3	0	0.1	0	0	0.1	0	0	0	0	0	4.1	1.3	0.3	0.5	0	0	0	0	4.7	0	0	0	4	0	0	0	0	0	0	0	0	0	0	0	0.4	0	0	0	0.4	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0.1	0	0	0	0.1	0	0	95.7	0	0	0	0	0	0	0	0.4	0	0.1	0	0	0.1	0.1	0	0	0	0.2	0	0.1	1	0	0.3	0	0.1	0	0.1	0.1	0.5	0.2	0.1	0.1	0.1	0	0	0
PTGDR2	"CD294, CRTH2, DP2, GPR44"	ENSG00000183134	Prostaglandin D2 receptor 2	Q9Y5Y4	11	60850940-60855971	"CD markers, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 51.8;lymphoid tissue: 28.1	Cell line enhanced	Detected in some		HEL: 10.3;Hep G2: 5.0;HMC-1: 6.5;K-562: 4.2;NB-4: 14.8	Low cancer specificity	Detected in many			Low region specificity	Detected in many			Group enriched	Detected in some	6	basophil: 35.1;eosinophil: 51.8	Lineage enriched	Detected in many	7	granulocytes: 51.8	Not detected	Not detected			Low region specificity	Detected in all			HPA014259	Uncertain									HPA014259: AB_1849304	unprognostic (9.77e-2)	unprognostic (1.35e-3)	unprognostic (5.45e-3)	unprognostic (1.69e-1)	unprognostic (1.90e-1)	unprognostic (1.85e-3)	unprognostic (1.70e-1)	unprognostic (2.30e-4)	unprognostic (2.61e-1)	unprognostic (7.92e-2)	unprognostic (8.68e-3)	unprognostic (1.52e-1)	unprognostic (1.32e-2)	unprognostic (1.52e-1)	unprognostic (3.31e-1)	unprognostic (1.49e-1)	unprognostic (4.99e-2)	1.2	0.3	3.9	2.3	8	0.4	2.8	2.3	8.2	1.7	10.7	4	0.3	7.5	0.9	0.6	1.4	1.5	1.6	5.1	4.3	2.8	0.5	0.7	1.4	1.9	4.9	5.9	0.5	1.1	5.9	0.6	1.9	5.7	0.9	7.4	0.6	0.5	0.5	11.3	1	10.8	0.9	2.2	1.1	13.3	0.5	0.8	28.1	0.4	5.6	0.6	1.1	0.4	0	1.2	51.8	7.8	0	0.3	0.4	0	0	0.1	0	0.4	1.6	0.1	0	0	0	0	0.1	0	0.1	0.1	0	0	0	0	0	0.1	0.1	10.3	0	5	1.2	0	6.5	2.2	0.1	0	0	0	4.2	0	0	0.1	3.3	14.8	0	0.2	0	0	1.1	0	0	0	0	0	0.2	0	0	0.2	0	0	0.1	0.1	0	0.1	0	0	0	0	0	35.1	0	51.8	0	2.5	0	0	0.3	0.2	1.2	0	0	0	0.1	0	7.8	0.2	0.3	0.4	3.9	8	2.3	8.2	4.3	2.8	4.9	5.9	5.7	0.8
PTGFRN	"CD315, CD9P-1, EWI-F, FLJ11001, FPRP, KIAA1436, SMAP-6"	ENSG00000134247	Prostaglandin F2 receptor inhibitor	Q9P2B2	1	116910057-116990358	"CD markers, Predicted membrane proteins"				Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in many			Cell line enhanced	Detected in many		U-87 MG: 45.3;WM-115: 33.5	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in some		myeloid DC: 3.0	Low lineage specificity	Detected in many			Low region specificity	Detected in all			Low region specificity	Detected in all			HPA017074	Approved					86000	86000			HPA017074: AB_1855888	unprognostic (1.18e-1)	unprognostic (2.11e-3)	unprognostic (3.03e-1)	unprognostic (8.58e-2)	unprognostic (3.20e-1)	unprognostic (2.91e-2)	unprognostic (1.48e-3)	unprognostic (3.39e-2)	unprognostic (1.76e-2)	unprognostic (7.28e-2)	unprognostic (2.77e-2)	unprognostic (5.28e-2)	prognostic unfavourable (3.98e-4)	unprognostic (1.61e-1)	unprognostic (1.95e-1)	unprognostic (1.12e-1)	unprognostic (4.15e-2)	6.9	14.9	3.7	8.4	4.7	0	6.3	1.2	6.6	17.1	26.2	2.5	10.1	6.5	23.9	10.7	23.5	17.8	20.5	29.5	3	2.6	3.4	5.3	4.4	1.7	2.8	6.1	15.6	17.1	4	3.5	24.6	3.2	13.3	13.2	8.1	13.3	15	2.4	12.4	15.3	27.8	3	2.5	8.7	6.3	2.2	2.8	5.9	13.5	9.7	15.2	15.3	0	3	0	1.1	0.3	0.9	0.3	11.6	3	5.6	12.9	1	2.6	0.8	0.8	1.3	4.7	1.8	2.1	2.6	0	11	3.1	20.8	12.5	22.3	3	0.1	7.6	0.8	7.6	3.2	0.3	0	1.2	11.6	20.2	0.6	11.2	9	4.7	0	7.1	14.8	0	1.6	6.5	0	0	30.7	0	15.7	9.6	2.7	6.3	23.9	16.9	6.7	14.8	3.6	23.1	6.9	10.4	11.3	7.3	0	0	0	45.3	0	33.5	0	0.8	0	0	1.1	0	0	0	0	3	0	0.9	0	0	0.3	0	0	0.7	0.3	3.7	4.7	1.2	6.6	3	2.6	2.8	6.1	3.2	2.2
PTPRJ	"CD148, DEP1, HPTPeta"	ENSG00000149177	"Protein tyrosine phosphatase, receptor type J"	Q12913	11	47980558-48170841	"CD markers, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Hydrolase, Protein phosphatase"		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in many			Cell line enhanced	Detected in many		EFO-21: 25.3;RPTEC TERT1: 24.6	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in many		neutrophil: 12.2	Group enriched	Detected in all	4	granulocytes: 12.2;monocytes: 5.3	Low region specificity	Detected in all			Low region specificity	Detected in all			HPA006026	Approved				Intracellular and membrane	840000000	840000000			HPA006026: AB_1078446	unprognostic (1.46e-1)	unprognostic (2.21e-1)	unprognostic (1.55e-1)	unprognostic (3.83e-2)	unprognostic (3.20e-2)	unprognostic (2.99e-2)	unprognostic (6.58e-2)	unprognostic (2.15e-1)	unprognostic (9.64e-3)	unprognostic (3.79e-3)	unprognostic (5.16e-2)	unprognostic (1.89e-1)	prognostic favourable (1.13e-5)	unprognostic (1.09e-2)	unprognostic (7.98e-2)	unprognostic (9.18e-2)	unprognostic (2.00e-1)	5.6	3.7	10.4	17.7	13.9	22.6	5.6	4.9	9.5	6.1	9	8.8	12.3	8.4	3.9	7.6	2.9	5	6.7	5.2	9.5	9.2	13.3	12.2	12.2	22.6	10.8	9.4	3	9.1	21.1	14.5	20.3	8.3	7.8	8.1	12.9	12.9	9	4.6	4.3	13.4	5.5	6.7	33	13.8	3.1	9.9	6.7	18.8	0.9	9.7	6	3.9	1	1.8	12.2	5.3	1.2	2.1	0.9	3.5	13.4	5.9	3.2	0.9	2.1	2	3.6	2.6	6.3	4.7	0.8	19.8	3.3	25.3	9.1	2.7	9.2	0.9	7.7	21.7	2.5	0.9	16.6	1.2	5.8	1.2	20.6	1.5	0.3	1.7	0.4	3.8	1.2	2.1	2.2	7.6	0	7.4	4.6	2.1	0.7	0.7	1.7	24.6	5.2	4	1.2	10	5.7	9	6.3	9.1	12.4	5	5.2	10	10.9	0.5	0.7	5.5	5.7	3.8	18.1	0.9	1.5	3.4	2.1	2.5	1.4	1	1.2	1.5	1	0.7	1	1.3	12.2	1.2	5.3	1.8	1.1	0.9	10.4	13.9	4.9	9.4	9.5	9.2	10.8	9.4	8.3	9.9
PVR	"CD155, HVED, Necl-5, NECL5, PVS, Tage4"	ENSG00000073008	Poliovirus receptor	P15151	19	44643798-44663583	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Receptor"		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		liver: 65.6	Cell line enhanced	Detected in many		TIME: 52.7	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Group enriched	Detected in some	5	classical monocyte: 6.4;intermediate monocyte: 6.6;myeloid DC: 5.6;non-classical monocyte: 8.1	Group enriched	Detected in many	5	dendritic cells: 5.6;monocytes: 8.1									HPA012568	Approved		Supported	"Nucleoplasm,Vesicles,Plasma membrane"	Secreted - unknown location	940000000	940000000	"Nucleoplasm, Vesicles, Plasma membrane"		HPA012568: AB_1846248	unprognostic (2.90e-3)	prognostic unfavourable (1.29e-4)	unprognostic (3.36e-1)	unprognostic (2.34e-1)	unprognostic (7.89e-2)	unprognostic (2.45e-3)	unprognostic (3.06e-2)	prognostic unfavourable (9.30e-4)	unprognostic (9.05e-3)	unprognostic (1.69e-1)	unprognostic (2.09e-3)	unprognostic (2.64e-3)	unprognostic (1.69e-1)	unprognostic (4.97e-1)	unprognostic (1.27e-1)	unprognostic (1.04e-3)	prognostic unfavourable (2.75e-4)	10	13.9	7.4	7.5	8.1	4.7	9.2	11	11	6.5	10.6	6.5	4.1	13.7	11.3	5.7	6.6	8.8	9.2	23.5	5.8	10	10.6	65.6	14.8	2.4	6	6.5	10.4	15.9	9.9	20.7	15.5	9.7	10.4	7.7	6.6	8.5	6.9	19.8	5.5	13	11.1	7	4.8	12.3	6	7.2	2.3	8.5	10.8	3.7	8.3	6.7	0	5.6	1.2	8.1	0.6	0.4	2.2	21.5	15.1	1.5	6.1	1.8	2.2	2.6	36.4	10.2	12	13.7	8.8	9.2	0	21	10.5	14.2	5.1	13.8	8	2.6	9.9	3.8	9.5	5.9	12.7	1.4	8.3	2.9	6.8	10.5	20.7	13	1.8	0	5.5	1.9	1.3	1.3	3.4	11.2	0	6.9	2	25.7	6.6	6.5	7.6	23.1	14.5	5.1	8.2	3.7	52.7	14.5	17.9	10.7	28.4	0	2.1	0	11.6	7.4	8.2	0	6.4	0	0.2	6.6	0	0	0	0.4	5.6	0	0.2	0.1	1.2	0.6	8.1	0.5	0	2.2	7.4	8.1	11	11	5.8	10	6	6.5	9.7	7.2
RHAG	"CD241, RH50A, SLC42A1"	ENSG00000112077	Rh associated glycoprotein	Q02094	6	49605158-49636884	"CD markers, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters"	"Ammonia transport, Transport"		"Disease mutation, Hereditary hemolytic anemia"	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enriched	Detected in many	9	bone marrow: 54.1	Group enriched	Detected in some	190	HEL: 85.7;K-562: 84.5	Not detected	Not detected			Not detected	Not detected			Not detected	Not detected			Not detected	Not detected			Not detected	Not detected			Not detected	Not detected			"HPA046051, HPA055331"	Approved		Approved	Endoplasmic reticulum				Endoplasmic reticulum		"HPA046051: , HPA055331: "					unprognostic (8.16e-2)						unprognostic (6.86e-2)	unprognostic (1.25e-3)		unprognostic (1.65e-1)				1.2	0.2	0	1.1	0.5	54.1	3.2	0	0.1	2.3	1	0.5	1.7	0.2	0.4	0.1	2.6	0.5	0.8	5.3	0	0	0.1	0.7	3.3	0.1	0	0	0.1	0.2	0.1	0.1	5.8	0.1	1.3	0.2	0	0.2	0.5	0.4	0.1	0.9	0.1	0	4.5	0.6	0.2	0	1.7	1.8	0	0.1	0.8	2.8	0	0	0	0	0	0	0.7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	85.7	0	0	0	0	0	0	0	0	0	0	84.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.7	0	0.5	0	0	0	0	0	0	0.1	0
RHCE	"CD240CE, RH"	ENSG00000188672	Rh blood group CcEe antigens	P18577	1	25362249-25430192	"Blood group antigen proteins, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Transporters"		Blood group antigen		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level		Tissue enriched	Detected in many	4	bone marrow: 40.5	Cell line enriched	Detected in some	5	HEL: 43.6	Low cancer specificity	Detected in many			Low region specificity	Detected in all			Cell type enhanced	Detected in some		basophil: 2.4	Lineage enriched	Detected in single	7	granulocytes: 2.4									"HPA060951, HPA077385"	Supported		Uncertain	"Nucleoplasm,Plasma membrane"				"Nucleoplasm, Plasma membrane"		"HPA060951: , HPA077385: "	unprognostic (1.37e-1)	unprognostic (3.53e-1)	unprognostic (2.38e-1)	unprognostic (6.75e-2)	unprognostic (1.41e-2)	unprognostic (4.91e-2)	unprognostic (7.01e-2)	unprognostic (3.12e-2)	unprognostic (3.81e-2)	unprognostic (1.35e-1)	unprognostic (6.08e-2)	unprognostic (4.61e-2)	unprognostic (5.77e-5)	unprognostic (1.38e-1)	unprognostic (3.94e-2)	unprognostic (7.15e-3)	unprognostic (1.63e-1)	0.6	0.8	2	0.6	5.1	40.5	0.9	3.3	4.7	0.8	0.7	3.5	1	0.7	0.7	5.2	1.4	1.6	0.8	2.1	2.6	1.5	0.8	2.2	0.7	1	2.1	2.5	0.9	9.6	0.5	4	1.6	5.9	1.6	0.8	2.2	8.4	0.8	1.9	1.1	0.6	0.5	2.9	2.1	0.8	2.6	1.4	1.2	1.1	1.2	0.8	0.5	0.6	0.1	0.2	2.4	0.2	0.1	0.3	0.9	0.1	0	0.1	0.2	0.4	0.3	0	0.1	0.1	0.2	0	0	0.7	0.3	0.5	0.5	0.1	0	0.1	0.1	0.2	0	43.6	0	0	0.5	0	0.3	0.9	0.7	0.3	0.2	0	8.5	0.2	0.2	0.4	0	0.3	0.8	0.2	0	0.1	1.2	0	0	0.3	0.4	0.1	0.1	0.5	0.2	0	0	0.1	0	0.4	0	2.6	0.6	0.5	1.4	0.4	0.2	2.4	0.2	0.6	0.3	0	0.3	0.1	0	0.1	0.2	0	0.2	0	1	0.1	0	0.1	0.3	0.9	2	5.1	3.3	4.7	2.6	1.5	2.1	2.5	5.9	1.4
RHD	"CD240D, DIIIc, RH, Rh30a, Rh4, RhII, RhPI"	ENSG00000187010	Rh blood group D antigen	Q02161	1	25272393-25330445	"Blood group antigen proteins, CD markers, Predicted membrane proteins, Transporters"		Blood group antigen		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in some		blood: 10.0;bone marrow: 16.5;salivary gland: 7.1	Group enriched	Detected in some	6	HEL: 27.6;K-562: 8.5	Not detected	Not detected			Low region specificity	Detected in some			Cell type enhanced	Detected in many		neutrophil: 10.0	Lineage enriched	Detected in many	5	granulocytes: 10.0									"HPA060951, HPA077385"	Supported		Uncertain	"Nucleoplasm,Plasma membrane"				"Nucleoplasm, Plasma membrane"		"HPA060951: , HPA077385: "	unprognostic (4.75e-3)	unprognostic (7.70e-2)	unprognostic (1.34e-1)	unprognostic (1.38e-1)	unprognostic (1.09e-2)	unprognostic (4.84e-2)	unprognostic (1.11e-2)	unprognostic (5.25e-2)	unprognostic (1.11e-2)	unprognostic (1.91e-1)	unprognostic (1.27e-2)	unprognostic (1.89e-1)	unprognostic (4.96e-3)	unprognostic (1.93e-1)	unprognostic (8.09e-2)	unprognostic (5.53e-2)	unprognostic (4.92e-3)	0.3	0.3	0.3	0.5	0.5	16.5	0.3	1.5	1.4	0.6	0.3	0.3	0.3	0.3	0.4	0.3	0.3	0.3	0.4	0.9	0.3	0.2	0.3	0.3	2.5	0.8	0.3	0.3	0.9	0.3	0.1	0.4	0.3	1.1	0.5	0	0.3	7.1	0.3	4.1	2.5	0.4	0.3	0.4	1.8	0.3	0.5	0.3	0.3	0.4	2.3	0.3	0.3	0.3	2	0.6	10	1.4	1.4	1.4	1.2	0.1	0	0.2	0.2	0.1	0	0.4	0.1	0	0.1	0	0.1	0.3	0.4	0.1	0	0.2	0	0	0	0.5	0.1	27.6	0.6	0.2	0	0.3	0.2	0.1	0.1	0.1	0.1	0.1	8.5	0.7	0	0.1	0.2	0.2	3.1	0.1	0.2	0.1	0.1	0	0.1	0.5	0.3	0.1	0.2	0.1	0.2	0.4	0.4	0.5	0.2	0.4	0.1	0.3	0.1	0.1	0.4	0.2	0.1	4.9	1.4	2.8	1	0.6	1.1	1.3	1.3	0.8	0.2	2	1.4	1.3	10	1.4	0.8	0.6	0.9	1.2	0.3	0.5	1.5	1.4	0.3	0.2	0.3	0.3	1.1	0.3
S1PR1	"CD363, D1S3362, edg-1, EDG1"	ENSG00000170989	Sphingosine-1-phosphate receptor 1	P21453	1	101236888-101241518	"Cancer-related genes, CD markers, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"	"Angiogenesis, Chemotaxis"	"G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes, FDA approved drug targets"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		blood: 88.9	Cell line enhanced	Detected in many		BJ: 19.0;HUVEC TERT2: 53.7;TIME: 29.9;U-251 MG: 36.8	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in many			Low lineage specificity	Detected in many			Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB010104, HPA075568"	Supported		Supported	Vesicles				Vesicles		"CAB010104: AB_2238920, HPA075568: "	unprognostic (1.41e-1)	unprognostic (9.35e-2)	unprognostic (2.46e-2)	unprognostic (2.61e-1)	unprognostic (9.78e-2)	unprognostic (4.49e-3)	unprognostic (1.34e-3)	unprognostic (1.99e-1)	unprognostic (1.36e-1)	unprognostic (9.12e-2)	unprognostic (2.34e-2)	unprognostic (2.23e-1)	unprognostic (5.82e-3)	unprognostic (2.54e-2)	unprognostic (1.04e-1)	unprognostic (3.64e-1)	prognostic unfavourable (8.78e-4)	72.3	8.4	24.7	16.6	26.2	9.7	46.3	21.6	21.8	13.3	10.5	9.5	2.5	5.7	12.1	5	14.7	11.5	17.6	43.5	22.9	15.4	8.9	20.5	35.7	24.5	23.2	14	7.9	11	13.4	4.7	29.6	21.2	8.9	7	9.3	7.5	5.6	21.7	8.2	9.8	19	11	35.2	8	5.8	13.9	4.4	17	8.7	15.7	15.2	18.5	27.4	0.2	88.9	0.2	33.4	49.8	30.8	3.5	0	3.8	0	0.4	9.1	0	19	3.4	11.5	4.1	0	0.1	0	4.7	6.6	0	0.5	0.2	7.7	1.3	0.3	1.3	0.1	0	1.8	0	0.8	12.2	0	0	0.9	53.7	0	3.9	3.6	0	4.5	0	1	1.2	0	3.7	0	0	0	0	0	0.1	0	0	0	0	29.9	1.9	0.7	0.4	36.8	0.3	0	0.2	0.1	0	0.1	88.9	0.1	4.9	49.8	0.1	40.2	25.1	45.3	44.1	0.2	27.4	35.7	36.2	1.4	33.4	0.2	0.2	26.8	30.8	24.7	26.2	21.6	16.8	22.9	15.4	23.2	14	21.2	13.9
SDC1	"CD138, SDC, SYND1, syndecan"	ENSG00000115884	Syndecan 1	P18827	2	20200797-20225433	"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters"			Cancer-related genes	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		liver: 113.2;placenta: 228.8	Cell line enhanced	Detected in many		HBEC3-KT: 60.9;hTCEpi: 56.3;U-251 MG: 58.0;U-266/70: 60.1;U-266/84: 126.7	Low cancer specificity	Detected in all			Low region specificity	Detected in single			Cell type enriched	Detected in single	17	memory B-cell: 3.9	Lineage enriched	Detected in single	40	B-cells: 3.9	Group enriched	Detected in some	4	cerebellum: 10.7;olfactory region: 5.9	Not detected	Not detected			"CAB002424, HPA006185, HPA067477"	Enhanced		Supported	Focal adhesion sites	Secreted to blood	1600000	1600000	Focal adhesion sites		"CAB002424: AB_442050, HPA006185: AB_1857705, HPA067477: "	prognostic unfavourable (2.22e-4)	unprognostic (6.80e-3)	unprognostic (6.80e-2)	unprognostic (7.84e-2)	prognostic unfavourable (5.02e-4)	unprognostic (1.15e-1)	unprognostic (4.02e-2)	unprognostic (6.32e-2)	unprognostic (1.70e-1)	unprognostic (3.66e-1)	unprognostic (2.27e-3)	unprognostic (1.79e-1)	unprognostic (1.63e-1)	unprognostic (1.94e-2)	unprognostic (4.27e-1)	unprognostic (1.62e-2)	unprognostic (1.52e-1)	0.8	3.4	0.5	5.4	0.6	0	4.5	0.8	0.7	21.4	18.3	0.5	3.5	14.3	2.3	8.7	103.7	1.6	55.3	0.3	0.4	0.5	68.5	113.2	15.8	6.3	1.9	0.4	1.6	7	0.6	0.6	228.8	0.7	13.3	6.2	1.5	16	5.2	0.5	69.5	21.9	4.3	0.4	3.7	16.3	2.6	0.4	1.5	3.5	62.3	48.4	30	37.7	3.9	0	0	0	0	0	0.5	30.8	17.3	5.5	13.8	1.5	0.2	17.3	8.6	8.3	8.1	6.8	3.6	18.8	0	3.2	6.1	30.4	2.4	60.9	5.4	0.1	1.6	0	1.6	18.5	1.3	1.3	0.1	0.8	56.3	7.2	17.3	0.8	0.7	12.1	4.3	18.4	0	0.3	4.9	33.5	0.6	2	23.3	10.3	46.3	1.6	12.8	6.5	43.9	1.9	4.3	0.3	1.3	32.1	10.3	1.1	58	60.1	126.7	0.1	9.6	0	3.5	0	0	0	0	0	0	3.9	0	0	0	0.2	0	0	0	0	0	0	0	0.5	0.5	0.6	0.8	0.7	0.4	0.5	1.9	0.4	0.7	0.4
SDC2	"CD362, fibroglycan, HSPG, HSPG1, SYND2"	ENSG00000169439	Syndecan 2	P34741	8	96493351-96611780	"CD markers, Predicted membrane proteins"	"Differentiation, Neurogenesis"			Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		liver: 115.1;thyroid gland: 111.2	Cell line enhanced	Detected in many		AF22: 101.9;EFO-21: 47.8;fHDF/TERT166: 44.1;RPTEC TERT1: 53.2;U-138 MG: 49.4	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enriched	Detected in some	7	neutrophil: 13.9	Lineage enriched	Detected in many	7	granulocytes: 13.9	Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB025123, HPA044416"	Uncertain		Approved	"Plasma membrane,Cytosol"				"Plasma membrane, Cytosol"		"CAB025123: , HPA044416: "	unprognostic (1.25e-1)	unprognostic (1.04e-1)	unprognostic (1.25e-1)	unprognostic (3.61e-2)	unprognostic (6.52e-3)	unprognostic (4.18e-2)	unprognostic (2.43e-1)	unprognostic (2.35e-2)	unprognostic (2.89e-2)	unprognostic (4.56e-1)	unprognostic (1.48e-1)	unprognostic (6.16e-2)	unprognostic (1.56e-2)	unprognostic (1.45e-3)	unprognostic (1.91e-1)	unprognostic (2.50e-2)	unprognostic (1.23e-1)	43.2	9.9	13.9	9.1	16.9	2.5	17	12.7	8.4	43.4	18.7	7.3	21.2	5.8	21.9	15.3	13.3	21	15	19.1	12	12.6	23.9	115.1	14.4	4.4	9.7	9.3	45.9	16.8	1.6	24	31.3	10.7	25.9	10.7	51.4	6.3	28.1	9.4	6.5	9.6	34.3	9.5	7.5	11.9	8.7	9.3	0.5	111.2	13.8	3.5	35.9	26.3	0	1.3	13.9	1.9	0	0.2	0.5	0	0	101.9	0	36.8	34.4	0.1	14.7	17.5	8.6	9.5	3	0	0	47.8	44.1	0	17.6	0.2	7.4	0	6.9	0	9.8	37.4	1.1	0.2	0.4	13.3	0.4	19.4	0.5	0.3	9.6	0	3.5	0.8	0	2.5	10.8	0.1	0.1	16	0.3	53.2	8.7	3	7.9	0	0	0.7	4.3	11.4	8	49.4	15.1	0.2	8.2	0.9	0	0.1	15.7	0	15.4	0	1.9	0	0	0.2	0	0	0	0	1.3	0	0.2	0	13.9	0	0.1	0	0	0.5	13.9	16.9	12.7	8.4	12	12.6	9.7	9.3	10.7	9.3
SELE	"CD62E, ELAM, ELAM1, ESEL"	ENSG00000007908	Selectin E	P16581	1	169722641-169764705	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Cell adhesion		Cancer-related genes	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		tongue: 50.0	Cell line enriched	Detected in single	5	HUVEC TERT2: 5.2	Low cancer specificity	Detected in many			Region enriched	Detected in many	4	pons and medulla: 5.4	Not detected	Not detected			Not detected	Not detected			Not detected	Not detected							CAB002143	Enhanced					640000000	640000000			CAB002143: AB_563608	unprognostic (2.39e-1)	unprognostic (2.16e-2)	unprognostic (1.37e-2)	unprognostic (2.09e-2)	unprognostic (1.61e-1)	unprognostic (1.40e-2)	unprognostic (1.59e-1)	unprognostic (2.94e-1)	unprognostic (3.63e-1)	unprognostic (3.88e-1)	unprognostic (9.74e-2)	unprognostic (4.32e-2)	unprognostic (1.56e-2)	unprognostic (8.13e-3)	unprognostic (4.69e-2)	unprognostic (4.63e-2)	unprognostic (2.55e-1)	14.9	2.7	0.9	30.4	1.2	0.2	8.3	0.3	1	13.7	2.7	1.9	4.4	0.4	18.1	3.2	6.7	20.1	7.4	4.4	0.9	0.9	2.5	4.9	10.6	2	1.2	0	9.8	1.4	21	3.1	0.9	5.4	21.2	1.9	4.3	2	4.6	2.2	3.7	2.4	13.1	4.8	0.2	3.4	5.6	0.5	0.9	9	50	15.5	16.4	4	0	0	0	0	0.2	0.9	0	0	0	0	0	0	0	0.3	0	0	0	0	0	0	0	0.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5.2	0	0	0	0	0	0.3	0	0	0	0	0.2	0	0	0	0.1	0	0.9	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0.2	0	0	0.9	0	0.9	1.2	0.3	1	0.9	0.9	1.2	0	5.4	0.5
SELL	"CD62L, hLHRc, LAM-1, LAM1, Leu-8, LNHR, LSEL, Lyam-1, LYAM1, PLNHR"	ENSG00000188404	Selectin L	P14151	1	169690667-169711698	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins"	Cell adhesion		Cancer-related genes	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	5	blood: 227.5;lymphoid tissue: 77.8	Cell line enhanced	Detected in some		Daudi: 7.3;EFO-21: 7.1;MOLT-4: 13.4;U-266/70: 25.2;U-698: 11.7;U-937: 7.3	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all			Not detected	Not detected			Low region specificity	Detected in all			"CAB002144, HPA051972"	Enhanced		Uncertain	Cytosol		8100000000	8100000000	Cytosol		"CAB002144: AB_563862, HPA051972: "	prognostic favourable (3.76e-4)	prognostic favourable (2.25e-4)	unprognostic (1.52e-2)	unprognostic (2.89e-2)	unprognostic (7.87e-3)	prognostic favourable (6.43e-4)	unprognostic (1.39e-3)	unprognostic (3.43e-1)	unprognostic (2.70e-3)	prognostic favourable (3.14e-4)	unprognostic (1.42e-1)	unprognostic (4.21e-2)	prognostic unfavourable (4.96e-5)	unprognostic (4.76e-2)	unprognostic (8.71e-3)	unprognostic (9.57e-2)	unprognostic (1.01e-1)	6.9	0.9	2	25.1	4.6	30.3	1.5	1.1	2.5	0.9	1.4	1.1	0	0.4	1	1.1	4.2	3.2	5.4	4.1	2.5	2.2	2.3	2.5	11.4	77.8	5.2	0.2	0.8	1	10.7	7.9	3.4	2.7	1.2	1.3	3.8	12.1	0.1	0.9	0.8	8.8	2.9	5.2	67.7	1.7	1	2.3	43.8	1.9	1.3	64	8.1	6.1	40.4	40.7	227.5	49.7	130.8	69.5	90.1	0	0	0	0	0.1	0.1	0.1	0	0.1	0.1	0.5	0	0.2	7.3	7.1	0	0	0	0	0	0	0	1.6	0	0	0	5	0.9	0.3	0	0	0	1.2	0	1	0	0.8	13.4	0.1	0	0.2	5.1	0.1	0.3	4.1	0.2	0	0	0	0.9	0	0	0	0	0.3	0.1	0	0	25.2	0	11.7	1.3	7.3	0.1	170.8	49.7	88.6	16.5	11.2	4.5	33.8	30.7	17	40.7	40.4	69.5	39.6	227.5	130.8	4.5	32.8	52.7	90.1	2	4.6	1.1	2.5	2.5	2.2	5.2	0.2	2.7	2.3
SELP	"CD62, CD62P, GMP140, GRMP, PADGEM, PSEL"	ENSG00000174175	Selectin P	P16109	1	169588849-169630193	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Cell adhesion		Cancer-related genes	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Group enriched	Detected in some	37	EFO-21: 24.7;HEL: 22.3	Low cancer specificity	Detected in many			Low region specificity	Detected in single			Group enriched	Detected in some	6	basophil: 6.0;neutrophil: 2.4;T-reg: 8.9	Group enriched	Detected in many	8	granulocytes: 6.0;T-cells: 8.9	Not detected	Not detected			Low region specificity	Detected in many			"CAB002145, HPA002655, HPA005990"	Enhanced					830000000	830000000			"CAB002145: AB_563984, HPA002655: AB_1078480, HPA005990: AB_1078479"	unprognostic (3.37e-2)	unprognostic (2.98e-4)	unprognostic (4.11e-1)	unprognostic (1.46e-1)	unprognostic (9.26e-2)	prognostic favourable (3.12e-4)	unprognostic (5.30e-4)	unprognostic (4.14e-2)	unprognostic (3.59e-1)	unprognostic (1.74e-1)	unprognostic (1.93e-2)	unprognostic (6.61e-2)	unprognostic (1.19e-1)	unprognostic (8.24e-3)	unprognostic (1.74e-2)	unprognostic (7.85e-3)	unprognostic (1.66e-1)	14.2	2.1	0.4	8.4	0.4	1	10.9	0.4	0.4	14.8	3.7	0.6	7.5	3.3	10.6	6.2	5.6	7.7	7	9.6	0.4	0.4	7.5	4.6	11.3	12.9	0.4	0.4	5	1.5	3.8	2.8	7.4	1.3	14.8	2.9	24.7	3.4	4.3	3.7	2.3	5.2	10.5	1	1.9	3.5	3.1	0.3	1.4	4.9	7.7	13	11.5	27.2	0.9	0.1	6	0.5	0.4	8.9	8.8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	24.7	0	0	0	0	0	0	0	22.3	0	0	0	0	0	0	0	0	0	0.5	0	0	0	0	0	0	0	0	0	0	0	0.6	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0.1	0	0	0	6	0.5	0.7	0	0.2	0	0.9	0.6	0.3	0	0.2	0.2	0.1	2.4	0.4	0	0.1	8.9	8.8	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	1.3	0.3
SELPLG	"CD162, PSGL-1"	ENSG00000110876	Selectin P ligand	Q14242	12	108622277-108633959	"Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Receptor"		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 126.9;lymphoid tissue: 60.5	Cell line enhanced	Detected in some		HDLM-2: 28.0;HMC-1: 27.2;Karpas-707: 42.6;RPMI-8226: 59.2;U-266/70: 69.5;U-266/84: 43.3	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all											CAB002431	Enhanced									CAB002431: AB_563509	unprognostic (2.32e-2)	prognostic favourable (1.46e-4)	unprognostic (3.64e-3)	unprognostic (1.02e-2)	unprognostic (6.32e-2)	prognostic favourable (6.94e-4)	unprognostic (2.52e-1)	unprognostic (1.29e-1)	prognostic favourable (2.92e-4)	unprognostic (2.26e-1)	unprognostic (2.12e-2)	unprognostic (3.24e-1)	prognostic unfavourable (5.86e-4)	unprognostic (5.88e-2)	unprognostic (2.37e-2)	prognostic favourable (2.74e-4)	unprognostic (5.44e-2)	10.6	5.5	11.3	25.3	8.9	10.7	4.2	2.2	12.5	5.8	5.4	27.2	0.1	5	2.9	4.1	5	6.8	9.6	5.9	12.1	9.6	4.6	3.9	23.3	46.8	16.2	5.4	2.1	2.9	1.3	3.1	7.3	11.5	3	5.2	3.4	5.2	2.5	1.8	2.7	10.3	6.7	19.6	60.5	6	2.1	13.5	26	3.1	2.8	18	14.8	3	2.2	50.9	126.9	68.4	28.1	63.2	77.1	0.1	0	0.3	0.1	0.1	0.3	0.1	1	1	0.3	0.3	0	0.4	0.1	0.3	1.5	0	0	0	0.3	28	0	9.9	0	0	0	7	27.2	0.3	0.1	0.5	0.1	0	0.1	42.6	1.3	0	5.6	4	0	0.3	0	0.1	59.2	0.6	0	0	0	0.1	0	0.4	0	8.9	0.3	0.5	0.1	0.7	0.2	69.5	43.3	1.2	0.3	14.9	0.4	126.9	28.1	88.8	43.8	49.5	35.8	2	41.8	37.4	29.4	2.2	32.4	34.1	125.8	28.1	68.4	50.9	63.2	77.1	11.3	8.9	2.2	12.5	12.1	9.6	16.2	5.4	11.5	13.5
SEMA4D	"C9orf164, CD100, coll-4, FLJ39737, SEMAJ"	ENSG00000187764	Semaphorin 4D	Q92854	9	89360787-89498130	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Differentiation, Neurogenesis"	"Developmental protein, Receptor"		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		brain: 107.1;skeletal muscle: 43.3	Cell line enhanced	Detected in many		HDLM-2: 42.9;HMC-1: 33.1;MOLT-4: 38.9	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all			Low region specificity	Detected in all			Low region specificity	Detected in all			"HPA015662, HPA023277"	Approved		Supported	"Endoplasmic reticulum,Vesicles"		4100000	4100000	Vesicles	Endoplasmic reticulum	"HPA015662: AB_1856671, HPA023277: AB_1856672"	unprognostic (2.94e-2)	prognostic favourable (4.17e-4)	unprognostic (1.12e-2)	unprognostic (8.22e-2)	unprognostic (1.41e-1)	unprognostic (1.76e-3)	unprognostic (1.27e-1)	unprognostic (1.58e-1)	unprognostic (7.79e-2)	unprognostic (2.74e-1)	unprognostic (3.18e-3)	unprognostic (1.50e-2)	unprognostic (2.29e-3)	unprognostic (3.05e-2)	unprognostic (1.28e-2)	unprognostic (2.43e-1)	prognostic favourable (4.06e-5)	3.9	5.6	18	18.6	20.7	14.3	3.6	7.7	20.9	4	5.9	54	3.1	6.1	3.9	7.4	9.3	6.6	7.2	4.9	28.2	18.8	8.4	2	6.7	32	42.6	15	4.1	4.6	4.9	5.3	3.2	27.5	4.9	5.8	2.9	6.7	4.2	43.3	8.8	9.6	3.3	107.1	19.2	9.4	6.1	23.3	25.3	4.9	3.1	27.6	8.3	5.3	2.6	4.6	21.2	4.1	4.7	14	7.8	4	3	2.8	4.1	0.1	0.2	6.5	0.4	0.2	0.8	0.6	2	4.6	15.5	1.7	0	2.1	2.5	1.2	0.3	42.9	2.5	6.5	1	0.2	0.5	8.6	33.1	0.1	0.9	0.2	0.1	1.6	1.5	10.6	0	6.7	38.9	10.8	6.9	0.1	12.4	0.9	4.3	5.5	4.2	6.7	4.4	1.1	3.6	0.1	3.4	4.7	1	0	2.6	0.3	2	11.9	5.1	2.2	2	10.5	2.5	7.3	4.1	20.4	13.3	3.8	8	2.6	10.6	11.1	1.5	1.6	12.2	14	21.2	4.7	4.1	4.6	9.5	7.8	18	20.7	7.7	20.9	28.2	18.8	42.6	15	27.5	23.3
SEMA7A	"CD108, H-Sema-L, SEMAL"	ENSG00000138623	Semaphorin 7A (John Milton Hagen blood group)	O75326	15	74409289-74433958	"Blood group antigen proteins, CD markers, Plasma proteins, Predicted membrane proteins"	"Differentiation, Inflammatory response, Neurogenesis"	Developmental protein		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		brain: 36.4;lymphoid tissue: 34.7;placenta: 54.0	Cell line enhanced	Detected in many		HMC-1: 99.7;hTEC/SVTERT24-B: 39.1;U-251 MG: 57.5;U-87 MG: 33.6	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in some		eosinophil: 8.9	Lineage enriched	Detected in many	5	granulocytes: 8.9	Low region specificity	Detected in all			Low region specificity	Detected in all			"HPA008210, HPA042273"	Uncertain		Uncertain	Vesicles		29000000	29000000	Vesicles		"HPA008210: , HPA042273: AB_10806234"	unprognostic (2.00e-1)	unprognostic (2.72e-1)	unprognostic (2.02e-2)	unprognostic (5.81e-2)	unprognostic (6.49e-2)	unprognostic (8.61e-2)	unprognostic (2.54e-2)	unprognostic (4.18e-3)	unprognostic (1.33e-1)	unprognostic (1.39e-1)	unprognostic (5.18e-3)	unprognostic (1.44e-1)	prognostic unfavourable (2.45e-11)	unprognostic (1.32e-1)	unprognostic (2.01e-2)	unprognostic (6.25e-2)	unprognostic (2.57e-2)	2.2	1.9	5.4	10.4	13.8	12.8	1.4	22.9	27.3	1.3	1.8	19.9	1.4	2.7	4.3	1.8	3.2	1.2	3.3	1.4	10.8	5.7	1.4	1.5	4.4	19	28.5	5.7	5.9	0.9	6.4	1.9	54	28.6	1.4	1.8	7.8	1.7	3.5	1.4	4.7	6	2	36.4	34.7	3.7	23.6	15.4	9	1.1	0.4	19.7	4.6	1.7	1.4	1.8	8.9	0	0.8	0.2	0	5.7	0	1.7	0.5	2.2	7.4	14.3	26.5	10.7	5.6	8.6	2.2	9.4	0	1.5	12	1.7	0.5	1.7	5.8	0.4	0.3	10.3	0	2.8	0.5	0.3	99.7	5.2	0	39.1	2.2	0	5.9	3.6	18.1	0.4	1.4	3.4	1.8	4	0.2	1.1	1.5	2.3	2.4	0.1	0.1	0.2	4.8	2.1	0.3	2.1	1	10.5	7	5	57.5	0.6	0.4	0.1	33.6	1.2	0.5	3.9	0	8.9	0.2	0	0.2	1.4	0	0.1	0.1	0.2	0	0.1	0.1	0.8	0	1.8	0	0	5.4	13.8	22.9	27.3	10.8	5.7	28.5	5.7	28.6	15.4
SIGLEC1	"CD169, dJ1009E24.1, FLJ00051, FLJ00055, FLJ00073, FLJ32150, sialoadhesin, SIGLEC-1, SN"	ENSG00000088827	Sialic acid binding Ig like lectin 1	Q9BZZ2	20	3686970-3707128	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Endocytosis"			Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		lymphoid tissue: 35.7	Cell line enriched	Detected in single	18	THP-1: 6.7	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Group enriched	Detected in some	16	classical monocyte: 4.1;intermediate monocyte: 2.5;myeloid DC: 1.9;plasmacytoid DC: 1.2	Group enriched	Detected in many	20	dendritic cells: 1.9;monocytes: 4.1	Low region specificity	Detected in some			Low region specificity	Detected in all			HPA053457	Supported				Intracellular and membrane	110000	110000			HPA053457: 	unprognostic (2.05e-1)	unprognostic (9.27e-3)	unprognostic (3.83e-4)	unprognostic (4.87e-3)	unprognostic (3.40e-2)	unprognostic (1.06e-1)	unprognostic (2.15e-1)	unprognostic (6.98e-2)	unprognostic (2.27e-2)	unprognostic (1.68e-1)	unprognostic (1.40e-1)	unprognostic (1.57e-1)	prognostic unfavourable (8.69e-5)	unprognostic (8.71e-2)	prognostic unfavourable (4.36e-4)	unprognostic (1.11e-2)	unprognostic (9.31e-2)	11.6	8	1.5	4.5	2	7	4.7	1.5	1.9	1.5	4.4	1.5	1.5	2.9	1.5	1.5	3.1	4.2	5.3	3.5	1.5	0.1	2.9	4.9	9.7	35.7	2.1	1.5	1.6	1.5	0	1.5	12.2	3	1.5	4.1	1.8	6.3	1.5	3.2	1.5	5.9	4.6	1.5	12	2.9	1.5	1.5	2.8	1.9	3.4	1.8	4.8	1.7	0	1.9	0	4.1	0	0.1	1.2	0	0	0	0	0	0	0.1	0.1	0	0	0	0	0	0	0.3	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2	0	0.1	0	0	0.2	0.2	0	0.1	0.1	0	0	0	0	6.7	0	0	0	0	0	0.1	0	0	0	0	0	0	4.1	0	0	2.5	0.1	0	0	0	1.9	0	0	0	0	0	0	1.2	0	1.2	1.5	2	1.5	1.9	1.5	0.1	2.1	1.5	3	1.5
SIGLEC5	"CD170, CD33L2, OB-BP2, SIGLEC-5"	ENSG00000105501	Sialic acid binding Ig like lectin 5	O15389	19	51611927-51645545	"CD markers, Predicted membrane proteins"	Cell adhesion			Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in some	5	blood: 46.7;bone marrow: 13.5	Group enriched	Detected in some	6	HMC-1: 34.9;U-937: 14.5	Cancer enhanced	Detected in single		urothelial cancer: 1.7					Cell type enhanced	Detected in many		neutrophil: 46.7	Group enriched	Detected in many	6	granulocytes: 46.7;monocytes: 13.7									"HPA009085, CAB024900"	Supported									"CAB024900: , HPA009085: AB_1079965"	unprognostic (1.83e-1)	unprognostic (1.94e-1)	unprognostic (2.02e-2)	unprognostic (1.03e-2)	unprognostic (4.39e-2)	unprognostic (1.62e-2)	unprognostic (1.73e-1)	unprognostic (1.01e-1)	unprognostic (3.28e-1)	unprognostic (7.44e-2)	unprognostic (1.01e-1)	unprognostic (4.05e-1)	unprognostic (3.71e-4)	unprognostic (4.37e-2)	unprognostic (3.55e-3)	unprognostic (4.02e-1)	unprognostic (1.95e-1)	1.2	0.4	0.4	6.4	0.5	13.5	0.2	0.1	0.2	0.1	0.3			0	0.2	0	0.2	0.1	0.3	0.3	0.3	0.2	0.2	1.2	1.5	2.5	0.5		0.1	0.2	0	0.2	0.5		0.2	0.4		0.4	0	0	0.1	3.4	0.5	0.7	5.9	0.3	0.7			0.2		1.9	0.8	0.1	0.8	4.7	46.7	13.7	0.2	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0.7	34.9	0	0	0	0	0	0	1.3	0	0	0	4.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0	14.5	0	3.6	6.4	0.1	0	7.5	0	0.8	0	0	4.7	0.7	0	0	46.7	0.2	13.7	1.5	0	2										
SIGLEC6	"CD327, CD33L, CD33L1, OB-BP1, SIGLEC-6"	ENSG00000105492	Sialic acid binding Ig like lectin 6	O43699	19	51519525-51531856	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	Cell adhesion			Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enriched	Detected in many	10	placenta: 87.4	Cell line enriched	Detected in some	7	HMC-1: 100.5	Cancer enhanced	Detected in some		thyroid cancer: 2.7	Not detected	Not detected			Cell type enhanced	Detected in some		memory B-cell: 6.5;plasmacytoid DC: 6.8	Group enriched	Detected in many	33	B-cells: 6.5;dendritic cells: 6.8;granulocytes: 2.3									"HPA009084, HPA018198"	Enhanced				Intracellular and membrane					"HPA009084: AB_1079967, HPA018198: AB_1856868"	unprognostic (1.97e-1)	unprognostic (1.41e-1)	unprognostic (2.38e-3)	unprognostic (9.31e-3)		unprognostic (8.46e-4)	unprognostic (2.91e-1)	unprognostic (2.02e-2)	unprognostic (2.64e-1)	unprognostic (8.96e-2)	unprognostic (2.03e-1)	unprognostic (6.89e-2)	unprognostic (1.10e-2)	unprognostic (4.15e-2)	unprognostic (4.42e-2)	unprognostic (3.28e-2)	unprognostic (5.57e-3)	1.8	0	0	5.6	0	0.1	0.8	0	0.1	1.2	1.7	0	0.3	0.9	2	1.2	1.5	0.5	8.6	0.4	0	0	0.4	0.1	4.2	1.5	0	0	0.1	0.3	0.1	0.1	87.4	0	3.7	1.5	0.5	1.4	1	0.2	1.3	6	3.1	0	1.3	1.7	1	0	0.3	0.2	1	2.6	2.2	1.9	6.5	6.8	2.3	0	0.1	0	0.3	0	0	0	0	0	0	0	0	0	0	0	3.2	0	0	0	0	0	0	0	0	0	0	14.4	0	0	0	0.2	100.5	0	0	0	0	0	0	0.1	0	0	0	0.4	0	0	0	0	0	0	0	0	0	0	4	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	2.3	0	0	0	0	0	6.5	0	0	1.4	2.8	0	0	0	0.1	0	6.8	0	0.3	0	0	0	0.1	0	0	0	0	0	0
SIGLEC7	"CD328, p75/AIRM1, QA79, SIGLEC-7, SIGLEC19P, SIGLECP2"	ENSG00000168995	Sialic acid binding Ig like lectin 7	Q9Y286	19	51142299-51153526	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	Cell adhesion			Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	4	blood: 51.5;lymphoid tissue: 29.4	Group enriched	Detected in some	9	Karpas-707: 30.8;RPMI-8226: 17.9;U-937: 18.9	Low cancer specificity	Detected in many			Low region specificity	Detected in many			Cell type enhanced	Detected in many		eosinophil: 51.5	Low lineage specificity	Detected in many																Intracellular and membrane	1100000	1100000				unprognostic (3.14e-1)	unprognostic (5.87e-2)	unprognostic (1.03e-1)	unprognostic (2.66e-1)	unprognostic (3.90e-2)	unprognostic (1.85e-1)	unprognostic (2.53e-1)	unprognostic (2.78e-1)	unprognostic (1.69e-1)	unprognostic (4.95e-2)	unprognostic (1.10e-1)	unprognostic (2.66e-1)	unprognostic (8.27e-2)	unprognostic (6.61e-2)	unprognostic (1.14e-3)	unprognostic (2.58e-1)	unprognostic (2.26e-2)	6.9	3.7	1.6	10	5.8	3.7	3	0.3	2.2	0.9	1.6	1	0.6	1.4	0.9	2.1	1.1	1.8	2.4	1.9	0.8	1	2.8	9.8	4.7	18.4	3.3	0	1.3	0.9	0.2	0.9	5.9	2.9	1	2.3	0.7	2.3	0.2	0.4	0.5	2.3	3.5	3.3	29.4	1.1	1.8	2.5	0.7	1	0	2.1	3.2	1.7	0.6	14.9	51.5	32	20	4.4	15.8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.5	0	0	0	0.2	0.3	0	0	0	0	0	0	30.8	0	0	0	2.4	0	0	0	0	17.9	0	0	0	0	0	0	0	0	2.1	0	0	0	0	0	0.6	0.6	0	0.1	18.9	0	0.5	32	51.5	2.5	23	4.4	0.6	0	1.1	14.9	0	0	1	26.8	20	9.1	0.6	0	15.8	1.6	5.8	0.3	2.2	0.8	1	3.3	0	2.9	2.5
SIGLEC8	"MGC59785, SAF2, SIGLEC-8, SIGLEC8L"	ENSG00000105366	Sialic acid binding Ig like lectin 8	Q9NYZ4	19	51450847-51458456	"CD markers, Plasma proteins, Predicted membrane proteins"	Cell adhesion			Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enriched	Detected in many	4	blood: 63.0	Cell line enriched	Detected in some	45	HMC-1: 57.4	Cancer enhanced	Detected in many		glioma: 7.2	Low region specificity	Detected in many			Cell type enriched	Detected in some	42	eosinophil: 63.0	Lineage enriched	Detected in single	623	granulocytes: 63.0									HPA012556	Uncertain		Uncertain	Cytosol				Cytosol		HPA012556: AB_1856869	unprognostic (1.27e-1)	unprognostic (1.88e-4)	unprognostic (1.28e-1)	unprognostic (6.70e-2)	unprognostic (2.97e-1)	unprognostic (1.30e-2)	unprognostic (7.84e-2)	unprognostic (2.51e-2)	unprognostic (2.72e-2)	unprognostic (2.17e-1)	unprognostic (1.10e-1)	unprognostic (4.19e-1)	unprognostic (8.62e-3)	unprognostic (7.18e-2)	unprognostic (6.02e-2)	unprognostic (4.28e-3)	unprognostic (3.29e-1)	0.6	6.7	5.8	2.4	8.4	0.7	2.3	0.7	7	1.4	2.9	7.4	0	2.9	1	1.1	1.1	1.1	2.7	0.3	8.6	4.8	0.4	1.6	4.1	9.6	8.3	3.6	0.3	0.7	0.7	1.2	0.1	7.5	1	2.8	0.1	1.1	0.9	0.3	0.8	4.5	1.5	14.8	9.2	2.1	0.5	6.2	0.6	0.7	0	4.1	2	0.7	0	0	63	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.8	0	0	0	0	57.4	0	0	0	0	0	0.2	0.1	0	0	0.1	1.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0.1	0.4	0	1.5	0.1	63	0	0	0	0	0	0	0	0	0	0	0.5	0	0	0	0	0	5.8	8.4	0.7	5.6	8.6	4.8	8.3	3.6	7.5	6.2
SIRPA	"BIT, CD172a, MFR, MYD-1, P84, PTPNS1, SHPS-1, SHPS1, SIRP, SIRP-ALPHA-1, SIRPalpha, SIRPalpha2"	ENSG00000198053	Signal regulatory protein alpha	P78324	20	1894167-1940592	"CD markers, Plasma proteins, Predicted membrane proteins"				Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		brain: 69.2	Cell line enhanced	Detected in many		fHDF/TERT166: 42.3;RPTEC TERT1: 30.7;SK-MEL-30: 35.6	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Group enriched	Detected in many	6	classical monocyte: 10.1;eosinophil: 20.9;myeloid DC: 6.3;neutrophil: 23.5	Group enriched	Detected in many	134	dendritic cells: 6.3;granulocytes: 23.5;monocytes: 10.1									"CAB002776, CAB015122, HPA054437, HPA058511"	Enhanced					170000000	170000000			"CAB002776: , CAB015122: AB_677430, HPA054437: AB_2682488, HPA058511: AB_2683738"	unprognostic (9.78e-2)	unprognostic (2.67e-1)	unprognostic (3.07e-1)	unprognostic (1.23e-1)	unprognostic (5.56e-2)	unprognostic (1.58e-1)	unprognostic (1.15e-3)	unprognostic (4.19e-3)	unprognostic (3.48e-2)	unprognostic (2.84e-3)	unprognostic (3.69e-1)	unprognostic (3.33e-2)	unprognostic (2.79e-3)	unprognostic (1.08e-1)	unprognostic (1.55e-2)	unprognostic (3.55e-2)	unprognostic (2.24e-2)	23.2	21.7	36.9	24.9	38.8	19.9	14	39.1	69.2	9.5	6.7	22.8	3	14.1	6.4	11.2	7.2	9.1	14.6	11.9	29.3	18.5	9.6	16.1	22	10.3	18.8	50.3	9.7	6.1	2.2	5.5	13.8	14.7	4.9	8.2	9.5	15	8.9	5.5	13.6	11.7	11.4	18	9.6	5.2	3.9	20.4	1	4.1	2.2	8.8	13.2	6.9	0	6.3	23.5	10.1	0	0	3.4	3.4	7.5	3.8	7	9.1	8.6	0.5	18.1	15.4	4.9	1.5	4.7	0.1	0	4.4	42.3	3.4	3	21	2	0	2.1	0	0.9	2.6	11.1	7	8.7	7.7	9.9	4.2	5.1	15.3	0.4	4.7	6.6	0.2	0	9.8	4.2	3.4	0	6.7	4.7	30.7	0	0.5	1.1	2.4	0	35.6	1.2	22.6	22.8	21.9	11.4	14.1	8.9	0	0	0	6.8	22.7	2.4	0.1	10.1	20.9	0	2.7	0	0	0	0	6.3	0	0	0	23.5	0	1	0.4	0	3.4	36.9	38.8	39.1	68.6	29.3	18.5	18.8	50.3	14.7	20.4
SIRPB1	"CD172b, SIRP-BETA-1"	ENSG00000101307	Signal regulatory protein beta 1	"O00241, Q5TFQ8"	20	1563521-1620061	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"				Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enriched	Detected in many	4	blood: 137.6	Group enriched	Detected in some	4	HMC-1: 24.7;NB-4: 32.8;THP-1: 25.4	Low cancer specificity	Detected in many			Low region specificity	Detected in many			Cell type enhanced	Detected in many		neutrophil: 137.6	Group enriched	Detected in many	6	granulocytes: 137.6;monocytes: 43.6									HPA047463	Uncertain		Uncertain	Vesicles		33000000	33000000	Vesicles		HPA047463: 	unprognostic (1.88e-2)	unprognostic (6.19e-2)	unprognostic (1.50e-1)	unprognostic (2.24e-1)	unprognostic (5.38e-2)	unprognostic (1.60e-1)	unprognostic (4.40e-2)	unprognostic (7.18e-2)	unprognostic (4.11e-3)	unprognostic (9.12e-2)	unprognostic (6.31e-2)	unprognostic (4.57e-2)	unprognostic (2.65e-3)	unprognostic (5.76e-2)	unprognostic (2.39e-3)	unprognostic (5.00e-3)	unprognostic (1.19e-2)	23.7	1.8	2.3	18.7	5.4	31.9	1.8	2.7	3.2	1.1	1.4	1.9	0.1	1	1	0.5	0.9	2.5	7.6	7.2	2.3	1.6	1.5	7.5	19.4	19.5	6.6	0.7	1.9	0.9	0.1	1.5	3.8	3.7	1.2	1.2	1.7	1.8	0.6	0.9	0.9	2.6	2.1	7.2	28.7	1.2	1.2	3.9	2.5	0.9	0.4	2.9	4.1	1.9	0.2	15.2	137.6	43.6	0.7	1	19.2	0.1	0	0.1	0	0.1	0.2	0.1	0.2	0	0.1	0	0.1	0	0	0.3	0.1	0.1	0	0.1	0	0	0	0	0	0	0.1	6.3	24.7	0	0.1	0.1	0	0.2	0	0.1	0.2	0	0	32.8	0.1	1.5	0	0	0	4.9	0.1	0	0.1	0.1	0	0.2	0	25.4	0.7	0.3	0	0.2	0.1	0	0	0	0.5	6	0.1	0.5	43.6	72.5	0.6	36.3	0.9	0.2	0.6	0.5	15.2	0.2	0.8	0.5	137.6	0.7	29.5	14.5	1	19.2	2.3	5.4	2.7	3.2	2.3	1.6	6.6	0.7	3.7	3.9
SIRPG	"bA77C3.1, CD172g, SIRP-B2, SIRPB2, SIRPgamma"	ENSG00000089012	Signal regulatory protein gamma	Q9P1W8	20	1629152-1657779	"CD markers, Predicted membrane proteins"	Cell adhesion			Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	6	blood: 60.1;lymphoid tissue: 44.0	Cell line enhanced	Detected in some		NB-4: 16.7;RT4: 4.5;THP-1: 2.9	Low cancer specificity	Detected in many			Not detected	Not detected			Cell type enhanced	Detected in many		T-reg: 60.1	Lineage enriched	Detected in many	6	T-cells: 60.1																				unprognostic (3.35e-3)	unprognostic (4.09e-3)	unprognostic (7.32e-3)	prognostic favourable (1.05e-6)	unprognostic (4.23e-3)	prognostic favourable (2.24e-4)	unprognostic (4.49e-2)	unprognostic (1.30e-2)	prognostic favourable (7.36e-7)	unprognostic (1.62e-2)	unprognostic (6.90e-2)	unprognostic (2.52e-1)	prognostic unfavourable (1.47e-6)	unprognostic (1.03e-1)	unprognostic (2.18e-1)	unprognostic (1.40e-2)	unprognostic (2.95e-3)	0.8	0.4	0.3	11.7	0.3	1.5	0.5	0.3	0.4	0.7	2.3	0.1	0.4	0.9	0.5	0.6	1.4	0.7	2.1	0.4	0.3	0.3	1.1	1.1	1.4	20.5	0.3	0.1	0.7	0.4	0	0.3	0.4	0.2	0.9	1.8	0.6	4.6	0.9	0.4	0.4	8.8	0.6	0.4	14	1.6	0.4	0.1	44	1.3	0.7	21.3	2.9	0.8	0.1	1.1	1	0.2	9.5	60.1	16.7	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.8	1.3	0	0	0	0	0	0	0	0	0	0	16.7	0	0	0	0	0.1	0.5	4.5	0	0	0	0	0	0	2.9	0	0	0	0	0	0.1	0	0	0	1.2	0	0.1	0.2	0.1	12.3	0.1	34.1	0.1	38.4	29	0.1	0.1	40.5	33.3	1	9.5	0.1	1.1	60.1	16.7	0.3	0.3	0.3	0.4	0.3	0.3	0.3	0.1	0.2	0.1
SLAMF1	"CD150, SLAM"	ENSG00000117090	Signaling lymphocytic activation molecule family member 1	Q13291	1	160608100-160647295	"CD markers, Predicted membrane proteins, Predicted secreted proteins"	"Adaptive immunity, Cell adhesion, Host-virus interaction, Immunity, Innate immunity, Phagocytosis"	"Host cell receptor for virus entry, Receptor"		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enriched	Detected in many	4	lymphoid tissue: 97.8	Cell line enriched	Detected in single	111	HDLM-2: 57.0	Low cancer specificity	Detected in many			Not detected	Not detected			Cell type enhanced	Detected in many		MAIT T-cell: 24.1	Group enriched	Detected in many	10	B-cells: 8.8;T-cells: 24.1									"CAB002438, HPA069319"	Enhanced				Secreted to blood	590000	590000			"CAB002438: AB_564011, HPA069319: "	unprognostic (2.99e-3)	unprognostic (3.33e-4)	unprognostic (2.93e-4)	unprognostic (1.38e-4)	unprognostic (5.87e-2)	unprognostic (6.06e-5)	unprognostic (1.64e-2)	unprognostic (1.70e-3)	unprognostic (1.69e-2)	unprognostic (2.74e-4)	unprognostic (6.12e-2)	unprognostic (3.58e-1)	unprognostic (1.24e-7)	unprognostic (2.46e-1)	unprognostic (8.46e-2)	unprognostic (1.22e-1)	unprognostic (2.18e-2)	2.5	0.3	0.3	14.2	0.3	4.4	1.4	0.2	0.3	1.2	2.3	0.4	0.5	2.2	0.5	1.2	2.2	0.8	2.3	1.3	0.2	0.2	2	1	4	14.8	0.2	0.1	0.6	0.9	0	0.5	2.3	0.3	1.1	2.1	0.6	4.1	0.6	0.8	1.1	7.6	1	0.5	10.6	2.4	0.4	0.2	97.8	1.5	1.9	26.3	3.5	1.1	8.8	1.6	0.2	0.1	0	24.1	3.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0.3	0	0	0	0	0	0	57	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.4	0	0	0	0	0	0	0.4	0.1	0	0.5	0	0	0.1	0	4.2	0	24.1	6.2	17.2	12.1	0.1	8.8	6.6	1.6	0.2	0	0	1.6	21.5	3.5	0.3	0.3	0.2	0.3	0.2	0.2	0.2	0.1	0.3	0.2
SLAMF6	"CD352, KALI, KALIb, Ly108, NTB-A, NTBA, SF2000"	ENSG00000162739	SLAM family member 6	Q96DU3	1	160485030-160523262	"CD markers, Predicted membrane proteins"	"Adaptive immunity, Immunity, Innate immunity"	Receptor		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 28.6;lymphoid tissue: 51.9	Group enriched	Detected in some	5	Daudi: 32.6;U-698: 48.1	Low cancer specificity	Detected in many			Not detected	Not detected			Low cell type specificity	Detected in many			Low lineage specificity	Detected in many											"HPA051363, HPA051903"	Uncertain		Approved	"Plasma membrane,Cytosol"				"Plasma membrane, Cytosol"		"HPA051363: , HPA051903: "	prognostic favourable (9.42e-4)	prognostic favourable (2.78e-4)	unprognostic (8.65e-2)	prognostic favourable (9.53e-4)	unprognostic (5.85e-2)	prognostic favourable (7.34e-5)	unprognostic (3.16e-3)	unprognostic (9.78e-2)	prognostic favourable (1.25e-4)	unprognostic (2.31e-3)	unprognostic (2.09e-1)	unprognostic (1.57e-1)	prognostic unfavourable (2.09e-6)	unprognostic (2.78e-1)	unprognostic (1.01e-1)	unprognostic (2.33e-2)	unprognostic (8.21e-3)	3.9	0.8	0.4	21	0.4	1.2	1	0.4	0.4	1.1	3.8	0.3	0.4	1.1	1	0.6	2.3	1.6	2.8	1.2	0.4	0.4	2.1	1.6	4.7	51.9	0.6	0.4	0.6	0.8	0	0.6	1.7	0.7	1.4	1.5	1.5	5.6	1	0.5	0.7	11.9	0.4	0.8	29.6	2.3	0.9	0.2	12.9	1.8	0.6	30.4	4.1	1.3	15.2	0.3	8.4	1	15.9	28.6	7.4	0	0	0	0	0	0	0	0	0	0	0	0	0	32.6	0	0	0	0	0	0	2	0	2.4	0	0	0	0.2	0	0	0	0	0	0	0.3	0	0	0	7.8	0.5	0	0	0	0	0.3	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	5.1	48.1	0	0.2	0	2.5	0.1	8.4	22.9	0.3	15.8	14.7	14.6	28.6	0.1	15.2	8.2	16.4	1	15.9	1	0.3	16.8	7.4	0.4	0.4	0.4	0.4	0.4	0.4	0.6	0.4	0.7	0.2
SLAMF7	"19A, CD319, CRACC, CS1"	ENSG00000026751	SLAM family member 7	Q9NQ25	1	160739057-160754821	"CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity, Innate immunity"	Receptor	FDA approved drug targets	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 32.9;lymphoid tissue: 45.0	Cell line enriched	Detected in some	5	U-266/70: 78.8	Low cancer specificity	Detected in many			Not detected	Not detected			Low cell type specificity	Detected in many			Low lineage specificity	Detected in all							Low region specificity	Detected in all			"CAB015445, HPA055945, HPA061654"	Enhanced		Approved	Vesicles		620000	620000	Vesicles		"CAB015445: AB_1121905, HPA055945: , HPA061654: "	unprognostic (5.82e-3)	unprognostic (1.81e-2)	unprognostic (1.84e-3)	unprognostic (2.12e-3)	unprognostic (2.75e-1)	unprognostic (1.07e-2)	unprognostic (7.87e-2)	unprognostic (7.19e-2)	unprognostic (2.46e-2)	prognostic favourable (3.93e-4)	unprognostic (1.08e-1)	unprognostic (8.13e-2)	prognostic unfavourable (8.57e-5)	unprognostic (1.35e-1)	unprognostic (3.91e-2)	unprognostic (1.02e-1)	unprognostic (1.50e-2)	5.5	1	0.7	28.6	0.7	2.3	3.4	0.6	0.7	4.1	11.9	0.2	0.4	11.1	1.9	1.3	6.7	1.6	6.2	1	0.7	0.7	2.4	3.1	10.2	24.6	0.8	0.4	2.5	2.2	0	0.9	1.3	0.6	1.8	10.2	2.9	15.1	4.8	0.9	2	15.8	0.8	1.2	45	11	1.5	0.4	5.9	2.1	4.2	38.7	11.5	2.6	3.7	27.4	1.1	14.9	17.3	32.9	8.7	0.2	0.2	0	0	0	0	0	0	0	0	0	0	0	1.9	0	0	0.2	0	0.7	0	0	0	0	0	0	0	0	2.8	0	2.1	0	0.7	0	0	1.9	0	0	0	0	0	0	0	0	2.6	0	0.2	0	0	0	0	15.8	0	0	0	0	1	0	0	78.8	6.7	0	2.2	0	0	0	1.6	0.3	32.9	11	25.4	3.7	3.5	22.4	7.2	0.6	1.1	13.6	1.1	17.3	14.9	27.4	0	8.7	0.7	0.7	0.6	0.7	0.7	0.7	0.8	0.4	0.6	0.4
SLAMF8	"BLAME, CD353, SBBI42"	ENSG00000158714	SLAM family member 8	Q9P0V8	1	159826750-159837249	"CD markers, Predicted membrane proteins"				Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		lymphoid tissue: 44.1	Cell line enhanced	Detected in some		ASC TERT1: 4.1;HL-60: 3.5;U-138 MG: 4.9;U-87 MG: 2.7;U-937: 2.5	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Cell type enhanced	Detected in many		myeloid DC: 12.1	Low lineage specificity	Detected in many			Low region specificity	Detected in single			Low region specificity	Detected in all			HPA067601	Enhanced									HPA067601: 	unprognostic (1.04e-1)	unprognostic (8.80e-3)	unprognostic (5.12e-2)	unprognostic (2.14e-3)	unprognostic (3.07e-2)	unprognostic (3.22e-2)	unprognostic (7.87e-2)	unprognostic (4.29e-1)	unprognostic (2.20e-2)	unprognostic (4.56e-2)	unprognostic (6.47e-2)	unprognostic (1.77e-1)	prognostic unfavourable (5.42e-5)	unprognostic (3.50e-1)	unprognostic (4.42e-2)	unprognostic (2.01e-1)	unprognostic (1.04e-1)	16.9	4.6	1.5	20.1	3.4	0.4	5.4	8.2	1.6	3.1	6	1.4	0.6	4.6	1.8	4.2	3.1	3.6	6.1	7.1	5.2	1.7	7.8	2.2	19.6	44.1	4.1	0.7	3.8	2	0.1	4.2	5.4	5	2.7	7.1	3	4.2	1	2.2	3.1	7	5.4	4.1	22.7	3.1	2.4	2.7	9.7	4.8	3	12.7	8.6	2.8	0	12.1	0.5	6.6	8.1	3.8	2.8	0	0.1	0	0	0.5	4.1	0	0.1	0.4	0	0.2	0	0	0	0.6	0.2	0	0	0	0.8	0	0.1	1.8	0	0	0	3.5	0.6	1.4	0	0.3	0.1	0	0	0.8	0.2	0	0.1	1.9	0.1	0	0	0	0	0.1	0	0	0	0	0.1	0.2	0	1.6	0	4.9	0.2	0	0.9	0	0	0	2.7	2.5	0	0	5.1	0	3.2	6.6	0.2	0	1.1	3.8	12.1	0	0.2	2.6	0.5	8.1	0.4	0.1	0	2.8	1.5	3.4	8.2	1.6	5.2	1.7	4.1	0.7	5	2.7
SLC3A2	"4F2, 4F2HC, 4T2HC, CD98, CD98HC, MDU1, NACAE"	ENSG00000168003	Solute carrier family 3 member 2	P08195	11	62856102-62888875	"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Amino-acid transport, Transport"		Cancer-related genes	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in all		hTCEpi: 129.8;SiHa: 132.3	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all			Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB010455, HPA017980"	Enhanced		Supported	"Nucleoplasm,Plasma membrane,Cytosol"		210000000	210000000	"Nucleoplasm, Plasma membrane, Cytosol"		"CAB010455: AB_638288, HPA017980: "	unprognostic (1.79e-1)	unprognostic (9.61e-3)	unprognostic (3.59e-1)	unprognostic (7.87e-3)	unprognostic (2.06e-1)	unprognostic (2.41e-3)	prognostic unfavourable (8.17e-4)	unprognostic (2.09e-3)	unprognostic (2.62e-1)	unprognostic (4.16e-2)	unprognostic (2.29e-2)	unprognostic (3.71e-1)	prognostic favourable (8.22e-4)	unprognostic (2.92e-2)	unprognostic (5.52e-3)	unprognostic (3.49e-3)	prognostic unfavourable (1.48e-4)	28.5	30.8	34.6	23	36.8	62.4	30.8	18.7	34.8	26	26.8	25.3	30.4	34.3	29.2	41.2	31.2	23.8	19.9	14.7	31.3	27.1	71.4	31.8	33.5	17.8	37.8	24.1	29.9	39.2	138.6	19.3	75.5	32.9	28.3	13.9	52.5	39	27.5	32.5	32.1	33.8	19.6	38	21.9	28.2	33.4	30.8	13.6	33.7	33.4	22.2	20.6	56.6	16.6	73.9	11.6	36.2	20.3	39.8	37.3	16.1	68.1	6.9	21.6	8.4	6.8	64.4	28.1	10.8	14.8	13	65.1	30.6	17.8	31.2	16.5	56	12.7	55.1	7.9	32.3	12	12.7	49.6	28.7	78.4	14.9	18.6	14.8	129.8	18	55	8.6	24.6	39.4	9	77.8	15.3	19	11.6	23	15.9	10.5	34.7	10.3	9	11.9	5.7	132.3	49.6	95.4	17.8	19.6	15.7	15	22.4	22	19.8	49	54.3	56.4	14.7	23.5	42.8	8.5	36.2	11.6	30.1	34.8	39.8	14.4	27.7	30.8	22.1	16.6	23.5	25.2	7.5	20.3	27.6	73.9	26.2	37.3	34.6	36.8	18.7	34.7	31.3	27.1	37.8	24.1	32.9	30.8
SLC44A1	"CD92, CDw92, CHTL1, CTL1"	ENSG00000070214	Solute carrier family 44 member 1	Q8WWI5	9	105244622-105439171	"CD markers, Predicted membrane proteins, Transporters"	Transport			Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enriched	Detected in all	4	brain: 111.6	Cell line enhanced	Detected in many		ASC diff: 71.8;ASC TERT1: 56.8	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in many			Low lineage specificity	Detected in all			Low region specificity	Detected in all			Low region specificity	Detected in all			HPA064714			Supported	"Nucleoplasm,Mitochondria"		270000	270000	Mitochondria	Nucleoplasm	HPA064714: 	unprognostic (3.49e-1)	unprognostic (2.25e-1)	unprognostic (1.27e-1)	unprognostic (6.54e-3)	unprognostic (4.77e-2)	unprognostic (1.74e-2)	unprognostic (2.21e-2)	prognostic unfavourable (4.49e-4)	unprognostic (2.48e-1)	unprognostic (1.95e-1)	unprognostic (1.64e-3)	unprognostic (6.20e-2)	prognostic favourable (1.85e-4)	unprognostic (2.13e-1)	unprognostic (2.07e-1)	unprognostic (1.33e-1)	unprognostic (2.07e-2)	8.7	7.4	40	6.4	48.8	5.3	14.6	7.2	37	9.9	26.7	69.5	10.2	12	8.8	18.4	10.1	8.5	11	6.9	50	29.6	12	20.3	9.8	4.6	64.3	21.3	8	8	20.5	3.9	12.3	38.2	6.6	26.9	4.6	6	14.8	4.8	11.4	14	9.5	111.6	4.8	18.9	2.3	59.4	2.3	24	5.1	7.9	12.4	7.9	2.4	3.7	2.5	5.4	8.7	1.8	1.6	6.7	5.7	1.5	1.9	71.8	56.8	4.9	5.7	14.9	3.7	5	6	18	9	2.9	21.5	13.5	4.6	8.2	6.4	7.8	3.8	11.2	4	7.5	4.8	2.2	5.8	31.5	6.8	7.1	6.5	11.7	0.3	18.8	4.2	9.6	8.9	2.5	8.7	5.5	1.8	6	6.8	5.1	15.9	7.5	2.9	8	8.9	8	8.8	6.8	10	3.7	3.4	4	4.1	14.5	9.5	6.8	7.2	4.9	4.9	2.5	5.4	1.1	1.1	2.1	0.8	2	1.2	0.8	3.7	2.4	1.8	0.6	1	8.7	1.2	1.3	1.1	1.6	40	48.8	7.2	29.8	50	29.6	64.3	21.3	38.2	59.4
SLC4A1	"AE1, CD233, DI, EPB3, FR, RTA1A, SW, WD, WR"	ENSG00000004939	Solute carrier family 4 member 1 (Diego blood group)	P02730	17	44248385-44268141	"Blood group antigen proteins, CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Anion exchange, Ion transport, Transport"	Blood group antigen	"Disease mutation, Elliptocytosis, Hereditary hemolytic anemia"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		bone marrow: 95.7;placenta: 32.7	Low cell line specificity	Detected in many			Cancer enriched	Detected in single	91	renal cancer: 16.3	Not detected	Not detected			Low cell type specificity	Detected in many			Low lineage specificity	Detected in all			Region enhanced	Detected in single		cerebellum: 0.4	Low region specificity	Detected in all			"HPA015584, CAB034438, HPA063911"	Enhanced					160000000	160000000			"CAB034438: AB_2123479, HPA015584: AB_1844824, HPA063911: "	unprognostic (1.36e-1)	unprognostic (1.42e-1)	unprognostic (3.36e-1)	unprognostic (2.44e-2)	unprognostic (2.32e-2)	unprognostic (1.56e-2)	unprognostic (1.55e-1)	unprognostic (1.59e-1)	unprognostic (1.68e-1)	unprognostic (1.58e-1)	unprognostic (6.72e-3)	unprognostic (1.19e-1)	unprognostic (9.28e-3)	unprognostic (1.93e-2)	unprognostic (2.18e-1)	unprognostic (1.94e-1)	unprognostic (2.13e-1)	0.9	0.1	0.3	0.2	0.4	95.7	0.2	0.8	0.2	0.1	0.1	0.6	0	0.2	0.1	0.4	0.6	0.2	0.2	2.6	0.2	0.3	18.6	1.3	12.9	0.8	0.6	0.1	2.8	0.1	0	0.6	32.7	0.9	0.6	0.1	1.2	0.1	0.1	1.2	0.2	0.1	0	1	8.4	0.1	0.3	0	0.7	1.9	0	0.2	3.9	11.8	1.8	1.4	6.3	1.2	2.9	1.5	0.7	1.3	0.4	1.4	1.7	0.6	0.7	1	0.2	0.4	0.3	0.8	1.3	3.2	0.7	0.6	0.3	1.4	0.5	0.5	1	1.3	1.3	1.6	1.5	2.2	0	0.8	2.3	0.8	0.5	0.8	0.8	0.2	4.7	3.4	0.4	0.6	0.9	3.5	0.9	0.5	2.5	0.7	1.8	0.3	0.8	2.2	1	1.3	1.4	0.5	2.5	1.8	1	2.3	2	1.4	1.4	1	2.3	1.1	1.6	2.1	1.1	6.1	1	2	1.1	0.9	1	1.1	1	0.9	0.5	1.8	1.5	1.2	6.3	2.9	1.2	1.4	0.7	0.7	0.3	0.4	0.8	0.2	0.2	0.3	0.6	0.1	0.9	0
SPN	"CD43, GPL115, LSN"	ENSG00000197471	Sialophorin	P16150	16	29662979-29670876	"CD markers, Predicted membrane proteins"				Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	7	blood: 52.1;bone marrow: 33.1;lung: 25.0;lymphoid tissue: 79.7	Cell line enhanced	Detected in some		HEL: 54.9;HL-60: 48.8;HMC-1: 27.5;MOLT-4: 18.9;THP-1: 26.4;U-937: 34.8	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Cell type enhanced	Detected in many		non-classical monocyte: 52.1	Low lineage specificity	Detected in all											"CAB002666, HPA055244"	Enhanced		Approved	Plasma membrane				Plasma membrane		"CAB002666: , HPA055244: "	prognostic favourable (1.40e-4)	unprognostic (1.63e-3)	unprognostic (3.14e-2)	prognostic favourable (3.08e-5)	unprognostic (2.68e-2)	unprognostic (2.49e-3)	unprognostic (4.02e-2)	unprognostic (4.17e-2)	prognostic favourable (1.88e-4)	unprognostic (1.70e-1)	unprognostic (4.67e-2)	unprognostic (2.68e-1)	unprognostic (2.61e-2)	unprognostic (4.52e-2)	unprognostic (4.14e-2)	unprognostic (5.85e-2)	unprognostic (4.72e-2)	5.7	1	1.2	12.9	2.7	33.1	1.6	0.7	1.5	1.3	2.8	2.6	0	2.3	1.5	0.6	1.9	1.7	2.8	3.9	1.2	1.4	1.8	1.9	25	18.3	3.7	0.2	1	1.6	0.2	1	0.8	2.3	1.6	2.6	1.6	5	0.6	0.8	1.6	6.8	1	4.6	15.9	2	0.6	1.9	79.7	1.6	1.7	17.4	2.6	1.4	1	8.8	3.5	52.1	17.5	26.5	10.7	0	0	0	0.1	0	0	0.2	0	0	0	0	0.2	0	0.1	0.2	0	0	0	0	0	0	0	54.9	0	0.4	0	48.8	27.5	0	0	0	0	0	17.1	13.4	0.1	0	18.9	12.2	0	0	17.1	0.2	0.4	0	0	0	0	0	0	0	0	26.4	0.1	0	0	0	0	0	0.9	7.2	0	34.8	0	2.4	5.5	3.5	26.5	24.3	14.5	1	10.7	18.1	8.8	0.3	7.6	13.2	0.9	17.5	52.1	7	9.1	10.7	1.2	2.7	0.7	1.5	1.2	1.4	3.7	0.2	2.3	1.9
TEK	"CD202b, TIE-2, TIE2, VMCM, VMCM1"	ENSG00000120156	TEK receptor tyrosine kinase	Q02763	9	27109141-27230175	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"	Angiogenesis	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Glaucoma"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in many			Group enriched	Detected in some	9	HUVEC TERT2: 35.8;NTERA-2: 17.8;TIME: 38.8	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in single		neutrophil: 2.2	Lineage enhanced	Detected in single		granulocytes: 2.2	Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB010359, HPA073265"	Approved		Supported	"Plasma membrane,Centriolar satellite"	Secreted to blood	8300000	8300000	Plasma membrane	Centriolar satellite	"CAB010359: AB_2203226, HPA073265: "	unprognostic (2.24e-1)	unprognostic (1.74e-1)	unprognostic (5.55e-2)	unprognostic (1.83e-2)	unprognostic (1.68e-1)	unprognostic (1.26e-3)	prognostic favourable (2.31e-5)	unprognostic (7.48e-2)	unprognostic (1.72e-2)	unprognostic (1.41e-1)	unprognostic (5.58e-2)	unprognostic (2.72e-1)	prognostic favourable (7.81e-4)	unprognostic (7.50e-3)	unprognostic (6.87e-3)	unprognostic (1.83e-1)	unprognostic (5.24e-3)	28.6	7.8	8.1	4.6	5.9	0.4	17.9	3.4	5.4	10.8	4.7	4.6	3.4	3.2	14.5	5.3	6.7	5.9	9.1	13	7.1	6.1	25.4	8.7	27.8	2.9	6.9	3.4	6.1	4.5	3.5	4	36.3	6.9	5.4	4.7	12.4	3.4	5.5	7.8	3	5.3	10.6	5.3	23.4	4	3.7	3.5	0.3	9.7	8.4	2.4	6.4	12.4	0	0.1	2.2	0.6	0	0	0	0.1	0	1.4	0	0.2	2.3	0	1.2	0	0	0	0	0	0	0	0.3	0	0	0	0	0	0	2.3	1	0	0.6	0	0	0.7	0	0.8	0.3	35.8	0	0	0.3	0	0	0	17.8	0	0	0	0	0	0	0.1	0	0	0	0	0	0	38.8	0	0.2	3.6	0	0	0	0	0.6	0	0	0	0	0	0	0.6	0	0	0	0	0.1	0	0	0	2.2	0	0	0	0	0	8.1	5.9	3.4	5.4	7.1	6.1	6.9	3.4	6.9	3.5
TFRC	"CD71, p90, TFR1"	ENSG00000072274	Transferrin receptor	P02786	3	196027183-196082189	"Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters"	"Endocytosis, Host-virus interaction"	"Host cell receptor for virus entry, Receptor"	"Cancer-related genes, Disease mutation"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		placenta: 110.0	Low cell line specificity	Detected in all			Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in many			Low lineage specificity	Detected in all			Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB000153, HPA028598"	Enhanced		Supported	"Endosomes,Lysosomes"	Secreted to blood	14000000	14000000	"Endosomes, Lysosomes"		"CAB000153: AB_2533029, HPA028598: AB_10601599"	unprognostic (2.95e-2)	prognostic unfavourable (3.67e-4)	unprognostic (2.55e-1)	unprognostic (1.48e-2)	unprognostic (6.75e-2)	unprognostic (7.88e-3)	prognostic unfavourable (1.15e-4)	unprognostic (6.92e-2)	unprognostic (3.30e-3)	unprognostic (4.35e-2)	unprognostic (1.34e-2)	unprognostic (1.14e-2)	unprognostic (3.63e-3)	unprognostic (3.65e-2)	unprognostic (1.19e-2)	prognostic unfavourable (2.96e-4)	unprognostic (2.62e-2)	24.3	11.9	11.9	20.6	11.3	73.8	7.6	9.6	17.8	11.8	25	9.5	3.8	11.9	12.1	7.5	18.5	11.7	11.4	18.7	9.5	8.3	15.3	13.6	28.1	8.1	7.4	9.5	50	7.8	18	6.9	110	26.5	7.2	19.4	8.5	8.3	5	25.6	9.9	37.4	10.9	13.2	7.9	10	8.3	6.1	14.3	7	10.5	12.9	11.2	8	5.7	7.5	2.2	12.4	1.8	6.5	2.1	21.9	20	9.2	18.6	20.4	11.8	57.5	31.4	23.9	22.1	36.7	48.7	20.2	22.5	59.6	11.6	33.9	31.5	10.4	27.1	107.6	10.7	85.3	17	22.6	16.1	69.9	17.3	13.3	10.3	19	17.2	7.3	35.5	21.6	17.2	20.3	22.9	14.8	28	41	12.2	13.7	27	19.8	55.6	21	8.7	30.3	79.7	7.1	77.4	14.6	9.4	26.3	21.4	23	47	6.1	47.5	35.2	30.8	19	15.9	0	1.6	2.2	2.5	7.9	1.7	5.7	2.7	1.7	3.7	3.2	2.5	1.9	0.3	1.8	12.4	7.5	6.5	2.1	11.9	11.3	9.6	17.8	9.5	8.3	7.4	9.5	26.5	6.1
THBD	CD141	ENSG00000178726	Thrombomodulin	P07204	20	23045633-23049741	"Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins"	"Blood coagulation, Hemostasis"	Receptor	"Disease mutation, Hemolytic uremic syndrome, Thrombophilia"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in many		ASC diff: 12.9;CAPAN-2: 20.0;EFO-21: 17.5;HaCaT: 16.8;hTCEpi: 22.2;THP-1: 12.5	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Cell type enhanced	Detected in many		neutrophil: 17.7	Group enriched	Detected in many	7	dendritic cells: 7.8;granulocytes: 17.7;monocytes: 6.2	Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB002425, HPA002982"	Supported		Approved	"Nucleoplasm,Cytosol"		690000	690000	"Nucleoplasm, Cytosol"		"CAB002425: AB_563497, HPA002982: AB_1078444"	unprognostic (1.96e-1)	unprognostic (2.93e-3)	unprognostic (8.70e-2)	unprognostic (3.00e-2)	unprognostic (3.07e-2)	unprognostic (1.88e-1)	unprognostic (7.81e-3)	unprognostic (4.70e-2)	unprognostic (1.38e-1)	unprognostic (1.52e-2)	unprognostic (2.30e-1)	unprognostic (5.33e-2)	unprognostic (2.23e-2)	unprognostic (7.35e-3)	unprognostic (3.01e-2)	unprognostic (7.58e-3)	unprognostic (9.71e-2)	27	6.3	1.4	10.5	6.7	6.9	11.8	1.2	2.7	13.2	14.4	1.4	4.3	2.9	9.7	11.5	21.7	15.8	18.2	24.3	5	1.5	7	10	61.9	26.8	2.5	0.1	10.2	7.2	10	10.9	16.4	6.2	6.1	3.3	8.8	6	4.2	55.5	32.4	14.1	8.5	7.7	44.4	14.4	15.8	2.4	2.1	18.3	32.2	10.4	14.2	10.4	0	7.8	17.7	6.2	1.5	0	1.1	5.6	5	0.1	0	12.9	0.7	0.1	0.1	0	0	0	0	20	0	17.5	1.7	16.8	0	0.9	0	0	0	0	0.5	0	2.5	0	0.1	0.6	22.2	0.3	1.4	5.6	2.1	0	0.5	0.4	0	2.1	0	0.8	0	0	2.4	0.1	8.2	0.3	0	4.7	0.6	8.7	0	12.5	11	0	0.3	1.6	0	0	0	0	1	2.9	0.4	0	2.8	0	0	6.2	0	0	0	0	7	0	0	0	17.7	1.5	5.8	7.8	0	1.1	1.4	6.7	1.2	2.7	5	1.5	2.5	0.1	6.2	2.4
THY1	CD90	ENSG00000154096	Thy-1 cell surface antigen	P04216	11	119417378-119424985	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"				Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		brain: 97.7;smooth muscle: 91.5	Cell line enhanced	Detected in many		ASC diff: 52.6;BJ: 82.2;BJ hTERT+: 92.1;fHDF/TERT166: 144.0	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in single		MAIT T-cell: 1.7	Lineage enriched	Detected in single	17	T-cells: 1.7	Low region specificity	Detected in all			Low region specificity	Detected in all			"HPA003733, CAB068243, CAB068244"	Enhanced		Approved	"Nucleoplasm,Plasma membrane"		9800000	9800000	Nucleoplasm	Plasma membrane	"CAB068243: , CAB068244: , HPA003733: AB_1846340"	unprognostic (9.98e-2)	unprognostic (2.71e-1)	unprognostic (5.13e-2)	unprognostic (2.61e-1)	prognostic unfavourable (6.87e-4)	unprognostic (7.43e-2)	unprognostic (1.43e-3)	unprognostic (2.38e-2)	unprognostic (1.29e-1)	unprognostic (2.90e-3)	unprognostic (3.38e-2)	unprognostic (3.52e-1)	prognostic unfavourable (2.40e-6)	unprognostic (1.75e-2)	unprognostic (1.90e-2)	unprognostic (3.03e-2)	unprognostic (1.14e-2)	28.7	5.9	42	23.2	72.4	0.4	7	17.6	97.7	26.9	9	7.2	2.1	3.5	20.3	13.9	9.8	7.5	31.6	4.3	63.4	41.1	46.6	2.6	6.5	10.9	29.8	34.8	3.2	5	7.3	5.5	19.1	53.8	4.6	13.6	8.5	2.9	15.7	1.4	4.2	4.6	91.5	9.3	6.7	5.7	4	6.9	3.1	12	1	10.8	36.9	7.2	0	0	0	0	0	1.7	0.3	0	0.3	12.3	0	52.6	38.1	0	82.2	92.1	29.5	32.7	0	0	0	0	144	0	0.4	0.1	22.6	7	0	4.4	1.5	0	16.3	0	0	28.2	0	37.4	1.3	0	0	0	22.7	0	0	0	19.7	0.1	0	5.8	0	0	0	2.1	5.6	0	0	0	0.1	0.2	0	42.4	14.1	12.2	12.1	0	2	0	0.1	0	0	0	0	0	0	0	1.7	0	0.7	0	0	0	0	0	0	0	0	0	0	0.3	42	72.4	17.6	97.7	63.4	41.1	29.8	34.8	53.8	6.9
TLR1	"CD281, KIAA0012, rsc786"	ENSG00000174125	Toll like receptor 1	Q15399	4	38790677-38856817	"CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Immunity, Inflammatory response, Innate immunity"	Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 43.3;lymphoid tissue: 40.4	Cell line enhanced	Detected in many		Daudi: 9.4;HUVEC TERT2: 10.8;RPMI-8226: 11.7;U-698: 17.5	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in many		neutrophil: 43.3	Group enriched	Detected in all	6	granulocytes: 43.3;monocytes: 13.1	Low region specificity	Detected in some			Low region specificity	Detected in many														unprognostic (7.82e-2)	unprognostic (3.35e-3)	unprognostic (4.02e-2)	unprognostic (1.19e-1)	unprognostic (1.71e-1)	unprognostic (1.85e-2)	unprognostic (1.12e-1)	unprognostic (1.80e-1)	unprognostic (3.88e-1)	unprognostic (1.04e-1)	unprognostic (3.94e-2)	unprognostic (1.76e-1)	unprognostic (7.25e-3)	unprognostic (4.08e-2)	unprognostic (1.91e-2)	unprognostic (2.08e-1)	unprognostic (3.97e-2)	10.9	4.6	7.1	17.9	11.4	21	5.4	2	6	3.4	3.7	5.9	0.5	4.2	5.8	3.9	3.2	5.3	6.5	4	6.5	3.4	4.6	5.8	9.8	26.4	12.9	2.6	7.4	7.7	1	4.2	6.6	10.6	3.9	4.6	2.2	11	2.5	1.7	3.1	6.7	6.5	19.4	40.4	4.2	1.6	10.9	10.1	2.4	1.7	13.1	6.3	2.8	2.3	4.5	43.3	13.1	1.8	1.1	2.4	0.2	1.7	0.1	0	0.2	1.3	0	0	0.4	0.1	1	0.2	4.6	9.4	1	0	0.2	0.1	1.1	0.2	1.1	0.5	1.2	0.4	0	0	1.8	0.5	0.4	0.2	0.4	0	10.8	1.3	2.8	1.4	0	0.4	3.8	0	0	6.3	0.1	11.7	1.1	0	0	1.3	0	0.1	0.4	0.1	2.3	2.8	0.9	0.4	0.1	0.6	1	0.1	17.5	2.5	6.5	0.3	0	6.8	2.6	1	10.4	0.8	2.3	1.1	0.8	4.5	2	1.1	0.6	43.3	1.8	13.1	1.5	0.4	2.4	7.1	11.4	2	6	6.5	3.4	12.9	2.6	10.6	10.9
TLR10	CD290	ENSG00000174123	Toll like receptor 10	Q9BXR5	4	38772239-38782990	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Immunity, Inflammatory response, Innate immunity"	Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in some	6	blood: 23.5;brain: 11.3;intestine: 11.2;lymphoid tissue: 31.6	Group enriched	Detected in some	55	Daudi: 37.3;REH: 12.5;U-698: 13.4	Low cancer specificity	Detected in many			Low region specificity	Detected in many			Group enriched	Detected in many	5	memory B-cell: 23.5;naive B-cell: 14.9	Lineage enriched	Detected in many	6	B-cells: 23.5					Low region specificity	Detected in all			HPA066755			Approved	"Centrosome,Cytosol"				Cytosol	Centrosome	HPA066755: 	unprognostic (5.41e-5)	unprognostic (2.41e-4)	unprognostic (1.91e-3)	unprognostic (8.22e-4)	unprognostic (6.48e-2)	unprognostic (9.98e-4)	unprognostic (9.31e-2)	unprognostic (8.76e-3)	unprognostic (4.08e-3)	unprognostic (7.26e-2)	unprognostic (8.76e-2)	unprognostic (6.90e-2)	unprognostic (2.98e-3)	unprognostic (3.90e-1)	unprognostic (1.81e-2)	unprognostic (3.14e-3)	unprognostic (1.88e-2)	0.8	0.5	4.2	24.5	9.4	0.9	0.6	0.6	3.5	0.6	1	2.5	0	0.9	0.5	0.3	1.7	0.9	1	0.5	3.2	1.8	0.8	0.7	1.2	27	5.5	0.5	0.5	0.6	0.1	0.7	0.2	4.8	0.8	1.4	0	2.6	0.3	0.5	0.5	11.2	0.3	11.3	24.4	1.8	0.4	7.4	2.7	0.9	0	31.6	3.2	0.6	23.5	4	0.7	1.8	0	0	0.9	0	0	0	0	0	0	0	0	0	0	0	0	0	37.3	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0.1	0	0	0	0.3	0	0	12.5	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0.2	0	0	0	13.4	0	0	0	0.1	0.2	0.4	0	1.5	0	23.5	0	0	3.6	14.9	0	0	0.7	0	1.8	4	0	0.9	4.2	9.4	0.6	3.5	3.2	1.8	5.5	0.5	4.8	7.4
TLR2	"CD282, TIL4"	ENSG00000137462	Toll like receptor 2	O60603	4	153684070-153705702	"CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Immunity, Inflammatory response, Innate immunity"	Receptor	FDA approved drug targets	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		blood: 72.9	Cell line enhanced	Detected in some		HSkMC: 7.4;hTCEpi: 7.4;RPTEC TERT1: 7.6;RT4: 9.3;THP-1: 35.5	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Group enriched	Detected in many	5	classical monocyte: 29.5;intermediate monocyte: 28.1;myeloid DC: 19.1;neutrophil: 72.9;non-classical monocyte: 18.4	Group enriched	Detected in many	46	dendritic cells: 19.1;granulocytes: 72.9;monocytes: 29.5	Low region specificity	Detected in many			Low region specificity	Detected in all			"HPA060231, HPA071546"			Supported	"Nucleoplasm,Mitochondria"				"Nucleoplasm, Mitochondria"		"HPA060231: , HPA071546: "	unprognostic (4.15e-1)	unprognostic (3.29e-2)	unprognostic (5.32e-2)	unprognostic (1.52e-2)	unprognostic (3.46e-2)	unprognostic (4.88e-2)	unprognostic (1.39e-2)	unprognostic (4.24e-2)	unprognostic (2.48e-1)	unprognostic (2.02e-2)	unprognostic (2.04e-1)	unprognostic (1.33e-1)	prognostic unfavourable (1.11e-4)	unprognostic (7.87e-2)	unprognostic (3.80e-3)	unprognostic (1.42e-1)	unprognostic (5.93e-3)	16.3	6.9	6.9	30	11.1	34.6	7.3	1.4	5.3	4.7	4.7	3	9.3	2.2	3.1	8	3.2	7.2	10	7.2	6.7	3.3	9.8	7.3	31.1	37.8	12.4	1.4	4.2	5.1	1.1	4.4	6.4	9.9	5.5	1.9	3.3	15	9.9	2.5	3.1	4	6.6	21.9	29.3	3.9	4.8	9.5	0.9	3.3	1	8.5	7.3	3.5	0.2	19.1	72.9	29.5	0.8	0.2	9.3	3.9	0	0.1	0	0.5	1.6	0	0	0.3	0.3	0.5	1.9	0.2	0	0.4	0	3.5	0.4	0.2	0.2	0	0	0.1	0	0.4	0	6.8	0.5	7.4	7.4	0	0.1	0	0	0	0	0	0	6.3	0.4	1.5	0.1	0	0	7.6	9.3	0	0.2	0.4	0	1.8	0	35.5	0	0	0	0	0	0	0	0	0.4	6.7	0.9	6.2	29.5	0.2	0	28.1	0	0	0.1	0	19.1	0.2	0.2	0	72.9	0.8	18.4	0.1	0	9.3	6.9	11.1	1.4	5.3	6.7	3.3	12.4	1.4	9.9	9.5
TLR3	CD283	ENSG00000164342	Toll like receptor 3	O15455	4	186069152-186088069	"CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Immunity, Inflammatory response, Innate immunity"	"Receptor, RNA-binding"	Disease mutation	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		placenta: 48.1	Cell line enhanced	Detected in many		ASC diff: 11.4;ASC TERT1: 12.0;BJ hTERT+ SV40 Large T+ RasG12V: 17.7;CAPAN-2: 27.6;HSkMC: 11.7	Low cancer specificity	Detected in many			Low region specificity	Detected in all			Cell type enhanced	Detected in many		gdT-cell: 7.6;memory CD8 T-cell: 8.0	Group enriched	Detected in many	7	dendritic cells: 2.5;T-cells: 8.0	Low region specificity	Detected in all			Low region specificity	Detected in all			CAB025658	Enhanced				Intracellular and membrane					CAB025658: 	unprognostic (2.13e-2)	unprognostic (2.15e-1)	unprognostic (7.26e-2)	unprognostic (7.47e-3)	unprognostic (1.10e-1)	unprognostic (1.81e-1)	unprognostic (6.39e-3)	unprognostic (1.56e-2)	unprognostic (9.28e-2)	unprognostic (2.25e-2)	prognostic unfavourable (3.09e-4)	unprognostic (1.17e-1)	unprognostic (4.72e-3)	unprognostic (1.18e-1)	unprognostic (4.52e-3)	unprognostic (3.89e-2)	unprognostic (1.83e-1)	11.9	10.7	3.1	6.8	5	0	11.1	1.7	3.5	9.9	20.1	3	6.8	13.4	5.6	7.3	12.9	7.8	8.6	7.7	3.5	2.6	12.4	11.2	12.2	1	3.3	1.9	8.9	8.2	4.8	2.7	48.1	3	11.3	9.5	5	8.5	10.2	2.3	3.8	34.9	6.5	8	7	8.2	5.8	4.2	1.2	11.8	7.6	3	10.3	14.6	0	2.5	0.5	0	0.7	8	1.1	1.9	0.5	0.3	0	11.4	12	0.9	0.1	8.2	5.1	17.7	0	27.6	0	1.1	1.2	2.8	0	5.8	0.9	10.6	0.1	1.7	0.5	0	5.1	1.7	0.7	11.7	2.2	6.8	0.3	2.4	0	0	2.8	0	2	0	0.8	1	2.5	0	0.1	4.8	2.7	0	0.1	1.4	1.2	2.2	0.3	0	1.7	0.9	0.6	0	1.2	0	0	0	2.3	1.1	1.9	0.5	0	0	7.6	0	4.3	0	1.8	8	2.5	0	1.2	3.9	0.3	0.7	0	0	0.2	1.1	3.1	5	1.7	3.5	3.5	2.6	3.3	1.9	3	4.2
TLR4	"ARMD10, CD284, hToll, TLR-4"	ENSG00000136869	Toll like receptor 4	O00206	9	117704175-117724730	"CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Immunity, Inflammatory response, Innate immunity"	Receptor	"Age-related macular degeneration, FDA approved drug targets"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in many		Karpas-707: 29.1;TIME: 21.1	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in many		neutrophil: 30.1	Group enriched	Detected in many	30	dendritic cells: 7.5;granulocytes: 30.1;monocytes: 21.4	Low region specificity	Detected in many			Low region specificity	Detected in many			"CAB004025, HPA049174"	Approved		Supported	"Golgi apparatus,Plasma membrane"	Intracellular and membrane			Plasma membrane	Golgi apparatus	"CAB004025: , HPA049174: "	unprognostic (1.60e-1)	unprognostic (8.34e-2)	unprognostic (7.22e-2)	prognostic favourable (6.29e-4)	unprognostic (3.39e-1)	unprognostic (7.48e-2)	unprognostic (8.68e-2)	unprognostic (1.80e-1)	unprognostic (3.38e-1)	unprognostic (5.18e-2)	unprognostic (8.00e-2)	unprognostic (9.42e-2)	unprognostic (4.08e-2)	unprognostic (8.63e-2)	prognostic unfavourable (3.79e-4)	unprognostic (1.09e-2)	unprognostic (1.96e-2)	29.2	12.1	15.5	23.5	12.5	17.8	21.9	9.4	10.3	6.9	6.8	10.6	3	4.4	5.8	7.7	5	6.8	10.6	10.9	19.9	7.5	9	16.5	16	30.9	12.4	11.4	6.7	3	2.9	3.8	22.8	10.5	5.7	7.4	7.2	9	3.6	7.4	5.2	6.6	10.4	11.1	41.4	4.5	2.4	13	1.1	8.3	5.6	7.5	12.1	16.1	0.6	7.5	30.1	21.4	0	0	6.9	0	0	12.5	0	5.8	11.8	0.1	5	8.7	1.2	0.7	0	1.2	1.7	0.2	12.8	0	0	1.1	1.8	0	0	2.6	2.6	0.1	4.4	9	0	7.3	0	2.7	0.3	15.2	0	29.1	15.2	0	0	1.8	1.5	0.6	0	14.1	9.1	0.5	14.6	0	0	3.1	0	0.5	0	4.9	21.1	0.6	9.5	0	2.3	0	0	0	0.4	9.5	7.4	17.6	21.4	7.2	0	19.6	0	0.6	0	0	7.5	0.2	0	0	30.1	0	20.2	0.3	0	6.9	15.5	12.5	9.4	10.3	19.9	7.5	12.4	11.4	10.5	13
TLR6	CD286	ENSG00000174130	Toll like receptor 6	Q9Y2C9	4	38823715-38856817	"CD markers, Predicted membrane proteins"	"Immunity, Inflammatory response, Innate immunity"	Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 14.2;brain: 16.0;lymphoid tissue: 16.2	Cell line enhanced	Detected in many		CAPAN-2: 13.0;RPMI-8226: 10.2	Low cancer specificity	Detected in many			Low region specificity	Detected in all			Cell type enriched	Detected in many	5	neutrophil: 14.2	Lineage enriched	Detected in many	5	granulocytes: 14.2	Low region specificity	Detected in many			Low region specificity	Detected in all			HPA062733			Approved	Endoplasmic reticulum				Endoplasmic reticulum		HPA062733: 	unprognostic (9.82e-2)	unprognostic (4.76e-2)	unprognostic (3.30e-2)	unprognostic (3.05e-2)	unprognostic (1.91e-1)	unprognostic (1.87e-2)	unprognostic (1.83e-1)	unprognostic (4.45e-2)	unprognostic (9.26e-2)	unprognostic (1.30e-1)	unprognostic (1.05e-2)	unprognostic (2.69e-1)	unprognostic (7.62e-7)	unprognostic (4.89e-2)	unprognostic (1.02e-2)	unprognostic (7.78e-2)	unprognostic (2.12e-2)	2.9	2.7	6.1	10.7	7.9	6.4	2.1	2	3.9	1.8	1.6	2.6	0.2	1.7	1.4	2	1.8	1.9	3.9	1.5	4.5	1.7	1.7	2.1	5	11.2	10.6	1.9	1.6	1.2	0.7	1.9	2.8	7.2	1.6	2.4	0.9	4.3	0.5	0.9	1.7	7.8	2.1	16	16.2	2.1	0.8	6.8	1.8	1.5	1.1	14.8	5.8	1.9	1.8	1.8	14.2	2.6	0.3	0.4	0.6	1.5	6	0.2	0.1	0.3	6.9	0	1.6	7.1	0.7	2.4	0	13	7.1	2.8	0.3	0.7	0.1	1.3	1.1	0	0.5	3.3	7.2	0.2	0.5	3.6	5.4	2.9	1.3	2.9	1.6	1.4	3.6	2.3	3.3	0	0	6.3	0.2	1	3.5	3.2	10.2	0.4	0.1	0	0.1	0.2	0	1	0.3	1.9	2	2.3	7.8	0.9	2.5	0.1	0	6	5.3	4.3	1.7	0	2.6	0.7	0.2	2.4	0	1.8	0.1	0.1	1.8	1.2	0.3	0.2	14.2	0.3	1.2	1.3	0.4	0.6	6.1	7.9	2	3.9	4.5	1.7	10.6	1.9	7.2	6.8
TLR8	CD288	ENSG00000101916	Toll like receptor 8	Q9NR97	X	12906620-12923169	"CD markers, Predicted membrane proteins"	"Immunity, Inflammatory response, Innate immunity"	Receptor		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 17.8;lymphoid tissue: 45.6	Cell line enhanced	Detected in some		HMC-1: 1.2;PC-3: 2.7;THP-1: 1.3	Low cancer specificity	Detected in many			Low region specificity	Detected in many			Group enriched	Detected in some	94	classical monocyte: 10.0;intermediate monocyte: 9.6;myeloid DC: 5.3;neutrophil: 17.8;non-classical monocyte: 9.2	Group enriched	Detected in many	100	dendritic cells: 5.3;granulocytes: 17.8;monocytes: 10.0	Low region specificity	Detected in single			Low region specificity	Detected in all			HPA001608	Enhanced									HPA001608: AB_1080295	unprognostic (1.32e-1)	unprognostic (6.94e-2)	unprognostic (3.96e-3)	unprognostic (4.43e-2)	unprognostic (9.63e-2)	unprognostic (2.48e-2)	unprognostic (2.59e-1)	unprognostic (6.61e-2)	unprognostic (1.93e-1)	unprognostic (2.23e-1)	unprognostic (3.72e-2)	unprognostic (2.73e-1)	unprognostic (1.74e-2)	unprognostic (1.03e-1)	unprognostic (4.14e-2)	unprognostic (1.52e-1)	unprognostic (5.66e-2)	8.5	1.4	0.9	16	1.5	4.7	1.2	0.7	1.1	1	1.5	0.4	0	0.6	1	3.2	1	2	2.4	3	2	1	2	4	13.7	33	1.7	0.1	1.1	1	0.2	1	4	1.9	1.4	1.7	0.9	1.2	0	1.4	0.8	2	3.5	3.3	45.6	1.3	1.2	1.6	3.5	1	1.1	2.4	4.2	2.4	0.1	5.3	17.8	10	0	0	2	0	0	0	0.1	0	0	0	0	0	0	0	0	0.1	0	0	0	0.2	0	0	0	0	0	0.3	0.2	0	0	0	1.2	0	0	0	0	0	0	0	0	0.1	0	0.1	0	2.7	0	0	0.1	0	0	0	0	0	0	0	0	1.3	0.3	0	0.1	0.2	0	0.4	0.2	0	0	0.3	0	0	10	0	0	9.6	0	0.1	0	0	5.3	0	0	0	17.8	0	9.2	0	0	2	0.9	1.5	0.7	1.1	2	1	1.7	0.1	1.9	1.6
TLR9	CD289	ENSG00000239732	Toll like receptor 9	Q9NR96	3	52221080-52226163	"CD markers, FDA approved drug targets, Predicted membrane proteins"	"Immunity, Inflammatory response, Innate immunity"	Receptor	FDA approved drug targets	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enriched	Detected in some	5	blood: 33.8	Group enriched	Detected in some	12	Daudi: 24.1;RPMI-8226: 15.4;U-698: 9.3	Not detected	Not detected							Cell type enriched	Detected in some	10	plasmacytoid DC: 33.8	Lineage enriched	Detected in many	10	dendritic cells: 33.8																				unprognostic (6.03e-2)	unprognostic (5.08e-2)	unprognostic (3.58e-3)	unprognostic (6.69e-7)	unprognostic (1.16e-1)	unprognostic (1.89e-2)	unprognostic (2.69e-1)	unprognostic (1.58e-1)	unprognostic (7.02e-2)	unprognostic (1.89e-1)	unprognostic (4.40e-2)	unprognostic (7.60e-2)	unprognostic (2.65e-3)	unprognostic (2.44e-2)	unprognostic (3.70e-1)	unprognostic (2.27e-1)	unprognostic (7.91e-3)	0.5	0.2	0	2.8	0.5	2.5	0.4	4.9	0.4	0.8	1.2			0.7	0.9	0	0.2	1	0.9	0.3	0.2	0.3	0.3	0.1	0.6	6.5	0.1		2.5	0	0	0.3	0.1		0.9	0.1		1.4	0.4	1.8	0.1	2.2	0.1	0.4	3.9	0.5	0.3			0.7		3.9	1.2	1.2	3.3	33.8	0	0	0	0	0.1	0	0	0	0	0	0.1	0	0	0	0	0	0	0	24.1	0	0	0	0	0	0	0	0	0	0	0	0	0.2	0	0.1	0.1	0	0	0	0	0.1	0	0	1.3	0.2	0	0	0	0	15.4	0	0	0	0	0	0	0	0	0.5	0.1	0	0	0	0	0.9	0.7	9.3	0	0.5	0	0	0	0	0	0	0	3.3	0	0	0	1.7	0	0	0	0	0	33.8	0	0.1										
TNFRSF10A	"Apo2, CD261, DR4, TRAILR-1, TRAILR1"	ENSG00000104689	TNF receptor superfamily member 10a	O00220	8	23190452-23225126	"Cancer-related genes, CD markers, Predicted membrane proteins"	Apoptosis	Receptor	Cancer-related genes	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Low cell line specificity	Detected in many			Low cancer specificity	Detected in all			Low region specificity	Detected in many			Low cell type specificity	Detected in many			Low lineage specificity	Detected in all											"HPA050958, HPA054475"	Approved		Supported	Nucleoplasm				Nucleoplasm		"HPA050958: , HPA054475: "	unprognostic (3.66e-1)	unprognostic (1.02e-1)	unprognostic (2.19e-2)	unprognostic (4.89e-2)	unprognostic (9.44e-2)	unprognostic (8.39e-2)	unprognostic (5.32e-2)	unprognostic (2.18e-2)	unprognostic (2.72e-1)	unprognostic (4.48e-2)	prognostic unfavourable (1.00e-4)	unprognostic (1.49e-1)	unprognostic (1.99e-3)	unprognostic (1.91e-2)	unprognostic (1.61e-2)	unprognostic (2.35e-1)	unprognostic (2.87e-1)	11.9	4	2.1	13	3.4	8.4	9.7	2	2.8	6	10.9	1.4	4.5	5.9	5.3	5.6	13.6	4.1	12.7	6.3	2.2	2	10.9	10.6	11	12.4	3	0.7	2.7	12.9	3.6	1.8	6.9	4	5.1	7.2	2.1	8.2	4.3	3.8	7.1	10.2	3.8	2.9	13.2	6.1	2.6	3	9.5	5.8	14.9	25.4	6.7	8.7	13.2	4.5	3.8	4.3	3.9	13.9	4.2	7.9	14.4	0.7	0	0.5	2.9	0	1.6	1	0.8	2.3	11	14	18.4	18.8	1	15.2	12.9	20.6	1.4	4.5	0.1	9.7	8.7	6.2	7.4	5.2	9.3	5	17	18.3	15.8	9.7	15	6.6	3.9	6.2	0.2	3.3	10	8.8	0.1	0	13.2	11	17.2	0.4	0.5	4	10.2	0	5.4	4	13.6	0	0.1	0.8	0	7.8	11	14.3	0.1	1.7	0.2	2	4.3	3.8	3.8	1.9	10.3	10.4	12.3	7.7	4.5	13.2	12.1	7	0.5	3.9	1.7	0	13.9	4.2	2.1	3.4	2	2.8	2.2	2	3	0.7	4	3
TNFRSF10B	"CD262, DR5, KILLER, TRAIL-R2, TRAILR2, TRICK2A, TRICKB"	ENSG00000120889	TNF receptor superfamily member 10b	O14763	8	23020133-23069179	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins"	Apoptosis	Receptor	Cancer-related genes	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Low cell line specificity	Detected in many			Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in many			Low lineage specificity	Detected in many											HPA023625	Approved									HPA023625: AB_1847860	unprognostic (8.43e-3)	unprognostic (7.43e-3)	unprognostic (3.04e-2)	unprognostic (4.94e-3)	unprognostic (1.13e-1)	unprognostic (7.74e-2)	unprognostic (2.15e-1)	unprognostic (9.51e-3)	unprognostic (2.70e-1)	unprognostic (2.82e-2)	unprognostic (2.30e-3)	unprognostic (1.96e-2)	prognostic unfavourable (1.76e-4)	unprognostic (4.01e-2)	unprognostic (1.03e-1)	unprognostic (1.86e-1)	unprognostic (5.52e-2)	29.6	18.5	5.2	16.4	7.3	7.6	19.6	2.3	5.8	11.5	23.1	7.5	13.3	14.1	10.4	13.9	12.1	11.4	22.1	13.2	6.4	3.2	14.3	36.1	21.3	11.6	7.9	2.6	16.2	20	14.8	6.1	8.5	8.2	15.1	14.3	7.9	11.5	14.5	15.5	6.1	31.2	10.5	8.6	17.4	11.2	7.8	6.4	4.1	17.7	13	15.2	17.9	9.9	3.1	12.1	2.8	12.9	0.8	4	5.2	8.5	22.7	33.3	10.1	15.6	20.4	32.6	20.6	26.5	11.2	17.5	9.4	8.6	5.1	14	11.2	8.3	8.7	39	20	5.1	7.3	0	8.9	17.6	52.3	1.9	8.6	30.3	35	24.9	26.6	35.5	3.6	0	22	2.8	0.2	2.8	8.3	8.2	4.6	12.1	3.2	21.7	13.5	0	5.6	10.3	2.9	10.9	5	2.4	31.4	16.4	8.5	5.2	14.8	6.6	1.1	2.4	16.7	3.7	23.4	2.8	12.9	0.4	1.6	9.3	2.7	3.1	1.9	1.6	12.1	1.6	4	1.6	2.6	0.8	11.9	0	1.3	5.2	5.2	7.3	2.3	5.8	6.4	3.2	7.9	2.6	8.2	6.4
TNFRSF10C	"CD263, DcR1, LIT, TRAILR3, TRID"	ENSG00000173535	TNF receptor superfamily member 10c	O14798	8	23102590-23117437	"Cancer-related genes, CD markers, Predicted membrane proteins"	Apoptosis	Receptor	Cancer-related genes	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enriched	Detected in many	6	blood: 173.4	Group enriched	Detected in some	5	BEWO: 37.1;HUVEC TERT2: 30.9	Low cancer specificity	Detected in many			Low region specificity	Detected in many			Cell type enriched	Detected in some	7	neutrophil: 173.4	Lineage enriched	Detected in many	113	granulocytes: 173.4									CAB025635	Enhanced									CAB025635: 	unprognostic (2.63e-1)	unprognostic (4.49e-3)	unprognostic (7.21e-3)	unprognostic (2.07e-2)	unprognostic (3.55e-2)	unprognostic (1.46e-1)	unprognostic (1.81e-2)	unprognostic (2.11e-3)	unprognostic (5.56e-2)	unprognostic (4.37e-2)	unprognostic (8.98e-2)	unprognostic (1.94e-3)	unprognostic (2.74e-3)	unprognostic (4.83e-1)	unprognostic (1.84e-1)	unprognostic (1.34e-3)	unprognostic (6.54e-2)	5.5	1.5	1.9	14	3.6	12.6	2	1.4	3.9	2.9	1.5	0.7	0.1	1.2	1.5	1.2	1.4	3.7	13.5	5.6	1.9	1.1	2.8	3.2	13.7	28.4	9.2	0	2.4	2.1	2.5	4.5	12.8	3.1	2.7	1.8	1.7	1.7	0.8	2.3	0.8	2.2	1.9	4.4	26.4	1.8	1.4	2.3	0.8	4.4	0.5	0.9	5.2	1.9	0	0.3	173.4	1.5	0	0	0.4	0.4	1.4	0.5	2.4	0	0.3	37.1	1.5	0	0.1	0.1	0	1.4	0.1	0.7	1.4	0.2	0.1	0.1	0.1	2.5	0.5	0.1	0.3	1.1	3.6	0.2	1	4.1	0.3	0.7	0.3	30.9	0	0	0.2	1	0	0.9	1.6	0	0.1	0.1	0	5.9	0.1	0	0	0.1	0.2	0.7	5.1	0.2	6.5	0.6	1.2	1.4	0.1	1.5	0.8	0	2.2	0.3	0.9	2.7	1.5	25.4	0	0.8	0	0	0	0	0.3	0	0	0	173.4	0	1.1	0	0	0.4	1.9	3.6	1.4	3.9	1.9	1.1	9.2	0	3.1	2.3
TNFRSF10D	"CD264, DcR2, TRAILR4, TRUNDD"	ENSG00000173530	TNF receptor superfamily member 10d	Q9UBN6	8	23135588-23164030	"Cancer-related genes, CD markers, Predicted membrane proteins"	Apoptosis	Receptor	Cancer-related genes	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in many		HUVEC TERT2: 24.1;LHCN-M2: 60.9;WM-115: 57.8	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Cell type enhanced	Detected in many		naive CD4 T-cell: 9.0	Low lineage specificity	Detected in many											HPA070971			Approved	"Plasma membrane,Actin filaments"				"Plasma membrane, Actin filaments"		HPA070971: 	unprognostic (1.49e-1)	prognostic unfavourable (1.70e-4)	unprognostic (1.41e-1)	unprognostic (8.78e-2)	unprognostic (8.13e-2)	unprognostic (7.49e-2)	unprognostic (2.69e-1)	unprognostic (7.06e-2)	unprognostic (3.56e-2)	unprognostic (1.66e-1)	unprognostic (1.61e-2)	unprognostic (1.32e-1)	unprognostic (2.12e-2)	unprognostic (2.70e-1)	unprognostic (1.35e-2)	unprognostic (6.32e-2)	unprognostic (1.72e-1)	16	3.1	4.9	7.3	10	10.5	10.2	3.4	10.3	5.9	8.5	2.6	5.5	6.2	8.9	5.7	4.1	8	11.5	6.5	7	3.4	12.1	31.5	12.5	5.1	9	0.9	9.8	5.2	2.5	4.3	4.1	9	9	10.9	3.9	3.9	4.4	3.9	3.1	11.2	10.9	6.3	6.9	7.2	4.3	9.2	2.9	6	6.8	6.6	7.3	26	2.1	4.5	2.4	3.3	0.3	9	2.4	3.5	3	4	2.2	3	12.1	0	18.8	7.1	1.4	1.9	5.8	2.9	0	4	11.2	1.2	3.3	16.5	12.5	0	2.9	1	1.8	5	13.3	0.6	1.3	15.1	18.4	5	3.5	24.1	0	0	60.9	0	0	1.9	3.2	0	0.7	0	0.9	4.7	1.6	0	0	2	0	0	0	2.3	14.2	0	0	1.1	0	0	0	0	15.7	0.9	57.8	2.4	3.3	1.5	0	1.4	0.1	2.1	3.2	1.1	4.5	0.8	9	3.5	2.2	0.3	1.9	0	1	2.4	4.9	10	3.4	10.3	7	3.4	9	0.9	9	9.2
TNFRSF11A	"CD265, FEO, LOH18CR1, PDB2, RANK"	ENSG00000141655	TNF receptor superfamily member 11a	Q9Y6Q6	18	62325287-62391292	"CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Deafness, Disease mutation, Osteopetrosis"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		gallbladder: 28.7;intestine: 23.9;salivary gland: 34.3	Cell line enriched	Detected in some	6	HDLM-2: 51.3	Low cancer specificity	Detected in many			Low region specificity	Detected in many			Cell type enriched	Detected in some	8	NK-cell: 8.9	Lineage enriched	Detected in many	8	NK-cells: 8.9	Low region specificity	Detected in many			Low region specificity	Detected in all			"CAB010391, HPA047976"	Approved		Supported	"Plasma membrane,Cytosol"	Intracellular and membrane			Plasma membrane	Cytosol	"CAB010391: AB_2205352, HPA047976: "	unprognostic (4.08e-1)	unprognostic (2.71e-1)	unprognostic (3.23e-3)	unprognostic (1.73e-1)	unprognostic (6.03e-2)	unprognostic (1.35e-1)	unprognostic (9.96e-4)	unprognostic (4.24e-3)	unprognostic (7.79e-4)	unprognostic (1.52e-1)	unprognostic (4.05e-2)	unprognostic (2.88e-1)	unprognostic (4.69e-5)	unprognostic (1.56e-1)	unprognostic (1.78e-1)	unprognostic (4.02e-2)	unprognostic (7.07e-2)	6.5	1.7	1.7	4.8	1.2	0.2	4.3	0.4	2.3	1.5	18.4	0.8	7.6	23.1	0.9	1.9	3.8	1.3	28.7	1.1	1.3	0.7	0.9	0.8	2.3	7.4	1	1	0.7	2.9	0.1	10.1	2.8	0.7	2.1	13.9	1.3	34.3	12.9	0.6	3.3	23.9	1.3	2.9	1.2	4.3	1.2	0.8	0.7	2	1.8	2.3	2.3	2.3	0	0.6	0.2	0	8.9	1	0	1.3	0.9	0	0	0	0	0	0	0	0	0.7	0.1	0.2	0	1.5	0.1	0.9	3.5	0.3	0.1	51.3	2.3	0	0.5	0.7	0	0.2	0.5	0.1	0.1	0.3	1.3	1.3	0	0	0	0.4	0	0	2.5	8.1	0.1	0	0.2	0.6	0.6	8.7	0.3	0.2	1.3	0	0.5	0.1	0.8	0	0	0	0	0.5	0	0	0.1	0	1.8	0	0	0	0	0	0	0	0.1	0	0.1	0	0	0	0.2	8.9	0	0.6	1	0	1.7	1.2	0.4	2.3	1.3	0.7	1	1	0.7	0.8
TNFRSF12A	"CD266, FN14, TweakR"	ENSG00000006327	TNF receptor superfamily member 12A	Q9NP84	16	3018445-3022383	"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Angiogenesis, Apoptosis, Cell adhesion, Differentiation"	"Developmental protein, Receptor"	Cancer-related genes	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		placenta: 81.3	Low cell line specificity	Detected in many			Low cancer specificity	Detected in all			Region enriched	Detected in many	5	pons and medulla: 25.0	Group enriched	Detected in many	8	eosinophil: 38.1;neutrophil: 29.9	Lineage enriched	Detected in many	9	granulocytes: 38.1	Low region specificity	Detected in all			Low region specificity	Detected in single			HPA007853	Approved		Approved	"Plasma membrane,Cytosol"		170000	170000	"Plasma membrane, Cytosol"		HPA007853: AB_1858463	unprognostic (1.44e-1)	unprognostic (2.46e-3)	unprognostic (8.90e-2)	unprognostic (2.60e-1)	unprognostic (4.06e-3)	prognostic unfavourable (5.50e-4)	unprognostic (7.04e-3)	unprognostic (1.98e-3)	unprognostic (4.17e-3)	unprognostic (2.85e-1)	unprognostic (5.02e-3)	unprognostic (3.88e-1)	prognostic unfavourable (8.78e-4)	unprognostic (2.98e-2)	unprognostic (6.00e-2)	unprognostic (2.80e-3)	unprognostic (2.17e-2)	10.8	14.2	2.4	11.3	5.1	2.7	21.2	0.9	3	8	18.9	3.2	4.1	14.5	11.6	10.2	10.7	6.4	28.1	27	5	2.6	50.4	36.2	23	2.6	4.8	0.5	6.4	47	51.1	20	81.3	25	11.1	1.9	2.8	17.3	6.9	23.3	5	31	16.8	4.3	3.9	13.2	5.3	3.3	1.2	11.5	11.5	4.7	14.8	5.2	0	4.1	38.1	3.5	2	2.4	1.1	24.3	19.8	2.2	4.1	4	9.2	13.1	51.3	37.2	44	28.3	8.5	43.5	0.1	68	34.1	27	0.5	37.5	16.9	0.9	1.3	0.1	6.6	7.2	27.8	0.4	1.8	8.5	26	46.2	55.4	12.7	2.7	0.3	46.3	46	0	3.2	10.7	43.4	0.2	24.7	1	44.5	4.8	2.5	0.8	36.6	17	30.3	8.9	0.7	22.3	79.3	36.6	52.4	84.2	0.8	0.3	0.3	24.7	2.2	62.3	3.5	3.5	38.1	1.8	2	2.4	0	0.8	1.5	4.1	0	0.4	0.8	29.9	2	1.3	0.1	1	1.1	2.4	5.1	0.9	3	5	2.6	4.8	0.5	25	3.3
TNFRSF13B	"CD267, IGAD2, TACI"	ENSG00000240505	TNF receptor superfamily member 13B	O14836	17	16929816-16972118	"CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor	Disease mutation	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in some		blood: 45.1;lymphoid tissue: 44.6;skeletal muscle: 30.5	Group enriched	Detected in some	8	Karpas-707: 54.6;RPMI-8226: 34.3;U-266/70: 24.3	Not detected	Not detected			Not detected	Not detected			Group enriched	Detected in some	42	memory B-cell: 45.1;naive B-cell: 13.1	Lineage enriched	Detected in single	65	B-cells: 45.1					Low region specificity	Detected in all			HPA030453	Uncertain									HPA030453: AB_10601700	unprognostic (3.94e-5)	unprognostic (1.11e-3)	unprognostic (4.88e-2)	unprognostic (4.30e-3)		unprognostic (1.23e-4)	unprognostic (2.16e-1)	unprognostic (1.62e-3)	unprognostic (1.47e-2)	unprognostic (1.61e-4)	unprognostic (2.22e-1)	unprognostic (9.78e-2)	unprognostic (1.59e-5)	unprognostic (1.20e-1)	unprognostic (4.49e-1)	unprognostic (1.39e-1)	unprognostic (2.05e-1)	0.5	0.3	0.4	17.6	0.3	0.2	0.5	0.2	0.3	0.7	3	0.1	0	1.9	0.3	0	2.7	0.5	0.5	2.5	0.3	0.3	0.6	0.5	1.2	12.5	0.3	0.2	0.3	0.3	0	0.3	0	0.1	0.9	1.2	0.6	9	1.1	30.5	0.3	14.8	0	0.4	44.6	2.4	0.3	0.1	0.9	0.6	0.9	37.8	2.3	0.4	45.1	0	0.1	0	0	0.6	0.9	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	54.6	0	0	0	0	0	0	0.1	0	34.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	24.3	0	4.6	0.1	0	0	0	0	0	0	0	0	45.1	0	0	0	13.1	0	0	0.1	0	0	0	0.6	0.9	0.4	0.3	0.2	0.3	0.3	0.3	0.3	0.2	0.1	0.1
TNFRSF13C	"BAFFR, CD268"	ENSG00000159958	TNF receptor superfamily member 13C	Q96RJ3	22	41922023-41926818	"CD markers, Disease related genes, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor	Disease mutation	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in some		blood: 20.3;intestine: 18.9;lymphoid tissue: 69.1	Group enriched	Detected in some	6	REH: 19.9;U-698: 10.8	Low cancer specificity	Detected in many			Low region specificity	Detected in many			Group enriched	Detected in some	51	memory B-cell: 14.5;naive B-cell: 20.3	Lineage enriched	Detected in single	59	B-cells: 20.3	Low region specificity	Detected in some			Low region specificity	Detected in all			"HPA003246, CAB008380"	Enhanced									"CAB008380: AB_590602, HPA003246: AB_1078264"	unprognostic (3.43e-4)	prognostic favourable (4.44e-7)	unprognostic (6.52e-2)	unprognostic (9.10e-2)	unprognostic (7.64e-3)	unprognostic (4.83e-3)	unprognostic (2.89e-2)	unprognostic (3.78e-3)	unprognostic (1.95e-1)	unprognostic (1.27e-1)	unprognostic (2.51e-2)	unprognostic (1.66e-1)	unprognostic (4.79e-8)	unprognostic (2.21e-1)	unprognostic (1.89e-1)	unprognostic (1.77e-1)	unprognostic (9.44e-2)	0.9	0.8	0.8	41	1	3.3	0.6	1	2	0.5	1.2	4.4	0	0.7	0.4	0.2	5	0.5	0.6	0.6	0.8	0.9	0.9	0.5	1.8	48.4	1	0.6	0.4	0.4	0	0.4	0.1	1.8	0.6	0.7	0.5	5.8	0	1.2	2	18.9	0.1	1.1	69.1	1.4	0.7	0.6	2	0.8	0.3	51.4	9.5	0.7	20.3	0.2	0.3	0.2	0.2	0.2	0.5	0.3	0.2	1.1	2.3	0	0	0.5	0.1	0.1	0.2	0.8	0.9	0.5	1.8	0.4	0.2	0.3	0.6	0	0.3	0.4	2.2	0.2	0.3	0.2	0.1	1.6	0.4	0.1	0	0.4	0.1	0	0.4	1.8	0.2	0.7	1.5	1.7	0.7	0.1	19.9	2.4	1.5	0	0.2	1.2	0.3	0.1	0.4	0.3	0.4	2.2	0.2	0.5	2.6	0.9	0.3	2.1	1	10.8	0.1	1.7	0.5	0.3	0.1	0.1	0.1	0.1	0.2	14.5	0.2	0.1	0	20.3	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.5	0.8	1	1	2	0.8	0.9	1	0.6	1.8	0.6
TNFRSF14	"ATAR, CD270, HVEA, HVEM, LIGHTR, TR2"	ENSG00000157873	TNF receptor superfamily member 14	Q92956	1	2555639-2565382	"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Host-virus interaction, Immunity, Innate immunity"	"Host cell receptor for virus entry, Receptor"	Cancer-related genes	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Cell line enhanced	Detected in many		CAPAN-2: 14.3;HDLM-2: 14.4;HHSteC: 16.9;Karpas-707: 13.3;SK-MEL-30: 27.9	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Low cell type specificity	Detected in all			Low lineage specificity	Detected in all											"HPA006404, CAB026150, CAB030007"	Approved		Approved	"Cytosol,Rods & Rings"				Cytosol	Rods & Rings	"CAB026150: , CAB030007: AB_2303380, HPA006404: AB_1851348"	prognostic favourable (4.39e-5)	unprognostic (3.48e-2)	unprognostic (1.53e-2)	prognostic favourable (8.01e-6)	unprognostic (1.11e-2)	unprognostic (6.83e-3)	unprognostic (9.62e-3)	unprognostic (2.32e-1)	unprognostic (3.25e-1)	unprognostic (1.62e-1)	unprognostic (2.31e-1)	unprognostic (1.64e-1)	unprognostic (1.86e-2)	unprognostic (1.16e-2)	unprognostic (2.72e-2)	unprognostic (1.58e-1)	prognostic favourable (7.79e-6)	15.9	24.9	4.9	38.9	2.8	11	21.9	2	4.5	16.8	36.3	3.2	18.5	36.3	15.2	20.5	13.7	12.3	36.7	12.7	4.9	2.5	19.3	20.5	30.3	33.2	3.6	5.7	12.8	7.3	3.5	9.3	8.3	3.9	21.5	8.2	44.1	20.9	22.6	5.2	8.4	41.9	14.6	4.1	36.7	16.7	5.9	2.7	23.5	10.8	10.6	25	15.4	17.2	18.2	9.7	30.2	25.8	8.1	25.1	14.2	1.3	0.1	0.1	2.3	5	2.7	0.7	0.7	2.3	1.3	1.9	0.2	14.3	0.8	0.1	2.1	1.3	0	0.8	0.2	14.4	0	8.4	0.4	2.6	16.9	1.1	10.4	2.6	1.4	0.7	0.1	3.7	1.1	13.3	1.2	0	4.6	1.3	0	1.2	3.8	0	4.1	0.2	2	0.4	0	0.5	0.1	27.9	0.4	0.3	9.4	0.2	0.6	0.2	0.1	10.8	2.6	0.4	2.3	1.2	1	3	15.1	8.2	17.2	25.8	14.9	16.6	18	14.8	9.7	18.2	17.3	14.9	30.2	8.1	24.1	8.7	25.1	14.2	4.9	2.8	2	4.5	4.9	2.5	3.6	5.7	3.9	2.7
TNFRSF17	"BCM, BCMA, CD269, TNFRSF13A"	ENSG00000048462	TNF receptor superfamily member 17	Q02223	16	11965107-11968068	"Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor	"Cancer-related genes, Proto-oncogene"	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 34.1;intestine: 17.8;lymphoid tissue: 28.8	Cell line enhanced	Detected in some		Karpas-707: 25.3;RPMI-8226: 39.9;U-266/70: 118.6;U-266/84: 58.9	Low cancer specificity	Detected in many			Not detected	Not detected			Group enriched	Detected in some	59	memory B-cell: 34.1;naive B-cell: 26.9;plasmacytoid DC: 27.9	Group enriched	Detected in many	62	B-cells: 34.1;dendritic cells: 27.9	Low region specificity	Detected in many			Low region specificity	Detected in all									2200000	2200000				prognostic favourable (1.35e-5)	unprognostic (3.41e-2)	unprognostic (4.00e-3)	unprognostic (1.41e-2)	unprognostic (6.47e-2)	prognostic favourable (1.58e-6)	unprognostic (9.75e-3)	unprognostic (5.93e-2)	unprognostic (2.13e-2)	unprognostic (7.96e-3)	unprognostic (2.46e-1)	unprognostic (2.58e-1)	unprognostic (2.85e-6)	unprognostic (2.06e-1)	unprognostic (2.48e-1)	unprognostic (3.54e-2)	unprognostic (1.10e-1)	0.6	0.4	0.4	24	0.9	0.3	5.4	0.5	0.4	1.5	17.8	0.2	0.2	12.3	0.5	0.2	3.7	1.1	4.9	0.7	0.4	0.4	1.3	0.8	3	22.4	0.4	0.2	0.9	3.1	0	0.5	0.3	0.2	1	9.4	0.6	14.2	0.2	0.4	0.4	11.7	0.2	0.4	22.2	9.4	2.2	0.3	3.1	1.1	1.4	28.8	7.6	0.7	34.1	27.9	0.5	0.1	0.2	0.1	3.7	0.1	0	0	0	0	0	0	0	0.1	0	0	0	0	6.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	25.3	0	0	0	0	0	0	0	0	39.9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	118.6	58.9	9.2	0.1	0	0	0.2	0.1	0	0	0	0.1	34.1	0	0	0	26.9	0	0	0.5	0.2	0	27.9	0	3.7	0.4	0.9	0.5	0.4	0.4	0.4	0.4	0.2	0.2	0.3
TNFRSF18	"AITR, CD357, GITR"	ENSG00000186891	TNF receptor superfamily member 18	Q9Y5U5	1	1203508-1206691	"CD markers, Predicted membrane proteins, Predicted secreted proteins"	Apoptosis	Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 46.6;skin 1: 28.9	Group enriched	Detected in some	11	RPMI-8226: 61.2;SCLC-21H: 43.9	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Cell type enhanced	Detected in many		NK-cell: 46.6	Group enriched	Detected in many	11	NK-cells: 46.6;T-cells: 19.0									HPA008025	Approved				Secreted to blood					HPA008025: AB_1849696	unprognostic (1.20e-3)	unprognostic (4.61e-2)	unprognostic (4.59e-2)	prognostic favourable (7.72e-6)	unprognostic (2.73e-4)	prognostic favourable (4.12e-4)	unprognostic (3.43e-2)	unprognostic (2.31e-1)	unprognostic (3.33e-2)	unprognostic (1.01e-1)	unprognostic (1.00e-1)	unprognostic (1.20e-1)	prognostic unfavourable (4.40e-11)	unprognostic (1.02e-3)	unprognostic (2.39e-1)	unprognostic (3.74e-1)	unprognostic (2.08e-1)	1.4	0.5	1	8.9	1	1.9	4.2	4.9	2.5	14.3	8.3	0.3	0.1	5.7	2.1	1.1	4.7	1	3.7	0.2	0.5	0.3	1.1	1.7	3	9.1	0.4	2.4	0.3	2.7	9.4	3.8	1.3	1.7	1.9	1.2	0.5	9	2.6	1	28.9	5	0.2	0.3	6.7	3.8	0.8	0.1	4.4	0.9	2.7	8.2	1.5	2.2	2.9	0	0.2	0	46.6	19	2.1	0	0	0	0	0	0	0	0	0	0	0	0	0.6	0	0.5	0	0.1	0	0	0	0.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0.3	0	4.6	0	0	61.2	0	0	43.9	0	0	0.1	0	2.3	0	0	0	0.1	0	0	0.2	0.1	0	0.2	0	0	0	0	0	2	0	3.6	1.3	8.5	1.2	0	2.9	0.3	0.4	0.2	46.6	0	0	19	2.1	1	1	4.9	2.5	0.5	0.3	0.4	2.4	1.7	0.1
TNFRSF1A	"CD120a, TNF-R, TNF-R-I, TNF-R55, TNFAR, TNFR1, TNFR60"	ENSG00000067182	TNF receptor superfamily member 1A	P19438	12	6328757-6342114	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"	"Apoptosis, Host-virus interaction"	Receptor	"Amyloidosis, Cancer-related genes, Disease mutation, FDA approved drug targets"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Low tissue specificity	Detected in all			Low cell line specificity	Detected in many			Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in many		neutrophil: 86.5	Low lineage specificity	Detected in many			Low region specificity	Detected in all			Low region specificity	Detected in all			"HPA004102, CAB010309"	Approved				Secreted to blood	170000	170000			"CAB010309: AB_2206639, HPA004102: AB_1846232"	unprognostic (2.19e-2)	unprognostic (3.76e-2)	unprognostic (8.14e-2)	prognostic favourable (8.22e-4)	unprognostic (3.07e-2)	prognostic unfavourable (3.68e-4)	unprognostic (1.50e-1)	unprognostic (1.41e-3)	unprognostic (1.00e-1)	unprognostic (8.05e-2)	unprognostic (4.78e-2)	unprognostic (1.54e-2)	prognostic unfavourable (2.70e-7)	unprognostic (1.43e-2)	unprognostic (2.92e-2)	unprognostic (5.14e-3)	unprognostic (1.74e-1)	55.1	43.9	16.8	28.9	16.8	13.7	40.6	7.2	15.6	40.3	41.5	14.1	22.6	39.2	38.2	27.5	39.4	34.2	37.1	26.8	14	7.5	49.3	61.6	40.9	37.2	19.2	6.4	59.5	21.4	20.3	19.9	45.3	18.3	37	23	31.1	25.7	22.2	34.2	30.9	81.7	38.8	25.1	43.6	28.2	21.8	15.7	31.6	42.7	25.4	22.3	49.1	58.5	0	20.8	86.5	27.1	1.8	11.6	15.9	7.4	57.8	8.1	11.5	56	57.3	15.3	15.9	27.5	21.3	18.6	6.9	29.7	0.6	5.5	34.3	20.8	2.5	18.6	14.8	0.1	4.8	4.1	16	15.3	49.7	19.3	13	59	18.7	17.7	26.1	26	6.2	5.7	24.5	10.6	6.1	18.2	19.7	16.9	5.3	12.9	5.7	16.5	13.5	0	0.4	22.5	11.8	11.8	3.2	21.1	28.3	16.8	14.4	12.6	14.7	0	1.8	2.4	20.1	18	20.8	2.2	27.1	15	11.6	21.8	11.1	0	4.9	9.5	20.8	0	4.5	6.6	86.5	1.8	17.5	6	4.8	15.9	16.8	16.8	7.2	15.6	14	7.5	19.2	6.4	18.3	15.7
TNFRSF1B	"CD120b, p75, TNF-R-II, TNF-R75, TNFBR, TNFR2, TNFR80"	ENSG00000028137	TNF receptor superfamily member 1B	P20333	1	12167003-12209228	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"	Apoptosis	Receptor	Cancer-related genes	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		blood: 70.1	Cell line enhanced	Detected in many		CAPAN-2: 17.1;K-562: 20.9;THP-1: 24.5;U-87 MG: 16.8;U-937: 17.7	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in many		non-classical monocyte: 70.1	Low lineage specificity	Detected in all			Low region specificity	Detected in many			Low region specificity	Detected in all			HPA004796	Approved				Secreted to blood	2500000	2500000			HPA004796: AB_1078436	unprognostic (4.45e-2)	unprognostic (2.27e-3)	unprognostic (7.62e-2)	unprognostic (3.82e-3)	unprognostic (6.30e-2)	unprognostic (4.47e-3)	unprognostic (5.28e-3)	unprognostic (2.79e-1)	unprognostic (1.69e-2)	unprognostic (1.73e-2)	unprognostic (7.26e-2)	unprognostic (2.48e-1)	prognostic unfavourable (8.35e-5)	unprognostic (2.02e-1)	prognostic unfavourable (8.68e-4)	unprognostic (3.26e-2)	unprognostic (1.10e-1)	43.4	4.7	4.6	44.3	13.8	29.2	42.3	2.1	6.1	13.3	13.1	6.6	1.9	11.9	9.7	10.2	6.5	11.3	11.6	21.8	8.5	6.2	6.2	22.2	24.5	60.6	9.1	2.2	9.4	4.2	2.3	4.4	24.9	15	7.3	8.2	8.3	5.7	3.7	11.5	6.2	17.3	11.5	22.6	48.3	10.5	6	6.1	10.9	6.2	5.6	16.2	18.3	8.4	2.7	13.2	25.7	70.1	2.5	12.7	19.9	0	0.1	2	0	5.5	7.5	4.3	0.5	1	2	2.2	0.8	17.1	0.1	0.3	1.8	0	0.4	0	1.1	6.8	0	0	0.1	0	12.9	0.1	1.8	7.4	0	6.8	0	10.4	20.9	3.1	0.9	0	0	3.9	0.1	0.6	0.5	0.2	12	0	0.4	0	0	0.3	0.1	0.6	0	24.5	3.6	3	0.1	13	0	0.9	0	0	16.8	17.7	0.7	0	20.7	3	9.4	49.3	5.4	2.7	6.6	7.7	13.2	1.7	2	3	25.7	2.5	70.1	2.8	12.7	19.9	4.6	13.8	2.1	6.1	8.5	6.2	9.1	2.2	15	6.1
TNFRSF21	"CD358, DR6"	ENSG00000146072	TNF receptor superfamily member 21	O75509	6	47231532-47309905	"CD markers, Plasma proteins, Predicted membrane proteins"	"Adaptive immunity, Apoptosis, Immunity"	Receptor		Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		brain: 63.4	Cell line enhanced	Detected in many		RT4: 102.3	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enriched	Detected in single	35	plasmacytoid DC: 31.6	Lineage enriched	Detected in single	309	dendritic cells: 31.6	Low region specificity	Detected in all			Low region specificity	Detected in all			"HPA006746, CAB009805"	Approved		Supported	"Plasma membrane,Cytosol"		1300000	1300000	"Plasma membrane, Cytosol"		"CAB009805: AB_2206956, HPA006746: AB_1078701"	unprognostic (1.19e-2)	unprognostic (2.70e-1)	unprognostic (3.26e-1)	unprognostic (7.85e-2)	unprognostic (1.44e-1)	unprognostic (3.41e-2)	unprognostic (9.80e-3)	unprognostic (1.11e-1)	unprognostic (1.46e-2)	unprognostic (7.53e-2)	unprognostic (1.38e-3)	unprognostic (1.74e-1)	prognostic favourable (7.23e-6)	unprognostic (1.48e-1)	unprognostic (1.34e-1)	unprognostic (9.78e-2)	unprognostic (1.45e-2)	25.9	3.7	9.7	8.7	13.6	5.9	7.8	7.4	20.8	9.6	19.3	26.9	1	6.4	9.1	3	21.8	9.9	18.7	4.1	13.8	16	26.2	4.6	9.5	11.5	26.8	7.9	5	17.9	35.6	4.4	17	29.5	10.2	18.5	3	15.2	2.4	3.5	2.7	10.2	8.2	63.4	11.6	30.4	5.8	10.1	11.5	2.9	19.2	16.5	41.2	11.6	0	31.6	0.1	0	0	0	0.2	29.9	9.7	9.5	3	26.1	7.7	10.8	3.5	6.9	1.1	0.4	16.8	21.2	2.2	14.2	2.5	18.1	1.4	12.9	0.6	0	2.9	0	1.2	16.9	15.3	0.4	0.1	13.7	15.5	0.6	11.8	5.1	0.7	0	0.3	5.9	2.6	0.2	7.4	10.1	5.6	2.9	3.2	18.1	102.3	6.8	1.5	3	2.8	2.4	2.2	2.1	1	2.8	2.6	0.1	3.2	0	0	3.1	4.7	2.1	7.9	0	0	0.1	0	0	0	0	0	0	0.8	0	0	0	0	0	0	31.6	0	0.2	9.7	13.6	7.4	20.8	13.8	16	26.8	7.9	29.5	10.1
TNFRSF4	"ACT35, CD134, OX40, TXGP1L"	ENSG00000186827	TNF receptor superfamily member 4	P43489	1	1211326-1214138	"Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins"	Host-virus interaction	"Host cell receptor for virus entry, Receptor"	"Cancer-related genes, Disease mutation"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		adipose tissue: 12.5;blood: 18.4;lymphoid tissue: 13.6	Group enriched	Detected in some	9	MOLT-4: 7.8;NB-4: 15.1	Low cancer specificity	Detected in all			Low region specificity	Detected in single			Cell type enhanced	Detected in many		memory CD4 T-cell: 15.9;T-reg: 18.4	Low lineage specificity	Detected in many			Low region specificity	Detected in many			Not detected	Not detected			CAB016128	Enhanced									CAB016128: AB_626897	unprognostic (2.24e-1)	unprognostic (8.69e-3)	unprognostic (1.36e-1)	unprognostic (8.55e-3)	unprognostic (1.02e-1)	prognostic favourable (3.50e-6)	prognostic unfavourable (6.03e-4)	unprognostic (3.30e-1)	unprognostic (1.48e-2)	unprognostic (7.04e-3)	unprognostic (1.04e-2)	unprognostic (1.47e-1)	prognostic unfavourable (4.52e-6)	unprognostic (1.61e-1)	unprognostic (5.46e-2)	unprognostic (2.42e-1)	unprognostic (5.91e-2)	12.5	0.2	0.6	8.8	0.4	0.7	7.3	0.3	1.2	1.1	3.1	0.3	0.3	2.6	0.8	0.7	1.7	0.9	0.8	6.7	0.8	0.1	2.2	0.4	5.3	8.4	0.3	0.6	0.5	0.9	0	1.3	5.9	0.6	3.2	0.3	0.6	2.2	1.1	4.4	0.8	4.3	0.3	0.3	13.5	3.5	2	0.3	13.6	4.1	0.8	10.9	1.4	0.7	0	0.6	4.1	0	8.1	18.4	1.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	1.2	0	0	0	0	0	0	0	0	0	7.8	15.1	0	0	0	0.5	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0.1	0	0	0	0	0	0	0	4.1	0	0.1	0.2	0	1.8	0	15.9	1.7	0	0	1.5	0	0.2	8.1	0	0.6	18.4	1.5	0.6	0.4	0.3	1.2	0.8	0.1	0.3	0.6	0.6	0.3
TNFRSF8	"CD30, D1S166E, KI-1"	ENSG00000120949	TNF receptor superfamily member 8	P28908	1	12063377-12144207	"Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Cancer-related genes, FDA approved drug targets"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 33.3	Cell line enriched	Detected in some	21	HDLM-2: 109.9	Cancer enriched	Detected in some	12	testis cancer: 9.3	Region enriched	Detected in single	14	basal ganglia: 13.1	Cell type enhanced	Detected in some		intermediate monocyte: 21.7;non-classical monocyte: 33.3	Lineage enriched	Detected in many	5	monocytes: 33.3					Low region specificity	Detected in many			"CAB000016, HPA014823, HPA032081, HPA032082"	Approved		Supported	Plasma membrane				Plasma membrane		"CAB000016: AB_563546, HPA014823: , HPA032081: , HPA032082: "	unprognostic (1.07e-2)	unprognostic (2.06e-2)	unprognostic (2.52e-2)	unprognostic (5.98e-2)	unprognostic (2.50e-1)	unprognostic (1.46e-3)	unprognostic (2.19e-1)	unprognostic (3.93e-2)	unprognostic (1.18e-1)	unprognostic (9.18e-3)	unprognostic (1.86e-1)	unprognostic (2.06e-1)	unprognostic (3.17e-8)	unprognostic (3.31e-1)	unprognostic (8.56e-2)	unprognostic (2.07e-1)	unprognostic (2.31e-2)	10.7	0.2	0.1	7.2	13.1	1.4	5.8	0.2	0.4	1.1	0.8	0	1.5	0.2	1.7	1.3	0.9	2.1	1.4	3.8	0.1	0.2	0.9	0.2	3.9	2.9	0.5	0.5	1.2	0.4	0	0.1	6.2	0.5	1	0.5	0	0.7	0.3	3.1	1.6	1.3	1.3	1.4	2.9	6.4	2.5	0.9	3	0.7	2.7	5.3	2.6	3.8	0	3.2	6.8	33.3	0	0.3	2.7	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0.1	2.4	0	0	0	0	0	109.9	0	0	0	0	0	2	0	0	0	0.3	0	0	5.1	0.3	0	0	0.2	0	4.4	0	0	0	1.7	0	0	0	0	0	0	0	0	0	0	0	0.3	0.2	0	0	0	0	0	0	0	0	6.5	0.3	0	21.7	0.1	0	0	0	3.2	0	0	0	6.8	0	33.3	0.8	0.3	2.7	0.1	13.1	0.2	0.4	0.1	0.2	0.5	0.5	0.5	0.9
TNFRSF9	"4-1BB, CD137, ILA"	ENSG00000049249	TNF receptor superfamily member 9	Q07011	1	7915894-7943165	"Cancer-related genes, CD markers, Predicted membrane proteins"		Receptor	Cancer-related genes	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in some	7	blood: 13.5;lymphoid tissue: 18.3	Cell line enriched	Detected in some	8	HDLM-2: 45.9	Low cancer specificity	Detected in many			Low region specificity	Detected in single			Group enriched	Detected in many	5	memory CD8 T-cell: 8.0;neutrophil: 6.6;NK-cell: 4.1;T-reg: 13.5	Group enriched	Detected in many	5	granulocytes: 6.6;NK-cells: 4.1;T-cells: 13.5	Low region specificity	Detected in some			Low region specificity	Detected in all			HPA071425			Approved	"Nucleoli,Plasma membrane"				Plasma membrane	Nucleoli	HPA071425: 	unprognostic (7.23e-2)	unprognostic (1.72e-2)	unprognostic (8.26e-3)	unprognostic (1.32e-3)	unprognostic (1.10e-1)	unprognostic (1.98e-2)	unprognostic (2.52e-1)	unprognostic (1.04e-1)	unprognostic (1.19e-4)	unprognostic (9.47e-3)	unprognostic (2.17e-2)	unprognostic (2.02e-1)	prognostic unfavourable (2.69e-8)	unprognostic (1.64e-2)	unprognostic (2.25e-2)	unprognostic (1.19e-1)	unprognostic (9.55e-2)	0.8	1	0.3	11	0.3	1.9	0.5	0.2	0.3	0.4	0.5	0.1	0.1	0.6	0.3	0.1	0.6	0.8	1.6	1.8	0.3	1	0.7	0.7	2.1	10.8	0.3	0.1	0.3	0.6	0	0.5	0.2	0.5	0.4	0.7	0.3	2.1	0.1	0.3	0.5	2.3	0.1	0.3	7.9	0.7	0.5	0.1	18.3	0.7	0.9	17.5	1.4	0.4	0.5	1.1	6.6	1.5	4.1	13.5	1.1	1.2	0.4	0.1	0.1	0	0	0	0.1	0.1	0.1	0.1	0.9	0.3	0.1	0.4	0	0.1	0	0.2	0.4	45.9	0.1	0.2	0.2	0	0.9	0	0.5	0.1	0.3	0.1	0.1	0	0.2	0.1	0	0.1	0	0.2	0.1	0	0	0.2	0.1	0.2	0.1	0.1	0.1	0.2	0.1	0	0	0.2	0.2	0.2	1.5	0.1	0.2	0.1	0.1	0.1	5.7	0.2	0	1.1	1.5	0.2	1.5	0.4	0.2	0.2	1	8	1.1	0.5	0.3	1.6	6.6	4.1	0.1	0.3	13.5	1.1	0.3	0.3	0.2	0.3	0.3	1	0.3	0.1	0.5	0.1
TNFSF10	"Apo-2L, CD253, TL2, TRAIL"	ENSG00000121858	TNF superfamily member 10	P50591	3	172505508-172523507	"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	Apoptosis	Cytokine	Cancer-related genes	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		kidney: 115.1	Cell line enhanced	Detected in many		BEWO: 20.5;CAPAN-2: 14.6;HMC-1: 67.6;RPTEC TERT1: 34.1	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Group enriched	Detected in many	4	basophil: 42.4;classical monocyte: 25.6;intermediate monocyte: 39.5;neutrophil: 50.3;non-classical monocyte: 38.3	Group enriched	Detected in all	5	granulocytes: 50.3;monocytes: 39.5	Low region specificity	Detected in all			Low region specificity	Detected in all			HPA054938	Uncertain		Approved	Microtubules	Secreted to blood			Microtubules		HPA054938: 	unprognostic (9.16e-2)	unprognostic (2.79e-2)	unprognostic (1.08e-1)	unprognostic (4.69e-3)	unprognostic (2.52e-1)	unprognostic (2.67e-1)	unprognostic (1.55e-1)	unprognostic (2.01e-1)	unprognostic (1.99e-1)	unprognostic (1.71e-2)	prognostic unfavourable (9.43e-4)	unprognostic (1.04e-1)	unprognostic (1.04e-1)	unprognostic (1.29e-1)	unprognostic (3.68e-2)	unprognostic (1.32e-1)	unprognostic (6.27e-2)	30.9	22.1	3.4	14.6	4.7	2	23.3	3	5.4	31.4	25.8	4.4	17.1	20.6	13	10.3	33.3	9.6	10.7	9.9	3.8	3.2	115.1	44.4	91.5	23.5	5.5	3.4	13.5	11.6	10.9	6.7	100.8	6.7	37.6	19.5	12	50.6	12.9	13.9	13	54	7.9	5.6	35.8	9.5	6	4.6	8.3	28.2	17.7	16.1	22.4	24	3.4	9.5	50.3	39.5	9.3	7	11.9	3.3	0.1	0	0	2.4	1.8	20.5	0	0.1	1	1.6	0	14.6	2.1	9.8	0	14.4	0	1.8	0.2	5.2	0	0	0.4	0.3	0.1	3.8	67.6	2.4	2.3	0.4	0	7.4	0	2.4	0	0	0.4	5.1	0	0.1	0.7	0	0.9	34.1	1.3	0	0.1	7.5	0.3	0.1	4.1	2.2	0.3	0	0	0	0.2	2.6	0.3	2.6	0.2	2.2	0	42.4	25.6	2.7	2.3	39.5	3.1	3.2	6.4	3.5	9.5	3.4	4.7	1.8	50.3	9.3	38.3	0.6	7	11.9	3.4	4.7	3	5.4	3.8	3.2	5.5	3.4	6.7	4.6
TNFSF11	"CD254, ODF, OPGL, RANKL, TRANCE"	ENSG00000120659	TNF superfamily member 11	O14788	13	42562736-42608013	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	Differentiation	"Cytokine, Developmental protein, Receptor"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Osteopetrosis"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in some		blood: 14.3;lymphoid tissue: 19.8	Cell line enhanced	Detected in some		Daudi: 1.7;HSkMC: 5.2;NTERA-2: 7.4	Low cancer specificity	Detected in many			Not detected	Not detected			Cell type enriched	Detected in some	8	NK-cell: 14.3	Lineage enriched	Detected in many	8	NK-cells: 14.3	Not detected	Not detected			Low region specificity	Detected in all			"CAB009193, HPA045142"	Enhanced				Secreted to blood					"CAB009193: , HPA045142: "	unprognostic (3.97e-4)	unprognostic (1.40e-1)	unprognostic (9.01e-3)	unprognostic (3.81e-3)	unprognostic (1.12e-1)	unprognostic (1.09e-1)	unprognostic (7.09e-2)	unprognostic (7.70e-2)	unprognostic (2.29e-1)	unprognostic (1.25e-3)	unprognostic (1.00e-1)	unprognostic (1.50e-1)	unprognostic (3.94e-5)	unprognostic (1.87e-1)	unprognostic (9.67e-2)	unprognostic (5.46e-2)	unprognostic (7.74e-2)	0.5	0.2	0.2	19.5	0.2	0	4.6	0.1	0.2	0.8	0.8	0.1	2.4	0.2	0.2	0.1	3.7	0.2	1.3	0.3	0.1	0.7	0.6	5.3	0.4	19.8	0.1	0.1	0.1	0.6	0	0.3	0.3	0.4	0.5	2.2	0.1	1.6	1	0.2	0.5	6	0.1	0.1	0.8	0.3	3.3	0.1	2.8	0.4	0.1	5.2	2.3	0.7	0	0.1	1.8	0	14.3	0.1	0.1	0	0.3	0	0.1	0	0.2	0	0	0	0	0	0	0.4	1.7	0	0	0.2	0	0.2	0	0.1	0	0.1	0.5	0	0.6	0	0.1	5.2	0.5	0	0	0.6	0	0	0	0	0	0.2	7.4	0.1	0	0.2	0	0	0.1	0.1	0.2	0	0	0	0	0.7	0.1	0.1	0	0	0	0	0	0	0	0	0.1	1.8	0	0	0	0	0	0	0.1	0.1	0.1	0	0	0	0	14.3	0	0	0	0.1	0.2	0.2	0.1	0.2	0.1	0.7	0.1	0.1	0.4	0.1
TNFSF13	"APRIL, CD256"	ENSG00000161955	TNF superfamily member 13	O75888	17	7558292-7561608	"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	Immunity	Cytokine	Cancer-related genes	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in all		salivary gland: 102.8	Cell line enhanced	Detected in many		EFO-21: 18.4;RPTEC TERT1: 46.5;U-937: 17.8	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Group enriched	Detected in many	5	classical monocyte: 63.5;eosinophil: 22.8;intermediate monocyte: 62.7;myeloid DC: 43.0;non-classical monocyte: 37.3;plasmacytoid DC: 19.8	Group enriched	Detected in many	10	dendritic cells: 43.0;granulocytes: 22.8;monocytes: 63.5	Low region specificity	Detected in many			Low region specificity	Detected in all			HPA004863	Uncertain				Secreted to blood	29000	29000			HPA004863: AB_1078187	unprognostic (2.46e-2)	unprognostic (2.20e-1)	unprognostic (3.42e-1)	unprognostic (6.53e-2)	prognostic unfavourable (9.73e-4)	unprognostic (3.57e-1)	unprognostic (3.32e-2)	unprognostic (3.70e-2)	unprognostic (3.75e-1)	unprognostic (1.15e-1)	unprognostic (6.95e-2)	unprognostic (2.65e-1)	prognostic favourable (1.30e-9)	unprognostic (4.69e-2)	unprognostic (1.42e-2)	unprognostic (3.46e-1)	unprognostic (3.38e-2)	12.1	14.4	18.7	15.4	24.2	18.3	12.9	5.7	15.3	15.7	20.4	8.7	27.4	32	7.7	12.8	6.1	14.4	29.1	9.5	11.1	10.7	34.1	11.9	43	39	14.3	9.4	14	20.7	5.7	10.8	6.4	31.6	13.7	18.7	22	102.8	69.4	3	5.3	18.5	10.9	13.1	16.2	23.4	5	9	3.3	14.1	8.2	11.5	10.4	8.4	4.1	43	22.8	63.5	1.3	0.4	30.6	8.3	3.4	1.1	2.3	1.3	0.7	1.4	1.5	1	0.6	0.5	1.8	5.2	3.7	18.4	1.5	5.3	0	1.5	0.6	6.5	2.9	2.3	7.5	3.9	2.8	2	2.4	1.5	1.4	0.4	2.4	1.9	1.8	1.4	0.5	1.2	0.9	6.6	1.1	2.5	6.6	1.4	15.8	46.5	5.5	2.1	2	2.9	7.8	1	10.4	5	1	2	2.4	0.9	3.2	0.3	1.1	0.9	0.8	17.8	3.9	9	63.5	22.8	0.1	62.7	0.1	2	0	0.1	43	4.1	0.4	0.2	8.6	1.3	37.3	19.8	0.1	30.6	18.7	24.2	5.7	15.3	11.1	10.7	14.3	9.4	31.6	9
TNFSF13B	"BAFF, BLYS, CD257, TALL-1, TALL1, THANK, TNFSF20"	ENSG00000102524	TNF superfamily member 13b	Q9Y275	13	108251240-108308484	"Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	Immunity	Cytokine	"Cancer-related genes, FDA approved drug targets"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in many	4	blood: 76.5;lymphoid tissue: 39.6	Cell line enriched	Detected in some	7	U-937: 59.5	Low cancer specificity	Detected in all			Low region specificity	Detected in all			Cell type enhanced	Detected in many		neutrophil: 76.5	Group enriched	Detected in many	10	dendritic cells: 31.0;granulocytes: 76.5;monocytes: 53.7	Low region specificity	Detected in many			Low region specificity	Detected in many			CAB009188	Enhanced				Secreted to blood	530000	530000			CAB009188: 	unprognostic (6.48e-2)	unprognostic (3.05e-3)	unprognostic (1.38e-1)	unprognostic (1.90e-1)	unprognostic (2.61e-2)	unprognostic (7.99e-2)	unprognostic (8.19e-2)	unprognostic (1.37e-1)	unprognostic (1.63e-1)	unprognostic (1.02e-2)	unprognostic (2.64e-2)	unprognostic (1.21e-1)	prognostic unfavourable (2.53e-11)	unprognostic (1.23e-1)	unprognostic (4.14e-2)	unprognostic (1.88e-1)	unprognostic (1.25e-1)	7.2	8.2	3	18.5	8.2	13.2	3.4	1.4	5.2	1.6	4.2	2.1	1	7.8	1.2	6.5	3.5	2.9	9.4	9.4	5.7	2.9	3.1	5	13.2	39.6	7.2	2.6	2.9	2.7	0.5	2.1	6.4	5.7	3.7	6.4	2.6	5.4	1.8	1.6	1.6	6.8	3.5	11.6	23.5	3.4	1	4.9	7.2	5.1	1.7	12.7	8.5	3.8	1	31	76.5	53.7	0.6	5.3	20.8	0	0.1	0	0	0.2	0.3	0	0.1	0.3	0.2	0.7	0	0.6	0.1	0	0	0	0	0	0	4.1	0	0.3	0.1	0	0.1	3.5	0.1	0.7	0.1	0	0	0	0	0.2	0.4	0	0	1.8	0	0	0	0	0	0.2	0.1	0.4	0.1	0	0	0.1	0	7.9	0	0.1	0	0	0.1	3.7	0.1	0	3.8	59.5	0.6	1.2	53.7	14.4	0.8	39.8	5.3	0.6	3.5	0.7	31	1	1.7	0.5	76.5	0.6	31.7	11.5	2.8	20.8	3	8.2	1.4	5.2	5.7	2.9	7.2	2.6	5.7	4.9
TNFSF14	"CD258, HVEM-L, LIGHT, LTg"	ENSG00000125735	TNF superfamily member 14	O43557	19	6661253-6670588	"CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"		Cytokine		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 50.8;liver: 50.6	Cell line enhanced	Detected in some		HDLM-2: 21.1;NB-4: 4.7;THP-1: 3.3;U-937: 12.0	Cancer enhanced	Detected in many		liver cancer: 4.4	Low region specificity	Detected in many			Cell type enhanced	Detected in many		neutrophil: 50.8	Group enriched	Detected in many	5	granulocytes: 50.8;T-cells: 16.6	Not detected	Not detected			Low region specificity	Detected in all			HPA012700	Approved				Secreted to blood					HPA012700: AB_1852870	unprognostic (2.78e-3)	unprognostic (2.11e-1)	unprognostic (1.62e-1)	unprognostic (2.35e-3)	unprognostic (3.82e-4)	unprognostic (4.51e-2)	unprognostic (1.09e-1)	unprognostic (2.63e-1)	unprognostic (1.05e-2)	unprognostic (9.23e-2)	unprognostic (9.22e-2)	unprognostic (3.59e-1)	prognostic unfavourable (6.07e-13)	unprognostic (1.09e-1)	unprognostic (9.56e-3)	unprognostic (1.75e-1)	unprognostic (3.62e-2)	11.2	0.9	0.6	4.6	0.6	2.5	1.3	1.2	1.5	0.8	2.4	0.4	0.2	2.8	2.7	2.3	1.8	3.6	2	2.1	0.6	0.1	1	50.6	4.3	8.3	3.8	0.2	2.9	2.5	0	0.9	1.8	1.4	1.2	1.8	1.9	1.4	1.5	0.2	0.7	3.8	1.6	0.3	8.2	1.8	1.6	0.2	1.5	1.4	0.9	5.9	2.1	14.1	0.3	1.7	50.8	4.5	7.2	16.6	2.9	0	0.3	0	0.1	0	0	0.3	0	0	0	0	0	0	0	1.8	0	0.5	0	0	0	21.1	0	0.1	0.2	1.1	0	0.6	0.5	0.2	0	0.1	0	0	0.1	0.1	0	0	0.1	4.7	0	0	0	0	0	0	0	0	0	0.1	0	0	0.1	3.3	0	0.1	0	0	0.1	0.1	0	0	0.7	12	0	28.3	4.5	27.4	11.4	1	16.6	0.1	4.9	9.2	1.7	0.3	0.8	4.2	50.8	7.2	0.1	0.1	3.9	2.9	0.6	0.6	1.2	1.5	0.6	0.1	3.8	0.2	1.4	0.2
TNFSF4	"CD252, gp34, OX-40L, TXGP1"	ENSG00000117586	TNF superfamily member 4	P23510	1	173183734-173207313	"Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins"		Cytokine	"Cancer-related genes, Systemic lupus erythematosus"	Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		lymphoid tissue: 11.5;testis: 14.4	Cell line enhanced	Detected in some		fHDF/TERT166: 18.3;HHSteC: 7.9;HUVEC TERT2: 35.9;LHCN-M2: 29.9	Low cancer specificity	Detected in all			Low region specificity	Detected in many			Low cell type specificity	Detected in many			Low lineage specificity	Detected in many											HPA059579	Approved		Approved	"Nucleoplasm,Vesicles"				"Nucleoplasm, Vesicles"		HPA059579: 	unprognostic (1.88e-2)	unprognostic (1.20e-1)	unprognostic (4.58e-2)	unprognostic (2.74e-1)	unprognostic (1.73e-2)	unprognostic (1.74e-1)	unprognostic (1.13e-3)	unprognostic (2.13e-1)	unprognostic (8.65e-2)	unprognostic (5.17e-2)	unprognostic (1.26e-2)	unprognostic (1.18e-1)	unprognostic (1.11e-7)	unprognostic (3.73e-3)	unprognostic (2.66e-1)	unprognostic (9.49e-2)	unprognostic (2.98e-2)	2.1	4	1.7	8.2	2.3	0.9	3.7	4.5	3.4	1.7	1.8	1	0.8	0.3	1.5	1.5	1.6	1.4	2.1	2.1	3	2	1.5	1.6	2.5	11.5	1.9	0.8	2.7	2.1	1	3.3	1.2	1.2	2.8	2.5	1	0.8	1	0.8	0.3	2.5	1.6	1.9	9.7	1.4	14.4	1.2	9.3	0.8	0.8	3.7	1.6	1.6	1.3	2.6	1.7	0.2	3.4	1.2	6.5	0	0	0.2	0.5	1.2	6.5	0	1.8	0.4	0.1	0.1	0	0	0	0.3	18.3	0	0	0	0.1	0.3	0	0	0.2	0.7	7.9	0.1	0	2.8	0.1	0.9	0.1	35.9	0	0.2	29.9	0	0.3	0.1	0.1	0.3	0.8	0	0.2	0.3	0	0	0.3	0.1	0.1	0.3	0	0.3	0.3	0	0	0.1	0.1	0.4	0.5	0.1	0.1	3.3	1.9	0	0.2	0.3	1.1	0.1	0.8	1.1	0.7	0.9	0.8	1.3	1.2	1.1	1.7	3.4	0.1	2.6	0.9	6.5	1.7	2.3	4.5	3.4	3	2	1.9	0.8	1.2	1.2
TNFSF8	"CD153, CD30LG"	ENSG00000106952	TNF superfamily member 8	P32971	9	114893343-114930595	"Cancer-related genes, CD markers, Predicted membrane proteins"		Cytokine	Cancer-related genes	Evidence at protein level	Evidence at transcript level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 18.6;lymphoid tissue: 48.1	Group enriched	Detected in some	111	Daudi: 34.3;U-698: 28.1	Low cancer specificity	Detected in many			Low region specificity	Detected in many			Low cell type specificity	Detected in many			Low lineage specificity	Detected in all			Not detected	Not detected			Low region specificity	Detected in many														unprognostic (8.82e-2)	unprognostic (6.56e-3)	unprognostic (7.79e-2)	unprognostic (6.05e-2)	unprognostic (2.67e-1)	unprognostic (5.58e-3)	unprognostic (5.26e-3)	unprognostic (1.82e-2)	unprognostic (2.37e-1)	unprognostic (1.24e-1)	unprognostic (1.70e-1)	unprognostic (2.02e-1)	unprognostic (4.75e-2)	unprognostic (3.01e-2)	unprognostic (2.76e-2)	unprognostic (9.61e-2)	unprognostic (1.82e-1)	3.6	1.7	1.1	12	1.7	12.7	1.8	0.5	0.9	1.6	2.4	1.4	0.6	0.3	1.1	2.5	1.4	1.5	4.6	2.8	1.1	1.2	1.8	1.4	4.9	48.1	1.6	0.6	0.9	1.1	0	0.8	2.2	1	1.3	1.9	1.4	3.7	0.9	0.7	1	7	1.3	2.8	14.9	1.7	1.1	1	45.6	1.6	0.8	18.5	3.2	1.3	1.7	7.3	3.9	14.1	1	18.6	8.7	0	0	0	0	0	0	0	0	0	0	0	0	0	34.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0.1	0	28.1	0	0	0	0	14.1	0	4.1	7.3	13.8	1	16.4	9.8	7.3	1.7	18.6	13.5	3.9	1	0.9	4	5.9	8.7	1.1	1.7	0.5	0.9	1.1	1.2	1.6	0.6	1	1
TREM1	"CD354, TREM-1"	ENSG00000124731	Triggering receptor expressed on myeloid cells 1	Q9NP99	6	41267926-41286719	"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		Receptor		Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in many		blood: 96.9;bone marrow: 38.5;lung: 34.2	Cell line enriched	Detected in some	7	U-87 MG: 23.6	Cancer enhanced	Detected in many		lung cancer: 9.6	Low region specificity	Detected in many			Cell type enriched	Detected in some	8	neutrophil: 96.9	Lineage enriched	Detected in many	8	granulocytes: 96.9									HPA005563	Uncertain				Intracellular and membrane					HPA005563: AB_1858259	unprognostic (6.41e-2)	unprognostic (1.47e-3)	unprognostic (1.22e-1)	unprognostic (3.39e-2)	unprognostic (6.07e-3)	unprognostic (2.97e-2)	unprognostic (5.73e-5)	unprognostic (1.29e-1)	unprognostic (1.24e-2)	unprognostic (4.13e-3)	unprognostic (2.24e-3)	unprognostic (7.65e-2)	unprognostic (3.18e-7)	unprognostic (6.32e-3)	unprognostic (4.95e-2)	unprognostic (1.08e-1)	unprognostic (7.26e-2)	10.2	0.6	0.7	21.1	1.5	38.5	1	0.6	2.1	0.7	0.9	0.7	0.5	0.1	1	1.5	0.6	4.2	5.1	3.7	1.2	0.9	1.1	3.7	34.2	8	2.7	0.1	2.1	1.8	0.2	2.7	31.2	2.3	0.9	0	2.5	1.3	0.1	2.4	0.4	1.1	3.8	3.9	12.1	1	2.6	0.6	0.3	2.2	1.9	1	3.9	0.7	0.2	5	96.9	12.8	0	0	4.1	0	0	0	0	0	0	0.4	0.2	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0.1	0.4	0.3	0.6	0	0	0.3	0	0	0	3.2	0	0	0	0	0	0	0	0.6	0	0	0	0	0	1.3	0	0	0	0	0	0	0	0	23.6	1.5	0	0	12.8	0.3	0	3.1	0	0	0	0	5	0.2	0	0	96.9	0	1.4	0.1	0	4.1	0.7	1.5	0.6	2.1	1.2	0.9	2.7	0.1	2.3	0.6
TSPAN7	"A15, CD231, DXS1692E, MRX58, MXS1, TALLA-1, TM4SF2"	ENSG00000156298	Tetraspanin 7	P41732	X	38561370-38688920	"CD markers, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters"	Host-virus interaction		"Disease mutation, Mental retardation"	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enriched	Detected in many	5	brain: 131.1	Cell line enhanced	Detected in some		HDLM-2: 13.3;Hep G2: 10.6;MOLT-4: 55.3;SCLC-21H: 31.0;U-266/70: 20.5	Cancer enhanced	Detected in all		glioma: 71.5	Low region specificity	Detected in all			Cell type enhanced	Detected in some		memory CD8 T-cell: 2.9	Low lineage specificity	Detected in single											"HPA003140, CAB062566, CAB068245"	Enhanced									"CAB062566: , CAB068245: , HPA003140: AB_1078454"	unprognostic (1.12e-2)	unprognostic (1.42e-2)	unprognostic (1.09e-1)	prognostic unfavourable (3.40e-4)	unprognostic (5.06e-2)	unprognostic (3.90e-3)	unprognostic (3.88e-3)	unprognostic (1.37e-2)	unprognostic (1.14e-1)	unprognostic (2.01e-2)	prognostic favourable (1.70e-4)	unprognostic (1.54e-1)	prognostic favourable (5.48e-7)	unprognostic (5.65e-3)	unprognostic (9.53e-2)	unprognostic (1.48e-1)	unprognostic (1.03e-3)	15.2	28.7	39.6	3.5	83	0.8	7.3	83.8	131.1	12.4	18.5	11.5	2.3	7.9	11.6	9.2	7.9	10.5	5.8	17.1	34.5	30.7	15.8	12	16.2	8.8	19.4	37.7	5.2	4.4	4.1	11.4	6.6	23.8	5.6	17.3	8.1	3.3	7.4	17.9	4.9	7.8	14.5	11.9	21.3	4.6	1.7	9.5	0	11.8	5.4	8.2	8.2	4.2	0.9	0.5	0.3	0.2	0.3	2.9	0.1	0	0	0.8	0	0.1	0	0	0	0	0	0	0.3	0	0	0.1	0	0	0.9	0.3	0	13.3	2.5	0	0	10.6	0	0	0.2	0.4	0	0	0	0	0	0	0.3	0.1	55.3	0	2.9	0	2.7	1.1	0	1.4	0.2	31	3.2	0	0	0.6	0	0.1	0	0	0.7	0	0.2	20.5	5.8	0	1.3	0.1	0.4	0.2	0.1	0	0.6	0.2	0.7	0.4	1.1	2.9	0.1	0.9	2.1	1.8	0.3	0.3	0	0.5	0	0.1	39.6	83	83.8	86.3	34.5	30.7	19.4	37.7	23.8	9.5
VCAM1	CD106	ENSG00000162692	Vascular cell adhesion molecule 1	P19320	1	100719742-100739045	"Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins"	Cell adhesion		Cancer-related genes	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Group enriched	Detected in all	5	kidney: 69.6;lymphoid tissue: 129.2	Group enriched	Detected in some	5	HHSteC: 56.9;HSkMC: 38.0	Cancer enriched	Detected in all	8	renal cancer: 89.5	Low region specificity	Detected in many			Group enriched	Detected in some	10	gdT-cell: 1.3;memory CD8 T-cell: 2.9;naive CD8 T-cell: 1.1	Lineage enriched	Detected in single	17	T-cells: 2.9	Low region specificity	Detected in all			Low region specificity	Detected in all			"CAB000154, HPA034796, HPA069867"	Enhanced		Approved	Cell Junctions		960000000	960000000	Cell Junctions		"CAB000154: , HPA034796: , HPA069867: "	unprognostic (2.96e-1)	prognostic favourable (3.82e-4)	unprognostic (1.31e-1)	unprognostic (7.49e-3)	unprognostic (1.04e-1)	prognostic favourable (7.19e-5)	unprognostic (1.60e-2)	unprognostic (2.48e-1)	unprognostic (1.18e-1)	unprognostic (1.20e-1)	unprognostic (3.95e-2)	unprognostic (8.23e-2)	unprognostic (1.80e-1)	unprognostic (5.47e-2)	unprognostic (1.68e-2)	unprognostic (3.12e-2)	unprognostic (2.55e-2)	10.9	18.1	1.5	20.2	3.2	1.3	5.2	0.9	1.1	3.7	5	3.3	1.4	3.3	4.9	4.5	5.3	4.9	6.8	7.2	1.7	2.3	69.6	11.8	9.8	26.8	2.8	1.7	11.1	6.6	10.6	3.5	10.9	4.2	8.3	5.5	15.3	4.9	1.1	4.7	1.8	6.3	4.2	3.7	129.2	3	2.5	1.6	13.3	3.5	2.8	20.9	8.2	2.8	0	0.1	0	0	0	2.9	0.1	0	0	0.2	0.1	0.2	1.7	0	0	0	0	0	0	0	0	0	0	0	0.5	0	0	8.2	0	0	0	0	56.9	0	0	38	0	10	0	0.6	0	0	0.2	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	8.5	0	0	0	0.1	0	0	0.4	0	0	0	0	0	1.3	0	0	0	0.1	2.9	0.1	0	0	1.1	0	0	0	0	0	0.1	1.5	3.2	0.9	1.1	1.7	2.3	2.8	1.7	4.2	1.6
VPREB1	"CD179A, VpreB"	ENSG00000169575	V-set pre-B cell surrogate light chain 1	P12018	22	22244675-22245515	"CD markers, Predicted intracellular proteins"				Evidence at protein level	Evidence at transcript level	Evidence at protein level	Evidence at protein level	Evidence at protein level	Tissue enhanced	Detected in some		blood: 8.1;bone marrow: 23.8;lymphoid tissue: 4.8	Group enriched	Detected in some	11	Daudi: 8.4;MOLT-4: 17.8;RPMI-8226: 4.8	Not detected	Not detected			Not detected	Not detected			Group enriched	Detected in some	4	memory B-cell: 5.8;naive B-cell: 8.1	Lineage enriched	Detected in many	5	B-cells: 8.1					Not detected	Not detected			HPA055886	Uncertain				Intracellular and membrane					HPA055886: 																		0	0	0	2.2	0	23.8	0	0	0	0.1	0.2	0	0	0	0.1	0	0.1	0	0	0	0	0	0	0	0	0.3	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	1.3	0	0	0.6	0	1.3	0	4.8	0	0	1.2	0	0	8.1	1.6	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0	0	0	0	0	8.4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	17.8	0	0	0	0	0	4.8	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0.9	0	0.2	0	0	0	0	0	0	0	5.8	0	0	0	8.1	0	0	0	0	0	1.6	0	0.2	0	0	0	0	0	0	0	0	0	0
